<SEC-DOCUMENT>0001144204-12-039245.txt : 20120712
<SEC-HEADER>0001144204-12-039245.hdr.sgml : 20120712
<ACCEPTANCE-DATETIME>20120712172317
ACCESSION NUMBER:		0001144204-12-039245
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20120712
DATE AS OF CHANGE:		20120712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-180562
		FILM NUMBER:		12959873

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>v318169_posam.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-3 ON FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B> <B>UNDER</B>
<B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SYNTHETIC BIOLOGICS, INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction of Incorporation
or Organization)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2834</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Primary Standard Industrial
Classification Code Number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13-3808303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer Identification No.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>617 Detroit Street, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address and telephone number of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copy to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leslie Marlow, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hank Gracin, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gracin &amp; Marlow, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Chrysler Building</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>405 Lexington Avenue, 26th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10174<BR>
(212) 907-6457</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address and telephone number of agent
for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate Date of Proposed Sale to the
Public: From time to time after the date this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&nbsp;&nbsp;See the
definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%">Large accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 39%">Accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">o</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD>Smaller reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(Do not check if a smaller reporting company)</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant filed a registration statement
on Form S-3 (Registration No. 333-166750) (the &ldquo;Original Registration Statement&rdquo;) declared effective by the Securities
and Exchange Commission on June 14, 2010, which registered shares of common stock of the Registrant. This Post-Effective Amendment
No. 1 to Form S-3 on Form S-1 Registration Statement is being filed to amend the Original Registration Statement into a registration
statement on Form S-1 to maintain the registration of certain securities previously registered on the Original Registration Statement.
On June 12, 2012, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;) was<FONT STYLE="color: black"> notified by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) staff that under its guidelines it was unable to grant a waiver request for the Company&rsquo;s
continued use of its existing Form S-3 because of the failure of Berman </FONT>&amp; Company, P.A. (&ldquo;Berman &amp; Co.&rdquo;)<FONT STYLE="color: black">
to follow proper partner rotation procedures that resulted in the Company&rsquo;s Annual Report on Form 10-K for the year ended
December 31, 2011 being deemed to be filed late. </FONT> Consequently, the Registrant is no longer eligible to use Form S-3 in
connection with the current offering. The Registrant is filing this Post-Effective Amendment No.1 to Form S-3 on Form S-1 to amend
the Original Registration Statement into a registration statement on Form S-1 to (i) continue the registration of: (a) 94,391 shares
of common stock issuable upon exercise of the warrants originally issued in the April 2011 offering subject to the April 11, 2011
Prospectus Supplement, and exchanged for warrants issued in July 2011 and (b) 18,182 shares of common stock issuable upon exercise
of the warrants issued in the July 2010 offering subject to the July 2, 2010 Prospectus Supplement, all previously registered on
the Original Registration Statement, and (ii) remove from registration the unsold portion of securities registered under the Original
Registration Statement. All filing fees payable in connection with the registration of these securities were previously paid in
connection with the filing of the original registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE INFORMATION CONTAINED IN THIS PROSPECTUS
IS NOT COMPLETE AND MAY BE CHANGED. THESE SECURITIES MAY NOT BE SOLD UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION IS DECLARED EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING
AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBJECT TO COMPLETION, DATED JULY 12,
2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>112,573 Shares of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus covers the sale of up to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&bull; 94,391 shares of common stock issuable upon the exercise
of warrants sold in our April 11, 2011 offering which were exchanged for warrants issued in July 2011 and may be exercised at a
price of $1.00 per share, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&bull; 18,182 shares of common stock issuable
upon the exercise of warrants sold in our July 2, 2010 offering which may be exercised at a price of $1.32 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock became eligible for trading
on the NYSE Amex October 16, 2008. &nbsp;Our common stock is eligible for quotation on the NYSE Amex under the symbol &ldquo;SYN&rdquo;.
The closing price of our stock on July 11, 2012 was $2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk.
See &ldquo;<FONT STYLE="color: windowtext"><U>Risk Factors</U></FONT> &rdquo; beginning on page 4 of this prospectus for more
information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus or the prospectus to which
it relates is truthful or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is July __,
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Page</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 92%">PROSPECTUS SUMMARY</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right">1</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>RISK FACTORS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>USE OF PROCEEDS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">15</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>DILUTION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>CAPITALIZATION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>BUSINESS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">17</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>MARKET PRICE OF COMMON STOCK AND OTHER STOCKHOLDER MATTERS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">28</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>PLAN OF DISTRIBUTION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">30</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">31</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">37</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>EXECUTIVE COMPENSATION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">41</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">44</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">46</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>DESCRIPTION OF SECURITIES</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">47</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>EXPERTS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">49</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">50</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>LEGAL MATTERS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">50</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>WHERE YOU CAN FIND MORE INFORMATION</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">50</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>INDEX TO FINANCIAL STATEMENTS</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">64</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>PART II</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">88</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information
contained in this prospectus. We have not authorized anyone to provide you with information different from that which is contained
in this prospectus. This prospectus may be used only where it is legal to sell these securities. The information in this prospectus
may only be accurate on the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information
contained elsewhere in this prospectus; it does not contain all of the information you should consider before investing in our
common stock. You should read the entire prospectus before making an investment decision.&nbsp;&nbsp;Throughout this prospectus,
the terms &ldquo;Synthetic Biologics, Inc.&rdquo;, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;our company&rdquo;
refer to Synthetic Biologics, Inc., a Nevada corporation.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Our initial
synthetic biologic product candidate is intended to treat pulmonary arterial hypertension (PAH), a serious life-threatening lung
disease, by locally delivering therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via
an oral daily pill. We also intend to expand new and existing collaborations in the area of DNA-based therapeutics. In addition,
we have several small molecule clinical-stage programs, the majority of which are being funded, or partially funded, by grants,
charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product
candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral
sclerosis (ALS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><FONT STYLE="font: 9pt Arial; color: Red"><B><img src="pg6.jpg"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Synthetic Biologics:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-left: 0.5in; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="width: 86%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">Our initial synthetic biologic
        product candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that
        encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries of PAH patients via a single
        procedure, and, via an oral daily pill, control the long-term local expression of such therapeutic protein. We are developing this
        initial product candidate pursuant a global exclusive channel collaboration that we entered into with the private synthetic biology
        company Intrexon Corporation (Intrexon) in November 2011. As part of this collaboration, we have access to Intrexon's UltraVector<SUP>&reg;</SUP>
        platform and RheoSwitch Therapeutic System<SUP>&reg;</SUP> for this product application. We anticipate that by continuously producing
        and delivering prostacyclin directly where it is needed, in the pulmonary arteries of PAH patients, this product candidate may
        overcome the dose limiting side effects of systemic prostacyclin treatments for PAH, a mainstay of PAH treatment. According to
        GlobalData, the global market for PAH treatments is estimated to exceed $3.6 billion by 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(UltraVector<SUP>&reg;</SUP> and RheoSwitch
        Therapeutic System<SUP>&reg;</SUP> are registered trademarks of Intrexon Corporation)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Funded/Small Molecule Clinical Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-left: 0.5in; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="width: 86%; padding-left: 7.75pt; text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Patient enrollment of 164 patients is complete in this randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. Patients are being dosed and monitored for two years. This clinical trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial through completion. Current sales of injectable disease-modifying therapies for MS are estimated at $8.9 billion annually.&nbsp;According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta&trade;, if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to $5 billion annually by 2017.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-left: 0.5in; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="width: 86%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.75pt; text-align: justify">Trimesta<SUP>TM</SUP> (oral
        estriol) is also being developed for the treatment of cognitive dysfunction in female MS patients. In January 2012, patient enrollment
        began in a randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at University of California, Los
        Angeles (UCLA). The majority of the costs of this trial are being funded by grants from foundations and charitable organizations
        and we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of
        MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5pt">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 7.75pt; text-align: justify">Effirma<SUP>TM</SUP> (flupirtine) is being developed for the treatment of fibromyalgia. On May 6, 2010, we entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is currently in Phase II development. The sublicense agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive certain payments if milestones are achieved and royalties on sales. Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-left: 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings 2">&mdash;</FONT></TD>
    <TD STYLE="width: 86%; padding-left: 7.75pt; text-align: justify">AEN-100 (gastroretentive zinc acetate) is being developed under an investigator-initiated Investigational New Drug (IND) application for the treatment of ALS, also known as Lou Gehrig&rsquo;s disease. We intend to sponsor a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients. It is anticipated that the clinical trial will comprise two phases. The first phase of the trial is anticipated to enroll at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months at which time the average change in functional rating between the groups will be compared via an interim analysis conducted on a blinded basis. Should the interim analysis meet the threshold criteria in favor of the treatment group, the second phase of the study will be initiated and will seek to enroll approximately 50 additional subjects to receive treatment for nine months. This study is intended to be conducted by PNA Center for Neurological Research (PNA) which previously sponsored and completed a successful pilot Phase I/II study of oral zinc therapy for ALS. Separately, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III clinical trial in ALS patients.&nbsp; We have committed to support approximately $400,000 to PNA for the first phase of the Phase II/III clinical trial, payable based upon study enrollment and milestones. There is only one approved therapy for ALS, the efficacy of which is considered to be marginal. Based on an estimated annual price of $10,000 per ALS patient, we estimate that the total market potential in the U.S. is $300 million.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 617
Detroit Street, Suite 100, Ann Arbor, Michigan 48104, and our telephone number is (734) 382-7800. Our website address is www.syntheticbiologics.com.
The information on our website is not incorporated by reference into this prospectus, and you should not consider it part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt"><B>Issuer</B></TD>
    <TD STYLE="width: 63%">Synthetic Biologics, Inc.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">Securities offered</TD>
    <TD STYLE="width: 63%; padding-left: 4.2pt; text-indent: -4.2pt">This prospectus covers the sale of up to:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&bull; 94,391 shares of common stock issuable upon the exercise of warrants which may be exercised at a price of $1.00 per share, and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&bull; 18,182 shares of common stock issuable upon the exercise of warrants which may be exercised at a price of $1.32 per share.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">Common stock to be outstanding after this offering</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">33,413,720 shares (assuming all the warrants are exercised)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">Use of Proceeds</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">We will receive proceeds from the exercise of the warrants if the warrants are exercised for cash. See &ldquo;Use of Proceeds&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4.2pt; text-indent: -4.2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-left: 4.2pt; font-weight: bold; text-indent: -4.2pt"><B>Risk Factors</B></TD>
    <TD STYLE="width: 63%">You should carefully read and consider the information set forth under &ldquo;Risk Factors,&rdquo; together with all of the other information set forth in this prospectus, before deciding to invest in shares of our common stock.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-left: 4.2pt; text-indent: -4.2pt">NYSE Amex symbol</TD>
    <TD STYLE="width: 63%">We list our common stock on the NYSE Amex under the symbol &ldquo;SYN&rdquo;.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of common stock outstanding before and
after the offering is based on 33,301,147 shares outstanding as of June 30, 2012 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">1,418,493 shares of common stock issuable upon the exercise of warrants with a weighted average exercise price of $3.10 per share;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">3,968,746 shares of common stock issuable upon the exercise of options with a weighted average exercise price of $1.73 per share; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">1,349,821 shares of common stock reserved for future grants and awards under our equity incentive plans.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves
a high degree of risk, and you should be able to bear the complete loss of your investment. You should carefully consider the risks
described below, the other information in this prospectus and the documents incorporated by reference herein when evaluating our
company and our business. If any of the following risks actually occur, our business could be harmed. In such case, the trading
price of our common stock could decline and investors could lose all or a part of the money paid to buy our common stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise additional
capital to operate our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the exception of the quarter ended
June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect to
incur additional operating losses in the future and therefore our cumulative losses to increase. To date, other than the licensing
fee we received from Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the U.S., Canada
and Japan and limited laboratory revenues from Adeona Clinical Laboratory, which we have recently sold, we have generated very
minimal revenues. Inasmuch as our sole source of revenue (with the exception of the Meda licensing fee) has been our laboratory
revenue and our laboratory was sold recently, we do not expect to derive revenue from any source in the near future until we or
our partners successfully commercialize our products. As of March 31, 2012, our accumulated deficit totaled approximately $53.1
million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our product
candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products.
For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings,
cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient to
sustain our operations, we will need to seek additional sources of financing and such additional financing may not be available
on favorable terms, if at all. Our recent loss of S-3 eligibility due to the failure of Berman &amp; Company, P.A. to follow proper
partner rotation procedures may also negatively affect our ability to raise capital. If we do not succeed in raising additional
funds on acceptable terms, we may be unable to complete planned preclinical and clinical trials or obtain approval of our product
candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product
development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Any additional sources
of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive effect on our stockholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not been able to sustain
profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than with respect to the quarter
ended June 30, 2010, we have a history of losses and we have incurred&nbsp;and continue to incur substantial losses and negative
operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still incur
substantial losses for the foreseeable future and may not sustain profitability. We also expect to continue to incur significant
operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we
do the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">continue to undertake preclinical development and clinical trials for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">seek regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">develop our product candidates for commercialization;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">implement additional internal systems and infrastructure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">lease additional or alternative office facilities; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&#9679;</TD>
    <TD STYLE="width: 90%">hire additional personnel, including members of our management team.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience negative cash flow for
the foreseeable future as we fund our technology development with capital expenditures. As a result, we will need to generate significant
revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability
in the future. Our failure to achieve or maintain profitability could negatively impact the value of our common stock and underlying
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our research and development efforts
may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must continue to explore opportunities
that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources
to research and development. A high rate of failure is inherent in the research and development of new products and technologies.
Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at
any point in the process, including after significant funds have been invested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of whether our clinical trials
are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial
success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory
approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish
or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully
develop new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry
standards, or competitors' innovations. Innovations may not be quickly accepted in the marketplace because of, among other things,
entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or
whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire
drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products
or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The technology on which our channel
partnering arrangement with Intrexon is based on early stage technology in the field of synthetic DNA-based therapy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our exclusive channel collaboration arrangement
with Intrexon contemplates the use of Intrexon&rsquo;s transgene engineering platform technology and regulatory control technology
for the <I>in vivo</I> cellular production of PGIS, a specific effector enzyme that regulates the production of prostacyclin. Such
technologies have a limited history of use in the design and development of human therapeutic product candidates and may therefore
involve unanticipated risks or delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DNA-based therapy has not yet been
proven to be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has not yet approved any human
DNA-based therapy product for sale. The field of DNA-based therapy, also referred to as gene therapy or gene transfer, is experimental
and has not yet proven successful in many clinical trials. Clinical trials with DNA-based therapy have encountered a multitude
of significant technical problems in the past, including, unintended integration with host DNA, poor levels of protein expression,
transient protein expression, viral overload, immune reactions to either viral capsids utilized to deliver DNA, DNA itself, proteins
expressed or cells transfected with DNA. There can be no assurance that our preclinical animals studies or human clinical trials
will be successful or that we will receive the regulatory approvals necessary to initiate such studies. To the extent that we utilize
viral constructs or other systems to deliver our DNA-based therapies and same or similar delivery systems demonstrate unanticipated
and/or unacceptable side effects in preclinical or clinical trials conducted by ourselves or others we may be forced to, or elect
to, discontinue development of such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not generate additional revenue
from our relationships with our corporate&nbsp;collaborators.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda AB whereby we may receive milestone payments totaling $17.5 million (including an upfront payment of $2.5 million
that has already been received), plus royalties on our flupirtine program. There can be no assurance that Meda AB will successfully
develop flupirtine for fibromyalgia in the U.S., Canada or Japan that would allow us to receive such additional $15 million in
milestone payments and royalties on sales in connection with such agreement. The successful achievement of the various milestones
set forth in the sublicense agreement is not within our control and we will be dependent upon Meda AB for achievement of such milestones.
According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is in Phase II development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have experienced several management
changes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had significant changes in management
in the past few years. Jeffrey Riley was appointed Chief Executive Officer and President on February 3, 2012. Effective February
6, 2012, C. Evan Ballantyne was appointed Chief Financial Officer. James S. Kuo, M.D., served as Chief Executive Officer and President
from February 6, 2010 until February 3, 2012. Max Lyon served as Chief Executive Officer, President and director from June 26,
2009 until February 6, 2010. Changes in our key positions, as well as additions of new personnel and departures of existing personnel,
can be disruptive, might lead to additional departures of existing personnel and could have a material adverse effect on our business,
operating results, financial results and internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to retain rights
licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to
develop, manufacture, and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own patent applications,
we also currently rely on licensing agreements with third party patent holders/licensors for our products. We have an exclusive
license agreement with the McLean Hospital relating to the use of flupirtine to treat fibromyalgia which was sublicensed to Meda
AB and an exclusive license agreement with the Regents of the University of California relating to our Trimesta technology. Each
of these agreements requires us or our sublicensee to use our best efforts to commercialize each of the technologies as well as
meet certain diligence requirements and timelines in order to keep the license agreement in effect. In the event we or our sublicensee
are not able to meet our diligence requirements, we may not be able to retain the rights granted under our agreements or renegotiate
our arrangement with these institutions on reasonable terms, or at all. Furthermore, we currently have very limited product development
capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would
need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed
the technologies. Our exclusive channel collaboration agreement with Intrexon provides that Intrexon may terminate such agreement
if we do not perform certain specified requirements, including developing therapies considered superior.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can give no assurances that any of our
issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection or
be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability, nor
does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional expenses
in connection with our exclusive channel collaboration arrangement with Intrexon.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our exclusive channel collaboration
with Intrexon, we are responsible for future research and development expenses of product candidates developed under such collaboration,
the effect of which we expect will increase the level of our overall research and development expenses going forward. Although
all manufacturing, preclinical studies and human clinical trials are expensive and difficult to design and implement, costs associated
with the manufacturing, research and development of biologic product candidates are generally greater in comparison to small molecule
product candidates. We have added additional personnel and expect to add additional personnel to support our exclusive channel
collaboration with Intrexon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our collaboration with Intrexon
is relatively new, we have only recently assumed development responsibility and costs associated with such program. In addition,
because development activities are determined pursuant to a joint steering committee comprised of Intrexon and ourselves and we
have limited experience, future development costs associated this program may be difficult to anticipate and exceed our expectations.
Our actual cash requirements may vary materially from our current expectations for a number of other factors that may include,
but are not limited to, unanticipated technical challenges, changes in the focus and direction of our development activities or
adjustments necessitated by changes in the competitive landscape in which we operate. If we are unable to continue to financially
support such collaboration due to our own working capital constraints, we may be forced to delay our activities. If we are unable
to obtain additional financing on terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments by competitors may render
our products or technologies obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies that currently sell or are developing
both generic and proprietary products to treat serious diseases include: Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec,
Eli Lilly &amp; Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck &amp; Co., Pfizer, Novartis, Teva Pharmaceuticals and United
Therapeutics. Many of our competitors have significant financial and human resources. The pulmonary arterial hypertension market
is highly competitive and several different product classes currently compete in this space, including prostacyclin-based therapies,
endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. Prostacyclin-based therapies for PAH are available in
a number of delivery formats, including intravenous, subcutaneous and inhaled routes and an oral prostacyclin-based product candidate
is currently under NDA review in the U.S. In addition, academic research centers may develop technologies that compete with our
Trimesta, sustained-release zinc preparation - AEN-100, and flupirtine technologies. Should clinicians or regulatory authorities
view these therapeutic regiments as more effective than our products, this might delay or prevent us from obtaining regulatory
approval for our products, or it might prevent us from obtaining favorable reimbursement rates from payers, such as Medicare, Medicaid
and private insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
environment</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical
companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these
companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources
significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships
and other types of joint ventures with larger, well established industry competitors that afford these companies potential research
and development and commercialization advantages in the therapeutic areas we are currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competitors could develop and/or
gain FDA approval of our products for a different indication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we do not have composition of matter
patent claims for flupirtine, estriol or zinc acetate, others may obtain approvals for other uses of these products that are not
covered by our issued or pending patents. For example, the active ingredients in both Effirma (flurpirtine) and Trimesta (oral
estriol) have been approved for marketing in overseas countries for different uses and an oral immediate release form of zinc is
approved in the U.S. and Europe for the treatment of Wilson&rsquo;s disease. Other companies, including the original developers
or licensees or affiliates may seek to develop Effirma or Trimesta or their respective active ingredient(s) for other uses in the
U.S. or any country we are seeking approval for. We cannot provide any assurances that any other company may obtain FDA approval
for products that contain flupirtine, estriol or zinc in various formulations or delivery systems that might adversely affect our
ability or the ability of Meda to develop and market these products in the U.S. We are aware that other companies have intellectual
property protection using the active ingredients and have conducted clinical trials of flupirtine, estriol and zinc for different
applications than what we are developing. Many of these companies may have more resources than us. We cannot provide any assurances
that our products will be FDA-approved prior to our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product containing our active ingredients
is already marketed or if the FDA approves other products containing our active ingredients in the future to treat indications,
physicians may elect to prescribe and substitute a competitor&rsquo;s products to treat the diseases for which we are intending
to commercialize; this is commonly referred to as &ldquo;off-label&rdquo; use. While under FDA regulations a competitor is not
allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot direct
physicians to select certain products for their patients. Consequently, we might be limited in our ability to prevent off-label
use of a competitor&rsquo;s product to treat the diseases we are intending to commercialize, even if we have issued method of use
patents for that indication. If we are not able to obtain and enforce our patents, if any, or otherwise receive orphan drug protection
in the case of ALS, a competitor could develop and commercialize similar products for the same indications that we are pursuing.
We cannot provide any assurances that a competitor will not obtain FDA approval for a product that contains the same active ingredients
as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on method patents and patent
applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited
or eliminated if we are not able to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitiveness may be adversely affected
if we are unable to protect our proprietary technologies. We do not have composition of matter patents for Trimesta or Effirma,
or their respective active ingredients estriol and flupirtine. We rely on issued patent and pending patent applications for use
of Trimesta to treat MS (issued U.S. Patent No. 6,936,599) and various other therapeutic indications, which have been exclusively
licensed to us. We have exclusively licensed an issued patent for the treatment of fibromyalgia with flupirtine, which we have
sublicensed to Meda AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our AEN-100 drug candidate (gastroretentive
zinc acetate) is the subject of U.S. and international pending patent applications, such as published U.S. patent application Ser.
No. 11/621,962 and corresponding international applications that claim priority to January 10, 2006 as well as additional patent
applications. On October 26, 2011, we received a final rejection letter with regard to U.S. patent application Ser. No. 11/621,962.
On February 15, 2012, we filed a Request for Continued Examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
companies are uncertain and may involve complex legal and factual questions. We may incur significant expense in protecting our
intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other
infringement litigation by or against us could cause us to incur significant expense and divert the attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others may file patent applications or
obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in any
such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how they
will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another party
claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large sum if
we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign our
product, which may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets and proprietary
know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors,
current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors
or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade
secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop
similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may fail to retain or recruit
necessary personnel, and we may be unable to secure the services of consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2012, we had nine employees.
We have also engaged regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities
and have been and will be required to retain additional consultants and employees in order to fulfill our obligations under our
exclusive channel collaboration with Intrexon. Our future performance will depend in part on our ability to successfully integrate
newly hired officers into our management team and our ability to develop an effective working relationship among senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our directors,&nbsp;scientific
advisors, and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology
companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are
obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly,
we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product
or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate
opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Losing key personnel or failing to recruit
necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for
qualified personnel in the drug-development field, and we may not be able to attract and retain the qualified personnel we would
need to develop our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on independent organizations, advisors,
and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval, clinical
management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may not always
be available to us on a timely basis when we need them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the parties we depend on for supplying
our drug substance raw materials and certain manufacturing-related services do not timely supply these products and services, it
may delay or impair our ability to develop, manufacture and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on suppliers for our drug substance
raw materials and third parties for certain manufacturing-related services to produce material that meets appropriate content,
quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution. Our
AEN-100 product candidate has limited stability data to date and is the subject of ongoing stability studies. To succeed, clinical
trials require adequate supplies of drug substance and drug product, which may be difficult or uneconomical to procure or manufacture.
We and our suppliers and vendors may not be able to (i) produce our drug substance or drug product to appropriate standards for
use in clinical studies, (ii) perform under any definitive manufacturing, supply or service agreements with us, or (iii) remain
in business for a sufficient time to successfully produce and market our product candidates. If we do not maintain important manufacturing
and service relationships, we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities
which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or
deplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements
with them on terms and conditions favorable to us and, there could be a substantial delay before a new facility could be qualified
and registered with the FDA and foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp; <B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If successful large-scale manufacturing
of DNA-based products is not possible, we or our collaborators may be unable to manufacture enough of our product candidates to
achieve regulatory approval or market our DNA-based products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Few companies to date have demonstrated
successful large-scale manufacturing of DNA-based products, including those that have had significantly more resources than us
and it is anticipated that significant challenges will be faced in the scale-up of our manufacturing process for commercial production.
There are a limited number of contract manufacturers qualified to perform large-scale manufacturing of DNA-based products. We or
our collaborators may be unable to manufacture commercial-scale quantities of DNA-based products or receive appropriate government
approvals on a timely basis or at all. Failure to successfully manufacture or obtain appropriate government approvals on a timely
basis or at all would prevent us from achieving our business objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical trials are very expensive,
time-consuming, and difficult to design and implement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time-consuming. We estimate that clinical trials of our product candidates would take at least several years to
complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or
repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%">obtaining an IND application with the FDA to commence clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>identification of, and acceptable arrangements with, one or more clinical sites;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>obtaining IRB approval to commence clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">unforeseen safety issues;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">determination of dosing;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">lack of effectiveness during clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">slower than expected rates of patient recruitment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">inability to monitor patients adequately during or after treatment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">inability or unwillingness of medical investigators to follow our clinical protocols; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we, IRBs or the FDA may suspend our clinical trials
at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the FDA finds deficiencies
in our submissions or conduct of our trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The results of our clinical trials
may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily
predictive of future results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, long-term safety and efficacy
have not yet been demonstrated in clinical trials for any of our diagnostic product candidates. Favorable results in our early
studies or trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned,
we cannot be certain that the results will support our product candidate claims. Success in preclinical testing and Phase II clinical
trials does not ensure that later Phase II or Phase III clinical trials will be successful. We cannot be sure that the results
of later clinical trials would replicate the results of prior clinical trials and preclinical testing. In particular, the limited
results that we have obtained for our diagnostic tests may not predict results from studies in larger numbers of subjects drawn
from more diverse populations over a longer period of time. Clinical trials may fail to demonstrate that our product candidates
are safe for humans and effective for indicated uses. Any such failure could cause us or our sublicensee to abandon a product candidate
and might delay development of other product candidates. Preclinical and clinical results are frequently susceptible to varying
interpretations that may delay, limit or prevent regulatory approvals or commercialization. Any delay in, or termination of, our
clinical trials would delay our obtaining FDA approval for the affected product candidate and, ultimately, our ability to commercialize
that product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on third parties, including
researchers and sublicensees, who are not under our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we have in-licensed some of our product
candidates, have sublicensed a product candidate and have a collaboration agreement for the development of another product candidate,
we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and medical institutions
or private physician scientists, to conduct our preclinical and clinical trials under agreements with us. These collaborators are
not our employees and we cannot control the amount or timing of resources that they devote to our programs or the timing of their
procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any of these scientific inventors/advisors
or those of our sublicensee become disabled or die unexpectedly, or should they fail to comply with applicable regulatory guidelines,
we or our sublicensee may be forced to scale back or terminate development of that program. They may not assign as great a priority
to our programs or pursue them as diligently as we would if we were undertaking those programs ourselves. Failing to devote sufficient
time and resources to our drug-development programs, or substandard performance and failure to comply with regulatory guidelines,
could result in delay of any FDA applications and our commercialization of the drug candidate involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These collaborators may also have relationships
with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors at our expense could
harm our competitive position. For example, we are highly dependent on scientific collaborators for our Trimesta development program.
Specifically, all of the clinical trials have been conducted under physician-sponsored IND applications, not corporate-sponsored
INDs. Generally, we have experienced difficulty in collecting data generated from these physician-sponsored clinical trials for
our programs. We cannot provide any assurances that we will not experience any additional delays in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also highly dependent on government
and private grants to fund certain of our clinical trials for our product candidates. For example, Trimesta (oral estriol) has
received grants totaling over $8 million,&nbsp;predominantly from the Southern California Chapter of the NMSS and the National
Institutes of Health which funds a majority of the ongoing clinical trial in relapsing-remitting MS for women. Although we believe
that the grant funding received to date is sufficient to complete the current clinical trial based upon current cost estimates,
if we experience any additional unanticipated costs or require further clinical trials, and our scientific collaborator is unable
to maintain or receive additional grants, we might be forced to scale back or terminate the development of this product candidate.
We will also need to cross reference our IND with the inventor/IND holder for this program should we elect to file our own corporate
IND for our Trimesta (oral estriol) program. The on-going and future development and commercialization of Effirma (flupirtine)
for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&rsquo;s acceptance
of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our AEN-100 program for ALS is reliant
on the investigator-initiated IND of PNA as well as their clinical trial capabilities. Although the planned Phase II/III clinical
trial that we intend to conduct with PNA has received regulatory approval to proceed, such clinical trial is still the subject
of further protocol development and IRB approval, either of which may alter the anticipated timing and budget of such clinical
trial. In addition, because AEN-100 is not the same zinc formulation utilized by PNA in its previously completed Phase I/II safety
study of zinc for ALS, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III
clinical trial in ALS patients. The IRB approval process is ongoing for the planned Phase I study of AEN-100 and the planned Phase
II/III clinical trial in ALS patients. Such Phase I study of AEN-100 may produce unanticipated and unacceptable safety, tolerability
or bioavailability results that may substantially delay initiation of the planned Phase II/III clinical trial in ALS patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our synthetic biologic
product candidates, we are dependent upon Intrexon&rsquo;s synthetic biology facilities and capabilities as we have no such facilities
and capabilities of our own. We are also reliant on their vector engineering platform, gene expression switch technology and know-how.
If any of the foregoing were to become inaccessible or terminated, it would be difficult for us to develop and commercialize our
synthetic biologic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur substantial costs as
a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated
with lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any other person files patent applications,
or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference
proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to
participate in interference proceedings involving our issued patents and pending applications of another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intellectual property environment in
the area of DNA-based therapeutics is particularly complex, constantly evolving and highly fragmented. Other companies and institutions
have issued patents and have filed or will file patent applications that may issue into patents that cover or attempt to cover
genes, vectors, cell lines, and methods of making and using DNA and DNA-based therapy products used in, or similar to our product
candidate, and technologies. We have not conducted freedom-to-use patent searches on all aspects of our product candidates or potential
product candidates, and we may be unaware of relevant patents and patent applications of third parties. In addition, the freedom-to-use
patent searches that have been conducted may not have identified all relevant issued patents or pending patents. We cannot provide
assurance that our proposed products in this area will not ultimately be held to infringe one or more valid claims owned by third
parties which may exist or come to exist in the future or that in such case we will be able to obtain a license from such parties
on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that the practice of
our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition
proceedings, either by opposing the validity of another&rsquo;s foreign patent or by persons opposing the validity of our foreign
patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also face frivolous litigation or
lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding
relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management
from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect
on our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we infringe the rights of others
we could be prevented from selling products or forced to pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our products, methods, processes, and
other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may
be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling
to offer us a license on commercially acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will seek to raise additional
funds in the future, which may be dilutive to stockholders or impose operational restrictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to seek to raise additional capital
in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity
or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions,
issue equity as part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity
that may be dilutive. Our stockholders may experience additional dilution in net book value per share and any additional equity
securities may have rights, preferences and privileges senior to those of the holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are substantially controlled by
our current officers, directors, and principal stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, our directors, executive officers,
and principal stockholders beneficially own a substantial number of shares of our common stock. As a result, they will be able
to exert substantial influence over the election of our Board of Directors and the vote on issues submitted to our stockholders.
Our executive officers and directors beneficially owned approximately 8.9 million shares of our common stock, including stock options
and warrants exercisable within 60 days of June 30, 2012. Our executive officers, directors and principal stockholders together
beneficially owned approximately 12 million shares of our common stock, including the stock options and warrants exercisable within
60 days of June 30, 2012. Because our common stock has from time to time been &ldquo;thinly traded&rdquo;, the sale of a substantial
number of shares by our executive officers, directors and principal stockholders would have an adverse effect on the market for
our stock and our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our shares of common stock are from
time to time thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to
raise money or otherwise desire to liquidate their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has from time to time
been &ldquo;thinly-traded,&rdquo; meaning that the number of persons interested in purchasing our common stock at or near ask prices
at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the
fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others
in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,
they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase
of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or
more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady
volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give
stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained,
or that current trading levels will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We cannot assure you that the common stock will be liquid
or that it will remain listed on the NYSE Amex.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will be able
to maintain the continued listing standards of the NYSE Amex (formerly the American Stock Exchange). The NYSE Amex requires companies
to meet certain continued listing criteria including certain minimum stockholders' equity&nbsp;and equity prices per share&nbsp;as
outlined in the NYSE Amex Exchange Company Guide. We may not be able to maintain such minimum stockholders' equity or prices per
share or may be required to effect a reverse stock split to maintain such minimum prices and/or issue additional equity securities
in exchange for cash or other assets, if available, to maintain certain minimum stockholders' equity required by the NYSE Amex.&nbsp;If
we are delisted from the NYSE Amex then our common stock will trade, if at all, only on the over-the-counter market, such as the
OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation
requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common
stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE
Amex could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of
institutional investor interest and fewer business development opportunities. In order to remain listed on NYSE Amex, we are required
to maintain a minimum stockholders&rsquo; equity of $6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be issuances of shares
of preferred stock in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we currently do not have preferred
shares outstanding, the Board of Directors could authorize the issuance of a series of preferred stock that would grant holders
preferred rights to our assets upon liquidation, the right to receive dividends before dividends would be declared to common stockholders,
and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock.
To the extent that we do issue preferred stock, the rights of holders of common stock could be impaired thereby, including without
limitation, with respect to liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATED TO OUR INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to government regulation,
compliance with which can be costly and difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., the formulation, manufacturing,
packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various
governmental agencies, including (1) the FDA, (2) the Federal Trade Commission, or FTC, (3) the Consumer Product Safety Commission,
or CPSC, (4) the U.S. Department of Agriculture, or USDA. Our proposed activities may also be regulated by various agencies of
the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA,
in particular, regulates the formulation, manufacture and labeling of over-the-counter, or OTC drugs, prescription drugs, medical
foods, conventional foods, homeopathic OTC drugs, dietary supplements, and cosmetics such as those that we intend to distribute.
FDA regulations require us and our suppliers to meet relevant cGMP regulations for the preparation, packing, labeling, and storage
of all drugs and foods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements,
reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling
changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their
subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced
inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure
to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of
production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors
will be able to comply with these regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA regulates prescription drug labeling
and promotion activities. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The
FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our
product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products.
Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing
clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country
to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to comply
with these laws and regulations now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to develop our zinc candidate,
AEN-100, as a drug and intend to file an IND with the FDA in order to conduct necessary clinical trials to support new medical
claims and ultimately file one or more NDA with respect to such products which would subject us to time, expense and uncertainty
associated with achieving approval of such NDA by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA, comparable foreign regulators
and state and local pharmacy regulators impose substantial requirements upon clinical development, manufacture and marketing of
pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control,
safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval
process required by the FDA under the Food, Drug, and Cosmetic Act generally involves:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%">preclinical laboratory and animal tests;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%">submission of an IND, prior to commencing human clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%">adequate and well-controlled human clinical trials to establish safety and efficacy for intended use;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%">submission to the FDA of an NDA or Biologics License Application (BLA); and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%">FDA review and approval of an NDA or BLA.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The testing and approval process requires
substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical tests include laboratory evaluation
of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy.
Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations
can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical
studies are conducted concurrently with clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will submit the preclinical test results,
together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before we
begin human clinical trials. The IND automatically becomes effective 30 days after filing, unless the FDA raises questions about
conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve the
matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials must be supervised by a
qualified investigator in accordance with good clinical practice (GCP) regulations, which include informed consent requirements.
An independent IRB at each medical center reviews and approves and monitors the study, and is periodically informed of the study&rsquo;s
progress, adverse events and changes in research. Progress reports are submitted annually to the FDA and more frequently if adverse
events occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials of drug candidates
typically have three sequential phases that may overlap:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase I:&nbsp;The drug is initially tested
in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase II:&nbsp;The drug is studied in a
limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and
establish dosage tolerance and optimal dosage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase III:&nbsp;When Phase II evaluations
demonstrate that a dosage range is effective with an acceptable safety profile, Phase III&nbsp;trials to further evaluate dosage,
clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that we will successfully
complete Phase I, Phase II, or Phase III testing of our product candidates within any specific time period, if at all. Furthermore,
the FDA, an IRB or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects
or patients are exposed to unacceptable health risk. Concurrent with these trials and studies, we also develop chemistry and physical
characteristics data and finalize a manufacturing process in accordance with good manufacturing practice (GMP) requirements. The
manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality, purity,
and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted
to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are submitted
to the FDA as part of a NDA (or BLA in case of biologic products) for marketing and commercial shipment approval. The FDA reviews
each NDA or BLA submitted and may request additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the FDA accepts the NDA or BLA for
filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation
of the data submitted. The process may be significantly extended by requests for additional information or clarification regarding
information already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee, typically
a panel of clinicians. Manufacturing establishments often are inspected prior to NDA or BLA approval to assure compliance with
GMPs and with manufacturing commitments made in the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Submission of an NDA or BLA with clinical
data requires payment of a fee. In return, the FDA assigns a goal of ten months for issuing its &ldquo;complete response,&rdquo;
in which the FDA may approve or deny the NDA or BLA, or require additional clinical data. Even if these data are submitted, the
FDA may ultimately decide the NDA or BLA does not satisfy approval criteria. If the FDA approves the NDA or BLA, the product becomes
available for physicians prescription. Product approval may be withdrawn if regulatory compliance is not maintained or safety problems
occur. The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval, and requires surveillance
programs to monitor approved products that have been commercialized. The agency has the power to require changes in labeling or
prohibit further marketing based on the results of post-marketing surveillance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Satisfaction of these and other regulatory
requirements typically takes several years, and the actual time required may vary substantially based upon the type, complexity
and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period
of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve
any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success
in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible
to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval,
the approval may be significantly limited to specific indications or uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after regulatory approval is obtained,
later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA&rsquo;s policies may change, and additional government
regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased attention to the
containment of health care costs worldwide could result in new government regulations materially adverse to our business. We cannot
predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative
action, either in the U.S. or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not have a guarantee of patent restoration and marketing
exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Drug Price Competition and Patent
Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions
of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections
to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the
same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies
demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating
that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA,
or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement
of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month
stay of approval of the competitor&rsquo;s application. The discovery, trial and appeals process in such suits can take several
years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period,
the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator
products by submitting significantly less clinical data outside the ANDA context. Such applications, known as &ldquo;505(b)(2)
NDAs&rdquo; or &ldquo;paper NDAs,&rdquo; may rely on clinical investigations not conducted by or for the applicant and for which
the applicant has not obtained a right of reference or use and are subject to the ANDA notification procedures described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law also permits restoration of a portion
of a product&rsquo;s patent term that is lost during clinical development and NDA review, and provides statutory protection, known
as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five years
of patent term for a patent covering a new product or its use to compensate for time lost during product development and regulatory
review. The restoration period is generally one-half the time between the effective date of an IND and submission of an NDA, plus
the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total patent life
beyond 14 years after the drug approval date. Applications for patent term extension are subject to U.S. Patent and Trademark Office
(USPTO) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there can be no guarantee
that it will be given at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hatch-Waxman also provides for differing
periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &ldquo;new
molecular entity&rdquo; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity
for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products
using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy
data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does
not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change.
These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that the net proceeds to us from this offering will
be approximately $118,391 if all of the warrants are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to use the net proceeds from this offering to fund
research and development and for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending use of the net proceeds of this offering, we intend
to invest such net proceeds in short-term, interest-bearing investment grade securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our net tangible book value as of March 31, 2012 was $7.9 million
or $0.24 per share of common stock. Net tangible book value per share represents total tangible assets less total liabilities,
divided by the number of shares of common stock outstanding. After giving effect to our sale in this offering of 94,391 warrants
to purchase common stock at an exercise price of $1.00 per share and 18,182 warrants to purchase common stock at an exercise price
of $1.32, our net tangible book value as of March 31, 2012 would have been $8 million, or $0.24 per share. The following table illustrates this calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-indent: -10pt; padding-left: 10pt">Offering price per share of common stock (weighted average price)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Net tangible book value per share as of March 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Increase per share attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">As adjusted tangible book value per share after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Dilution per share to new investors in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of common stock outstanding used for existing
stockholders in the table and calculations above is based on 32,776,127 outstanding as of March 31, 2012 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">2,414,922 shares of common stock issuable upon the exercise of warrants outstanding at March 31, 2012 with a weighted average exercise price of $2.36 per share;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">3,843,465 shares of common stock issuable upon the exercise of options outstanding at March 31, 2012 with a weighted average exercise price of $1.79 per share; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">1,349,821 shares of common stock reserved for future grants and awards under our equity incentive plans as of March 31, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our capitalization as of March
31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">on an actual basis; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">on a pro forma basis to give effect to:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 5%; vertical-align: top">o</TD>
    <TD STYLE="width: 87%; vertical-align: top">the issuance of 112,573 warrants to purchase common stock and our receipt of $118,391 in cash proceeds from that issuance</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read the information in this table together with
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements
and the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">March&nbsp;31,&nbsp;2012</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Actual</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Pro&nbsp;forma</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,802</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,920</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&rsquo; equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $.001 par value: 100,000,000 shares authorized, 32,970,182 shares issued <BR>
and outstanding, actual;32,888,700 shares issued and outstanding, pro forma</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,946</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,064</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(53,073</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(53,073</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 40pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,906</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,024</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 50pt">Total capitalization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,906</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8,024</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of common stock outstanding used for existing
stockholders is based on 32,776,127 shares outstanding as of March 31, 2012 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">2,414,922 shares of common stock issuable upon the exercise of warrants outstanding at March&nbsp;31, 2012 with a weighted average exercise price of $2.36 per share;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 92%; vertical-align: top">3,843,465 shares of common stock issuable upon the exercise of options outstanding at March 31, 2012 with a weighted average exercise price of $1.79 per share; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>History</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Our initial
synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease, by locally delivering therapeutic
DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill. We also intend to expand
new and existing collaborations in the area of DNA-based therapeutics. In addition, we have several small molecule clinical-stage
programs, the majority of which are being funded, or partially funded, by grants, charitable organizations and corporate partners.
In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting MS, cognitive
dysfunction in MS, fibromyalgia and ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; color: Red"><B><img src="pg22.jpg"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Synthetic Biologics:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial synthetic biologic product
        candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that encodes
        a therapeutic protein called PGIS locally to the pulmonary arteries of PAH patients via a single procedure, and, via an oral daily
        pill, control the long-term local expression of such therapeutic protein. We are developing this initial product candidate pursuant
        a global exclusive channel collaboration that we entered into with the private synthetic biology company Intrexon in November 2011.
        As part of this collaboration, we have access to Intrexon's UltraVector <SUP>&reg;</SUP> platform and RheoSwitch Therapeutic System
        <SUP>&reg;</SUP> for this product application. We anticipate that by continuously producing and delivering prostacyclin directly
        where it is needed, in the pulmonary arteries of PAH patients, this product candidate may overcome the dose limiting side effects
        of systemic prostacyclin treatments for PAH, a mainstay of PAH treatment. According to GlobalData, the global market for PAH treatments
        is estimated to exceed $3.6 billion by 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(UltraVector<SUP>&reg;</SUP> and RheoSwitch
        Therapeutic System<SUP>&reg;</SUP> are registered trademarks of Intrexon Corporation)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Funded / Small Molecule Clinical Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%; text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Patient enrollment of 164 patients is complete in this randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. Patients are being dosed and monitored for two years. This clinical trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial through completion. Current sales of injectable disease-modifying therapies for MS are estimated at $8.9 billion annually.&nbsp;According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta&trade;, if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to $5 billion annually by 2017.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is
        also being developed for the treatment of cognitive dysfunction in female MS patients. In January 2012, patient enrollment began
        in a randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at University of California, Los Angeles
        (UCLA). The majority of the costs of this trial are being funded by grants from foundations and charitable organizations and we
        have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of MS patients
        are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="text-align: justify">Effirma<SUP>TM</SUP> (flupirtine) is being developed for the treatment of fibromyalgia. On May 6, 2010, we entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is in Phase II development. The sublicense agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive certain payments if milestones are achieved and royalties on sales. Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%; text-align: justify">AEN-100 (gastroretentive zinc acetate) is being developed under an investigator-initiated IND application for the treatment of ALS, also known as Lou Gehrig&rsquo;s disease. We intend to sponsor a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients. It is anticipated that the clinical trial will comprise two phases. The first phase of the trial is anticipated to enroll at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months at which time the average change in functional rating between the groups will be compared via an interim analysis conducted on a blinded basis. Should the interim analysis meet the threshold criteria in favor of the treatment group, the second phase of the study will be initiated and will seek to enroll approximately 50 additional subjects to receive treatment for nine months. This study is intended to be conducted by PNA which previously sponsored and completed a successful pilot Phase I/II study of oral zinc therapy for ALS.&nbsp;Separately, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III clinical trial in ALS patients. We have committed to support approximately $400,000 to PNA for the first phase of the Phase II/III clinical trial study, payable based upon study enrollment and milestones. There is only one approved therapy for ALS, the efficacy of which is considered to be marginal. Based on an estimated annual price of $10,000 per ALS patient, we estimate that the total market potential in the U.S. is $300 million.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into a
Channel Agreement with Intrexon that governs an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we intend to
use Intrexon&rsquo;s technology directed towards the production of PGIS, through the use of <I>in vivo</I> conditionally regulated
embedded controllable bioreactors for the treatment of PAH. The Channel Agreement establishes committees comprised of our and Intrexon
representatives that will govern activities related to the PAH program in the areas of project establishment, chemistry, manufacturing
and controls, clinical and regulatory matters, commercialization efforts and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As partial consideration for execution
of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon a number
of shares of our common stock equal to 9.995% of the number of shares of our common stock issued and outstanding following and
giving effect to such issuance (the &ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares,
which issuance was deemed paid in partial consideration for the execution and delivery of the Channel Agreement. We also agreed
to issue additional shares of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored
by us in the U.S., or similar study as the parties may agree in a country other than the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2011, we announced that
the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic biology.
In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement, and
certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC, an entity controlled by the
Lab&rsquo;s former owner, in consideration for (i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable
up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000) payable pursuant to the terms of a two-year
non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2012, upon stockholder
approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues trade
on the NYSE Amex stock exchange, currently under the symbol &ldquo;SYN&rdquo;. Prior to this time and since October 16, 2008, our
name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE Amex stock exchange under the symbol &ldquo;AEN&rdquo;. We are
incorporated in the State of Nevada. We continue to maintain our principal executive offices in Ann Arbor, MI, and are currently
located at 617 Detroit Street, Suite 100<B>,</B> Ann Arbor, MI 48104.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of June 30, 2010, we emerged
from a &ldquo;Development-Stage Entity&rdquo; as defined by Financial Accounting Standards Board Accounting Standards Codification
(FASB ASC) 915-10. On May 6, 2010, we entered into a sublicense agreement with Meda&nbsp;AB of Sweden. This agreement provides
that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. As consideration
for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon
filing of an NDA with the FDA of oral flupirtine for fibromyalgia and $10 million upon marketing approval, plus royalties. We consider
the agreement with Meda AB to be an indication that we have commenced our principal operations and therefore are not required to
report as a development-stage entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have financed our operations
primarily through public and private sales of our common stock, and we expect to continue to seek to obtain the required capital
in a similar manner. We have incurred an accumulated deficit of $53.1 million through March 31, 2012. We cannot provide any assurance
that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required
regulatory approvals, or complete additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Product Candidates and Medical Indications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Synthetic Biologic Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are engaged in the emerging field of
synthetic biology directed for the purpose of developing new human therapeutic products. Synthetic biology in an emerging field
that combines molecular biology and automation to design, optimize and construct new biological systems and functions. These technologies
utilize a combination of automated processes including, DNA sequencing, computer-aided design, DNA synthesis, fabrication of modular
transgenes and high throughput testing to create and optimize biologic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial efforts in this area are being
conducted in collaboration with Intrexon, and are directed towards the design, optimization and development of synthetic DNA-based
therapeutic product candidates utilizing Intrexon&rsquo;s UltraVector<SUP>&reg;</SUP> platform for the treatment of PAH. Synthetic
DNA-based therapeutics comprise constructs of DNA that can be administered to patients via a single procedure. Once introduced,
they are intended to continuously produce therapeutic proteins <I>in vivo</I> in a controllable and localized fashion for up to
a period of years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An important feature of our product candidates
developed in collaboration with Intrexon may be the incorporation of Intrexon&rsquo;s RheoSwitch Therapeutic System<SUP>&reg;</SUP>.
Such system is intended to provide unprecedented control of therapeutic protein expression through the use of a highly specific
orally available activating ligand that can be taken by patients on a daily basis as one or more pills. In this way, the levels
of <I>in vivo</I> protein expression may be adjusted from time to time by treating physicians through simple dose adjustment of
the oral activating ligand. Such system also provides an important safety mechanism not previously available in gene therapy clinical
trials since in the absence of taking an oral pill, protein expression would not be expected to occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pulmonary Arterial Hypertension (PAH)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Synthetic DNA-Based Therapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PAH is a progressive, disabling and life-threatening
disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery, the blood vessel that carries
blood from the heart to the lungs. Hypertension occurs when most of the very small arteries throughout the lungs narrow in diameter,
therefore constricting blood flow through the lungs. The constriction of blood flow causes the pressure to increase in the pulmonary
artery and in the right ventricle (the heart chamber that pumps blood into the pulmonary artery). Signs and symptoms of PAH take
place when the increased pressure cannot overcome the constriction and there is insufficient blood flow to the body. Shortness
of breath during exertion and fainting spells are the most common early symptoms of PAH. Despite current treatments, PAH generally
has a very poor outcome and is associated with high rates of mortality within three to five years of diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Synthetic DNA-Based Therapeutic for
PAH</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial synthetic DNA-based therapeutic
product candidate is intended for the treatment of PAH, a serious life-threatening lung disease. This product candidate is designed
to deliver DNA that encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries of PAH
patients via a single pulmonary catheter procedure and via an oral daily pill, control the long-term local expression of such therapeutic
protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing this initial product
candidate in collaboration with Intrexon. Under the collaboration, we intend to utilize Intrexon's advanced transgene engineering
platform for the controlled, precise and continuous <I>in vivo</I> cellular production of PGIS. PGIS is a specific effector enzyme
that regulates the production of prostacyclin, a potent mediator of arterial dilation that also prevents smooth muscle proliferation
and arterial wall thickening. PGIS expression is decreased in the lungs of PAH patients and deficiency in prostacyclin production
is strongly implicated in PAH. We anticipate that by continuously producing and delivering prostacyclin directly where it is needed,
in the pulmonary arteries of PAH patients via PGIS, this product candidate may overcome the dose limiting side effects of systemic
prostacyclin-based treatments for PAH. While systemic prostacyclin-based treatments for PAH are currently a mainstay of PAH therapy,
their considerable systemic side effects limit their dose and ultimate long-term utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global market potential for the treatment
of PAH is estimated to be up to $3.6 billion by 2015, according to GlobalData, Pulmonary Arterial Hypertension (PAH) &ndash; Drug
Pipeline Analysis and Market Forecasts for 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Relapsing-Remitting Multiple Sclerosis
(MS) in Women</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trimesta (oral estriol)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MS is a progressive neurological disease
in which the body loses the ability to transmit messages along central nervous system nerve cells, leading to a loss of muscle
control, paralysis, cognitive impairment and in some cases death. According to the National Multiple Sclerosis Society (NMSS),
currently, more than 2.5 million people worldwide (approximately 400,000 patients in the U.S. of which 70% are estimated to be
women) have been diagnosed with MS. Young adults, ages 20 to 50, and two to three times as many women than men are predominantly
diagnosed with MS. According to the NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting
form, compared to 10-15% with other progressive forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently&nbsp;eight Food &amp;
Drug Administration (FDA) approved therapies for the treatment of relapsing-remitting MS: Betaseron<SUP>&reg;</SUP> , Rebif<SUP>&reg;</SUP>
, Avonex<SUP>&reg;</SUP> , Novantrone<SUP>&reg;</SUP> , Copaxone<SUP>&reg;</SUP> , Tysabri<SUP>&reg;</SUP> , Gilenya<SUP>&reg;</SUP>
and Extavia<SUP>&reg;</SUP>. These therapies provide only a modest benefit for patients with relapsing-remitting MS and therefore
serve to only delay progression of the disease. All of these drugs except Gilenya <SUP>&reg;</SUP> require frequent (daily, weekly
&amp; monthly) injections (or infusions) on an ongoing basis and can be associated with unpleasant side effects (such as flu-like
symptoms), high rates of non-compliance among users, and eventual loss of efficacy due to the appearance of resistance in approximately
30% of patients. Despite the availability of multiple FDA-approved therapies for the treatment of relapsing-remitting MS, the disease
is highly underserved and exacts a heavy economic toll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current sales of injectable disease-modifying
therapies for MS are estimated at $8.9 billion annually.&nbsp; According to various reports, sales of oral disease-modifying therapies
for MS, of which Trimesta, if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to in
excess of $5 billion annually by 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It has been scientifically documented that
pregnant women with certain autoimmune diseases experience a spontaneous reduction of disease symptoms during pregnancy, particularly
in the third trimester. The PRIMS (Pregnancy In MS) study, a landmark clinical study published in the <I>New England Journal of
Medicine</I> followed 254 women with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated
that relapse rates were significantly reduced by 71 percent (p &lt; 0.001) through the third trimester of pregnancy compared to
pre-pregnancy-rates, and that relapse rates increased by 120 percent (p &lt; 0.001) during the first three months after birth (post-partum)
before returning to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol, produced by the placenta during
pregnancy, plays a role in&nbsp;&ldquo;fetal immune privilege&rdquo;, a process that prevents&nbsp;a mother&rsquo;s immune system
from attacking and rejecting&nbsp;her fetus.&nbsp;Maternal levels of estriol increase in a linear fashion through the third trimester
of pregnancy until birth, whereupon they abruptly return to low circulating levels. The anti-autoimmune effects of estriol are
thought to be responsible for the therapeutic effects of pregnancy on MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rhonda Voskuhl, M.D., Director, UCLA MS
program, UCLA Department of Neurology, has found that pregnancy levels of estriol have potent immunomodulatory effects. She further
postulated and tested in pilot clinical studies that oral doses of estriol may have a therapeutic benefit when administered to
non-pregnant female MS patients by, in essence, mimicking the spontaneous reduction&nbsp;in relapse rates seen in MS patients during
pregnancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estriol has been approved and marketed
for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by
the U.S. FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Trimesta (oral estriol) drug candidate
is for the treatment of relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover
clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting
MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured by brain magnetic
resonance imaging (an established neuroimaging measurement of disease activity in MS). Over the next three months of treatment
with Trimesta, the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82%
(p = 0.09). They remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and
numbers decreased by 82% (p =0.02). Following a six-month drug holiday during which the patients were not on any drug therapies,
median lesion volumes and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month
retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion
volumes of 88% (p = 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase II randomized, double-blind, placebo-controlled
clinical trial is currently underway at 15 centers in the U.S. The purpose of this clinical trial is to study whether 8 mg of oral
Trimesta taken daily over a two year period will reduce the rate of relapses in a large population of female patients with relapsing-remitting
MS. Investigators are administering either Trimesta or matching placebo, in addition to a standard of care, glatiramer acetate
(Copaxone<SUP>&reg;</SUP>) injections, an FDA-approved therapy for MS, to women between the ages of 18 to 50 who have been recently
diagnosed with relapsing-remitting MS. The primary endpoint in this clinical trial being run under an investigator-initiated IND
application,is relapse rates at two years. As of January 23, 2012, 164 patients have been enrolled in the clinical trial and the
trial enrollment has been closed. The patients will be dosed and monitored for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With over $8 million in grant funding to
date, the ongoing Trimesta clinical trial should be funded to its completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cognitive Dysfunction in Multiple Sclerosis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trimesta (oral estriol)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the NMSS and the Multiple
Sclerosis Society of Canada publication, <I>Hold that Thought! Cognition and MS</I> , it is fairly common for people with MS to
complain of problems remembering things, finding the right words, concentrating on a task or something they are reading, or following
a conversation. These are all cognitive symptoms of MS. Of those affected by MS, 50-65% have cognitive dysfunction issues. Despite
the fact that most symptoms are mild to moderate, they can have a significant impact on a person&rsquo;s ability to normally function.
The overall cognitive dysfunction can be described as a reduction in mental &ldquo;sharpness.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The major areas of cognition that can be
dysfunctional include what are termed complex attention and executive functions<I>.</I> Complex attention involves multitasking,
the speed with which information can be processed, learning and memory, and perceptual skills; executive functions include problem
solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related
physical problems can widely vary, not all people with MS will display these cognitive issues, and no two people will experience
exactly the same types or severity of problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the investigator-initiated, 10-patient,
22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement from
baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores (p = 0.04) was observed in relapsing-remitting
MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of
neuropsychological disorders such as MS. The PASAT scores are expressed as a mean percent change from baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Trimesta (oral estriol) drug candidate
is also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled
Phase II clinical trial to evaluate Trimesta&rsquo;s potential neuroprotective and therapeutic effect on cognitive dysfunction
in female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at UCLA. Up to 64
patients between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Dr. Voskuhl will administer
either oral Trimesta or a matching placebo, in addition to any FDA-approved MS treatment. Each patient will be dosed and monitored
for one year after being enrolled. The primary endpoint in this clinical trial being run under an investigator-initiated IND application
is expected to be improvement in PASAT cognitive testing scores versus matching placebo. We and a private foundation have pledged
to equally support this new clinical trial, and we will also provide Trimesta drug supply. The trial also received contributions
from several other supporters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fibromyalgia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Effirma (flupirtine)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fibromyalgia is a chronic and debilitating
condition characterized by widespread pain and stiffness throughout the body, often accompanied by severe fatigue, insomnia and
mood symptoms. Fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million people in
the U.S. There are presently three FDA products approved for this indication in the U.S. &ndash; Lyrica<SUP>&reg;</SUP>, Cymbalta<SUP>&reg;</SUP>
and Savella<SUP>&reg;</SUP>. Flupirtine is differentiated from these products in that it employs a unique mode of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an estimated annual price of $1,200 per fibromyalgia
patient, we estimate that the total market potential in the U.S. is $6 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Effirma (flupirtine) product candidate
is for the treatment of fibromyalgia. Effirma is a selective neuronal potassium channel opener that also has NMDA receptor antagonist
properties. Effirma is a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that
Effirma should also be effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable
from most marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits
no known abuse potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed.
One common link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major
receptor subtype for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic
acid-mediated neurotransmission. Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda AB) and has
been approved and is marketed by Meda AB in Europe since 1984, as well as other countries, for the treatment of pain. It has never
been approved by the FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Meda Corporate Partnership</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda AB, a multi-billion dollar international pharmaceutical company, pursuant to which Meda AB assumed all future
development costs and may commercialize flupirtine for fibromyalgia in the U.S. As consideration for such sublicense, we received
an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon the FDA&rsquo;s acceptance of the
New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million upon FDA approval of such NDA. Pursuant to the sublicense
agreement, we will also receive a 7% royalty on net sales of flupirtine for fibromyalgia in the U.S., Canada and Japan, with such
royalties being shared equally with our licensor, McLean Hospital, a Harvard teaching hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Flupirtine is approved and marketed by
Meda AB and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to millions
of patients worldwide. We believe that such substantial human experience with flupirtine should greatly assist the FDA in its evaluation
of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia. According to Meda&rsquo;s 2011 Annual Report,
flupirtine for fibromyalgia is in Phase II development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amyotrophic Lateral Sclerosis (ALS)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AEN-100 (gastroretentive zinc acetate)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALS, also known as Lou Gehrig&rsquo;s disease,
is a devastating progressive neurodegenerative disease that affects the motor nerve cells in the brain and the spinal cords. It
is estimated that as many as 30,000 Americans may have the disease at any given time. The progressive degeneration of the motor
neurons in ALS eventually leads to the death of the patient. Motor neurons reach from the brain to the spinal cord and from the
spinal cord to the muscles throughout the body. When motor neurons die, the ability of the brain to initiate and control muscle
movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally
paralyzed. While non-invasive ventilation and gastrostomy tubes prolong life by 6-12 months, the average lifespan from time of
symptom onset is 2-5 years. Currently, RILUTEK <SUP>&reg;</SUP> is the only FDA-approved drug for ALS. RILUTEK is an N-methyl d-aspartate
(NMDA) receptor antagonist and has been shown to prolong life in patients with ALS by 3 months. Presently, there is no cure for
ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an estimated annual price of $10,000 per ALS patient,
we estimate that the total market potential in the U.S. is $300 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical investigators at the PNA cite
multiple lines of scientific research that suggest a potential benefit of zinc therapy for ALS patients, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%; text-align: justify">The use of zinc therapy for ALS patients is supported in animal models of ALS. Approximately 2% of ALS diagnoses are associated with a mutation in the copper/zinc superoxide dismutase (SOD1) gene. In ALS mutant SOD1 animal models, zinc supplementation has been shown to delay death.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%; text-align: justify">Genetic mutations affecting the ability of a protein known as copper/zinc SOD1 to properly bind zinc are associated with the familial form of ALS, which shares many of the same features as the more prevalent sporadic form of ALS.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%; text-align: justify">Zinc is an important modifier of glutamate toxicity, a neurotransmitter linked to cell death in ALS patients.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparations are underway to evaluate the
safety and efficacy of our proprietary drug candidate, AEN-100, a gastroretentive, sustained-release zinc-based tablet, in a multi-center,
double-blind, placebo-controlled clinical trial in ALS patients intended to be conducted under an investigator-initiated IND application.
Manufacturing of AEN-100 study material has been completed and stability studies are ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to provide the study material
and support a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients to
be conducted by PNA. It is anticipated that the Phase II/III clinical trial will comprise two phases. The first phase of the trial
is anticipated to enroll at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months at which
time the average change in functional rating between the groups will be compared via an interim analysis conducted on a blinded
basis. Should the interim analysis meet the threshold criteria in favor of the treatment group the second phase of the study will
be initiated and seek to enroll up to a total of 114 patients, inclusive of the 65 subjects from the first phase who continue to
meet eligibility criteria at such time, to receive treatment for nine months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2011, PNA reported top-line
results from its pilot Phase I/II open label, three month safety study of oral high dose zinc therapy in ALS. The clinical study
met its primary outcome as no safety issues related to zinc therapy were observed. In addition, an average decrease in the monthly
rate of disease progression was observed in the ALS patients on zinc therapy, compared to published historical controls, as well
as compared to the average monthly rate of disease progression of the subjects prior to enrollment in the study. AEN-100 is not
the same zinc formulation utilized by PNA in its previously completed Phase I/II safety study of zinc for ALS, and PNA intends
to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III clinical trial in ALS patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have committed to support approximately
$400,000 to PNA for the first phase of the Phase II/III clinical trial, payable based upon study enrollment and completion milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to (a) obtain, maintain, and
enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, (b) preserve
our trade secrets, and (c) operate without infringing on the proprietary rights of other parties, worldwide. We seek, where appropriate,
the broadest intellectual property protection for product candidates, proprietary information, and proprietary technology through
a combination of contractual arrangements and patents. Below is a description of our license and development agreements relating
to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>McLean Hospital Exclusive License Agreement and Meda AB Sublicense
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2005, as amended in 2007 and 2010, we
entered into an exclusive license agreement with the McLean Hospital, a Harvard University teaching hospital, relating to U.S.
Patent No. 6,610,324 and its foreign equivalents, entitled &ldquo;Flupirtine in the treatment of fibromyalgia and related conditions.&rdquo;
Pursuant to this agreement, we paid an upfront fee and back patent costs of approximately $62,000 and agreed to pay McLean royalties
on net sales of oral flupirtine equal to 3.5% of net sales of oral flupirtine for indications covered by the issued patents, reduced
to 1.75% if we have a license to other intellectual property covering those indications. In addition, we agreed to use our best
efforts to commercialize oral flupirtine for the therapeutic uses embodied in the patent applications. Furthermore, we agreed to
reimburse McLean Hospital all future patent costs and pay the following milestone payments: $150,000 upon the initiation of a pivotal
Phase III clinical trial of oral flupirtine; $300,000 upon the filing of an NDA for oral flupirtine; and $600,000 upon FDA approval
of oral flupirtine. The due diligence requirements of the exclusive license agreement were amended in April of 2010 and further
amended by a Non-Disturbance Agreement that was signed with McLean Hospital, Meda and us.&nbsp;The agreement remains in effect
until the later of (i) the date all issued patents and filed patent applications within the Patent Rights (as defined in the agreement)
expire or are abandoned and (ii) one year after the last Commercial Sale (as defined in the agreement) for which royalty is due
or ten years after expiration or abandonment date set forth in clause (i) above, whichever is earlier.&nbsp;We have the right to
terminate the agreement at any time upon 90 days notice. In addition, McLean may terminate the agreement (i) upon 10 days notice
for nonpayment unless payment is made within such 10 days, (ii) immediately upon written notice if we fail to maintain required
insurance or become insolvent, make an assignment for the benefit of creditors or petition for bankruptcy is filed for or against
us or (ii) if we, our affiliates or our sublicensees default in performance of their obligations under the agreement and such default
is not cured within 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective May 6, 2010, we entered into
a Sublicense Agreement with Meda AB of Sweden. Pursuant to this agreement, Meda has been granted an exclusive sublicense to all
of our patents covering the use of oral flupirtine for fibromyalgia. These patents have been issued in the U.S. and are pending
in Canada and Japan (the &ldquo;Territory&rdquo;). This agreement provides that Meda will assume all future development costs for
the commercialization of oral flupirtine for fibromyalgia. As consideration for this sublicense, we received an up-front payment
of $2.5 million upon execution of this agreement and are entitled to milestone payments of $5 million upon&nbsp;filing of an NDA
with the FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. This agreement also provides that we
are entitled to receive royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued
patent claims in the Territory. Pursuant to the terms of this agreement with our university licensor, we are obligated to share
half of the royalties we receive with the university licensor, McLean Hospital, and we were obligated to pay them $375,000 upon
receipt of an upfront payment, which we did pay in May 2010 when we received the payment from Meda. The agreement continues in
effect country by country until the earlier of the expiration of the Royalty Period (as defined in the agreement) or the termination
of the McLean license.&nbsp;Meda has the right to terminate the agreement at any time upon 90 days notice. In addition, a party
may terminate the agreement upon 30 days notice if the other party breached material obligations and such breach is not cured within
a period of time set forth in the agreement. The parties also have the right to terminate the agreement upon 60 days notice in
the event of the filing by a party of a bankruptcy petition, the filing of an involuntary petition not dismissed within 60 days,
a party proposes a written agreement of composition or extension of its debt, a party becomes Insolvent (as defined in the agreement),
liquidates, dissolves, ceases to conduct business or makes an assignment for the benefit of creditors.&nbsp;Upon a termination,
all licenses revert to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Regents of University of California License Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2005, we were granted an exclusive
worldwide license agreement with the Regents of the University of California (Regents) relating to issued U.S. Patent No. 6,936,599
and pending patent applications covering the uses of the drug candidate Trimesta (oral esteriol). Pursuant to this agreement, we
paid an upfront license fee and reimbursed patent expenses totaling approximately $61,000 and agreed to pay a license fee of $25,000
during 2006.&nbsp;We also agreed to pay annual maintenance fees, milestone payments totaling $750,000 that are payable on filing
an NDA, and on approval of an NDA with the FDA, as well as royalties on net sales of Trimesta covered by the licensed patents.
We may be permitted to partially pay milestone payments in the form of equity.&nbsp;The duration of this agreement is from the
effective date of July 11, 2005 until the last-to-expire patent in Regent&rsquo;s Patent Rights, or until the last patent application
licensed under this agreement is abandoned and no patent in Regent&rsquo;s Patent Rights ever issues.&nbsp;We have the right to
terminate this agreement at any time and termination will be effective 90 days after the effective date of the termination notice.&nbsp;The
Regents may terminate the agreement with a written notice of default if we violate or fail to perform any material term or covenant
of this agreement.&nbsp;However, we have 60 days after the effective date of the notice of default to repair the default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The Intrexon Collaboration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into a
Channel Agreement with Intrexon (the &ldquo;Channel Agreement&rdquo;) that governs an &ldquo;exclusive channel collaboration&rdquo;
arrangement in which we intend to use Intrexon&rsquo;s technology directed towards the production of PGIS, through the use of <I>in
vivo</I> conditionally regulated embedded controllable bioreactors for the treatment of PAH. The Channel Agreement establishes
committees comprised of our and Intrexon representatives that will govern activities related to the PAH program in the areas of
project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Channel Agreement grants us a worldwide
license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use,
importing, manufacture, sale, and offer for sale of products involving the production of PGIS through the use of an <I>in vivo</I>
conditionally regulated embedded controllable bioreactor for the treatment of PAH in humans. Such license is exclusive with respect
to any clinical development, selling, offering for sale or other commercialization of Products, and otherwise is non-exclusive.
We may not sublicense the rights described without Intrexon&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Channel Agreement, and subject
to certain exceptions, we are responsible for, among other things, the performance of the PAH program including the development,
commercialization and certain aspects of manufacturing products. Among other things, Intrexon is responsible for the costs of establishing
manufacturing capabilities and facilities for the bulk manufacture of products developed under the PAH program, certain other aspects
of manufacturing, costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and
maintenance of Intrexon&rsquo;s patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain expense allocations
and other offsets provided in the Channel Agreement, we will pay Intrexon 50% of the cumulative net quarterly profits derived from
the sale of products, calculated on a product-by-product basis. We have likewise agreed to pay Intrexon 50% of quarterly revenue
obtained from a sublicensor in the event of a sublicensing arrangement. During the first 18 months, neither we nor Intrexon may
terminate the Channel Agreement, except under limited circumstances. Following the first 18 months, we may voluntarily terminate
the Channel Agreement upon 90 days written notice to Intrexon. Following the first 18 months, Intrexon may also terminate the Channel
Agreement if we elect not to pursue the development of a PAH program identified by Intrexon that is a &ldquo;Superior Therapy&rdquo;
as defined in the Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon termination of the Channel Agreement,
we may continue to develop and commercialize any Product that, at the time of termination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&bull;</TD>
    <TD STYLE="width: 91%; text-align: justify">is being commercialized by us,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">has received regulatory approval,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">is a subject of an application for regulatory approval that is pending before the applicable regulatory authority,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">is the subject of at least an ongoing Phase II clinical trial (in the case of a termination by Intrexon due to our uncured breach or a voluntary termination by us), or an ongoing Phase I clinical trial in the Field (as defined in the Channel Agreement) (in the case of a termination by us due to an Intrexon uncured breach or a termination by Intrexon following an unconsented assignment by us or our election not to pursue development of a Superior Therapy), or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">we have spent at least $4.5 million developing.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will be obligated to pay 50% of net
profits or revenue with respect to these &ldquo;retained&rdquo; products, which will survive termination of the Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As partial consideration for execution
of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon a number
of shares of our common stock equal to 9.995% of the number of shares of our common stock issued and outstanding following and
giving effect to such issuance (the &ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares,
which issuance was deemed paid in partial consideration for the execution and delivery of the Channel Agreement. We also agreed
to issue additional shares of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored
by us in the U.S., or similar study as the parties may agree in a country other than the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Stock Purchase Agreement, Intrexon
is entitled, at its election, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) participate in our future securities
offerings that constitute &ldquo;Qualified Financings&rdquo; and purchase securities equal to 19.99% of the number of shares of
common stock or other securities sold in such offering. For this purpose, a &ldquo;Qualified Financing&rdquo; means a sale of our
common stock or equity securities convertible into our common stock in a public or private offering, raising gross proceeds of
at least $5 million, where the sale of shares is either registered under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), at the time of issuance or we agree to register the resale of such shares, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) without restriction, purchase an additional
number of shares of our common stock in the open market, or otherwise, that do not exceed an additional 10% of the number of shares
of common stock then issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Stock Purchase Agreement contains a
standstill provision pursuant to which, among other things, Intrexon has agreed that, for a period of three years, subject to certain
exceptions and unless invited in writing by us to do so, neither Intrexon nor its affiliates will, directly or indirectly: (i)
effect or seek, initiate, offer or propose to effect, or cause or participate in any acquisition of our securities or assets; any
tender or exchange offer, merger, consolidation or other business combination involving us; any recapitalization, restructuring,
liquidation, dissolution or other extraordinary transaction with respect to us; or any &ldquo;solicitation&rdquo; of &ldquo;proxies&rdquo;
or consents to vote any of our voting securities, or in any way advise or, assist any other person in doing so; (ii) form, join
or in any way participate in a &ldquo;group&rdquo; with respect to any of our securities; (iii) otherwise act to seek to control
or influence the management, Board of Directors or our policies; (iv) take any action reasonably expected to force us to make a
public announcement regarding any such matters; or (v) enter into any agreements, discussions or arrangements with any third party
with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>AEN-100 &ndash; Gastroretentive Zinc Acetate</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to file for orphan drug designation
in the U.S. and Europe for AEN-100 (gastroretentive, sustained-release zinc-based tablets) for the treatment of ALS. ALS qualifies
as an &ldquo;orphan disease&rdquo; in that it affects less than 200,000 people in the U.S. Orphan drug designation provides for
seven years of market exclusivity following approval in the U.S. and ten years of market exclusivity following approval in Europe.
AEN-100, is also the subject of U.S. and international patent pending applications that may provide exclusivity beyond the expiration
of orphan drug exclusivity, such as published U.S. patent application Ser. No. 11/621,962 and corresponding international applications
that claim priority to January 10, 2006, and additional patent applications. On October 26, 2011, we received a final rejection
letter with regard to U.S. patent application Ser. No. 11/621,962. On February 15, 2012, we filed a Request for Continued Examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We utilize contract manufacturing firms
to produce our investigational products AEN-100 and Trimesta in accordance with &ldquo;current good manufacturing processes&rdquo;
(cGMP) guidelines outlined by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2011
and 2010, we spent $3.3 million and $1.6 million, respectively, on research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Environment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical
companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these
companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources
significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships
and other types of joint ventures with larger, well established industry competitors that afford these companies potential research
and development and commercialization advantages in the therapeutic areas we are currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the general area of commercial products
for the treatment of serious diseases, we potentially compete with a variety of companies, most of whom are pharmaceutical or biotechnology
companies. These include: Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly &amp; Co., Genzyme, GlaxoSmithKline
Pharmaceuticals, Merck &amp; Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc. was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we reincorporated in the State of Nevada. After reprioritizing our focus on the emerging
area of synthetic biologics and entering into a collaboration with Intrexon, on February 15, 2012, we amended our Articles of Incorporation
to change our name to Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2012, we employed approximately
nine individuals, seven of whom are full-time employees. A significant number of our management and professional employees have
had prior experience with pharmaceutical, biotechnology or medical product companies. None of our employees are covered by collective
bargaining agreements, and management considers relations with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 617 Detroit Street, Suite 100, Ann Arbor, Michigan 48104 and we also maintain executive offices in Rockville, Maryland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information about Synthetic
Biologics is contained at our website, <U>www.syntheticbiologics.com</U>. Information on our website is not incorporated by reference
into this report. We make available on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance
documents are also posted on our website: Code of Conduct, Code of Ethics for Financial Management and the Charters for the Audit
Committee, Compensation Committee and Nominations Committee of the Board of Directors. Our phone number is (734) 332-7800 and our
facsimile number is (734) 332-7878.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MARKET PRICE OF COMMON STOCK AND OTHER
STOCKHOLDER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has traded on the
NYSE Amex under the symbol &ldquo;SYN&rdquo; since February 16, 2012. Prior to this time, our common stock traded under the
symbol &ldquo;AEN&rdquo; since October 16, 2008. The following table states the range of the high and low sales prices of our
common stock for each of the calendar quarters during the years ended December 31, 2011 and December 31, 2010. These
quotations represent inter-dealer prices, without retail mark-up, markdown, or commission, and may not represent actual
transactions. The last price of our common stock as reported on the NYSE Amex on July 11, 2012 was $2.01 per share. As of
June 30, 2012, there were approximately 349 stockholders of record of our common stock. This number does not include
beneficial owners from whom shares are held by nominees in street name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>YEAR ENDED DECEMBER 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Second quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.51</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>YEAR ENDED DECEMBER 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>YEAR ENDED DECEMBER 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid any cash dividends on
our common stock to date, and do not anticipate paying such cash dividends in the foreseeable future. Whether we declare and pay
dividends is determined by our Board of Directors at their discretion, subject to certain limitations imposed under Nevada corporate
law. The timing, amount and form of dividends, if any, will depend on, among other things, our results of operations, financial
condition, cash requirements and other factors deemed relevant by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Item 11 &ndash; Executive compensation for equity compensation
plan information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will deliver the shares of
common stock being issued to the purchasers electronically upon receipt of purchaser funds for the exercise of the warrants,
if any, offered pursuant to this prospectus. We have agreed to indemnify the holders  of the securities offered in this
offering against some civil liabilities, including liabilities under the Securities Act and the Exchange Act. Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling
persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in
the Securities Act and is therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion of our financial
condition and results of operations should be read in conjunction with the audited financial statements and notes thereto for the
year ended December 31, 2011 found in this report. In addition to historical information, the following discussion contains forward-looking
statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements
by using words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intends,&rdquo; or similar expressions. Our actual
results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including,
but not limited to, those set forth under &ldquo;Risk Factors&rdquo; in Part I, Item 1A of this Report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Our initial
synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease, by locally delivering therapeutic
DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill. We also intend to expand
new and existing collaborations in the area of DNA-based therapeutics. In addition, we have several small molecule clinical-stage
programs, the majority of which are being funded, or partially funded, by grants, charitable organizations and corporate partners.
In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting MS, cognitive
dysfunction in MS, fibromyalgia and ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Synthetic Biologics:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 82%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial synthetic biologic product
        candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that encodes
        a therapeutic protein called PGIS locally to the pulmonary arteries of PAH patients via a single procedure, and, via an oral daily
        pill, control the long-term local expression of such therapeutic protein. We are developing this initial product candidate pursuant
        a global exclusive channel collaboration that we entered into with the private synthetic biology company Intrexon in November 2011.
        As part of this collaboration, we have access to Intrexon's UltraVector<SUP>&reg;</SUP> platform and RheoSwitch Therapeutic System<SUP>&reg;</SUP>
        for this product application. We anticipate that by continuously producing and delivering prostacyclin directly where it is needed,
        in the pulmonary arteries of PAH patients, this product candidate may overcome the dose limiting side effects of systemic prostacyclin
        treatments for PAH, a mainstay of PAH treatment. According to GlobalData, the global market for PAH treatments is estimated to
        exceed $3.6 billion by 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(UltraVector<SUP>&reg;</SUP> and RheoSwitch
        Therapeutic System<SUP>&reg;</SUP> are registered trademarks of Intrexon Corporation)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Funded / Small Molecule Clinical Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%; text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Patient enrollment of 164 patients is complete in this randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. Patients are being dosed and monitored for two years. This clinical trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial through completion. Current sales of injectable disease-modifying therapies for MS are estimated at $8.9 billion annually.&nbsp;According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta&trade;, if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to $5 billion annually by 2017.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trimesta <SUP>TM</SUP> (oral estriol) is
        also being developed for the treatment of cognitive dysfunction in female MS patients. In January 2012, patient enrollment began
        in a randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at University of California, Los Angeles
        (UCLA). The majority of the costs of this trial are being funded by grants from foundations and charitable organizations and we
        have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of MS patients
        are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%; text-align: justify">Effirma <SUP>TM</SUP> (flupirtine) is being developed for the treatment of fibromyalgia. On May 6, 2010, we entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is in Phase II development. The sublicense agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive certain payments if milestones are achieved and royalties on sales. Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-left: 0.5in; text-indent: -34.55pt">&#9679;</TD>
    <TD STYLE="width: 83%; text-align: justify">AEN-100 (gastroretentive zinc acetate) is being developed under an investigator-initiated IND application for the treatment of ALS, also known as Lou Gehrig&rsquo;s disease. We intend to sponsor a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients. It is anticipated that the clinical trial will comprise two phases. The first phase of the trial is anticipated to enroll at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months at which time the average change in functional rating between the groups will be compared via an interim analysis conducted on a blinded basis. Should the interim analysis meet the threshold criteria in favor of the treatment group, the second phase of the study will be initiated and will seek to enroll approximately 50 additional subjects to receive treatment for nine months. This study is intended to be conducted by PNA which previously sponsored and completed a successful pilot Phase I/II study of oral zinc therapy for ALS.&nbsp;Separately, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III clinical trial in ALS patients. We have committed to support approximately $400,000 to PNA for the first phase of the Phase II/III clinical trial study, payable based upon study enrollment and milestones. There is only one approved therapy for ALS, the efficacy of which is considered to be marginal. Based on an estimated annual price of $10,000 per ALS patient, we estimate that the total market potential in the U.S. is $300 million.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into a
Channel Agreement with Intrexon that governs an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we intend to
use Intrexon&rsquo;s technology directed towards the production of PGIS, through the use of <I>in vivo</I> conditionally regulated
embedded controllable bioreactors for the treatment of PAH. The Channel Agreement establishes committees comprised of our and Intrexon
representatives that will govern activities related to the PAH program in the areas of project establishment, chemistry, manufacturing
and controls, clinical and regulatory matters, commercialization efforts and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As partial consideration for execution
of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon a number
of shares of our common stock equal to 9.995% of the number of shares of our common stock issued and outstanding following and
giving effect to such issuance (the &ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares,
which issuance was deemed paid in partial consideration for the execution and delivery of the Channel Agreement. We also agreed
to issue additional shares of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored
by us in the U.S., or similar study as the parties may agree in a country other than the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2011, we announced that
the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic biology.
In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement, and
certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC, an entity controlled by the
Lab&rsquo;s former owner, in consideration for (i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable
up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000) payable pursuant to the terms of a two-year
non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2012, upon stockholder
approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues trade
on the NYSE Amex stock exchange, currently under the symbol &ldquo;SYN&rdquo;. Prior to this time and since October 16, 2008, our
name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE Amex stock exchange under the symbol &ldquo;AEN&rdquo;. We are
incorporated in the State of Nevada. We continue to maintain our principal executive offices in Ann Arbor, MI, and are currently
located at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of June 30, 2010, we emerged
from a &ldquo;Development-Stage Entity&rdquo; as defined by Financial Accounting Standards Board Accounting Standards Codification
(FASB ASC) 915-10. On May 6, 2010, we entered into a sublicense agreement with Meda&nbsp;AB of Sweden. This agreement provides
that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. As consideration
for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon
filing of an NDA with the FDA of oral flupirtine for fibromyalgia and $10 million upon marketing approval, plus royalties. We consider
the agreement with Meda AB to be an indication that we have commenced our principal operations and therefore are not required to
report as a development-stage entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have financed our operations
primarily through public and private sales of our common stock, and we expect to continue to seek to obtain the required capital
in a similar manner. We have incurred an accumulated deficit of $53.1 million through March 31, 2012. We cannot provide any assurance
that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required
regulatory approvals, or complete additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December of 2001, the SEC requested
that all registrants discuss their most &ldquo;critical accounting policies&rdquo; in management&rsquo;s discussion and analysis
of financial condition and results of operations. The SEC indicated that a &ldquo;critical accounting policy&rdquo; is one which
is both important to the portrayal of the company&rsquo;s financial condition and results and requires management&rsquo;s most
difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are
inherently uncertain. We believe that the following discussion regarding research and development expenses, general and administrative
expenses and non-cash compensation expense involve our most critical accounting policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accounts Receivable and Allowance for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at realizable
value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded.
We estimated and reviewed the collectability of our receivables based on a number of factors, including the period they were outstanding.
Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for
doubtful accounts associated with Adeona Clinical Laboratory. In addition, we regularly assessed the state of our billing operations
in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances
for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged
against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance
for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We record revenue when all of the following
have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the
sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&nbsp;&nbsp; We recognize milestone
payments or upfront payments that have no contingencies as revenue when payment is received.&nbsp;&nbsp;For the three months ended
March 31, 2012 and 2011, our only stream of revenue was laboratory revenue.&nbsp;Laboratory revenues are a component of discontinued
operations for the three months ended March 31, 2012 and 2011. <I>See Note 4 to the Notes to the Consolidated Financial Statements
&ndash; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our licensing agreements may contain multiple
elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees
associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or
regulatory event specified in the agreement. When we have substantive continuing performance obligations under an arrangement,
revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under
the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on the elapsed time
compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent
payments received or due. When we have no substantive continuing performance obligations under an arrangement, it recognizes revenue
as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, we have not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We primarily recognized revenue for services
rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and
Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such
payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintained a sales allowance to compensate
for the difference in our billing practices and insurance company reimbursements. In determining this allowance, we looked at several
factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance
carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged
yearly average adjustment amount for these prior periods and multiplied by the period&rsquo;s actual gross sales to determine the
actual sales allowance for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense research and development costs
as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation
and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses
resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-Based Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of share-based payments,
including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value
on the awards&rsquo; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation
awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair
value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are recorded
in cost of goods sold, research and development or general and administrative expenses in the consolidated statement of operations,
depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Three Months Ended March 31, 2012
and 2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
to $1.5 million for the three months ended March 31, 2012, from $1.2&nbsp;million for the three months ended March 31, 2011. This
increase of approximately 19% is primarily the result of the increased salary expense and consulting fees. The non-cash charge
relating to stock-based compensation expense was $499,000 for the three months ended March 31, 2012, compared to $759,000 for the
three months ended March 31, 2011. The stock-based compensation expense for the three months ended March 31, 2011 includes a one-time
charge of $398,000 relating to the modification of certain stock options, prior to expiration,&nbsp;held by a member of the Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $386,000 for the three months ended March 31, 2012, from $231,000 for the three months ended March 31, 2011. This increase of
approximately 67% is primarily the result of the expansion of our pipeline, including the initiation of preclinical and clinical
programs. Research and development expenses also include a non-cash charge relating to stock-based compensation expense of $9,000
for the three months ended March 31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Income (Expense), net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $5,000 for the three months
ended March 31, 2012. Other expense was $759,000 for the three months ended March 31, 2011.&nbsp;Other expense for the three months
ended March 31, 2011, included $810,000 relating to the estimated fair value of the warrants associated with the January 2011 financing,
adjusted for the change in their fair value at March 31, 2011. Other&nbsp;income for the three months ended March 31, 2011&nbsp;included
$63,000 relating to the settlement of accounts payable previously&nbsp;accrued in prior periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Loss from Continuing Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss from continuing operations
was $1.8 million, or $0.06 per common share for the three months ended March 31, 2012, compared to a net loss of $2.2 million,
or $0.09 per common share for the three months ended March 31, 2011.&nbsp;&nbsp;The decrease in net loss from continuing operations
resulted from no warrant liability offset by increases in general and administrative expenses and research and development expenses
for the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Income from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net income from discontinued operations
was $649,000, or $0.02 per common share for the three months ended March 31, 2012, compared to net income of $37,000, or $0.00
per common share for the three months ended March 31, 2011.&nbsp;&nbsp;On March 8, 2012, we entered into a Membership Interest
Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the Adeona Clinical Laboratory,
LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC for a gain of $677,000. This resulted in the classification of the Lab as discontinued
operations. <I>See Note 4 &ndash; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</I> for summarized
statement of operations data for the three months ended March 31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Years Ended December 31, 2011 and
2010</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Revenues, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total net revenues for the year ended December
31, 2010 were $2.6 million.&nbsp;&nbsp;Total net revenues consisted of $2.1 million from the oral&nbsp;flupirtine sublicense fee
with Meda AB, which is net of the $375,000 payment to McLean Hospital and $489,000 of grant revenues from the Qualifying Therapeutic
Discovery Project (QTDP) Program to support our clinical programs.&nbsp;&nbsp;There were no net revenues reported for the year
ended December 31, 2011; net laboratory revenues for this year are included in discontinued operations. See Note 3 - Discontinued
Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
to $2.6 million for the year ended December 31, 2011 from $2.1 million for the year ended December 31, 2010. This increase of 22%
is primarily the result of increased salary expense, consultant fees and stock-based compensation expense. General and administrative
expenses also include a non-cash charge relating to stock-based compensation expense of $919,000 for the year ended December 31,
2011, compared to $310,000 for the year ended December 31, 2010. The stock-based compensation expense for year ended December 31,
2011 includes a one-time charge of $398,000 relating to the modification of certain stock options, prior to expiration,&nbsp;held
by a member of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $3.3 million for the year ended December 31, 2011, from $1.6 million for the year ended December 31, 2010. The increase of 111%
is primarily the result of recording the fair value ($1.7 million) of the common stock issued to Intrexon as consideration for
the Exclusive Channel Collaboration Agreement. This is a non-cash charge. Research and development expenses also include a non-cash
charge relating to stock-based compensation expense of $54,000 for the year ended December 31, 2011, compared to $90,000 for the
year ended December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Expense, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total net other expense was $1.7 million
compared to $112,000 for the years ended December 31, 2011 and 2010, respectively. Total net other expense for the year ended December
31, 2011, included $1.7 million relating to the estimated fair value of the warrants associated with the January 2011 and April
2011 financings, adjusted for the change in their fair value for the year ended December 31, 2011. Other income for the year ended
December 31, 2011 included $63,000 relating to the settlement of accounts payable previously accrued in prior periods offset by
other expenses of $41,000 and $14,000 of interest income from our short-term investments. Total net other expense for the year
ended December 31, 2010, included an impairment loss of $121,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Loss</I> <I>from Continuing Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss from continuing operations
for the year ended December 31, 2011, was $7.6 million, or $0.27 per common share, compared to $1.2 million, or $0.06 per common
share for the year ended December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Loss from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss from discontinued operations
for the year ended December 31, 2011, was $523,000, or $0.02 per common share compared to a $516,000, or $0.02 per common share
for the year ended December 31, 2010. On March 8, 2012, we entered into a Membership Interest Purchase Agreement, and certain related
agreements, pursuant to which we sold all of our interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab,
LLC. This resulted in the classification of the Lab as discontinued operations. See Note 3 &ndash; Discontinued Operations of Adeona
Clinical Laboratory for summarized statement of operations data for the years ended December 31, 2011 and 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have financed our operations since inception
primarily through proceeds from equity financings and various private financings, primarily involving private sales of our common
stock and other equity securities, corporate partnering license fees and to a lesser extent from the&nbsp;proceeds from the sale
of our common stock under our registration statement on Form S-3, laboratory revenues and miscellaneous equipment sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $6.8 million as of March
31, 2012, an increase of approximately $100,000 from December 31, 2011.&nbsp;&nbsp;&nbsp;During the three months ended March 31,
2012, the primary sources of cash were proceeds from the stock option exercises of $68,000 and warrant exercises of $1.5 million.&nbsp;&nbsp;The
primary use of cash during the three months ended March 31, 2012 was for working capital requirements. During the first and second
quarters of 2012, we received proceeds of $1.9 million from the exercise of warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $6.7 million at December
31, 2011, an increase of $4 million from December 31, 2010. During the year ended December 31, 2011, the primary sources of cash
were net proceeds from the issuances of common stock to institutional investors&nbsp;of $7 million and stock option and warrant
exercises of $15,000.&nbsp;The primary use of cash during the year ended December 31, 2011 was for working capital requirements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $2.6 million at December
31, 2010 the primary sources of cash were $2.1 million from the sublicense fee relating to the Meda Agreement and proceeds from
the issuance of common stock to&nbsp;a single investor&nbsp;of $885,000 (net of offering costs of $115,000) and stock option exercises
of $129,000.&nbsp;The primary uses of cash for the year ended December 31, 2010, included working capital requirements and $12,000
in capital equipment additions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued operations will primarily
depend on our ability to raise additional capital from various sources including equity and debt financings, as well as, license
fees from potential corporate partners and joint ventures. Such additional funds may not become available on acceptable terms and
there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term.
We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give
no assurance that any additional capital that we are able to obtain will be sufficient to meet our needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current and Future Financing Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred an accumulated deficit
of approximately $53.1 million&nbsp;as of&nbsp;March 31, 2012. With the exception of the quarter ended June 30, 2010, we have incurred
negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts
in connection with implementing our business strategy, including our planned product development efforts, our clinical trials,
and our research and discovery efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current plans, we believe
that our cash will be sufficient to enable us to meet our planned operating needs for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, the actual amount of funds we
will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="width: 94%; text-align: justify">the progress of our research activities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">the number and scope of our research programs;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">the progress of our preclinical and clinical development activities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">the progress of the development efforts of parties with whom we have entered into research and development agreements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to maintain current research and development&nbsp;licensing arrangements&nbsp;and to establish new research and development and licensing &nbsp;&nbsp;arrangements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to achieve our milestones under licensing arrangements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">the costs and timing of regulatory approvals; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">profitability of our clinical laboratory diagnostic and microbiology services business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimate on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential
sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek
to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not
have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we
need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other
securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able
to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit
our operations and our business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License and Contractual Agreement Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a table of our contractual obligations
for the years 2012 through 2016 as of December 31, 2011 <I>(in thousands)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 22%; text-align: left">License Agreements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Lease Agreements</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">59</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">79</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional In-Licensed Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may enter into additional license agreements relating to
new product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS
AND CONTROL PERSONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below is certain information regarding our directors and executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; font-weight: bold; text-align: center">Name</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; font-weight: bold; text-align: center">Age</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 62%; font-weight: bold; text-align: center">Position</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jeffrey Riley</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">49</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Executive Officer, President and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>C. Evan Ballantyne</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Financial Officer, Corporate Secretary and Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jeffrey J. Kraws &nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chairman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Steve H. Kanzer, C.P.A, J.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>James S. Kuo, M.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Nelson K. Stacks</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">41</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Scott L. Tarriff</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jeffrey Wolf, J.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">49</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey Riley.</I></B> Mr. Riley,
a member of the Synthetic Biologics&rsquo; Board of Directors since March 2010 and Chairman of the Board from November 2011 to
May 2012, was appointed as the Company&rsquo;s President and Chief Executive Officer in February 2012. Since November 2009 until
January 2012, Mr. Riley served as the Managing Director of 526 Ventures, a life science-focused consulting firm with a commercial
and transactional focus, and from April 2009 until February 2012 he was the business officer of Ruga Corporation, a Stanford University
spin-out oncology drug discovery company focused on targeting tumor adaptive responses. From January 2005 until January 2010, Mr.
Riley was a member of the advisory board and a venture partner of Queensland Biocapital Fund, an Australia-based venture fund.
Mr. Riley has held senior corporate and commercial development positions with multiple venture-backed biotech companies. In these
positions, he was responsible for raising equity and negotiating alliances including in-licensing, out-licensing, distribution
agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Mr. Riley's
pharmaceutical experience includes commercial management and mergers and acquisition roles for Pfizer and SmithKline Beecham. Additionally,
Mr. Riley served as CFO and VP Corporate Development for Nichols Institute Diagnostics, later acquired by Corning and spun out
as Quest Diagnostics. Mr. Riley&rsquo;s education includes: a B.S. degree from Boise State University, coursework at UCSF/Berkeley
in drug discovery/development and participation in a dual-degree graduate program, an M.B.A./M.I.M. sponsored by Arizona State
University and the Thunderbird School of Global Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley brings to the Board extensive
knowledge of the pharmaceutical industry. Having served in senior corporate positions in biotech and pharmaceutical companies he
has a vast knowledge of the industry.&nbsp;&nbsp;His business experience provides him with a broad understanding of the operational,
financial and strategic issues facing public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. Evan Ballantyne.</I></B> Mr. Ballantyne
joined Synthetic Biologics as its Chief Financial Officer in February 2012. He also serves as our Corporate Secretary and Treasurer.
From 2006 until its acquisition in April 2011, Mr. Ballantyne served as Executive Vice President and Chief Financial Officer of
Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. for $1.3 billion.
While at Clinical Data, he was instrumental in leading corporate financings totaling approximately $220 million as well as a number
of acquisition and divestitures totaling $116 million. Mr. Ballantyne has also served as Chief Financial Officer of a number of
private medical technology companies, including Avedro and ZymeQuest. Earlier in his career, he served as Vice President and Chief
Operating Officer for ACNielsen Europe Middle East &amp; Africa and held the Chief Financial Officer position as well for two years.
There, Mr. Ballantyne was responsible for all aspects of operations, strategic planning and finance in more than 45 countries for
a corporation with 9,700 employees. He also helped lead the company's successful ISO certification process. He began his career
at the Dun &amp; Bradstreet Corporation where he held several senior financial positions. Mr. Ballantyne earned a BA from the University
of Western Ontario, and took a post-graduate degree in Business Administration with Honors from the University of Windsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey J. Kraws.</I></B> Mr. Kraws
has been a director since January of 2006, and was appointed independent, non-executive Chairman of the Board in May 2012.&nbsp;&nbsp;Since
2003, Mr. Kraws&nbsp;has served Chief Executive Officer and co-founder of Crystal Research Associates, and since February 2012,
he has served as partner and co-founder of TopHat Capital, LLC. Well known and respected on Wall Street, Mr. Kraws has received
some of the most prestigious awards in the industry. Among other awards, he was given a &ldquo;5-Star Rating&rdquo; in 2001 by
Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior
to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing
primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research
for Ryan Beck &amp; Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal &amp; Co., LLC
(prior to its merger with Ryan Beck &amp; Company). Mr. Kraws served as managing director of the healthcare research group and
senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for
the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation
of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown
&amp; Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within
the treasury group at Bristol-Myers-Squibb Company. He holds an M.B.A. from Cornell University and a B.S. degree from State University
of New York-Buffalo. During 2006 through February of 2007, Mr. Kraws served as our Vice President of Business Development, on a
part-time basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Kraws brings a strong business
background to Synthetic Biologics, having worked as a pharmaceutical analyst for over 22 years.&nbsp; Mr. Kraws brings to the Board
significant strategic, business and financial experience related to the business and financial issues facing pharmaceutical companies.
Mr.&nbsp;Kraws has a broad understanding of the operational, financial and strategic issues facing pharmaceutical companies.&nbsp;
Through his services as the Company&rsquo;s Vice President of Business Development during 2006 and a part of 2007, he developed
extensive knowledge of Synthetic Biologics&rsquo; business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Steve H. Kanzer, C.P.A, J.D.</I></B> &nbsp;Mr. Kanzer is a co-founder and served as our President from
our inception in February of 2001 until May of 2006.&nbsp;&nbsp;&nbsp;Since January 2, 2012, Mr. Kanzer has served as our Interim
Director of our Biologics Division. Mr. Kanzer previously served as our Chief Executive Officer from September of 2004 until November
of 2008, Chairman of the Board until February 6, 2010 and currently serves as a director. Mr. Kanzer has also been a director
and officer of our subsidiaries, including Solovax, Inc., Effective Pharmaceuticals, Inc., Putney Drug Corp., Epitope Pharmaceuticals,
Inc. and CD4 Biosciences, Inc. Since December 2000, he has served as co-founder and Chairman of Accredited Ventures Inc. and Accredited
Equities Inc., a venture capital firm and investment bank, respectively, which both specialize in the biotechnology industry.
Prior to founding Accredited Ventures and Accredited Equities in December 2000, Mr. Kanzer served as Senior Managing Director-Head
of Venture Capital at Paramount Capital from 1991 until December of 2000. While at Paramount Capital, Mr. Kanzer was involved
in the formation and financing of a number of biotechnology companies and held various positions in these companies. Prior to
joining Paramount Capital in 1992, Mr. Kanzer was an attorney at the law firm of Skadden, Arps, Slate, Meagher &amp; Flom in New
York where he specialized in mergers and acquisitions. Mr. Kanzer received a J.D. from New York University School of Law in 1988
and a B.B.A. in Accounting from Baruch College in 1985, where he was a Baruch Scholar. Mr. Kanzer is active in university-based
pharmaceutical technology licensing and has served as Co-Chair of the New York Chapter of the Licensing Executives Society.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Kanzer has been associated with
the Company since inception, initiated and negotiated our syntnetic biology collaboration with Intrexon and brings to the Board
extensive knowledge about our business operations and in particular our licenses and products.&nbsp;&nbsp;&nbsp;Mr.&nbsp;Kanzer
also brings to the Board significant executive leadership and operational experience.&nbsp; Mr.&nbsp;Kanzer&rsquo;s legal background
provides him with a broad understanding of the legal issues facing Synthetic Biologics, the financial markets and the financing
opportunities available to Synthetic Biologics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>James S. Kuo, M.D.</I></B> Dr. Kuo
has been a director since February of 2007 and since February 3, 2012 has been a consultant to the Company. From February 6, 2010
until February 3, 2012, Dr. Kuo served as our Chief Executive Officer, Chief Financial Officer and President. He also served as
our Chairman of the Board from February 6, 2010 until November 2011. He currently serves as CEO of ApoLife, a privately held biotechnology
company. Dr. Kuo was the Chairman and Chief Executive Officer of Cordex Pharma, Inc., a public biopharmaceutical company, from
September of 2007 until February 1, 2010 and remained as a director until March 13, 2010. From 2003 to 2006, he served as founder,
Chairman and Chief Executive Officer of BioMicro Systems, Inc., a private venture-backed, microfluidics company.&nbsp;&nbsp;Prior
to that time, Dr. Kuo was a founder, President and Chief Executive Officer of Discovery Laboratories, Inc. where he raised over
$22 million in initial private funding and was instrumental in the company going public. Dr. Kuo was also a founder and board member
of Monarch Labs, LLC, a private medical device company. Dr. Kuo is the former Managing Director of Venture Analysis for Healthcare
Ventures, LLC, which managed $378 million in venture funds. He has also been a senior licensing and business development executive
at Pfizer, Inc., where he was directly responsible for cardiovascular licensing and development. After studying molecular biology
and receiving his B.A. at Haverford College, Dr. Kuo simultaneously earned an M.D. from the University of Pennsylvania School of
Medicine and an M.B.A. from the Wharton School of Business.&nbsp;&nbsp;He holds a B.A. in molecular biology from Haverford College.
From 2004 until October of 2009 Dr. Kuo also served as a director of Soligenix, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Kuo brings to the Board significant
executive leadership and operational experience.&nbsp; Dr.&nbsp;Kuo&rsquo;s prior business experience and board service, along
with his tenure at the Company, gives him a broad and extensive understanding of our operations and the proper role and function
of the Board.&nbsp;&nbsp;His prior service on the board of other public companies has provided him with a strong corporate governance
expertise. In addition, his medical background allows him to bring to the Board extensive knowledge about our industry. Due to
his business background, he has a broad understanding of the operational, financial and strategic issues facing public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Nelson K. Stacks.</I></B> Mr. Stacks
has been a director since February 3, 2012.&nbsp; Mr. Stacks currently serves as CEO and Director of WaveGuide Corporation, a technology
spin out from Harvard University. From July 2009 to August 2011, Mr. Stacks has served as the President, CEO and Director of Vascular
Pathways Incorporated, a venture capital funded medical device company and as a venture partner with QBF/QIC, a life science venture
fund. Prior thereto, Mr. Stacks has held several positions in several biotech companies.&nbsp; From April 2006 until December 2010
he served as the Chairman of Xbio Systems Pty Ltd, an Australian software company with a financial and integrated drug development
program. From May 2007 until July 2009, Mr. Stacks served as the Chairman and CEO of Telesso Technologies Limited, a publicly listed
Australian healthcare company.&nbsp; From March 2006 until August 2008 he also served as CEO and Executive Director of Xenome Limited,
an Australian biotech company as well as director of Columna an Australian medical device company. &nbsp;In 2011, he was appointed
a Director of Molecular Insight Pharmaceuticals, Inc., a company focused on cancer diagnostics and therapeutic treatments. In addition,
over his career, Mr. Stacks has been a venture capitalist, most recently as the General Partner at 3i Ventures and earlier at Oak
Investment Partners. Mr. Stacks is a member of the fourth class of Kauffman Fellows and has invested in all areas of healthcare
and information technology. Mr. Stacks received an M.B.A. from the F.W. Olin Graduate School of Business at Babson College and
a BA from The University of Rochester.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Stacks brings to our Board extensive
executive and senior management experience in the biotech industry and is an &ldquo;audit committee financial expert&rdquo; as
such term is defined under applicable SEC rules. He is further qualified for service on our Board because of his relevant business
expertise and leadership experience acquired through his experience serving on several boards of directors of other healthcare-related
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Scott L. Tarriff.</I></B> Mr. Tarriff
has been a director since February 3, 2012.&nbsp; Since January 2007 he has served as a director and Chief Executive Officer of
Eagle Pharmaceuticals, Inc., a hospital specialty company. Eagle is focused on developing branded parenteral products through the
application of various in-licensed drug delivery technologies. Prior to forming Eagle, Mr. Tarriff was president and chief executive
officer of Par Pharmaceutical Companies, Inc. Mr. Tarriff joined Par Pharmaceutical Companies, Inc., in 1998 as executive vice
president. Mr. Tarriff was named president and Chief Executive Officer of Par Pharmaceutical, Inc., the company&rsquo;s principal
operating subsidiary, in 2001, and was elected to the company&rsquo;s Board of Directors in 2002. In September 2003, he was appointed
President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. Mr. Tarriff joined Par following a 12-year career at
Bristol-Meyers Squibb. He received his M.B.A. from Rider College and his undergraduate degree from Pennsylvania State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Tarriff brings to our Board of Directors
significant knowledge of and experience in the pharmaceutical and medical industries. He has extensive business, managerial, executive
and leadership experience that further qualify him to serve as a member of the Board and a valuable understanding of the role played
by the Board of Directors acquired through service on the boards of many companies. He has had a long and successful career in
top executive leadership positions with leading, publicly traded pharmaceutical companies including Par Pharmaceuticals and Bristol-Myers
Squibb.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey Wolf, J.D.</I>
&nbsp;</B> Mr. Wolf, a director since 2006, has substantial experience in creating, financing, nurturing and growing
new ventures based upon breakthrough research and technology. In August 2008, Mr. Wolf founded Heat Biologics, Inc., a
company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010, Mr.
Wolf has served as the Chief Executive Officer of Heat Biologics, Inc.&nbsp;From 2006 until April 2010, Mr. Wolf served as
the Chairman and Chief Executive Officer of GenerationOne, a company that was focused on mobile-based
collaborative care.&nbsp;Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group formed in 1997
and focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics, Inc., an
antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company
and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the
Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was
responsible for supervising the formation and funding of new technology, biomedical, and service oriented ventures. Mr. Wolf
currently sits on the board of Elusys Therapeutics and Netli, Inc. Mr. Wolf received an M.B.A. from Stanford Business School,
a J.D. from New York University School of Law and a B.A. with honors in Economics from the University of Chicago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Wolf has extensive knowledge of the
industry and in particular research and development.&nbsp;&nbsp;His legal and business background provide him with a broad understanding
of the legal, operational, financial and strategic issues facing Synthetic Biologics.&nbsp;&nbsp;Having served as a board member
on other public company boards, Mr. Wolf has an extensive understanding of the operational, financial and strategic issues facing
public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors&rsquo; Term of Office</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors will hold office until the next
annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by our Board
of Directors and serve at the discretion of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee is comprised of Mr.
Wolf and Mr. Stacks. The Audit Committee is responsible for recommending our independent public accounting firm and reviewing management&rsquo;s
actions in matters relating to audit functions. The Committee reviews with our independent public accountants the scope and results
of the audit engagement and the system of internal controls and procedures. The Committee also reviews the effectiveness of procedures
intended to prevent violations of laws. The Committee also reviews, prior to publication, our reports on Form 10-K and Form 10-Q.
Our Board has determined that all audit committee members are independent under applicable SEC regulations. Our Board of Directors
has determined that Mr. Stacks qualifies as an &ldquo;audit committee financial expert&rdquo; as that term is used in Section 407
of Regulation S-K.&nbsp;&nbsp;Our Audit Committee charter is located on our website www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Compensation Committee consists of
Mr. Wolf and Mr. Kraws. This committee performs several functions, including reviewing all forms of compensation provided to our
executive officers, directors, consultants and employees, including stock compensation. Our Compensation Committee charter is located
on our website www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nominations Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Nominations Committee consists of Mr.
Wolf and Mr. Kraws. This committee performs several functions, including identifying qualified individuals to become members of
the Board and recommending appointments to the Board and appointment of executive officers. The committee seeks individuals who
have an inquisitive and objective perspective, practical wisdom and mature judgment, and the talent and expertise to understand,
and provide sound and prudent guidance with respect to, our activities, operations and interests.&nbsp;&nbsp;Candidates must also
be individuals who have the highest personal and professional integrity, who have demonstrated exceptional ability and judgment,
and who are likely to be the most effective, in conjunction with the other members of the Board, in collectively serving the long-term
interests of stockholders. Our Nominations Committee charter is located on our website www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 16(a) of the Securities Exchange
Act of 1934 requires our executive officers, directors and persons who beneficially own more than 10 percent of a registered class
of the Synthetic Biologics&rsquo; equity securities, to file with the SEC initial reports of ownership and reports of changes in
ownership of our common stock.&nbsp;&nbsp;Such officers, directors and persons are required by SEC regulation to furnish us with
copies of all Section 16(a) forms that they file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based solely on a review of the copies
of such forms that were received by us, or written representations from certain reporting persons that no Form 5s were required
for those persons, we are not aware of any failures to file reports or report transactions in a timely manner during the year ended
December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have long maintained a Code of Conduct
which is applicable to all of our directors, officers and employees.&nbsp;&nbsp;In addition, we have adopted a Code of Ethics for
Financial Management which applies to our Chief Executive Officer, Chief Financial Officer, Treasurer and Controller.&nbsp;&nbsp;Each
of these codes is posted on our website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors are elected at each annual meeting
of shareholders and hold office until the next annual meeting of shareholders following their election.&nbsp;&nbsp;To date, none
of our directors have received any compensation from us, whether in the form of cash or securities, for their service as directors.
None of our directors are independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes all compensation
awarded to, earned by or paid to Max Lyon and James S. Kuo, M.D., during the fiscal year ended December 31, 2011 or 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<BR> Awards($)&nbsp;<BR> &nbsp;(1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All&nbsp;Other<BR> Compensation<BR> ($)&nbsp;&nbsp;(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; text-align: left">James S. Kuo, M.D., President,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">199,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">12,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">211,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CEO and CFO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">179,000</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">328,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">527,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Max Lyon, Former President,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Former CEO and Former CFO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 3%">(1)</TD>
    <TD STYLE="width: 91%; text-align: justify">Amount reflects the grant date fair value of the named executive officer&rsquo;s stock options, calculated in accordance with FASB ASC Topic 718.&nbsp;&nbsp;For a discussion of the assumptions used in calculating these values, see Note&nbsp;6 to our consolidated financial statements</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">The all other compensation column is comprised of the portion of medical, dental and vision premiums paid by us on behalf of our named executive officer. These benefits are offered to all full-time Synthetic Biologics employees.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">Dr. Kuo resigned as our President, Chief Executive Officer and Chief Financial Officer on February 3, 2012.&nbsp;Dr. Kuo remains as a consultant to the Company.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD STYLE="text-align: justify">Mr. Lyon resigned as our President, Chief Executive Officer and Chief Financial Officer effective as of February 10, 2010. This amount represents the amount earned by Mr. Lyon prior to his resignation and severance in the amount of $23,000 paid in shares of our common stock.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below reflects all outstanding
equity awards made to each of the named executive officers that are outstanding at&nbsp;December 31,&nbsp;2011. We currently grant
stock-based awards pursuant to our 2010 Stock Incentive Plan (the &ldquo;2010 Stock Plan&rdquo;) and have outstanding awards under
our 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;) and 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Grant</B>&nbsp;<BR> <B>Date&nbsp;(1)</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Underlying<BR> Unexercised&nbsp;Options<BR> Exercisable</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Underlying<BR> Unexercised&nbsp;Options<BR> Unexercisable</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Exercise<BR> Price&nbsp;($)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Expiration<BR> Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 30%; text-align: left">James S. Kuo</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">02/06/10 </TD><TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">275,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">125,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.82</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">02/06/20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12/22/09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12/22/19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10/02/08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10/02/18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11/02/07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11/02/17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">02/07/07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">02/07/17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 3%">(1)</TD>
    <TD STYLE="width: 91%">Unless otherwise noted, options vest immediately on the date of grant.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>These options vest 100,000 shares immediately and the remainder in equal monthly installments over a three-year period beginning on the date of grant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2012, Jeffrey Riley was
appointed to serve as our Chief Executive Officer and President, and on February 6, 2012, C. Evan Ballantyne was appointed to serve
as our Chief Financial Officer. On February 3, 2012, James S. Kuo, M.D., resigned as our Chief Executive Officer, President and
Chief Financial Officer. Dr. Kuo remains as a consultant to the Company. On February 6, 2010, Max Lyon resigned as President, Chief
Executive Officer and Chief Financial Officer, and James S. Kuo, M.D., was thereby appointed Chairman, Chief Executive Officer,
Chief Financial Officer and President. The following are summaries of the agreements that were executed in connection with these
changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Jeffrey Riley Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with his appointment, Mr.
Riley entered into a three-year employment agreement with us (the &ldquo;Riley Employment Agreement&rdquo;). Pursuant to the Riley
Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance
and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of our common stock with
an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis,
over thirty-six months. The Riley Employment Agreement also includes confidentiality obligations and inventions assignments by
Mr. Riley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Mr. Riley&rsquo;s employment is terminated
for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense
reimbursement and any other entitlements accrued by him to the extent not previously paid (the &ldquo;Accrued Obligations&rdquo;);
<U>provided</U> , <U>however</U> , that if his employment is terminated (1) by us without Just Cause (as defined in the Riley Employment
Agreement) or by Mr. Riley for Good Reason (as defined in the Riley Employment Agreement) then in addition to paying the Accrued
Obligations, (x) we shall continue to pay his then current base salary and continue to provide benefits at least equal to those
which were provided at the time of termination for a period of six months and (y) he shall have the right to exercise any vested
options until the earlier of the expiration of the severance or the expiration of the term of the option, or (2) by reason of his
death or Disability (as defined in the Riley Employment Agreement), then in addition to paying the Accrued Obligations, he would
have the right to exercise any vested options until the expiration of the term of the option. In such event, if Mr. Riley commenced
employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provider
plan, the medical and other welfare benefits to be provided by us as described herein will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. Evan Ballantyne Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 6, 2012, C. Evan Ballantyne
was appointed our Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment
agreement with us (the &ldquo;Ballantyne Employment Agreement&rdquo;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne
will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus
payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price
equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six
months. The Ballantyne Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Ballantyne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Mr. Ballantyne&rsquo;s employment is
terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay,
expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &ldquo;Accrued Obligations&rdquo;);
<U>provided</U> , <U>however</U> , that if his employment is terminated (1) by us without Just Cause (as defined in the Ballantyne
Employment Agreement) or by Mr. Ballantyne for Good Reason (as defined in the Ballantyne Employment Agreement) then in addition
to paying the Accrued Obligations, (i) we shall continue to pay his then current base salary and continue to provide benefits at
least equal to those which were provided at the time of termination for a period of six months and (ii) he shall have the right
to exercise any vested options until the earlier of the expiration of the severance or the expiration of the term of the option,
or (2) by reason of his death or Disability (as defined in the Ballantyne Employment Agreement), then in addition to paying the
Accrued Obligations, he would have the right to exercise any vested options until the expiration of the term of the option. In
such event, if Mr. Ballantyne, commenced employment with another employer and becomes eligible to receive medical or other welfare
benefits under another employer-provider plan, the medical and other welfare benefits to be provided by us as described herein
will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dr. Kuo&rsquo;s Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, James S. Kuo,
M.D., resigned from his positions as our President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered
into a nine-month consulting agreement with us (the &ldquo;Consulting Agreement&rdquo;). Pursuant to the Consulting Agreement,
Dr. Kuo will be entitled to a consulting fee of $16,666 per month during the term of the Consulting Agreement, receive health and
dental benefits for one year and retain the right to exercise the stock options held by him that have vested as of the effective
date of the Consulting Agreement for a period expiring on the date that is one (1) year from the effective date of the Consulting
Agreement. The Consulting Agreement also includes confidentiality obligations and inventions assignments by Dr. Kuo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2010, Dr. Kuo had entered into
a three-year employment agreement with us (the &ldquo;Kuo Employment Agreement&rdquo;).&nbsp;&nbsp;Pursuant to the Kuo Employment
Agreement, Dr. Kuo was entitled to an annual base salary of $199,000 and was eligible for discretionary performance and transactional
bonus payments.&nbsp;&nbsp;Additionally, Dr. Kuo was granted an initial stock option to purchase 400,000 shares of our common stock
(with an exercise price of $0.82, the fair market value on February 6, 2010, which is the date of grant).&nbsp;&nbsp;Of this stock
option grant, 300,000 shares vested prior to his resignation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Mr. Lyon&rsquo;s Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with his resignation, Mr. Lyon received $23,000
paid in shares of our common stock, as a severance payment.&nbsp;&nbsp;This payment was made pursuant to a Separation Agreement,
dated February 6, 2010, between Mr. Lyon and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information for the fiscal year
ended December 31, 2011 regarding the compensation of our directors who at December 31, 2011 were not also named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fees&nbsp;Earned&nbsp;or<BR> Paid&nbsp;in&nbsp;Cash</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Awards(1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other<BR> Compensation</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 52%; text-align: left">Steve H. Kanzer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">37,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jeffrey J. Kraws</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">37,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">49,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Jeffrey Riley(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">85,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">99,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jeffrey Wolf</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">37,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">(1)</TD>
    <TD STYLE="width: 97%; text-align: justify">The amounts in the &ldquo;Option awards&rdquo; column reflect the dollar amounts recognized as compensation expense for the financial statement reporting purposes for stock options for the fiscal year ended December 31, 2011 in accordance with SFAS 123(R). The fair value of the options was determined using the Black-Scholes model.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(2)</TD>
    <TD STYLE="text-align: justify">In consideration of Jeffrey Riley serving as our independent, non-executive Chairman, in November 2011 we issued Jeffrey Riley options exercisable for an additional 100,000 shares of our common stock.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2007, director compensation for
members who are not employees was approved at $2,000 per board meeting that they attend in person, $1,000 per telephonic board
meeting and $500 per committee meeting.&nbsp;&nbsp;In addition, we grant non-employee members of the Board of Directors upon appointment
25,000 stock options to purchase shares of our common stock at an exercise price equal to the fair market value of the our common
stock on the date of grant, and an additional 8,333 stock options each year. Directors who are employees or who are compensated
for board service pursuant to a separate agreement or arrangement do not receive additional compensation for attending board, committee
or shareholder meetings. We also reimburse directors for travel and other out-of-pocket expenses incurred in attending Board of
Director and committee meetings. We have agreed to pay Mr. Kraws for his services as our independent, non-executive Chairman of
the Board annual compensation of $150,000 as well as a one- time grant of options exercisable for an additional 100,000 shares
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
about the securities authorized for issuance under our equity compensation plans for the fiscal year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Plan&nbsp;Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> to&nbsp;be&nbsp;Issued&nbsp;Upon<BR> Exercise&nbsp;of<BR> Outstanding&nbsp;Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR> Average<BR> Exercise&nbsp;Price&nbsp;of<BR> Outstanding<BR> Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Remaining&nbsp;Available&nbsp;for<BR> Future&nbsp;Issuance&nbsp;Under<BR> Equity&nbsp;Compensation<BR> Plans</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Equity compensation plans approved by stockholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 9pt">2001 Stock Incentive Plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,320,354</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22,690</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">2007 Stock Incentive Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,201,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,033,932</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">2010 Stock Incentive Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,542,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by stockholder</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,979,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,599,122</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information,
as of June 30, 2012, or as otherwise set forth below, with respect to the beneficial ownership of our common stock (i) all persons
know to us to be the beneficial owners of more than 5% of the outstanding shares of our common stock, (ii) each of our directors
and our executive officer named in the Summary Compensation Table, and (iii) all of our directors and our executive officer as
a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.2pt; text-align: center"><B>Principal&nbsp;Stockholders&nbsp;Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares&nbsp;Owned&nbsp;(1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Address&nbsp;of&nbsp;Beneficial&nbsp;Ownership&nbsp;(2)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&nbsp;of<BR> Shares&nbsp;(3)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.4pt">Accredited Venture Capital, LLC (4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,086,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21.28</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Intrexon Corporation (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,123,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.38</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">C. Evan Ballantyne (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,833</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Steve H. Kanzer (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,766,017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey J. Kraws (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,105</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">James S. Kuo (9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">354,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey Riley (10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">233,333</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nelson K. Stacks (11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Scott L. Tarriff (12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey Wolf (13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,332</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Randall J. Kirk(14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,123,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.38</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">All officers and directors as a group (8 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,870,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25.56</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* represents less than 1% of our common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%">(1)</TD>
    <TD STYLE="width: 88%; text-align: justify">The address for each beneficial owner except Intrexon Corporation and Randall J. Kirk is 617 Detroit Street, Suite 100, Ann Arbor, MI 48104.The address for Intrexon Corporation is 20358 Seneca Meadows Pkwy, Germantown, Maryland 20876 and the address for Mr. Kirk is The Governor Tyler, 1881 Grove Avenue, Radford, Maryland 24141.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Except as indicated in the footnotes to the table, to the knowledge of the Company, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws, where applicable. Pursuant to the rules of the SEC, the number of shares of our common stock deemed outstanding includes shares issuable pursuant to options held by the respective person or group that are currently exercisable or may be exercised within 60 days of June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">As of June 30, 2012, we had 33,301,147 shares of common stock outstanding.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD STYLE="text-align: justify">Consists of 7,086,380 shares of common stock issued to Accredited Venture Capital, LLC. Pharmainvestors, LLC is the managing member of Accredited Venture Capital, LLC, and Mr. Kanzer is the managing member of Pharmainvestors, LLC. As such, Mr. Kanzer may be considered to have control over the voting and disposition of the shares registered in the name of Accredited Venture Capital, LLC, and therefore, such shares are also included in the shares listed as held by Mr. Kanzer. Mr. Kanzer disclaims beneficial ownership of those shares, except to the extent of his pecuniary interest.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD STYLE="text-align: justify">Does not include additional shares that have not yet been earned but may in the future be earned under the terms of agreements with Intrexon Corporation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(6)</TD>
    <TD STYLE="text-align: justify">Includes 70,833 shares issuable upon exercise of options held by Mr. Ballantyne that are exercisable within the 60-day period following June30, 2012. Does not include an additional 354,167 shares issuable upon exercise of options held by Mr. Ballantyne that are not exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(7)</TD>
    <TD STYLE="text-align: justify">Includes 7,086,380 shares of common stock issued to Accredited Venture Capital, LLC and 304,391 shares issuable upon exercise of options held by Mr. Kanzer that are exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(8)</TD>
    <TD STYLE="text-align: justify">Includes 312,105 shares issuable upon exercise of options held by Mr. Kraws that are exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(9)</TD>
    <TD STYLE="text-align: justify">Includes 349,999 shares issuable upon exercise of options held by Dr. Kuo that are currently exercisable.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(10)</TD>
    <TD STYLE="text-align: justify">Includes 233,333 shares issuable upon exercise of options held by Mr. Riley that are exercisable within the 60-day period following June 30, 2012. Does not include an additional 625,000 shares issuable upon exercise of options held by Mr. Riley that are not exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(11)</TD>
    <TD STYLE="text-align: justify">Includes 25,000 shares issuable upon exercise of options held by Mr. Stacks that are exercisable within the 60-day period following June 30, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify">(12)</TD>
    <TD STYLE="width: 88%; text-align: justify">Includes 25,000 shares issuable upon exercise of options held by Mr. Tarriff that are exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(13)</TD>
    <TD STYLE="text-align: justify">Includes 83,332 shares issuable upon exercise of options held by Mr. Wolf that are exercisable within the 60-day period following June 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(14)</TD>
    <TD STYLE="text-align: justify">All such shares are held by Intrexon Corporation. Mr. Kirk, directly and through certain affiliates, has voting and disposition power over a majority of the outstanding capital of Intrexon Corporation. Mr. Kirk disclaims beneficial ownership of the shares held by Intrexon Corporation, except to the extent of any pecuniary interest therein.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our charter,
our Audit Committee shall review on an on-going basis for potential conflicts of interest, and approve if appropriate, all our
&ldquo;Related Party Transactions&rdquo; as required by Section 120 of the NYSE Amex Company Guide.&nbsp;&nbsp;For purposes of
the Audit Committee Charter, &ldquo;Related Party Transactions&rdquo; shall mean those transactions required to be disclosed pursuant
to SEC Regulation S-K, Item 404. On January 2, 2012, Steve H. Kanzer was engaged as our Interim Director of our Biologics Division.&nbsp;
In connection with his appointment, Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the
&ldquo;Kanzer Employment Agreement&rdquo;), which was extended for an additional three (3) months Pursuant to the Kanzer Employment
Agreement, Mr. Kanzer will be entitled to a base salary of $90,000 for the six month term, healthcare coverage pursuant to our
healthcare insurance plan, reimbursement for certain relocation expenses and rent expense. The Kanzer Employment Agreement also
includes confidentiality obligations and inventions assignments by Mr. Kanzer.&nbsp; Mr. Kanzer is not entitled to severance pay
upon termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -1.25pt"><B>CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS AND AUDITORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 3, 2012,
we dismissed Berman &amp; Company, P.A. (&ldquo;Berman &amp; Co.&rdquo;) as our independent registered public accounting firm and
on July 9, 2012, we selected BDO USA, LLP (&ldquo;BDO&rdquo;) as our new independent registered public accounting firm responsible
for auditing its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Berman
&amp; Co.&rsquo;s reports on our financial statements as of and for the two years ended December 31, 2011 and 2010, did not contain
an adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles;</FONT><FONT STYLE="color: #1F497D"><I>
</I></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">however, after being filed with the Securities and Exchange Commission
(&ldquo;SEC&rdquo;) on March 30, 2012, the original audit opinion included in our Annual Report on Form 10-K for the year ended
December 31, 2011, was withdrawn due to the failure of Berman &amp; Co. to follow proper partner rotation procedures. On May 11,
2012, a new audit opinion for the year ended December 31, 2011 and an amended Annual Report on Form 10-K/A for such year was filed
with the SEC.</FONT><FONT STYLE="color: #1F497D"><I> </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decision to dismiss Berman &amp; Co.
and the selection of BDO was recommended by the audit committee and unanimously approved by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2011
and 2010, and in the subsequent interim period through July 3, 2012 (the date of dismissal of Berman &amp; Co.), there were no
disagreements with Berman &amp; Co. on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of Berman &amp; Co., would have caused it to make
reference to the subject matter of the disagreement in connection with its reports on our financial statements for such years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2011
and in the subsequent interim period through July 3, 2012, there were no events otherwise reportable under Item 304(a)(1)(v) of
Regulation S-K other than the following which was previously reported by us: the failure of Berman &amp; Co. to follow proper partner
rotation procedures that resulted in the withdrawal of Berman &amp; Co.&rsquo;s audit opinion included in our Annual Report on
Form 10-K for the year ended December 31, 2011 and being unable to rely upon such audit opinion. Such matters have been discussed
by both our audit committee and board of directors with Berman &amp; Co., and Berman &amp; Co. is authorized to fully respond to
inquiries of BDO concerning such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During our two most recent years and in
the subsequent interim period through July 3, 2012, we did not consult with BDO regarding the application
of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be
rendered on our financial statements, and neither a written report nor oral advice was provided that was an important factor considered
by us in reaching a decision as to the accounting, auditing or financial reporting issue, or with any of the matters outlined in
Item 304(a)(2)(ii) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We provided Berman &amp; Co. with a copy of the Current Report
on Form 8-K that disclosed the foregoing information prior to its filing with the SEC, and Berman &amp; Co. furnished us with a
letter addressed to the SEC that was filed as an exhibit to such Current Report on Form 8-K stating that it agreed with the statements
we made in such Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of 100
million shares of common stock, par value $0.001 per share, and 10 million shares of preferred stock, par value $0.001 per share.
As of June 30, 2012, 33,301,147 shares of common stock and no shares of preferred stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of common stock have
the right to cast one vote for each share of common stock in their name on the books of our company, whether represented in person
or by proxy, on all matters submitted to a vote of holders of common stock, including election of directors. There is no right
to cumulative voting in election of directors. Except where a greater requirement is provided by statute, by our articles of incorporation,
or by our bylaws, the presence, in person or by proxy duly authorized, of the one or more holders of a majority of the outstanding
shares of our common stock constitutes a quorum for the transaction of business. The vote by the holders of a majority of outstanding
shares is required to effect certain fundamental corporate changes such as liquidation, merger, or amendment of our articles of
incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in our articles
of incorporation or bylaws that prevent us from declaring dividends. We have not declared any dividends, and we do not plan to
declare any dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of our common stock are
not entitled to preemptive or subscription or conversion rights, and no redemption or sinking fund provisions are applicable to
our common stock. All outstanding shares of common stock are, and the shares of common stock sold in the offering will when issued
be, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-align: justify; text-indent: -23pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-align: justify; text-indent: -23pt"><B><I>Outstanding
Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2012, we had issued and
outstanding a total of 1,418,493 warrants to purchase our common stock outstanding at a weighted-average price of $3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrants Issued in our July 2, 2010 Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant represents the right to purchase
one share of common stock at an exercise price of $1.32 per share. Each warrant was exercisable 183 days after the date of issuance
(July 2, 2010) and before the fifth anniversary of its date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exercisability. Holders of the warrants
may exercise their warrants to purchase shares of our common stock on or before the expiration date by delivering (i) notice of
exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise provisions with
respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant is being exercised.
Warrants may be exercised in whole or in part, but only for full shares of common stock. We provide certain additional payments
if we fail to deliver the shares of common stock underlying the warrants by the date on which delivery of the stock certificate
is required by the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the warrant holders are entitled
to a &ldquo;cashless exercise&rdquo; at their option. The number of shares to be issued would be determined by a formula based
on the total number of shares with respect to which the warrant is being exercised, the volume weighted average of the prices per
share of our common stock on the five trading days immediately prior to the date of exercise and the applicable exercise price
of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock issuable on
exercise of the warrants will be, when issued and paid for in accordance with the warrants, duly and validly authorized, issued
and fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fundamental Transaction. In the event of
a merger, consolidation, business combination, tender offer, exchange of shares, reclassification of our common stock, redemption
or recapitalization or similar event as a result of which the shares of common stock are converted into or exchanged for our or
another company&rsquo;s securities, cash or property, each, a &ldquo;Fundamental Transaction,&rdquo; then the holder shall have
the right thereafter to receive, upon exercise of the warrant, the same amount and kind of securities, cash or property as it would
have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration
payable as part of the Fundamental Transaction. Any successor to us or surviving entity shall assume the obligations under the
warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of Certificates. Upon the holder&rsquo;s
exercise of a warrant, we will promptly, but in no event later than three trading days after the exercise date, issue and deliver,
or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise of the warrant. In addition,
if the transfer agent participates in the Depository Trust Company Fast Automated Securities Transfer program we shall issue and
deliver the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System
(DWAC) or another established clearing corporation performing similar functions. If we fail to deliver certificates evidencing
the warrant shares by such date, we are required to pay to the holder, in cash, as liquidated damages and not as a penalty the
amount to be determined as set forth in the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitations on Exercise. The number of
warrant shares that may be acquired by any holder upon any exercise of the warrant shall be limited to the extent necessary to
insure that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by
such holder and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder&rsquo;s
for purposes of Section 13(d) of the Exchange Act, does not exceed 4.99% of the total number of issued and outstanding shares of
common stock (including for such purpose the shares of common stock issuable upon such exercise), or beneficial ownership limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Adjustments. The exercise price
and the number of shares of common stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence
of specific events, including stock dividends, stock splits, combinations and reclassifications of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional Provisions. We are not required
to issue fractional shares upon the exercise of the warrants. No holders of the warrants will possess any rights as a stockholder
under those warrants until the holder exercises those warrants. The warrants may be transferred independent of the common stock
they were issued with, on a form of assignment, subject to all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrants Originally Issued in our April 11, 2011 Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants were originally issued in
April 2011 and exchanged for warrants issued in July 2011. Each warrant represents the right to purchase one share of common stock
at an exercise price of $1.00 per share. Each warrant may be exercised after January 28, 2012 and before August 10, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exercisability. Holders of the warrants
may exercise their warrants to purchase shares of our common stock on or before the expiration date by delivering (i) notice of
exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise provisions with
respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant is being exercised.
Warrants may be exercised in whole or in part, but only for full shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the warrant holders are entitled
to a &ldquo;cashless exercise&rdquo; at their option if, at any time of exercise, there is no effective registration statement
registering, or no current prospectus available for, the issuance or resale of the shares of common stock underlying the warrants.
The number of shares to be issued would be determined by a formula based on the total number of shares with respect to which the
warrant is being exercised, the volume weighted average of the prices per share of our common stock on the five trading days immediately
prior to the date of exercise and the applicable exercise price of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock issuable on
exercise of the warrants will be, when issued and paid for in accordance with the warrants, duly and validly authorized, issued
and fully paid and non-assessable. We will authorize and reserve at least that number of shares of common stock equal to the number
of shares of common stock issuable upon exercise of all outstanding warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fundamental Transaction. If, at any time
while the warrants are outstanding, we issue options, convertible securities or rights to purchase stock, warrants, securities
or other property pro rata to the record holders of any class of common stock then the holder shall have the right thereafter to
acquire the same amount and kind of securities, cash or property as it would have been entitled to receive upon the exercise of
the warrant if it had exercised before such event or it may require us to repurchase its warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro Rata Distributions. If, at any time
while the warrants are outstanding, we distribute evidences of our indebtedness, assets, or rights or warrants to purchase any
security other than our common stock to all holders of our common stock, then the then the holder shall have the right thereafter
to receive, the same distribution as the other holders as if it had exercised its warrant. upon exercise of the warrant, the same
amount and kind of securities, cash or property as it would have been entitled to receive upon the exercise of the warrant if it
had exercised before such event exercise price will adjust pursuant to a volume weighted average price based ratio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Adjustments. The exercise price
and the number of shares of common stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence
of specific events, including stock dividends, stock splits, combinations and reclassifications of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of Certificates. Upon the holder&rsquo;s
exercise of a warrant, we will promptly, but in no event later than three trading days after the exercise date, issue and deliver,
or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise of the warrant. In addition,
if the transfer agent participates in the Depository Trust Company Fast Automated Securities Transfer program we shall issue and
deliver the shares electronically through The Depository Trust Corporation through its DWAC system or another established clearing
corporation performing similar functions. If we fail to deliver certificates evidencing the warrant shares by such date, we are
required to pay to the holder, in cash, as liquidated damages and not as a penalty, in the amount to be determined as set forth
in the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitations on Exercise. The number of
warrant shares that may be acquired by any holder upon any exercise of the warrant shall be limited to the extent necessary to
insure that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by
such holder and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder&rsquo;s
for purposes of Section 13(d) of the Exchange Act, does not exceed 4.99% of the total number of issued and outstanding shares of
common stock (including for such purpose the shares of common stock issuable upon such exercise), or beneficial ownership limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional Provisions. No holders of the
warrants will possess any rights as a stockholder under those warrants until the holder exercises those warrants. The warrants
may be transferred independent of the common stock they were issued with, on a form of assignment, subject to all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no shares of preferred stock
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have 3,968,746 options outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transfer Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have retained Corporate Stock Transfer
as our transfer agent. They are located at 3200 Cherry Creek Drive, Denver, Colorado 80202. Their telephone number is (303) 282-4800
and facsimile is (303) 282-4801.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements as of
December 31, 2011 and 2010 and for the years then ended included in this Post-Effective Amendment No. 1 to Form S-3 on Form
S-1 Registration Statement have been so included in reliance on the reports of Berman &amp; Company, P.A., an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation provide that
no officer or director shall be personally liable to us or our stockholders for monetary damages except as provided pursuant to
the Nevada Revised Statutes. Our bylaws and Articles of Incorporation also provide that we will indemnify and hold harmless each
person who serves at any time as a director, officer, employee or agent of us from and against any and all claims, judgments and
liabilities to which such person shall become subject by reason of the fact that he is or was a director, officer, employee or
agent of us, and shall reimburse such person for all legal and other expenses reasonably incurred by him or her in connection with
any such claim or liability. We also have the power to defend such person from all suits or claims in accordance with the Nevada
Revised Statutes. The rights accruing to any person under our bylaws and Articles of Incorporation do not exclude any other right
to which any such person may lawfully be entitled, and we may indemnify or reimburse such person in any proper case, even though
not specifically provided for by the bylaws and Articles of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the small business issuer pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the small business issuer for expenses incurred or paid by
a director, officer or controlling person of the small business issuer in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless
in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of our common stock offered hereby will be passed
upon for us by Gracin &amp; Marlow, LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the Securities and Exchange
Commission this Post-Effective Amendment No. 1 to Form S-3 on Form S-1 to maintain the registration of certain securities previously
registered on the Original Registration Statement under the Securities Act.
We are subject to the informational requirements of the Exchange Act, and file annual and current reports, proxy statements and
other information with the Commission. These reports, proxy statements and other information filed by Synthetic Biologics, Inc.
can be read and copied at the Commission&rsquo;s Public Reference Room at 100 F Street, N.W., Washington, D.C. 20549. You may obtain
information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Commission also maintains a website
that contains reports, proxy statements, information statements and other information concerning DC Brands, Inc. located at http://www.sec.gov.
This prospectus does not contain all the information required to be included in the registration statement (including the exhibits),
which we have filed with the Commission under the Securities Act and to which reference is made in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain, free of charge, a copy of any of our filings
by writing or calling us at the following address and telephone number: 617 Detroit Street, Suite 100, Ann Arbor, Michigan 48104
or calling (734) 332-7800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Consolidated Balance Sheets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,678</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts receivable - net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">405</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.24in">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,122</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Long-term note receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,349</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.24in">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Preferred stock,&nbsp; $0.001 par value; 10,000,000 shares authorized, none
    issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Common stock,&nbsp; $0.001 par value; 100,000,000 shares authorized,32,857,609 issued and 32,776,127 outstanding and
    31,374,002 issued and 31,292,520 outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0.24in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.24in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(53,073</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(51,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.24in">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,906</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,349</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to unaudited consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Consolidated Statements of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three months ended March 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,468</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,233</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">231</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Operating Costs and Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,854</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,464</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Loss from Continuing Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,854</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,464</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(716</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(94</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss on the sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Other Income (Expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Net Loss from Continuing Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,849</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,223</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Income from Discontinued Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">649</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,200</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,186</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Net Income (Loss) Per Share&nbsp; - Basic and Dilutive:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Net Loss Per Share</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Weighted average number of
    shares outstanding during the period - Basic and Dilutive</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,003,164</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,220,694</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center">See accompanying notes to unaudited
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center"><B>Synthetic Biologics, Inc.
and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center"><B><U>Consolidated Statements
of Cash Flows</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center"><B>(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.75pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,849</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,223</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Net income from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">649</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">508</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock issued as employee compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock issued for consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">716</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Provision for uncollectible accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss on sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on the settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Note receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(700</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deposits and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Assets of discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(192</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,415</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Proceeds from the sale of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Provided By Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock for stock option exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock for warrant exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Cash paid as direct offering costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(296</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Provided By&nbsp; Financing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,539</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,712</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.75pt">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,432</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">Cash at beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.75pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,802</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,080</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left; padding-left: 0.75pt">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash paid for taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center">See accompanying notes to unaudited
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(Unaudited)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.&nbsp;&nbsp;&nbsp;Organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Synthetic Biologics&rdquo;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development
of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic
biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also
intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage
programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we
are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS),
cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%; font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1pt solid"><B>Medical Indication</B></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 23%; font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1pt solid"><B>Product Candidate</B></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1pt solid"><B>Status</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">PAH</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Synthetic DNA-based therapy</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Preclinical</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Relapsing-remitting MS</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Trimesta</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">All patients enrolled in Phase II clinical trial;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(oral estriol)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">dosing and monitoring underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Cognitive dysfunction in</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Trimesta</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Patient enrollment underway in Phase II</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">MS</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(oral estriol)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">clinical trial</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Fibromyalgia</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Effirma</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Partnered with Meda AB</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(oral flupirtine)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">ALS</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">AEN-100</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase II/III clinical trial preparation underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(gastroretentive zinc acetate)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.&nbsp;&nbsp;&nbsp;Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The accompanying
unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim
financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The financial
information as of December 31, 2011, is derived from the audited financial statements presented in the Company&rsquo;s Annual Report
on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in
conjunction with the Company&rsquo;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto,
together with the Management&rsquo;s Discussion and Analysis, for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain information
or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and
Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary
for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however,
that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial
statement presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for
the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has seven subsidiaries, Pipex
Therapeutics, Inc. (&ldquo;Pipex Therapeutics&rdquo;), Effective Pharmaceuticals, Inc. (&ldquo;EPI&rdquo;), Solovax, Inc. (&ldquo;Solovax&rdquo;),
CD4 Biosciences, Inc. (&ldquo;CD4&rdquo;), Epitope Pharmaceuticals, Inc. (&ldquo;Epitope&rdquo;), Healthmine, Inc. (&ldquo;Healthmine&rdquo;)
and Putney Drug Corp. (&ldquo;Putney&rdquo;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics,
Solovax, CD4 and Epitope are majority-owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All inter-company transactions and accounts
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and
assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates
and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property
and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability
and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected
future operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating
its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounts Receivable and Allowance
for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at realizable
value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded.
The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they
were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related
to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the
state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve
estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables
deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off
are recorded as credits to the allowance for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records revenue when all of
the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation,
(3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&nbsp;&nbsp;The Company
recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&nbsp;&nbsp;For
the three months ended March 31, 2012 and 2011, the Company&rsquo;s only stream of revenue was laboratory revenue.&nbsp;Laboratory
revenues are a component of discontinued operations for the three months ended March 31, 2012 and 2011. <I>See Note 4 &ndash; Discontinued
Operations of Adeona Clinical Laboratory and Note Receivable.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s licensing agreements
may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones
and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion
of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations
under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance
approach. Under the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on
the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the
amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under
an arrangement, it recognizes revenue as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, the Company entered into
the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&nbsp; As consideration
for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment
was recorded as license revenue in 2010. Pursuant to the Company&rsquo;s license agreement with McLean Hospital, the Company paid
15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled
to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and
$10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of
7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&nbsp;The
Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for
fibromyalgia. Pursuant to the terms of the Company&rsquo;s agreement with McLean Hospital, the Company is obligated to pay half
of all future royalties the Company receives.&nbsp;&nbsp;Future milestone payments will be recorded as revenue when payment is
received as there are no future deliverables, and it is non-refundable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company primarily recognized revenue
for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including
Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts
from such payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintained a sales allowance
to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance,
the Company looked at several factors, the most significant of which is the average difference between the amount charged and the
amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The
allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&rsquo;s
actual gross sales to determine the actual sales allowance for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company generated reimbursements from&nbsp;3 significant
insurance providers in March 31, 2012 and 2011, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Customer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 33%; text-align: center">A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 34%; text-align: right">68</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">69</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risks and Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's operations could be subject
to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business
failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases
in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may
not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and
plan future business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash
and highly liquid short-term investments with original maturities of three months or less.&nbsp;&nbsp;At March 31, 2012 and 2011,
respectively, the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill was not amortized, and was tested
for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying
value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available
and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was
assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC No. 350 requires a two-step approach
to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests
to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific
assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification
of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit,
and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially
affected by changes in these estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2011, in connection with
the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired.
<I>See Note 4 &ndash; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Earnings (Loss) per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net earnings (loss) per share is computed
by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding.
Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number
of common shares outstanding including the effect of common share equivalents.&nbsp;Since the Company reported a net loss for the
three months ended March 31, 2012 and 2011, all common equivalent shares would be anti-dilutive; as such there is no separate computation
for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations
of net loss per common share for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the
three months ended March 31, 2011 were 2,273,072 and 2,554,650, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses research and development
costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based
compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal
expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement
of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of stock-based payments,
including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value
on the awards&rsquo; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are
ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either
the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The
expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense
in the consolidated statement of operations, depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To conform prior period amounts to current
year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona
Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&rsquo;s previously reported
financial condition, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify"><B>4.&nbsp;&nbsp;&nbsp;Discontinued Operations
of Adeona Clinical Laboratory and Note Receivable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&rsquo;s
outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year
non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid
interest are due on March 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 205-20 &ldquo;
<I>Presentation of Financial Statements&mdash;Discontinued Operations</I> &rdquo; (ASC 205-20), the Company determined that all
the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and
cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately
under the caption &ldquo;Assets of discontinued operations&rdquo; in the accompanying Consolidated Balance Sheets at March 31,
2012, and December 31, 2011, and consist of the following <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Assets of discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Property and equipment, net</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summarized statement of operations data for Adeona Clinical
Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Laboratory fees, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">115</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">323</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.24in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.24in">Cost of&nbsp; laboratory services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">116</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">251</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.24in">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Income (loss) from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Other Income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.12in">Gain on the sale of Adeona Clinical Laboratory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net income from discontinued operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">649</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify"><B>5.&nbsp;&nbsp;&nbsp;Selected Balance Sheet Information</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts receivable consisted of the following at March 31,
2012 and December 31, 2011 <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Accounts receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">736</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Bad debt allowance - customer</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(296</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">440</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and Equipment consisted of the
following at March 31, 2012, and December 31, 2011 <I>(in thousands)</I> :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Manufacturing equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Laboratory equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(392</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(372</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the three months ended March 31, 2012
and 2011 was $20,000 and $80,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify"><B>6.&nbsp;&nbsp;&nbsp;Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2001, Pipex Therapeutics&rsquo;
board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;). This plan was assumed
by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding
under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may
be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000.
All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&rsquo;s employment for any reason.
Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &ldquo;Awards&rdquo;).
The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment,
as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise
price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of
an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2007, the Company&rsquo;s
board of directors approved the Company&rsquo;s 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;) for the issuance
of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation
rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees,
directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The
exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors,
and may be equal to or greater than the fair market value of the Company&rsquo;s common stock on the date the option is granted.
The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one
employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become
exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2012,
there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2010, the board of directors
and stockholders adopted the 2010 Stock Incentive Plan (&ldquo;2010 Stock Plan&rdquo;) for the issuance of up to 3,000,000 shares
of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined
by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&rsquo;s
common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally
expire seven to ten years after the grant date. As of March 31, 2012, there are 1,746,064 options issued and outstanding under
the 2010 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of an employee&rsquo;s termination,
the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial
grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has applied fair value accounting
for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of
grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and 2011
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP>Exercise price</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">$1.14 &ndash; $2.47</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">$1.21 &ndash; $2.22</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="width: 64%; text-align: left">Expected dividends</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="width: 15%; text-align: center">0%</TD><TD NOWRAP STYLE="width: 1%; text-align: center"></TD><TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="width: 15%; text-align: center">0%</TD><TD NOWRAP STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Expected volatility</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">108% &ndash; 174%</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">185% &ndash; 188%</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Risk free interest rates</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0.37% &ndash; 1.98%</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">2.81% &ndash; 3.58%</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Expected life options</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">10 years</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">5 years &ndash; 7 years</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Expected forfeitures</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0%</TD><TD NOWRAP STYLE="text-align: center"></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0%</TD><TD NOWRAP STYLE="text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis
over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-size: 10pt">immediate vesting,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">one-half vesting immediately and the remainder over three years</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-size: 10pt">monthly over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">quarterly over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">annually over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">one-third immediate vesting and remaining annually over two years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">one-eighth immediate vesting with remaining vesting over two years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">one-half immediate vesting with remaining vesting over nine months; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">one quarter immediate vesting with the remaining over three years.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31,
2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3 million based
upon the Black-Scholes option pricing model.&nbsp; During the same period of 2011, the Company granted 324,502 options to employees
having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activities as of March 31, 2012, and
for the year ended December 31, 2011, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR>
Average<BR> Remaining<BR> Contractual<BR> Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 52%">Balance &ndash; December 31, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,539,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">557,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,333</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Forfeited or expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(93,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.59</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Balance &ndash; December 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,979,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(289,343</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Forfeited or expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(146,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.80</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,843,465</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.79</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="text-underline-style: double">7.18
                                                                            years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,230,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; exercisable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,323,320</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="text-underline-style: double">5</FONT>.73
                                                                   years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,814,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable as of March 31, 2012,
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted&nbsp;Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted&nbsp;Average</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Range&nbsp;of</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 16%; text-align: center">$0.09 - $4.57</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">3,753,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.69</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">7.29 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,233,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">5.86 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$4.58 - $9.05</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">2.51
                                                                            years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">2.51
                                                                            years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $9.05</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,843,465</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.79</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><FONT STYLE="text-underline-style: double">7.18
                                                                            years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,323,320</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><FONT STYLE="text-underline-style: double">5.73
                                                                            years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options outstanding and exercisable
as of March 31, 2011, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted&nbsp;Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted&nbsp;Average</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Range&nbsp;of</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 16%; text-align: center">$0.09 - $4.57</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,721,921</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">6.75 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,183,073</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">6.27 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$4.58 - $9.05</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">3.51
                                                                            years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">3.51
                                                                            years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $9.05</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,811,926</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><FONT STYLE="text-underline-style: double">6.65
                                                                            years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,273,072</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.50</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><FONT STYLE="text-underline-style: double">6.16
                                                                            years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options of Subsidiary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2004 and 2007, CD4 granted 30,000
options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding and
exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2012, Epitope has 50,000
options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&nbsp;&nbsp;These
options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes
model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47%
and an expected life of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0in; text-align: justify"><B>7.&nbsp;&nbsp;&nbsp;Stock
Purchase Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2012, the Company entered
into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012.
As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for
250,000 shares of the Company&rsquo;s common stock based on achievement of certain milestones. Upon initiation of the program,
50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement
was executed for an exercise price equal to the price of the Company&rsquo;s common stock on the date of execution. The fair value
of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company
are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 85%">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.37</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2011, the Company entered
into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services,
the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&rsquo;s
common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal
to the price of the Company&rsquo;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and
was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 85%">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.71</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered into
a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase
844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested
immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company entered
into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants
to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants
vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2010, the Company entered into
a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606
shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life
of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an
equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As
of March 31, 2012, 18,182 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of warrant activities as of March 31, 2012, and for
the year ended December 31, 2011, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average&nbsp;Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%">Balance &ndash; December 31, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,131,078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3.49</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,272,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(129,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.08</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Balance &ndash; December 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,259,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,194,264</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 - outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,414,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; exercisable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,214,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants outstanding as of March 31,
2012, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise<BR> Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR> Remaining<BR> Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic&nbsp;Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">344,391</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">344,391</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">0.36 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 17%; text-align: right">443,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.84 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.75 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">746,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">721,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">577,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.66 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.30 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.88 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">6.36</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><U STYLE="text-decoration: none">0.61 years</U></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,414,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,214,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="text-underline-style: double"><U STYLE="text-decoration: none">1.81 years</U></FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,142,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0in; text-align: justify"><B>8.&nbsp;&nbsp;&nbsp;Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31,
2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately
$68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise of warrants, for proceeds of
approximately $1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0in; text-align: justify"><B>9.&nbsp;&nbsp;&nbsp;Subsequent
Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, the Company was informed
by Berman &amp; Company, P.A. (&ldquo;Berman &amp; Company&rdquo;), the Company&rsquo;s independent registered accounting firm,
that during a regular Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) inspection of Berman &amp; Company, the PCAOB
issued a comment that the audit opinion included in the Company&rsquo;s Annual Report on Form 10-K for the year ended December
31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act
as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original
engagement partner rotated off the account under the Securities and Exchange Commission&rsquo;s independence rules as it pertains
to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received funds from the exercise
of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it
receives guidance from the SEC whether the issue disclosed herein affects the Company&rsquo;s ability to continue to issue securities
thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC
staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2012, Jeffrey J. Kraws was appointed
as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr.
Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the
Company&rsquo;s common stock with an exercise price equal to our per share market price on the date of issue. These options will
vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company
measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were
indexed to the Company&rsquo;s own stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Black-Scholes assumptions used in calculating
the fair value of the stock options are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 77%">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">1.70</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1pt solid">Page</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Report of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Consolidated Balance Sheets</TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Consolidated Statements of Operations</TD>
    <TD STYLE="text-align: right">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Consolidated Statements of Changes in Stockholders&rsquo; Equity</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Consolidated Statements of Cash Flows</TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Notes to Consolidated Financial Statements</TD>
    <TD STYLE="text-align: right">70</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="pg71a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We have audited the accompanying consolidated balance sheets of Synthetic Biologics, Inc. and Subsidiaries as of December 31, 2011
and 2010 and the related consolidated statements of operations, stockholders&rsquo; equity and cash flows for the years ended December
31, 2011 and 2010. These consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility
is to express an opinion on these consolidated financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States).&nbsp; Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.&nbsp;
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&nbsp;
Our audits included the consideration of internal control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting.&nbsp; Accordingly, we express no such opinion. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements.&nbsp; An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation.&nbsp; We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly in all material respects, the consolidated financial position of Synthetic Biologics,
Inc. and Subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders&rsquo;
equity and cash flows for the years ended December 31, 2011 and 2010, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Berman &amp; Company, P.A.</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><img src="pg71b.jpg">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Boca Raton, Florida</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: -5.4pt">May 11, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg71c.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(formerly Adeona Pharmaceuticals, Inc.)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,678</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,649</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable &ndash; net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,545</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">91</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,111</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Long Term Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accounts payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Preferred stock,&nbsp;&nbsp;$0.001 par value; 10,000,000 shares authorized, none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Common stock,&nbsp;&nbsp;$0.001 par value; 100,000,000 shares authorized, 31,374,002 issued and 31,292,520 outstanding and 23,420,189&nbsp;issued and 23,338,707&nbsp;outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,901</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(51,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,724</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,579</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,111</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(formerly Adeona Pharmaceuticals, Inc.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;years&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">License revenue, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,125</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Grant revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Operating Costs and Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from Continuing Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,083</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,492</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(242</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Impairment loss on equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(121</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Other Expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,698</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss from Continuing Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,195</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Loss from Discontinued Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,711</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss Per Share &ndash; Basic and Dilutive:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Continuing Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.27</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Discontinued Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Net Loss Per Share</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -8.6pt; padding-left: 8.65pt">Weighted average number of common shares outstanding during the year &ndash; Basic and Dilutive</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,710,428</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,393,568</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(formerly Adeona Pharmaceuticals, Inc.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Changes in
Stockholders' Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Common&nbsp;Stock&nbsp;$0.001&nbsp;Par</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Additional&nbsp;Paid-</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Subscription</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&rsquo;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">in&nbsp;Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Receivable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="width: 34%; font-weight: bold">Balance, December 31, 2009</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">21,449,352</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">22</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">45,553</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(42,013</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(17</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">3,545</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock for employee compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock for license fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock for consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock for options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock, net of issuance costs of $115</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,212,121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss for the year ended December 31, 2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Balance, December 31, 2010</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23,338,707</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">47,280</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(43,724</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,579</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock for employee compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,585</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock for exclusive channel collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,123,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,684</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock for consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock for options and warrants exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,948</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Issuance of common stock, net of issuance costs of $539</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,545,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant liability reclassified to stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss for the year ended December 31, 2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2011</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">31,292,520</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">31</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">58,901</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(51,873</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,059</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(formerly Adeona Pharmaceuticals, Inc.)</B>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;years&nbsp;ended&nbsp;December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Loss from continuing operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,626</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,195</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Loss from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(523</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(516</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash&nbsp;used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock issued as employee compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Stock issued for license fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock issued for exclusive channel collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,684</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Stock issued for consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Provision for uncollectible accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of premium on investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Loss on sale of short-term investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Gain) loss on sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Impairment loss on equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gain on the settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(438</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(335</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deposits and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Assets of discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(196</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(181</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,875</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,145</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Purchase of short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,370</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds from short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,293</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchases of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from the sale of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By (Used In) Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds from issuance of common stock for stock option and warrant exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of common stock for exclusive channel collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds from the issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash paid as direct offering costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(539</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,979</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,014</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Net increase (decrease) in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash at beginning of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,649</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at end of year</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,678</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,649</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exchange of equipment</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Reclassification of warrant liability to additional paid-in capital</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(formerly Adeona Pharmaceuticals, Inc.)</B>
&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31, 2011 and 2010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Organization and Nature of Operations and Basis of
Presentation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Description of Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Synthetic Biologics&rdquo;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development
of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic
biology, the Company is initially developing a product candidate to treat PAH. The Company also intends to expand new and existing
collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being
funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have
partnered the development of, product candidates to treat relapsing-remitting MS, cognitive dysfunction in MS, fibromyalgia and
ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center">Medical Indication</TD>
    <TD NOWRAP STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center">Product Candidate</TD>
    <TD NOWRAP STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 48%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center">Status</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">PAH</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Synthetic DNA-based therapy</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Preclinical</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Relapsing-remitting MS</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Trimesta</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">All patients enrolled in Phase II clinical trial;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;(estriol)</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">dosing and monitoring underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Cognitive dysfunction in</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Trimesta</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Patient enrollment underway in Phase II</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">MS</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;(estriol)</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">clinical trial</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Fibromyalgia</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Effirma</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Partnered with Meda AB</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">(oral flupirtine)</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">ALS</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">AEN-100</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Clinical trial preparation underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">(gastroretentive zinc acetate)</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2011, Synthetic Biologics
announced that the Board of Directors had taken several actions to prioritize its focus on our entry into the emerging field of
synthetic biology. The Company also announced that it intends to seek marketing partners for its zinc-based products <I>reaZin</I>
&trade; and <I>wellZin</I> &trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis of Presentation and Corporate
Structure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2011, the Company had
eight active subsidiaries, Pipex Therapeutics, Inc. (&ldquo;Pipex Therapeutics&rdquo;), Adeona Clinical Laboratory (formerly Hart
Lab, LLC), Effective Pharmaceuticals, Inc. (&ldquo;EPI&rdquo;), Solovax, Inc. (&ldquo;Solovax&rdquo;), CD4 Biosciences, Inc. (&ldquo;CD4&rdquo;),
Epitope Pharmaceuticals, Inc. (&ldquo;Epitope&rdquo;), Healthmine, Inc. (&ldquo;Healthmine&rdquo;) and Putney Drug Corp. (&ldquo;Putney&rdquo;).
As of December 31, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax,
CD4 and Epitope are majority-owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the outstanding
common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&rsquo; equity and cash
flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware
on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was incorporated in
Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006, Healthmine which was formed in Delaware
in December of 2007 and Adeona Clinical Laboratory which was incorporated in Illinois as a limited liability company on August
8, 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner, in consideration for (i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable up through the
date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all the
assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued operations.
This transaction is described in more detail in Note 3 &ndash; Discontinued Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Summary of Significant Accounting Policies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All inter-company transactions and accounts
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Emerging from the Development Stage</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2010, the
Company emerged from the development stage.&nbsp;&nbsp;&nbsp;A development-stage enterprise is one in which planned principle operations
have not commenced or if its operations have commenced, there has been no significant revenue.&nbsp;&nbsp; The Company&rsquo;s
strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage
that results in a significant commercial collaboration.&nbsp;&nbsp;On May 6, 2010, the Company entered into a Sublicense Agreement
(the &ldquo;Meda Agreement&rdquo;) with Meda&nbsp;AB of Sweden (&ldquo;Meda&rdquo;) and received an up-front payment of $2.5 million.
The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement
of principal operations, and therefore development-stage reporting was no longer required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and
assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates
and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property
and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability
and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected
future operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating
its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounts Receivable and Allowance
for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at realizable
value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded.
The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they
were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related
to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the
state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve
estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables
deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off
are recorded as credits to the allowance for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records revenue when all of
the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation,
(3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&nbsp;&nbsp;The Company
recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&nbsp;&nbsp;For
the year ended December 31, 2011, the Company&rsquo;s only stream of revenue was laboratory revenue. During the year ended December
31, 2010, the Company&rsquo;s streams of revenue were license revenue, laboratory revenue and grant revenue.&nbsp;&nbsp;&nbsp;Laboratory
revenues are a component of discontinued operations for the years ended December 31, 2011 and 2010. See Note 3 &ndash; Discontinued
Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s licensing agreements
may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones
and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion
of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations
under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance
approach. Under the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on
the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the
amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under
an arrangement, it recognizes revenue as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, the Company entered into
the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&nbsp; As consideration
for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment
was recorded as license revenue in 2010. Pursuant to the Company&rsquo;s license agreement with McLean Hospital, the Company paid
15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled
to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and
$10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of
7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&nbsp;The
Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for
fibromyalgia. Pursuant to the terms of the Company&rsquo;s agreement with McLean Hospital, the Company is obligated to pay half
of all future royalties the Company receives.&nbsp;&nbsp;Future milestone payments will be recorded as revenue when payment is
received as there are no future deliverables, and it is non-refundable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company primarily recognized revenue
for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including
Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts
from such payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintained a sales allowance
to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance,
the Company looked at several factors, the most significant of which is the average difference between the amount charged and the
amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The
allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&rsquo;s
actual gross sales to determine the actual sales allowance for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generated reimbursement from&nbsp;three
significant insurance providers in 2011 and 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Customer</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 31%; text-align: center">A</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 31%; text-align: right">70</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 30%; text-align: right">65</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">B</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">C</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Grant Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2010, the Company was awarded
two grants totaling $489,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company&rsquo;s clinical
programs. The QTDP Grants Program was included in the healthcare reform legislation and established a one-time pool of $1 billion
for grants to small biotechnology companies developing novel therapeutics which show potential to: (a)&nbsp;result in new therapies
that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions; (b)&nbsp;reduce
long-term health care costs in the U.S.; or (c)&nbsp;significantly advance the goal of curing cancer within a 30-year period.&nbsp;&nbsp;All
grant income was recognized in 2010 and there are no future obligations associated with these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2010 and March 2011, all amounts
awarded under these grants had been received. See Note 9 regarding the taxability of grant revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues, net (in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.75in; border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left">License revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">License fees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(375</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">License revenue, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Grant revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total revenues, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,614</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks and Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's operations could be subject
to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business
failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases
in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may
not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and
plan future business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash
and highly liquid short-term investments with original maturities of three months or less.&nbsp;&nbsp;At December 31, 2011 and
2010, respectively, the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Classification of Marketable Securities
as Held to Maturity, Trading, and Available for Sale</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines the appropriate
classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at
each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability
to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity
are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance
sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally
for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized
gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading,
are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included
in the determination of comprehensive income and reported in shareholders&rsquo; equity. At December 31, 2011 and 2010, respectively,
the Company had no marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2011,
the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds
and certificates of deposits as follows <I>(in thousands)</I> :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 78%; text-align: justify">Purchase of short-term investments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 19%; text-align: right">(4,370</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Amortization of premium on investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Proceeds from short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Loss on sale of short-term investments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Fair value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is recorded at cost
and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease
term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following
table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center">Asset&nbsp;Description</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center">Estimated&nbsp;Useful&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Office equipment and furniture</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">5&nbsp;&nbsp;years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Laboratory equipment</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">7-10 years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Manufacturing equipment</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="padding-right: 0.8pt">Leasehold improvements and fixtures</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0.8pt; text-align: center">Lesser of estimated useful or life of lease</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was approximately
$144,000 and $346,000 for the years ended December 31, 2011 and 2010, respectively. When assets are disposed of, the cost and accumulated
depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2010, the Company reviewed property
and equipment for impairment and determined that certain items had been impaired due to obsolescence. As a result of this review,
the Company recorded an impairment loss of approximately $121,000. For the year ended December 31, 2011, there were no significant
events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the
estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the
carrying value of the asset exceeds its fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill was not amortized, and was tested
for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying
value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available
and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was
assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC No. 350 requires a two-step approach
to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests
to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific
assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification
of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit,
and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially
affected by changes in these estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2011, in connection with
the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired.
See Note 3 &ndash; Discontinued Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Beneficial Conversion Feature</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For conventional convertible debt where
the rate of conversion is below market value, the Company records a &quot;beneficial conversion feature&quot; (BCF) and related
debt discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company records a BCF, the relative
fair value of the BCF would be recorded as a debt discount against the face amount of the respective debt instrument. The discount
would be amortized to interest expense over the life of the debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value accounting requires bifurcation
of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their
fair value for accounting purposes. In&nbsp;determining the appropriate fair value, the Company uses the Black-Scholes option pricing
model. In&nbsp;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional
convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered
conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once determined, derivative liabilities
are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded
in results of operations as an adjustment to fair value of derivatives. In&nbsp;addition, the fair value of freestanding derivative
instruments such as warrants, are also valued using the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Debt Issue Costs and Debt Discount</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may pay debt issue costs, and
record debt discounts in connection with raising funds through the issuance of convertible debt.&nbsp;&nbsp;These costs are amortized
over the life of the debt to interest expense. If&nbsp;a conversion of the underlying debt occurs, a proportionate share of the
unamortized amounts is immediately expensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Original Issue Discount</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For certain convertible debt issued, the
Company may provide the debt holder with an original issue discount.&nbsp;&nbsp;&nbsp;The original issue discount was recorded
to debt discount reducing the face amount of the note and is being amortized to interest expense over the life of the debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Earnings (Loss) per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net earnings (loss) per share is computed
by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding.
Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number
of common shares outstanding including the effect of common share equivalents.&nbsp;Since the Company reported a net loss for the
years ended December 31, 2011 and 2010, all common equivalent shares would be anti-dilutive; as such there is no separate computation
for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations
of net loss per common share for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively, and for the year
ended December 31, 2010 were 1,990,444 and 1,070,472, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses research and development
costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based
compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal
expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement
of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value accounting standards define
fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an
asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify">Level 1 inputs: Quoted prices (unadjusted)&nbsp;for identical assets or liabilities in active markets;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In many cases, a valuation technique used
to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant
input determines the placement of the entire fair value measurement in the hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&rsquo;s
short-term financial instruments, including accounts receivable, other current assets, accounts payable and accrued liabilities,
approximate fair value due to the relatively short period to maturity for these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of stock-based payments,
including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value
on the awards&rsquo; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are
ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either
the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The
expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense
in the consolidated statement of operations, depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes in
accordance with accounting guidance now codified as FASB ASC Topic 740, &ldquo; <I>Income Taxes</I> ,&rdquo; which requires that
the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts
and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.
Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation
allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance now codified as FASB
ASC Topic 740-20, <I>&ldquo;Income Taxes &ndash; Intraperiod Tax Allocation,&rdquo;</I> clarifies the accounting for uncertainties
in income taxes recognized in accordance with FASB ASC Topic 740-20 by prescribing guidance for the recognition, de-recognition
and measurement in financial statements of income tax positions taken in previously filed tax returns or tax positions expected
to be taken in tax returns, including a decision whether to file or not to file in a particular jurisdiction. FASB ASC Topic 740-20
requires that any liability created for unrecognized tax benefits is disclosed. The application of FASB ASC Topic 740-20 may also
affect the tax bases of assets and liabilities and therefore may change or create deferred tax liabilities or assets. The Company
would recognize interest and penalties related to unrecognized tax benefits in income tax expense. At December 31, 2011 and 2010,
respectively, the Company did not record any liabilities for uncertain tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the FASB issued guidance in
regard to fair value measurement. The new guidance results in a consistent definition of fair value and common requirements for
measurement of and disclosure about fair value between GAAP and International Financial Reporting Standards (IFRS). This guidance
is effective for interim and annual periods beginning after December 15, 2011. The adoption of this guidance is not expected to
have a material impact on the Company&rsquo;s financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2011, the FASB issued guidance
in regard to goodwill impairment. The new guidance is intended to reduce the cost and complexity of the annual goodwill impairment
test by providing entities with the option of performing a &quot;qualitative&quot; assessment to determine whether further impairment
testing is necessary. An entity can choose to perform the qualitative assessment on none, some, or all of its reporting units.
Moreover, an entity can bypass the qualitative assessment for any reporting unit in any period and proceed directly to step one
of the impairment test, and then perform the qualitative assessment in any subsequent period. The new guidance is effective for
annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption
permitted. The adoption of this guidance is not expected to have a material impact on the Company&rsquo;s financial position or
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To conform prior period amounts to current
year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona
Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&rsquo;s previously reported
financial condition, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Discontinued Operations of Adeona Clinical Laboratory</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&rsquo;s
outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year
non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 205-20 &ldquo;<I>Presentation
of Financial Statements&mdash;Discontinued Operations</I>&rdquo; (ASC 205-20), the Company determined that the sale of the Lab
should be classified as &ldquo;held for sale&rdquo; at December 31, 2011. In accordance with ACS 205-20 all of the following criteria
must be met for an entity to be classified as &ldquo;held for sale&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt; text-align: justify">Management, having the authority to approve the action, commits to a plan to sell the asset.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">The asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">An active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">The sale of the asset is probable, and transfer of the asset is expected to qualify for recognition as a complete sale within one year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">The asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that all the criteria
had been met and has classified the Lab as discontinued operations and its results of operations, financial position and cash flows
are separately reported for all periods presented. The assets and liabilities of the discontinued operations are presented separately
under the captions &ldquo;Assets of discontinued operations&rdquo; and &ldquo;Liabilities of discontinued operations,&rdquo; respectively,
in the accompanying Consolidated Balance Sheets at December 31, 2011, and December 31, 2010, and consist of the following <I>(in
thousands</I> <I>):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Assets of discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 9pt">Property and equipment, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">178</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Liabilities of discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Current portion of capital lease</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summarized statement of operations data for Adeona Clinical
Laboratory for the years ended December 31, 2011 and December 31, 2010 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left">Laboratory fees, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,169</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">551</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Cost of&nbsp; laboratory services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Impairment loss on goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">178</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(523</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(516</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Selected Balance Sheet Information</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Accounts receivable (in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: justify">Accounts receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">472</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Bad debt allowance - customer</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;Other current assets (in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: justify">Grant receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">320</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">343</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Property and equipment (in thousands)&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: justify">Leasehold improvements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">863</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Manufacturing equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Computer and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Laboratory equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,570</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(372</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,095</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">475</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Accrued expenses (in thousands)&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: justify">Accrued vendor payments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Bonus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">210</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Stock-Based Compensation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2001, the Company&rsquo;s Board
of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;). As of the date of the
merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect
to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any
one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate
upon the termination of the grantee&rsquo;s employment for any reason. Awards include options, restricted shares, stock appreciation
rights, performance shares and cash-based awards (the &ldquo;Awards&rdquo;). The 2001 Stock Plan contains certain anti-dilution
provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan
provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all
other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2011,
there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2007, the Company&rsquo;s
Board of Directors approved the 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;) for the issuance of up to 2,500,000
shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price
of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal
to or greater than the fair market value of the Company&rsquo;s common stock on the date the option is granted. The total number
of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the
Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over
various periods from the date of grant, and generally expire ten years after the grant date. As of December 31, 2011, there are
1,201,156 options issued and outstanding under the 2007 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2010, the Board of Directors
and stockholders adopted the 2010 Stock Incentive Plan (&ldquo;2010 Stock Plan&rdquo;) for the issuance of up to 3,000,000 shares
of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined
by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&rsquo;s
common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally
expire ten years after the grant date. As of December 31, 2011, there are 457,500 options issued and outstanding under the 2010
Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of an employee&rsquo;s termination,
the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial
grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has applied fair value accounting
for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of
grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2011 and
2010 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">$0.49 - $2.22</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">$0.56 - $0.87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Expected dividends</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">0%</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">0%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">175% - 188%</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">187% - 207%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk fee interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1.30% - 3.58%</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.54% - 3.63%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5 - 7 years</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">10 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">0%</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis
over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">immediate vesting,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">half vesting immediately and the remainder over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">quarterly over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">annually over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">one-third immediate vesting and remaining annually over two years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">one half immediate vesting with remaining vesting over nine months,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">one quarter immediate vesting with the remaining over three years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">one quarter immediate vesting with the remaining over 33 months; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">monthly over three years.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2011, the Company granted 557,002
options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.&nbsp;
During 2010, the Company granted 743,332 options to employees and consultants having an approximate fair value of $597,000 based
upon the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average&nbsp;Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; padding-bottom: 2.5pt">Balance &ndash; December 31, 2009</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; padding-bottom: 2.5pt; text-align: right">2,561,332</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="width: 12%; padding-bottom: 2.5pt; text-align: right">1.26</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">7.16 years</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">304,000</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">743,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(255,954</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(509,619</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.69</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">2,539,091</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.32</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.97 years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,028,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">557,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,333</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(93,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.59</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2011 &ndash; outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,979,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.01 years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2011 &ndash; exercisable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,454,607</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.62 years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Grant date fair value of options granted &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">609,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average grant date fair value &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Grant date fair value of options granted &ndash; 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">597,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average grant date fair value &ndash; 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.80</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding options held by related parties &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,283,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable options held by related parties &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,070,660</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding options held by related parties &ndash; 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,083,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable options held by related parties &ndash; 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">858,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable at December 31, 2011
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="11" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="9" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Range&nbsp;of</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 14%; text-align: center">$0.09 - $4.57</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,889,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">6.11 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,364,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">5.72 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$4.58 - $9.05</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">2.76 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">2.76 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $9.05</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,979,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">6.01 years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,454,607</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5.62 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable at December 31, 2010
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="11" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="9" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Range&nbsp;of</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 14%; text-align: center">$0.09 - $4.57</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,449,092</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">7.09 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,900,445</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.28</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">6.47 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$4.58 - $9.05</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">3.76 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">3.76 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $9.05</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,539,091</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.32</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">6.97 years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,990,444</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.48</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">6.35 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Company&rsquo;s non-vested
stock options at December 31, 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>Unvested</B>&nbsp;&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>Grant</B>&nbsp;&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date&nbsp;Fair&nbsp;Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%">Non-vested&nbsp;&ndash;&nbsp;December&nbsp;31,&nbsp;2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">548,647</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">0.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">557,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Vested/Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(528,017</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.07</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(53,229</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.57</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Non-vested &ndash; December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">524,403</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.82</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average remaining period for vesting</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.67 years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Warrants and Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2010, the Company entered into
a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606
shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life
of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an
equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As
of December 31, 2011, 30,303 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company entered
into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants
to purchase 1,428,572 shares of common stock. Each warrant was exercisable&nbsp;for thirteen months&nbsp;at $2.00 per share and
subsequently exchanged for new warrants with substantially the same&nbsp;terms as the original warrants except that the expiration
date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities
at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price.
However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered into
another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40 per
share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in
capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants were initially recorded as
liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair
value recorded as a warrant expense&nbsp;in the Company&rsquo;s statement of operations at each subsequent reporting period. On
April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000.
The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the
following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remeasurement</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Commitment</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Date</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">April&nbsp;6,&nbsp;2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%">Closing stock price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.39</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.08</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected stock price volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.28</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2011, the Company entered
into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially
the same terms as the original warrants except that in the new warrants the expiration date was&nbsp;extended by two months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered into
a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase
844,391 shares of common stock. The warrant was initially exercisable&nbsp;for thirteen months&nbsp;at $2.0725 per share. The warrant
had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less
than $2.0725 per share,&nbsp;the&nbsp;exercise price of the warrant&nbsp;will be ratcheted down to the lower offering price.&nbsp;On
July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i)
the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was
extended for an additional&nbsp;three months to August 12, 2012,&nbsp;and (iv) the warrant&rsquo;s initial exercise date was changed
to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in
capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrant is&nbsp;initially recorded
as a liability at&nbsp;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated
fair value recorded as a warrant expense&nbsp;in the Company&rsquo;s statement of operations at each subsequent period. On July
28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair
value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remeasurement</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Commitment</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Date</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">July&nbsp;28,&nbsp;2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-indent: -0.25in; padding-left: 0.25in">Closing stock price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.08</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.84</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Expected dividend rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Expected stock price volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Expected life (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the estimated fair value of the
warrant liabilities <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in">Balance at December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; text-indent: -0.25in; padding-left: 0.25in">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">Reclassification to additional paid-in capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in">Balance at December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity for the Company
for the year ended December 31, 2010 and for the year ended December 31, 2011 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%">Balance at December 31, 2009</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,070,472</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3.27</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,606</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Balance as December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,131,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,272,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(129,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.08</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,259,186</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all outstanding and exercisable warrants as of
December 31, 2011 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise<BR> Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR> Remaining<BR> Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Aggregate <BR>Intrinsic&nbsp;Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">844,391</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">844,391</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">0.61 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 17%; text-align: right">219,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.00 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.33 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.91 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.41 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.13 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.36</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.86 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,259,186</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,259,186</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.33 years</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">219,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options of Subsidiaries</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2011, CD4 Biosciences,
Inc., a majority-owned subsidiary of Synthetic Biologics, has a total of 20,000 stock options outstanding and exercisable.&nbsp;&nbsp;These
stock options have an exercise price of $0.20 and a remaining contractual life of 0.37 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2011, Epitope, a majority-owned
subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 20,000 stock options exercisable. These stock options
have an exercise price of $0.001 and a remaining contractual life of 6.50 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Stockholders&rsquo; Equity</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Year Ended December 31, 2010</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2010, the Company sold 1,212,121
shares of the Company&rsquo;s common stock at a closing price of $0.825 for gross proceeds of $1 million.&nbsp;&nbsp;The Company
paid direct offering costs of $115,000.&nbsp;&nbsp;See Note 5 regarding warrants granted with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2010,
the Company issued 255,954 shares of common stock, in connection with the exercise of stock options, for proceeds of $130,000.
The Company also issued 279,724 shares of common stock for consulting services, having a fair value of $214,000 ($0.76 per share),
81,035 shares of common stock for license fees, having a fair value of $70,000 ($0.87 per share), and 60,521 shares of common stock
for employment service, having a fair value of $47,000 ($0.77 per share). The fair value of these issuances were based upon the
quoted closing trading prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Year Ended December 31, 2011</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2011,
the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of
$15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common
stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for consulting
services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The Company also
issued 3,123,558 shares of common stock as consideration for the Channel Agreement with Intrexon, having a fair value of $1.7 million
($0.54 average per share), based on the quoted closing trading price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company sold 2,857,144
shares of common stock and warrants exercisable for&nbsp;1,428,572 shares of common stock&nbsp;for $4 million. Direct offering
costs were approximately $296,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company sold 1,688,782
shares of common stock and a warrant exercisable for 844,391 shares of common stock&nbsp;for $3.5 million. Direct offering costs
were approximately $243,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>License, Collaborative and Employment Agreements and
Commitments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into various option
and license agreements for the use of patents and their corresponding applications. These agreements have been entered into with
various educational institutions and hospitals. These agreements contain payment schedules or stated amounts due for (a) option
and license fees, (b) expense reimbursements, and (c) achievement of success milestones. All expenses related to these agreements
have been recorded as research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September&nbsp;of 2005, the Company
entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored
research of approximately $460,000 per year.&nbsp;&nbsp;On March 20, 2008, the Company terminated the agreement.&nbsp;&nbsp;On
March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&nbsp;&nbsp;The
Company agreed to pay $5,000 per month, until the balance is paid in full. At December 31, 2011, the balance is approximately $32,000
and is recorded as a short-term accounts payable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Employment Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2010, the Company executed
a three-year employment agreement with James S. Kuo, M.D., Chairman, Chief Executive Officer and President.&nbsp;&nbsp;The agreement
provided for an annual base salary of $199,000, discretionary performance and transactional bonus payments, and 400,000 stock options
with an exercise price equal to the market price on the date of grant.&nbsp;&nbsp;Of these stock options, 100,000 vested immediately
upon grant and the remainder will vest pro rata, on a monthly basis, over the following thirty-six months. The fair value of the
options totaled $328,000 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield
of 0%, expected volatility of 204.5%; risk free interest rate of 3.59% and an expected life of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, Dr. Kuo resigned
from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month
consulting agreement with the Company (the &ldquo;Consulting Agreement&rdquo;). Pursuant to the Consulting Agreement, Dr. Kuo will
be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that have vested
(324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year from the effective
date of the Consulting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, Jeffrey Riley
was appointed to serve as the Company&rsquo;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley
entered into a three-year employment agreement with the Company (the &ldquo;Riley Employment Agreement&rdquo;). Pursuant to the
Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary
performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&rsquo;s
common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata,
on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million
using a Black-Scholes valuation model; these warrants were indexed to the Company&rsquo;s own stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 6, 2012, C. Evan Ballantyne
was appointed the Company&rsquo;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year
employment agreement with the Company (the &ldquo;Ballantyne Employment Agreement&rdquo;). Pursuant to the Ballantyne Employment
Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance
and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock
with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly
basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes
valuation model; these warrants were indexed to the Company&rsquo;s own stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Black-Scholes assumptions used in
calculating the fair value of the stock options are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 54%; padding-right: 0.8pt">Exercise price</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 39%; padding-right: 0.8pt; text-align: center">$2.30 - $2.47</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Expected dividends</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">0%</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Expected volatility</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">174%</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Risk free interest rate</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">1.93% - 1.97%</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Expected life of options</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">10 years</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Expected forfeitures</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">0%</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Commitments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2011, amounts due for
license agreements are as follows <I>(in thousands)</I> :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Year&nbsp;Ending&nbsp;December&nbsp;31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 79%; text-align: left; padding-left: 17.3pt">2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt; text-align: left">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Operating Lease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2007, the Company entered into a
non-cancelable operating lease for office, laboratory and production space in Ann Arbor, Michigan.&nbsp;This lease expired on February
28, 2011. In March 2011, the Company entered into a month-to-month lease, at a different location, in Ann Arbor, Michigan.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2011
and 2010 the Company recognized rent expense of $64,000 and $214,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Capital Lease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2006, the Company acquired $65,000
of equipment under a non-cancelable capital lease. The Company agreed to guarantee and to release the seller from the seller&rsquo;s
personal guarantee of the remaining balance and the amount was placed in escrow.&nbsp;&nbsp;The effective interest rate of the
lease was 8.51%.&nbsp; Related monthly payments of principal and interest were $1,400 over a period of sixty months.&nbsp; In September
2008, the lessor extended the term for repayment by eight months, with a final maturity date of January 2012.&nbsp;&nbsp;The remaining
balance of this capital lease at December 31, 2010 was $24,000. In January 2011, this capital lease was paid in full and the funds
were released from escrow. See Note 3 &ndash; Discontinued Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Stock Repurchase Program</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 3, 2009, the Company&rsquo;s Board
of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December
31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of December
31, 2011, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted closing
trading price.&nbsp;&nbsp;These treasury shares are not included in the computation of earnings (loss) per share and are deemed
to be canceled and retired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Income Taxes</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no income tax expense for the
years ended December 31, 2011 and 2010 due to the Company&rsquo;s net losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s tax expense differs
from the &ldquo;expected&rdquo; tax expense for the years ended December 31, 2011 and 2010, (computed by applying the Federal Corporate
tax rate of 34% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows
<I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Computed &ldquo;expected&rdquo; tax benefit -  Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,618</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(550</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computed &ldquo;expected&rdquo; tax benefit - State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(448</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(94</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Non-taxable federal grant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Meals, entertainment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Non-deductible stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Change in fair value of warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Realized loss on debt securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">673</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effects of temporary differences that
gave rise to significant portions of deferred tax assets at December 31, 2011 and 2010 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Deferred&nbsp;tax&nbsp;assets:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Stock issued for services</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(321</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(223</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Bad debt &ndash; change in allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(205</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net operating loss carry-forward</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,644</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total gross deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,951</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,916</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,951</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,916</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2011, the Company has a
net operating loss carry-forward of approximately $27.7 million available to offset future taxable income expiring through 2031.
Utilization of these net operating losses may be limited due to potential ownership changes under Section 382 of the Internal Revenue
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation allowance at December 31,
2010 was approximately $8.9 million. The net change in valuation allowance during the year ended December 31, 2011 was an increase
of approximately $2 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred
income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences
become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income,
and tax planning strategies in making this assessment. Based on consideration of these items, Management has determined that enough
uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation
allowance as of December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2010, the Company received grant
revenue of $489,000.&nbsp;&nbsp;Under the terms of the grant, this revenue is not taxable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2011, the Company entered
into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services,
the consultant will be paid a monthly fee of $10,000 and was issued a warrant exercisable for 100,000 shares of the Company&rsquo;s
common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal
to the price of the Company&rsquo;s common stock on the date of issue. The issue date of the warrant is February 2, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrant approximated
$200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 75%">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">1.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.71</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, the Company was informed
by Berman &amp; Company, P.A. (&ldquo;Berman &amp; Company&rdquo;), the Company&rsquo;s independent registered accounting firm,
that during a regular Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) inspection of Berman &amp; Company, the PCAOB
issued a comment that the audit opinion included in the Company&rsquo;s Annual Report on Form 10-K for the year ended December
31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act
as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original
engagement partner rotated off the account under the Securities and Exchange Commission&rsquo;s independence rules as it pertains
to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the previously
filed financial statements for the year ended December 31, 2011 are accurate. In addition, the Company has not been informed by
Berman &amp; Company or the PCAOB, that the previously filed financial statements for the year ended December 31, 2011 are not
accurate or otherwise invalid. As a matter of precaution the new engagement partner at Berman &amp; Company has since: (i) taken
full responsibility for the audit as the lead engagement partner on the audit, (ii) performed a detailed review of all audit procedures
related to the original audit for sufficiency and (iii) reissued the audit opinion. The review performed by the new audit partner
did not result in any changes to the Company&rsquo;s financial statements or notes to the financial statements for the year ended
December 31, 2011, other than the addition of the May 1, 2012 and May 10, 2012 disclosures in this subsequent event note to the
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2012, Jeffrey J. Kraws was appointed
as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr.
Kraws will be issued options exercisable for 100,000 shares of the Company&rsquo;s common stock and will receive annual compensation
of $150,000. The fair value of these options will be measured using the Black-Scholes valuation model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II - INFORMATION NOT REQUIRED IN
PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that expenses in connection
with the distribution described in this registration statement (other than brokerage commissions, discounts or other expenses relating
to the sale of the shares of common stock underlying the Warrants by the selling security holders) will be as set forth below.
We will pay all of the expenses with respect to the distribution, and such amounts, with the exception of the Securities and Exchange
Commission registration fee, are estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 85%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,069.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">930.50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,000.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the provisions of Section 78.138
of Nevada Revised Statutes and our Articles of Incorporation, we may indemnify our directors, officers, employees and agents and
maintain liability insurance for those persons. Section 78.138 provides that a corporation may indemnify a person made a party
to a proceeding because the person is or was a director against liability incurred in the proceeding if the person's conduct was
in good faith. In the case of conduct in an official capacity with the corporation, the person may be indemnified if the person
reasonably believed that such conduct was in the corporation's best interests. In all other cases, the corporation may indemnify
the person if the person reasonably believed that such conduct was at least not opposed to the corporation's best interests. In
the case of any criminal proceeding, the person may be indemnified if the person had no reasonable cause to believe the person's
conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation obligate
us to indemnify our directors and officers to the fullest extent permitted under Nevada law. Additionally, our Articles of Incorporation
and Bylaws grant us the authority to the maximum extent permitted by Nevada law to purchase and maintain insurance providing such
indemnification. We have purchased directors' and officers' liability insurance policies for our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the employment agreement that we entered
into with all of our officers, we agreed to indemnify our officers for all claims arising out of performance of their duties as
officers of the company, other than those arising out of his breach of the agreement or his gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
for damages arising under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) may be permitted to our directors,
officers, and controlling persons pursuant to the foregoing provision, or otherwise, we have been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 15. RECENT SALES OF UNREGISTERED
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following information sets forth certain
information with respect to all securities which we have sold during the last three years.&nbsp;&nbsp;We did not pay any commissions
in connection with any of these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January, February and March 2009, we
issued a total of 139,935 shares of our common stock to two consultants for services rendered. These offerings and sales of shares
qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering.
The offerings were not a public offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number
of persons and because of the manner of the offering. This offering was done with no general solicitation or advertising by us.
Based on an analysis of the above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities
Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2009, we issued a total of
257,813 shares of our common stock to a university for license fees. These offerings and sales of shares qualified for exemption
under Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering. The offerings were not
a public offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number of persons and because
of the manner of the offering. The offerings were done with no general solicitation or advertising by us. Based on an analysis
of the above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities Act of 1933 for these
sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2009, we issued
a total of 72,840 shares of our common stock to three consultants for services rendered. These offerings and sales of shares qualified
for exemption under Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering. The offerings
were not a public offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number of persons
and because of the manner of the offering. This offering was done with no general solicitation or advertising by us. Based on an
analysis of the above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities Act of 1933
for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2009, in connection with our acquisition
of all of the outstanding membership interests in Hartlab LLC, an Illinois limited liability company and CLIA-certified clinical
laboratory, in May 2009, as partial consideration for the purchase of the lab, we issued 50,000 unregistered shares of our common
stock to the owner of the lab. This offering and sale of shares qualified for exemption under Section 4(2) of the Securities Act
of 1933 since the issuance did not involve a public offering. The offering was not a public offering as defined in Section 4(2)
because the offer and sale was made to an insubstantial number of persons and because of the manner of the offering. This offering
was done with no general solicitation or advertising by us. Based on an analysis of the above factors, we met the requirements
to qualify for exemption under Section 4(2) of the Securities Act of 1933 for this issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2009, we issued
a total of 19,697 shares of our common stock to three consultants for services rendered. These offerings and sales of shares qualified
for exemption under Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering. The offerings
were not a public offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number of persons
and because of the manner of the offering. This offering was done with no general solicitation or advertising by us. Based on an
analysis of the above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities Act of 1933
for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2009, we issued
104,633 shares of common stock, in connection with the exercise of stock options, for proceeds of $27,834 and issued 3,066 shares
of common stock for consulting fees, having a fair value of $65,786 ($0.28 per share), based on the quoted closing trading prices.
These offerings and sales of shares qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuances
did not involve a public offering. The offerings were not a public offering as defined in Section 4(2) because the offer and sale
was made to an insubstantial number of persons and because of the manner of the offering. This offering was done with no general
solicitation or advertising by us. Based on an analysis of the above factors, we met the requirements to qualify for exemption
under Section 4(2) of the Securities Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first three months of 2010,
we issued a total of 33,118 shares of our common stock to two consultants for services rendered. These offerings and sales of shares
qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering.
The offerings were not a public offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number
of persons and because of the manner of the offering. This offering was done with no general solicitation or advertising by us.
Based on an analysis of the above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities
Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2010, we issued warrants to the
placement agent and its designees in connection with our sale of shares of our common stock pursuant to our registration statement
on Form S-3. The warrants are exercisable for 60,606 shares of common stock at an exercise price of $1.32 for a period of five
years. The sale of such shares was exempt from registration under the Securities Act in reliance upon Section 4(2) thereof since
the issuances did not involve a public offering. The issuances were not a public offering as defined in Section 4(2) because the
offer and sale was made to an insubstantial number of persons and because of the manner of the issuances. These issuances were
done with no general solicitation or advertising by us. Based on an analysis of the above factors, we met the requirements to qualify
for exemption under Section 4(2) of the Securities Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October of 2010, we issued 52,180 shares
of common stock to Thomas Jefferson University having a fair value of $41,250 ($0.79 per share) and 28,855 shares of common stock
to the University of Southern California having a fair value of $29,087 ($1.01 per share) in payment for licensing fees. The fair
value of these issuances was based upon the quoted closing price. These issuances and sales of shares qualified for exemption under
Section 4(2) of the Securities Act of 1933 since the issuances did not involve a public offering. The issuances were not a public
offering as defined in Section 4(2) because the offer and sale was made to an insubstantial number of persons and because of the
manner of the issuances. These issuances were done with no general solicitation or advertising by us. Based on an analysis of the
above factors, we met the requirements to qualify for exemption under Section 4(2) of the Securities Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2011, we exchanged the warrant
issued in connection with the April 6, 2011 financing for a new warrant with substantially the same terms as the original warrant.
We exchanged our warrant with existing security holders and no remuneration or commission was paid in reliance on Section 3(a)(9)
of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 2, 2011, we issued 130,000 shares of our common stock to Chardan Capital Markets, LLC (Chardan) as compensation for the
execution and delivery of a Financial Advisory Agreement that we entered into with Chardan on June 3, 2011. The offer and issuance
of the shares of common stock have not been registered under the Securities Act, and therefore such shares of common stock may
not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">This
issuance and sale of shares qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuance did not
involve a public offering. The issuance was not a public offering as defined in Section 4(2) because the offer and sale was made
to an insubstantial number of persons and because of the manner of the issuance. This issuance was done with no general solicitation
or advertising by us. Based on an analysis of the above factors, we met the requirements to qualify for exemption under Section
4(2) of the Securities Act of 1933 for these sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2011, we entered into an
agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants. We exchanged our
warrant with existing security holders and no remuneration or commission was paid in reliance on Section 3(a)(9) of the Securities
Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 7, 2011 a closing was held
for the transaction previously announced on November 21, 2011 between us and Intrexon. We issued 3,123,558 shares of our common
stock at a purchase price equal to the $0.001 par value of such shares, which issuance is also deemed paid in partial consideration
for the execution and delivery of the exclusive channel collaboration agreement, dated November 18, 2011, between us and Intrexon.
This issuance and sale of shares qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuance did
not involve a public offering. The issuance was not a public offering as defined in Section 4(2) because the offer and sale was
made to an insubstantial number of persons and because of the manner of the issuance. This issuance was done with no general solicitation
or advertising by us. Based on an analysis of the above factors, we met the requirements to qualify for exemption under Section
4(2) of the Securities Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2012, we issued five year warrants
exercisable at the closing price of our common stock on the date of issue for 100,000 shares of our common stock to Griffin Securities,
Inc. (Griffin) as compensation for the execution and delivery of a Financial Advisory Agreement that we entered into with Griffin
on December 20, 2011. This issuance and sale of warrants qualified for exemption under Section 4(2) of the Securities Act of 1933
since the issuance did not involve a public offering. The issuance was not a public offering as defined in Section 4(2) because
the offer and sale was made to an insubstantial number of persons and because of the manner of the issuance. This issuance was
done with no general solicitation or advertising by us. Based on an analysis of the above factors, we met the requirements to qualify
for exemption under Section 4(2) of the Securities Act of 1933 for these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 16. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Incorporation, as amended (Incorporated by reference to (i)&nbsp;Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 16, 2008, (ii)&nbsp;Exhibit&nbsp;3.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001 filed August 14, 2001 and (iii)&nbsp;Exhibits 3.1, 4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 1998 filed August 14, 1998)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Articles of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.4</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Articles of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.5</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">By-Laws (Incorporated by reference to (i) Exhibit 3.4 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009 and (ii) Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed June 3, 2010. )</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Amended and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed November 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 16, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&rsquo;s Current Report on Form 8-K filed December 1, 2006.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">2001 Stock Incentive Plan (Incorporated by reference to Exhibit 4.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed January 18, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">2007 Stock Incentive Plan (Incorporated by reference to Exhibit 4.2 of the Registrant&rsquo;s Registration Statement on Form S-8 filed January 18, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.4</TD>
    <TD STYLE="width: 92%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">2010 Stock Incentive Plan (Incorporated by reference
        to Exhibit 4.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed November 29, 2010.)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">4.5</TD>
    <TD STYLE="padding-right: 0.8pt">Form of Warrant Certificate issued to Enclave Capital LLC (Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant to Purchase Common Stock issued January 2011(Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant to Purchase Common Stock issued April 2011(Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.8</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Exchange Warrant to Purchase Common Stock issued in exchange of the Warrant issued April 2011(Incorporated by reference to Exhibit 4.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.9</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Exchange Warrant to Purchase Common Stock issued in exchange of the Warrant issued February 2011(Incorporated by reference to Exhibit 4.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.10</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Form of Warrant to Purchase Common Stock issued February 2012 (Incorporated by reference to Exhibit 4.10 of the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">4.11</TD>
    <TD STYLE="padding-right: 0.8pt">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.10 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 30, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">5.1</TD>
    <TD STYLE="padding-right: 0.8pt">Legal Opinion of Gracin &amp; Marlow, LLP (1)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">10.1</TD>
    <TD STYLE="padding-right: 0.8pt">Unit Purchase Agreement (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K filed December 1, 2006.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">License Agreement between The Regents of the University of California and Epitope Pharmaceuticals, Inc. (Incorporated by reference to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2008 filed November 14, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Form of Director/Officer Indemnification Agreement (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed January 6, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.4</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Warrant Cancellation and Registration Rights Agreement between Accredited Adventures Capital LLC and Adeona (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed January 20, 2009.)*</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.5</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Stock Purchase Agreement with Neil O. Colwell and Connie Colwell&nbsp;&nbsp;(Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed April 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Escrow Agreement Nayaran Torke (Incorporated by reference to Exhibit 10.5 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consulting Agreement with Nayaran Torke (Incorporated by reference to Exhibit 10.4 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.8</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Purchase Agreement 1st Amendment HartLab LLC (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.9</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Purchase Agreement 2nd Amendment Hartlab LLC (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.10</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Agreement and Plan of Reincorporation Merger (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.11</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with James S. Kuo, M.D., (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 9, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.12</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Separation Agreement with Max Lyons (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 9, 2010.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">10.13</TD>
    <TD STYLE="padding-right: 0.8pt">Sublicense Agreement between Meda AB, Adeona Pharamaceuticals, Inc. and Pipex Therapeutics, Inc. (Incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed May 11, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.14</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Non-Disturbance Agreement among Pipex Therapeutics, Inc., Mclean Hospital Corp and Meda AB (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed May 11, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.15</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Placement Agent Agreement with Enclave Capital LLC (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.16</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Common Stock Purchase Agreement with Seaside 88,LP (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.17</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Agreement with Chardan Capital Markets, LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.18</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Securities Purchase Agreement with investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.19</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">McLean Hospital Corporation Exclusive License Agreement (Incorporated by reference to Exhibit 10.21 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 31, 2011)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.20</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Agreement with Chardan Capital Markets, LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.21</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Securities Purchase Agreement with investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.22</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Exchange Agreement with respect to Warrant issued April 2011(Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.23</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Exchange Agreement with respect to Warrant issued February 2011(Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">10.24</TD>
    <TD STYLE="padding-right: 0.8pt">Exclusive Cannel Collaboration Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.25</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Stock Purchase Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.26</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Registration Rights Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.27</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with Jeffrey Riley (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 6, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.28</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consulting Agreement with Dr. James Kuo (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 6, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.29</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with C. Evan Ballantyne (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 7, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.30</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with Steve H. Kanzer (1)Incorporated by reference to Exhibit 10.304 of the Registrant's Annual&nbsp; Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.31</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Membership Interest Purchase Agreement by and among Synthetic Biologics, Inc., Hartlab LLC, and Adeona Clinical Laboratory, LLC, dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.32</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Pledge and Security Agreement between Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.33</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Non-Recourse Promissory Note between Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">10.34</TD>
    <TD STYLE="padding-right: 0.8pt">Financial Advisory Agreement with Griffin Securities, Inc. (Incorporated by reference to Exhibit 10.34 of the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">21</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">List of Subsidiaries (Incorporated by reference to Exhibit 10.34 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">23.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consent of Independent Registered Accounting Firm (1)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">23.2</TD>
    <TD STYLE="width: 92%">Consent of Gracin &amp; Marlow, LLP (Included in its opinion filed as Exhibit 5)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>24</TD>
    <TD>Power of Attorney (Included on signature page)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt; text-align: center">(1)</TD>
    <TD STYLE="width: 92%; font-size: 10pt; padding-left: 0in">Filed herewith.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Management contract or compensatory plan or arrangement required
to be identified pursuant to Item 15(a)(3) of this report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 28. UNDERTAKINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrants, pursuant to
the provisions described under Item&nbsp;15 or otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification by it is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) to include any prospectus required
by Section&nbsp;10(a)(3) of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) to reflect in the prospectus any acts
or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement
(notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) to include any material information
with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such
information in this registration statement; provided, however, that subparagraphs (i), (ii)&nbsp;and (iii)&nbsp;do not apply if
the information required to be included in a post-effective amendment by those subparagraphs is contained in periodic reports filed
with or furnished to the SEC by the Registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act
of 1934, that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) To remove from registration, by means
of a post-effective amendment, any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) if the Registrant is relying on Rule
430B: (A)&nbsp;each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration
statement as of the date the filed prospectus was deemed part of and included in the registration statement; and (B)&nbsp;each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information
required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale
of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) if the Registrant is subject to Rule
430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date
of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: the undersigned Registrant
undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless
of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser: (i)&nbsp;any preliminary prospectus or prospectus of the undersigned Registrant
relating to the offering required to be filed pursuant to Rule 424; (ii)&nbsp;any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant; (iii)&nbsp;the portion
of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant
or its securities provided by or on behalf of the undersigned Registrant; and (iv)&nbsp;any other communication that is an offer
in the offering made by the undersigned Registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) That, for purposes of determining any
liability under the Securities Act of 1933, each filing of the Registrant&rsquo;s annual report pursuant to Section&nbsp;13(a)
or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in this registration statement shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) That for purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
(4)&nbsp;or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the time it
was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) That, for the purpose of determining
any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) To file an application for the purpose
of determining the eligibility of the trustee to act under subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act in
accordance with the rules and regulations prescribed by the Commission under Section&nbsp;305(b)(2) of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on the Post-Effective Amendment No. 1 to Form S-3 on Form&nbsp;S-1 and has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Ann Arbor, State of Michigan, July 12, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 31%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey Riley</TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Date: July 12, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; padding-right: 0.8pt">/s/ C. Evan Ballantyne</TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Financial and Principal Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Date: July 12, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the undersigned hereby severally constitute
and appoint each of Jeffrey Riley and C. Evan Ballantyne our true and lawful attorney and agent, with full power to each to sign
for us, and in our names in the capacities indicated below, any and all amendments to this registration statement, any subsequent
registration statements pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully
do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid; padding-right: 0.8pt">/s/ Jeffrey Riley</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Date: July 12, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey J. Kraws</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey J. Kraws</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chairman</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Steve H. Kanzer</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Steve H. Kanzer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">James S. Kuo</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Nelson K. Stacks</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Scott L. Tarriff</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Scott L. Tarriff</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: July 12, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey Wolf</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey Wolf</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 102; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v318169_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GRACIN &amp; MARLOW, LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Chrysler Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">405 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">26th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10174</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone (212) 907-6457</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Facsimile: (212) 208-4657</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 12, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617 Detroit Street, Suite 100, Ann Arbor, Michigan 48104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-Effective
Amendment No. 1 to Form S-3 on Form S-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At your request, we
have examined the Post Effective Amendment No 1 to Form S-3 on Form S-1 (the &quot;Registration Statement&quot;) to which this
letter is attached as Exhibit 5.1 filed by Synthetic Biologics, Inc., a Nevada corporation (the &quot;Company&quot;), that is intended
to register under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;),112,573 shares of common stock (the &ldquo;Shares&rdquo;)
consisting of 18,182 shares of common stock issuable upon exercise of warrants sold in the July 2010 offering and 94,391 shares
of common stock issuable upon exercise of warrants initially sold in the April 2011 offering. (the &quot;Shares&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have examined originals
or certified copies of such corporate records of the Company and other certificates and documents of officials of the Company,
public officials and others as we have deemed appropriate for purposes of this letter. We have assumed the genuineness of all signatures,
the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all copies submitted
to us as conformed and certified or reproduced copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing,
we are of the opinion that under Nevada law that the Shares when issued will be duly authorized and validly issued, fully paid
and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the use
of this opinion as an Exhibit to the Registration Statement and to the use of our name in the prospectus constituting a part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 66%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt">Very truly yours,</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 1.6pt; font-style: italic">/s/ Gracin &amp; Marlow, LLP</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1.6pt">Gracin &amp; Marlow, LLP&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v318169_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex23logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public
Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the use of our report dated
May 11, 2012 on the consolidated financial statements of Synthetic Biologics, Inc. and Subsidiaries as of December 31, 2011 and
2010, included herein on the registration statement of Synthetic Biologics, Inc. and Subsidiaries on Form S-1 (Post-Effective Amendment
No. 1 to Form S-3 on Form S-1), and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Berman &amp; Company, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex23sig.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 12, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex23logo2.jpg" ALT="">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg6.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!#P*>`P$1``(1`0,1`?_$`0\``0`!!`,!`0``````
M```````!`@8'"`,$!0D*`0$``@,!`0$``````````````@,!!`4&!P@0```%
M`@,"!0L+"@X($`L$"P$"`P0%!@<`$0@A$C%1$Q0)06&1H2+3U9<86!G1,E(5
M51:6UA=7&O!Q@9(C5)25UPJQP>%"TC-3X[8G-W<H.'(DU"6U)F>'8H*B0[/#
M-$1%-E9V1[=(>,*CM#5E=87%9L;'<Y-&:/%C@W2$I,2EAJ>X$0`!`@,#!@D(
M!P4%!P(&`P$!``(1`P0A$@4Q49'1%`;P06%QH2)2$Q>!L>$RTE,5!\%"8I+B
M5!9R@B,SDZ)CT^,T\;+"0W,D-40E\H.SM%4V=)1E1?_:``P#`0`"$0,1`#\`
M^W?2O=,U>CH^M25-V6H*SUN;A0,]:R(KCVVJJ<J&,E&LD]G9F+58HHQ31R@J
M@+:/`V\80''U/Y?_`"[E;T89WIO]6RP@`\]B^>;U;X/P-Q;8OF(7\Z&U+F]9
MICLF;//+<JZL3@`E."8E,8D<(%,!S`&0Y#CZ)(^1-``73'.:[D('_"O'-^9E
M4^49H`NCD]*K^E#:F`SSTPV2'+ASJVL<^J'`,=F.0AMXNKC7F_(RE#HL+CHU
M*4OYHSQE`T>E4C^=#ZEPS$-,%D@#8`Y596(;1X`V1N>W+`?)*GF"Z73##.01
MYE*9\U9SP``V(Y/2I+^=#ZF#CNDTR62.($,H8$ZOK`X$(4HG,8YB1XE3W2EV
M[V0@.P=H@&*G?).DEVQ=I&I5>*-3F&CTJKZ4)J;\V"RN>0#D-6UD!@`P`8,R
MC'9ES*(#MZ@XDSY)4LT7@7Y891J6/%*>,L-"H-^=#ZF29[VF.R11W0.!1K"L
M`.8HFW,TT_:_?4R-P[H#D&T=F)^!M-G=I&I/%.?]G1Z4'\Z&U,@.0Z8;*@.Z
M)\C59691W`R[O(8P,R?Z+@QF7\BZ.:^X;T?)[*D[YGU+&"99`C-Z5/TH74OD
M4?)CLCD81W1"L*O$#9%`_<F"/R,`E$,LN'$IOR)HI,(DC1[*Q*^:%1/,&PCS
M>E4_2A-3(9`.F"RQ1$0#(U65H3:8<@+W4:'="/ZWAZV+G?(_=AH-W$'$_M/]
MA8;\U*MQM`AS>E0'YT1J5R`P:9;)[0*(?XX5CF(&#8.[[7[V6W;LV=7&M,^2
MN`M:3)K'3)G$V+K>2UD-*N/S-G!E[JQYER#^="ZF@,<HZ8;*@8AMT0-5E9@&
M]EGW(C&Y'`0ZH9ABEOR4I)AA%^D:E3XHU.8:/2I#\Z$U-=73!9(<Q*4,ZMK'
MUQC`4H;8[9F(XV&?(NE=;%X@,XU*7BI/EVN#8<WI4#^=":F<Q_HPV7$2B8!`
MM6UF;UAMTV0%C1`<A'J8K\%J.]<O/TCV5J^*53WEZ`AS>E5!^=#:E=I?)BLD
M!BB(&*%75B`E$!$H@<H1V939E'AQ:_Y&4X@;SS$9Q[*WF?-&9/$1"SD5)OSH
M;4OGLTQ63X/^5U9^#L0\#:?[>D:E/Q*FG-H]*CZ4-J9ZFF*R?PNK+P=AX&TW
MVM(U*A_S0G,<6B%G)Z4^E#:FO-ALG\+JQ\'8>!M-]K2-2CXI3_LZ/2GTH;4U
MYL-D_A=67@[#P-IOM:1J3Q2G_9T>E5C^=#:E\ARTQ64SRV?XW5GX.P\#:?._
M2/93Q2G_`&='I5'TH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_9T>E/I0VIKS8;)_
M"ZL?!V'@;3?:TC4GBE/^SH]*?2AM37FPV3^%U8^#L/`VF^UI&I/%*?\`9T>E
M5%_.AM3&W>TQ63ZW^-U9?I1V'@;3YWZ1J3Q2G_9T>E0;\Z&U,9[-,5D\LO\`
ME=67Z<=AX&TV=^D:D\4I_P!G1Z5'TH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_9T
M>E/I0VIKS8;)_"ZL?!V'@;3?:TC4GBE/^SH]*?2AM37FPV3^%U8^#L/`VF^U
MI&I/%*?]G1Z4^E#:FO-ALG\+JQ\'8>!M-]K2-2>*4_[.CTI]*&U->;#9/X75
MCX.P\#:;[6D:D\4I_P!G1Z4^E#:FO-ALG\+JQ\'8>!M-]K2-2>*4_P"SH]*?
M2AM37FPV3^%U8^#L/`VF^UI&I/%*?]G1Z547\Z&U,;=[3%9/K?XW5E^E'8>!
MM/G?I&I/%*?]G1Z5!OSH;4QGLTQ63RR_Y75E^G'8>!M-G?I&I/%*?]G1Z5'T
MH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_9T>E/I0VIKS8;)_"ZL?!V'@;3?:TC4G
MBE/^SH]*?2AM37FPV3^%U8^#L/`VF^UI&I/%*?\`9T>E<GTH;4MYL5E/A=6?
M@[#P-I\[](]E/%*?]G1Z5Q_2AM37FPV3^%U8^#L/`VF^UI&I/%*?]G1Z4^E#
M:FO-ALG\+JQ\'8>!M-]K2-2>*4_[.CTI]*&U->;#9/X75CX.P\#:;[6D:D\4
MI_V='I51?SH;4Q^NTPV3^%U9?I1V'@;39WZ1J3Q2G_9T>E#?G0VIC9NZ8K)]
M?_&ZLOTX[#P-I\[](U)XI3_LZ/2J?I0VIKS8;)_"ZL?!V'@;3?:TC4GBE/\`
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MV3^%U8^#L/`VF^UI&I/%*?\`9T>E/I0VIKS8;)_"ZL?!V'@;3?:TC4GBE/\`
MLZ/2GTH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_9T>E/I0VIKS8;)_"ZL?!V'@;3
M?:TC4GBE/^SH]*?2AM37FPV3^%U8^#L/`VF^UI&I/%*?]G1Z4^E#:FO-ALG\
M+JQ\'8>!M-]K2-2>*4_[.CTI]*&U->;#9/X75CX.P\#:;[6D:D\4I_V='I3Z
M4-J:\V&R?PNK'P=AX&TWVM(U)XI3_LZ/2GTH;4UYL-D_A=6/@[#P-IOM:1J3
MQ2G_`&='I3Z4-J:\V&R?PNK'P=AX&TWVM(U)XI3_`+.CTI]*&U->;#9/X75C
MX.P\#:;[6D:D\4I_V='I3Z4-J:\V&R?PNK'P=AX&TWVM(U)XI3_LZ/2GTH;4
MUYL-D_A=6/@[#P-IOM:1J3Q2G_9T>E/I0VIKS8;)_"ZL?!V'@;3?:TC4GBE/
M^SH]*?2AM37FPV3^%U8^#L/`VF^UI&I/%*?]G1Z4^E#:FO-ALG\+JQ\'8>!M
M-]K2-2>*4_[.CTJ0_.AM3.>W3%9/+_G=67Z4=AX&TV=VD:D\4I_V='I4F_.A
MM3&6S3%9///_`)75E^G'8>!M/G?I&I/%*?\`9T>E4_2AM37FPV3^%U8^#L/`
MVF^UI&I/%*?]G1Z4^E#:FO-ALG\+JQ\'8>!M-]K2-2>*4_[.CTI]*&U->;#9
M/X75CX.P\#:;[6D:D\4I_P!G1Z56'YT-J7RVZ8K*9_\`.ZL_TH[#P-I\[](U
M)XI3_LZ/2J!_.AM3.8Y:8;)Y9[/\;JR\'8>!M-]K2-2>*4_[.CTI]*&U->;#
M9/X75CX.P\#:;[6D:D\4I_V='I3Z4-J:\V&R?PNK'P=AX&TWVM(U)XI3_LZ/
M2GTH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_`&='I3Z4-J:\V&R?PNK'P=AX&TWV
MM(U)XI3_`+.CTI]*&U->;#9/X75CX.P\#:;[6D:D\4I_V='I3Z4-J:\V&R?P
MNK'P=AX&TWVM(U)XI3_LZ/2GTH;4UYL-D_A=6/@[#P-IOM:1J3Q2G_9T>E/I
M0VIKS8;)_"ZL?!V'@;3?:TC4GBE/^SH]*VDLO^<"ZA;G:>=9EZI&PUIXV0TS
MTG9*?IZGVM1U.K'U(YNA>6G+:R1))THR!RV3C(Z<.X3!,O=*IE`=@B./-5OR
MLD2,?H\&!==G/>W*.*3,F666>I:NQ2;_`,V9A-5B!A&6&$69YC&_2M#?SF`.
M4UWVY`$R*[^GBG,DU$Q5(<35/5@@!D0,05,Q_6YACW_R&GNE[OO+N(GSK@_-
MILH5[9-H>[4OG7830E3ER],L[JTN_J'86.M"SN0%IH*1+0-17,?A5C&/5=2L
ME6_O7;J(T+3:1B@!7:I1+NB`B.W'>QK?*L9BYPNC9?G.!<8N:P!H.6+A;D.3
M)9'*N+A^`R&[O/FS_7ZL(`GC&9:UHZ7]0SZI*&IV*M354Y)78I"H[D6I"(8)
MJL[BV\II22]MZ^I=7ES)*PH1\29PL"ATSH\`ES$,^K0[\T%.#*K9HOL====@
MZ#B,AAD-HTKDS-WYCVA[&.ND1$01$6Y/*(:5=J^B'6&VMH\O,YTW75):>/I^
M!JMW7:4$D:"/2]2)IK1$RV<@Y%PLP<$63,9=$ABH$/O'R#&T_?[`VS1*;/`F
MN)@T@`F%I@,X!!(RPM3#MUZJIF3`UD+H%IB!:8<:W5ISH=]0,5>K3';.^G.Z
M+H[4S0\M5L/65(QI9U2EZQ8T?)U@6V<A$RBJ;5>LBL8\@N29F0$AC9&$Q0#'
MF:[YDX:YDYU*]SGR7AK@6W8$D"-HR98'C@NQ^BZR(B&"([0UK1^M]%NK:W-P
MJ'M55VGJZ-/U_<\70VSI%[3X#,5NT8JG14>0J;5PX99@U2!TY3,L7FB:F:FX
M7+'3PO?C#IE,^8)H+63'`Y+(0C$95S:O=2KE3A+=+ZQ:#ELMY5GBS/19:T;O
MWJE;##;61MM6D3;"3NV\6KH@MX92#:"NSB&[!]"KO4YIU5<@W]KT@;JG315R
MY02YXE4_,C!*62)\V:[NRX-B&QM.?,!E,86*$O<ZNFDM;+$8<;H*P*JT7UI!
MVOLE+0M.W4FM0%U[SW-LM,V64H%-!E"57;@$0/#TS4S!VZ-4<^D@OO.T`R2;
M@'=FV#C1=\P9&&8@9E6Z[23@'2W`AQ()(ZS`(L@1E-AMAD6U6;JSC0M:QG\5
MH@<N7+8>->S9_H^KX5CK#MAHSO!$3.G.X5R&$C*(.ZPADY-=K"1=.S=1-))F
MRCUW"#TSIS`F2."9^Y'8.6-[>#?0,P48U3O;-HCD+7-B2#`B!%D..*TL`P$3
MJHTSFN$SE!\ZS^;HPJ2&M-.Y8+49(7%L[J28WK"D*JH6T,U&718U39>'>2-0
MHR%LZF5830PAG#7DU9`KA5-,N9BE,.0#P*7Y@3N\>V?0R1,EED09]D'Y""&P
M)RQ&4&`XPN]B&ZTN4.H#`C,>(+22C=&VJ^XUJ)2_%":?;HU=:6,1F)!:OH>!
M(,2XB8PK@961C$C+)2<G'(JH"5PLW043;B4X&$-T<>AG[_X0Z2:0R94JK>(-
M-\F!CRB$<P.7BBO-,W9KS,[T,_[=IMSPYLJRI5VARN3PFC$MCVE87EKW5I9:
M;NH%$0E/-2.J:5@)T8MVU;GCU3I.8QDS#-PZ<G2*D82[PYFQK2=[V4IJ'5;@
MV53S);'&P_S&M+2+,EI!S06\-WWP%UKB2(V`YSJBL<N]$VKYE=@;#O-.URT+
MP*TPYJQ"A'<0DW?FII-,"J5(>0,["&2@VJRI4U'8N>1*L($WMX<L=F7\P,'$
MKO6SKTDFX"!$%VB/1&-D%3-W5K*H]U)9UVF)!LLY_*LBRVABX-OK7:D:COM3
M]S[3W4L+$6@J")MTZHII-0LK3UU:B<4HVE*QJ)E(."TPBLHFIS#<Y0[M41#(
M,BB/`;OFV=52)TCKTM0^:&NB,LH1=%L(YX<RM.ZSVL+'`"8(61/GS*UWN@76
MU&/;:14AICNHPD;NI/%+=,7<,V0<5`C&Q03;LYB&>![3%0AS%<G]L#-\DC@8
M1`!#'2'S)P2JI]HDS7=W+$'=0@CR<>:SCLRK0&Z6(,G"3<;>?:.MQ"Q:\W)M
MO<"S]:3-N[HTK*436]/\U]MZ=ERH<[:IO6Z;MDN55HNZ9NFSQJJ51)5%51,Y
M#`(&QZ##<9=BM.*JCZTD@$$]6P\A$5SJ_#'89-[FJ`#^0Q\Q5C;W7XNIQAC<
M;5U3A$`0Y_0JF4],YH)RGGUIO=?M!B6TU>8:?0I[-2\(ZTWNOV@PVFKS#3Z$
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M/L[SO9O_`-K4+T^'2)'Z<Q!OU;LO_P"M+6^_YS&`#KJMV0P$,'D[TV00.82$
M'_&>J@[LP'3$"EX?7!P<./,?(T_^P/;;$D^=>@^;+B[&F9A!:Z=&3JQL/I0B
M92LKBZE[O4VT5E:B>71TEM+/-KAVEU'TT$4X9PA(J2>*EC*,GURB5)T]62R`
M,Q*8>'&YOCNS68A4WZ&0#5.L;.$091!O1,&QNGB@;76$0M6IA>.2:.0T5)C3
MB%YO$X9LJVNM%JYI:-Z*C4_=T]$M:5N/;.YM[--6D5<\@V7<TG0FJF5C9]_0
MT2H*B:[E*VT`"P).P(1,JR0`4V1A`?`/W7Q9N-2L/>X=Y.EF:\6Q/=P%_)QN
M(A^RO3RMX<+=2F<&BZTAHR<<3#+IYU@J-Z1*S3:=A&RE6W3/;V*Z*66T;JP1
M(F=-%(7Z?4T$6E*DIDSWVN*P+)$*893D3<F(%,!@#8'I)OR]Q1S6SF73-V@O
MC;&[=#8>KER\D%R9N\U'?+::PW8&$,_.KOI?I`--3*X?1L:@IVYMTF]5Z<-.
M3RPEX+2GI*?E&D)-1=OYV-C;CP]2>VZS.HYF5GG**7)(HG<G;F,H*Q=T2"E?
M+G&)QG27AHEO<UP)O6^K>!%W*+IX^,<JK&\C!=,3$"!Z>7A:O&TN=)K9NU,/
MH:1N>XK^N)RT*VM2G;KSDW#NJJ5IF%U*/57-'5/$^W3ITM5J4,U4(61BB/"*
ME*)TTSAL*&GB_P`O<:E53Q1&ZQXENLO")8XDQ@,L(`=*Z=%O3A\JGNU8#ID7
M989"!"$3GM61:/Z1^QU&ZI+%JS5\25E8.AK"7PLZ>I[0Z:INR4%;=:[:1FT(
M>.M^M5<Y4E:-H9\47KL_+I<W74,*11X<5'<3&9E',GACS/=,$PRWDQ-TB+?5
M,";L!EA855-WPH&ONMNP`A$<O'EY5CO3/T@6FC3/$:2Z$=3]SKD0UBKY:PW%
M67!4I=\UJ5S0=^Z;/2U*77@B/73Q9U5#,%#.G4:"IW3<<A`PCB[$?E_BV(SF
MNEPO,E,:`;T8ASG$.ZILZT!#E2EWRP^;(?+<.NTG-QC+ZV5:\:;[[Z8M*'2*
MV'O5!7YO1?\`LG:]A5"M17)J^B9^/KA.6JNG*IAFL13U+R\O+RRT'&FG$7#@
M#<GSAT54Y2E`Q0QZ#$]T\8Q/=IM()8DU#CZCB3"T#K0;E('$#9!<'"-[L-I,
M5=`1&>SEY5O&7I2--$?6^E.1K"Z%VM2-2V4E-0\O4NIBJ[.QEN:D94]=JAI.
MGJ=M%35'1"IGCN&:3#I)5PY<*%3#<WS'/P!YAGR^QF7-F=W=;3NN0:+V5IB2
M>K998,N0'F]%7;ZX;,`#@"^)B;./)"WAY%9EB^D&TD4E!Z0KUU37]Z8&Z.CS
M3C7UA`TM0]'2,C;J]<M.MI1K'56-7HR#6#B(R:YZ5:4Y^@+E4X#W)0*`C&=N
M-C?>S&!D1,>U]^V#0RZ('J^M82R%EIB1QJ?>G#3)O.`NM;;DX_+I5JV=Z0?3
MDRIFSUNJUE*_H>,D="ET=*ER;D4=33Q:7LW6]PKD-:UBZDI!D@YCWD_`HMVX
M,7:[)8JBB8[I0$HB(=/$]R\9[JMG1>XLJZ-X:">M`0ND0M,?5^U!&;V8.#``
M"R!,!KT\BWDT@WJL'>IS-6'H!>N-0EKM,_1YSEB:@J"K:5DD;HZB9*K+J4Q/
M/T*?M*>L(*MY:#AT(D2(()33=9N*HJ;XD`<>>Q_`\7PP-K*@=Q-GXH(-,8L<
M99-I+87X@Q,"NU@V.87B%3,DRX&Y)))LR`@9\EJUQU7ZCJ:TX73UN45=>NR7
M<N#?N#T*U;;:!I*D_>_%4C3=F*V/53FR=<,SS]3HT=4=-4['(M.1</G8K*F#
ME#9[XXZ&[F$8A54V'&!+>]K;;<MTVBS/',N1B=?2,GN,LCB_V>96!4FL72J7
M6V]U76PUGWHI<]Y'=P)BX-)71L'*7)MO:F)J:CX"$F+83E+.)IFXK*-J!=@J
MU(YC10!JU(D5'>S..*Y.[E>W`^[F2G-<UH`<P]9UTEP+8BRVT1^M'G6M3XM2
MNQ%CGN!)!(CF)X^&1?+/7!7&GRY.IBX%7Z7:7DJ1L]()PB$/&OT'T>U=2[6.
M3).S%-T]).G[VD:3DGAMYA$*+JBP2*)-[+8'VC<.CK*;`PRN-Z>,I'&(V1L%
MH$`3`1-L%XG?*9*G8A&1ZIR<.=:G<&SB`/T,>B;"[9D7!:"UH:<H"C$EE,$3
M!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1
M,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!
M$P1,$3!$P1,$3!$P1,$3!$P1,$3!%]*M)?\`4-Z5_P#FSTC?_P#5]O<?/L7_
M`/W;"O\`JS?_`+6>O3X=_P#KN(?LRO\`ZTM?9GIT-&FI#5MKLBU;#4$C5J5`
MZ>Z&+4ZKBHX2#!DI-U36`L"(!*N4#.-\J)A,(`&[ECYS\J]XJ'`<&/?D.)<0
M+81A'D/$O;_,#`*[%,0%3+$(`66'BSQ"^/@]#CTAX@8H61B=XP@8/XPZ-,!1
M+^M(!I40*GF.>[P9X^D2/FA@G6=-E@-!RWOP+R5/N+BV(-#7$L;#-'_B"J/T
M.W2.F:@S/9]N9F7>$&2MS:4<QXJF3Y/G8QSB849$?J$V'6(0IC`4H;,MNMB?
MS"W<DEM2"R\X0!A:!FC=C#D4J?<W$W3#2M#H#ADBGH<ND0..8V0C#@4@@F4U
MQ:.W2G,8YS")AE14.GOB403SY/9M`0QOTWS)P"12LJ`]LSO++MHA"V,;IBN>
M[<S%Q5OE-#@0!;GMYU/H<^D3*(YV2B\C@7/*XE&IB0Y1W^5232E"($/O@&0"
M02`&>S;GBSQ+P><.K=;Y?PJ]NY&,$6N(\GXE0?H=.D0,!@/9&)-OA^ON#1:@
MCF83"!]^3$%B"<1$`-GD([-F*9GS0W8ICW=6\]Z1$0:XV<61I&=2.Y&+@\;A
MS0_XE27H;^D3W<_D4CC'$-P5/E$HDP<@)>341*1614*4#$#(!_6?K<L:;_FI
MNF[U9SA_\M_L*]FY^(M'7EDGG&M/0W=(GF42V2BR%(8QDTRW&H_(,P`HB9<T
MJ9V!MT-NZH4INJ`ALQC#_F-@PJ'S&.#I3SU28BSF+8CRJ,G<W$I,V9,$LW7G
M)$6>6*GT-O2([N[\B$3D`[Q2A<*BBI\I[,4RR0`.+ZCYC85(G=X2'`\4?PKG
M-^7^),JC4!IM.3TWE2'0Y=(@`@?Y%(LQRE$@#\HE');Y1`0'E!;2R*@B.?`!
M@*/5#$S\QL&`C=$>?\*WYNX>)NZQ!T?B0>APZ0X3#_$E%B42B`E-<.C#!MV"
M``:3R`N76SZ@B(9YUGYD8.[JW0`>.]^%6G=/$6T[J=LLQ=9'@55Z&[I#!*!/
MD1C1`R8HJ@-Q:+$5$0',J9-Z2$C<@&`!W4P*79P8LG_,;!YC9S>K=FS9+\N3
MN86>K;>S\7*M,;CXH3"#AP_:7.VZ'KI'V+E-['6?;QKY(%>3>1USZ3CG)!73
M%)44W+&7;N4\R'-ENG`0SQK5>_\`N_73S,J9;'2]I[T-)C`PA"-WER]"W*7<
MW&*9Y?(+FN+8&SBL^TNN?H;ND744655LPP64<")W!G-RJ/=*NE1*4IEG;IQ*
MJ/%UU`(&\<5-\<@R$,7T'S"W8H64[&26GN'SG>L1'OAD]2R[Y8\B/W*QZ8^\
M]Y-O9_$H-T./2)9B)[)Q>^(I''.XM''WQ1_:BK*FE17533_6YGW@X\8\1-W!
M1"D$IIA]:\?-<5$S<C'=MEU37&ZQL"("VW+&]]"GT.'2&]UR=DHW=$1$`-<2
MC#&#/:("?VS`3]T([39FRX1QF1\RL%IJ<T\M@MX[_P!%U;$[<O%:J<V;,)%W
MDC_Q+HR?1`=('#QDG+25F(YLSB8YW+/5??Y2BI4XYBW5>.EP%*0/F9)JV5/N
M]7<RSVXA2_,'"G`2S"SCO?A6*C<ZO#RYL8<WI76IOHBM?M6P4%4\#9N,=0=2
M0[">AWAZ_H]$SF-DFY'3-8R)Y,#I"J@H`Y#M#%T[Y@85)$8`_O?A6:;<G$*D
MPB1Y(_\`$%ZWH;^D0^9.+\8=&>%,6S/F#N\P`B:#9RZE%NY6)N,#$>3TIZ&_
MI#_F3B_&'1GA3$&_,+`'"(F"]FM]E6'<?$N(Q\GXD]#?TA_S*1?C#HSPIAX@
M8/G&D^RH_H?%<QT#6H]#?TA_S)Q?C#HSPIC!^8F[TH7ZJ8)<K/:ZWB$`U1=N
M3BS1&!T#6GH<.D/^9.,\8=&>%,1\3=SOS7]A^I5?HS%NR>C6GH;^D0^9.+\8
M=&>%,6M^8NZLR0^=(J`X,A$77#+DRCD4Y6Y>*/G-E.!%[CA'Z5/H;^D0^9.,
M\85&>%,0D?,/`)\DS6/%G%$^>ZLU6Y>)4LX2K71XX0^E0/0W](@`_P`B<8/^
M<.C`_P#>F->1\T-TWRXU$_NYL3%L'.AFM#>/*KW[B8HQUT1-@XOQ*/0X=(A\
MR49XPZ,\*8N\3=S?S7]A^I0_0V*<NCTIZ'#I#_F4B_&'1OA3%1^8^#$QEVLX
MC$B(XC"[QJL[E8H#"!T>E/0X=(?\RD7XPZ-\*8QXCX3F_M?A3]%8IF.CTIZ'
M#I#_`)E(OQAT;X4P\1\)S?VOPI^BL4S'1Z5(=#ATAX_]"<7XPZ-\*8B_YF8#
M(;WE4ZY)&4Q)RY+`U29N3BCG0M'D]*>AOZ1#YDXOQAT9X4QML^9.YSV!^U\7
M8?J67;D8FS+&'-Z5;=7]$]KNH.`<515-H8Z/A&CV)8.72==4DY,FXFY1K#1P
M"FE)CW*TD^23$1$,M_&*7YB[NUIF"EF7C+A'*,L896\A6E-W4Q*46B!,3F]*
MN=3H;.D22-N'LE&`<`S$!N!2)<LQ,4/VR13$1S*.>0;,:\WYCX5+?<N@\M[\
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M[2CT-_2(?,G%^,.C/"F(U'S'W>I`'53[C'&`-IM\C56W<K%'&$#DS#6I]#=T
MB(\%DHL?KW$HP/\`WH.*F?-'=!__`*C^R_V5/]#XKF.@:U/H;.D3^9&*\8E&
M>$\;`^8F[LT7J:9?;QFUL#FM;TJ/Z)Q,.#3'0-:CT-W2(!L&RD7G_.'1OA3&
M&_,'!R;8#R_A4G;D8D!&/1^)/0W](?\`,I%^,*C?"F(.^8>$AQ``(_:_"J_T
M7B7+H]*>AOZ0_P"92+\85&^%,1\1,*S#[WX5G]%XERZ/2H]#?TB'S)Q?C#HS
MPIAXB85F'WOPJG]'XKV3T:T]#?TA_P`RD7XPZ-\*8R/F'A1,(#[WX5(;G8H2
M`6D#F&M=20Z'[I!8J.D9:0LQ&HQ\3'OI1^L6OZ05%%C'-57CM4$TY,QSBFV0
M,;(`ZF)4GS#PFJG=S`-Y;T?^%7UFY.(4D@3B2Z/%=A_Q%=2G^B,U]U3`0M30
M5FXYW#U#&LIF'<'KNE&YG,7(-&[QHZ$JLB!2<JFOZW,1V9X5/S&P&CJ#)J77
M98'K6F)S0#>E5R-S,2G4HJ19%T(0^F*]?T-W2(!ZZR46'%_&'1@_^],5>*&Z
M?O\`^R_V5G]%XGRZ/2GH;^D/^92,\85&^%,9'S*P";;2N[QHRFUL#Y6I^B\2
MY='I3T-_2'_,I%^,*C?"F,^(F%9A][\*?HO$N71Z4]#?TA_S)QGC"HWPIBSQ
M$P,-Z[@'YHGV5$;F8F7W2"!GAZ5'H;^D0^9.+\8=&>%,29\Q-WW&#I@&GV5L
M?H;$.T?N_B4^AOZ0_P"9.+Z_\85&^%,!\PL$)A>$.<^RM/\`1^*QA=/1K3T-
M_2'_`#)Q?C#HWPIC!^8>`M,7O`EC*8DP'&87;5?^B<5NWH'0-:CT-_2(?,G&
M>,.C/"F,^)>Y_P":_L/]E5?HW%NR>C6JB=#;TB)QR"R<6&P1'.X=&<`?^U,!
M\R=TWV2JB\_-=<.DA9;N9BI-K2!S#6ANANZ0X!R"RL6/'_&'1FS_`/NN(.^8
M^[S?^8#I]E7MW(Q)PB21Y/Q*D.AOZ0_YDXOQA4:/Z$IB'B-@KOY1#O*1_P`*
MP_<C$6Y"3Y/Q*?0W](?\RD7XPJ-\*8>(F%9A][\*A^B\2Y='I3T-_2'_`#*1
M?C"HWPIAXB85F'WOPI^B\2Y='I3T-_2'_,I%^,*C?"F'B)A68?>_"GZ+Q+ET
M>E/0W](?\R<7XPZ,\*8/^8N$MXA][\*O;N+B+A&\1^[^)6Y-]$YKMIR8HZ`F
M+11K>5KZ4=P5+MR5Y2"H/9EE'NY9PT44"4*"!`C6*B@''//=RRZN-Z5OS@[Y
M3ISW!K&M+C:38+<RT:C='$I$P,`+HD<4/I5Q^ANZ1'JV2B\OYQ*,\*8Y_BAN
MG[_^R_V5+]'8KV3H&M1Z&_I#_F3B_&'1GA3&1\S=V9G5IYM^;Q"#ASVEL%EN
MYN*$P(('-Z5/H;^D/^92+\85&^%,9\1,*S#[WX59^B\2Y='I3T-_2'_,I%^,
M*C?"F),^8>$N,"`/WOPK!W+Q/B!T>E/0W=(B.TMDHL0SRS^4.C0_]YXF[Y@X
M0T1$(_M?A1NY>*$P((\GI0>ANZ1`/763BP_SAT8.S\:8K;\Q,((M`!_:/LJ;
M]R,3;DB?)Z53Z'#I#_F4B_&'1OA3%9^9&#C*!][\*K=N9BHR-)\GI57H;^D0
M^9.+\8=&>%,6CYF[H@`3:F[,XQ=<8'-&%JD-S*V'6<0[-=]*>AOZ1#YDXOQA
MT9X4QGQ.W.-@JK?V'ZEG]&5G;/W?Q)Z&[I$/F3B_&'1OA3%A^8&##C&D^RL#
M<O$B8&.CTIZ&_I#_`)E(OQA4;X4Q`?,+!R860_:_"K#N/B0$8]'XD]#=TB'S
M)Q?C#HWPIB?B!@V<:?PJO]%XERZ/2GH;ND/^9.+\85&^%,0?\PL(:(M@?WOP
MI^B\2Y='I3T-_2'_`#*1?C"HWPIBOQ$PK,/O?A3]%XERZ/2GH;^D/^92+\85
M&^%,/$3"LP^]^%/T7B7+H]*>AOZ0_P"92+\85&^%,/$3"LP^]^%/T7B7+H]*
MW"TY='CJ[H_3MTBNGN>MDT:W6NY9W37-T+`DJZFUFLG&TEJ9H^=FU5I0C_F;
M0[>*AW*@`<<C"F!0'>,&/-XEO/1S,=P[&1#N)<R82(YY$YF6&=PXEZ"EW5J)
M.!U5/?C/FM9U;N0MF,/:MC!?J-N`(#K@O.7<+DC86Q8)9E#>('OBN<0X;P@)
MAY0%^$1S`2ERQ^?:25W&#FX^!M&7R+[),J#.<`YD<G%G5XE+O"4I0[H3`4H!
MO9F$1``*&0#M'@SQY652SZN3,#IA#+PMB,_,N[2UU/3R2`SK0X<:UID-5MJX
M[4]$Z2W2%5$N7-TRPJ*,EU(HA*%=N).,D9N/ID*A!P<6]0O8B)<*(IG2W3BB
M?;LRQZV?N#.Q&@8]DXPA'*,Q^RO.T>\5)(KG%[!EX_\`:NK;?5Q9^Z5T[W6E
MIMS-,Y73^U2?5U5U0-&T+0#QIS\T>_<T[4CE\9%ZUA)!-5F[6.4I$W*!NH(!
MBNLW`Q/#\/D.ES'$.>1T?L+$K>G#ZK$9S&M$6M'G/VEFA*Y=L%*3]_QKDT.2
M@.6(V-7BE3P1:51<G521Y!63+*G;%6,LH!"IB<JPB8O<9#C7D[I8S9UG</W5
MF=O-12LC1#A]I88MWJ=@KFO*=0IFC)IW&S]Y;K6<-/I3M-KL(Q>U:+@SJKP;
ME>E<SU/SSA(J;8K`5E2D,"I^X$,7/W>WDD&Y3RA.8!$DA\1'BZK8<2G2[R44
M]A?<!ZT.'666?EAL^,?4,N%U;;C%4<]]JZPD$:[I]PQI>6,03I1\X\(X!K&G
M=;ARHF.<1653,0I=[9B/P/>R,-D9'FF:EL?'J++W8X>56FYOU1Q[O6CM-!%]
M\Y;RV_N!<6FJ^@I1A)4@U@[?/(*.?<[7:F.HY5>O)Y,$P2-W`)GWMH8H?N]B
MTMW>3B63C:YHCU3FM;'2L?'J/L#AY5V::OW;JI*WO%0IGZE.R-D*HIFCZOD:
MI78P<(O,U?`-ZAA$X65>.2-Y$3,U3%4(<$!`Y!`##C#-WL2JB0'NX?NI\>H^
MP.'E5XHW-M>I1Q[A'N-0B5`D<BS-71ZLA#4>D["1/')-EZ@0>KL$U'JI!Y,`
M,8Y5"BF)1$0'$I6[V)O>`7NMX=E8F[S44(71P_>6&[>:FH*Y4C2S6!HJ=.QJ
M:[5U;3GES3=-"WAG5K!4!U4:[('WMC,1$X),FY(]-RJ4IRJ&#<$1#=J-U,2E
MTKYH>Z+6QX=5:LC>.CF5+)=P0)APM655+P6?2C:@F#W5MNE#TE)FAJKFSUM3
MX1-,2Y503+&3SD[U(L:\7'N4R#O&.8>X*;=,&.93X!B<PW;[N'[JZ4_'**7]
M0</*K=F-15C(*M[86]?W(ISWS7FCIF5MJ@VE6B[&IF<(0BC@4)0%"QS=9V94
MJ#(JJA`?.`,5,0$`(.].W9Q27+#R]UIX?56A+WGHA,(N-A#Z?VE1#WVH;Y/H
M.X5Q9&&LTQGZ@GZ<9,+AUG2+4XOH24D8<A22C.56AWCE^NR*X!NV765104`B
MNZKLQJ#`,3)A?=P_=6Q^J*+L#AY5>\_<>VU*G;$JBOZ*IP7OM6+$9VJX"-!Z
M6=5,A`BR%](-1>!-*D$$#$`"&$0#>ZN)C=K%'M,R^Z`LX=59&\M"\>H(\.57
MGD3N@`2&R,8HBFIRA0,0VZ<`5*')J@!@]<03$'J&'AQS9]'5TAA,?:.&96#$
M94_U&='I5F7'#^+6Y8\'\7->E$0$2F'.E)4`$3E$!'<*(@'6,.)T39[W!PF9
M3G]"TZJJ`L,O)R'6K<L*`!8JRN68"%IZ(R[H?<!EP]7&U62Y\/YED,_H5^&U
MC2?4Z#K5MWNU`4_9"1M=3[VB[@W`JV\=13=,T-25N(>-F)UX^@:=<50]4=)R
M<U$1Z"98E#>`.<[YC;`#@#%F`;GSL2#IDV?"6VTDD0`Y>JIXIBDFD`+60X<Z
M\FUNIRB+R'M>ZH.GZE>4Y<ZG[@R_OCEW-.P)Z*E[<R_M/.4G5E-24NE/EE0<
M%4$7#)-W'H`B855R`(#C?Q+<FIH:H,9,<'-</*81LZMN8\JYU)O'3O\`XCF"
MZ.&==BYFIZU%O[.7;O1!SL/=6&LS%*2%5P5O*FI^6F`<ED&S0L495%VZ:1CP
M4UQ$!<9)GW1$AARW1I_3N*=MW#]U;WZIHNP.'[RRD-R;>-Z@IRBY*MZ0BJ\J
MR*:2L!0TE5$*RJF3;N&B+P5&<,N\+(+IB1;(FZD8QMP3`!@,&-:JP"HERKU<
M'3)%X60C;Q<0Y4_4M',ZMP</WEUY6Z5O(U]*0*=:4D^K*.:/CDH=.JH%I5+R
M0;,'3]&.;QKV11%,ZA&A@,9P9#<#:8`X,<[X11>X?]U/CU'V!P_>7BTW>:AY
M>EK=3]3RL%;:9N@R8O*8H:LJNII*IG"[\R)4HID+=_[65"Z3,L0IE6"RR1C'
M`H9"`@.RS=D5E'-=27I0:1&(A&,8<157QZFVR4&,'']'*K0O#J1I.TE84I;=
MO1MQ+I71K6+FY^`MG:^!2G:I+2M/*`A+UA+B\=Q[")IYN[$J"1U3E.Z<'Y-,
MN89FZ^";I.ET#^]G"/./95.*XW(VMC;@C'AQJ_(B[MNY->DX5[4\/2E;UK$L
M9>%MS6<Q#0%P$ROR`=&/>TF>3<RA),ANY.B4HF*8-F\&W'$G8'229KI;V.FN
M!]8"(/ELR9%T)V\M)+F7',$8#S?M+VV5Q+>2,^2E&%=T<^JM5E(/4:69U/#.
MIYPG$.#M9$K6.;/EGRXH+)'!411(#829*;1S"KX10^X?]U5?JBB[`X?O+%-2
M:E;<1-TZ0M)3[R/KRIJEC;I/9)*E*GIV04I.0M=`-:@=P%1-T'ZYXV7GT5CI
M-P6%-)N9,3*'$-F.TS=JN,MKFN<V60(#,#D'J\P6L=YJ*/J\-*\VK]4=OZ#L
M4A>BKR-*<DWELI"YD;:>3JZE5*[ET(UN=RZIR&]K9)]&2\LFF7]M:J+-QSV"
M/!BS],8CVG</W5C]3479X?>65V%U+:O']*P#NMZ3A*QK*(C)F$HB4J.'3JEP
MC,QS60CT$H<SY&266!%SRAAY`A3I$$2CU</TQB/:=P_=3]2T79X?>5K4-J+L
M9<>-K^=I.Y%-.H.U=43%*5])/))G&MH&2A%4VKM55P_=-FRD,X>G%)K)`<6K
MHP&!/,4C`-%1NO4&616!\R3$=6$8YN(*;-Z*%CKQ;9P^TLJ0,[!51$,9^FYB
M*J&"DTA7CYJ$D6DI%O$RJ'04YL_CUW;)<6ZZ)TSB14V1B\`8\_52<-P]QES)
M+P!]D:PMMN-TU58Q@)X<JP#J]*'R`56`<!JBMD`ES$2CE<ZD52"(<9%4BF#'
M1P-]).;/^'@RW`-O6`1M,,^2U<W$YHEF4XRX!Q/$>3E6SSX!%VX`XB<0<+=T
M(CGW1]\0^L!C#EC5J)=0)]DPPCG]"ZU-5M[D$LZ#K75R*'4[?JXEW52?^9T^
MA9VIKK>[Z#K3(O%V\.ZJ?>=/H3:&^[Z#K3(O%V\.ZJ?>=/H3:&^[Z#K7"Y70
M9LWCYQF5"/:O7SH2CF8K1@T5>N#%Z@G!)$<NOC+9%4]P8)EI(&7/9F47536-
M+S+$`">/BMSK32S^NNSUW9*CV`P%RK9,;D4S4U:VRJ:ZD!&TW2EPJ8HQR5E5
M;VG)IM-R)%'$*H<BZJ*Q$5.9G!7+J8[,[<[%V$@.=$91KZJXLC?"C?`W1`\.
MTMDW-V;1LV3&3>W0MZPC)687I^.D7M;4RG'.IQHH5)[$-GQ)-1!Z_CU%"\L1
M+,"`.T0'&C)W7Q<U`EO>Z%OF/V5UY6\M&X1#!'A]I>A-5Y1%-RT93U05;2\1
M5$ZQ>/J<I"0J&*:U-4R;!JH\<E@HU1V+A]]R)W!B$,500'<WMF,/P+$Y<X2P
M]P'#[*Q.WEH\A8.'[RP/9O572]X86BJF2I22HJEJRM8O=$:GJFI::2BX)%&K
MW%'&IM^U(Y3G5'Y7;85^><T28F*8$@/R@#C?Q'`'4U+*F8BUTR6YQ`LC`PB>
M(<2UI>\M$UQ-P0AP^LLD59>BD8>BIJLJ/7CKK%IVJ8.CIF(H6KJ05<,)F6F6
MD:[(\E'\PE!LC1#5WRYD%G!'#@$Q*D4PCD&C(PS"L@DN^[Z5=^J*+L#A^\KS
M>5_;QA44M1[FOZ-0JJGXM:9G:><5+&-IV(BD2`8\O)Q!EE%8^,2#,5E%5"D0
M*&8G'/$GX2^94M;AUZ7)NVB$.M'+D/%!'X[2SI)G,8+##A:L/UKJ<ME3,3;*
M=IJ3B[H0US[RT;9./EJ`J.(FV4-4%9"ZYI*32K8ZH-&+,K%3E41$%LS$R'AQ
MN5>[N)R)5\O=#A]E<^EWAD3IMRX(<.5;&"4`'(0#/AV#EEGMR$!V@8N>0]?'
M$%/5RQ<?,ZPY?0NT:ICC>;+$#R'6HR+Q=O&>ZJ?>=/H6-H;[OH.M,B<0=G&.
MZJ?>=/H5^V2O==!UJ<B\0=G$FRJF\(S+.?T*$VME]V82[89CK5FW&``MQ<<2
MY@/R?5MMS'@][$IF'UC!L'K#B[!I=1MYA,LY_0M/&:QNP-ZEMG$>3E5M6%*7
MY![+#P96OHH@9"(`"80++DR``YANIEV!C.)ND2,0)Q$F9)+;!8;8Y>+BBH89
M5M=AK0)8];,<W.LKAN\8C]GU`QI[7N_[IWW1[2VMH'NQH.M!`O%V\2:ZFG];
M#8RY8L<#`1/$;(\2;0/=]!UJ,B\7;Q+NJGWG3Z%G:&^[Z#K7(FCRATRER,*I
M^2(4!'>Y7<,;='A#(>YR^OB^BPHUL^XZ<!,/%$:ELU%7)D4`G&7UH'S\ZT:A
MM>]HY:>5B5Z,NM!PCFO+D6JI6XDW3D<E;FM;H6P9RCZ=H.$GXZ;DY!K,O"0S
MA)F+MBB1=1,?6ALQWZC<2<1_#G1>`"0"(VQ@?5Y#H7DV;TR"^%T0X<JS;8K4
M-;:_=NZ;KZFYB&C'$M1$37E048^J6'>590D5+HJJ$;UC'L5#>T9V0D`5UW`I
MH@7/=WASRX-=NOB]+U;[KO#[*ZDO>&BO#J"'#E5Z,+N6@EJ>F*QBKIV^DJ/I
M]US.<J=E5\&ZA(5V*R:!8^6D6SU9FRD3*'-NHF/RATRB<A3%QFDW;Q%THSZD
MN=3L!+AG:,H]7Z5OC>"CN$7!D/#UEV)&YML8AC3,A+7%H:*85LJ#6C9&2JB%
M:,JH=&4(FH6`.M($&7,U.LFF8J0\FHJ8"`J!A`N&Q83[AWW1K5'QZC[`X>5>
M!<&\M)6TKBS5OZ@:S:D[?:KYFAZ.&-:$<-(Z:@H`U32*=2.#JI)LFY8I,Q05
M3%0G.!`F8Y#G-N"TE>=GHV.E3LMZ`%@RB-OF6#CE(\0#!P\JPE<W6%3-JJSO
MC$3=)R<K0.G2VM"5E<BKZ>63>S!:NN15"L)3M!14*L+9-=VG$`G(KK&5W2HG
M#(-H8Z$C<.JF$?QC`\OX5SI^\$B4;&\-*S90EY:/N'7]W;:P3:92J*R;RB(Z
ML7#]H5"*=NZ]I)M6D.:#<;XJ.4D8AX0BX&*`I+`(`8P"&5&)[MU.!B7_`!">
M]!-I[,/LC.K<-QEE?WEU@-PC/QQY>196+D(9B'5X\<KNJGWG3Z%U-H;[OH.M
M59%XNWAW53[SI]";0WW?0=:9%XNWAW53[SI]";0WW?0=:;I>+MCB4R74`"$P
M\/(ILJVPA<Z#K6NEZ3B6[6DG(3"/RMU:7>,<3#N!:Z9*F4,P[GDP4-D(;>Z'
M/'>HF36TCS-?&6)9O#DA:/*%PZRL;M+.I9>;Q'..5;%``=;L_J8\YM>[W%*=
M#]D>TO0[7)]UT'6I[GB#[`CC(GX5._AT+2RI.0D`6<=L3Q<B@^KEEL!+MYCK
M3(O%V\2[JI]YT^A5;0WW?0=:9%XNR/J8SL]8]I+)F3E]"LE5<IKH/EY>0ZU!
MQ(0ACB.6Z`B;,VX0@!EF8QQ`>H/``9CC7I)%=/GW`\\/(MNKJJ>1([PRQDX<
M:TVG-<%J::N55UO9RD[J-(B@+JTQ9:N+MEI=DO;&EKAURS9KT7#3#X)M.;:M
M9]S*-4@><T%ND=0`S,)NY]E+W6K9LMKA,-]P,!QF$(D"[D$1'-%>4&]-(QY8
MYHCPY5D>P^I.VU^XM9:"?Q\%52$_7L*:W4K4,0YKDS.@*RDJ+?5/[2,U3.4Z
M>D7T8=5!8Q0`J8]V)<M['$K=VL3EF%X\/W5T)&\5%,;:T</*LFPUS[6U"2HS
MP-RZ`FB4818]8+1580#UO2Y&V9W"M0*MY)0L2FW+]S$5<DC*["J=3'/^#TS>
MK/E/=.'K&[E/&5L[9A$SKNNAQM.36NHYNY:=G2\?73JY-!-J'EG/-(JKWE80
MK.GI1V<YDDX^+E%'1T)"13515`Z1=T?N8^M#;A\(HH]62^]Q=7C3:L'&0MCS
MC6O'NO>:BK.0%%5'4Q9"2C+@W&H6V%..H#FSYN:H;BR7M?3;M=<BQT'$%]S4
M,NZ0.<"`7,"CP8Z4G`\3>;KIAX?NJJ=B\B6/4LX<JQ.TUD6E=RD=$I1E9\[D
MM4-0:2D"*12*8DN93$(>?E7SG=<K$;TP+(@E27WCG.J8H"4,]EU5@.(R*5T_
MO#`,#O(2!'(M.1CTF95-E7!`F'0>5;9'*4@B42]T"ITA`!'N3);P*;W^G#(,
M<'N*_P!X>'D7:^(2.P.'E49%XNP(_IXDR36@]>99S^A0?6RGV-8(^76F1>+M
MXL[JI]YT^A0VAON^@ZTR+Q=O#NJGWG3Z$VAON^@ZTR+Q=O#NJGWG3Z$VAON^
M@ZUBNFDP'4A<L=\^Z32_1P"3,H@(FO,JIF!A+OER`-W(!RR''?GSJEV$2:<N
M]5I$><.UKA2WCXI,F7;+PLT*Y;@"!M<-ZS!P#86QGU_^,EQMF.53&GFX3_$[
MR]=,8.(7<ESY(=D$89E>&6>09`(F-ND$RW(@4YL@(<5<_N?)FR-GUL<&EJJ9
MDB9+F=YW%X1@2#ESP6[(;33YH9DB#YE\M=2>E6^=<74U!7HM(A3#>OF]/::*
MKTM2,G+MVAG-U;.OYM"H8>>(4A"Q45-0,^NW,=3,CDI\C!MQ]0P7?#!Y-*V1
M.O\`=`=HQ/\`9*\!C.$3V51=261/';](6&JHZ/:^(TA<NF**=PX#4.G[3K%*
M2XU,R8'N%>.C;QOKJW:AI5RDU<FC(VK'$DZW7:Q#-C&Y,JI3$V8[4W?S!9S&
MR'7BR6XEMILB`+>K;D6C2[KUE$XUDC^=.`#HVBPQL$;+5=CK2+=%&CJ3K"#M
M`\J:<C-6%/7]N38*[%S+<S<)<R*C:$<4HKR,C2=+QMOJ==1AG23DL<HT^ZBU
M!8X<IC49OCA$N3W3"0_NRT.B21F-K;2,MO'R*<W`,1FGK0RY@/I7)0^BV^#!
ME8UDM35&6S-1^H76-<B60H^IF4JQMS3=\[=SM-VW4HM0K9JK/.6<O+(`HU:@
M!D"(B<!W2EQ"?O;@E3,[R8Z8.J!!KG-!A$Q(#;<JS3X'B5,RY*A=C&T`VGRK
MMTI8?4K2^G>WMJH3359FAZLMS*6SA*YJFG9:W%2U3>2E:>=39I>K*3<5-3C^
MFXFK%I`$'B*U1`[6*"[G<'8`!KNWEP5P(,VHB8P_BO&7):!'G@KQA>+`Q%V/
M,-:];29I$O9:"M=,D]6D9!^U=JZ8UBQE4+,:KB)55BO>>Y$+55OV$86-:L8N
M1%>/36%SS9!)ND)1W"%+EC&([VX'+I@6!Q=G+B3FM);$K89@^)%HO0C#,-:K
MN]H]NU7M6ZC7I*=I:<I2[&KW2C=V(9O*@:%3FK96R81D?7))QJ7<4;.#\@J0
MC$YC'<I&S#(#98HPC?#!7S"Y[70@>,^RI_!L0Y-`UKIU?I"N=$R4E,43:6W]
M84=36NI?4)3]@U9FG*=HZO;<S5OF5,F%5FZ:'I6FY&FICE'J#!\V424<`(BF
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M)2%*40VYV^&"36%EH$01:;#]W(0M1N`8BTWA"/DUJWJ9T<W[M]`VO?3%D[<:
M@"15IM0MI).U-5U?3:#*B9FYURI:KJ:NRR<SD9)1LD>0AUD$'X(%*_1*1+D#
M@8YQ&J9O3N^X=4.'6!RG(#$CU>,6*8P3$^30-:]HW1]UV-/S5-U;!4'=->+Z
M.AEIWI"H:F=(/##>-M-5'*.UV:<XW%]%-(]FZ;(LY53-4.0`J9BXR=Z<,=*(
MIQ!D>'U5=)P2M!C,A'ARKZQT'&2D%0="P,X(&FX&BJ2A)<W+D=`:3B:>C6+W
M=<)9)+$*X0,4IB@`&*`#PYB/AL8K:.K)+0[+Q&'T+U^'8?5L:(78<PUK@N/_
M`":7*SX/D[KO^"LL''CF88^0V=W4'W1DM]"S6R)]XAUR]^R%;EA_Y"[+Y?-5
M09>#/8>`8Y[.KMQO8G,D2Y46A\><ZE9ATB=&VY'F"U6USV#K2]50:7YRFK?F
MN=3]H+F5Q4->T<QNH%EYB1B9NBI*GXH(2X"2S-SOBHJF584U1-N9@`9XZFZF
M\]!1,?*87"800"Z+@#Q$B%H!XEH8MAM36"+H>00^E:K4]H1U,)4A;RE7\Q3=
M*HPNGC6%;&*?1E0GD/D>+?&4@WUK+?M91U&A)UFV9M62K>5G``%134,;?./#
MZW$M[]WI\^7-G7S4WFDF\X-+A83"[H!7D?@N-27=W)N=R3;%H)ASWEP3VBV^
M%;V^O42.L9;BQDQ.:+:1TP1-NJ5JR'?0UU*[IFKHZ<?5]+2$%%-6;6()'M%$
M(UQ))GD5@4,50P&$N(,WMP-HMB>L3E.0Y!ZMGF4_@F)_9T#6KJK[1C?"J*TN
MI2B=O:`FF]T-1%B[T06J%_4S%O5MH*5MN>CCS]#L(U:(/697+=6F3M(X(]RW
MCUBNC"X[D-NW1[SX'.K1=:'2Q+<+KK;21;`MA8!99$<1M*FW!L4;$B[>YAK6
MO]G%6E1:K*L8SM**U;-U3=;60RM?%1R,`C5UJ9RM(V88O:\O#3LA3*U8PU.2
M:,:5!H_?2:K!(SKE6A0(.6.C4XM@K)!=*E2[Y#(Q:/J$&SJV1X\_&M1U'C8F
M78RX1/U1K6Q]C])U\;.U3:*2JNQMN+UQIM-%EK.2Z53UA%D#3S5-O*DDI&>J
M"#=3,)((S<)4;9^1=-W%';O%GB*:8&R'9YJNWEI*P&5<:R7'Z@#(QSP`CR+J
MTN$XB(3IUWO!DL&M;'WMMS?:E-4%):H;*T33=Y$SV4D;%U_;FH*W86XF&<62
M>;55#U5"5'+-7T:?F<GR*3MJXR7!-$`#:..:S$J*7+,IAF!IR]8ZELS\*J:B
M8)LR%\<,ZUPO9ISU=7FO/2U5SE"4+!P<7>'3I<V//2]14>Q;0S2@EVCRYD/5
M$\_I[Y2*UKF+:D$(Y6/<MHUPPW0W#GV8[N%8YN_04S!,EWIK&S!%_6/7<'`F
M+2#"&4V@6"R*UJG!\0GS"_JVPXAQ"&=>Y;+1-7-*U!:"K!I"CH"M8#6)J+NW
M65<1DC'$JDMG[EQE9Q-)N&THHB1V_3$)INLK%',`)*%WC)[V*ZG?G!F1`DRH
M%@'J-@#;$^IQ^8+7^`XC]G+F]*QI8W1M?:C9>S+6>L7:NE#6>M9J=MM4=VJ<
MK"-D:AO)*W692A:&J2181T4G(F:RD@Z`'8R*BKAJZ.<,^1`N+1OC@KA>(A&!
MA;`9(B%V'-F5!P'$8\6@:U84SH1U%M;8>\I6R%J[M2U8:%;7:>V<A6=;0\>I
MI^N);@SQ:=6I8TE%++.H^:=.LV[N-.@=0Z9`6-N`(X/WOP1SF.9>:&NB1$]8
M0(@>KRQ'*$^`XCR:/2LQ7TTP:G;E7.HUPTIRD'-!T16>EVK*?J&.E*&B%QA;
M5LXY*X[6X$@\IYY7,O5S<[=1*-!)^C&+,P$AB&S#/!WMP*]>`>.H1ZQXS&,+
ML(\N59^`XE"%F@:UY-::+[V*T_?&E*3MY1D"DIK<8:E*)EJ2J:BH-6[]ON=(
MO1MQNO8)\WIAU10*G=,&\D@K$KNS]VB`"(XV:3>W!S4DM$8R7,`=:!$&\8%N
M6$+IRMM(RJ)W?Q%_5)`MCQ:UOQI+M(O9NUTA`O("J:5?U-<"L:_D:=JZLJ9K
M2282-5NFSQZND\HR*B:1CXR3.4'#=G'HIMVXG4R+F;9XG'MXY$^<);94DM``
M_EMXN.,(DGC*]-A.$U5-UGW8\WI79U>CE8"JQSVA4EL<MG^4JE<^KQ8KHIU,
M9+GMEAKC"-T!L=`73QIDY[:>-RQSOJ\RV???[K<\/^Z%?T0Z^.#/FR.],0_+
MG]"W*>3.[D0NQAF"ZN?U9?JX@:B4#`!T/VO0K&29L+;D8]D*,_JR_5Q':9>9
MWWO0I]S,^S]T)G]67ZN&TR\SOO>A.YF?9^Z%UY)NL\BI=FVY/G4C`SK!'EC%
M(B#V1BG;-KRJ@CDDERRQ=XP["AF.+9-7*ESV3"'0:]IRGB(.95SI$UTA[1=B
M6.&3."OD'171WS5/Z)YNDII*;J75$KI]N9:>D6%0W(&<H6WKVOW3I9>"HH$4
M6S&FDZD032.X>?=E>1`$Q-D&6/IU?\Q,/+S=:+IY+3ERF[FR+Y[A&Y\R9+C-
MC>`S^E=J^&B&LUYRU!:!MX5_;-CII=V/KFU-NZJM_;J1@:PF%(M:H:C8NZSI
M>492;*H'Y7"3Z1;"E+(KD)N*=UBBEWRP=[6SGB,X.C&T"!XH!O$#9RP*MJ<%
MQ&GJ.ZD0[LYP#]*R=2VG&Y%N=0E3S(66HJ]%!U_;ZS%/4M<>X56PZ]=V(2MA
M1+N`>1J2<Q"O'TT\</@YTW=PYT%5E5#**[`RP?O+N],F"=,#KX/$XPY/JJ@X
M+BCLL-`UK6-SH/U''LVXHI2!IPL^XT*/K`*;U7L@3]_*^H5O<%LV.^Y),X1Q
MJ8*8Z:R)^3!03(CW8XE4;Z8*V6&.8U[!-O`$1^J!;%MN2WR+8I=WZU[CWD+&
M_3SK,-U-%->.6^H**M905"4_3-PVVB12FJ>B)&(IR+=S%D*I*[N@X>-$D>XD
MRL6R9B.MKB1$<]\<AQ?1;V[OO<QSY3+K7.)ZH^L,GJ9`39S!2G;OUK(AA&CT
MKTXS3UJ'H5'533=/V3LG6=8UY5]YKA6UU*5S-4X]DJB1KE[&OH>C*PI%[%.J
MA*UB6S8[(0=N3QB"!$%!2$!4QBLQ_!*G$F3),NZP2X$"P1B<S1;`Y5M4V$8D
MS#G@W8W\PS#E6-*"T7ZAV-0.ZDG:<CF/MYK#TT7P>-I2I*)+)L*8ME1SF*K9
MU)-:$BH.D.?(2W)"V39-4B.4%""83&`3#MUV+X4RA9)%XM:TBTDGDM(CI7-P
MW"<3%5%UV!Y!K7VB4$O**"43"!E53YGW#'`3J&.8IA)W(F(8P@.6S,,?*JRK
MD/JICY8=<+K+?0OH<NFGLEM8\LO@0/5"HS^K+]7&KM,O,[[WH4^YF?9^Z$[/
MU?9QG:9>9VGT*.S3,XT('U?5GB3*F47@0=ES^A0F4\P,)BW)F5GW'$/DWN/_
M`#?5OU/_`(8E,;6"SI&WFQVGT+5QF1.V%OJ0LXAR*VK"?R#66_FQHOJ?^@60
M8GB55(EXD77+W4A!UHRYB,JAADF>W#6^IZV89EE;;]0!ZN-;XA)]S+^Z-2W+
MD_['W0H^K@#U<5OK)3S$,#?V>KI@%8R5.(MN?="9_5E^KB&TR\SOO>A2[F9]
MG[H79:BF#ELH)C?<ET#B0`Y(`.DZ15`XJ[<R\F`@8.J&)T<VBD51JHS1/,(]
M<PLR0$%"KI*JJI>X==[D`P@`#IBOEY8;0HO3C"XU773&>GKB)W9U&UW9ZE%:
MX,]ME2JEQS3K2C:O;4R1-*.C:E<,9<QEUG!E3-%5#"`=3'T*1O*Q\H!Q.3*,
ML!RP7A)V[3I,R,OUE8%K=%5V+6TE9ES0M!V<@KD4GHDNO9ZM7;X(AY3E17MJ
MF4AI6FVE=FC6K96O(<J;=4#+*\JF4%!(H.Z`XW9^]N"5!/>WHWF\9L``!'J\
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M#'!P]6T")%MHXUU9F"5$J5?E0[V(%MMG'QK6IM8VZ-^-`]^WS.'+\M^L6N7-
MXB0M3.48)Q'0"E:P'R>TQ+G?I`$1[0VYI](2)*$`0<+*```.,3-Y*.DJ>ZDE
MUR,+22?,N9,P.OF^O#0-:VVL?:*N*"U`ZM;B5&QBFM+WEE[*2=#.&$B1ZZ?-
M**M5'4A/J.VF\91@W0G6BB:&8[JA0,)0`,<G>O%Z:M92]V7DL:^/6/&6\G(N
MW@&$SJ`3KT!?+<H!R1UK:\``-@?5V\>/VF5F=][T+T/<S/LZ`IS^K+]7&-IE
MYG?>]"=S,^S]T)G]67ZN&TR\SOO>A.YF?9^Z%.?U?4.-A\^G`!Z\8#ZQU*#9
M,Z)]6$<P6N%ZQ_C;TD?SMU9_U82_4SZ^._13Z84K[''^&;">3CL7!K9$[:F>
MK"\WB&=;'?5P!ZN//C$),/Y,K[K=2[^S3,XT)]7`'JXBZNE.;#NV-Y6@`Z0%
M@R)K1$%L>9-OU`'JXJVF5F=][T*%RH^Q]T)]74Q8RO$N(8#!V6V*JF2*IY!;
M=B.0*2%'?$0[DY]TI!V9JD2*JHN@F`[Q3G$I@'++;EC9HJN1)F=XT.O\_H2?
M*KZB5W,TR[D(6-`^E?.VAM$S.?U$:BKH7P/44E1E5W_H.[5M*&BZY=A0LZ>D
MZ5I]K%U=7E&M@3!Y44%,L#BS*X4%`IB`/)B(9X]W1;\2::G$J<QIFB,#`1`/
M%&$>+S+QU;NK,=4]Y+C`@<=D=*Q=9_1;<*WKG3U5"E`VUC+C4;?G5;7]Q:F2
M4A%9)]1EVF57M*&"2DHUHG(5+&N"/V0/(4#[R(ESW0W1.-$[>W#I[W/>UUH;
M"W)",>+CBDK`:V4(,AT:UB2E-%VH:=E[D5#?"U$9/Q]5:9WUH*@I2BZ\MO0+
M65JEO<R&JUM\G;^C:>:Q5/TTVBTB.XT)HKUR"R?-W)LC&#'4IM\,!IY-UDIA
MF&!)>T.M@!"UF2S3$K3FX'B;IA,;(\W_`!*X:ETHZLZJIW3_`%%6+%&L)6W)
M;\TA5=`494-KZ-J%S3MRRLT:6JB2EW=)+6GG*]:T^V.VG%6;-(42J"=N8JHC
MB/ZLW=93F2V4TD0()$3$6BVY&$<HX^-&X'B?>`D\?#C6T%P],]7/=..E*T%N
M8LW*69O%IYK.585;5[:8?P-(6[J*1D*B;>^;F",?44G',5Q`!3*F98<@V9X\
M_2[X8:'6MLAP^JO35>&5;FF%W1Z5AV&TA7N8U72TF>&ILK:(Z3RN]5CL2U"T
M%RE9RHJ)<T^QD`12`H'GADUB@H@`;QDQ$X^MQTJ[>7#ZG#YDAOK.DM9`9P\&
M/JY(<2XU%AE6S$9;G0NWB39R'E7U?W^4`5LQ$%<RE,4@;IS<LX66$QL_7[QP
MV]4,>.VBF^UI.I>NV29]G0H^KZMN->IJ9%T70[+G]"NDTTQI)ZN3,$S^K+]7
M&GM,O,[[WH5_<S/L_="9_5E^KAM,O,[[WH3N9GV?NA,_JR_5PVF7F=][T)W,
MS[/W0L84SEY1]SMG_9=HHWV1O$X#CZV/137M^"RIEMVZ>.W([C7`ERC\7F9+
M]X<W%Q*+I0]\);7!>,+1VZHZN40L18PDTM5%?+T4>/4&H;D*-BQ_)0DJ1X1<
M"#OYY9=00QTZ&HPF5@_\:U[G.`A;S9#D@M5LF:^9RW1R9E<@43K6#:&GZT8;
M!`1&_#S+(0R$.YHT!R$!RQQJ29@8O-G_`,LGBM^E;9D5;)9,G^;"RT>50-%:
MUSB836!M".\8IS?Q\R'=&(0B9<\J/V@4B9<@X`$,^'$9C]V[T&'A]Y:9I,4<
MZ^^!/.-2@:'UJ#GGI[L[M`P9EOH[*;(QBF,&\%&`(`(D#@X,L38S=V4+YO6\
MA]I;A.(N8&`"(Y0JC47K7.83*:?;0J&$V\)E+[O%#";?!01,)Z-,)A,8`SS]
M<`9#F&S%G>;N9ST^TH7,2S#2%`45K7#_`+/]H_\`0B-^WXF)ZX`%,PT>)DA*
M!Q`-W+(!R#9AWF[F<\/*ES$N32%!:'UJE#=+I\M"0@@8.3)?AZ1+=,!0W.2+
M1P)[A0+W)<LBYCEEO#F[S=S.>'E2YB68:0JC47K8-_T`6ASS,("-^7^\!CY;
MP@;WG[Q1R#(,O6EV!D&S%<P[N31=<<G)^)6!^)-$("'.%0-#ZU,Q'R?+1AF)
MQ'=OP[*`@<,CIY!1H?<#]5/U@CMRSPE-W;D6@G0?:6;^)9AI"D:(UKB4"FT_
M6=,4!S`#7U>FVB(CGW5&CF.8]7&0=VVY]'XE7=Q$9M(4FHK6P8XJFL!9\ZIE
M#+&54ON^.H=4V6:IU#4<8YE`W0R$1S+D&66+=IW=NW(V</M)<Q+,-(5/O'UK
M#NYZ?K/&!,H%3*:_$@8B6PP;R9!HX2)J"!AS,``8<]HXAWN[F?H_$ES$>32%
M4-%:V!%0PZ?[/9JFWU1^7=_]T4$-TZQ_\3>Z74*&1SCW1P#NA'#O=W,YT?B2
M[B/)I"CWDZUQ',=/UH!',!`0OP_S`0,)RB`C1V8&*8VP0VAP!P!C/>;N9SP_
M>6+F(YAI"GWCZU!*4HZ>[0"5/<$F=]G@B44Q*8ABB-&B('*)0'>SSSZN*)IP
M=S@:>-P"WGTJ)E8B3>LTA5&HK6N8PG-I^M$8QQ$QSFOR]$YS&',3G,-&B8YA
MXQ$1Q)D["V#KY?+K5C3BK<AZ0K'N52NLEM;>Y//K!VE;M@MU7`KK)7S<.54$
M1IB5Y1=)J:E$C+J%`=@"8H;,;N'S\&%5>.0D0@">3.N96RL:F.=,$+N7*WB"
MMVQ-(:Q7-CK.'A[$VG>1AK8T1S!Z[O<\9NG;+V@8F:N'#0E)K%;+*)"`F3`Q
MMPVS/9C;Q6JP9X,MH-YIAD,-,5G#Y.,"$QT('E&J*RU[R];.8"%@K0EW2E*&
MY?E^3=*0=XH%`M'`!0S';EP]7'+ES-V)8ZI@Z'#ZRZ(&*@Q=#2-2H]Y.M7E!
M5#3[9TJHF$QE27V>D64'+(HJ*EHT#J<F&P@&$0)U,L4S&;O3)HFDF`,<GXE:
M9F($78"\1G"&HC6J8QCFT^6?$Y_7F-?9X.\(F`QCF_Q-S%0Y@[HWKC=41Q=W
MF[F?A]Y4W,2S#2%'O'UJ"(";3Y9X<BG(7*^KPVZ50#E,4I3T:)0*(*#L#@':
M&T`Q$U&!RNO3'^)'HX_K*V4VO#NM"$,X4DH76>F=54NG2S!5'"*3=PH-[E2F
M<H("44T7!B424SA+>*!C%/O`8=HYB(XV36T+F0))\A6J^1B!FQ`$(YQG4C1&
MM(3&.&GNS0',<QC&"^CS>$15%8`$?>9GN$5-O%+ZTHY9`&09:4J=A['.B;##
MAE6S.9B4&W(1A;;Z%/O*UK9YCI_L\.0'``&^SX0#E3F54W2C1@@45%3"81#A
M,.?#BW:L-S]'I5'=XMR:1J4#1&M?=.3R?K/;J@9*?Q\2`&4'>WQ.<WO-WC*B
M?;OB.]GMSQ8*O`B(3G=?A]I7RVXB&]8"/.$&B=;(@)?)]L\)1S'<&^SX2%,(
M`4QRD&C=TBI@#:8``PCU<5..[3SE,>;\2LA7YAI">\G6MF<?)]M#O*`8%3_+
MP]WU=\``PJG]YV^H82@`9F$1W0RX,2#]W!Q\/O*@LQ*-@&D(%%:V"Y;FG^SR
M>0%`.3ON^3VE#(#YDHTH\KQG]</5'#O=W,YT?B2YB/)I">\K6SO%-\@%G]XH
MYE-\O#_,!ZHY^\[A-U>,.'#O-W,YT?B2YB/)I"D*+ULE`H!8"T!0(``3=OP_
M*)<C";N<J-#(3"/=#PF#8.88PZ=@0$:<GO.$?K%9:,1:8F&D*`HC6J4!`NGZ
MSQ0,(&,4+[/@`1`3"`Y!1O4WQRX@V!LQJPPR^)CXZ/2L.^*NM;#2%K=JVI35
MVWL549:@L;:V-C%JBMP11Y'7I<2+A)<MQ:6,V#FJ]*MBBFJL`%,;>[D!SRQZ
M3"JS!YC7R#E@#_MML7"Q65C(=*?E%X\8Y.("/$MDU*1UJN5EU1T_6BR.NH<N
M[?AR'<G',H&*%(FW3`7+,.H(]7'+GS\'=-+FQRYCK74D2\9;)`,-(U*D*(UJ
M]33_`&A_TU]WHC_J:-RQ!\_!B;1$PY=:FV7C(C`C+G&I3[R-:WF_V?\`'N_^
M)N(=]@O9\^M2N8SG&D:E'O(UJ>;]:3[%^'>7V,Z.SRQGO<&S=!UI=QC.-(U)
M[R=:FT/)^M)MX<[\.\MG'_B=G@9N#0R>?6EW&,XTC4AJ)UK'RW]/]GE,@`/N
ME]GR@]SF!#")Z.-F<@&$`,/=`&P!Q&5^FWB+HD\@C_Q+8ES,2DBZ`-(0M%:U
MR9<G8"T)!`QE,R7YD"F%10<U%#&+1X&,HJ8,S&$1$P[1S'$2[=QDP`'J].B\
MH/\`B4UU\PTA4!0VM,"&2#3W9PJ1C*'%%*^KU-+?6+N*F!(M&@F`JEV&R#;B
MSO-W,YT?B4;N(\FD*HM%:U4QWD]/MH4AZG(WX>)%+W*A!$I4Z-*4H[JI@S``
M';];`G=U]D3H/M+!.)R[6@6\H4DHG6HG^U:?+0$[@I`Y._#PF10`"B'<4:&6
M^`!OCPG$.ZS'&1,W<88QAI]I6,=B;AU@#Y0A:(UK%`A0T_VB`J9@.0IK\R!P
M(<IA,4Q=ZCQR$!,/V!RX,5S)V$NF"9()+0.'&K'3,28WNVP@>4(-#ZU1`0\G
M^T&TV\?^/A^)CF]DH;WG;QS;.$PB.S!]7136W''AI5#!B4IU\0CSA2-$ZUQ'
M,;`6?$1X1&^[_,1XQ_Q-VB/5P;-P=K0UPZWEUH_XQ,>7B$#RC4H]Y&M3S?K2
M?8OP[R^QG1V>6)][@V;H.M0NXQG&D:D]Y&M3S?K2?9OP[R^SE1V>6'>X-FZ#
MK6;N,9QI&I3[R=:WF_V?\>[_`.)N)2Y^"AX,./EUJ#Y>,N81$:1J5F7&H[66
ME;ROSR%A;2-V`T/5Q'[EM?)XNY:LS4[)`Y7;H'I!,BRZ268E()@`PAPXVL*J
M,%EUI>X&T@6`FTY[;%JXK*QE]"&L(L$3:,@%L++?(K8L-26L5S9&SX1=AK5/
M(\+:4<+5=U>]=DZ40&%:':*+M"4JOS=55DHF8Y=XV1Q'@V8GBT[!CB#CF$,G
M+Q6Y.5489*Q<X:T<=[.!9#E"RQ[Q]:OF^VE\?#OXG8T.^P;-T'6MKN<8Y-+5
M(41K5#@T_6A#^SOP]$?]31O!AWV#9O/K5TN7C(%A&D*?>1K6\W^S_CW?_$W&
M.^P7L^?6IW,9SC2-2CWD:UMO]'^S^TIB#_'L^$-TP"!@VT=LS`>'&NXX29E]
MHLX<JM:[%PVXXC2$]Y&M83;XZ?;1"?=`@'"_+X#@0!`VZ0X4=O)D$0X`$`'%
MXJ,+;D/#2H.EXD_+#2-2@]$ZV5!,*FG^T*@FW@,8]^I$QC`8V^(',-'B)NZX
M,^#J98EWN[O&;>;\2V`*\"$!I"&HC6N<1,II]L\<PD(D8QK[OS&,DGRNXF81
MH[,4PY<V8<`YAGP!D[W=_P#Y9/><5G'Q?66'MQ!S"T`1(SA5>\G6L(YCI^L]
MF`J"41OL^'<%3(#"G_B:/)Y%`"EW<MTH``9```$VU6&M]:.CTK3%/BC3$`:1
MJ5/O'UJ"8##IZLZ8X;V2GRZO!4#>#(P`H:C1,!1#A#@VCQCBX5^%0NL];F]*
MO:<5:;0".<+D4HO6TH*ASV"M-RBHYG4&_DER@CD)<R*EI`%$\BB(!NB&0"(!
MLQSI_P`.>^_;H.M3[S$LPTA<841K4#8&G^SR89F$"IWT>$(`F,)S;I"T:!2@
M)S"(@``&8B.+)<_#"(3>M#)PBH/^*OM9`>4*KWD:U>I8"SX_7ON^_2HW$^^P
M;L^?6J[F,YQI&I0-$ZU.KI^M'_I;\/,O]51V>,][@V;SZTNXP.,:1J4>\G6I
MYOUI/'PZ^)V'>X-FZ#K2[C&<:1J4^\C6KYOUI?'P[^)V,/J,',(\7#.HM9B[
M8Y+3G&I:W7HIO5RWNUI42E;%VO:/0NE57M&@A>A9TC*/#VWERJ)/W`4P08U)
M!(@B50H'%0V1=T!$,=JBJ\'V:9G##Q98B&>U<2ND8R*F7&'6F#C'$1R6+9+W
MDZU>KI^M"'7^7A[LZ_\`Q-QQ1-P;-Y]:[MS&<XTC4H]Y&M0?^@&T)NL%]W@#
M_`W&>^P;-Y]:B^7C!;"/2-2CWCZU?-]M+X^'?Q.P[[!LW0=:H[G&.32U2%$:
MU0_[/UHP_LK[O![&5'8=[@V;H.M6,9B[,L-+4&BM:V67D_V@RZF=]WP"4=F8
MD$*.S(;9PAD.6S$'5.$-R0'#G5G_`+OR:0@T3K5-Z[3]9XP;V_NC?9Z)-_,#
M`<4QH[<$X"&8#EF&,RZC=Y[8SSU^3-]Y7,=BC1`@$\X4^\K6L)M\=/\`:,3B
MH=43_+V_WM]3+?'>]YV]NCNALSRZV+.^W9S\/O*5_$^R-(5)J(UJF,4PZ?;.
M`9,1,F8+[/2F3WB[IP*):-#=!0![H`V&':.8XCWN[G$3#A]I0(Q$F)AI"CWD
M:ULQ'R?[/YFS`X_+S(9J`8P'$J@^\[-0H&#,`-F`=3#O-W,YT?B6+N(\FD*L
M:)UK&'>/I_L^8VS:>^STX@)1*("`FHT1`V90S$-H]7&6S-UV&(/#[RBYN+OR
MW;>4:E2:A]:ABB4VGVSYLP$!_CW?@<<P$NT_O.WLP*.7#L#%NV[N`791C,XN
M%Y4&EQ4"(`CSC4GO(UJYB/D^6B#/+/=OR]`-@``9%]YVX&P.+&-KPGA'6H;/
MB_)I:I]Y&M7JZ?K2^/EW\3L1=4X0\0(\^M62Y6,-,;-(0*(UJ]33_:+_`$]^
M'H]C=H[$.^P891Y]:MNXR<A&D:D&B=:O5T_VB_TM^'@!]G>H[#OL&.0>?6EW
M&1QC2-2CWDZU/-^M)X^'7Q.P[W!LW0=:7<8SC2-2QE2T'J40U#W3BI>TM`L;
M@O=,=&!2E,MKJF>P<XT;WK`TFK(U"6G2.(8S*+YPLF!D#\LHF5/8!]X-U\VC
M-$QP'_:!T,AS.^DJAC:SOGC_`-5`<8Y/)D6[=OBE'7%J,$0`1"Q>GH`V<`&F
M[L;P!_9;@9_6#'&<UK<,9=`'6/F*ZTJTVYA]"W&.4-S8&0[Q?6[H#EO!GM'@
M+EP]7+@QQJ>6UTET`(DK=O73',M,M0.IZH[0UY#T#2EJ7=R)-Q:NM+S3;A&L
MH6E6T325`/HUG,MFQY@O)OY)R@^,9(HB4@[H]T`Y8Z<C"I$\7BQ@ZP;ZHC$Y
M.+.N=4UCFN#61B1'+"P1CQK)-(ZDK1U7;X+C!6D7&03*DZ`K:H$IER#)]2,-
M<R(:3-'EGFP`L*+N4:/R$1`1$%U@'(-F,3<(FR'W)C7723=!@19E@I2:QA9$
MFU6Q&:H:`9,ZW?W$FHJ@&%*W9JJU$$N\=N7R]7+TW!PT\5Q&MFS-=TO+.&<H
M8W-DDEE#<@8"E$<0^&M-@8#9'(%;MDN$5=5)ZG+`5S)!%4?=*EY^1&GGM7))
M,':YT5J=8`49630=KI(Q[M*&*N`OTDU16CA$"KIIB&6,.PX-$7,$+.((*N6;
M`>`76AM4VG>I(FIYR&NY2JD-0[1A*U1)N'3F.0C(=Z\.U83JQI1FSYW3+YTD
M9,C]'E&:N615L9^&PAU+>8)MDN.52WU/6+>4K+5PPN7$OZ;AIQ*F)%RQ8SSM
MZWJ%5#VQ0BSPC6)6G2KNV("LB4&A^7;CRI#F3VXB<)=&+60)$<@R)MDGC((7
M9<ZC+*H1]&29[H4XHSN0W,XH4S%RX>NJG11=E8KNH=JU:NG+A&/7#<<&%,I6
MRF\#@"\`!@\Q_5NQ@;>3GYDVV4+8J\H6Z%!5$YI%K!5K$2;JNJ??5/2"#)XF
MX/4U/L`;`_FXY($1%5K'@Z1`XE$A0.IM+U,9V&7+)OM!AG`4J:IES!$E>"2^
MEJ??ZG:L*X8A<%PHNW:TTLA)MEW+INP"34C&DBZ:!#OIAI'B"RB"3H5MP<S$
MRP^%RW$NN`-SP$%&;6RV3`+#R:5ABK-<^G6FG=O$6U=#4;>X%S&UJV,K3#24
MF8=C4SME(/P(^>H,5&B[9H,:JDX,W.H9!?(@E'(0Q;\$<(FYDYK5@XE3$@1%
MO0LRJW[M,2LSVZ]_D.6MTS&04@S\^Y8CA&--,KQBC[FY(1*<3A]YP#,7`/!2
M*)N2$2[N*OAC6B_<%PV1($%G;9,RQOK9E;D5J%M]6DO2Z=NZMIBLJ>EIRHZ?
MEIYK/F:H1KNGZ76J)3VC06;(>_1<C9(0=E9+'*T*"ASB)DQ(3/PT`1+`/($V
MR7&PJUZMU:VV;T#7M5VYFF%>3=OU*6]M:<RDH9X1O5=2,*>C),$I-A&G<PZR
MCQ4R+E(JB*W([H'SQ=+PYP%T-NWLG.!$A53,1E2N,%;<(%#DPWC`<V6TP@`"
M(B`=0-A<@ZF-$4X:_K6CE6VR:)H#AQK&=[P`++7A,4``?DNK_:```_\`%*7Z
MH;<6R6,9.@P`6C)Y$FV,\A\RM?2V0GDV6%#=+D6T-O0#N0V![V8W8'%BVI`+
MG`Y(E5T[G70(F$-:SYNE]B'8#&J*:G[#-`5T3G6.;M*7`0MI7ZMIV\0YN:E1
M]0*4`VGC<G"KU:6,7-!)21]],"M#R&X!A,8I?9"`9XV)$F1WK6N:.[+A&P9%
M14$MD/>WU@TD9_(M#K+:J4H%E2%.W(JJY%15C-U_!6XNK'W1@:9HVK+&5Q.T
M:]E8<DA#T['1K.7H:M9Z&7:Q,@V!TV4563`CA0!$`W*C#)4XGNV-`A81QP\G
M-I6A2UL&0FN))AERKTY37)4KBF#5=1=CYF>AVEI:AOO,N92M(."*TMC35835
M/`]C4%FKA=]+5%"01Y-@@)"`NFJ4@G*(@;%SL$ER98)#(WPSU;;T(YLRIVN:
M9I@70`CELAI5C53JDO14$?K$&$AF<)0UM+%T#<&U=9QDJ@-6)/:SHJ4J2-%[
M!N1$KI_(JM!`,U"HMSI@0W*;PCC>^&2V]TVP%[G60LL\ED.E53*N<`7!SK`#
ME*O!]K@DK>P=81]V+:RE-5U2+2RBT=!LJIC)IK4[:]J\K%TL_D9UBQ%"'4:3
ME,2`2I"D,#=J4ID@.)@#'/;A6TO'=`%G6$0.,<4/,K9-;.ZS9KG7A=L)C8X1
MS\O""\*/UG7;KRN-/,+;NWL'[7UG=ZZ%L[IEE*@>)QHN*+MLK7#*0H"HGT+'
M#*P2C+=>@L9J)E5T58\034`XDR["VR&N#P"X`'U;1&/#D6QMIO0!,(YUD6%U
M+5@HM#43;ZBZDNO7%35;?$S-&K:HIBE$(BD[25FA`3#UY.,V161V2CZ;9M(I
M'FYG9B*`+H^9#*#JU>'R2Z_<;"`XAF4)56\SH7B1SZS!7)J/J^Y;2K])]$4C
M6L[;$+Q73GJ?K9U#LZ8EIII$1EH:XK,\2S7J*+J&,!\2?A&Y`422W1(4VZ&Z
M.)T=+2M8][Y8-T#)`1MYN1;%14NL#21$K5:J;Z:J$HNJ;5T77$;.7AM%JAIV
MAD*I>TQ$M6MYZ$^3B8NP2AIR*2;&CZ>J*HHJ,&'6DF/-]QVHDN0A""<@=&7A
MM!,'>M8!*+(VAI(M@8F%N=<Y]5/!+`YUZ.<J\HC6X[E*/U77895`@I1E*TG9
M1W9V(FT(R&5IZL[HTQ)QXTQ4KY443D=,[A';H/2O3%YF*"A!W2YXK&!,-3)D
MOECK$ET`!U6D1/E'G49M5--/->US@0.K:<I!Y>*RWDY5D32[J>9(VEG&%_KM
MP%2W#M'<5U:NM:_B46KB'J]_)(-I^B:A0CJ/1D8Q@2?IJ80**:([B;ENJ!A`
M0QJXQAT@3"ZFEALIP!%@B(Y08#*%=@4R>Z3_`-P]SYG*28\ML5O]&NDWZ+5V
MW5!9LY1*Y25`#%(N@NF!T%"IJ`*A`,4<P`VZ/6QS)=-+E2[0TOYK5V77N\A]
M5>ONEX@[`8G=;D@(*<2,BTPU\%*.FNIB"4HE-65I`,`@&Z(?*K1FP0XAQMX?
M+DMGP(#0<L+(V%<W$IDQC99;:;ZW'*`#F80X3<&S+',KKC`UQ,+=/.NE*FF8
MP60*&V#D!2B'7#$)K@719*F.;#*V`'2K6Q(M)BJ<Q]@3L?JXKB?<3M+=:E`9
MRF8^P)V/U<(GW$[2W6D!G*9C[`O8_5PB39W$[2W6D!G*G,?8E['ZN(M:&"#*
M>:!R75$M:<JXU3"!!'=RR$NT@!GGO!EPCENB/#UL3E29<Z<!,DS&_:-V`LY+
M4[L.%T&"P%;_`%+6-NK7M?VTH2YU*5!<"U\ZZIBO*';2H-ZKIV68$0.X3>P+
MOD'HMLG!1!R@55`=X.[SQO3Z2?*8#)IVF6;8W0>FS.N=,QBDDS=E+F][&'+'
MBT\2SV@5,5E0$3GS`H[ALA*GU!*'".]GPXUS22Y+1-?87<7$.9;39#@.^)):
M[("<B[0$)GD!0^MD&)=S33!8&Z$#7-MC8JRE*`;"@&W;L#AQ-DB7*!:T6$Q6
M8AQBJL@X@[`8G<8,@&A#;E4;I?8E[`87&9AH602+`;$W"^Q+V`]3"XS,-"7G
M9RFX7V)>P'J87&9AH2\[.4$I0`<BE#8/4#`,9'(-"7G9RL6WB#^**['\W%;_
M`,&);%6!]9].YUI=.(/*`^R.=5X@3LIYCYE:&E;;IPL1F`#G:.A!V[1S&GHX
M1',=N8B..MC$N6,8K&AK;K:AP`A8!F&8*%%_H)9XX:UL%NEX@[`8YO=L[(T*
M^)SJ-TOL2]@,+C,PT)>.<IN%]B7L!ZF,W&9AH2\[.5.Z7B#L!A<9F&A(F,>-
M1NE]B'8#&.ZEG*T:$B5.Z7B#L8CW$CL-T!(E-TO$'8#`29+3$-:".0)$YU&Z
M7V)>P&+"UIR@%+SLY4[H<0=@,1$N6#$-$>9(E,@X@[`8D0#818L)NAQ!V`Q'
MNY8R-&A(E1NE]B7L!C-QF8:%F\<Y3<+[$O8#U,+C,PT)>=G*;A?8E[`>IA<9
MF&A+SLY5`%+F;N0X>(,5S94H@1:W0H2W.BZTY5ICJ.(4+\:)P`I0_C@K<VP`
M]<-JZC-O?7WMOU\;E(UHDS(`>I]*UJLDS9?_`%!]"W1W">Q+V`QK7&9@MR)S
MJ=TO$'8#&;C,PT)$INEX@[`8QW;.R-"1.=,@#J!V,9N,S#0D2FZ4>$`[`8@9
M,EWK-:?(%B)4;A?8E[`8CLU/[MF@+,2FX3V!?M0]3#9J?W;-`2)3=+[$.P&)
M=Q([#=`6(E-TOL0[`8=Q([#=`2)3=+[$.P&([-3^[9H"S$YTW2^Q#L!@*:G!
MO"6P.Y@EXYTW2^Q#L!BSNY>8)$J=TOL0[`8=VS,-"1.<J-POL2]@/4QFXS,-
M"7G9RFX7V)>P'J87&9AH2\[.4W"^Q+V`]3"XS,-"7G9RM0$"E\O.1V!_52B1
MX`X?E7ER_H!E];'1/_C@SZEXV<2Y38_$W'C@/,NE;W^O#J,_F,T\_P"&[MXC
M,_\`&,_:/F*VI.7R#Z%N.H43)F*'5V#L`VP1#/,#`)1#+AQQZ<ELDD98K<(!
ML*T:O;I`@;[:C+:72N#%PU36]H&UU:4HO2;M_4""S^HJCGHF38.5FD>[:,I*
M"2C8XZ:[9QRI3**%^YF`N8=JFKIE++/=&#X@Q@#D'*,JY=32!TP&TB"P_?72
M-=VK)B_,3:<;4QU#ZBH2QJ<TYJQS.LWU%/+)R4>+2,A("&@)"/F(Z=I]EDV,
MHLWYJL4`$@!MP9B7?N:U\8RHP)XRXV\7TK#J0LEP!L<LMT_IRJ*-N!`U$[EJ
M7=$I[477UZ5H]4RCIZ6#K2W<?1D8V:(`W6.C)(OF2JG*'*D4"%'='//$C.O7
MB(@%@;TJ+9):&QM:'1\VI8FE]$-73%'V?H92JZ;I]*BHS5%#5#*P+1XBX`+Z
MP]0,8*0ATDVS0CQ2*=R:)WZ*QD2G(`B!C")<9-6UI+@1;`PCF412QRQXUTYG
M2A>VZL6Y&Y9+.TG4$-8V+L52\+2+F;G::J*-;UA2-5RU25&=_3+!5BB@G114
MXR)*V=IHJ*K9K;H[PX;52VQMO&,<N2-B&E<=&;,LAUII]O,A=&\5R;=U-$1+
M.XUPK(S@TXA/RU'2LQ2M`6W<47-13ZHX^%>.J;=.IYRV<I"S`><M&IT3F("N
M,-J)=QLMXO!L>,\9\RR^0XO+A$$\-*]>P^EZM+;5!:>;JU[1<FK0-'WD@)-"
M'&7>)&=W-N(6L6BD"K-1J3A-DR:_VNX,;<.<V9ASS'.<VL$P.RAQ(R<BPVF+
M2#"(`/2K$T?6<GJ4NOJ`FYE)S[PJ*KBH+2Z<47<?(P[R*MX^DT[C5PBF1PEO
M&9EN'42[%D]:B5%S&M")Y"5(,58A4%H:0!?(!,+;>`!Y,BE22,L38+!',KDD
M]/U\I^_U-UC4-74_,4+1U\D[HP3B0J6H&[EI1ZM'OH-A1L10,7$(TO&2T8_=
M*J'E5W!G$DF;=4R$`#$I-1+-*^__`#',ADY8QY5AU.X5#"/5#H\-"X'6EZO(
MNS^ER`HQ6WSNKM/]V(.X<G&O'#B&IBI4D%YYI4J+:68P\PY:S";:;4<)G%ON
MJ.$MTYR`(F"UU8U[IA,1?8&Z.1&T);=@1!ICPM5KQ.CRJX^[%6SDS&TW5M%3
MEX*JOO3U0O;G7`C):D:MJ!N\<M$U[8,VCJA9N6AY9V*39Z55)([$YQ4)RAMW
M$G5UZ6)8`N`0A#ICQ#4HFA##>)MCG63:=TVUE"TAI<I^,EZ<B)2Q;6NT)>29
M,'2D>:3J6W=34JSDH9!1BB1X"$Y4"*QDU@2*JB"ALC"4`&C:`"XFV\0=!Z%+
M9B0!Q`06&8S2-?ZI(NN#UW5%*KU-4=JK;V[":5JFIZN=R4[1%RUJUF*HD'#^
M)B&T/`S*`B#"+9-RIL`,">W+>&WX@V5([MF2]>\L"%@8<)QO..007U/9D,1$
MH'R,.11S`5.H0H#^V")\A,`Y=;+'';.,QYL@%U)<H2FAHRA8VOA_(K>'^:ZX
M'\$IC$Y?\[RCZ%*;:SR'S%6SI;_JVV&_FBM[_!F-Q94>N[G*II_5'-K6>\5#
M(KU;-84\WJFFIFGG4A+1+:68N6:TI`2KR#FX\BZ1R"[B9B/43?1D@W$V\DLD
M8#D,&88D'%IO"TA1>T/:6G(0OGY=#1=3E<V=OS;BDZRE*QNQ=Q"D:<KBZ-P:
MR=R%81C>G)R+DH=L,A`HM7%/N:+A>4=13=HW:D5=+%,J4P'.8>C35CY8:YP@
MT6@0Y[?*N54TH!@PQ//FU+9E_IYMX_9SD>9@];1L]9).P+U)I(K,R)6X11<,
MRM6AT"FW)--!XIR:XYG*7(,MHXYT_&YA(IX.+1,OBPY;>3H6]*I);1?<1$B'
MFU*T_)&MH#BJA:2=7,HNM[1T[9FKZ82J1;VGJ2#H^/6AZ7F'I5$SK)U3"P[E
M9N1TGEO$..8".W&R,4<0TO$7M)+<MD<O.HOHY9!:"('BCE7%<;2U:"KEJKJV
MJ7T["R,U2ULHEY4K6IO:9Q2P6?D9R8HFJ(:54[B+GH-Q4#DQW2IS-UP,'*IB
M`8HDXS.E?PV--V)XB8W@8\7+SK`HI9)<X@F`Z!`+UG6FNGYUI;!U)7"N?-5%
M:^M'U=TE7JM3-`J,5IF(>PLFP<.&;-O'.*9E8"259G;I-DR\FL93UQQ-BYE:
M7AS6@W'908\W'PL4MDEQ!CU@K;?Z6;9SKYBI3=7UM1M2415-?3#6I+>5LI'U
M/#+W9=-IRO:6=N12713B9UTFT=&;*D$Z`-VZR(D4S/C,V>2T@Q@?0H,I);9U
M^(L"O>\6G.E+U1EMV,G5UQZ2E[35(2I*,JZ@JN<4_5;>36IN2I=\NXGA1<+/
MAD(.9<`ZWP,*ICB(CF.-636$$L<+'"V/(KIU.PM!:0"+1DUJBFM.5MJ/CZ:"
M+:39'=.7(>W1]M9*>DI*9J6O9:*D:=>5)54K(B9_+/7C.353(F<>02S3`@%(
M7+&P*]X#FPZI$..$,RJ;0RA`Q$1;EX]*L1KH;L.QJJL*I;T\_/\`*#>BF;^5
MC`*R;AY2LI<2EH1["1*QX%8P-#T^E[8*O3QX@**D@8K@0$2Y8N&-3KHB3?;+
M+`8&(!R^7EXLN5#122("$"<D?2LS4I9&A*,N+5UQ:;B$H>5KF"IB"J2*8)-F
MU-/"4DO)J0,FA`HID:M9EFUDUFYW`!O')EF&P,5/K'3V!KB3#.;?*>.U9ER1
M3GJ"Q9J(7=-L+D'!F`9!D`;`^L&-3O;SKD%MB)$2N;$D7SQZ4^N!MGH>O7<4
ML;[<'H%I2%:DB>=\Q+*&I:NZ;FO:T[L"J<W*]YIN;VZ.6>.M@>%G%\4E4@==
M))M\AY1F7&QK$68;3"<]MZ)\W,"OS[_2G:@.!#>1DS*!R$4W37E6(;NPSVI^
M\S),0#J`8P=?'UV;\DI\V2UPJV/!@?J6:)B^957S6923S+$AT!R.]A/I3<^/
M_8R9>.A8/_D[&_+^13VRP'UY:<S90>(?M";EY.)62OFW(>V)D.!YG>PGTIJ?
M\S)CXZ%OB=BSP,__`-%__P#7_P`Q6>+-/[AVAWL)]*:G_,R8^.A;XG8>!G_^
MB_\`_K_YB>+-/[AVAWL*KZ4W->9DT\="WQ+P\"S_`/D7_P!#_-6/%JF]P[0[
MV%3]*:G_`#,F/CH6^)V'@9__`*+_`/\`K_YBSXLT_N':'>PH'\Z;G0#,VB]H
M<`V[B=Y55#B(;0R*-&'`=H<0Y<.*IWR)>^66RZ^\^RQTH2VFT97F;`?2;.-/
M%67-ZDJ2[O#DL=["_.+?+4U5MU]5US-65$J3=HJSN%7;FN8D*0J:1"7I1TX1
M9\D@VJ5@E'KOB%.S`3"9`2$RR$NW'UG=[`L'P/"!@]=([ZINPOAKB"2(1B(M
MZ5\LQ?>FIF8@:DDM-[)'EYE]MM&7YQO?FUB4+1>KZGSWRH)H4&R]S(`&T#=*
M/2(;)`\B0RK2FZK13+L4.LHW=*CPF'@Q\NQ_Y'%C'XK23I<NE>#W;'.;:1$P
MBZ8"(YX+WV$_,FIK&RZ5\M[BWZT#DR=B"_7_`*4M55F]8MJ8^\MC)V4G:)DG
M"C$%IB!EZ>D&<FU(4'L>NPF&S90PMC"!>40Y1L<<Q34.&W'YYQ;=^IPBM,B8
M6MG`1@UP>(6_6!(XLB^SX;6"MI1-$8<H@<F:Q;-%#(-O'BIMZ[U\JVP(1YU5
MB2RF")@B8(H'@'ZPXR,J+%MX/Y([K?S<UO\`P8EL48#ZU-_UG?\`U%#$/]*?
MV3YE:6E;^K?8C^:2A/X.QV.QC7_FJW_^2Y54/^@E_LA;`8YJV$P1,$3!$P1,
M$3!$P1,$3!$P1,$3!$P14!PF^OB,W(%"7E=SK3+4E_+KHF_GCK3_`*K:GQM4
MO\F9^Q]*UJK^9+_;'T+=#&NMQ,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1
M:?H_U\Y'_NI1/_6Q+XWS_H!^T5RV_P#DG<P\RZ-O?Z\.HS^8S3Q_AR[6(-_\
M9*_:_P"%;<K*?V0MRP$-NT.SCET_UN=;1568<8=D,;"PN%40'<V\!L\\PR`<
MA`-X,\Q`1'J8`D'D4'LOCE"^4^I*O;HVJO'J)NU;VI:8C8JU.GJU5=5%3L]!
M.9=2K$8^IJS,:)0?^V31.FVKF-*N45DDU%!6%,39$*.?7IVRITIDE_K.F$>G
ME@N7437R"2S*UH/F&?E5<5JVN@^J*=MLW9TTA<&VS2\=RKGI\R5,S:6;B*&/
M5-FYEDU/*":+<5M(5)%LU'(G5(LI'/Q*`"0-W+L*D0$PPN.+0.=QAFM@!:M:
M7B<YX+;0X1/D`LXUCBI]9-[+;4HZJ)]5EJ[L.:CT^45=JFF]%P?,F%M9NKJ]
MINB549?_`!B5">II1.I"N&2KQ5HN"\<Z!98J1\BS9@M.]Q;DNS'-,>.`C$6<
M`I'%)HARB/3"VWA8LK1=W]5KQ>E*(>'IVFG]87J;41"U_5L!3#F1F*`);2<K
MFH'0T=1%:SD#'U)$SL3S)JJ=R4CIL;E!;CNB(S%!3,EEP<"QK8]4QSBPP'^U
M5NQ*;>@`1$PM_P!JQ0E?N]MHVNM:HW%P37+D:>U14A;*B:9DXB*22HA.NT*!
MB`GC-'$_`(N*?C"3QU4VJSR-8KKE,<RY<Q#$64<B89;69',+K<PLADR^E2?7
MS67[V5K@+,]N2W)9YEEB+N_JRF7EOJ`D3TU14K7%SJSI:,N+5-/TA.2\O2$'
M0B=0-IAC1U(U=*T]$5*QE^4:'276,V71`BNYEGBDTM.&EP=&Z(F!SF&;)P@K
M]HF$BS*8#R>56M2>K"\\C$V!N!6[^"IVV4Z]JJB;C5;2-,,ZB)(W.@+S2-KH
M=E+0#^5&I:'HVLSQPG3D6"3]-J]<%(X403*`&SLC+[F")>WILYC$C*>18[]T
M!RZUWZ-O%7DLI0UKJ%JRW=DC2D5J+KIY4M10B<]$/S4+=IW2\7!Q32=F.:J"
MJ#PS^;5*Y*L5!+-N"8&#*R=12Y8)M(#@+,L2!ELT<JRR<\V9+#PX>16F\U<:
MAJEM),WBI]]0E(1]`Z<:'OC4E,25*/)5Y5LT_J6M(>>BH]Z[G2&IJCYV/IA-
MRR.+==TF*A#E5Y,QRFA54C*>5>#HF_=Z#R:>53E37S7&(@`(](UKZU4E))35
M/PLZ5+FXS4+$R@(F.*ID4I%BB^21%R)2<YY('&0GRS$>$<<>9D*Z,JP!7,`A
MQAV<52N/G5Q4YAQAV0Q:L+%=\?Y%KP_S75__``1E\)?\WRA1F_R_(?,5;&EL
M0\FVPVW_`*(K>_P9C<65'KNYRJJ?(.;6L]YAQAV0Q4,BO7&J/W-3=$,]PV6W
MJY;.`IQ[0XD+#%1>+S"W.%\<JKN555NKR:GI2A+OP<54C+4189@RL8_A8%XZ
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M!J%O?>>I[-7SHRZ=W:#M'+4QI%C*O/`QS2G:EAKL2U=2M7P3R3]O09*)242W
MB8IFU*T@3AS26E-XPBW32$ULFF9*<'`%PC"T'JV9<EAY["/(K65#RUT;+-/2
MMMM5+B<8V6TMNH*Y4];!!&^.FJ-F9Z'4APYI$/W4?&K%D%Z@1<QB4>CD)7!5
M\FZYAR/^MQJ4[&&800'93#.1Y./BL5CI[K#Q6>98LJ*M+CVMN9?NYE+W!*E3
M26KO3K0,U0/O>B58ZKV-RH.U5%3KV5J)XB]D&3OF%0$7CA9&9-T%42\IRA3Y
MXZ;9=`\2I$T0>Z47%T1U2+0TV<>0J#ICX.?&P.`AGB"O*HG4IJ0JN6K"L&SJ
M":T_"26H**GZ9E):WX,Z*CK8DJ,M'NJ<I1F9C<]>J&LQ'M"RB<F3FKIG(<H0
M^ZF3%)PW#770]UX$,XN-V6)A"`TCC51J'\H-J7)O]>"W]J(.1<7PGGMVB6$C
M-0%0G1I*TT%;T?;M-@X0AG*%2BG*R4`JHFNQ;,855U*H@)EU1'E4QQJ2Z:4^
M:93/4O%OD&2%GHR++I\P9<L`=*N:X.I*Y<%7=W58V\5-Q3FV]T;$P-+V,+2<
M&XE[A1ET"TT2<A%W\B*=2O73U&2<KQSA@FU!DHT-RXJI%.7&XW"PYC06N(>U
M\3Q-NQA>LX^>/(@GN;&9'U8&&=9/L1?B[==7_-8>>>QJ=2V0>W+>Z@'J44W;
MJSE.2;]%'3X=HER`)1AJH@9;GZJB(ARYXQR0!$"FRY510RI4H36Y'0@MZFQ!
M\^86/$",O"*^DV\'&&-"/6NKI"T13,!$,ASV]3ZPXRBT.Z22F(6M](MS*-J1
MF$C3E6R=N*8GV&^JF+Z%GKD4K%R30%D%D54!6:N3!O`.P,;E#4SZ2H$^F_F!
M:-?34U5*$NI,&\2U:]`QT7P%`/)N3(4ACE*7W\UIF)0-D4V9)8X9'#:`9[.#
M'II?S!WFHV7)<^ZW]D+S9W)P2HF%[F$VYQ[*I'H&>B^$=FG!/[-=UN`]CVT'
M$V?,[?V'_9UTQDG,"6V\9@`0K3N)@)_Y;M(]E1Z!GHOO-Q2^'=;^$\3\3OF/
M_P#D9OWW:EC]!X![M^D>RGH&>B^\W%+X=UOX3P\3OF/_`/D9OWW:D_0>`>[?
MI'LJ?0-=%_YN*7P\KCPGC'B=\QO_`,A,^\[V4_06`>Z=I'LJ/0,]%]YN*7P[
MK?PGC/B=\Q__`,C-^^[4GZ#P#W;](]E4J=`UT8`%$2:<$]X,A#*O:Y*(;0S$
MHA)Y@8`VAU\4S_F7OU,E%F(USWT9A>:22#:(1!`!ZT%"9N/@LEAF2);Q-&2T
M>SF7Y4Z]Z)+4)?37-J,M)I+LE(4]8^@+L/Z5AZYK):0A;<TG$-6,68$"5!*+
M.']1.BF744,DV076-EL#A$/O%!\T*>DW8E/JYK=J[H6#UG&`B0T.R1.:Q?)\
M0^7[Z[$"YK21'+Y<]U?H?T6_F\^EVP)XFM-1#@VIFYS8R3KF$TQ486H@WF0!
MR<?1IC+*SXMS^L<21U<P#,2%X,?(=Y/FO7;P2OA\DL9(EN+@8DNB1=[1`Z3S
M+Z1@.X<G#I37OM=`6<`%^@>G(*)IJ-:0D%%QT'"1K5NSC(:(CV47%1C5`#@D
MV9,F)$T$")D$`$"@!`R#=ZN/E[ZHSY\3$DE>]DR&T\L,$(!7``AMVAPCU0Q:
M58IS#C#LAC")F'&'9#!$S#C#LA@B9AQAV0P10(AD.T.`>J&,C*BQ=>`0^2.Z
M^W_HYK?^#$MBC`?6IO\`K._^HH8A_I3^R?,K1TK"'DWV(VA_))0G5_\`AV.Q
MV,9_\U6__P`ERJH?]!+Y@M@,PXP[(8YJV$S#C#LA@B9AQAV0P1,PXP[(8(F8
M<8=D,$3,.,.R&")F'&'9#!$S#C#LA@B9AQAV0P1,PXP[(8(F8<8=D,$3,.,.
MR&")F'&'9#!$S#C#LA@BH`0S-M#AQ7,R^10EY7<ZTRU([;ZZ)LOGBK4?L?)=
M4PY_6R''1I?Y$W_ICSA:]5_,E_MCZ%NAF'&'9#&DMM,PXP[(8(F8<8=D,$3,
M.,.R&")F'&'9#!$S#C#LA@B9AQAV0P1,PXP[(8(F8<8=D,$3,.,.R&")F'&'
M9#!$S#C#LA@B9AQAV0P1,PXP[(8(F8<8=D,$3,.,.R&"+3]#^OG(C_\`E1B?
M^MB8QTC_`.+'_47+;_Y(\P\RPRO?FR5G-<-]RW9NW;FVIIVQM@@AB5S6$%2Y
MI3F<U=(70L2S#UH+D$.=I[VYGD)OKY3E4=5,P>7-EL<Z6)D++;;IU+,VMI:&
M;W-6\,F%N0Q^B*SP;7+HQ+PZK=/8?YW*'']":QSI&'UK;P[MYB<Q6'8UA;#!
MTYN@ZE'ES:,/.MT]>-RA_#6+]@K?=3-!6/C>%&T3A#F=J5(ZXM&2@D`FJS3X
M;(Q=X/E>H8@;N>>\.<UW60EV!U\9V&K:"72I@L[)5DK%\-G$B7-:2!;81YP%
M:,WJ@T"5"$XG/ZA-+TPE5,0C3U2)OKG6_72FH!J=P=K$R1#RZO/62!G2FZD8
M0)F81X<42Z?%1,C+E/N@Y0#J4G3\-F1+YC3Y5AP+E:`T:OOK6Z^K6P!9N^UO
MZ6MC*N"70MJ)J;HFE(&H8B,A80Y7Z:RR)'%3.G(\X,H4QS$+N`5,,]__`-S(
M8R7)>6L,18?6B3F7/J*G!I$73)P:"(9";!S17JT'=3HV;>TO(TW3E\-)J;2>
MIV-IVKG7OYMFFI63>(C4H]M[?-2R)VCI%4N^8R0%*B0QS"5/,V\&'?&'/O&3
M,O1CPLX<RJ;68(Z5?;-;<AE@[4KII2_W1Q41$Q4?2=[M+%.M(F1]O8MHQN;0
M1^839F*D:>0;+KS*JJ;L8Y4Z`*Y@/)FX`Q668LZ(,M\381"'F$%:*_`6L8\S
M6AKK08.TY(JJ0O[T=+]_5\K(7TTIO7UP8A&GZY?.KC6]5<5?"()'11C*B'VT
M$)1!-(P%**H&.4-H"`@7+`EXF8-$M_5R6>A3?78"QO>/F@`\AU+GI>_G1TT0
MTB6-(WTTLT\T@7TC)PI(VYM!%4BY.5;$9/Y)FLM-+JIO';,@)*GSS5)L'9BD
MRL4,1W3X'D.I;#Z["91@^:P%=)2]G1K&?P$PI>/26,A23QW(TRY^4.WQ1@7D
MC(+3#US'%+,<F1RM,NUG0J&(8P+J"8,AQ,2\6+H=W,MY#FSP3;\($LSN\9W8
MRFW_`&K@J.]/1K5G$,8&J;S:3)V#C7\E*Q\4_N';\[1A(S"ZKR8<LP),HJ$5
MEWJQU79A')P)NZ`<3[O%FN)[N9>.6S1Q<7$JVXG@TP19-:1S'4O?>:F.C^?1
M\E&O[_Z67+*;I^-I2<9N+DV^7925,1?.`9TZY;A*)D7B&O.EC(I"`%3,J;(-
MHXDVGQ)XN3)4RYE%ARV\G*H3,5PE@BV:V/'8[)H5[1^MK14S9H,FFJG3PD@U
M01;H-T[L4,BW;(-TB(HMVR7MSDD@DF0`*4,P``Q7-P^N&62\1Y"LT^-X7._E
MS@2,MCAYPNZ77%HR-GNZK-/0[HY#_&[0P;>'JS09XI;05LN-Z4^VWU3J6RW%
M\-F1NSFV&!RCSA5>7!HT\ZO3UXWJ%\-XELE5[M_W3J4OB=![UJQW>#6GI`E+
M1W5C([5#8-](/[;5VT9,VEUZ)7<.7*U*RJ:2**24R8ZBASG````$=N+)&'UK
MYP#93R21Q%9?B%$Z79,;D/&K:TWZS=(D/I]LG$RNIZPD;)QMK*$92$>^NM13
M5XR>-:<CT7+5TV7F4UF[A!4@E.0Y0,4P"`XE4T=6)KV&6^\'$>J5"GK*1@!,
MQF3/SK,H:YM&`[`U6Z>LPX?XW*'ZG#_PUBO8*T#^4_05`8WA3C`3A'F=J5)]
M<FB\P"F.JS3V.\`ER^5RB-N?4S";#]$,2%!6QCW3]!43C>%>J9PO'D=J5HOM
M4F@!_.-:F=7_`-*;FI6:PK-9]Q7ULE9ILL=$Z"CAK,'>GDFSHR!S(@H57>(B
M<P`.W%HI<0`ZDJ9]T\-:@_%,)=_,FMT'4N@34[H`;OI"3;7]TEMY"5!X65?H
MUM:])]+A($*D_"3>(NTW#@LBAO)K@H*G*ERWA'$72<7A<$J;=\L+/(M;;L"E
MNO\`>MB?LNU+KGU(]'6>G4J3/>W2(K2R2Z3KWK#6%K#TX9RD83$<EAEG9V`/
M"!D!5#$,8<N$,1-/C67NIEO.IG%L"]\V'[+M2[#S4ET>DRC'(R5]-)$@6$9.
MXR%YY6%JW982.>D*FYCX9-X]5+','2!`(JBCN)&`.`,@QGN<4#2'2YMZS(#;
MSJZ5B>#3(EDUIAR$9><+VI?5EH6GHQ:GYS4;ICG:==(I(.8.;N9;V2AU46ZB
M:C=`(YU+K,^1;"D04R"F.X*1<A#+&LRFQ9LR/<S`/V3J5VWX3QS6KK*:KM"R
MR2[-74?IA717=,GBR:]Q+;+E<O(X6ZC)\[(K)F06=-09I%05$AE&_)$Y/=`H
M`&)U#BCW]X&3+F06%5;?A#GEC9C;PY#J@ND&ISH_"3KVH"7XTG#4$JW5:2TZ
M:N+7'F91L[`J;U"2E`>)/G9'*1"[^^H8%,@`Q1`-NRRBQ%K8F7-AS%0.(X.Z
M86&:WO#R'4N25U,Z`IT\8K-7^TI2[J$;.F<0O+5_;"1-%LW:";5PTC3.GJIF
M+9RU2*FJFCR13$#=```,8[G$&F+9<S0=2V.^PXCUV*T(6]'1Z1%;U;<,^H_3
M9*U55E0,*@&7F+E6RD7]//8Z#:TZW3I=ZY?JOH=FI'M@Y0J:I0$3'R`-X<67
ML6#0P2YH:`19$1!,3Q6H9N&P(+V0*]"B+_:$J'KFY]Q6.JNPCRJ;MRU.2552
M$C>2@ESI-*3A0@Z;@8P$Y<@(1,*U47.B`B)A7<K&'/?V5.97S&AAE/@.0ZEE
MD[#)3KS)C8K+?EOZ-?.JT]_9N[0WAO$-CJ8Q[N9']DJ[XC1`?S&0YU)=<.C,
MH[=5>GK:'SO4+Q_^N\9V.K]U,^Z=2Q\1H?>M6I>MC6#I.J73Y4433^I>Q4U*
M+59:QPC'QETJ-?.U&[*Y]'N7BQ6[:744%-LW3,<XY9%*`B.-[#J*M?40ER7N
M-T\1S'.N=B&)X4&L[^>&B]9`./F"VP4UR:,TA$I]5.GQ/+,!WKMT2`[!$!V#
M,AF("&WB'&D_#Z\N'\%\.;T*[XQ@[9<1.@(9G<?D7$77'HR5#>)JNT]"7,0_
ME<H<-H</#-`.->HPO$>\Z@<P0%ETZ<H21B^%SI=]L\$1(R.'G`57EOZ-/.MT
M]>-VAO#>*/AF)YW?</M*[XEAGOO.GEOZ-/.MT]>-VAO#>'PS$\[ON'VD^)89
M[[SIY;^C3SK=/7C=H;PWA\,Q/.[[A]I/B6&>^\Z>6_HT\ZW3UXW:&\-X?#,3
MSN^X?:3XEAGOO.J3ZWM&ABB'E6:>3`.P2C=VA]I?UP;)P!S$O!U\/A-<_JSK
M[I7&+I$?+%2;BF&-,>^'2N$-;.C),3')JIT\`=0QCJ`2[=!D()QV"H!0F0R4
M,4``QAS$<L2KZ?%G,$NDE/+2(&/$/+]"K=7X0Y]X3&CR'4NT&N#1CYU6GK/+
M;_&]0W#^.^#&*?")TE@C+?WA%I@5=\9H80[UO)EU(&N/1IG_`%J]/0!_.[0W
MAO&R<.G-$62WWN8K5;BU*Y\7S6W?+J4AKBT9[<]5FGKA^=VAO#6,MI*PCKRW
M1YBMEV+8:<DUN3EU*?+BT9^=9IZ\;M#>&L2V2J]V_0L?%L.]ZWIU)Y<6C/SK
M-/7C=H;PUALE5[M^A/BV'>];TZD\N+1GYUFGKQNT-X:PV2J]V_0GQ;#O>MZ=
M2>7%HS\ZS3UXW:&\-8;)5>[?H3XMAWO6].I0.N+1GD/]*S3UP#_TNT-X:Q)M
M)51_EOT+!Q;#@(F:WIU+'=U=:NCV0M=<Q@QU26`=OI"@*R:,FC>[-$K.'+IQ
M3<HD@W013F3'5664.!2E*`B(CD&W$<&PVNE3:=CY3PYLXDV<1?$="IK<9PR;
M3%C)K2X`\1S<RM335K.TB0VGVR45+:G;#1LE'VLHEH^8OKIT:T=-'*$`Q260
M<(KRZ9TE4E2&*8I@`0,40ZF.KC=!6-Q>L>9;KCJEQ!AQ9/H4:+%\.%'+E&:+
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MP[WK>G4J0UR:,0S_`*5FGKA^=RA_#6(NH*QQB);]!54O&,,871G-M.8ZEJ;?
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M63`0P"\8&`C`#BY5^6?\YD:H+:\;;&.DDL'D[T\)2JI$5!/=JJJ>3W"'*<3&
M,B)@WA',O4Q^@/D=*H<1P-W?MB(DGRGG7R7YH'$96,-[MUAX9E^=@Z,<F(`=
MFW*.Z"ALVJ'<IY`8QQ`$MX0(!BYE#,X[P9`(CCZP^9@.&U![F6V94@V-XSGL
M#HY%X,-QMLQE1,O&4`>(\8AV5S!'M!,4O,FA14#>2`S=N45$S%S24Y,4N42*
ML;N2@<"&SX0``$<=*7B%--9W@H!H?K5,S&:^4_NR#H4"Q:``?V@V`1*!@#FJ
M&THI$44'>%/DR@B*FZ.8AO&`=S>#;BF5B,FJG;/+H@''D?K4Y\Z?42VFIFF2
MV-AL$>2T<2Y6D.,BIR,;$'?K"DLN1*-B_;%55%LF*SI4B3%NX4Y-F@43JB(`
M"9`$398Q75;<*FMIW4@%[D=QV+5N2OS9TL7"1DS.&8-&BA#"4"*<V;F(H50,
MT#IB5(V\1<-I.J.W,`R'+<,D[4RAV01F2Q,R/XXZE=-JY]/AQET\PS67XQL-
ML!999_M7.G#\L"YT8L%"-43.79D8\JZ31LFHFDHY<JHHG21;$.ID941Y,-T=
MNS;JS:D4]2,/-(V+C#(Y;U-B5=\--AR<.)>Q1]"5)<&H&%(T+1DO5]62XN/:
MBFJ<@_;B:E>:-U73D63)BDN=0$6C=14PF$H`1,PCP;=/$O@^$S?^[8V7,>>L
M#9`GG(.E<J@^-XI>$LN+9>09NA>`X8MFBJJ#EHW060<K,EDEFS9)=-\W,)7+
M([90A7)5VP_MG<;A<\A-GLQ?-IMV:.F%<\-ZV2T>TKJ:5CE=4&A!=%L>C]U"
ML&IBD$&S;[J<Q$PYNVWCBGF"HE+N9B"0E[KJ@(AC8[MOY0:'*4VDI:@_ZNP<
MK%QBU9Y%$&S8PG`PIE*V;"8X%'=$/6@"*@GR`"*BF<PCL`0VXG);+9-:Z91M
M+`;;'JJ;3MD4SV4M5?J(=5L6VF.2RW/D"[3>(,],5-C%#(JGY02H1D:21<&*
M@05'9RH,DEU139``\L;+=3R$1V!GC4K,1H)<S_1"',_6K:"7CO=6%T8</JKB
M6C2MRD4<1H-TEB<LU5<,46R3U$,P%RQ4<$2(\:E$!`54Q,GF`AGF&-R14R<5
ME.E4DF5(?*;?+G$M$!9"))MB8PY$F5&+4DX&H+BR8;N3C/D&94@T9")PYLT,
M)"B<X&:I)BF0#&*8YN51(`)E,0<S>M'+8(XJHVC$;P=.I>I_>#AQ*6(5N*X2
M`0'=;D.I4%;QRA!.1HT,0A=\YP;-P(F0X;R1U#G3*4A5RY&)F.9@'/%;)TJI
M<YC&2:CNS=)8XN#>.!+<AXX&U#)GSF,GXC.,F8]L6BP1;GZP''8NTC$INDU5
M64.=^BW;\[<JL8@[Q)HT`<C.W9V[50K5H4<\UE-U(!#+>SV8L[MOY0?VU#9:
M7\X=+%PF8,RY9,4%A%,<DR((`H"+E,4E%FYT2[QBF;GWMF>P=N6,]VW\H-#U
M4Z7*:;K:TW>=B`S8J"7[@S6.IL*<4VZAUE@$0%+/<$YEQ*03;=ARAF41P[MO
MY1O]I1NR_P`X=+%V4(4'1^290_/E=Q93DF48+I0"-$$W#TPIH-CF`&*!]Y79
MW`%'BQ&H:*>!-&!'D>M^BQ&N`@+Q`XX9>A=3FK(Q=XK)J),A/RI&B)R$1`W)
M`Y/N)&,1N*W<;Q@#(W#D&W%M'3FK<`RF:QQ,+QO`#E)-@`SJJLQ#$'&#;P<<
MEGH5"[=@V`1728I;I53""B30IMU$!,H;(Q0[C+@-ZT1V9YXC6LFT)NNG4O\`
M4&I:[1CKS`.='F_"NVC#&<IMUVL.JY0>.3M&3EM$'<-'KE$N^LW9O$&IVCE=
M%/NCID.)REVB`8T37,9+OS]GJ&1]1K[QXX&`@8#/D6UW>,4P[Z>77,F3C/D"
MXO:]MF``W:[XE(;D1:HD5`#E.(`*1DP.)@!,1$`S'K8ZK<4H>Z`V)N3,_6H[
M97?:T+E]J"`D@X-'@#9SRPM71X[DFCHK==1NN9L[6;IMG!4%4Q`XD.;=ZO5R
MYTNIEU+W/I6[*&0B!9>C:#UHY/I4'EU1;53C)(R1@(Y\JZI6C,W(B#9J/+%W
MBEY!IO$`,P/R@"`;@)B&0F]:(\`CC<=53GMN;4=+5#N*;\YTL79]I_[73>>U
M"H,E5EVR+XT.H1@LZ:I$6=-47YVI6:KINB?>.F"F^!=N6)45,^OJ#0NGR"]@
MB;[P'6VV@*]XQ*AI6UE%-+Z9Q(#K+2+#D$+#RKI\C';Q2<FS`RF>Z4[=!(!`
MA@`QM]5(B>Z`9&]=F)>`!X,:U5.V2J^'&?2AP_O`M@TV.BC^)`NA".3\*YN8
MM0`<VK;>+O@)"M$E1`R9=]0@BDDH0#$)M';EGW.>^`EQ890!_P!*UW+UK>7R
MY5S.J_KS*LB8;2(LL)RC2I%@U+N[[5J4#E*<HF;($3$IQR`#K&3!%%0<_6*&
M*?\`T.`EM_*"',Y9NR_SATL5`,V)@`2,VP@)!4*9-LV4`2%`O*&#DTS#DF)L
MC<60]0,2NR?RC=#EB[+_`#ATL50,6F\`"T;B(J`F!1:MQ,83$WRG*0$Q.=$P
M<"@`)!'8`XB^5+>+K:1I/,[6HO9+(_UATL3F;#J,FHYB(`(-VW=;H!OF+F0,
MR)B.1C<!!`=[+(<2;,+&]WL8T/57=ROS9TL7(5FT*'+IM42E`N9%T$4$R*)G
M`"*'(\Y+FID43&$3=UM.EW.>6>)2:R3A]XS:)O\`$A"Q_%Y>562YTVE-^FFF
M=GR&&;)GY5QE8,TR@0S)H*H!FH(HMC&.)\Q*H?=!0H'5+D;UVW/&O,G,<_O)
M=`".9^M=$8]/>WNYMBGF;+9FR:!__#-^]8;%A^(?]Q62>ZG9+L"+!D-IC:J3
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M-F_>L/@^"R^N&B(X9U@U>+.$+QX>12#5D`@(-&Y#`("0Y6[??3.`YE4(()[#
MD':'7QC8\([(X>50[[%^V[AY%2+-F8^^+1`V]O&`%$43G3%00.L05!3R4*9P
M)U`V!N[^7!@,.P>=U2T0R\+5EM1B[#$N/#R*>9LOO)K^#-^]8S\$P7LCAY5/
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M[`((]7#8L(=U2T6\,ZP)V+BV^[AY$YFR^\FOX,W[UC/P3!>R.'E5FV8KVCP\
MB<S9?>37\&;]ZP^"8+V1P\J;9BO:/#R)S-E]Y-?P9OWK#X)@O9'#RIMF*]H\
M/(G,V7WDU_!F_>L/@F"]D</*FV8KVCP\B<S9?>37\&;]ZP^"8+V1P\J;9BO:
M/#R)S-E]Y-?P9OWK#X)@O9'#RIMF*]H\/(G,V7WDU_!F_>L/@F"]D</*FV8K
MVCP\B<S9?>37\&;]ZP^"8+V1P\J;9BO:/#R)S-E]Y-?P9OWK#X)@O9'#RIMF
M*]H\/(G,V7WDU_!F_>L/@F"]D</*FV8KVCP\B<S9?>37\&;]ZP^"8+V1P\J;
M9BO:/#R)S-E]Y-?P9OWK#X)@O9'#RIMF*]H\/(G,V7WDU_!F_>L/@F"]D</*
MFV8KVCP\B<S9?>37\&;]ZP^"8+V1P\J;9BO:/#R)S-E]Y-?P9OWK#X)@O9'#
MRIMF*]H\/(G,V7WDU_!F_>L/@F"]D</*FV8KVCP\B^DVDIBS+H+Z6(`:-\U+
M<Z1A,7D$0*"8:L;=*``%*F!3`94-X=X!R,4!#;CYYBM!1C?C#*<C_L^]FB')
MLL\Y\XSKU=!4U/Z:KWQ.UW9=O_SI?T+Z!_G,.S7;;K+/9IWIP"Y``CE[Z*K#
MJB`<&.=\B9M%3[M3!W3B^)M!&2)@,BZ?S5K)TK'F,-K+%7T>4\RMYT5U_;BM
M+T68TW57'ZM8*G6]X+O6=3O6P&+=6[:/G5`,(3VHD9)-U4:R)#-C)CN)'(.T
M!'/'B][Y^)5.]K&4)J&N#'.NRYEPV.RV$`YCZ5V\(=2OP@S:@,A$"T1R@\G$
ML9TIT=5D:ZN)H@9.CW%GX+4_I%OWJ5N]/PS\Z$<>O*/6J%_#RU.%+'KIT93$
MM*M$%.9*=P5%4B(F*(F`>Y*^9>.4QGT9E,<^5/;+#AD(-V,8NR]8PA9D54S<
MREJKE6R<QK'LO0+22+79N*SSKO6>T':*:SMCIQI6I6=^O*%U+:,KR:E8:M8B
MK8@UMJ`G+)'F3K-I*`7B$9.1)5)&Z2?(\H@1LF013,(CD&A4;Z[UTM3\0D]V
M),NI#"(.BX0;'ZT!"^.16#=[`:UK:2L#G.EM+HM@+;1V3$0'(MEM%^FW35IU
MEJ!9^]Z]-5:E+O\`1?WKU)SEU0DF1K&LX6MK=RB:U#'IUO$IN4)2$*5,/;)-
M]RI7'W,0$%,PXF]F^F]V/U+:D/9+II4YC;I!B2'M(C!\/6A9F4Y.YNZK7>I,
MC==Q@_5/%<XL_%EXEK#4W1P:1K8Z5J;E+EW:CJ8OM6>DV-U&TK64Q=>)02E*
MTJ1,\I$VOB;$(TPYD7]&&8(G1/4"<H98'"8!D0HYF]1XG[W.Q25BXEM,B1+;
M(<T`Q-PF\^-^%I-@S9;56_=7!#(V&B<)<>M%W6$39"QH6U-(::]-.E2C-?-F
M*"I6^$A?Z!Z,)*M;F7EJ5TR6M'636ZK*D*F3B:0@DX\5J=DXV1,1NQ5!ZKRI
M$'I"`3DQ#'F9^^6].\F\%)B=]DN2VKBQL'>LT.@3U[188@?1%75&`T6%4#I3
MGL>ZY:0++8'-9T]*^9?1XG6L-8?63KK6**$U:ZV(:=+&JD4-N_+7?:-&(>O6
M"Z8IG6<TS1Z9W?*9[Z95SY"!L\>[WPQ!V\]318>\%M>]UZ:[ZIN6ET`287BT
M0,8Q*\Y@\N7NY)GXE-A-D3[6-;86@V0)-D;";%>'1,WBM-;96]=!UO-*6ENS
M>1&WU`V-U72-G6UZJ<MK53F:.LZHZJ8F9C)>);!6HF^[NCYK"18=O<EQK?,R
M@Q.BW=I6R9Y+6$7KA<TNL;"!Y+;#9;'B"MW/G2'8S-KIS0)3XP!$81CEXN/B
MS+:"*T$6-8UK=67UZLJUJR\$OK^I'2NJ339.P%O;>.U[M4Q$2<!7)84(98D%
M'L0?$=J1Z!2K&,`IB`#GCETV_.]ID2I=--8YFPS)P+P\N(D@`M<;]KG0A>SV
MD+J2-R]VI-XS;Y)<<C@.7L+S;C]&-I??LGC&P5.:E*MJRS>O9#1Q=&G7U648
M22O<@JR=R:T[;D5HM.%MX>-(@"(N71E-U--193N@`,9;\P][*=S9U4Z49!I&
M5$`'"`=E:27F,#`QADL`BHS=R<"?/#J%SFU0=U2XQ$>4!N;BBMGK%:*K$V!U
M"::+SV5%:,)>"SVOJW]6T::[L1?ZGX6>MG:"K4DG\/<QC`1#>4D"\B9&0:@@
M9!NZ`0*90`QYC%M]]X,6IG4M8&CK2G1:"/\`F!S<KC"T`:ET96$-HG=68QP@
MX9#FX%?'CI`2I^3OT51FOW,BVAEL(`@1/:DO="HR&Y554A3+`@D`]T8"F$<@
M$,LLO?[F55;7U6)LQ)S[DR7_`,MQ8>\[N4`8Q/5NBT92;8KRF-299V5\PM<Q
MDX&`&8N7WXU':1K0ZT9>P5*P],4;0\KHM=Z;:HU".H&.BJ=<5#ICN)8R(N5.
MSLZ=!)J64?-:BIA=F03@;,[HXB;+/'S>EQ5^#3)P<^LFF<9C98$^[UV3'-@8
MY1"$`+;">;W^(8)AF\5/*F20R2);1>#F@Q$!;8.E:W:O+1:<M6%?TYJKKJ@)
MFG+)6JZ.Z.U!N[/6%:PE(U3<!*6O#5-*T>P82B,.NE&`SB(Q)=Z]%)8Z*1@S
MR+BW=?'=Y-WI=2RAFN?M=4''O2Y]US9<"!UA9!L8#C.5:V\6";MXFZF#V%KJ
M>1<ZMUH/6B#"[I)6'8K359ZR-)ZI:WL>6KXNW.I?HD'5]Z;H6ZL@UGZYMNXD
MKC,8=S3LC,D9,B/VQ79070<@DDJJ7;ZW+'?=OUO;4.E">6=[)J@!=#@"X,-M
MK\D'&S/QV+@#=#=I@-ULRZYG&X9_V>30K3U&]&3HVLU;R=MHSO"S@]2E)4_8
M5Y3E13MVHN><7<JFZDO34?4<#)V+CZ=9OZ)IZ)9U#R\9**2A^=<D&8@`Y!=3
M_,/?"HJVRKTKNB2T]5W5()ZQ-^T&`$!;%3&Z&Z89![9E\"/K"V,+/4XHQ\G,
MNVQT$:&:CUQ.]#$)0^JR*F[1PUR&=S;IU=5S`*6NQ+4W:16L8MS2;5&".-*B
M[J8`4;,D'"X/HXIQS*&+'_,#>V11BMFS9#FO:'-:UKQ`&%A)?:>-9.Z.Z=^Y
MW<R/[3?87L='1IIH6U]4]'K?UM'U(SKN_P!0/2+1U=,9\52QBD-;&A*PA:&7
MI2%6CFCIFC+1.:RBYA626[DX"`98SO'O3O5B^&5;9KI>ST\ZB80`;SC43&W7
M`WB`&$`F-I&11PW!J)LT!I`;$BT<63-Y"K*@>C?T<TQI3MI5UYKMH4C>"\>F
M.J=0E-UY(W;BHIC!UJ+MPYI&WM.V-5IZ0D:S@I-O&BA(2R;Y,6SHPAN@..IA
MV^F]DC>%V[]:6S*5F+-H9KF`M+KP!,QA+S=`!L!!*WJ[="D913*X3Y5Z7++P
M+IMA$CBXUC[2+.36G+HM;S:R+'413,SJ6DM2E,VHEJUJ"A8RYCVT]JRPX2IG
MT'3\JTDVD2K4,B5-/G*R`I@5R(9Y[N-+'VC%-Z_@DB;5RI#99-LXQ<\.A>B/
MJ@91E),>)<+#I+6L,TEA=>`M$0!ER<OT+=73-55>7>HC0'5]<M6MK+@7"Z3:
M]H5*C1%`Q-O3,';FQ*8+/XZD9B*DV4*XF4$4W3C>:'26,N91,A`/F'F\2;4X
M!B5114[YTR;L#[Q>\N%T1+@,AB01=[)B>->@V.3/DM$PLAW@.2R,,RP!I]T*
MZ*KI)Z98Z];.^\C>36M>35-;RGJIH>L(&'HVB:DM=5=4+QU<2\%[4YO2.FT?
MR)FB!RH`=03B4,P`.]4[X[T4TFH+.[+*7"Z:M=$&+V3YG=]T.M`/9$.+C%I@
M1"U4-P7#W0!+;SK!98#$<G#*O7M]I#I34%97H\:-NM6-<S%M:"H#I!Z_J*EZ
M4CJ<8U5(4U8NO%D$J)H)VUA6\FE.5*1H0%E70NE4BG,8F0"`8E*WNWCP&IKN
MZ-*^HF/IFGO99>(O:0TMBX70`[K6]8@<BYE=NY@]8^4VJ#C!KX7++!`F/5,>
M?BRK#>E32OHXU-5=4];-+"W^I&PC^KK/6]AW%WM2M(6P+1M4UP"B,DP95-(T
M@\E[SU'+D!)6"CFC!(AT4\CK`(".+:O?_>RA=&.%NG6F`IC:!E/KV?1%:]-N
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ME>2-<5LO'$*P<[QRQAP$0*H<<>NF[Z[UTFT2VS9(D4LXR6Q#HFZYK`YQO@`"
M,3GRV+DT>ZVZ\^GDOF2YIG/E-<[K-A$MB8=4JX;:]'1I!U.L]+EX+00VH"T-
MLKMW(OU;6N;.W#K.)F*\F7=DJ3>U4SE(&X7M/"MJ-C*A6:%92+YRU61C3G-O
MF'=SQS:[YD;UX=,?25$Z2^<UC3>:UX;UB1D+XV0CRK?&Y6Z\QH<R7,ZQ(`O-
MC$0^QQQ7._T.]'LO?Y[;AW'W>IZ+MSHKK/4SJ%I*E[Z4U<^:I:MZ?F&;^+H2
M!J="$2A'KI2F6SL'9R@*!#+E'A+B^FWOWRJI0FLJ9`#IS&"+9EH=#K6/XK;.
M."Y51NYNU33+DREJ#!I-CV91Q6M5%!]';I1O9IXKFX%-6PN[9.;J'35='4[8
MJ0N7J(H6K:PGZ8I-V]D8!BYLO"TJV=O+>*,3%;*S#AV@H=8HE`F60XJ/S`WO
MH<3;3]])G"^&$!KQ`NA;:_B!!@MB5NENQ/I^_=)FL:<[FZ+&+W4]!?1T0E'7
M')54/JE7K2S>B"R6MJNIRGZ_IOVFJ6&K1FT4FK9TY&.X$ZC`TT_%8!=N`Y./
M;N!$F_NXWF[X[ZU%2UDN9):'8R,/$6O]<L[P3K'^H,A;ECQP4F[F;J0)+9EC
M8^L./B]1>BCT:6B@E^YVA6*EQ:DE+G6&L7>/3%IXJF[L7;2I*K>7.9RC^LJ6
M=7?5I.2BY>M*=;-`&(9*)M0D$C`4=F1L:5=\P=[&4TE\XRBYLZ;+<ZZZZ.Z<
M&N<07Q@X`G..5;$K=/`),N8:)KA%HL<02<L(0:+0=/(OSXUO3[NDZUK.EG\3
M+0#VF:LJ.GW<#/+(K34$XAY=VP/"RYFPBU/)Q94"HKJI`";A0@J%``''W7=W
M&,2K*%LUYE0+8^K'Z2OD^)TS)=6Z6P0@5:PCMX,=.?,?/F7YT+\(=40&A0NS
MI/48X7?*HS#B[>*;K.58OU':'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8
M<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':
M'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8<7;PNLY4
MOU':'2F8<7;PNLY4OU':'2F8<7;PNLY4OU':'2F8<7;PNR^,&"DV94`Q+A#R
MIF'7QFY3]D]&I7=_-SA,PXL"R2/5!!4'SISA!I`*9AQ=O&+K.557ZCM#I3,.
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MG*E^H[0Z4S#B[>%UG*E^H[0Z5]*=)?\`4-Z5\?\`)GI&['E7V]V8\#BY;^M,
M);"SO9O_`-K/7J,/,S].UYC_`!+LNW_YTM;]_G+P#Y=UN2B!3;FG>FLP,&93
M`%457F4P`(9@/U\>9^0Y:,#>QV0D^=>D^;363,786^M#Z%\)6EX+GLK3R=B6
MM:3"5GIJL6UQ)2@P,W&)=UU'MA8QE1B8S<5RN(^/'DTR@;+,`-GLRQ],G;NX
M9-Q;XH6`U36%@=$^J3$B$89;8PBO%3,1J9.'=Q+)N&!ARCR+.]":_P#6?;"U
ML-9:W^H:M:5MI3S67CH2G(Y.$.$?$3C-RTD(!*3>13J5&G%.=J*`PY;FX*'$
MV[O`42\BJW'P:KK-NFR@:B+3&+A:TQ:8!P%D,UO&K9.\5?)D]R'&$".+C\BQ
MW"ZH]0M.N*"=PEV:GCW-KK=51:.WJZ811U:6MK6N^-54:S.I&FYW"SQU5.<E
M=<NL)3[I%$P#&]/W2PRID&098@Z;WCK3:[JP.7[#>2S)E6M)QJN9.<^))NP\
MEO)RK(],=(%K0HNU4)8^E=1%=PUJ:>@YJEXND6YXA1-&EJA:+,)6E3S"T6>>
M4IH6;E0B#+G0(H"<3``CEES)ORYP.=4&JFR8SW.:XF\[UF^J8!\+(#BYUNMW
MBQ)@`:2``1Q9#E&3C7DL]<6J]E94^GI.\TVYM-[WG%'H4_*Q-.3DE'T<Z(0K
MBCH>K)N(D*KA*67%,H':,WB'<%`I3EVB-K]QL)[UT[NX3WN:XF+K2T0:87H6
M#DMXU1^H*]KP">JUMF3C/,O7E^D$UI3MK6]DY/4373BUB-%+VX<4D;VF$DM0
MKA#F@TS.3:D4I4DS',V@`FU!R\4,U*)MP0$QA&FDW$P614BJ,H=\V=WHM=8_
M)>]:&09,G(E9O#B-5*[J\;I;=.3)EADSJV*MU+/)G2;:'23`48UI2F*#N%6-
MTZVJ=I)KKOKK5I4J)&$1(SK0Z2"4<G2,*7FC8I%%N4*83#N9Y8G2;LS)V\%5
MB`),N+0T0]5K;;#QQ))MYDFXF^9A$FF<;6,MY]"ZNGK5_J1THFJ8+`W1D*!1
MK'D!J1BC"TS4$5(.6)?[V2:$=5$+--8V8C3E**+MJ"2Q0*`9]7'1QC!:+>>[
M05;;[I5Z%I$(BZ[(1&(LY,H4L&Q1](XEI`/""\5OJAU#H%4*>\%:.3KWBC]0
M3MX[?HO))[>J+%0S"Y#J3>MG+U>HV@J`"1C'%%,I"E!/(,L4#='#)<L,#(-:
MP4D(GU)MEW+QY\O*I?'Z^,8VWH\670KCBM:.JZ"D)*7A[Z5G%R\[=YK?^>D&
M!X]LM,WI:)*H)W#?`5D.],*-UCIJD*)6ZJ1S%,00,.*9NY6%/E&6^6"R7+-+
ME=ZC"#=];D'+9E5DK>*N;-#W'ZT3DRZ%>%5=(;K3K2H(*IY^_P#52\I2K>M&
M=*%81M,P4;3;*X4*XINLFD1"P$)%P[1&H*?=J-7&X@4QBG$X""O=XA+^76#N
M#WF4#WA:76NM+/5/K<7^U;$S>*I?]:!$<W'8>+,M;*UN;7]QX:W=.5Y5DK5,
M#::E/>-;B,E`9"A2=(!)JRY(*/%!F@=5L207,H!EA44WA]=EF`]RCP6DPV9-
M?(:!,FPO&VT@!H.4\30/(N)78C.FM;>/5!LZ3]*RRMK#U1KRE>38WQK=.7NC
M;."LU<200<L$'%76MIN--#0M&2HI,"E-&Q\2JHBD8H%5("@CO[<<1VXV"32P
M&4.[ESC-:(NL>227>MG)L-G(NA*WEKY<LMEN-K0WBR```9.0:%V:'UEZI+;5
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M42!GD7(:J;Y>X6RH=52X,O/+B(G*?6-KN/\`V+<EXY5&6+YM`AQ9SR*YY[I'
M-<%3REIYN<U'5O)35D9,DU;F:7:TLC,QLR$<XA%)*9DF%/LG%5N'$`N+$XR0
MN<VV9?UPCBN=\LL$,ETB4&B4\0(O'.3VXY238KOC]4'!X<;S<ALLAY%Y%4:_
M=:%:5C3=P*EU$UO)5A11*\1HB8Y"G&9J-9W/C@B:\CZ<9,(-K'1L=4D7_:R[
M<B/-P0[DB9#=WC8IMS,);1U5))9!L^;2N-KC'9W1&5W%#7%5'>*K9`RW6B.;
MCR\7':O.IG7'JNHVS:VG^F[QR[*TJD1+4XUIIW"TQ,N86FIQ109:FJ<GI>%>
MS,%`/DW"W*-4%03%143AD(98V)^ZF&_J"9C!;&=,Q)M1&+OJY++T+#R+4F[Q
MXE,89$3W1!'%D.7B5KZ>=5VHC2C+2TKI^NI/VY]\235"HXU@E&2T)42;(3E:
M#,P50L)>%?JMDE3`0YVXF*;(WZT`Q'%=S\,Q2J-57R[\DOO0BYMMH%K7`\:J
MI\6JJ8Q8X@D0R#Z0O>D=;>K:5G:>JB4OY7+ZHZ4N'+W9IN9<J1"KR&N5/0@4
MW+UDQ,:*$$I-_3^;,Q`_M8C?N4TB9!CG.W,PQTYQDR[M/LKI($7'JGBB71XS
MQQY5M/WAK'B#3U[T>++H5KT]JBU"4F\M;(TW=6HX=]9*I*LJ^TSAH6._Q&J6
MO%7KBLIF(168K(&?U"O(K&7,J50H"H.Z4!R$.A4;KT<^35RBT0J,,D4QR_\`
M*>'0R\,ZI&.X@""'&+3$9+.A=VE=6^IFB)"ULK25Z:Q@Y&R;JN'EJG#1=B(4
M8M<R6<3-P$V"2K%0CQG5CQP)G3=WSA$P\!0*.[C%9N1AF)3Y\QX$)K6!UIM#
M&@#ZPA#D6/C-82"\GJQAY<O$LLM.DGUS,*GKRL6FH:HT*AN26'"J784Y0BC0
M%:=140IYY3T.M2RL-2,A`(*"DS7BV[55%$`+O#M$=,_+3#[G=L]6W*XD];+:
M7QM6W*W@J&VDVV9N+)Q+`MR=1=\[PQ$K`7/N?4=9PLW<*:NQ*1TM[7"@\N/4
M;%&,G*K.9!@DN5_)L4=Q0"G*0!$1*!0V8Z&![H4&[]0Z8UH!+`T&)R",!ZQ%
MD3I6KBN*5&*R!))C=<3I5IUQ<^X-S(RAH6X%5R%51-LJ.:V\M^RD2-0)2=#L
M'SR18TQ'&1;IBM&-G+]4P<YY=81..:F60!NTF[^'T>)G%)30'.F%YRVN.4Y>
M.`Y%8_%Y[\,&&.-EV'1S*[DM1U^FU6VJKQI=>K(^L['4Y'4?:2I8U=G'2E"4
MM#F.:+@X95BS;@#%`%U2'*H!^634W3<&8[,W<7!9[)Q-VY4N<]XCE,SUOK61
M&:$.*"E3XW42@Q@-K&@#]WR+=NSG2G7]A=1])7ZU&3M37[2HRCJ^HNF8"-D:
M?M^K;T;@1Z,5(5S04?3T`QIUI6',BF#EG;1RBNJ8#K`;(<_`8[\JZ.IEO90O
M#"8$GUHAO$8OR0L7:H]XYLB>VH?U@TQA_L'%E7FZKNDBKF^,W1SNTJ=76V84
MY9^J[+U17=5R]+5->>]]*5K*-Y"IVUWY^$IB(BUVQ4FJ;-HBV02,DUW@!7,V
MS8W8^6LBC865$R^WO`]C3$!A`L`ZYCQDYR<BEC&^QJC?E,@8&,./HXU@>"UZ
MZP*9M''6)IZ^M30]K(FEIFA(^F&C"GUC(T'.MSMG]#GGY&)?U2K2/(JG*DPY
M\""0&S*4#=UCK3OEWA0Q!E=`&:V:U^4^L`!&%[,,T%POU?6SI.R,!`/)Q9>R
MK#<ZI]1;WWW%<W<JE4E>V?B+`UF`C'E/4-FZ>1%O`V_>K)LB*)P46B(%("0I
MJB`9"?+,!WF[L44B:UX`!;C.V<>6Y=CE]'(JCCF(0(#C:`.+((0&3D"RK2?2
M*:UJ'D7LM35_*A;R;JD*:H)L\D(&CII:(I.C&3F-I)A!K25.N',,]IV/>K)-
MGK91)T0JFTYMT,:0W.PNJ:6S&`M$Z:\B)'\UUX_6&6`6_1;Q54MLP3G>L`!D
MXH\BTYE).2FY65G)F0=RTS.23R7EY605YP_DI*06,Y>O7SD2E.Y=NG*AU#G-
MF)C&QZ^5*E4DGNI=D+%PY[N_G&85YX\.(6\:B\DF)48*"8(F")@B8(F")@B8
M(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")
M@B8(F")@B8(F")@B8(F")@B8(F")@B8(F"+Z5:2_ZAO2O_S9Z1O_`/J^WN/G
MV+__`+MA7_5F_P#VL]>GP[_]=Q#]F5_]:6ON'TUNA*_NM+781Q98E$F0MYI]
MMZC.&JJI4X$QE:@JVL0:@V!5%0JH`BW/LSX0X<?*_EKO7A^!X,6EPOQ.6$(1
M/*%[[??=VNQ3&`]@BV`S\V9?*+T%>NT?];LYP_.*S[QCW<KYIX(+TRHF`,C;
M`CZ2N+.W%Q0!H+.H1F.I1Z"O7;M^Y6<\8[,`_P#)QQL5_P`W=UZ24V8R8;<L
M2WHM6H_<#$R>JTD\QU)Z"S7;^XV<^O\`*,S-_P#TQ<;=/\U=UYU*VHD37&>[
MUK6W1S0*-^7^._5EC0=2GT%>NWJIV<\8C/O&-?Q9P>_=#VPYQ[2N;\O\:(ME
M]!U)Z"O7=^YV<\8K,/\`:,6N^:6"1%YXC#.-:KF?+_%HP<PZ#J4^@IUWC_K%
MGQZX7&99?8^X8@[YI8"[*]ND>TH-W!Q5IB)9T'4H'H*M=NT!1LYMX0-<1D80
M[+<0Q.@^;^#4KYDIIE%CK(G+_O+#_E[BTS*QUN8'4GH*]=N0!R5G?&*R`=@9
M<'(9!C09\SL!P^J-=3S`Z:8V.(+;>0$'I46?+S%6>JU_3J3T%>NWAY*SGUOE
M%9];_P#48O;\T\$>"'/'6J9<_*/6E&+1ZWJGC&7E"Z+_`)?8F!8PZ#J3T%FN
MW8')6<X/G%9\7_V&-D_-#`7AY<\=>H?..3UGY0+?5'$,O*M4[@XJXW"RP\AU
M)Z"S7;^Y6<\8K/O&+F?-K!);+C',ARP]I9'RYQ0<3NGV4]!7KL#_`%NSGC%9
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M;MJ9=`R!C)*BBJ&\7A`=F)5OS#P>D;&7.>71^L1T6A6TGR_Q2>.N#Y(ZE[_H
M*]=O#R5G`S_RBL^\8ND?-G=.G@X3B7`&,2WCRQMT*(^7V)D]5CB!R'4GH*M=
MV09)6=';P!<9GGG_`/<8IG_-S=V8X,E/%\-NB);Y(];*KSN#B36&\TA]VRPZ
MD]!5KO`?VBSX<8C<9ED`_8;ALQ9XL8<Z5W,PRQ*SC+_O+6;\O\7?ZS3#F.I/
M05Z[1V<G9S9MS^45GWC%H^:>[TJ0&!X+[P-L-:L=\N,6E_Q);7%V8QU*?05Z
M[?W.SOC%9]XQ2WYKX$T@WVV.+LHX^+ULBAX?X[[OH.I`Z"K7:'`G9SAZMQ6?
M>,1\7-TY(NUDY[7_`%;KF".>,2K&_+_%2#WS'`\4`1]"#T%>N[@Y.SF7\XK/
MB_\`L.O@/FU@$S_1SB>=P/F*HF_+K%W#^&UV@ZE'H*M=V6Q"SQAXPN*R_N?%
M4WYKX3,`D3IC1#C!$>EROI?E[C5.TS+D7G.##S(/05Z[@X4K.AQ@-Q6>8=;]
MHQ>WYHX$^1W1>+L,L1'SJAVX..LG[0&6QR0,/,GH*]=P[!3LX(?SBL^\XUC\
MR\'!@)[H#[0UH/E[C1<7W3$DG(>/R*`Z"C7:4-WFUG^3`!*!37%9&R3$!#D^
M4%ORVZ7/8.]F''BZ7\TL%;U'38L.6T1AQ\:M;N#C0ZMVPV9#Q^15#T%NO`1,
M.[9T=_=`V=Q60B($#(@"8S<3#NAU\0J/FM@4E\*:;9RD1Z"K!\O<2E^K+B.8
MZE'H*]=N?[79T?\`.*S[QB<GYHX0/XYFQ=F)$+1SY0H^'^+$Q[H#F:=2>@KU
MV_N=G?&*R[QB;_FIA$S*]OJ7<HT^ME3]`8MV#H.I6;7_`$,VLZVE*/JSJ<EJ
M4X2.>PC%THQKQJ[7*M4$TQI^.`$"([VZ:2DT=XW`4F>-FA^9."3+_7R`9(0X
M\MO`KG5^X>+L,L77").?DY%>RO02Z\4%#IJHV=(<ISEW37%99[I1W0$<D1VC
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MY/K0RP66_+S&Y@NRV'O>*PP\V91Z"O7=^Y6<'/\`RC,P[?-S8GXM[IGU)G2W
M6LCY:[R@]9@T.U*?05:[<OVJS@?YR&9OT&P8J=\U<"F64SFD\<2,GD<K!\NL
M89_.:;<D`=2!T%6NW]SL[XQ6?>,2'S1P:%KV7N<:U!WR_P`4'JM<?(=2>@JU
MV_N=G?&*R[Q@?FC@XRN;I'M*/A_B_8=H.I/05:[?W.SOC&9=XQCQ2P;M-TC6
ML>'^+]AV@ZE:3/H7M:CVN:BMX@C:HU24Q2\!6,DF>O6:3(82HW<DTCSH/!2,
M51?E(I7,F68[-F+)GS+PQLH3FN9=/#M+39N3B[JITAS2&@PXX^97;Z"K7:'Z
MRSALMF\%Q&@9_P"BR%#,,^+&:?YHX$XPGO`YH:UU#\O,2'U7=.I/05:[?W.S
MOC&9=XQ7XI8-VFZ1K6OX?XOV':#J3T%6NW]RL\/6"XS+/_8,/%/!!:Y[;O./
M:66_+[%R87':#J4CT%6NT-HHV=('&>XS,`X<LLP;CPXB?FSNX#ZXASCVE,_+
M[%&BUKH^74J?05Z[.H2S7^EN0S,/8YL&,CYM;LO%V7,'><[<FE4LW`QB8\M:
MTZ#J3T%6NW]SL[XQ67>,9\5<`[;=(UJWPZQOL]!U*?05:[?W.SOC%9=XQ6[Y
MKX$'`![8'E'M+!^7N,ML<TQYCJ3T%6NW]SLYXQF?>,7-^:>`N^NW2-:QX?XM
MV':#J3T%6NW]PL^/7"XS++_8,0=\T,)CU'-+?)[2SX?XMV':#J4>@KUV_N=G
M0ZWRBL]G_P#+X>)^%]IFD>TL>'^+]AV@ZD]!5KN_<[.^,5GWC%?BGA7:E\/W
MD\/\6[#M!U*M/H)]>"AR)D1LZ8QS%(4/E&9!F8P@4`S%#(-HXDSYI84YX;>9
M:>+_`.)5S=PL7ERG/N.L!.0ZE9E$=#'K0N#$R,S3I+3J,HNJJGHYVJZKYLU.
M69I&0&-ETRHJ-]\R)7&0$/P#B<WYG89)?=>60X?:4*'<7%:EEY[2#R1U*\?0
M5:[?W.SGC%9]XQ:?F?@1E18\&;'.(0TK9F_+[%6#JM='RZE'H*M=O[G9SQC,
M_P"Y\4^)^%]IFD>TM?\`06,]@Z#J4AT%6N[J(V>-_8W%9[/K_P!KX>*F!2_Y
M[FB.2!'TN6U3_+W%)C7&8UP(A#+J4^@JUV]5&SQ?[*XK/;UP^X<&),^;>Z@/
M\699R%NM19\O\3=,NEKH>74H]!3KM_<[.Y<?RBL^W]PQ*9\UMVGNC23`9?%$
MMCRY"KIGRZQ-KX-#KOEU)Z"K7;^YV<^Q<5GWC%8^:F!BUSVPYQ[2B[Y=XI]5
MKM!U*?05:[?W.SGC%9Y_[!BMGS7P0N-Y[;L<X]I6/^7.)!H(:Z,!PR*/05:[
M?W.SH_YQ6?>,;'BA@9'4>TGG&M:KMP,588%KM!U)Z"K7;^XV?#KC<9EE_P"3
MXJ\4,+SLX?O*G]!8SV#H.I/05:[/W.SOC%9_W/B7BAA`M>Y@;SCVEENX6,$V
MM,.8ZE!N@KUV@`B"-G3"!39%^49F43&$,DP`1;B`9G$.'J8IK_FKA-.&FG<P
MQSP]I;WAWB-R]=?'A]E6FSZ&#6B]KJHK<HI6J&I:6IJGZIETU:\:(LR1M3/)
M%I%BV<BD<CDYC1I]X`RW?LXZ<_YBX3)HI%3>;?FDQR0LADM6E)W#Q6:]S2TP
M&3+J5UAT%>NX0S%&SI>L-Q6?>,:/B?A7:9T:UL^'N)]EV@ZE/H*M=O[G9SQB
ML^\8>)^%=IFD:T\/<3[+M!U*?05:[OW"SP]<+C,LO]@QCQ0POM,X?O)X>XGV
M7=/LIZ"O7;^XV<SZ]R68=KFHY#@/FSNXWJS7@/&6UOM*R9\N\1:P.:'QAPXD
M]!5KM_<[.^,5GL_\0&+Q\VMT81=-/D+=:KE?+W%)D8M=DLR^RI]!3KM_<[.^
M,5GWC&IXV;BYYWWI?M+6\/\`'>P=!U)Z"G7;^Y6='K!<5GWC$F?.C<F:X2Y;
MIH><D3+AT.4F?+[&RX!S#=YCJ3T%6N_J-K0>,9EWC%A^;6ZX'\P:6ZU9,^7V
M+-]5IZ=2CT%6N_[VM!XQF7>,0\6]V8V3!#G'M*$K<'%"3WH($+,NI/05:[MG
MW"SY<^#>N,RV_P#B,6CYM;J9#,MYVZU)WR_Q4&QKH>74GH*==O[E9WQBL^\8
MP?FKN_,,:=X+>.)&7R%1_0.*GU6NT'4GH*M=O[G9WQC,N\8CXI8-VFZ1K3P_
MQ?L.T'4MJ]/71>ZIZ)L?T@VF>:2MP-R;T66TX5%1AF5:-W$$5A1VI.F*BERS
M$CR!2,%QCJ?<`D'=`=7<+^NQY_$=\**;C6'XY$;++FS#Y#(FLSYW98PL78IM
MUITK#*C#&WMLFM:",Q$QKA"R/$OTI7!'/6_>H!`#%+8>Q0ID,`&(42U+<K<,
M`&`>Z`%C;?4#'PBGI9,K!26N+3UAQZU]/GS*E^+M!;$"&97LD&^HF0"%,*BA
M2`7=3#>,<VZ&9C"4`+MV[>#'DY%$V=(F&9,=W=X<9S\Z[N*U[I=V6&#AY%I;
M,:R8FG]8\#I.E:$?M&50Q--$8W94EF9(E&N*QA9VH:8HU_`<W3>IDEV=.N44
MW!5,Q5(4``1-CWC]QJ3$<-:]LPY,[O:7GYN\+J2(<T=&I6U;+7U05?71U%4G
M/084%;:P$4E,MKN3LT@\BJ_8#5+FBGCJ.A&;,K]H5.L&#F.:(D,=9^*902`5
M#8OJMP'89ALE\F8Z+W$93Q`'M+:PW?&543'RRUO5:.+E_96:UM6.GAC0CFY4
ME<=C&TDPJMC04D,E%S;>IHZN7Z2+EK23JD302%0IU([:*E73:<U$QVXBJ`B0
M,<>DW.J)TZ%]VG\2G4[WLEQ@T:![*PY:+622ZKFWB[-I;=E3EP+^WUM-'R;J
MJ)!A(S5-6DC'LI&U%0S)VR!*9EY=!J"KU!SR";%H(G-W0#C?Q+<ZHDSVM#W>
MH#EY3]I42-Z15,[QK1889![*RG#ZQ=.%0T_4U20%Q"3\72DG'PTBZA*4JQ\5
M_(32Z\?$*TFBA$JN:VC7LBR7236C4U4^4)F)]P<\<X[J3P(F80.<^TK_`-0'
MLC0-2\.'U74O6UY[!T';08:L[=7KMG>:NS5ZV.[3EHI[:*8I^$=P3:)4(DDG
M(GD)9=%VDZ(!VZC80R`<\2=N?4,;?#W1AG_$L?J#[(T#4N5KJZMY$UKJ(IZY
M2\7;:G+!W$M_;<]93;_G494\S<6F6\]$IMT63<R[)RDL8[<I39E5,`99YAC$
MG<^IJ#=+W$\_XD.\'V1T:E[2.L336M;,;PA=.(^3SWY#;[VU3BID\I[\TWBC
M-6EVU*+1:%4.:A36``49\W!4J63C]J$1Q*7N?4!T+[M)]I2F[RV>J-'H6+K/
M:R4+L*6\D&B%L6=-5]>N^EMFC\:MD`D)&F+2MG3QK4]'-U6`,9==VT:G7>).
MUVQ&;8@F.;>#(=FHW1J&4KWWW6-CE/M+1_4W7'5$.8>RLFQ6L?394-.5!5=.
MW&"H(&F)9I#OWD)254RKN2=R:JQ(@]*QL?#.G-81TL#57D7,>51$Q4E!$P``
M#CE2-UZEUIF$-Y_Q*[]3_8'#R*TW&NW3R>X-B:!A*C5J9/4)'U:^HRKH*/>2
M5.1[BCUA;J1E1.&[0'4>\G)4JC`A0;G&/.@)G.[M,':9N757(WS'G_$K)>](
M88EHR</JKCB=:UH*?ME1]?7IK:@J4=5C+ULTCX^@7%2U^R6BJ-J9W`2$NR]K
MX09M:/AT2I&DWR[5NQ;.C"F!C$R-CF5&ZE5+CUW:?Q*W]6L[(T?A5YU[K$TR
M6S3C%*RO'2,:G,TO!UM'.&PR$FD]HJI'"K:*JYN,;&R16]/IJ(YNWJQN;M0'
M,XE#8$Z7=&IGT4V=>=U'0R\D>TI#>Z3ZI:(\WX5LBBY0=(-W;11!PT=-T'3-
MTD!#HNV;E(B[1Z@<HB"C=ZW4*JF;(N^F<#```(8\JZDF4U3W;WN@##CUK:E8
MJ:OU6"WFU*S[E%*I;2Y.\&8EMU7P%ZFZ!J3E@-NY99</V!QOT%(XUKC?/%QG
M-SJFKK'M%VX(^34K;L.4!L7941VY6JH(N8\.1J?8YY\8CQXW,8I']S$O,><Z
MU;AM:_O+&CHU++.8`/`3+/+:4H;`ZX@.78QQIF$4H@'33&&<ZUU*2>Z:'=06
M',-2UKU&W]G;*&L[$4E;IE<:KKWW5;6JI:'D*J0HF.CY-Y`2-1(/Y":<QTL"
MS4&\2HF?<0`0WMX`S`,>TPO=*DF4#ZL3"7,8793Q1^TO.XIB[J:>&%H@3R:E
M8-+:WK:,HZOVFH%N73O7-J*[C[>5[2]12[6I6P3DW`JU)2[ZD)ZGV#]K5<-6
M$,U<+1ABH(*.#("B`<H8`QN-W:=54U^6XVC.?:54G>'+U1P\BS"QU+6.D8B6
MJ!*X$,G%0%5411<XLHSDDABZJN65@O0]./6R[-%ZA*SB,D@1)$Q2G345^Z"`
M!CR/Z9J78@97>.NW2<IXH?:6Z=Y!+%XM&@:EQ(ZG;".+D-;1)W!8GN`\GY6C
MF<.A$S:[5[5=/-3/:HA&<^G%JP#R1I9,2E?@DL)$3"`"`".>-W])5';.G\2C
M^JF=D:/PK&M>:DZ^+>ZHK"6(LJG=^K[>4=3E<78EI6N8R@J:I"/K1PNVHZ!A
M9"0BI$M2U-.HQR[H$LT$TB9E,/K<NE0[IX4&N&,3")D1<M=DMO9'<RUY^/FI
M<'2VB#<M@U+)J&I>S!K@,[4OZG0A;CO`<MDJ>D8R:;QR]0QL8:5G:08U8>-/
M3<S/0C1,ZADVK@3&2`IMWNL1J-T93HC#GDCG/TN5DO>)LF%]HX>1>3;_`%:Z
M:;J3[JF[?7?IFH91E2;VNG!2<^9M"4;%N#,YVI4Y=_%L8B08TVY%-)^1JJJH
MS55**O<8T!N=6W_XSG"9SZ/K*3][I8^J(#D'LK7EWT@]OZBJ.X;"STK;VLZ6
MH33?-7K7K2KI*HJ1A&\Y&5:C3Z47-#[5*/&U(/F(G=MY=))1%RAD8@CF&-Z5
MN?4\3W9<_P")<^=O=+AZ@CP^RKFOSKJMM9R$:0S"<I&I+TN"V;7<6[(K.!'M
M6MTYVFV!3A.I1239%V,5-*/F#5RHBX=LT14W"B(`$';GU%XP>[+G/M*UN]K+
MHZ@R</JK.DKJ7L9"7&>6KE;@(Q=9MW<U'HQ\C`3*#-_+T[%&GYR$AYL600<W
M+QD"'.%&K5RLXR(8"E,(98@[="H(+1,=>AG/M([>UETP8(PY/96*;7Z\-/ET
M+0QMX4YR3I.(EJKD*)9TW,P,D]K%U5,<XD"IQ,'!0[%\]J('L7'GDW"C-)P5
MA'B`K"FH13%`W'J6-B][LD<OXEBGWD,QP!8+>;4MIJ/K&E[@TQ"5M14W&U'2
MM21Y9*$F(LX*Q\DT!8[5=RT4533<GY!REN*)J$(=-0X@8.YQRZO#9E&+CGFS
ME.M=R1BG?N$L-&3,-2N3>#V)?M"^ICG=T[MG2=:W._/8'0M:]7IOZ/\`5>[W
M`^^2UX;Y``AMT]SZ0(<N\&W=,4W!Q@`]3';P>G<X3>N;`WC/+RKBXO5%CY/4
M$2YV;,.1;/O1R=NS`4H"HNHH;N0$-\1W1$`'@SW=O7QH5%(X3K7F,<YS\ZZ-
M/6NV<=49.34NKO!U2EX/8%]3%$VG<Q\"\Y,YUJV54N<V)8,O)J4;P>Q+]H7U
M,5=T[MG2=:L[\]@="U'O_J1K.U%SK6VHM_::)N555R:+NG7:)9VX4=;R,91%
MIV#*5FT"NW4/-B[?/F$B7FXCR"152;IAX<>WPK=BBK:=DZ=,(O-;&TY7&':S
MZ\B\SBN\&R%S`T7FDYM2XK5ZY-.US8*U+L]:M:2JRZU'Q%91-OYYL\&H8V(D
MDI<HOYD631PRCHM)6"<F.]56(TY-/>!0`4(7&<5^7<N4]MR8Z).<^VM;#=YC
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M!@`R92BF<`S`%2JD,8<NH<,>$GRYDNH,N^8`YSK7:IJUTT>J-`U)O!U2E^T+
MZF+Y\@M(ZYM;G.M;SI[K.H,G)J4;P>Q+]H7U,4=T[MG2=:CWY[`Z%KO3!LM6
MEWA*`9%LE9E3=R[D3DGZI.4XEX!$#'''KNX:<&D]<W[G+G/*O.BL+<3FMN#U
M^3-S+8G,2]R.1LL@S.4#&'(,LS&$,S&'JCU<>.?13S,-QYRYSK7>FUKKHZHC
MS#4HW@]B7[0OJ8L[IW;.DZU9WY[`Z%!C!NCD4F>0Y9D'+>'87/<*8W#Q!MQ.
M7*!F`3'GNXVVG)I4FU)8X.N"`YM2TJU`:L:NL]<\MM*-LXRN6^CK$U7J&JAW
M*W#B*`3CZ)HN70AY1G#ED63Y.5F7A5CN$4E%$`'DMT3D*(CCWV$;J8=7R0[O
M#:0!:<IL`]9>0QO>8TLXM#1#R:E8=`])#9:I+@U)3-:2T7;RFGD-866M1*3A
M'ZDI4Y;UTF$Z@6JU6J"T33J<;)*IL@<"";91PJ0@'$3AB.+;@-HV";3S#>+H
M93DM/:Y%5AN]8_F%@@1FY>9;4OM1-EHZYC:SKZMVL?<23D3T]#1LE$SD9!R%
M4I,#2JM.-JK?0:=..I]*);*NC,BNP5%#(X;`QP?TG41A?,>?\2ZOZM9V!H_"
MO,BM4U@9ND:JK^-KYF:B*0>,&DC4SZ%F8R)>+2LH,%%-J?7?,T"U8K,S11:,
M319W0.7)1(`;,L:\W=2HO@7SI_$HG>83K0T6<@]E)K490(V$NA?Z@W+>NX&U
MM,5[/3$.4CJG)5.:M]$N'\K1DXSF6R4A2TT95L8#INT2J%(8AB]R8,;,G=2I
MLA,=`\OXEC]0'LC0-2R5;JL"W!MY0-?DCRQ)*[HJEZR)%`Y(_P#:LE3PC*:+
M'"\(B@5R9D5[R8G`H;PESV\.-*IPJ;2SG2'/,6\IXQ'.NS2UW?R&S;@MCFSP
MS*\M[_0D^T#U,4;%-]X=)UJ_O_L>;4JMGL2_:%]3&OL;^V=)UK&T'L#HU+F;
M;HN6P"4N0N$<^X`/]=+UL;5!1N%;*)>8=XWC.?G6M65)%)--P?RW9LW,M:-+
M1SJ6_K0ZAS*G+?N^0%.IW0@4U;.1$NW];G]6S'3QRF#G&X\].M:&$UKKGJC)
MR:ELAO#[$F?]@7K=;'G*:AGWK7F[#.=:Z4RK<Y\`P0\FI-\WL2?:%]3&]L4S
MWATG6H=^_L#HU+7[4Y?=33I:DUQT*0+7$@ZK>@:`B*<-,%IQNXF+AU*SIF+=
MO9D(Z6,S9,WCLIE1!LJ(DSR#/+'<P3`)>(S',GS#81"T\?[P7/Q#&G8>P`L`
MO1/%Q>3E6I\ATB[.E:OI>B[GVYB[:3$;J%GK&7K,:JE*_AJ2!A;%[<6-E[?U
M'2L9NU@^DLFK4C11@1=`ZJA5DP,3,?3U'RZI:BC%1(F.+7-B/6!T%XAY5YYF
M]A$Z%T1\GLK:61U;Z=HVWU)76-<9K(4#6S&2E:=J"%@9Z>:NX>$7*TG95TA$
MQ3A]&,Z>D#F2DE7B35-H1$PF`!`<>*;N?.D5QIFS'7!#C.4_O+TQWA!H!.NC
MCS<1YE<\?J&LS+UI3UNH2MF$_5=30D%4T0G!L)&2AE86J8TTI3#R3J.,92,'
M!-ZCCR&<L>>+H&=I%[D0R-C:Q'="HD2XWR#S_B6MAN\@J)UVZ(<WX5%`ZB+)
M7.JE_1-#5_&5#4<:VDGG-R1\K'MYUA"/31LK)4A(2$8TBZK81LJ(MGZT>LZ3
M:B3/JYC54;H5$JG9,#W1<T'+G$>TK:;>2_43)=T0:\C)F/,M<I#7`UCIZ:A3
M6Z77]I];E,Z-BKEFV@E=NJEIAO4R=<`4C<!;-VB;CDA9GR7W@VXWJ#=&>^FF
M3"]W4EN?EX@(]I<ZOWC[NJER0T=9[1D'&0,RWW4`$SF2R*)TU%R&S*&WDS"!
M=G6#'GMC>?\`F'2=:]#W[NP.C4N/>'JE)]H7U,4S\/FOEW6S"3$<9S\ZB:ES
M1&X.C4@CZT0``R40'("@`#]V)L,&61B[>#%6(44R6V7>><N<ZUL[:[N/5&@:
MEK?2Q2IZK[R;H99V0LQL',0#^_%8<`"(@'#CUF)R>^P>C$MYB"^-IY.5<F16
MN,QQ#1'R9SR+8X@]R&PO5X2`/5ZX#ECSNQ3/>'2=:VML?V/-J5>]UB?_`'9?
M4PV.;[PZ3K3;)G9\VI5I%%9=%(-TH+""8FW0R(8JB9C''K&2,)?K[<-BF=LZ
M3K6-LF=@=&I?-V(Z0&1=5M[7S%F`C;:O]0]Q=,-/UQ'W!CYFIU[E40QD7+&0
MF;;IPS>5:T;-.HU1(7+=PJ=J0`,IGCZ)3;A4E5029QF.VB93MFD=:$'69;T(
MQXLJ\Q6[U.DS7R2T`,>6\7%Y%D32SKFM)J)H6GG;RH:8I^ZZM`25P*XMZS/,
MKMJ<B8.2>L:A=1,P_C6R4U'P#=NBL_%`7*K0SDI5,LPQY^MW+D4[R!,=$9+3
M;_:6_AF\U]L;H)AR>RLB,-8.G&5@*MJ1G<J.:-:$<TPQJ6.FJ=J2)GDE:T6!
MM1:\?3$BS85',IU@]/R$=S-!8KM4-U,<QQI#"JMPBVE)'(0<F7B6]^JF=D:!
M[*]BJ=45A:)A*8J"J:[]J&%7Q#VI8ALYIVHAFD*:BU^;S=05%#(PJDE2-/T\
M[,"#QY(HI((#D<3B4#8Q\'FS1<GR3+DG*Z.31#SK(WH8XW;HT#V57=2^S"VE
M4:;:>;0R56,]1EU?DWB9V-?HI,H9J>F7M2H5(W`=[WP-W*#=/D"HBD"J"H+!
MW.S&[(W4HYG_`##'G/M*N;O!9ZHZ-2P1:O6\VN;,Z=X@ENUX@+_5AJ&I)-TI
M/LG9:64T_OGK)=T8"((^W):J,SS+R8$YOO[F1C!O8Z3MS*&X3?,0,Y]I<Q^\
M!+FAK1$F&3T+?(-X-X1`@Y',4P;FZ"9Q^Z"B!%`Y4`23.4-XWKL>*J<#I9=1
M<$TY<Y]I>QI9[YM-?NB,.34@F#V)?M"^IB-7AS*-S9<EY+2V.4ZU1)J7.!BP
M9>34HW@]B7[0OJ8T^Z=VSI.M6]^>P.A8NI@I1U(W/-D&S2W1)0[D-A?EE='R
MX-H;P]C'IYSIAP*3*+C=##;'/>7#ER@,5F55WK%P,-"]^X`@.N&]8Y9!\@EB
M\OA)<;%U)52CA!$V5>L),0>/RK8:^$_O(]:RWZ5>66_F7(H@("'=D.H4H99"
M82)]V(%#;LVX\W3U4F9*F2>Y!EEPL@86&.=;<QK:H_Q#%_:S+YXZA=%-97BJ
MC436E+W'C*,JRY-&6#/9:=7CGZ[^UES[)U!)/6-43#GNC+,73.4,W*5#(Y$U
M.ZS#/'T+"=XY5)3MES)?4'%#TA>?Q#=_:@0QXX>18PJOHUE)VF:PI"#N#"0\
M5)V$L!;ZG%'3>8.J:XUE;@.[E258U@"3EHZ<P563;I8SCD#&=D5<`<N1@`<;
MM5OM(F,$E[(L:20.(1$.TN#(W/JZ>8Y\J:67A"P\L>RKM4T4W&CZ?HFJZ."S
M=#WYM_J+C+_#_;UU:QMY7CR%I1]1;J/K:3KB8<5F_F$8F1.5NY2S11`B:)>`
M!QH,WNIV,+6L@XM+8@0-O,ZR"M?NE5S#%\TGG/X5%.Z#:Z4;VQ0K2Y-(.U*=
MO;JCNC6+NCX*9IU!TQU'T1,TRRCJ1;+*N!AY"GW$NHL8S@2H+IMQ*.0FQ=,W
MTDSGWYK+S[H$3E@(P^MRG2MBFW7J:=G=MFD`F.7/^[R+M1>F75G&V$MS9(+R
MVG8Q-G7]$1M+.J*;5C0B]R+;4LA*M75.W!J**=HU#1KB7;\U<J>T(%`JS80$
MP"J(C5,WMHYK"Q\H%CA`@C+_`&E7,P.M88B<X$<H]E<NG'1!6-B*OL)4#^N*
M6G&=H('4Q&2"$>QJ1%:?>7^KJ'K6%/&NIA5>1*C3B;14JZKLYUES"`G$1,.)
MG>MDP6,ZAXN!6[)W?J3):7S270MM]"[U>Z**IK2MKX5*C6=)IQ]UM3NFS4#%
MQLE$R2QHJ!L>UC6<O3LJ14IFTC(RW,!424`HM4BB!5`SSQ%F\[9;KTMETVY.
M7RJT;OS_`'G3Z%R5CH_N6I6<I=*W]>V]9W"BM8LCJ@H%G6D9.KT2:-G:!9T-
M-TK6Y8\I9`90J+<QVKN._:5<C[VS#]4"$+EA$/)I6@=WJLVF<=/X5;L)H,K4
M[.W$;7%QJ0=*P%T-4E9UJO2L%(TZ[=L=2M%R=(I1M*Q9WYC0LM3#B5,J<JQ@
M34(!3B.\80"P;U@]6:V,DPB"+"-*A^FZB,>]Z?PKTX[35JZ;V(MK9QS>:U;&
M'L](4%"P9:&:W"H):Y-LZ,9/XEU3U?U5!R!:HI:4F.41=)I1&21CHJ$,8"*C
MBQV\V%EKF"0RZX9(1&@N61N[4C)-Z?0O-M/HHNO9PNE%W3UQ;;3$UI\K#4![
M\&\M%U5[3SM)7[?*.I!M3PE<NYUC45)).Q`"/P,FX,8RF\(F$!MG;Y2GLNR6
M0,;8?_$L'=NI/_-Z?PKP**T0WUL\WH2:M7<BU+ZNXVUMZK*U2PK^&J=U1R]#
M79N%+5]!RM,%C%D'1:LA3RI47""X<W>E`I%.Y1`,:,S>9DT==D>'.GZ:J/>=
M/H7OP.@9[2<%45+4]7M/R4.]T($T@0CZ?A'"DJA40S%1SLA4STB"CEJ6'DG,
MX"*;1J(*DW";V8`&*SO4V1*,B6VZQQO$#C,(6VYEM4^[H83W[P7<7""^A-$0
M+BE*)HNDWBQ'3RE*1IJF7;E,JQ2NG4%"LHUPY#G`<YR66;B(<IF<"Y!P`&/&
M5M5+JIIF,DB^>.!UKUF'X6R4WJS`".4:EU;D?R:7*_F[KO\`@I+!M^OC&%58
M947)DJ+QR'6J,2HIAFNNS3=LX^0<BMNP^VQ=E@XK64!P?^H&/Z6.AC-<SNK9
M5O,=:QAU$^]_.Z1J65A$`S$0'(!S'+AZ^66T1RQP:[NVP/<C)F/)RKL2::9)
M!(G0CRC4M3-55E;F795L9/VDJ>W\#75B[SQUVV2%RF-0OZ9GFC.F*@@`CGX4
MLLWD6P*#-%6-OJD]9P@&/;X%C]-(P]\ATH1+(9/2O*XKA3ZJ>(S2;<XU+!PZ
M':ZFJH@;I5]<>D*KN[*ZJ+97^N6K'TU(L:*4I>UE-2=.T[;NWD"H]?F0:MSS
M0*-SO%BE.MR@#EGECH2MYVR6=W+80V'#C6G^G9PR3(<.957!T=7HJNY]VY2E
M;FVMC;27DO\`V1U"2T7+TW4,C7C6IK2JP2+RF&DC'NU(1*GY5M!B=)X8@KI.
M`W<N3`1PIL=PMU2)E:!*;`B^8"VRR)="U4UF[]69$&S2#'/Z%@'3G1UZZ7U>
M/9Z7M-6<K&S5[=03]ZUJNGZ_IN&L-1E92RBK>XU+U0Y6-9VH)>MVT<T9E3C0
M.\726`1R,`X]#,Q+=E])?EU#&U!:(EKF90.*W)'(N93[OUCIUQ\YQ;SCV5N%
M6-@+]4WJ)K?4#IOKJUD6YO%25&TC="D+RTI4TI#I.Z"]L&U/5-1C^FW;<[5T
M@Q?N2+,'F:;I8H&,8H"&/%"LP:9,F;<16.!ZCG0)ECC#8$0#K,L<B[E1N_42
M&LV>;=O--ZW+FXEBEUHNO?4&H2CKO5Y>>F:O@Z"O!4%RH)62<5LTEVM.3]!R
M=*C;]K1",B-"TVG34A)\KSE$IW3HAQWCB`%R[,K>/"J=I;32&2H@#JC)`_M+
MGNP"K<8NG$D<OX5VZ4T!ST7;*P-LZCKN"YC:O3;J&L+53^FXEZV<RCR^BC<$
MJCILZQSH$:Q#=+^VA=&Y180,8@<&*JO>X3ZHS`TEIAT#G66[M37-ZTSAH5E+
M:&-053436%/7&N990L@_T3.M'-'N*-I>HHJ*0CF3]N>GZQJ%>4>%4D17CF9$
MWK9ND"+)P8.1`0..-B3O5*8/4`MCY3QY5$[J1]9\1PY%Z%::&;SR[NZ5/T=<
MFU:%L[OU;IVN-58U;34_,U[%5;8-A246_AJ5?,Y`6+>G*E:TR91NX6$%FICB
M3+UP#9^K:2^U]P1:'"`R&]"TB]E$+.<JL[KS+1?'#R*]GFCJ\U0:I*.O=55V
MH.JJ7M[J&D[N4S$OWE;JU(PI*<HQY$1UM&%+M9(MNHE*G.>*K(R234KB0((B
MHJ!L@Q#]6T;&NF&6WO>[`C"VR-L;UMO%D3],3+`'B$<_H6,0T"79;6^M'3*U
M?6XD973W>&[U=6V!9U<&E8*I:)O&M+NY>*KF6I>;9U-3M91DA*[B#F,4*S52
M2,FL(E.(#*7O735E.YKY;27@`DC,8CZRFS=RJ9-'=37`1XCZ%]#K%6OC;-VG
MI2WD9!4Q3:%/HO2*P]&KSCRFFSZ2?KRLD>'>5&Y?RJS-V_<G6$3JYF4.(];'
M@,6Q(SZTN=+C)S0,(\7&O84&#S)$D/,S^+Q&/H66-GU"'J8YVUR/<MT'6M_9
M:GWITC4M:]7H?T?:MR_Y26PZH=2YE*&#J=02@/V,=K"*EKA-[J4!8V,`>7E7
M%Q>CG.=)O3;;QX^;D6SS_P#W6YV#L75#BV`.S]''/GSG=\8R[8YCK70IZ&9W
M('?60SC4NI]7#BF;5,#H390O0XP=:OETD\-@V<81SC4IV?4(>IBO:Y'N6Z#K
M4]EJ?>G2-2TXO[I(IS4)?"QERK@-H"I+:VJI"Z=.U)0<I[=\^J9[6YHE.%63
MD(IRS;-8N+=QQCK-W!Q37V@8I@V8]50;PR:.2P29=QX:+0/2O-5N[;:N<]T]
M]Z+B;2,_,N*1TD1CFY%]YMJ[IZF+>W>TLTMIJI^FJ4AUFDU1,=`IU`G)/811
MNDDBUCR#4*(H-T1(14K?+KXZ(WM[V:PS0YT'#*.7G5$O=:73M(D/#8@Y/]BQ
MCIYT*(6^A9N!N[&4/+N%[;4Q:DM<VPK6\#*M:AI:CI-M(1Q)12I)TQ*1BUW;
M=%?F428S--?E"E#<S*.YO!O%(,QQE2Q=<\NL&0FT\=L<ZS08%/D-N]Z19G]"
MX[I:%IJL'NHTM(5Q%0$+=VR]@;:4@RGAJ.H)*EGEE*L0J1U(5#**JJO)9*7;
MMS%(43&^ZF*([`'%.$;ULIKLPL@6_2",_*M&MW9GU,PGO#$\OH7C5QT>DE+:
MA+XW7H:X4+3-OKT6`NU0,C;]TT?N$J=NS=R!BZ=GKB1Q&!`CT*?ED(I!5^V$
M`46>E,8>ZSQUW;YTLUMV=+#QR_\`Q*F7NOB$DQE3W-/(?PJ]K.Z5[WM:ITY5
M-J&N+;6H8[2C2KR#LS1]H:9J6'BI>HGE(M:)4K.KI.JI)VL\>LH=N9)-NW;H
M-TE53'`1V!CSN,;P4TR6T4$H,>7&]=&40R&T\=O.NU0837M<[;ZATR7#J@D6
M'C(ZHXEO_N`GW('S`"IY9#F!=U,I!*4VW>*4Q1#'DGSZ>8_O'R&E^>!UKLLH
MWR_Y<Z'E&I3]<<_LAZF(3JR5>%Z2,F8ZUM,IZEPCWY/E&I3L^H0]3%.UR/<M
MT'6I;+4^].D:EKM30_TL[P!_D/LY_ARI\>AVN5\,9"2/5S'.>5>>%#,.)S3W
MUM[/QPYEL2;A'J;1ZH8XS*Z6)AA*&@ZUVYE%,A;.AY?0FSZA#U,:^UR/<MT'
M6KMEJ?>G2-2`.Z(&`PDW!`^^40WB[@@?N<Q`!,.6P.J.+9-51NFM$Z0UTHFT
M$&!&E5S:.J=++1.()&<:EIA=?1S1M[=3=)7BNDQIJLK>TI9.9MF:WLPVJ'E7
M-4356M*CC:C=>UJ[6.DXA*-14;':KBH4%3[2CCU5'O%3X>(4,ONA]D>E>>J-
MU9=6;U20\\O^Q69<C1C.5<\U<##3]%T]%:B2Z<$J1B%(=X5.B8VQ[>/([BI`
M[-#N2.ACC&9`B4"MQ``V!C?E[WAQA4-+V`9#GTK6G[J,ER@V2X-MXO\`8K7K
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M(KOE50$=TI`*`E$1TYN\DN2T,DL`:!"P0^E=2FW?>YT9DPD<=OH6S=KJ1=6^
MMC;B@7S]"5?4/0=(T@]DVI%4FLB[IN`80[AZU2<9K(MG*K,3ID-M*00#J8\C
M6XSM-2Z<YD7&'$<P&=>DD8=.IY0DLFP:.7T*^OJX0]3&K\2;[OH.M7;)4^].
MGT)]7"'J8AMLGW0T'6FRU/O3I&I=AI_NIK_^\(=4/W4O6QL4E9+-5+#90O%X
MXCGYUKUE)4&EF`S3"X[CY.9:SZ6/Y/*WX?Y?;X?PU<8W\4G.[P?P^+,5S<)H
M9G=V3NGT+8_ZLL\<X5;I3+QE]7F.M=38IE^R=;S^A3L^H<1^)CW8T'6I[#.]
MZ=/H6L6KO3Z\U/6<"TK&9C(0SJX5LZL?.9<CQ9DYA:*J^/J";C`!B9-=!Y)Q
MS0Z*"I3%.FH8!*(#MQV\(QN53MF.=+%^R!ADA'E7'Q;!9M667ID0V.4YX<BM
M^8TGT:PKW2]/6<I^D;<T986\=77AJ&GB1LDYD:J<U30\C3K=P,@Y.Z=&GDWC
MQ-1R[?**"9)/<`P"4<=-F^-8]QES'3#)(A#BAFRKB#=5H=>:1'AR+6R>T*7N
M>6KI:U=.WEIQO3)%=19JQIX\C5U+T_,$O74KR=I.LUG%'2$3+O'E"MWQDQB7
M!E&$@IO',0Q1RQMG>>DO7G26]X'`WH1-A!MZRM=@-5<[D3B)79C9;^ZKOI#1
M=<6DZ\T_R\57=&TC3EL+;4?;:YE3T,I7$%7%ZJ2I2AGE'KTE5%/*O$;>S$?S
MET5W&R#E,KZ,$HD)F!AQ;/WMI:@ATZ2'0!A$9(Y?K<:JD[NU,@QDS2T\A]"[
M&D/1#-:<JKIE_5B5N*L0MO3E44=;VN(N7N:XN$W@ZJES/G;)S3,Y-2]OZ556
MCDT".R121!>J)B?(F>,8GO)(,H/E,`!:W(,D!`<?GR*_#,`GB>XS)A)+G&,<
M]N942>B2L'U25/-(U_2Z#6<U_4UK"*@M&R7.&U*T[3+:G7E&+&-W*M6/'Z8*
ME<#L%(!VY!B&'[S@4LXD&)D/9DXB.=9Q'=Q[JN5,#[&S&&,<Q!S+Z.JJ%577
M7#8"JYQ*&S,-\3&$/LX\(,2$/Y?0=:]8:*:3'O>GT*.SV<9&)VB$L1YCK4'T
M,V[;-@.?T*,_6[/]=1V__MD\,5K9;VLO2@?(=:B^CG"7`3K.<:EKI2^0ZL+R
M]7^(^S'#_P"N:OQW\1K94O"*,LE`$E_$<PY5QL/HYKILR_/C`#C&<\BV+RR*
M7(,N'@^OC@?$F^[&@ZUT]B=[[I&I1]GMXN97M<V/=`^0ZTV)_ONGT+L)'Y-1
MN82B*9ET2G-Q$3$ZJX`/$<!+G];$]N'NN@ZTV)WOND:EHO8C1+1%K9J[-<U9
M"T=6-V:\N_>>O:+KM5E*O7M'Q-T6JJ$9',8I^N9JRG8-HZ52=O6:)3+"<PE/
MMSQZJ3OE5,HY=&7/[EC`T-X@!D&6*\U4[K,GU#YSBTN<XF.>/D5BT+HEN%0-
M(Z=86-N?3%.5/8S35?.RP59$4\^,[5K&ZK]D_AZLIZ.D""8L7!*-B@Z*],)E
M52B(;W<XH=O+)F3!,F2[S@X&,,Q'+R+#-VYDEI$I]VSB/H6.*4T`W4C&=WG]
M9SUI;G5'="B;/4HO%5?4-X'[,L]:YY*O757HUF\EO?U!5`J[?I23%=@*;2)<
MEY)(F10''J9>^\N3+,J0+@+G.,`+7.B22+T+3:<ZTOTK7G+/.G\*Y*IZ/ZZ-
M1'M/4%2W+I.]=9PUBY*PET4KJS%S(.&K.GUJC>U#&/6\W0TPC/RZT4QDQC)%
MI+AR,NWY-90-[>`-6MWNI:JB=2/E@RBX.NPLB./UE9)W8KI<T/,\F'+^%;<W
M$T_+U-+Z.75//X2EX;2_<>&K9Y`+-US!*T]%4&K1?M!329GCM>*-'NUPYNH\
MWA%J0`-U,<)F-T4O^7(:/)^);QW?J#EF=/H6#;1:(*NMA/:89*2KBF)EOI\N
M'J6JJ;;MF,@W<5&QOK(R,A",HU1V`G:/H4KXH+G4VJ`41)W&+CO"R8QS6R^+
M)#TJ^DW>$N873W`@"RWCT+Z*)"4"%*"@JB`%WE3&,)CFRR,`;X;QDRB&0&X#
M#GQ8\/65+'U!F&2,N8ZUWF2*B6RY+J"&9HC4J_K\?'^I@ZNEO`OR@2!F.M62
MJ2<&F[.X\XU*=GU"'J8CM<CW+=!UJW9:GWITC4L7TR/])"Y_%Y+E$]CY870\
M./239C/@DJ;=%VZ>K#]KB7GY7?\`Q>93WS&^!&/,NS<BD+Z5;KAO$%H&]J5T
M6MA[(IS0W'>U8T<E54J&Y!VYF!*?1%)5MD4<S#MSV8ZU%5X?(P<":TESG.`@
M.>&466!5RW.<Z&8#+Y%=WR+ZWN'FFEKZX2]T0R_\5CCTM5ATHNC+C;D`"VWR
MY\R5<ED!Q4#936X8``6&ED<A.(![;70$`$X!OB`<EL$X!MX\0FU]$YUUK8#R
M+6;3XA+M#H^7TJ1LMK>SSYEI;SV[1F+H9AO>NVBE^NRV\>,NF8>0(-=>YE9"
MNXW#3Z546S>N`N]DSTN=T(&-_?BZ.T2G%0!'[EM$%#";ZXY\.(7Z#LG0D*SC
M<-/I0MF=;I0``8Z629`H!0"7NB&0*Y\J`9)!D"OZ[CZN%^AXF.T*;95:]L;U
MG#E57R-ZWP',&6EK,HJ"`^W%T<P,J!`4_P!;V"H5,H&XP*&?!A?H>-KM'H6K
M,HZXVWNGTJD]EM;ZF>]'Z7C@8!S`9BZ0E,!A`YM@IB`@8VT>,<6"IHFB[=-G
M#,I,D8BUH;')R^E<1K+:XCCM9Z7#"5450WIFZ(B540W>4VIB(*[NS/ARQG:Z
M+L'AY%/NL1S]/I5);)ZX`RR9Z6]T.H$Q='++/:&7)998;91=@ILM9VN&E=D+
M-:X``2@RTM@4PB)BA,72W3"(9&$2@ED(B`[<-KH386&'D39:SM<-*@;,:WA`
M`!CI:V%!,N4O='84NP"%^Y;"@`\'`&(F?A_8=T+&RUG:X:5QGLKK?$"@#/2V
M&X!2$_OQ=$-TA!WB$+]R[DI!',`#8&,BIH6F(88^1-EK!];AI5)+*:W2\+'2
MR(AD)?[[W0[D0$P@(?<MFTPXSME'V"L[+6=KAI51[,:X1$!*TTM@&6[LF;HA
ML`0V?M8;`R#$75%"\Q+#9PS*N915Q,6NX:4+9;6_N@`L]+@[H;I0]N+HB!2Y
MY[H?<]@9CGEB8KZ!GU!T:E$4V*-]5YAS^E6)<ZT&M-I;>X[A^PTT!'HV_KCG
MQV,K<@[KFXTK*B<6Q79"(F4`H]4V77Q=1UV&&K,RYE(XO)F6I4TN*$%Q=;S^
ME>%86T.LM_8VSCJ$9Z:!B#VNH@T8:1EKEE?F8C`,3-3/2MBG0*YY(0W]P1*!
ML\AQLXI7X9-!9<,6F!L$%;A]+B+1?<_*,_I66!LMK>R_W%I;$!#+_P`[W1'/
MJ=5(,:3L1PZ>`"P6#DU<BNJ).*96OZ8?2N,++:X0*0`::7``A@.0/;BZ(`4Y
M0R*8@<GD4P`&P0VABL5%`RQC##AR+$BCQ`CO7NZP\OTJ2V5UP`8!YEI;S`,L
MPF+HYY9F,`?M6>6\81^N.>,[71=@J_NL1S]/I7*%EM;Y<A!EI;+N@8I1"6NB
M&Z4Y1*8"Y)!D!BF$!XP'$)DW!I[;E<UXD1C9EB,GTJ3)%<XP>X`0X<:CY'-;
MH`4IF>EL0)R8)@,O=+[GR/[5N!R?<\GEW.7K>IC+:K<V2RZ1.AS^A:KJ&O;,
MBUW'G]*D+,ZW#!ES#2R)0RR`9:Z.09#F&0"EEL'&&U.[CXG#6S"/K1S\7%F6
MY,D5KFM#G9!G]*K^1G7`([P--+@#LVA,72SS+GD.?)\(9XR9V']EW0JMEK.U
MPTKC"RFMTN8`QTMEWLQ,`2MT`WA$!*.]]RVYE'+ZPXM;58<UH%PQY@J7TN(7
MNJZSG]*?(MK?`1$&>EP!$H%$0E[H`(E+D)2B/)Y[H"`9!BIU91#(WS+&RXEV
MNGTJL;,ZWC"`F9:63"`$*!C2]T1$`3$3)@`BELW#"(AQ".S&1/H"(W'*\4M9
M"UUO#E4&LOK<,42FC]+)B"&0@,M=$2B7//(0%+(0S#LX&=AYL+'6K#J6LNF#
MK8<.-5?(WK?ZC32V`CN_\,72S'=`V[P);1+OCEQ9CQXLE5-#($&,=#F"LIZ6
ML#(O=;PY5Q?(KK=`0`&.EL!`,@REKHALSSR_:M@8E,K,/>V)EV\P4"S$.\$L
M/ZO/Z5!K+:WP#_<>EO[,Q=$`_P!BQK[5AWNQT*?<5_;.DZUK3JXM1J^C;$U&
MO5#33>6&-4=N".#PLI<M9Z54UQ:6!IDFNF!12,Z$@'$-H%SQV,)Q'#)7>,=+
M]8#B'%'D7(Q:FQ(F4YKB0'&-N>'*MG%+.:WUU5%.8Z7@WU#F$#2US`R$QL\O
MN266>[EGGU>MCGS\3PYTV-P9>34NC(I\2;)NW[89^3G7'\BNM_[RTN?C>Z/>
ML5S*W#ICKUSBS!6,I\0`M>8\YUI\BNM[[RTN?C>Z/>L5[5AWN^@*7<5_O#I.
MM1\BFMS,3<QTM[Q@(!C>VMT,Q!,1,0!'DLQ`AAS#B'&>^P\VW#H"UW2<2O&#
M[(Y_2I"RVMT!`P,M+@&#=R-[;71`0$@YDR'DLPW1X.+`3L/%H8;.98$G$8B+
MA#G]*#9;6X`%#F.EO=*3DB@$M='=!/>,?<*')``$WS".7!F(CU<3?6T=08O:
M3H4Y\G$&G^&X7='TH-EM;PY9LM+8Y#O%`9>Z.>89=T'W+8(9=K&!44`;=###
MF"ME2:X2[SG"_P`.5`LOK=`Q3"PTMB8H&*41F+HYE`Q^5,!1Y+,`,H.\/&;;
MPXQWU!V7:%F%<,KAI]*&LQK?,`;K+2V7(3&V3%T0VG',X_M7"<VT>,<2%10-
M^H=`5<R57S1!KK1R^E4DLKK@`-WF6ES(`R*`2]T,BAF(Y`')9`&8XEM>']CH
M&I5[)B7;Z?2JOD5UOC_O+2Y^-[H]ZQ!U5AY-LOH"MET^(-$"\Y<YUI\BNM[[
MRTN?C>Z/>L0VK#O=]`4^XK_>'2=:UNIBUVKU?5C=R,2::=`J-M9^TH2A59"X
MIHA&("8JH6BS`X)E<*O5E4S`H4XY%#(0X0QVGUN&?#99##&$,@RQ/)D7#;28
MG\2F]:R,<O%`<N5;)!9;6^(9\PTN`/#NA+W1R+UOVL>#'';4X<'$AEO,%VIE
M/B+V@!_#2H^176]]Y:7/QO='O6([5AWN^@*7<5_O#I.M/D5UO_>6ES8("']]
M[H\)1`0']JX0$,PPVG#C9W?0$[FO%M\Z3K0;+:X!W1%CI<$2F$Y1&8NCW)S&
MWC'+]RV&,;:(\(CC/>X=V#H"Q<Q'M=/I0++:WBY_VAI:V@<!SE[H9#RF>_G]
MRV[^8Y\>>,&9AYR-.@*#Y6(O;"]QY_2JPLUK?*.\5CI9*;;W19>Z(#M'>':"
M6>TVWZ^(WZ#LNT*K9<1[73Z52%EM;W<B5CI:)N`4I=R6NB&Z4GK"ADEL`G4#
MJ8L9544D0#3;S*QE+70ZSK>>/TJ!LMK?$`*+'2V)2CO%`9>Z.13;PGS*`I9`
M.^.?U]N,FIH'VEAMY`IB5B#;`ZSG]*?(KK?',19:7,Q$1'^_%T1S$>$1'DMH
MCB.TX<++G0%/NL0=UB^WG.M/D5UO?>6ES\;W1[UC&U8=[OH"QW%?[PZ3K3Y%
M=;WWEI<_&]T>]8;5AWN^@)W%?[PZ3K1*S6M]-5)3F>EH>343/D$Q=`1'<.!L
M@`4@`1'+JXOIJW#950R8Z78UX.0<1YE34TN(OIWL:\WBT@1-F3G6M&EBUVL*
M3H&LS4XRTX"Q3OC>4KP9>1N,DX+*C63T),A.23$>:%7(')B&W+K#CHXGBN&%
M]C+"(Y!Q^1:&%4V)"7>+CFR_1%;*A9?6^8<N9:6OL3%T1_VK'+^(8<^7<N<>
M8:ETS3XC?B7D#G]*J^176]]Y:7/QO='O6*]JP[W?0%+N*_WATG6GR*ZW0V\Q
MTMYY;/[[71SV"!@V\EP`8H#]<,1-30%X`9`>2U8,G$!D='R^E2%EM;X#O`QT
MN`.\)MX)>Z.>\(B(FS!+/,1,.WKXO=/PP-ZK#>Y@L=SB6?AI4C9C7`(9<STN
M9`(CE[;W1$-X1$1-^U\(B.-9LZA<(EIBJ7T^).=&]T^E3\C6M\!$>9:6MX1*
M(C[;W1WA,3UAA'D\Q,7J<6)7Z#LNT*.S8CVNGTJ@;+:WQ'>!CI;SWA-F$O=$
M!WA#(39\EGO"&S/BQ::NA>VXYI@!F"V&4]?*M:ZWARI\BNM\0R,QTMY;P'R&
M7NB/=E*)2GVI>O*4<@'A`,&U=!+%UK#`\@672*^88O=:.&=1\BFM[@YEI;RS
MSR]M[H\/'^U<.(;3AWNQH"SW%?[PZ3K5065UOA_O+2Y^-[H]ZPVG#C_R_,HO
MI\0+;'F/.=:@;+ZW0#NF6EP"Y]T8)2YZATP#:!TR'(!!.`@`;>IB&(56'36L
M@R$#Q@9="A,I\1=*NW^+/Z5K?2MKM8#C5==^/:L=.)*B:V:M(:53<2=QPAQ8
MJ3=8%CU&2B"7+<Z,=%3E2G[DI=W+AQZ+$:O#'X-1ELO(Z8#$#BN\F1<FAH\3
M;4S0YW$WCSQY5LD-E];YMO,]+@=39+W1R_V+'`VG#O=CH73-)B7:Z?2H^1;6
M_P#>6ET?_:]T.]8L95X>!9+Z!J6-DQ+M]/I3Y%M<&67,M+N68CE[;W1RS$,A
M'+DLLQ#$MKH.QT#4L['B7;Z?2@V6UPCO`+'2Z(&R`V<O=$=X`X`'[EM`,5F?
MAQ,;IT!7"3B($(\-*H"R>MX`W0C]+0%R,7="6N@`;IQS.&0(Y9&':/'C'>X=
MV3H"SW6(=H:?2I&RNMT=HL=+8B(E$1&8NB.8E#(H_M7"4.#BQGOJ#LNT*4*[
MM#3Z5/R+:WLS"+'2V;>#(^],71'>`!,8`-]R[H`,<1V]41X\9;/H`8EKM`6+
MM>;`X1Y_2I-9C7`(9%8Z6RB!M\!"8NB&1LLA-^U<.6S/%NU8?V3]T+'=8CGZ
M?2N,EE=<!<O[2TMAD42ERF+HCD!AS$H?<M@&'AQ%U?02R"&Y3F`4'T^)/$+T
M/+Z5R#9?7`.[FRTN")2%3+G+W1$2IE$1*F7[GL(43#D'`&>+G5>%.;UI9O<P
M5>R8CVSI]*#976^/^\M+GXWNCWK&GM.&@F$OCS!6RZ;$&BUYRY_2N,UD]<`C
ML9Z6^#W8NB'^U8;5AWNQH"GL^('ZYZ=:Q;3-O-3K;41<VFY=I8LMPY+3)1PT
MF$9(UT-(*MFMYS+RGOD4<`,L!RQ1%^;"W``YP"8&[@38WYD^F-"R8!_VX)$/
M(X><KG2Y51MLR7'^/9;H.?-RK<^@-NN'47UK&:>?\.W:'')F?^-;^T?,5VY7
MK'F'T+<)P8I4#F,`&`!#,IA`H&#>#,!$0$!`0ZF0[W!CE48O2R.5;;WA@+BO
MFC%:XJE?WO=VX/0U'.Z61U&5%IX.UIZLSO[M1:D+3(U*VNK,T25LBDC;O=1Y
M%ZY%0O-BG3$1$#98[C**]*O`]:$;19FA'/R+B3L0:)D"+(PY5E*M]9MNRV_N
M%-6UDTYZJJ9I5U5-,LYB(G(:"K9G$3#&$D9.DI!\V;H5)!LY)T1(RS03``&`
MP9D$#C3)H"R9>=8'6<N0D1S?0KZBL#I;;EKK5EUQJ!MTSKR`MI,KS,;5=0+-
MHR&6>4O4;.DI>H5XX9<*>BZK48DA7LJ+,BIP;\L)3&2.`CO%RQ%U'?;?,+H$
M>6&2,%*7773#*[FXU9T5K(T]3L@JQ9UN<$B1-93;69>0521=-33:@%'"5<(0
M$](1Y8F9D*:!J<[ENB8YR)IF,3>`!$([#42NK+!/-Z.92.(L/'Q</*O0CM04
M!43NWKZ`<I,:4K%6M1-[\86J*8JR894Q2YJC]L:0C'4>"#]BLP(#M9R[,D`L
ML^2S4S*$>YJ1$<0R\EMG-:H_$&V0C:O(IO638"I6LR\85MNQ-/T2G<(TQ)P=
M0PK*=H@SE)BK45&JR3%NM4$:A*)\R.5L"BIG)TRD*;?#.XX5,F0<\"^\G(8V
MYCF/T11U>UC;YC`VK)UH[ZT#><E6FHE2<([HJH?>I5,74%/3%,2<54)XYM*D
M9+MI=JS5<&4CW:9RF(!BD`<A'/&M,I33``P,<EN5&5PG=5L8A6DOJELLP?7"
M8&JUSOVO?H0M<+LX">7CXBJG#AFV94>V?`RYO)5C*O99`J48W,NY5Y8F0!O`
M.+#0D`$0MY>%G*K!7-.5>>XU=V5;PL=,.9J;37E:ED:/84E[TJE4KT:MAHA*
M=D*76I)%@K,M9=O!."/\E"%%=F<%";Q<A%L%\721#GLASK(K6Q@!:O`;:R;,
MUA$3@V_JYG(21:`G+@TQ*S\'5,)1L]%P3=1Q++M)A2-25DCTV8Q0F$V:9G+,
M0.!B[Q1`),PJZ1?'5+H9S'AD4)M<+O5RP5HO];5*P4S>RG9*C:L?S%C;*TK>
M2=D*>IZ7D*<JUI4-,RU0!$4M+J-`Y54!A>0247W>6!<!`?N"F[MOPP,8U[2.
MLZ'+EAD\^942<0_B%IR0BKTIK5+2TU"TG<"3494C04[8Z5O3+M*I83L77<%$
MQBD$>1<J1*S0C4\+&>W0I*'WN4.82G1`Q3YXHV-W$8F,.3/EX6K:V]O0O4C]
M85BY*-J&4;5.^!.F'5*-W4<\I6IHF:>KUZH1O1)8*!?QR$C4*-9N'!DHY1JF
MHFJJ40,(98&DF-LY/-PM5;JQKG"V"RY9Z[U$7IIEY5%`.I)U#QU0R]+O#2L+
M)P+QM.TZXYC-1:["7;M7I5XUT`I*&,0`$X#EL#/&I,:6Y5MRG!XB%R7O``LK
M>$`X/DON"/9I.8$>V.*I1!FQ&<*<W^7Y#YBK:TM_U;;#?S16]_@S&XMJ/7=S
ME54_JCFUK/>*AD5Z#P#C*P<BXQ#""J(7&.Z8![H,B[1'/8'U^+$'-+A`98J-
MV\(<2I*!,Q#?+F`"(AF&>11W3#EQ%-L'B'&!?;;!!)"Y`,0N\&\7,H`8P;P9
ME*.>1C;=@#D.W#O'.R""M:QK%482[,S`&?!M`,]@CLSX=F,1>I08N$PDX=\N
M0@(@.89"`99B`AL$`SPO/"I?*:YT0J@W!`,CEVE`P;0]:/`/UAQ(3'IW+<ZT
MJN7K8M_:BH[EP=8T1<=%"U$/25051),(.-D&98BO*G2H^D744B25!T]6FYM8
M4@3*0#[N6S,<L;M/2EP%PB\[/QGC"I=57"6P,!YN(^594I._]`UG=Z=LO`N)
M-W5%.4)3ERGSPL>J6G5Z>J5\5E'%82?.%`<R1.41,LV%(I$2J@8!VXC/IBWK
M/R1LYQE\RRRJONNCDCIA]*V#`HB.T!RQKK<5>X'7[7J8(H,3(-F8[?JZF"+3
M37KF&FJI>IE65I!'/9L"ZU&[?K;<;E$]DN=>F>K`](6G6.FM##*$3>M6Y(@4
M=HY`;J[>W]<<<^:]C#>-I"VV]X]ETV*`*7V75'BP%7+-HBJVR'M$(\:;I?98
M;2SE4NZ?GX:$R+[+]##:I?*G=/S\-"JS#V7Z&,;3*Y5GNGYU3NE]EC.TLY5C
MNGY^&A-TOLL-I9RIW3\_#0FZ7V6&TLY4[I^?AH4AD'`;]#`U,OCBG=/SH.0\
M)OT,!4R^**=T_.HW2^RPVEG*G=/S\-"I%,@CGO?H8SM;!9:L=U,SK3VC<RZX
M;Z<7R#V8RZX!45=!GVL;,RH9LK8\43IBM>,T3G-&0`0Z.3G6XA3;P!P"&09;
M>IU,:3*F6XP$5LM[Z[%-TOLL3VEG*G=/S\-";I?98;2SE3NGY^&A-TOLL-I9
MRIW3\_#0I`"AP&_0P-3+XXIW3\Z#D/";]#&!4RQG3NGYU&1?9?H8SM3.5.Z?
MGX:$W2^RPVEG*G=/S\-";I?98;2SE3NGY^&A59A[+]#&-IE\J=T_.HR+[+]#
M&=I9RIW3\ZJSXC;?L8-GRW&Z(Q*&6\6Q6E^B`P_)K<G+:`ZC;\@`AM`<J[>A
ML';U0'L8MJZB6""8P@!H6O*=.+(_6B?HY.=;FE#;F.08I%3+++8K9_C.ZKLB
MJ'(>$WZ&&TRQG6.Z?G5GUQ4T51-,5#64YRP0=)T]-U),J-DN<N"1<%'K2LAS
M=F!TA<K\R:*"4@F`!$,NJ&-BG[NJF!C(=]$!N>)47R&!AGS3:P6?3F6$=,^K
M73SJSHUK7%@;HTI<2%72(LZ0AY`"3T%RQ4SE:5!3CPQ)F$<I\J!1!9(J9C`/
M)F,7&Q4X5CE$>]K93V4I-A+7`&-H@2T`F'$"N13X_2UTS96/!,2(61LLR+94
M@DW<@$H9";N<]H9#MSSV[,<\55.T=4]7A%=8TTIA[IIMX<JYBE*)0,&0[./U
M,9OR*D<3AS^E#)[G)Q+EW`Z_U?8Q8``(#(%:+0FX'7[7J8+*;@=?M>I@BI,4
M`#/;PAB+\GE"@_U52IZT?K_I#BJIR-YU;]3R+3JAOZ\6H#^9"R/^&:[QZ.J_
M\%2_]6;_`,*T97^JF?LM\RW(*3,-N8;?JZF.&MQ3N!U^UZF"*H`R#+!%."*C
M<#K]KU,$3<#K]KU,$4@0`'/;@BJP10(9[!P14[@=?M>I@B;@=?M>I@BJ`,@R
MP1:@(?U\9'_NJQ(_8^5:8V_6QOG_`$`YSYURF?\`D7^3S+HV]_KPZC/YC-//
M^&[MXC,_\8S]H^8K;DY?(/H6XJQ3&2$"``FWBB4#"8`W@,40WMSNMT!#;UL<
MBF+FRB6VNBMF:T/86E?.I/0^K%5?+7*AJBB8^X4EJ9JZ[AJI0@@;2#ZU%Q8-
MM3%96BGW29C+23%:)3YPV.I]R2?M6QQ`"E-GW9&)2Y3;DXB!&0YP8@K@S,.F
M/F=1IC&PV9%C^B-`,I2U"5+0"TC:A-9K03ZW=N[F,Z=J56XK>,7DHURLI/H2
MDBM!)+O8B/(F[]K"%3<K9*=R`98E.Q"7,(=+O1O1.2&3BX]*Z#:`F6`X6P62
M9;2I<B6O;#W"DKB0LM2L#>.F+FQ#*72J1]4,=&0%*%@4;=0[,LBVHZ#AX]\=
M9\B\;HJ.EU5U"J[<A&,NI;<+"+2V'%SJF;0S6D.:";8K$EA]/-X*PI6W1J^J
M6VRU+VJ<7O"EZ!>4F]>2ZM3UT-44V>G;KYR"K$8&FX*9.04F1>6DRK%.H5'=
M`!VWUPDO=W37$O#0398!&$(\ZHET4ZX!,'UCE\G0LH6NTG55"IP;A]<^GWC.
MF*ONJYB*/I\\O-TK;Z+K.VBMOT:`HJ3G';BH(6+@IU8\NHS6R*W57,U1(FB0
M@!1-Q4%KFA@!-V)@(D@Q,>*U6BB<#:`1P\RPMJ*TLU>E0%+M:0FF-85?;[2X
M^LDO15/Q^]4DTSG;BV^?2]<Q<2:28.5(N(8TTLHLT(=N[<'R(U735R'%E%BT
MM]8YSX!CIA=R>J6]*A74L:1K&VS`V$!SK*^F.T*-4P==-+IT"_D(%.X["L*1
MKRI4Z[I2JKA3CZGVS"9F9N#JFJ9ZJU#PRR1&"2KMX9NX:@`E(7<$1KQ6=3SC
M+?(@UEVUMG5@>2Q8PJE=%SIT28Y3QJ][DZ0'%P+/W.ML:J8U.0JN^87RIYZ^
MAG1X=O*1TI!S$)351-6JS9\YC55X'FSERV4!TF@<#(COE+C6[_KAT/JP5PDM
MNW8V1CR:/I7-:_3D2DJLH&7.I:J`JJ@ZMK"NZR@K=M9Q9::+6U"DHJ'>/G=1
MO'E0+2@-&!RF=K@7ED42)DRW1P=4=0MRV0&3/H1LAM\$&V,>'&K1=Z,ZC<05
MI81"OX1%6V%L-0]`N%$85XD#YS>F.&.CI1@BW4(9HA`I.!,Z`0,9=41`!`<3
M;B!:XDPB7-.A1F4;B(#,5=YM+E8DJVZ9TZPIY.BKR:;Z1LI5[$8F0]\4745%
MT[5-.1-04\\!?VL7AW[.K55%D'(`ORA``@\.+'5@(:YT26O+AY3$Q495$\.-
MD`6@:(6^5>$IIAK61H&F*7K6OZ#;S[?3-4^F1%:,CGJ,1)/)52FPB)QHSDW/
M/E5D8FD?[98%$PG4,8Q!`I1Q6*IC1!L8!]Y;!HYCC:+80\@$%B#5;IJK\CEW
M<>BUI6;3E([3+1,@UHZ"D7U141%V8K"H:F>URT81LO"34JT27>I<DUC'3:1;
MJ`"@*&2!0N-NDJZ8-+9Q`A>//&%G/T+GUU'5]ZTRFN((`,.*"VTT8156P5I7
MT/4]$EI!-C7-5G@)!9G,1LU7\-(NV\J6X=2Q51R\]4#"?J9^^<&=%>O%EQ,E
MO`()F(`<VM,ISHR3$%=2B;-:V$T$+,M[M[Y%;P[P``_)=<'8`Y[/>G,9;>N&
M-*1'O+<L1YUN3H7+,D#YE;>EO^K;8;^:*WO\&8W%]1Z[N<JFG]4<VM9[Q4,B
MO0<91<1C9%$=NS+@#,>$.#/9B4"HW79E\\=5]+S*UY=+Q(6Z%VZ0876N\]H*
MLXBBJ]>T_"O(&/M77M2M"(L$4#';O%).%;*'<)&S*!!#+(V-ND:&.?,>`2V6
M2`;1&(&M:\XN8&FVUX&E>3$WFN#.P%*RL]3@4]1C;4M"V:H]S#7#F%JUJL],
MU+4U'/*IKIY[1H-WS"1-#[ZT<913G*Q!Y4V0`([\VDIPZ#7`S2PO,/5%@L%F
M7*M#:YI;$9(@>=<$1J=U$53/T0QI^UELB1EVZUO9;VC)&3K>=3=PLA9N2J1(
M*IJR-9PRA0AJA:4^L446(F>-5C$W\P$,4"ED-+HQ`9`GF/TJM]74]6X!UB1H
MAR\JQRMTB=734)1"U%6I&0J:3M(XNK4\$9&K9XCSDJQE:')1=)N*:A'SD)*1
MD:>?+(/9)%%N1,"%',QC"%NPLB>,1`XLT8G2(P5.W3\W%PX]"O2X>K"Z2:-]
MJ990E+VJJ>EK.U%7-IH^OF\^E4=5'BJ(850-5PW]YGM*RL9`O5U&SYB@Y,\9
M*-RJ+)Y'$`P*&6Z[`$V@&$(`QA#3G5@KY@;!]AAT*BH]5MTK;6-M=5,PYM)5
M%P7]C8.[=8TZ1S6Z<I/PYX2/=OEJ>;1%.O&\"U?`<PF?/CMF@R!@2*&X`F!*
MH9<UY@'70Z[Q9;=5@RJ;ZYS,I&0'CY#]-JV)JK37;Z\;RIJ^EU*H1<W6IFSB
M<R@W>,V[8S*UM6QUSJ4*W;J,%Q:KN9ILDD^$QCE50WDR[H]UCGRYYD3BUUEQ
MYAYETFR&S&AY^LT%>[:O3)1=IZY-75,K5"$BO2+ZBE&\Q)^V;4T$\K-U6;=,
M<TR+<[B5W!&+,YA$$(MNBAD(I[PQJ*LS8`9U-E,UAB,OIBMG\4*],"8943$;
MS<Z+YT=*W6CVW&A&^EPHU@TE)&@X^EZVCXZ077;1SY[2E:4Y,MFC]9MFNFU7
M6:`4VZ`X[6`T$K%,1923'76.RGR$YCF7!W@Q*9AE()TML7$^;RA?F53_`#H;
M5.4I14TUV-.91-)?NJPK(I?NQ-\`(/,52'*`>Q-D'!C[91?*+"*R2)DR>089
M_P#+7RJ=\SL1IYY8)5D<WXE)OSHO5*`[-,]BLNM659?I1N-KP7P06&H.G_+4
M_$_$GVB59S#VE'THO5-YM%B_AE67@W#P8P+\P=/^6GB;B?N3H'M*H/SHG5&(
M9CIIL3GU?\<JR\&8>#&!?F#I_P`M8\3L5]T=`]I5?2A]4OFT6+^&58^#</!C
M`OS!T_Y:SXG8K[KH'M+C^E%ZIO-HL7\,JR\&X>#&!?F#I_RT\3<3]R=`]I/I
M1>J;S:+%_#*LO!N'@Q@7Y@Z?\M/$W$_<G0/:3Z47JF\VBQ?PRK+P;AX,8%^8
M.G_+3Q-Q/W)T#VE)?SHK5*;8.FBQ?'_QRK+P;AX+X%^8.G_+3Q-Q3BE=`]I2
M;\Z)U2ERRTT6+V__`!E67@W#P8P+\P=/^6GB;BG'*.@>TJ?I1>J;S:+%_#*L
MO!N'@Q@7Y@Z?\M/$W$_<G0/:50?G1.J00S'338H!_P">59>#</!C`OS!T_Y:
MQXG8H/\`E'0/:6-HS\XPU'QEUJMO"CI[LPI,5G25)4:_C%*KK$L8S84G(3;U
MF[:NQC-Y9\LM+&`4@SRV9\&-^;\F<#%&P;0;(G+ECQ'^'D'%F6B[YFXCW[B9
M<"0!DYOM9;%DHOYT1JDW2Y::[&FR``S-658%,.SA$H1N11'JAU,<R5\G,!+H
M.J8<Q_RUO2_F;B)$.[Z/Q*CZ47JF\VBQ?PRK+P;BSP8P+\P=/^6L^)N)^Y.@
M>TGTHO5-YM%B_AE67@W#P8P+\P=/^6GB;B?N3H'M)]*+U3>;18OX95EX-P\&
M,"_,'3_EIXFXG[DZ![2D/SHK5*(Y&TT6*`.O659>#</!C`OS!T_Y:QXG8H,D
MDZ![2J^E$:H_-IL3\,JR\&8>#&!?F#I_RT\3\5]T=`]I4C^=%:I0'(NFBQ0A
MUJRK+P;AX,8%^8.G_+3Q.Q0Y9)T#VE'THO5-YM%B_AE67@W#P8P+\P=/^6L^
M)N)^Y.@>TGTHO5-YM%B_AE67@W#P8P+\P=/^6GB;B?N3H'M*H/SHG5&(9CII
ML3GU?\<JR\&8>#&!?F#I_P`M8\3L5]T=`]I4_2B]4WFT6+^&59>#</!C`OS!
MT_Y:SXFXG[DZ![2K#\Z(U29AEIJL1GF&6=:5D4.'A$WM8.66)RODM@3IC0:A
MT"1Q_P"6H.^9^*!I/=')F'M+&5J?SC'4;:*!F8"&T_V:DVTY6U85PJXDJGK%
MDX2?UA,.)9TT(@$7D+1)50VZIPCBW$/D[@5\`3\@`RYN/^7ESE:DCYF8@T`=
MW9'C'XEDX?SH?5*'#IML08.+WYUEG]?_`,V8UV_)G`G,CM!T_P"6MX?,S$0V
M\V5;S#VE'THC5'YM-B?AE67@S#P8P+\P=/\`EK'B?BONCH'M*TJ\_.6M35?4
M36%$OM.UE6#"KZ7G*5?.F=55@NNV:U)'KPJSE`%&*21W"*;T1(F(]V/5#+&]
M0?)K!::<W$&3X]PX.@3E@8^[R66B-JTZ[YBXM5T[I(EEL00?+S.7Y^;9W+N9
M9"JHZN;2U[5]MZSBW!Q:U'2$T]@Y8%&RIA(FHT17*:6:HGS*=!1-9(Z7[:0Q
M!RQ]0F4.!;TTC<`GR)0A`!Q:VP@0B#`D&!/$O!4N.UE'6;4'.$PG.>/RK]-^
MAK\X^N7&RE,6PUA6Y=W5-*N&L7%W.LW!&4N`JLHJFV;J3ELHENHVJE;>,`J*
MQ!4%@`,^:CPX^)[^?)2CW:>9&'U$HRVLONO`GUA$782Q`BV,5]8W=WTJ\3J@
M9P.4`&WRQZQBOV+4943*KJ6@*HC491&/J&*:R[-&9C'<++(MWR8+I)2,3(%*
M]CG:9#Y'15`JB9@R$`'8'YX^'MIII#7$$'.OL@(?+!,+1]"NS%ZBF")@BH/Z
MW[(?HXBX$B`SJ$SU5QGX/L_^";%=0"0V&=6?5\BT\H;^O%?[^9&R'^&Z\QZ*
MKLP&E)R=[-_X5IRO]4_]EOF6Y6.#>;G6VF)`QR(F")@B8(F")@B8(F")@B8(
MF"+3]'^OG(_]U*)_ZV)?&^?]`/VBN6W_`,D[F'F72M]LUPZC,^K8S3S_`(<N
MT'Z.(S/_`!C/VCYBMJ3EAR#Z%N3U`^N..52?RSSK=XU;=9OG<92\_),#I)/8
M^%EWS118HG3(Z:1;MPW,<H&*(D!9,N]EF(ES#+;F&S+DLF31>SK4J9SI3"6Y
M8+Y+$N'J@4I1M4`ZC7O+SFC.0U)K))VQH9L,-6U,MD';:!A^5BG9FM#R*:AD
M7Z+L7TJ<>Z1=H#L#N.IJ9LN-T1;,NY<H(!CTY%S)==47H6VMCDR6D=,%U)76
MU<:.H*]D[/U?2M-5*,#H^J:R].&:1Z+UW'WE5IUG6*L%'+%"5G(U>4>ND4CF
M!PJS$,CJ=T4,991R3.ELA>EF]>,2,G'EZ%B;7SKCB8AP(A9IXE;%0KS3&YUG
M'S*Z,W;"&7Z12_\`$U"I&G@V4;-*OJ,F"1C:H7$\Q=-G7/'Z`-VR"QRHJ*NB
M9)G4(F(7N;)8PM(C_!:1RVD0\V1:FV5#G`<5XCS6Y/.LPREXZ@@YREJ-;7/I
MVQ5-U]JFU'T/4-8M:9I)J\!C1\?.3$*HQ?50W7IB.J.3>L"$7D7K-T"^]M3%
M0X'QK3)$HR>\`#G7`>6))CQY!Q+#:JH,R[:!&'"Q8$2U%740I%_?AJ+"L;C0
M>E"NRPE4-X8K&-JIC3U^Y2FZ>KU.'`QVS9)_",PD3@0@-53$Y4NZB(`&Q)H*
M8.(<;"\#R%EZ&7/8KGSISI+7'UH?2M[M-E9W;J..NF-65I2]74U'$C7%OZK<
MU=;ZK)]JH]@07E$:P5M>"5/M80DH8BS$NZ9V9H)B+"(Y"/+K=F:1W$;G*"./
ME6_0F=:7VNYX\6?AF6I5/ZE[GD94I;:K;QOJ2K!Y=NGZ4O+>-5"UU14+3*$U
M1,O4T*G::K(6&0H48NKWD1S9,LX1U(0P"5!P4RJA#&WWR)`89K1&6&V"T$V\
M=L1`\ENA:+732X#(8Y<R].[%V:QM.O=RK+?5<A6DQ+PVD.EEKD%;4XU3)3%3
M3M>1LM<5$YP"D&;U-NH9,SQ<J4:W65(<Y-T@!C;I:6EG3939P+6N+KPC'(#R
M\D1!5NF3I8+VVD!7Q2EPM1-45+9^@GUW(6)85I=.Z4>%8TZK;JXM7S%O:)HE
MI5L9#RTI3:)K?0E6MIWEV3ATR:JF.R*D91$%SF$-*KD4(:9E,20("!!;;QF!
M,5AM35=YW;K#;;8?1Y5:T#J/O`_F:0J)M=AD[JRJ-05;6AGM.;^GJ:3;6_HB
M'=U1%-:W>E1;-;AMAI%K!MIJ2EG;QS'.&HJ%;MR@JD&*>ZDN:YKLH;&.<\85
MDFLJ+P)LB2(9LEN3GT*:$O?6T^\ME1=<5$UK&YU/:A:0C*TEY9C0E2T.P]]%
ML:]G(N9M+6%"QD=&(LW(,2B=-V49U@W.J1<2BJ3.9D2`2Z6!<NDC+;`BR!X%
M7;9/R.L,>3C6PVCJZ]85A*W+H.Z%;/:SN?1IHJ>FW$2I1DI:PL75+V83IU>V
M]0T1'L129*M(X2KQLL)YAJJ&\L;=4*.-&L;*:YIE>J0>@P70HYLR:UQF901T
MB*WV1`H$S*!@`X[_`'6>\83``B8V\(F`1QIK<6,+X_R+7A_FNK_^",OA+_F^
M4*,W^7Y#YBK8TM_U;;#?S16]_@S&XLJ/7=SE54_JCFUK/>*AD5Z8RB@=H9=G
MKAU0^R&$0BL2JK=4I6<O0DY4,0G(R-MJC4JNCW"BZJ01$ZM"R=.J/B$1$`74
M]J)=PD!3YDR4$>$`Q-LTLB0<H@?*HN8U]CLB\!*S%O4HF'A"TVA[60=?N+H1
MK073@2-*X=RTM.KSA3"?>WAE)IRIR?K`%38&S%FV/C>CUH0R<2CL\J$.)<<-
M9.WE/K4>M#TV@U5H&>K.HJ35!VZ,:+DKAKR;BKW0%$^2QY1::<F$A]XH;^S(
M0#`UCR71-CA:JWTDIQ!&4+&JFCVQB4;2[&&I:6I?WH14K`0SJCZRJNEY88"8
MFE:A?0<G+0DU&O9:'7F%CN`;+J'(DHH?<W0,8!R*^:"3'+R*K8).97))Z9[2
M3%6NJSF:;6J"9>1,Y"@6HYR;G(>+8U3'I0U4>T<(_D%8^#=U!$$Y%VJT31,Y
M`1Y3,1S'(Q.:P7`8#+D478=*)B,JLU_HKL#(4]`TH[I*6=P5/46K;9HW7KFL
MN6>6[67%V6BYUY[<G?3].L'"AQ:,W:BB+<IA`FX&6,C%IH,8\>;T+!PV4>);
M41K-*.CF$>@0$D&#)JR13`3"":35!-!,@"=14X@0A`#:8P\8CPXY[W%[R\Y2
M8KH-:&M#1D`@N[C`RCG655B]84#B#_514B(!PXJ65H]TBT%"57I-KVF:BCD)
MB`J"?MG"S42[(*C23BI2YE(L7[!VF!T^4;NFJYBG#J@.-_#YDZ5/[R19,"T:
M^52SI095>H2L>>B$Z-$1,8-%UC,A'84*9`I0X=H9*YYFX1SZN.]^M-XZ>6)<
MN>8#[+/97'_2N!3G]X^7$'E.M4^B$Z-$=OD66-^#?[[B(W]WG`_U!^ZSV%>[
M=7`B8MEV>7VD]$%T:/F66-^#?[[C/Z]WG_,'[K/86/TG@?N^D^TGH@NC1\RR
MQOP;_?</U[O/^8/W6>PGZ3P/W?2?:7)Z(7HT?,ML;\&?W_#]>[S_`)@_=9["
M?I3`_=])]I<?H@NC1\RRQOP;_?</U[O/^8/W6>PGZ3P/W?2?:3T071H^998W
MX-_ON'Z]WG_,'[K/83])X'[OI/M)Z(+HT?,LL;\&_P!]P_7N\_Y@_=9["?I/
M`_=])]I5%Z(3HT0S_H6V-^#6?^W!A^O=Y_S!^ZSV$_2>!^[Z3[2&Z(3HT1R_
MH6V-^#67^W#A^O=Y_P`P?NL]A/TI@?N^D^TJ?1!=&CYEEC?@W^^X?KW>?\P?
MNL]A/TG@?N^D^TGH@NC1\RRQOP;_`'W#]>[S_F#]UGL)^D\#]WTGVEK)2_1=
M='R\U:W=H5QI&LVM2U/6>M5.0D&I3:0QT;+3<W6;:7DVA.4WTWKM!L0#F'UP
M$#+'1G;];RNP^7&>203$W66CB'J\6?*M-VZ6!]\[^'Q#C-ALMR]'*MFPZ(3H
MT1`!\BNQ@#D&P*:$``>J`9+99!CC-WWWDO?SB/(WV%LLW3P0"V7TG6GH@NC1
M\RRQOP;_`'W&Q^O=Y_S!^ZSV%/\`2>!^[Z3[2>B"Z-'S++&_!O\`?</U[O/^
M8/W6>PGZ3P/W?2?:3T071H^998WX-_ON'Z]WG_,'[K/83])X'[OI/M)Z(+HT
M?,LL;\&_WW#]>[S_`)@_=9["?I/`_=])]I/1!=&CYEEC?@W^^X?KW>?\P?NL
M]A/TG@?N^D^TGH@NC1\RRQOP;_?</U[O/^8/W6>PGZ3P/W?2?:3T071H^998
MWX-_ON'Z]WG_`#!^ZSV$_2>!^[Z3[2>B"Z-'S++&_!O]]P_7N\_Y@_=9["?I
M/`_=])]I/1!=&CYEEC?@W^^X?KW>?\P?NL]A/TG@?N^D^TGH@NC1\RRQOP;_
M`'W#]>[S_F#]UGL)^D\#]WTGVE)>B#Z-#>+GHLL;D`@.VFLPV#GP"J`#B3=_
M=Z+PA4$&/99["B[=/`BT@R[.<^TM8-)W1=]'Q75!5O(U3I)L[//HV^EZ*?:N
M)&FTSK-8F*K-TTCV":A%2_VJS;(D*F7;NA]G%E=OSO&YP/>G(.)N7C/J\:U)
M6Z."%OJ",3GU\2V?'H@^C1\RVQOP:_?<4MWZWF:R(GD?NL]A;@W3P/W?2?:4
M>B"Z-'S++&_!O]]P_7N\_P"8/W6>PL_I/`_=])]I8OO9T3G1V05GKK25+Z,[
M.H53'6TKN3IM2(I,[B5).,J9D58I2-(F<RHORR`)\B!0$PJ99;<=#"M^=Y'U
M\ITZ>33B8V]8P1;&T>J,HCS+5K=S<)FTLSN60F!IA:?:7Y?=#OYOUJQU)-(*
ML;^.5-,-LGR"#DC2;CPD+ORS%0"GWV%*++&8P9%FQR\DI)*!N[3`B;J_;,<^
M;N!4^#BGPAA.*EH$1$0,+28MAES1/(OEN';C3JC$836PD7CEX[>*WIR+]<VC
MOHQ](.B5DU5L[;)@ZK8C0&TC=>L@1J6Y$N;,IEA/.NT2)PZ*R@9\W8(MD,OU
MN/SSBV^&\N-,/Q*8]SXD0B`"(V1@T`V<1R+ZS0;H8?ADT.DM$!SQY>.Q?0I(
MIBI%`3B.0#M'>$=HB(`(G.<P[H#EPCCRTJ15/F7YSH#R+T;Q=9=:%V@X`^L&
M-_)8HC):IP64P14'];]D/T<8<8"*A,]5<9]@9]?/LE$,5SW@-;SJSZGD6G5#
M"'EQ7_\`YD;(?X:KOU<>@KB#N_2#^]G>=JTY/^J?^RWS+<K'G%N*0Q:SU5A3
MB:)@B8(F")@B8(F")@B8(F"+3]#^OE(CU/)3B0^S\J\P.-\_Z`?M%<MO_DG<
MP\RP5,:A+0V2UQ7Q3N95Y*;6J&Q=ACQ20Q,W)G72CYNZ9W:J@Q,<^(W!/G!0
M`%!*8VW(!Q<VEG5&%L=*$1>=Y+#K69M2RDJ.XF1+R!DY_(LQ#K^TG!D'RLI]
M7@I2L]G%G_B]CG4M#/8P@B-JV9E8R48$.B>3TJ#Z^]):Q3)J75153.!B*)*4
ME61B*)G*)#D.4:>,!B&*8<PZO!C+J*LOWF"`5>VT[A![70\FM>.76WHT!)-(
MM?P92I1X1*?^(=5[A(HHANQA$@IL"$C1`,A;_M0Y9B`XLF2:^Z`(BV/'IYUF
M7.HXF#'="\9YJYT+2#UE(/:DHUV]BVJ<?&/W5LYMU(,(U!<CQ%@R=N:/579,
M4W9`,1%(Q2)&(4Q,A`,&LKVY(]/#G6'.I7#U#H"[<AK+T12;,8^4K&FI-F:2
M+,F;/;<U$[;FE2*`JC*G1<4JJF,JW4(4Q7.0+[Q0$#@/!4^5B#G@AP%G'%5F
M?12A<<QQCR!6-5VI/0E750T74%35Y&2`42]JB59PB]"U*[@)24JV&5@Y)S-1
MCVE7#>0%-LL<Z8J%,/+'WQS,4!QLRI=>!#D&2/0L;701_EN/D&M7^36IHN10
M*BTKN`;I)Q(0;=%.W]4%12APWA"&Y).FDR>TP;PAS4`*CD(]SBC9\3[YV3NX
MQ&6/^U2?44I8'-8X#F&M=.G]96B&DV2T92=64Q2L<LLJNX9T];6H8AL[74)N
M@Y6;1]+-6RBQ<Q#[H13,.'"?35LTQ<1'EBHRL2I)8+0Q^@:UYJ&J_0@WAW%/
M%J"BB4Z]<+.G]/(6IF4H)\NHY*X(Y=19Z45:+.TCD`_*&*)Q4#,!``*`3;)Q
M!_6:8N\JP*RDAZCH<PUKU2:S-$Q6B\=[]*;/'O(\(IY'#;NI21[F+3Y7DHE9
ME[USIK1:8*F`C<^\BEF(E+F.`EU['BW^(,EIC%3;54CLK'0YAK7%%:P]$=/-
M8QE3E74E!,HD72C)E#VVJ6);-%GQ.3?*QR<=3*"<>L^(.2IR%$QP#NL\0FR,
M4FO+G'+EM,5+:*'B8=`5*.L'1$A..ZH1JVD4:GD&W,9"HT[:5"2=D6(]R=H_
MEDJ53?NVYT0`@)G4,GW/=`?@";J:N+`&@W@>6";111C<.@*N/U@:'8=N#2$J
M^F81J5^>4!O$VWGV#<9)1/D5I,6[6DDD"R2J0B7G!2E7*41*!]T<L4F571@2
M(^58[ZB`]0Z`NY3VM'132I'B=-UG3=.I/W7.GJ=/V]J:'(]7$!Y1P[*RI9(%
ME!,<QB[V\(9Y9CBW9JL_S1$\2DVJIV6,:X`\@5Q$U^:3BER^5A,HYCGE2E:B
M`Y#D4=M/YYB0`SZ^&S3LREMLK,[0-:L&[NNW2S+6ENG%L;H%</']M:[;-R>]
M6LB%,JK2TNF0#*'@"D)M'JB&)2:.<Z<`!E(49M=*$N)#LAXO2K:TYZZ-+D'8
M*RT+)713;2$7:^AF#U#WK5@IR3II3S!!=/E$H$Z9]Q0@AF41`<MF+*JDGM>X
M0XS;Q*NEK)9A8Z,,D/2LS^7[I/\`G:3^"=9_%_%.R5'9*V=J9F=T:T\OW2?\
M[2?P3K/XOXP:2H(@&F*;4S,[HUJ/+\TG_.R3X*5G\7L5;#5]GSIM;,SM`UIY
M?FD_J793^S2E9_%[&6T-3'K-LY%AU4TCJAT>;TIY?NE#YV4O@G6GQ>Q/8)O9
M<J]I/+H]*>7[I0^=A/[%)UI\7L8V"=V7+(K6,]<'AY4\OW2?\[!/@E6GQ?QG
M8)W9*S\1DYCT:T\OW2A\["?P3K3XO8J=AU03$`P43B$J/'T:U'E^Z4/G73^"
M=:?%[$?AE3F3;Y7+P\J>7[I/^=DGP3K3XOXF:*H8.L+%(5TF&1W1K3R_=)_S
MLD^"=:?%_&64=0ZUHB`L[=*-D':!K57E^Z3_`)VD_@G6?Q?Q;LE1V2I;4S,[
MHUH.OW2?\[2?P3K/XOXBZDJ"/5*;4S,[HUJGR_=)H>NNRF(?\U*TX?@_BL45
M0>)#5RQ]5V@:UJKK1ULZ8ZLT_P!00T%<Q-X_4JRU[D">]FK42$097,I)VX4.
MHO!ID#)%$<@`<Q'(,L=3"\/JWS77+K8--KH@<W.N9B-73EK`]K_6S#6MJC:^
M])^8E&Z8);HB40/259@.\`B!@_XO#M*8,AZF.7-HZ[O8=6[');Q+;%13&7%@
M<+,L!K5!=?FE$`_E83X1_P#PI6GQ>#$GT563%K1"'*I4U3*$N#PXF)M57E^:
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M2E$=@".6.O,H*H8;)<0+7.LMB.4\AXEHBOI'5+Y=U]\0C8.3)]*VE'7]I.`1
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M&Z%)UH(CF(``!_B]U1Q)E#6%X`;$QY5!];3M:7%KX`9@M5=(&MG3+3%O*]:S
M5RB,UW]_+VRK<GO8JY8.9O:V>*H'.9""4(4VZ(9ESS`1QT,0P^JDS`TW3U`8
MB.CG6O3U=--9%K7W8\8$>%BVJ\O[2@.SY6$O@I6?6_\`A_&F:2H?+@T=;H6U
MME/&[=?'R*?+\TH?.PG\%*T^+^*MAK,PZ5G:Z?LOZ%UW&O;2BKR>5V$0,01$
M#^]2M@.0=F0IY4^)`,(9AW0"&0XR*6N8;H#;IRQ!CY%1.J[0)40P^M'Z/2JT
M]>^DM(QQ+=-$I3&,<<J3K41WC[3!F-/CO;QLQQ4<(>UW?`.$SEA#S15NU4LM
MMX-=?\BY2Z^M)8<-U$BCF.P*3K3+^#W5QM,DUCFQ<`3R1@LMQ)KVQ@[1Z54.
MOS2=U+KI`'%[U*S^+N*)M+B9_E-;'EC]"P:MCC%P=H]*GR_-)_SLI_!.L_B_
MBYM)571?;UH6PR13:I>9V@:T\OW2?\[2?P3K/XOXSLE1V2FU,S.Z-:>7[I/^
M=I/X)UG\7\-DJ.R4VIF9W1K4&U^:3Q#+Y64QX/\`\)UI\7AQ";1U)9`-@>50
MF54N[D<.'.H'7YI.,)2?*PD8QQ$I0]Z=:<.X([1][V1<@*/#BJIH*EUP0AS\
M:LVN7W>1T(<FM:KT;K<TQ-M8-[:H7N61.%F+.6?81[HU,5?O+N8V8K47:8(!
M!"N4$P<ICO&*!3`.P=@X])7X?/E8!1N>`"Z;.LX[+IB>0\2Y\JOD;3,/6A=;
MQ9K,ZVG#7]I.'@NR0`X@I.M/B_CSNQSSD"V_B$G,[HUJL-?ND_YV2?!.M/B_
MBUM'4`0NE2%9*<(@.AY-:>7[I/\`G:3^"=9_%_&=DJ.R5+:F9G=&M/+]TG_.
MTG\$ZS^+^&R5'9*;4S,[HUIY?ND_YVD_@G6?Q?PV2H[)3:F9G=&M/+]TG_.T
MG\$ZS^+^&R5'9*;4S,[HUIY?ND_YVD_@G6?Q?PV2H[)3:F9G=&M/+]TG_.TG
M\$ZS^+^&R5'9*;4S,[HUIY?ND_YVD_@G6?Q?PV2H[)3:F9G=&M/+]TG_`#M)
M_!.L_B_ALE1V2FU,S.Z-:>7[I/\`G:3^"=9_%_#9*CLE-J9F=T:U`Z_M)P<-
MVD_@G6?Q?QG9*CLE8-7+'U7:/2L!0FK&P4WJOKFY\97R;BBJ-TP4PQJ.9]HJ
MC2&/<RUY7,7'@#!:))(NB+OY-%/>22.4HGS,(%`1#==3S11-81UKQLZ?H6@R
M:W;73;;MG/S+/]"!EK>U$Y9@!+(V`5$O*&$BACS%TDTS"4XB5,Z?-\NYR`V]
MMVAGBN;,N86QHXGN\Q5UT3<3)=V1YPLYW%O3;BT;&+D+E57%THVFGB[")&07
MWW,@\0;G=G;,HYISF3>*%;)G4,*2)R))D$3B79GRJ;O9TMSX1`UP74J>Y9,$
MHGK%7?3U6PU61$54-+O&U00$XR3D(F;B5^>1DBS73*JW<,WB1#-E4EB;V1A,
M4H"`%SWAR"PEXRA5!C>(E>^#K,"F23,J00*8R@#W!2"!3&$!*4YC&*!O6Y`(
MCQ<.(F^;`(%2``MBNI+3D?"1K^9DUP;1<6P?23YV8ISE0:QK=5V\4Y-(BBJ@
MI-D3GR*`F,!<@`1V879L80M68M5K$N71RL6O,DF6AV+6E&];N!3.=1ZA2CI)
MPNA.+11$_;1)@NDU4%,YD0$W)F#(!#(9B5//);#RJ!,HGK&U7)$S3.;BX^9C
MCBO'2S%G)1RY`.;G#%^F19HL!-T%"<HB<#F`0S(`AGMSRP>\;81$A8C(SGI7
M?%X!3"GN&'NLB'R'=.`%`5!WA`"E,F.?<B.\(%$0`<L5S3,:V\T*<M\IYNM.
M1696=Q*8M_#(U!6#X(6&=3]/4RWD%TW)T3S-63L?35.-!!%!02#)SDJW;E-Z
MTIE`$1W0,)=BBDU%48-`+LL+,F=:]8Z33MO.C`E7J"^9A)N#F4`WMN6Z(AF`
M&#A)O?K<\A-U,:P=.!ZPB%M.9+`C%8TKF\5$VYEZ-@JG<OT9JX$PX@J/B(N*
ME)^6FW[-L#V07;Q<&TD'R</%,S`J[>J$(W:IB`JF)F&>TV5,>PO`L:(E:W>R
M6S&M)M)L61TGPG`PG1.02K*)=SFJ!MU3DRB0R8"`F,/KBCD)!`0'@Q3ULRVB
M69U6#LP#D=(2YCNE`N9Q,)3@13@*`=R8P9!F(F#,0#8.'6S(3+%D;5T',_'M
M9!O%+.6Q)-XU>OF<>9R@1Z\9QAVI))PT:G4!=PDP,]1Y4Q2B4G*%S':&>;C\
MO$D9>=="EJQA*TA&M1TR[+*0SX78,WR2;A(BPL7J\>Y**3A!%RF*;QLH0<R;
M=W>#,H@(Q(?Q!(R\Z]TKT#&,&X8H%(4X"<-P3%$"CO`4V0`4H&`!S$!`=@AA
M=F)%F=8UO2H)K,W=7`_K+85\)=PV^0#)TK+B8.(3%.40SQF3-<V<!Q@A5SF,
M=+C&(@5;FEL3>3;883',J?Y(;?9G,([QA][$;M',1Q.I>0]SG92573,:&`#(
M!K6>-X>MB,%LP";P];&8)`)O#UL()`)O#UL()`)O#UL()`)GGPAA!8+`5&SB
M[>%JCW;5&9?J'"U.[:F\7K=G"U.[:O*&<8@LHW*[8<NF)P%(TBS*H`$$"FWD
MQ5Y4AB&,&\`E#(!X1'9B-UYR`K,98L)7?YT7E01WT16R*8R0*@*I4S&,4JG)
MY;XD,)=@Y``CF&>S"#AE68R^(VKL;P];$H+,`F\/6^K[.(N@T12`4CF/`.7V
M/U<0[P9EB`6FVO-15+394QTCF(J%7VI(0Y3J)B3EKI4>D)LTSD-L*?@SR'&_
MAT]S)]YEA@?,N?B$ICVLO9+RW'*&Z&68B'4ZP9`&77X,:#YI#X06XU@#(#)!
M`'+9UQQ;EM6931=/.5.\/6P@K(!-X>MA!(!-X>MA!(!-X>MA!(!-X>MA!(!-
MX>MA!(!-X>MA!(!-X>MA!(!-X>MA!(!0(FX\OL?JX02Z.5:;T=O#K@ON3>-N
MFL39HP@)E!((C/5R0`Y,3BF7(<QS*`".>T<;\R8X8?+;Q->XCI7-9+8:^:[C
M(:/)`+<8!./5[7ZN.6U]YT(6+J$#(J]X>MBV"C`)O#UL()`)O#UL()`)O#UL
M()`)O#UL()`)O#UL()`)O#UL()`)O#UL()`)O#UL()`*K,?J#]7%5\9EA4"!
MO9=K]7&1,B8047`73E6F&B%5<UM;BB=8RG)ZBK\)_=#'4-NEKMZ"92F4.8Q"
MD`1V!LQNXA.<YX<[*&-&A44,M@E`#.MS@,/#EMX,:<MU\+8+&A]A,55O#UL3
M@I0"ZSIV5HD9=42$13*8ZRJBB:22"90WCK+**G*!$B`&T=N6%TFQOK<2PXL8
MTN<8`*A)Z5<AU$\C$`!,0^\3<53R`Q%$S`80,51,0,4>`0ZN-:4RK;-(G_R_
M(H2ITF:8-*YFZIE4BG$,M[/8.6>6>S:41*.SJ@(AC:<&D]7(KYC&M=`9(+FW
MAZV,04(!-X>MA!(!-X>MA!(!-X>MA!(!,\\0>;C;RP6@A<2N]ED`Y;=FT<A[
MD=AMT0$0$.N&(S'E@:6Y24+6ED#D6GM#&.&M^_B8J&.4MD+);I1`"@7>G*^'
M8!1`!]=PY9X[V(U#AN]1M`L$V<>EBTI,IFTO/'=;PZ%N.`;/J_5QP)<TNRA;
M?=MXDSRX,704@T`03>'K8068!-X>MA!(!-X>MA!(!-X>MA!(!-X>MA!(!-X>
MMA!(!-X>MA!(!-X>MA!(!-X>MA!(!0(F'@'+[&$$NCE6GR!3>7G(CO?]E6*4
M`<SAPW3E4]T2@;DS;2YYB&89XZ1/_M@']XN2T?\`N;N8>9=.A@$VMW4:!<LS
M6-T]`&8;P;9R[@9"`\(#GB#VAV'L!XWGS%9$63S.;ZT!]"Q7>N29VNU;VSOI
M7L#44Q:1*Q-86SBZHA:2GZ_]X5Q9&KVLZJJXA:9B9BHF85G3Z!&A'K9LH!E&
M((G$@&`1A13HT+Z1H`!>"2"8V<7*%IU7>OJV5@C>8TB[]4QLY_2L-WXJ*5J6
MJ*XEWC74-3D!+V"BG>E2+H:&KJF13NX1]/)OFDS"4VS($96X3"D<";>H"I,@
MBULQ`N2AB;LD!P`ZI<7=:/9Y/1QK9OS"PNA]7IX_)&,%C:EZMKJH-15.+7;K
MFJ*9=4?>2W\).5*UJ&XZ-"350$M'$MY2Q\7&0;,+8N$9ZOWZCO??+)NT%TS(
MJDWQ2`=WNJ)M(^:"._`L&<DP!RQ@&K1E553.FN8]D);86VVQRC(KL84U>2F(
MZT]71K^]DC5=?0>L.'N4,Q(U5-M6L<PIZN).SY0A%B)QL`,?),V2$*Y(U04<
M%-D4#\H40S7-H9,ZHE27@LE5$AK39%PF0,QQ@>(V9LZV@9ET'ZQCHA8NS3])
M3L-?2L:^F8ZYS&X5<]'G;R/I>;.2KG#28N/3,3</WR1+HY`&"1JZ*+)L'"39
MV1)4SA7>1WE=\`HFU%')C3`M@VI-MD;D8Q%N4K6F![W%SB8W.E74<M^_E(MS
M:EN]N<2E-1%,V6KZ0K=-.602MDO:J%;EO/2+^:53!W2DG7[:*B3-T%R"=9])
M/_8FRKF5&'/CUK&E\!9;$]7CR0Z0JQ+FQ`O&)APX<2\S2HUO+,WCBI.X]PIV
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M%;%.4.4,3&GW=&0UX)+WD66`"SK<W)G*V)LRKFQ!@`T91Q\5EENI=:W5'2UR
M;MZ/*MF:$KNGFELYK4C3*E4,ZDNFYHR?8HTE''IJN$7=728U3%T_4\L!N:MY
MA4SA8R2B8[R(I@;;$^3)I9\B4&N#[A`(MA&T9<O+S+2ETLTSV3)A?83'GA9Q
M9!8K3@*_OO*TO8JB&P7V&NZ!T_ZEX2\;U>FJQ8,'5T8FCCMJ,4=RKF.:L*CF
M5I9`7D,J@H<%-@[QC'$!UG,E%Q<Z%PN;"WBLBMX-FCG@5<->4[=^W`U-3E)2
M>H67HJI;'Z;*ZN-,(R55U35Z$RM=1U#WH>TG*2"3Q]`U:ZH'[JZ8Q9$3\D45
M$$4U"9C2.Y>TM@!"8X69"(&$;>99<R:#U2?5'T1XLZR%[SK:O-3.E"Z-)L;R
MOK?DHS431U*U-,+W>=(-JKDYRWTU3T9))3A%95E3LBTC)06;B93!LX3;`0PJ
M%(GNVRZEK:4R2R7>!!\T8VY;(IW<R]83=M5AK/*G"$MRC?ES?YK2#JR%PO>V
MK;@*[;OG-\%;DU8FS0GE*%*I4;:>&CRQ1J>!^0D.;-3>`1[D(P86O+0TN[P9
M<D(<7-QJ#N]!:.*Z>>,3EX9N5="K*5U*.[2W!K^J9>\Q[WVRL9IGE*/BZ:EJ
MG9P"ESFCE-W7#UO3\(D5E5U0O6Z1$)Q%4KYOW:A>2(.1@BZ9(9=#0'-#G6G+
M`CTP'(K&2Y\P$NB#`9!QV<.=?5:[!UE+`W/5<*"JX/:"MCKG%$6XF6/1DJ94
M3-Q`!;FY01S)D&X.SJ8XP@:@D<9'T+K"66TX!-L#T@KR=+8?T;K##_DBM[VZ
M8C<2J+7.'%$K%,R`%IR:UGO=ZXX@#8K[G*5`AD`CF.P,8<Z`B@EVY2J%!$A#
M'VCNY"(=SZW,-[:82@`[N?".,-?>XD[OE*U&OGJ#N?:>OK9493MG8:M6MW:J
M7H>D9MW<IM2X-ZF:4K4%6KDFF"]-R*J$8,?3RI"JHG5.*QR%W!SS#?I)$J<7
M&:7!C6%U@B;%2]Q81F.=>PVU24/-+L8BE9ZC)VI6=>TW;^N(LM2/&L=2T_,+
M2#&3@&U0'@S,)JJHJ3C54TV!`35<`01'D@R'&7TA:"Z#PV!A$6F!U*HSQD!$
M50_UFZ;HV0?Q+R[-+EDXU27168(^W+EPN[@7QHZ=B&`,XER24J&`<D$'T<T%
MR]:@`F42*3NL4;-5/CW#"X#+E^@*;:J6SUG"U7'(ZH;$Q432DX_N33J<77$2
M6H*7>(+/'Z3ZF^50;JU,Z-&M7Q8JFV[ERFFJ_="@U14.!%#D.`E!L>(Q+1*M
M'([+",,BEMLK+>$%Y-=:J[-T-'W&>N:H3FG5K*7F*IJR)I]I*2;I!M"PK>=<
MQK=^@Q&&/.&CG:2@,A<<XW%2G,4I<QQ)E-4%O680[F*&L`]4B"Z#36!8LU`4
M)<F4J\:>IRX5-L*J@U9B'J%([6*>-6:BJ\\9O%.$X-LQ>O2-E7+C<;`IM`XE
M$#8D::;:+IB.18VW.1`K3S47I,K.X]P;_3M%TBT39W*HW3E#TS.P\P%/2!G=
M/WBB)NZSUDZ8JLU6#PU!BJJLX,8!DRE*@(GVEQN4U6RG+">)QO`YH$`9["N>
M^GG/<YS>/)YUF*PEJ;V0NH^HKK7.*86D]9*&MZ=1M42[Z&)*49<)\WAE&D*/
MW!%]-TLW+*N'(%`P*OA;&$3)8C5SY$R6&RA`@N)\L?\`8I29,X/B_)9YPOH7
MN]<<<J*ZMSE*;O7'`P.4)<Y2HW>#:.T?TA'&(-S!+ASE:'=)-5D'0>D.YE:5
M.[%C35'2%O:IGWQ45G2K6(@KBTK)/UDFC8BB[DQ&[8P[I0SQU\#I=KQ!M.V(
M+P19G@817.Q&;0TLGO:^:Z7+!B(`6D<5I"TW'\X3Z,`IA*-XZJR#9O?)C66Z
M;CY,P1^Z<`'9F&S'IY_RSWP#6OD4X?$Y1?(ASAB\M^O=W63NX=.(&3ZOMJL/
MSA'HOLOY9JJX_P"3"LO[@QM'Y6;Y"%^F@Z'V_86P[?;=R6;O?\N5GM*?I"71
M??/-57BPK+^X,8\+M[_R_P#O^PH_KK=SWY_L>VH^D)]%[\\U5>+"LO!^*3\L
M=\`8;/T/]A/UUNY[_P#W?;3Z0IT7OSS55XL*R\'X>&6^'Y?H?["?KK=SW_\`
MN^VI^D)=%]\\U5>+"LO[@Q=X7;W_`)?_`'_83]=;N>_/]CVT^D)=%]\\U5>+
M"LO[@P\+M[_R_P#O^PGZZW<]^?['MJ!_.$^B]#:-YJJ\6%9?W!C'A=O?^7_W
M_83]=;N>_P#]WVE`?G"G1>?/-57BPK+P?B+_`)8;X-'^GZ'^PGZZW<]__N^T
MI^D*=%Y\\U5>+"LO!^(>&6^'Y?H?["?KK=SW_P#N^VI#\X2Z+X=H7FJG[-L*
MS\'X>&6^'Y?H?["?KO=SWY_L>VI^D(=%_P#/-5/BPK/^X,/#+?#\OT/]A/UW
MNW[\_P!CVEKE3G3D]'1%ZG[J74>7;J$M&U3:RVE*PK\EN:O.JO-T[-U,M+LU
M&Y6`JIG1++H"`B&61AVXWW_+'?'8Y;33=6T_7XX_87-_7>[K*R9,$XF\!V>*
M'VN1;%_2%.C`#8:\55%,&P2C;&LLP$-@@.3`=H"&W'/E?+#>Y[B!3V\S_871
M&_\`N^\1[W_=]M/I"?1>CL^6:JO%A67@_&?#+?#\OT/]A9_76[GO_P#=]M5?
M2$.B_P#GFJGQ85G_`'!AX9;X?E^A_L)^N]V_?G^Q[2@?SA'HO@VC>:J<OYL*
MS\'X>&6^'Y?H?["?KO=SWY_L>VH^D*=%Y\\U5>+"LO!^'AEOA^7Z'^PGZZW<
M]_\`[OMI](4Z+SYYJJ\6%9>#\/#+?#\OT/\`83]=;N>__P!WVT#\X3Z+T>"\
MU5>+"LO!^)L^6&^#A_I^A_L)^NMW/?\`^[[:GZ0ET7WSS55XL*R_N#$_"[>_
M\O\`[_L)^NMW/?G^Q[:CZ0GT7H?],U5>+"LO!^*G?+'?`&&S]#_83]=;N>__
M`-WVT^D*=%Y\\U5>+"LO!^,>&6^'Y?H?["?KK=SW_P#N^VH^D)]%Y\\U5>+"
MLO!^(^&&]_Y8:'^PGZZW<_,?[OMJKZ0AT7OZZ\]4`'5$;85F``'5$1]K]@!B
M3/E?O>7`"F$2<S_86';][MPMGF'[GMK7+3%TX_1SVOHFL8:K[MU&PDYR\5U:
MS9-26YJQ<YH&JJH7EH9X;DV1@`'#%<AA#/>`1'9LQMU'RPWPFN!-,!U0/K\7
M[BA3;\[MRFW1/S]CCA]I;&#^<(=%Z7;\LU5?8MA67@_&F/EEO>+!3]#_`&%<
M_??=P&^9]O[GM)](4Z+SYYJJ\6%9>#\9\,M\/R_0_P!A1_76[GO_`/=]M8DO
MWT\G1LU_9"\%&4Q>&JU:DJJV5;4Y3Y!MM6[0JLW-T](1\4B#]..*5FJ9\L02
MG$Z>Z(9@.S&]A7RWWGEXM3MK9%VD,P%SH/L`-L(MADSK3K]]<!FTKVR)Y,\M
M-T=6T\O6)T+\S^B/IL-:&CIM#TS.58-_+4QB;9F\H.ZTP[?3,$V*B5,J%-7`
M,HI-0BIR&R02=`Z3$>Y,!0VX^R[U_*;=.HH6C":JH.+N`O`-9:80@8$F`/)Q
M!?.*+Y@XWA]=&IIY&P1]:\^($8QR0!/':OU]:*>F;T;ZQB1=+PU6!:.[CTY&
MY[3W7=,:>F'L@H0#G0I"8.L$%5I"B8`*FV5(Y,`Y@B.0X_/V+?+3>C=62)57
M(F/#KS@X->0!EZ\&"[&-F>U?7,'WWW=QM@<)X9/-A;%F7(81=%?6U!515$BI
M@(43E`Q=T^\0<^`0.`99"&WK8\-*F3;Y94M:WF.M>K>P.9>IG7LT?0NT!1R#
M,=N09Y<&?6Q?$<618#'0%XF\IW>N.$4N<I3=ZXX12YRE4G#(,\QX0_1Q%YL\
MJPYL!&)5!^#[/_@FQ54&QO.K(=2$>):=T*'].&_H?Y$;(_X;KS'H:T!^`T@/
M%-G>=JU)$6U,P?9;YEN5D&.&T71`+=B5&[UQ#$HJ#FWC&*;O7'"*C<Y2F[UQ
MPBESE*;O7'"*7.4IN]<<(I<Y2F[UQPBESE*;O7'"*7.4IN]<<(I<Y2F[UQPB
MESE*;O7'"*7.4IN]<<(I<Y2M0$0_IY2(9_\`92B=O^=B8QT"[_V\-XK\5SFC
M_P!P<WD'F70M^4%-;VHP#;0&QNGD/K_W]NV/U\9F&%`S]L^8J<G^(3'+='T+
M;U1HD`B;>4,<QA$`,<13*41)OD`@;H`4^[GF.8D$1$N6..U[V4[G,S_2N@*=
MAM(6E*6J`M-D4BE("K[KU5/7<NG;VDXBEZ:C:?=(K6T0:2#QF[/(2QXQI'1T
M4N<?;-54G.!*`<F4YP#'3IY#YLLN+K@:T$Y?K?[%JSITN5`0C$PT?[0K1)(Z
M4W-LF6M<+9RSQE)2L550Q\>QG',NI7KFI"6[%\ZMTWE"4O)5^PJ+)F>2,T5<
MB=$5BK9%*?&62Y]1/V5OKF(^G18J6F2S^)"(*N-#6W3C>><0=56ENA11XJYE
M+6MKV6F8Z+7A:.J:N46*]"JOW;>2.64B*C2DFZ9G#4#\R4.4JH`.6(2,-JY[
M9;PPD393YG%_RC"'.($J[OV<8A`P,>)7`MJXH&<I"D)J&;5`W6N;7%W;4TH#
MJ*14!I6]JF5:GF'TFGOJ)A%$=T(ZYNIGN+)B0PAW6)-P[OB0\P<&-<>8PUQ5
M$V;+(#B.J8PYPL/6RU87$J.KJ#MA/T4[DFD_I)CKZR]TXX8\B3:?4EY6-?BO
M3H.D>5B/[41(B5,0.LZ,8F12!OXM?A4EC7.,P1:\MA;:<W.<JK$UI@`WBCZ?
MH\BO4-9\13M)03U>BKCW-=Q]G:3O+6]14M3;"'81E'2ZTDS>SKUB]F!3(^9F
MCU5CQ2*SA4J)!,7UH!B+Z-TN:9#3$-==$>,\G*5N-GRS)$>(17F):OXRDW=U
MYNJWBE2PKRZM&T-9F.C31$&642JNV[:N&C0\M-N8Z)8(F1(X<&=OE";HY$`3
M;"XRRDFW02;K0"23Q0LXK5K/GRHD9270`Y%?-"7OL<TLW=G4[2$.\:P*S^I)
MZ[!HY`)>I'=:40BE2\\Q=<S?.F3J0ABQJ30BC5;F)FY.5*(%WAQI]W.)#0;>
M(=.=;%Z7:3%5*:K$>96^9Q%IZVJBN+B0DU5$91-*2].3ZS.A:==MFKZL7-1M
M93WLN(@7CQ!)J1%=1RNHH">Z`B;$VRIH=$D!L8'GS)>EYCDCY%:9-7+6@??N
M6X0J2\U)7_GK86HII!Q!T\X79QE`TS6KEC+3<Z^8P<>,.U=NE'+ERL!A5`$2
M`8<@QLOIIA=`0NAL2>+AE4!42LUL5[U(ZVK<UZ]H5G15,5=.-JNHZ9K^6F&R
M#)I!4#2%+U`\I6J9*L)DSWFQ%X6::'1(BW,L9Z4!4:F.0#F+!U.]K2286]/)
MSK(J)1-@7E$UU4%'0SFI:KH2Y5(TS+6[JFZ-O)N<A6@DN925&-FCF="GXI%Z
M9S$2Z$?)(O$&<@*"BS`XK[^XF<`B*=^0&T&',FT2LV57"XU)LT%J,JR82EJ9
MIV5M?=ZX\A1R+&$KAS/0MN$Z6D',_"593<VY:YLVLMFU1;%52>G7V*)<D.;N
MW!I#3$Q]$%CO);G`D6+/-F;EH7>M_#UVVIM:G8NHRG<Q3)U*04VF]C5@(X;2
M2<A3[I[&*%=HJ;QTM\3I+`<ANZ*.-68)@6XPL(B%VKVB`V3N^(#O`-K*_$#<
M&8#2,N(#]D,5R(]Y;EB/.I387+,Q\RMO2W_5ML-_-%;W^#,;BZH]=W.533^J
M.;6L]XJ&17J#<`_6'&'^J>99&54'`13.``!AW1R*(`(#UA`<\\\1EY$*URO-
M:>H+@U[IUJJ(>L&[2S]UY6OYML[%<%Y2-=6[J^E$&#$Z1@W7AG]0)*=W]R$B
M9LPSRQO2IPE,?'Z[+NM:DUCGEH;E!CH6*8_394<;0='4VE)4\VD*<U.2E\)"
M0;,W"3=W"N*WJFH?:\YBD!=Q-G9SY$S+*"IM*;(V60!MS:YLV89GU;D(<,BU
M!1S+MTY8QRKCH;3145+R=B'TDO3+OY*;F7]K62%-JL=9X%W7%6^U/M9DENI2
M#%K42?+F'=3-D8<L\LH;8&,F,;&[,:!Y`8^CFB%4^CJ(LN9&DG3`?0M4H?H_
M*_IB.H<C@M&7&:&M3,68KJFW];7%MW#E@'-PZHK-A)L'=&NVCFH&BK.I%&CR
M-<EW3\@F9,P[<MSXV\6AHO7@8P!A``6<L`M3X95'/D/'Y<ZS+4>DZO7U>U\2
MCI&!M5;FO;4UG0M21<'.5+4[:XDI-4/&4E1DO.4?-G-#4_,T29D0#2;!4J\D
MW*5%??WA$M0Q!C[KYL"YK@18(@#*,F3,,ZW)5%.:RZZ,>.W0K=K[3+J;K:U%
M&6]5G:$CF;#3^K9J?IAC4E41E)QM3(,BPC"Y9%8V.:257(N8%HBB,,Y.FU2-
MO&$#&R,&9-=3RG$PC%]ZUHR&-@Y0>-6OI)CX')U8:%]-*:BCQ-.4_%.!*9Q&
MP<1'.#E$PE.JP8MVZA@%7>4,45$ARWLQRZ^.+.+GS7.;&Z7$Z2NDP!K`#"(`
M7L)M4$C`8B8%,&?=`(Y]T;>.&P<@`Y^Z$.`3#GPCBL!\;8J41R+LXL1,$3BZ
MW_Z,$7SOZ4^@BW.T07JM\,D>%"NVU(42>:3:)O58A&J:[I>'6D2-E3$(MS1-
MT)]S,-X0#;CM8!5;'B<N?Q-,=`*Y&,81*QB0)$XW6"/3#4OA"'YK)!B'=:U*
MC$V>\.5I(<H9FV%W4_?3]S)NE#+@SX<?8ZGY^S*.G932:8,>T`"-TQAS$+YY
M4_*BBG3.\9-@[RZE/T6.#'_MK5('6^22(^-.(.^?.*/@Z;)`=#,,GWE4[Y34
MY/\`-XN74GT6*$\]:I/%)$?&G$?'?$/<C0/:4?"6F][Y]2GZ+!!^>G4?BDA_
MC3BD_/C$8_R1H'M)X34_OO/J3Z+!!^>G4?BDA_C3@/GQB/N1H'M)X34_OO/J
M4?18H3SUJD\4D1\:<7>.^(>Y&@>TGA+3>]\^I/HL4)YZU2>*2(^-.'COB'N1
MH'M)X2TWO?/J3Z+%">>M4GBCA_C3AX[XC[D:![2>$M-[WSZD^BPP?GJ5&/\`
MFDAP_P#FG$7_`#XQ&'\D:![2>$U/[[SZE/T6"#\].H_%)#_&G%?CQB/N1H'M
M)X34_OO/J4?18(3SU*D#ZUI8?XTXQX[XC[D:![2>$U-[[SZD^BP0GGJU+XI8
M?XT8>.^(>Y&@>TGA-3>^'3J6&H7\VZAY.^5>V='5O/IDHFA:-K0)Y.V$6HX?
M%K)]/L3QBC`M1`FU!%*&$X+`<PG,)>#+'0F?/C$-D8#)%@S#E^TJO">D$PDS
M+?+J692_FK\(4I2CK4J0-T`*.5I(@-H=8:J$>R(XTI'SXQ$.)$D1YA[2W6?*
MJC`AWEGEU*?HL$'YZ=1^*6'^-.(^/&(^Y&@>TM?PFI_?>?4H^BP0GGJU+XI8
M?XT8QX[XA[D:![2>$U-[X=.I/HL$)YZE2#_FEA_C3AX[XC[D:![2>$U-[[SZ
ME/T6"#\].H_%)#_&G&?'C$?<C0/:3PFI_?>?4GT6"#\].H_%)#_&G#QXQ'W(
MT#VD\)J?WWGU*/HL,('_`&U:D#_-)#_&G$V?/?$8?R1H'M)X34Q_YWGU)]%B
MA//6J3Q21'QIQ/QWQ#W(T#VD\):;WOGU)]%A@Q_[:E1CU_DDA_C3BIWSXQ&/
M\D:![2>$U/[[SZE/T6"#\].H_%)#_&G&/'C$?<C0/:3PFI_?>?4GT6"#\].H
M_%)#_&G#QXQ'W(T#VD\)J?WWGU*DGYK%#`<HEUK5(([P9!\D</MV\&VJ#!M^
ML.)2_GQB`F`]R,N8>TH/^4D@L([X6CEU+#-D/S;J(N]2]03X:MIVGR0MQ:\H
M7FJ-L(I]R_O)GW4*5\9R>HB&`SD$L^3V`4,N+&[.^?&(6_P6Z![2U9/RGDD?
MS3FRGB\BS*'YK%"B.W6K4@[.K:2'^-.-#QWQ`9)0T#VEN#Y42389L!Y=2K^B
MP0?GIU'XI(?XTX>/&(^Y&@>TL^$U/[[SZECZ['YLY!VNM?<:Y0:P9^84H"A:
MKK%*+4M-#I%E#4[!O948T[D*C75;D=%:B&\F4QRCD(!LQNX5\ZJG$,6IZ2IE
M`2WONFP6`PMRG(M:M^5TFEHIE1*F%T]C8M%N70OS>:<]+VH+5E532C]/5IZE
MN+.J`3G3R*3!*GJ<;K`'-UZHJMR5*%B$E$NZ,(KF7*.8;H\&/LN/;S[LX#(E
MXJV:TU)`,#QF$8>K]*^2X=@&]6*8L,/JY;A17B(\D81]8^9?JKT5_FU="4NK
M#UGK7K=6XM0)BUE"VEMV[=4_1L4^143.#*J:V8&;SM5*HG`,R("W34,`]T(<
M/P???YX5^\$U[*66QL@L:VT<0$,@=Q\NA?<\'^5.&X:6S^\=>Y#QY<V2*_5%
M2],PE(4W"TI3C$D7`4[&M(B'CDCK*)L8YBD5!HU3.Y567.5%$@%`3G,80X1$
M<?#C-;63#-<(='F7TZGE;+*;*;:`KB#@#ZP8MA"P*9RJ<$3!%0?UOV0_1Q%^
M3RA0F>JJ#\'V?TC8JJ,C>=6?5\BT[H;^O%?W^9&R/^&Z\QZ.J_\`!4O_`%9O
M_"M*5_JG_LM\RW*QPUN)@B8(F")@B8(F")@B8(F")@B8(M/T?Z^<C_W4HG_K
M8E\;Y_T`_:*Y;?\`R3N8>9=&@1`NN#44(>M^0[3QU/\`T[=OJ]<,2/6PV6?K
M7SYEM,=3L)NB!`Y5M^LHF0AE#[^1!`XB7+,"E$!,.S,=W(-N6W+@VXXTN14-
M:6N<"V.0P`TJ_:F$0!L6L$'IRIB`JN#JI"<J)=Y`7%NQ<8&1D6B+5S(W68L6
M,XQ7,FW!3F46DV*HT,`@HH;,IQ$,PQO,F5S&%K.[#'-:#UADC8,G%QK6>REF
M'KB)!CE.7CXUT(/3-34/I[C-/;:H*B&G(V>3J4L\HW:HU#SA.ZZEUSM1021!
M@@`S1N:EY,A=UKM#;B4NKQ.DJQ429<F;.%G\P`6C+8+5B%)=#'#J^76N*MM+
M=,5NI78O*EJ-H-<WAMC=U\1J+,Q(R:M:A3OM9#,2KH*`>&D?:!(7F]F(<H?<
MR-MQ.1CF/R)<F6R1)`E29LMO\0>K-)O?5XS'EYEF[1$>KE,>/*/+I6/&>B*.
M0K6!G$;JUV6CZ1N==&ZM$VW+'TTG3D#-W?BZLCZJ9+/"Q9)V6ATG-6/'#%-1
MP86XJY&S)N`7/QFO$KNYM%),^XUM[OB+&P@(!L%%U)(G0,LPEB,!RGG/,KNC
M-)L73$];V?IBN*G8^\ZR<A8"88+-8EXTK&AWJZK^.>.C<U(I#SD7,N.52<H"
MF04Q$ARB!<L0=B]8YLQKJ*3UWWF_QG=3)8++<G'G6-@E`@AP!`ASC2L22.C6
ML)&HGM-QET*QHFUHZ>Z#LK(.X(*;=3=;L(:7JDE1-99O)Q;@L"^4BI%/F\BP
M,B)4G2H'(8Q2&+>W&ZD.+G8?),7WA_'=8<U@MARY50YDB6[NS:`(1SYUD&JM
M%U$SC1R2(J";IZ497`IZY%$OQC(JH&](2]+4":W+.+;0DXU>1]003NDU%$%V
M[S=4,<X*$.50I3!%F-5[2R]1R2`TAW\4B]$QCDLA&Q0,JC>;1;Y==JS[!V\E
MH&UQZ!;U<JC+FCG;-.LF5)4O$G3?OU17!TWI=K'>]HK5N4>34051$%2Y@8^8
M[P5/J9IF7S<('%?S<JW@RF`R=)6L%+:)&=!C`SEM[OUI1-=QKVMGTG/PU.TR
M--3,1<5U#R-24W%4$[:.J<I>,9R%/-WD:BTS,U><H<QE>64*-SJ^<T7G,E3A
M$=3O(1AG($1&.7C4;E(+8#AY5=U7Z/Z?JK*8:U;,Q%=,[M2]W(2JWD)3U1$C
M)FHZ1C:,J*#?TY(M/::>@YF"9\FJ0=Q1)TJ*B9R"4!"#,:KF/'_923)$N[=[
MYV41ZP,(CI6.[H'');'EUJ^*<T^143-(R\M./9YR:T3RSTVU3B(2G8B8A9.:
M5F73_P!JZ>;L&,:^=\X.BDFCDDW3$QAS4,;>JFXE73VEC*.4SKW@>]<3`"$+
M1;$V]`4FLH@8W>3*>-8SH[1\I2RM-J&NY6=5_);1M1T)8DL]`4F[+:J.J,C5
MK(O-X[`S:L9E*!8(Q2;B0#(&)3DW!.H8XW.Q&K]84<D--KAWSHNLA#)9;;8L
M7*(V$9!`9>!7J6\TC0UL08/*>K683FV1[MOD7Z$-`,8-"H;TF@!F).(H\K<(
M"%C(16FT3M(]%$$%ECJ&7,<QS"-$W$:XG^'1R8.A_P`TY!EMA&U2#:,"&N%O
ME63M/-A8JPT+5S&/EW<W(5S6;^NJB=A&,*;A$IEZS9L3^T%*18!$4\U,V8D%
M5)`OW1P910XF,;/&O45>(S(%E+);Q'^*3'2%8U]*W)'I5^WM-G9.[X!PC:RX
M&66T/^*4QNY84[*A[@Z:`V8XPNBT"V&7C69DZ7W<6^K`^8JV]+ALM-UABCF!
M@M#;X#<'"%,1OZ(XNJ94P/<V/6!(55-.EN`#<VM9TYR4.H;L#C2C5"R$O[P6
MU>EYU'.2C^M-V!P.TD0(EP_;"S?EYTYR0?UIN$!X!Z@YAVPQ@"I;D$O[X2_+
MSJD5DQX2FX!#@,.8".8@/#GMP=M+Q=<)9;^V$:9=Z((C!49H?N8\`E]:/K3"
M)A+GEM*(CP<&(ALX9!+^^IQ;G"D3H]4AN/@,&>6W;EEF'6'BQ-IJ6Y!+^^%@
MO:WZP5(&0`,@(?@`!-FIOCNAD41/GO"8`ZN>>)7ZO^[^\-2QWK3E<F;8,LDA
M#(`+D`"`"4`,`%$.J4-X1RX,]O#A<G/ZSFL+OVU@S61M<%)3-R;"$,4-O!O!
MPY;WV3"&WC'AP[J9V&??3O9?:"K!5,H`4"GR```,P,.P-@;1`1'"]4BP"7#]
ML+%R2;8C3Z5/+DXC=@?4POU6:7]\)<DBV(T^E5<Z+Q&[`XQ&JS2_OA+TO.I!
MP4PY9&#KY>KC+14/-TW`.1P)T(7RP(Q5?*EXQ[`8M[F;VCT*'?2UIKKV$A]-
M=29!O"%9VD':'^5:C<;^'RIW?W08N(/F*TJV9)<&7A'K<JW&`J1=N0\(CM,8
M1':/5,.8Y=3'*?2!\X3OKCCS+>;,8R79D5'*)$S#<'ASX!'AZ^W$YFTAT&EI
M$.,@="RV<QXO$IRR7L![`XA&J_N_OC4I7Y>=3RZ?L3=@<8C5?W?WQJ2_+SIR
MZ?L3=@<(U7]W]X:DOR\ZCEDO8#V!QF-5_=_?&I+\O.G+)>P'L#A&J_N_OC4E
M^7G3EDO8#V!PC5?W?WQJ2_+SIRZ?L#=@<8C5?W?WQJ2_+SJ>73]B;L#A&J_N
M_O#4E^7G3ET_8F[`X1JO[O[PU)?EYTY=/V)NP.$:K^[^\-27Y>=:=T4FD.N2
M^Y]S+E[$67$X[<S[D_71"@;C`"F$,N#'7?*F?#I4PP!<YV8V\:Y[7RWUDQAM
M``XX9EN.')D*```AD`!EQ9?7''/$N<3:ZSF"VWS)4L6*CET_8F[`XHC5?W?W
MAJ5M^7G3ET_8F[`X1JO[O[PU)?EYTY=/V)NP.$:K^[^\-27Y>=.73]B;L#A&
MJ_N_O#4E^7G3ET_8F[`X1JO[O[PU)?EYU'+I^P-V!PC5?W?WQJ2_+SIRR7L!
M[`XS&J_N_OC4E^7G3ET_8F[`XQ&J_N_OC4E^7G4\NG[$W8'"-5_=_>&I+\O.
MG+I^Q-V!PC5?W?WAJ2_+SJ.52S#(I@',,A[H.KB3-I+@'"7=CVAJ47S&!A,>
M):9Z(#I?)I<7[GD4FHR_)2`0HD`-VNWQLS`4``3B*@YB.T<='$F55/,:P"42
M9;38\$0(B+<^<<61:M%W4R4'&`,3Q^E;F<NGGZPW8-CFC:;L2)<?VAJ6U>EA
MT(J>73]B;L#C$:K^[^\-2E?EYUX%44Y3];4[.TE4T<65IZI8>2I^<C%E'"2,
MA#S#55C),E3MU$EB)NFBQB&$ABFW3#D(8DR;629@F,[L/!L-X:E6]M/,A?MA
MPSJVK7VFM=9.CHFWUI*#IJW=$P;5)G%TU2<0VAXIH@D4"%W6[5,G*K&`,SJG
M$RAS")C&$PB.)U55B%:;U4YKSRO"LC)A=ZL.8+((F1#8)##EP>OR`?9!MV&V
M\/#BEIJ6M@T2X?M#4J[L@6#)S^E5<LGN[NX;=XLC?H\.$*@&($N/[85C7RV>
MJ55SDH;-TW8'$HU6:7]\)?EYU/.B\1NP.$:K-+^^%B]+SISHO$;L#A&JS2_O
MA+TO.G."G[G(>QEC(%0\AKK@'(X$Z%&8^4&Q)BI,<HYY9_6_THB/5PJ9,YX;
M<,""L]ZP,O<4%IU0A_Z<>H$3#W(60LAN[/\`TU7N?%U<L>AJY4[X'2F/5,R;
M#GZL5I29K#4S,X:U;D<J7C'L!CA]S-[1Z%M]]+5!G!2CED8=F>>7J8K<*AA@
MVX1RD`Z%(3)9MBHYT7B-V!Q&-5FE_?"S>EYTYT7B-V!PC59I?WPEZ7G3G1>(
MW8'"-5FE_?"7I>=.=%XC=@<(U6:7]\)>EYTYT7B-V!PC59I?WPEZ7G3G1>(W
M8'"-5FE_?"7I>=.=%XC=@<(U6:7]\)>EYTYT7B-V!PC59I?WPEZ7G3G1>(W8
M'"-5FE_?"7I>=.=%XC=@<(U6:7]\)>EYUJ*B?^G?(J9#EY*$2;__`&Q,8ZQO
M_"0Z#>]OY[-*Y;2WXB7?5@/,L'R]G4+HZX;X&5N'>&@SQ-B;$D$;77%EZ*1E
M>6GKF&3/)HL#%(Z5:@8P)B<-@&'&U)F=UA+"6M=%Y%HCQ&T<MBMV-Q),3D68
MQT@-1#^L/J\-E_E_J'+A`>/K8YM)BTAKS_#D/`]XTN;Y0#'F6-B?QDPY_0N/
MR/FGG":N]NT?X_ZBVY9\.WKCCH?&J?\`+X;_`$GZUG8G9SI0VC]MD'](;5T'
M]E?^H^++CXL/CLUEM%284]_'>E/L'%#K!9%$>,D\.94^1^T#/>U#ZMPSZOR_
MU)MV[W4'V0YX#>#%C_Z#"/Z3_;4MBSWN'D5)]'[8=@:B=6NZ(&X;^5(;UQ@,
M;(<]@&,4!'KXO9O#6@?Q</PDN_Z3_;5$R@J'.C)<\-AG4^2`EGO>4/JV$1#(
M3!?ZHPS#,PY9;W!F<>R.)?J.I_\`QV$_TG>VJ_A];VWZ56&CUKL,.H35P)]T
M"[P7_J+8`;V0!W7``&'LXB=Y*N-F'X1#_I/]M;+</-T7RXNX[?0J@T?-0#(-
M0VKH``!``#4!47`.T0]=U1P_4E9D^'X1_2?[:EL'*>'D5'D>-!-O#J%U=9Y"
M43#?ZHQR*;UP99[0'JXY_P`4E?E\-_I/UK&R'.=*!H]C^`NH?5OF(B.07[J,
MH"(EW1X,@VEV?6Q.7BXEO#Y=+ACG@V`RG0/]I#1693!5>1ZTZNH;5P`9``YW
M^J00'=]:`@`]3/&Z-Y*L?_\`/PC^D[VU$4<.-R@VCUIPEU#ZMA-F([+^5(&0
MFSWC;1RVY[<5S-Y*\C^%A^$WH^Z?[:D*,<1<J0T?-PSRU#:N`S',<K_U&&8A
MP".0[1Q3^H\6/_\`S\(_I/\`;38AG<H'1ZU$Y5#:AM6XJ$`P$.-_ZBWB@;+>
M`!SX#;H=C&1O#BQ_]!A']*9[:;%FO*0T?MPX-1&K@/7<&H"H_P!=Z[]=U1Q+
M]08M^0PC^D_VTV+]KAY%8UV=)K-A::Y[H^H35>Y(UMO7"ZC5]?>H7+1?DZ9E
M511<I'S*JW.DD)3%'8)1'%#,3,ZH[VHE4S)\1%LMI#&_L@DD9^=)M(X2KK21
M85;VG/2BSF+`V6E3Z@=5+#VQM=0[WF</?6HF<6TYS3K!7FT>U3+R3=FCO;J1
M"]R4@``8S5X@PN<Z[+M,8PM/*;<JJI*0@B))L\BS`.D%OF.6H?5WEU/X_P"H
ML4C&*:'\C"_++?'RVK;V5V<J/)!;^</J[\?]1>KC/QFF]QA?]-^M-E=G*>2"
MW\X?5WX_ZB]7#XS3>XPO^F_6FRNSE!T@-AX=1&KL`ZU_ZC#]`</C--[C"_Z;
M]:BZG<T1M*CR0&@<&HK5W]F_]1F_1-A\9I_<87_2=K59E.Y5(:06W4U$ZNA^
MM?ZH@_3P^,T_N,+_`*3]:FRG<[C*>2"W\X?5WX_ZB]7#XQ3>XPO^F_6I[*[.
M52.D%MG_`%A]7?C_`*B_98V96,R+EE-AAYI3]:TYU.X3"(E<"VDJ-;@!G&I+
M5@S*(E*"CK4%4J!#&$<@3*=4.1,<>L.>)'&I(_\`28=_3/M*`IG9RB.DJ,73
M`Z.I35DX3$QB[Z6H&I54.4*/=$%TW*;(P#L$,\^MC4=C4@./_;89_3=[2VA(
M=='K+F+I%9JAO)ZBM7`D`<MX+_5%Z[/@X>$!V8?&:>%E/A</^F_6L"2XFR,%
M7Y(+?SA]7?C_`*B]7#XS3>XPO^F_6KME=G*!I!;^</J\^Q?^HO5Q@XM3O%T2
M</:<\MC@[R$F'/R)LK\Y50:06H^NU%ZO"!QC?ZHAV\6S/&/B$GB;+X>58V5^
M=:KZT=+32`T^U#)!??5'/<E5UKTQC9R]E123)<75R*89IF,W.)"`HW4<`L0P
M[2J)E$-H8Z.&8G*9.)[N7ZN6%HL/+QY"M&MI'FY`GULBVL4T@MMX0'43JY'N
MLB\G?VI2AED&T>4.8?7"/%ECGS,1DWK)<L'F]*WME)EPB28?0N(=(+;/9J'U
M>?9O_4/JXS\6D2^JZ30..>8QQ=I!A#,H2J5P;E.51Y(+?SA]7?C_`*B]7#XS
M3>XPO^F_6K-E=G*>2"W\X?5WX_ZB]7#XS3>XPO\`IOUILKLY3R06_G#ZN_'_
M`%%ZN'QFF]QA?]-^M-E=G*>2"W\X?5WX_P"HO5P^,TWN,+_IOUILKLY3R06_
MG#ZN_'_47JX?&:;W&%_TWZTV5V<IY(+?SA]7?C_J+U</C--[C"_Z;]:;*[.4
M\D%OYP^KOQ_U%ZN'QFF]QA?]-^M-E=G*>2"W\X?5WX_ZB]7#XS3>XPO^F_6F
MRNSE/)!;^</J[\?]1>KA\9IO<87_`$WZTV5V<IY(+?SA]7?C_J+U</C--[C"
M_P"F_6FRNSE:N4GI>9J:P;T0IK]ZGD1C;*VBD!E4;WSZ<VL1Q-UH`,I%^`<J
MX9)F0,*93=R43"(8ZDW$Y;\.E?PI`;$F#6D,'*T1B(\N5:$NF<*V9:Z%GF%G
M,MIO)`:@&7E$:OC;N09FO_40B.6S,1$<Q$<<EN(2KWJ2\N;TK;GTA+;"8*CR
M06_G#ZN_'_47JXE\9IO<87_3?K5FRNSE/)!;^</J[\?]1>KA\9IO<87_`$WZ
MTV5V<IY(+?SA]7?C_J+U</C--[C"_P"F_6FRNSE/)!;^</J[\?\`47JX?&:;
MW&%_TWZTV5V<IY(+?SA]7?C_`*B]7#XS3>XPO^F_6FRNSE/)!;^</J[\?]1>
MKA\9IO<87_3?K3979RGD@M_.'U=^/^HO5P^,TWN,+_IOUILKLY3R06_G#ZN_
M'_47JX?&:;W&%_TWZTV5V<IY(+?SA]7?C_J+U</C--[C"_Z;]:;*[.4\D%OY
MP^KOQ_U%ZN'QFF]QA?\`3?K3979RJB:0&93D$=1FKDP`<HB4U_*E$ILC!L,!
M>Z$H]7+;EBR1C<ALYKA3862'"SNW6\GK*,VE)EN%XY%JKI"TO-)VWE=./EPU
M/PG(WYO8P,C`WLJ-B@KS"MWR7/W)4SB0\@_]>JH(;QQX<=#$\8DWA_VV&`$`
M_P`MW'Q>ME'&M>@I")0!)R\-*VH\C]J`YEU%:NS?Y_:C#BZN>.=\9D=W;3X9
M#/W;]:OV2$RPG(GD@M_.'U=^/^HO5Q#XS3>XPO\`IOUJ>RNSE2&C]J.TVHG5
MV7+J?+]4@Y]C&/C-/D%/A9_^6_6FRGC)4!I"9#G_`$B=70Y#D/\`']4A1#+;
MD(9AELP^,TWY?"_Z3M:;*>5/)"9!_P!HO5T'6^7VI!R^SMP^,T_%3X7_`$G:
MTV4YRGD@MAX-1&KL0Z@_+]409XS\9I_R^%_TWZTV5V<IY(+?SA]7?C_J+U</
MC--[C"_Z;]:;*[.4\D%OYP^KOQ_U%ZN'QFF]QA?]-^M-E=G*>2"W\X?5WX_Z
MB]7#XS3>XPO^F_6FRNSE2&D%MGMU#ZO/L7_J+U<8.+T[NJV3A[3GEL<'>0DP
MY^15S:1Q9")50:0FI1S\H;5V(AGD!K_5")1$0$!W@SVY`.(5F)2V!O5EMB>(
M0\Y4MD)DPMC!:LT=I<9KZP+U0'R]:GTPC+,6?>#,(7OJ!*??&>S=:DYM)2`%
M!9TS:@AF@0W<D$Y\MHX]!6XE+."4C2R6(3)ED+/JVY<IXRM*FI2*B88GU6Y5
MM*.D)I^MU%:O#<>5_P"H@R[(XX/Q"3V9?#RK>V5W$5`Z06_G$:N_LW_J+U<9
M&+4[.J9-`[EF,<YVD&$,RSLK\Y4>2"W\X?5WX_ZB]7&?C--[C"_Z;]:;*[.4
M\D%OYP^KOQ_U%ZN'QFF]QA?]-^M-E=G*>2"W\X?5WX_ZB]7#XS3>XPO^F_6F
MRNSE/)!;^</J[\?]1>KA\9IO<87_`$WZTV5V<IY(+?SA]7?C_J+U</C--[C"
M_P"F_6FRNSE/)!;^</J[\?\`47JX?&:;W&%_TWZTV5V<IY(+?SA]7?C_`*B]
M7#XS3>XPO^F_6FRNSE/)!;^</J[\?]1>KA\9IO<87_3?K3979RGD@M_.'U=^
M/^HO5P^,TWN,+_IOUILKLY3R06_G#ZN_'_47JX?&:;W&%_TWZTV5V<K`D)I]
M;QFK"MZ%"[^H%\%2Z7Z:5-5$I=>9>US"A&WA7E`1IFIU#"ZAFSL[3DG)$\BK
M(*J)CL..-]U7+V!M7W=-W=^-VZ>YR$>K&,/+E7/;*.W.EQ,8!;`6^_KPZC.M
M8S3R(=81F[M9C]<<@[&-*9_XQG[1\Q6_))CY`MRB]3ZXXY%(T=V;!E6V57C9
M@,RBN-0`'=SV9#GVASQ)O5R#*LW[@)*U'NEJ!J:D+WTI9*B[<,:PFYRW$G<A
MW-3-P8RAHUA"1M6P]*N&*`2#1TI+R:SF6*L0B8!N$3',!SQN,D"8R^XD",+`
M3YER7U3N^N@6CE@O%J757!4#+T<UK;WLP4#4]SKFV^D)YI51ID(<:(IQY/QJ
MJO,6!5B2[Q9`&JD>":BB(&`PF'J9F888BZ206@YLOEY$?B%UP''PY%E5OJ0L
M@\+;\S>Y5-O%;HMRNK>-&3L[I]6$>9SS`7;%FDD=Z+=B\4R=*[A"-S;%!*.S
M%/P]]I`-AMM]*V&5S#ERKJ1.IRPLY)U!"Q%U*8?R=,Q,Y.RZ:#Y,$4(2G%Q;
MU%.-')TRLY-A`KGY-TJV.H5(-HXAL=8(71U2;,G'D5AK6`VY5XJ&LC3&X,<B
M=Y*(-R3R,C'&[(KAR2DNFFI'.1$[4F4*]*X)R;X<FQM[U^S&=BK^(>98VZ7P
M_P!BR02\=KE(V/E$JV@#1LM451TQ&+!*&,9W4=*)R2E0PR2()F5%Y"EA'1G"
M8!]Q(@)MH"&=?=U,?4$?)PM6?B$JQW%S9O(L0SVJZ@%:.-5%M9>.K]Q&5[;J
MB:@C3.G<,ZB@KV<;1322>LWS5!R4!9K&<MB`4"NA((`.P0Q.53U#Y@8YH`MS
M<0M4'8C*[LD<1'3Y.171*ZFK,DJ:7MS&W!IZ2N(Q:5<HVI@LFNS4>R5&12DK
M/QZ,J+56.;KPZ0!SS)0W,R"8QPS()0V30SBP3"(2SS:XK#*^677.,<,RZ[;4
MM:N+:T(VK:MZ<IR?KB)IQ_'1J,HO-QH*U0N9O#)-ZC;,DXYTS=NBBDU='.F#
MHV8Y%R#%;*28PF8/5@4J:IDQC6BPWAYELDW5W\R[IPW0`-XP;<RF,0Q#F`Q@
M,J!BB(Y=00QHS/76XV-T178#;GGQXM*BPFWG4Y!Q!C"G$K%=\=EEKPY?-=7_
M`/!&7QB6!WWE'T*,W^7Y#YBK8TM_U;+#?S16]_@S&XLJ`+[N<JJG]4<VM9[R
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MK1`XNG(-%SFW,B;U-3A3),";(B(_V@F'""V*;$A/CR'AQ+.B>J'3Z#*8?$NK
M2QXZGYB.IJ:D?;$Z[5G4<FX>-8^`.[%'^V99VYCUB@DF)E"F(`&`-XN</@\R
M,+O6-N49,^5;&VRU-(ZHK`5Y*0\#2=UJ7FY>HF$C(P[)D\/SAZC$"K[9-Q,J
M@1-*58%;J"NS,(.$P(81)D`CC6GX-,NEY!#19EX_(5`8G)$X2S:>'(L7W:J^
MVNJ6R]]K76KFX6N*V;6_J1"-A%#O(MRQFI&)EHZGY<IGQ8Y4C)681,FD\2,*
M0*%'NM@XNI9!HG-#X$1MC`ZU76.%9+(9&T<5FI:BM]+M^8F6N:SI2'4AZ9N5
M9.U-II1@6LBLT(P8FTDA[[9^%1%=3<J%I7:0,%72(D.N+\'&\((9XZKJRG=+
M`>UA>U[CZHM$3#BS'(M.7)F-=!I-P-:#:<H`CQYPOI78&!GJ0LA9RE*M*J2K
MJ=ME0<%4Z*[Y245)4<93D8RFTEI!0QCNU$Y%!43*F$14':([<<*;.EO>8-;:
M>(`?0N[+B)8'&`LV9!Q8Q<9F&A$R#"ZT<01,9@,R+17I'J@@Z0TDW$J^IWS:
M+INDYBW-23\J\%4&L5#PMQJ4D7\DL".:AB,T&PG$``<\L;5#-GRZR7+II=^9
M,);Q66<H7/Q%LL2A/FNNB68K"9>FFZ,$3F4#5U;C=WS%*/+3`$-N9;QB%&-]
M:(FQWJGY<[SSKE5W):V`(M;;Q]I<([_8$)NR.F?Q,F0ZEV`Z:GHO^KJ^MF'U
MSS`CV?:X,;'Z`WEF=;98_O,UK;_5&"RK)DZ#C;D/'Y$]-3T7_G?6R^WF/!V'
MA[O+^4_M,UK'ZLP'W_0[4GIJ>B_\[RVOV#2^7V/[V\&(^'V\OY7^TS6I?JS`
M??C0[4I]-1T8/G=VT^WE_!^,^'N\OY3^TS6L?JO`O?=!U*/34]%_YWULOMYC
MP=C/A[O+^4_M,UK'ZLP'W_0[4GIJ>B_\[ZV7V\QX.P\/=Y?RG]IFM/U9@/O^
MAVI/34]%_P"=];+[>8\'8>'N\OY3^TS6GZLP'W_0[4I]-3T8'4U>VS-]8\Q^
MG'X>'N\OY3^TS6L_JS`??]!U)Z:GHP`X=7MLR_7/,?I1^,>'N\OY3^TS6GZL
MP+W_`$'4H]-3T7_G?6R^WF/!V,^'N\OY3^TS6L?JS`??]#M2>FIZ+_SOK9?;
MS'@[#P]WE_*?VF:T_5F`^_Z':EJ_3O2U]'5':K+PW%>:I+=I4;4UI+5TY"S8
M^WQF\A.0$O53J08)[D=D8&R4HB)@```=X<QQMS/EYO-LC":<@DFR\VP<1]:W
MF6D=[,![]Y$ZV`SVFSD6SY.FFZ,$A2D\KRVH@!0`!$\QMR#+,=^/WNIU=N.=
M+^7^\T;*8G]YNM;C-Z\!N_SK/*I]-3T7_G?6R^WF/!V+O#W>7\I_:9K6?U9@
M/O\`H=J3TU/1?^=];+[>8\'8>'N\OY3^TS6GZLP'W_0[4GIJ>B_\[ZV7V\QX
M.P\/=Y?RG]IFM/U9@/O^AVI3Z:GHP.IJ]MF/6`\Q^G'XQX>[R_E/[3-:S^K,
M!]_T'4H'IJ>C`#AU=VU#ZQI?P<.'A]O+^4_M,UK/ZKP+WW0=2>FIZ+_SOK9A
M_9'F/THT,!\O=Y?RG]IFM8.]F`^_Z':D]-3T7_G?6R^WF/!V,^'N\OY3^TS6
ML?JS`??]#M2>FIZ+_P`[ZV7V\QX.P\/=Y?RG]IFM/U9@/O\`H=J4^FHZ,'SN
M[:#UP/+Y?X/QCP^WE_*?VF:UG]5X%[[H.I1Z:GHO_.^ME]O,>#L9\/=Y?RG]
MIFM/U9@/O^AVI0/35=%^'#J]MJ4-FT33`@&WJY1F>#?E[O/>%VDM_:9K6'[V
MX`&DF>(0S.6L.E3I:NCLMY0U81%7ZIJ"AI"2O5>"IF+.0)-D<N(.>J]Z_B'I
M1*P,F#==LL`E$1VAD&S%\_Y>[S1`;3WA`?6;8>,6NXEI2-ZL!`MG<?VO)Q+:
M#TU'1@^=W;7[>7\'XTF_+W>6]_IHC->;K6]^K,"]];S'4GIJ>C`ZNKNVOV#R
M_@X<6^'V\OY3^TS6L_JO`O?=!U+%][.F4Z.*=L[=2%I#5S0*U4R]N:WBZ<;1
MZ\\C(N)U_3,FUB$&2S:/(Y;.5Y!5,B:J9@434,42CGMQNX;\N]XIE;*;-I?X
M)>+W698(VG+Q98<:TZ[?+!)%*]\N=&==-T0-IAS+\QNA_I_=7>FAC`45>P`U
M-6ICTFK06U6/#QEU8!B@"29FT'6"B`K3JD<BF!$TI5(YSE#>$Y-X#X^R8]\D
M\..%-JL,F!N(6$B$8V&+8%\!;QP7R_"_F?B'Q/N:YG_9WC:89(Y;&Q7ZZ=&_
M2B:/];K5NA:*Z*$=7*B.^^M/7W(TE<1DIR8<J#6*>KF1J!D@?/-U&K."999[
M1V?GC&MT-X,`F7JJ20UQ==L!!`Y1&'E7V6BWBP/$Y0FR)S22!QD0TPM7T=2.
M4Z0")3!LR$#;Q1S`<A'(W=;1#/;PACS4MS:N,F:RZ\9>$`NRV$`9=K5V`RR#
M9U`QM"6QHN@"`L0Q4Y!Q8S<9F&A83(.+"XS,-"*@_K?LA^CB+FM`L`RA1>3=
M5!^#[/Z1L0J0"&Q'&I_5\BT[H;^O%?W^9"R(?8]NZ\V=O'HJH#X%2V?\V;_P
MK3E?ZI_[+?,MRL<.`S+;3+&+K3E`1,@XL+C,PT(F0<6%QF8:$3(.+"XS,-")
MD'%A<9F&A$R#BPN,S#0B9!Q87&9AH1,@XL+C,PT(F0<6%QF8:$3(.+"XS,-"
M)D'%A<9F&A%I\@`>7G([`_JI1/\`UL2X8Z!_\>!Q7BN6W_R3N8>9=*WHAY<.
MHS:'\AFGG_#EVP_1QB8#\,9^T?,5M2""8"TP"W)`Q<P#>#/,=F8<6.-23)?=
MFT95ND&$8+DWB\8=D,;/>2\X48',N%4W<ANY".8<&W(-XN]V0Q)LR7&UPTK(
MEW['+3*YVDRF+NZH:,O3<"!I>K*0HFS\G1D)#3!)$TM%ULZN!!54UJ*-YFLU
M0*V2C(I1$_*G'-0Q<B"&8XVY5=W+(2W@.C&((7+?17IT2V+(<MG-""QQ(:<+
MS4S4U,UM0:-LI^7I;4=>>\B$%5[N88LI&F[E4M)4Y'1S.981#Q2G:EC"O"!R
MW-W*7)@/<B.W&RW$I,V463G`1:&QX[(\O*J9U#,$YKI;286\D5Z=BM*%6V^D
MZ=E*PE:4=OR6JNY351.::8/&I8NLKPW)3KR5&C@=(E59P,2S$S<3[R9G*A4Q
MW";N08G8A)F,(:X0O"R.4`#SD*<JB>QT2#DS9(Q6)&.C*]\K2=OK<5=*VQCH
M*Q=L+NT-;RHZ52E0>5S(7&IIW1D<[JN*<1Y$::BVD2Z!U(MFZCHKQ^4BH&'<
MV72\9IY+G.;$E[V$QA9=,;+;<UO$IFC?8T@F`@LC7`T@U95%(WC@XAY1K*2K
M[1[2&G6`<K-'2*4;4=.-II`SAZ[;-N?&I@%Y!(Z14@`0*0>Y`>!+QR6Q['&'
M5FO>>6_'EXHK+J1QB(&UH&B"QI3%A;ANM3%_STY,FIRE*'H=6=LM*.H%V,/3
M^HJ]U&!3MPJHBP61*VJ"+A$J99+%*F(\U>/7&^.:@YS?BU),;=<&Q+K3&TM#
MB0TVY,EF;C6B*6>#`-=`"RRR)`C_`+5[\)I,O@[+5TO6E1TX>:J&2T[N#.'E
M65/6DHZ+9ZIY*=J![*3TC$Q@'6GAE3BS109II-S`4@AD&^-@Q>A:`UC6@"]D
M@/6$,_D5;Z&I((+76PZ%KI9"GJZE+O2T'(455#UY/U;JKBH.!FFE9P)=/<9<
M9W5[SWWS\:YCCT*N2LU%D$0-&/U!,DY`6Y5!,?=5-=2/E7&S&E[;IC$=:[`P
MR\JS3TM0Q]XL=`@C)DB",RS[6&DG49/0%*T$G6]+2-&1%&63A4V3F<J"$AZ9
MG+?3R,A6<@UI>.AG*-6C5J3%`6JSQTB=CR9B"GDIO!J.Q"E<'=;K&]FX\EL5
ML['/`$`8`A?4Q#/,QAWB`;:5,XE`4\S&$P=R)BF$3"(Y[P[!RQQ'O87QB(+L
MM!NBPKL%,&W:'#QXM,R7VAI46-<(Q!RJK>+QAV0QCO)><*<#F6*[X;;+7ARV
M_P`5U?\`\$I?&93V&;81E"C-!N>0^96SI;V:;;#9[/XHK>\/_-F-Q;4.;><8
MB$2JJ<&Z.;6L];Q>,.R&*!,EYPKX',F\7C#LAC/>2\X2!S)O%XP[(8=Y+SA(
M',L1W[HF6N;92ZUN:?>-6$W7EO*SH^*?/=X6#21J.G).(8KR'))+KA'D=NR<
ML*9#'!/,0`<7TU3+DSA-B++<JU*VG-3(,JVTA:-6^TOWD0H>Q=(S]"V.M<I9
MF^=J+C2`VRG:AF(NMX&C*)J&F9I=R20IV&=-*B6=2+<S<I@.D!2")C;,L=-^
M+,<YSW3+Q<QS8&%@/$N5\(@`T-A`@V1MX<BR73^F&N8MS.+NING%R2VMA;4H
MW.D>2!PSHP8:(C20F2S<"^^0ZD<??']H$BG<B`\%1Q1F=MLJYPMR*Z5ASI0L
M!M='ARKEIO2W4<+;VR]'+.J0.O;O4,[O'4*C=DNFPE8YS5-25$)&+7FX",Z`
MS"(<HL&0'3,8!];B#L2!<]X<`7RPW+F6PVE<+H+20UT?-J7E.=*M:MT:$4@I
M2D(B4I;5%=N^RC]%FY$Q(RO("XL;#%10(V(D_J1DYJEHJ[%P)45N04*!QWBE
MQ(XHQSW->1<+`W0L'#06!^29$G(NUILL!>:@+F/KD7=GH6?>NK1P]NGCMM4D
M[5TU4%0,JJF:DE:G7<2\5#MH"$D@D`!O%-TCILQ'<`3`&\--75T\T?PR,ZOH
MY$R78\6+?0"DW0S(41R#,1,!C"/5$1R#,1'JXY9<USK2-*W.Z:#$"U<O<<8=
MG"[)B#>$1RI`CB5>\7C#LAB[O)><)`YDWB\8=D,.\EYPD#F3>#C#LX=Y+SA(
M%?.[I6:+>7)T(7SMU'2#>+>U^PI6BFLDZ15<MH]Q5%;TW#(O'#=`2JK(-C.]
MXY0,7,`RSQV]W\2E8=BLJL<+[&&)`MXCRA<?&:%U?2]PTP)/#B*_-X7\UHOR
M7/E-7-HQ-F!`%.U]6D`4R%*1+[G[Y1(4Q2!D(E`H".W+'VJ?\\Y8ELD2Z<AH
M`!B/)Q3%\OF_*HNJ35MF"]&.7\*K#\UHOL.WRN;3!]>V56`.S_\`R,<3/SRI
MFP#:<PAR9?ZJG4_+&?6S.^,X-@T-AS?N%3]%HOMYW5I?%E5GQBQCQTD?E_-_
MBK7\)IWOQP_<3Z+1?;SNK2^+*K/C%AXZ2/R_F_Q4\)IWOQP_<3Z+1?;SNK2^
M+*K/C%AXZ2/R_F_Q4\)IWOQP_<3Z+1?;SNK2^+*K/C%AXZ2/R_F_Q4\)IWOQ
MP_<3Z+1?;SNK2^+*K/C%AXZ2/R_F_P`5/":=[\</W$^BT7V\[JTOBRJSXQ8>
M.DC\OYO\5/":=[\</W$^BT7V\[JTOBRJSXQ8>.DC\OYO\5/":=[\</W$^BT7
MV\[JTOBRJSXQ8>.DC\OYO\5/":=[\</W$^BT7V\[JTOBRJSXQ8>.DC\OYO\`
M%3PFG>_'#]Q/HM%]O.ZM+XLJL^,6'CI(_+^;_%3PFG>_'#]Q8MBOS;V\<S>"
MM+-EU0VR3D:.HFD*O>3)[=52HQD&-6R$RQ3CVK/WRYM'+7VG4$ZV69P.`8W)
MOSR8:1I%.Z$(9.?^\6EX23C.<!4",0<O-]A91+^:T7YR#?U=VD$P`&\/R8U8
M`";JCE[XM@"..=*^>,IKH]P='^8MMOREFL;;4`>7\"GZ+1?;SNK2^+*K/C%B
MWQTD?E_-_BJ7A-.]^.'[B?1:+[>=U:7Q959\8L/'21^7\W^*GA-.]^.'[B?1
M:+[>=U:7Q959\8L/'21^7\W^*GA-.]^.'[B?1:+[>=W:3Q9U9\8L/'.3^7\W
M^*L^$L[W_#[BCZ+1?7SN[2>+.J_C%C/CG)_+GH_Q4\)9WO\`A]Q3]%HOMYW=
MI/%G5GQBQCQSD_E_-_BIX2SO?\/N)]%HOMYW5I?%E5GQBP\=)'Y?S?XJQX33
MO?CA^XGT6B^WG=6E\656?&+#QTD?E_-_BIX33O?CA^XGT6B^WG=6E\656?&+
M#QTD?E_-_BIX33O?CA^XGT6B^WG=6D\6=6?&/#QTD?E_-_BIX33O?CA^X@?F
MM%]A$`\KFT09B&8A;&KC"`9[<BFJ;=,.74'&6_/23>'_`&YR\4/\51?\I)SF
M%O?BT9_P+$]H/S<"\EX*?GIZ)U16QAV\!7U<4(JU?6ZJQRHJ]HR<5A74@1<M
M2;Q47ID-XJ>S(,L7SOGE)88.ISDS:Y@6I*^4DXC^>-/X%ECZ+1??JZN;1A]:
MV=7_`/A5((8TV_/.1>CW!Z/\1;OA-.]^-/X$^BT7V\[JTOBRJSXQ8L\=)'Y?
MS?XJ>$T[WXX?N*T+@?FS%Z;?4+6E<R&JVU4DSHVDZCJUS'(6WJI!=\A3,0ZF
MEF;==6HSHH.'*;(2$.8AMT38W</^=K:RJ90,IGW9SVM)`C`DP$83##*M>I^5
M8II9K)M0+\II+6Q'6LB0.H(FSB7YV+36FNC?BKH^A[-4!6-RZUE`(HQIRC8=
MQ+OT>6'>*M(J%1*Q9QIR#D=5VND1N4!,)^IC['53*'=_#/CL^MD%T`[NS,;'
M)&$+#'RKYY>Q#&*OX**&H8R,.\,MUVRR-ZT="_3WH@_-M*Z=OJ<N=K,N4[H4
M6CIK+QEJ++32S6LXU9$4U4T)FZ;$Y#03DAR]T,.!E@#N>7Q\+WR^>$K&Z1V'
MTE,RV(O.B`(61A?,>A?3MUOE+\.NSIU5%L;T`1QG)Z@R<:_7]1].1](4I`TI
M&'DU(VG(EE$,E9=^ZEI99LQ1*@DI(2;]9P]D7BA"9J+*G,HH81,8<QQ^>ICV
MS*HSV%K2>6"^T2Y(H)`E,C,#1Q6GZ%=93%W0V@&P-@B&?!U<2,R7'UAI4A%P
MO0(BJMXO&'9##O)><)`YDWB\8=D,.\EYPD#F5!Q`2\(<(=7KX@^;+AZPRCC4
M'M-W(J#B&6689B/!]@V(5+V`-B1ESJR!N^1:>4-LUPW]$>#Y$;([?_;=>8]'
M5O:,"I8D?S9O_"M*4#M3_P!EOF6Y.\7C#LACA=Y+SA;D#F3>+QAV0P[R7G"0
M.9-XO&'9##O)><)`YDWB\8=D,.\EYPD#F3>+QAV0P[R7G"0.9-XO&'9##O)>
M<)`YDWB\8=D,.\EYPD#F3>+QAV0P[R7G"0.9-XO&'9##O)><)`YDWB\8=D,.
M\EYPD#F3>+QAV0P[R7G"0.9-XO&'9##O)><)`YEJ`A_7RD3?K?)2B=O4_E8F
M.KP8Z)(^'!_U;QM7+:#\2=S#S+!,G?RVMF=<E\T:]?U.R5G;$6#6BR05!US6
M)%TV4]=8'1EAI"G)P&0IBL78OR8FS[G/&Q*DS:C"Y98`8.)/-!8:\28D<8`6
M:_+LTZY_^=[C]7;\A%[OR>XT).'&!=+:"./(IMKRYX9'+R*KR[=.GNQ<;Q#W
MN_)]BS8)G8'0K]I.?AI3R[=.ONQ<;Q#WN_)]AL$SL#H3:3G3R[=.ONQ<;Q#W
MN_)]AL$SL#H3:3G3R[=.ONQ<;Q#WN_)]AL$SL#H3:3G3R[M.ONQ<?Q#WN_)]
MAL$SW8Z$VCE4>7=IT]V+C^(:]_Y/L8V%_8'0FT'.GEWZ=/=BX_B&O?\`D]PV
M%_8'0FTG.J`UV:<@,!O;:XV8[``MA[Y`(`(`'W7.WVZ8>OC&P3.P.A-H.=5&
MUV:=#`(#,7'R'ARL1>\![);?9]C$M@F=@=";2<ZXT]=6G4O=#-7($3!M*%A[
MW%3*(<`@3Y/<\Q`>$3#GE@:!\8A@AY%C:3QE<WEVZ=?=BXWB'O=^3[#8)G8'
M0L[2<Z>7;IU]V+C>(>]WY/L-@F=@=";2<Z>7;IT]V+C>(>]WY/L-@F=@=";2
M<_#2GEVZ=/=BXWB'O=^3[#8)G8'0FTG/PTK'=W];VGF5M'=2.;3%P@=/;:UZ
MU1Y:QM[&R1EEJ3ER)E,Y7M\FV1`PCEO'.4@=40Q*3A\PS@`T91')D_V*N=57
M9=XGB/F*M_3IK5T_05@[+0\A+7`*\C+6T.Q=%1LE>9XD1PUIV/16*F[94"X9
MN2`H4<CI*'3,&T!$,6U6'S`]PNBY$PR9%12U5Z`,8@+,GEVZ=/=BXWB'O=^3
M[%&P3.P.A;>TG.GEVZ=/=BXWB'O=^3[#8)G8'0FTG/PTIY=NG3W8N-XA[W?D
M^PV"9V!T)M)S\-*>7;IU]V+C>(>]WY/L-@F=@=";2<Z>7;IU]V+C>(>]WY/L
M-@F=@=";1RJ!UW:=/=BX^W_(->X?T+?8QL+^P.A-H.=3Y=VG4?\`ABX_B'O<
M'Z-OL-@F=@=";0<ZCR[].ONQ<?Q#7O\`R?8;"_L#H3:.53Y=VG7W8N/XA[W?
MD^QG8)G8'0FT'.GEVZ=/=BXWB'O=^3[#8)G8'0FTG/PTIY=NG3W8N-XA[W?D
M^PV"9V!T)M)S\-*>7;IT]V+C>(>]WY/L-@F=@=";2<_#2GEVZ=/=BXWB'O=^
M3[#8)G8'0FTG/PTIY=NG7W9N,7K_`"#WN_)Z.&P3.P.A-I.?H]*U5UI:R;$5
M3I_GX>(E:^</EJNM<LDFZLM>",2$C.Y5*OG`B[DJ&9LR&(U:J&`IE`,?=R*`
MF$`QT<,PR:^?&X!+`,;1F,-)6A6U)%P1MO9EM6?7;IR`Q@":N*<2CD.[8B^(
M@`A_96\`<AZ@\`AP8YSL.G!W79UN<+?VD7+(Y%1Y=VG3W8N/XA[WC_\`3W`T
M,SC8.A5RZHEN4Y5/EW:=/=BX_B&O?^3W&-A?V!T*S:3G3R[M.GNQ<?Q#7O\`
MR>X;"_L#H3:3G3R[M.GNQ<?Q#7O_`">X;"_L#H3:3G3R[M.GNQ<?Q#7O_)[A
ML+^P.A-I.=/+NTZ>[%Q_$->_\GN&PO[`Z$VDYT\N[3I[L7'\0U[_`,GN&PO[
M`Z$VDYT\N[3I[L7'\0U[_P`GN&PO[`Z$VDYT\N[3I[L7'\0U[_R>X;"_L#H3
M:3G3R[M.GNQ<?Q#7O_)[AL+^P.A-I.=/+NTZ>[%Q_$->_P#)[AL+^P.A-I.=
M:M4AK'L.CK'O)4BLI7Q8J5LO:*,9K_(K>(RRKQI/5BHX248)T(>0;D33<D'E
M54B(FS[DPB`XZLW#9QPR4YK;;SHB(R<2T954#6S8QNV#H$5M(&N_3D8I1),W
M&,4P%$I@L/?``,40S`0SMX&P0QRFX?,O6,$?(MN?50:,JGR[M.GNQ<?Q#7O_
M`">X;"_L#H4]I.=/+NTZ>[%Q_$->_P#)[AL+^P.A-I.=/+NTZ>[%Q_$->_\`
M)[AL+^P.A-I.=1Y=^G3W7N./^8:]X?\`T]QG87]@="A,JRQL8G*GEWZ=/=:X
MWB(O?^3W#87]@="IV]V<Z%/EWZ=/=>XP?6L/>\?_`*>XQL+^P.A6RZLO$8E/
M+NTZ>[%Q_$->_P#)[AL+^P.A6;2<Z>7=IT]V+C^(:]_Y/<-A?V!T)M)SJ#:[
M].90S-,7&+ZW+>L->X!'?'(NZ`V^S-F/%C.P3.P-(3:3G4CKNTZ!L]N+C[/\
M@U[_`,GN,;"_L#H3:3G4^7;ITS#^_%QN$H?R#7O'A$`_6V],;L!B;,/G.<&M
M8+Q-EH6'54&DDV!:FZ/=9-B*:M[7S68E*]2</+^WME6Q6UE[PR!#,9&M7BS-
M4R\;0KMLFJLGF(I&.58F61RE'&UB.&.;,#;L6W&\8R\:TI59!H%MZ)^A;9CK
MLTZ!E_?BXWB(O</Z-OL<]F'N'JL\RW14G/T>E1Y=NG3W8N-XA[W?D^Q9L$SL
M#H6=I.?AI5M5CK#TOUQ2E34=.R=S%X2JJ?F*<F$6]D;YLW"T5.,%HR02;.$;
M?`JDNHU<F`#%,40SS`0'&Q38/B4YQGT0NF6(F!&7*WC&2&54SYM/,E%M0<HL
MX6K"VGJONCXTK40PH*P]$3MN:=;-D6RZ<#IXO7[:2HHI%1YQ4<V\M\XF)IPH
M)=_>774R,.P`#9C;K*7>?&&"FFSIDS)`%Y-TYQ%_I7+P^FPR5/O,`$>.'H6Q
M"&NK3JDGN>W%R`R,8=MB;WG$0$<P$3#;[J];(.MCDMW=K,(&Q532Z<+2203U
MK1;$^==Z;/8U\)9%SD$`N;R[=.ONQ<;Q#WN_)]B>P3.P.A5[2<Z>7;IT]V+C
M>(>]WY/L-@F=@=";2<_#2GEVZ=/=BXWB'O=^3[#8)G8'0FTG/PTIY=NG3W8N
M-XA[W?D^PV"9V!T)M)S\-*@==NG0?^%[CC]:P][@_0M]B+Z!Q'68(>10F51#
M8Q0==>G0V8>VUR!,(#N@%A[X#M`IAZEO1';EU<8G8:XW>]:``;+0I&J_@Q$8
MK5BC=9-AFFL&]E3*RU?>U<Q9FSK-DH2RUX5G!EV$Q6AG)%H].AC2+0"`Z+D=
M9),AQS`@FR''I*_#9DO`:.\T=X9LVR(R=6&E:5-57JF80;+K=*VH\NW3I[L7
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M;IT]V+C>(>]WY/L-@F=@=";2<_#2GEVZ=/=BXWB'O=^3[#8)G8'0FTG/PTK`
M$+JDLY,ZM*WN.PD*P-3%'Z7*7:SCE:U]S6DFFO*WF=QC,C2FG=(HU#*"9W(I
M`86K58J9!%0XE(4Q@WG4SQ0-DP$2_)I/T+0;,_[UTSCL^A9UH$ISZX=1`;``
MECM/PGR,;?.)YVZ`D-M[DH$*D8!`/78H<]K<*8!EOG_=*VI+'.<>\R0'T+<D
M$SYAM#+;U!_98X<B;43&EQA"-EJWNYE#BM5?)&XP[`_LL7WYV8:5CNY>9.2-
MQAV!_987YV8:4[N7F3DC<8=@?V6%^=F&E.[EYDY(W&'8']EA?G9AI3NY>9.2
M-QAV!_987YV8:4[N7F7"=<J9@(;(!SW"B)1`#'[G=(7,X;QSB?9EGC7%6\S#
M*#>L#!2,J6UMXY%0#L@F$NZ("`B`B)#9!NY;XCD<1*!,P`<P#+,.IB;ITY@B
M6V*#>X?D4`[*8Q2%(8P''(%"ICR8`.6Z;?$X`)3Y]R(9YB`];.[_`+C,W2L`
MR'9(KM<D;C#L#^RQB].S#2I=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPOS
MLPTIW<O,G)&XP[`_LL+\[,-*=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPO
MSLPTIW<O,L87KWB6<NX<PB4$[85X;>+W0=S2LL8?N9A$!'+LXE)?-$VT"PB%
MJC-EL,OR%6II:(?R;+"B)@`WR0V^WM@Y9C3,:/4-ELSQ94OFE[C9>B>/C5-/
M+E@"&99ZY(W&'8']EB@/G0R#2MCNY>9.2-QAV!_98S?G9AI3NY>9.2-QAV!_
M987YV8:4[N7F5!RBF43".?4```1$1'J``G#,<0?-FL$2.-.[EYEURN43@<P'
M$"D,(;YB'`A@*&8G(;>W3)@'5_2RQALZ<[(WSJ#NY;E50N4T@()Q`@JG,FF5
M0-TQU"@8P$(45.[.H4,R@&8C@^=.80"W*C>Y()X@JP5*?>$1W-P`$V9#`&Z8
M1`HY[V0YB`]?&'SYK&WG-L66B3,,&Y0@+%[H`W1W`S/F&0DV`8`-F?8(@.*V
M5;Y@O-:8*;F26&ZZ$5P\[1.!S$,8XEV;A$SB83;VX)"AO!F<I]@ALW>$=FW%
MXF3C]50(D\BGG*.>0*9]<I3"&[O;O*;#C]SW@$-[@S##O)_96;DGD79`N>T!
M[0_L\8[V;&$!I6+LK,JN2-QAV!_98G?G9AI4N[EYDY(W&'8']EA?G9AI3NY>
M9.2-QAV!_987YV8:4[N7F6F&O@_)Z::F-F;,M8VF`3%2,IN%4NI1R9S`!3@.
M]N'$`VAPXZ.&.GF?!MT.@>.'$2M&MERXRP087N(16XZ:Y1%0@#P*&*8!$%-T
MW`)0$@CN@`!P#MQPJJO%-/$IX=>,(0!(M72;*!99`B"Y=_+9D`_7(;](0QL/
MG36F%WBXE%DAL+<Z<IU@^U/ZN(;1-[!T%2[ABG?_`+'[4_JX;3-[!T%1[N4F
M_P#V/VI_5PVF;V':"G=RE'*=8/M3^KAM$WL'05+N&)O]8/M3^KAM$WL'05@R
M98$2IW_['[4_JX;3-[#M!6.[E)O_`-C]J?U<-IF]AV@IW<I-_P#L?M3^KAM,
MWL.T%.[E)O\`6+]J?U<-HF]@Z"LB3+.11RG6#[4_JX;1-[!T%9[ABTSI+E3Z
MW[^$`50*-A[*%`J89&$ZL_79.53,8P`0I,^[V9@!<\=9\V:</E6&`+B,T<I\
MH6G+D-VN8\$1LX\P]"W,WQ,&T2Y@'#N"'U^J(=3'-9,G1]5;4V4(<J<H/L?]
M0?U<2O3?L:5+N):;X^Q_U!_5Q@OF@1ZIYC:G<RTY3K!]J?U<5;1-[!T%.X8@
MGZP?:G]7&=HF]@Z"G<2SE4;X^Q#[4^&TS>P=!6-GE\JD#]8/M3^KAM$WL'05
MGN)8R)RG6#[4_JXQM$WL'04[AB`IGGZT,NJ8IP`?K#GMQED^;,<6M;:%%\N4
MP1=D6%-0=[Z<TY69N5?.M6,F_HRU]+/ZNJ-&$1!S,'C(Y4"OPC6RRJ0.'1&Q
MMY-,#%WQ#(!#/&Y0RJS$*@4M,&]\XP$3`1RY8<BUJJ=2T<DU$Z/=BVP1.B*L
M+2]K9TR:QJ43JO3W=6G:Z12:-W,O3Z2X,JSIKERDR0J.E7ATYF-5(<^X8XI&
M0$X#NJ&#;C>Q?!\9P-Q;7R7```Q`<08B(@8`%:.%XQA.+MC1O!,2(&`-EF2*
MVD*H4=P<Q`#B&69<NJ&7"<?7=3AQQ:>J?4&QI'[5AT+J3I<N3E$8\8M6FVA\
M@FMM</=/D`:B;]@)"EW2;:[>99@)A$1)ELR$.$<="O?47@;+P8-'$M6E;+F2
MP1ZL3]"W/!(WL@[`_LL:+'SSEAI6WW<O,IY(W&'8']EBR_.S#2G=R\RXU&PJ
M9#OY;N>S(=N>7^BV<&(G:'$0=<''"!CI54RFDS"+PL"XP;*9AZP`X\S"/8WL
ML9?+?`EDUP?S!6"FI&BP6\.5<Q43%#(3!U>H/[+%<DU360FD.?$V_P"Q9[J5
MQ"Q5<D;C#L#^RQ;?G9AI3NY>9.2-QAV!_987YV8:4[N7F3DC<8=@?V6%^=F&
ME.[EYDY(W&'8']EA?G9AI3NY>94F3,`>N`.#J#Q_V6(/?/`L`CSJ+I<J%HL4
M&*8H#M$0X@$2B.0#P#O;.#$*A]0T-N0RVVJRXR[#B@M/Z'`1UO7[+OB(A9"R
M>P2@`%WIRO!R`2F`38])63)IP*D``NB;-X^/JQ6C)EL%3,C:;K="W#Y(W&'8
M']EC@WYV8:5N=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPOSLPTIW<O,G)&
MXP[`_LL+\[,-*=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPOSLPTIW<O,G)
M&XP[`_LL+\[,-*=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPOSLPTIW<O,G
M)&XP[`_LL+\[,-*=W+S)R1N,.P/[+"_.S#2G=R\R<D;C#L#^RPOSLPTIW<O,
MM04"G\O"2(([/)7BCAW1L@SNE*$SW>#:8OU\=0O/PL#Z]Y<QK6_$7-XH#S!=
M:WO]>'49_,9IY_PW=O%<S_QC/VCYBMN3E\@^A;EEZGUQQR:3^6>=;A5>-E13
M!$P1,$3!%I1KBN<%"6F1IEG64E;^HKQ5A3MIX2M:?3<K5#23"H%57-85=#$:
M,)5US^DJ38/GA%$VY^15*F(Y;!QNT%/*?/#W-C`$G)$Y@/2N=73WRV%H,`;(
MYEJC;G4+55?4QHA)'U=-N)B.U45A8RZTCRCN/>UZA;VV5S0)*SC5VR:/'Z%3
MLH>+F%.511,HL8#`4,=&?2RFNFCBN!S8\48V>0A<NGJ7FY:/7@<_%;H-BR97
MLK6-J]4[>O[TRUR5[+UY6EM*0M!4E"5L[84;;>J9!LK3P4!=BWD8JW5EF=>5
M.^162DU$7B:2RB2*ATBE`<<EQZL`NU*%MH.1?3G&NMM,$3!$P1,$3!%BN^/\
MBUX?YKJ__@C+X2_YOE"C-_E^0^8JV-+?]6VPW\T5O?X,QN+*CUW<Y55/ZHYM
M:SWBH9%>F,HF"+IOC%*@(F.*8;Q>Z*8"G#=S/W.>P=A=H=4N>)LA>M$0J9Y<
M)?5RQ7QUL?JH"HM7@S2]S)*=MU?VHKCVHH.WZS>6+3M$RMG%SA2<_!N5X=I&
M+N+GMXZ:,<Y'!P721;%#U@"/7?2,;37H0>T")XK<HYQYRN2^9-,V`C;P'#,K
M3L?/7-G-'=Z;HU')7O;U0\I2[\=%W*EKNK2,!)G;72JRGV$A1%-)R[LU)3,1
M",TDV[HZ">Z!,@S'9B^=(DBJEL!EED80`ZP$(F)R9<D%33OF=P^-Z]GC9Y!G
M5V6KOU<V"O?I_LI<^JZBFJNM;2%Y#7$*U0!W(WIH=M0,!/6FNH2$9(IK2+N8
MCU%D%R)%$P2[%TGPEVTU5+)$A[V`$$B`.4&T.:>*PZ%=2S)G?M!CDTYBLY:M
M*WJ.;M%;:[=OJONC;AHA?.Q\8[I].,5HN5J-E4EWJ6I278U&A(,UYY""?1CY
M4G-TQ03<"8#'$0QITDJ1'NG-$;;>81S9U?6=YWA<#D@.%JQOJ!J6L92;ULU@
MVNC6MOI+2Y35OY*U<5$SJ\;21':])-*\=2]4TLU=(QU<M:JFG!H]1*234(1`
MO)I`!NZQOT\F2&R(@.$TF\<UF09H93S%4N+[[P(@-UJV'%=W'F(QSJ`4N!6%
M,UK&:UZ4LRRM\O4#U*B2V^<UE3-#S-$+T:@X"*?R\K$33B4!\[2%^BL!%$S%
M*0H&E52Z9KS)E0N-9&-D23DR`6+3ES:D]:9'UR.2`X>1?8Q/]`1R^MG^ECS$
MZR:(<B]#(M;;E7/B]7)@B8(OG!TLU72ENM`&H>OX+VO]O:(I^#K"%-*)BM')
MR5-59`RK0[Q`%$C+H`LW+F0I@$W4QW=V\,.+8S)H[UT.<8Z#9Q\2Y>+U[,/H
MW37"+X&"_(B'YRETA2^2AG.G$IA*F8$R6ZD1W0.F0Y14.M7`&.<P#F.12`'%
MC]"U7R0W=;32Y_?N,T@92#Q1L_AKX74?,3>"77F7+9_`CF/MKD^DH=(5]]:<
MP_S<O/CQB,KY,8-W8-RMG1^M+>P-YNM+C$<:Z4[Y@XPQP#6CU1Q<?WD^DH=(
M7]]Z<_%R]^/&+/!G!OR^)??E>PJ?$3&NR-!]I1]).Z0H?]]:=/%R\^/.,^#6
M#?E\2^_*]A/U]C9M[OH/M)]).Z0K[ZTZ>+EY\></!K!OR^)??E^PL?K[&Q_R
M^C\:GZ2ATA?WWIS\7+WX\8QX,X-^7Q+[\KV%GQ$QKLC0?:3Z2?TA0[.=:=/%
MR\^/&'@S@WY?$OORO83Q"QIW5N`^0^TH^DF](5]\Z=/%R\^/.,^#6#?E\2^_
M+]A8_7V-^[Z/Q)])-Z0K[YTZ>+EY\></!K!OR^)??E^PGZ^QOW?1^)/I)O2%
M??.G3Q<O/CSAX-8-^7Q+[\OV$_7V-^[Z/Q*0_.3^D*#_`'UIT\7+SX\8QX,X
M,?\`T^)??E>PL^(6-,LN`>0^TGTE#I#.HYTY9?S=NP[0USGC/@Q@OY?$OORO
M86?$3&NR-!]I6&P_.!==$;<>IKJ(+V`&IZRI6"HR3%6AW@QQ(VEG<B]CRMD2
MU:8R;I1246`0,82&R#(=F.D_Y*X(:*7_``<4NB)_F2X`G+]1<Z7\P\;-;,==
MM,!Y(<77L5^&_.3ND)';SG3D']C;E\'ULMZMP-V0`<:4KY*X%,=!TC$X1[<K
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MCQAX,X-^7Q+[\KV$\1,:[(T'VE0?\Y-Z0D^6;K3KD&W9;IX'_P`\8S*^2N`.
M<\F;/DO'U'N%\6<<)<+<HAQ+2KOF'C]UMUG5)S'VUC"]G3V:W-0-J:^LA7J]
MAS4C<^DY"E)]."H9]&38Q<D)45EF#H:N>[AR$`>Z$H``[0QL;K_)["!C37-G
M.BTF%ODM_AYE'&M^\5?A!OLZQ;F_$OE!0=<5O:NIHBL[;5?5%`5G`N$G,14U
M*S,A!U"V42`I1!F_:N=YP40+F8!!5(0$0%(=HX^JUN$;KX])-)72I<&=6UK<
MK;(VM*\5*G8Y@3VU5'-?!\'0!=QVYPOU'=&=T\VK*L*UIRP]Z+)53JM</W+!
M@C7UH:?(UN3`,EG*+1%[6D0D0E,RS)J53E%W9UF#@2E$2I&$<L?F[?GY;87A
MAFUV&3FM#8N(=ZL(9&P8(',(K[+NIOU65TME-B$LF8Z#0>/GM<5^E+0JN"UL
M*]5$AT3+ZA;[J"@KN@L@8]<.SF;N`*8Q4W*.>1R9B("`\6/C-?8_/U`OIF'_
M`,F'*?H6[(8T&9%T"IQ8L)@B8(F")@B8(F")@BH/ZW[(?HXB_)Y0H3/55!^#
M[/Z1L55&1O.K/J^1:=T-_7BO[_,C9'_#=>8]'5?^"I?^K-_X5I2O]4_]EOF6
MY6.&MQ,$3!$P1,$3!$P1,$3!$P1,$3!%I^C_`%\Y'_NI1/\`UL2^-\_Z`?M%
M<MO_`))W,/,NE;T/Z<&HP?\`(;IX#+Z\W=OJXKF'_LVR>(.-ND+H-E-8;'1L
M6Y6677X<<Z4PRNIE!.56Q!568\7;#%\%BS.F8\7;#""69TS'B[8802S.F8\7
M;#""69TS'B[8802S.K%G;=4I4564G7$M%-W=44,G4*5)RBX"HI"!539FQG5F
M1!-NI.GC%D"/*AW1$SG`/7#B,L.EO+KQ+3Q*F=)ESFP)@5A.X6C;3_=$LV-8
M45R[JH*]BKG2,E#S4[3DK[^H>G'%(M*D:RD%)L'[&2&G7:C90R*A"JE-F<IA
M#&R9[R`T&`"UI=#+8XO+HN/(JHK1O8")JJFJQ3H]T^F:3+#J0WMU4E0S<<24
MI]!-M"U(^B)64=Q<K5<<@3=2DW*2KTG""@"`#B+IKG"!6RR2QAB"MH\QXNV&
M*H*ZS.IS'B[8802S.F8\7;#""69TS'B[8802S.F8\7;#""69TS'B[8802S.L
M5WPVV6O%_-;7_P#!*7Q"7?[XP%D1"W*L.`<V[%6SI;#^C988>.T5O?X,1@XG
M4.?>=U;8GC49;!+LC$06><QXNV&,`6*=F=3F/%VPQF"69TS'B[8802S.O/E(
M]&68.HUT43-7J"S1T0#"456KI%1NY2`Y!*HD8Z"I@*<H@8ILA#@RPR6@VH;I
MRE8H/8.UYJ.H"@2TLP2I.ULG2<O0$2CRJ!*6?T2DJC3CR+<(JINBO&::IMY1
M0ZG*[Y]\!`PXM$YX,8JETF6X0C!8OHS1!IUM^6M$*4HZ0C8VX#6?95+3QZOJ
MQ[2RS:J)I6H9Y-A33R:7B(D'\RN=P;FR2>2ILPV;,2=437D$GU>11932F-+0
M<N59:7L9:]U<JD+PN*2C%;FT+24I0E,5D*8EF8VD9HS4\G!$6(<I%&CA1H4P
M;Y3&3$ZFX)>4/G%\U[V7(]52ER9<MQ>#:5:-^-+-H-2K*GHZ\4/+U*PI:2]N
M(5FRJBH::0;2A5VKI%\J%.248H]7;.F**B7+&4!(Y,R`41SQ5)<^4V[>C;'(
MIS9<J:Z\5T:CTBV'JR8I6=J"BDY21I.%I^G4#NY6761J"&I9<KNG8^MFQG_(
MUJA!/2`X9^V8.10<!O@(\&-AM3-9ZILCF4-GDKUU=,%EE[GJWA5H]`]=.)5K
M4#IUSZ0]I7=3,HWVF9U8ZI?G8T\M536($6R<B+;G1$AR`^8`(4E[X0#K.;BS
M*7<R3:<JS\4HAV>MQY\>*>[!,28J0:!D*Y,QXNV&+(*5F=1F/%V\1<8"(M*6
M9U.?U9XKON[/3Z$LSK2;I"(YC,:7*RC)-FSD8Z0J:U\=(1LBW*\CY!A(7/H]
ML\:/6AQ!-PW704$IB&S`0';C=H)M6RI:^F=W<QML81XCH7.Q*GDSY;.]M`=D
MX<ROD=%VDC:(::;'"'$-LJ1$0X`$,QB\^$,65>-;R3"'-KIX:.(DGZ49@^$.
M`C(EQ50:+=(Q@S'3-8W/@_DSI'P7BQF.8Z]H+ZN?>R>L[B\JP_!,()MDLZ=:
MGR+-(OFS6-\6=)>"\2^-8W^;G_>=[2C\$P?W+.G6GD6:1O-GL;XLZ2\&8?&<
M:_-S_O.]I9^"X1[EG2GD6Z1O-GL;XLZ2\&8?&<:_-S_O.]I/@V$>Y9TIY%FD
M7S9K&^+.DO!>'QK&_P`W/^\[VECX)@_N6=.M/(LTB]33-8WQ9TEX+P^,XU^;
MG_>=[2#!,''_`"6=.M/(MTC>;/8WQ9TEX,P^,XU^;G_>=[2S\&PCW+.E/(MT
MC>;/8WQ9TEX,P^,XU^;G_>=[2?!L(]RSI3R+=(WFSV-\6=)>#,/C.-?FY_WG
M>TGP;"/<LZ4\BS2+U=,UC?%G27@O#XSC7YN?]YWM+!P3"#_R6=.M1Y%>D3S9
M;&>+*D?!>'QK&_S<[[S_`&D^"8/[EG3K6I5*:3-+ZVLF]5-KZ>K.+4_'67M'
M)L88]NZ6&-;/WT]6"3QX@V]K-Q-RNFU(!CAP@4.+'0FXOCHPZ6\5<X@ET!>=
MQ<L8PY.)<GX3@TNNFN%.PD`9X?5MY[5MF&B_2*<N?DSV.'JC_%I2>?V1&+S$
M<<>GQ['7.-ZIGMA]MVM=48)@\UHC)9#RZU7Y%FD7S9K&^+.D?!>+/B-?[^=]
M]VM/@>#^Y9TZT\BS2+YLUC?%G27@O`8EB+3>943@\9#?=K3X'@_N6=.M/(LT
MB^;-8WQ9TEX+Q9\:QO\`-S_O.]I9^"8/[EG3K3R+-(OFS6-\6=)>"\/C6-_F
MY_WG>TGP3!_<LZ=:>19I%\V:QOBSI+P7A\:QO\W/^\[VD^"8/[EG3K3R+-(O
MFS6-\6=)>"\/C6-_FY_WG>TGP3!_<LZ=:>19I%\V:QOBSI+P7A\:QO\`-S_O
M.]I/@F#^Y9TZUQCHNTC[PE\F>QN6S+*V5(Y_9$(O,=N-)^.;RRIKG2ZN<6')
MUCFSQM5CL#P>9*#'2&%HY]:T[U^:';)RNC/4G"65TNVP=W9FK6ST7;]K2%O:
M78U&ZJB0#D8M&,>(LVJC5<S@V?*<H0"[1SQZ#=K']X:/$&53JV9E)()L@`<H
M)@>+SKE8K@6#U5*ZD,IK086B)@5\)M%/YM95\\V@JUUQ5R6D(Q=)JL:REL'B
M*U0N,TTU!:U;710%FQ=B.95$(\BQ@#,.5*;:'U7>GYN4LZF[K"Z>[-#`"^^2
M"Z%I#;HC;;99;E7S[!_EW5TM27UE3WTF\2!W8;9&P>L<@7ZM+!Z6K":7J-84
M!8&V5*6OIIH5$JS:GHM!-_+'3,F8[N=FU`/,S3Y7<'>5<KJ&,)AWL\?#JG&\
M2QF;WU1/<YH,;IR>09`OJE+@]#22;LJ2UK@/6C$K&6API`MI<`"@!>2U$WY`
M,@*`&-[_`"0$QA`"[@"<5.$``>OPXS5`S'YNJ`I4CQ*EAHM!)Y,RW6`>+]'&
MFUI;85OAS7*<QXNV&)P6;,Z9CQ=L,()9G3,>+MAA!+,Z9CQ=L,()9G3,>+MA
MA!+,Z9CQ=L,()9G3,>+MAA!+,Z9CQ=L,()9G5!\Q*.SBZH<>,%H=9%"T.ZL5
MQF$1#@RX>KU=T=F-=Y=-FB41``Y5,@!N7B6GM"[=<-_NM9&R/^&J\']+'H*Q
MY&"4S0(PFS?.U<^00:E_[+?,MR<_JSQPK[NST^A;MF=,^MV\6-)<(FPI9G3,
M>+MAB4$LSIF/%VPP@EF=,QXNV&$$LSIF/%VPP@EF=,QXNV&$$LSIF/%VPP@E
MF=,QXNV&$$LSIF/%VPP@EF=,QXNV&$$LSIF/%VPP@EF=:?H#_3RD1_\`RJ1)
M<N/^-:8'//'1+!\-#HVWRN6`?B)/%Z%8-1TM?B-U0W0KFQ]0:?IA>I+66J@J
MCHNX<M5*584X6G)FO%HB:<1E-*"X:PM0(RRQ6ZRZ12+JM5`3,.X?$2^6Z0UC
MPX`&,8<=MBN`F1)$(05X\\U^^XNDS\:78[UBN%+"POCS!9@_[.E.>:_/<729
M^,[L=ZQB%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQ
MWK"%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/
MG?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=
M?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G
M/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN
M+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&
M=V.]80I\[]`3KYFZ59]P6VNR=H6MX.:1TBP<)-4?4D5+SCB9N@@C"QLA#O6<
MA)N%794VJ*#!DL=4RBA@3(!!$X[H#BV3L@F-<XS#`@@`"VW(@$R)]7)G7DV?
MC-<=*VIMO3-.J:0JI@*?HBF8:%J5C.7-=LI^+CHAJU8S#1TQ!9FX;R+9(JI3
MI&,F8#9E$0RQ.I-&^:YX[T/))((%AS)"9`#JY,ZR-SS7Y[BZ3/QG=CO6->%/
MG?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=
M?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G
M/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN
M+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&
M=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&=V.]8
M0I\[]`3KYFZ4YYK]]Q=)GXSNQWK&"*>%A?'F"0?F;I3GFOWW%TF?C.['>L1_
M@YW)!_V=*P9J,I?6?7]JI6F:WF-'E!T^ZGZ*>N:CE*BN-&,V[J'J^%EHID9]
M+<DQ26EI=DW:D*8=Y4RVX3NQ+C8IGRI<R\`]SH&P#2J)['/;`E@$<ZSH#O7X
M7+=AM)AAW2[X^V5V`#?R#?R^YCW.]P=;%+A3'C?H"V)7>MR7?(4%YK]'AA=)
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MI6"X.F-:3/4'<2N6LQHY>5A/6YH6!F*)3J&XRDI!1$+)U`YAIMW&IC[:-6<P
MY?N$R+*E!)44,DQS*;&V^9*-)+EPF7&ET#"PDY;>."TG2B:A[R9=X@`@FT0A
MJ&7.LZ`[U^`&00VDP0#J^V=V,AZ_[4.-(;.3UBX<P"W98F@673Y4YYK\]Q=)
MGXSNQWK$H4^=^@)U\S=*<\U^>XNDS\9W8[UA"GSOT!.OF;I3GFOSW%TF?C.[
M'>L(4^=^@)U\S=*<\U^>XNDS\9W8[UA"GSOT!.OF;I3GFOSW%TF?C.['>L(4
M^=^@)U\S=*<\U^>XNDS\9W8[UA"GSOT!.OF;I3GFOSW%TF?C.['>L(4^=^@)
MU\S=*D'FOWJ0NDS\9W8S_P!BQ("BAUC,CS""M!G7(`""ZJJ^O8YQ%2)TEE,4
MN8A[;W8(.[F.?*9)@)D\QX!V8P#+;_+O$<RTILMSG1):#SJE-UKR(<=V&TD&
M/F0H_P!];K&-O``@41[CUXAGD.6>(SVX>X#OG.'/`:%)CZUL+K06^5<XOM?.
M8#[2:3`RXI&[`C]<"@F`FR'J8LIV80)9$MTR/V;I'E5YGU]PATNSRP6!]/E*
MZSZ&I.IXRCYK1U6["2NC<:I)"2C*CN+(MXZ?GJ@6?SM/*K1?*HHNX.04,@HB
M<>71$NZH&]BZ<ZF>Z/\`$:;H&3I6A)EO#0(L(B>/F6?.=Z_0_P"!M)8_6E+L
M=ZQJ#N(VEVA;]UX%ET^5.>:_/<729^,[L=ZQ*%/G?H"QU\S=*<\U^>XNDS\9
MW8[UA"GSOT!.OF;I3GFOSW%TF?C.['>L(4^=^@)U\S=*<\U^>XNDS\9W8[UA
M"GSOT!.OF;I3GFOSW%TF?C.['>L(4^=^@)U\S=*<\U^>XNDS\9W8[UA"GSOT
M!.OF;I3GFOSW%TF?C.['>L(4^=^@)U\S=*<\U^>XNDS\9W8[UA"GSOT!.OF;
MI3GFOT."%TFY_P#K.[`_H)80IN,OZ$C-%K0"54+S7Z)3?WETE@.7<B,G=C+/
MJ[WW$1`-W/$0*</M+[ODBM@B8Z7UX`K!=/4QK08:@[EUTQF-'C^L*AM];^"F
MJ&3J&XQY2GH>#D*C7AYQXP1,>30;3:L@N1-14A$E!;B!!$2FQT*F;)=0R9+!
M,$IKWD.(L),(@'(8+GRFO$^8[JEQ#1".0#)I6<N>:_?<729^,[L=ZQSOX.=R
MV(/^SI3GFOWW%TF?C.['>L2`I^,OCS!(/S-TISS7Y[BZ3/QG=CO6,PI\[]`3
MKYFZ4YYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4
MYYK\]Q=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]
MQ=)GXSNQWK"%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GX
MSNQWK"%/G?H"=?,W2G/-?GN+I,_&=V.]80I\[]`3KYFZ4YYK\]Q=)GXSNQWK
M"%/G?H"=?,W2L;0M-:I0OA6E?3<QI?\`E8/8ZG:3HN@8J<K8R'M4E<Q25EZI
MJIBY.:HDX51BNY;-'#=,J0OTRIF$0W@Q:7M[@,@_N;V6'`*-SKWHM[R&2*__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pg22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg22.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!#0*>`P$1``(1`0,1`?_$`0X```$$`P$!`0``````
M```````!`@<(`P4&!`D*`0`"`P$!`0$``````````````P$"!`4&!P@0```%
M`@,"!0D/#`42#1$$"P$"`P0%!@<`$0@A$C%!41,)89'1(A05U1@:<8&A,E+4
M5946EA>76!D*\+'ADB-3TY16UE?7P4+2DR5RHC-#)'0U1;4F)S='=X<H.$CQ
M8H+#-&2$A7:VQF>WLL+B<X.SXT2DQ&7%-D:&>+BCM'5F>6-4I::G:(B8*CH1
M``$"`P(("P8$!@`&`@(!!0$``A$#!"$2,5%AD=$3!0;P07&!H2)2TA0'%^$R
MDE,5%K'!\6)"<H*B(S.RXD-CTU3")),T\B6S)C8W_]H`#`,!``(1`Q$`/P#[
M;]-GTFFI;0%7]A:;L2A;]:(N#3%7RM1)5C3:LTHD\C)&(3:#&G)(--S?*JJ(
M[^P,O,Q]1\M=RZ?>&3,9-!@UW$2/P<,:\#O5O+-V/+B,7#B*^)7E(/2'Y"88
M^Q8%#=^Z#1TKS8@;TIBJ#-;ABFY0'+/'U:3Y,;)$PB:#@[3ORF+YY(\Q:V?>
M+,#1B'=3C_20.D13$"J1MC"".Z!0/1LJ43";+=W<YH,\\\9YODOLX_Z@<Y[Z
MCU)K.`'<2!])`Z1(PF`(RQPB4HB(!1<L(B!0$PY?PSM'(.+"9?DU0F8);@8D
MPPGOJ#YDUD/8.ZD3^D@](<J(`2/L7F.7IJ.E29;R0+!O;TT&[F00X>,<N'9B
M\WR;V9*===AY3WU3U'K<?0.ZG^4>=(D`E`T98LHF*8Q0/2$H7/<$"F+VTV&2
M@;V>[Z;+;EEC1*\D]G31>&#E/_D57^9-8P7B>@=U!OI'O2)%`N<78T1/L*5.
MC990PCLR*!230B)ASX.'%W>26S68\Y_\BLWS'K7V`V\@[JQF^DA=(:0Y"&CK
M&%.H052`:CI4`.F4VX8Y3#-;HE`VS/EQ63Y+[+FO+#'!C=WU:9YB5TIM\FR,
M,`[J"?21.D--M)'6,..8EW`HB75..0;PF!,)U,VX`?MMH8N[R0V:SK$]7E/_
M`)%5OF-6S+`>@=U/4^DA](BCSF_'6)+S2ID%1]PTH8"*D/S9DS"%2"`'W^+C
MXL5?Y/;"L8T.OQMZS^^F'S#K98B[`<@[J4/I(72)B<$^]MBP.*O,@4U!RQ1Y
MS+,2B!JC#(`XQX`S#EQH]$=DW;T'?$[_`,BCU)J^`'=2%^D@](DJ!3%CK%&*
M8J9BG+14HF0Q5BE,00-W_4`VPP9Y#VHCD.,A\F-ES"0P$0PVN/\`\T>I-7P`
M[B/*/ND2V_P=8O88Q1SHZ3#:4=T>&;#9GU\'HGL[@7?^1'J56<`.XL9_I(/2
M'E$!%A8<N8@7,U%R1NV',0+O#428`(@&P,+]&]G,G"4<!$<+N^LTWS%K7/O\
M4(8!W4\/I(G2(DWRFC+&E,F`&.!J"EP$"F#,H[:CVYAR8WO\D=E%L0'1_F=_
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M8=Q'E(/2(^QUC/>=*>&L'HM08CG=WT>I=5C&8=Q`?20>D1#^EUB_/HR4-_&]
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MND1`<^]UB_/HR4,'VO?PF?7#!Z+4&(YW=]'J758^@=Q*/TD/I$1V=[K%>=0\
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M.=W?4'S,JH81F'<2E^D?](>(@'>ZQ8YB`"!J-E1+MY0[\[0Y<0_R6H9<DS8&
M($<)[Z53^9=7,F!KR('(.ZOM-272@ZH)?H3;H:_7J%`J7SI:NHJ'AV:,"HE2
M#:,<:@:&MZX!W&"[%1T12F:B7,4`.!BG$H\(98^.5&YU.S?&GV3;%Y=;$]E_
M[OVXU].D[Q37;OSMH=EK>EPR9<2H5]*-WANUI.,&P1HFO!*.7&G)1FW+J"/G
MX^F^0U:ULJ<1C=^`"\UYKB2UC61@\A?(O1)H8MUJ,LO?;4'<NL;M!2MD9^GJ
M;DK>V$HUC7]WG)I\@J2M;NH5T;,:2BS@)C%13$Q2E$`VY8]?O=OC44&TVTLJ
M-Y^#%80(6@F-L1D$5X?=;8##1S)M1"UCH0,<(,,!4)-]$=]:MG;4+6EIQ_6U
M!ZDZOK^F=/M2"LE$O*I:6](NI,DKZ+R4/1\^P;(&450=`D!0*(CD`".';/W_
M`*2D)%?,(N^]`7H1MX@DRMV9\T`L:,Z[F!Z,?6E5=KSW<@[<0TG1`4Q4%91I
MV]=TTE.5/3]*/GK"H7%-0@O.^DT,:XCEN>!`AMQ,N\.P<=9_F/N^X%TN:\S&
MF'^MV&$0,"G[9GM>&N;:>&-6;I?HC:MAYG034ETJY@96UVL*=81%6LZ&G88U
M8T5(3J#U]`1,$W%P=6:1,T8@1T[2(=!HMFFH8IQ`,>-VAYBRJJ?-$@NC*[0@
M#$1B+"8<1CRP@M0W5FNA`")X8U6>]_1J:K;-W(I*C4[;-YIC>*XE6T)94:;J
MN$K)>?&G9)ZJBSJE[#N7#:GJE9P*173\BXD,W3*;?`,AQW*#S*H)$B[/F.O@
M"(#281P<72JS]T*ITHW&@GBM&/E4M6<Z(74O<6_5`V3J^3HJ@8JX%,5O5+"X
ML95M/5I2KHU"(&)(15/R<6Z.SE)AO*B5NY0(8%&Q1.<P`!1PO:'F=0ME.FRW
M3'0X@TQM(&+BPJM)N?5-,)C6@Q[7M4=U#H(JJ,M/!LJ>I2K:IU+36K"4TWO6
ME+3-,3]HYUTQAE9*/BZ95BW#EXWD&+%,KETX$_<J0**`H("4,9)7F"VGJ"^:
M^$FY&(PVDX1#!9AYELKMU9DZDN2&"^'1(CQ`6VQPY%CHCH\+E,M9>G[25J!D
M8*B5KYR:K`:BM]45,W$!C$I=UM9%B56'>.(]&9CI-J**Z"I@.BL7=,&-==Y@
M.?LU]73.+FM:3`B[&'*VS@5S-F;NF?4"E#?\P,#^L5;NJ.BULS3]Q-,#:&K7
M4-/45?\`N[<NR[^V%=49#6MO4YFK;14JY6KFD4'92Q;FBW1V('1=''^:4LC$
MSSQY'9^_57XQ^O/4:T&P@B)-HP<2[&TMTITIC&AHC$\?%#E5(J`Z-[5K>*D*
MBN-;"@&[ZB$JBK1C0Z%6UG3M/W#KYI0<D]839Z0IF0<(256R+`L8477<1#E.
M00,79CVY\RZ!M-JG3'B9#LG\807)&ZU1V!G78R6@JIJPMCH3?6*@JHJF[^J"
ME+JSEP:9EG+1C#TFC;>HG41(21W2_-MJ>A(ANB/=B[DQ2%.3A[4<8MG[]M;K
MG3G0EWFP..,>*&/.I&ZM0<#1'E]JXB9Z-O5_3MS(.UDG0%/FEY^B)6XD?6;.
MNZ8D;3$H2GA%&:JY[<QJ[4I9K"1RP;JRYU@`AQR'+'09Y@4DQMYKS`&%H((.
M(@@$<X5QNC5G`P0Y1I7?S?1\UM::@-4(WWIZH"W6M#:"WMV:#2M35=+U/21:
M?KJJTH*/DJJ!H=P>9:5"F/\`,!&@BH<H[Y=@ACE5._!G5DJ;3/:Z026DQ@8M
MO$@`BT@B!YRA^Z4^6PZQEH$>8\ZYIWT7^M*+E+:TVYM[3*=271*NXB:62N'3
M+FHJ;CD80:H7DK@0_=@R=#1C2GS`Y55?ID*D3AX,=IGF-1ME1=--UMA,+(QA
MAACLL7+=NO43':N6R).7VJHMV[6U796NI*WM;KTTO/1B;%91U2-31%8TZ[;R
M")5VZT94,&NYCWQ$D3`*VZ;>1V@8`$!#'J-F;;F;1HVU<B)E.)@39@)!XER:
MG9#Z.<:>:T"8(<>,14<>88I@'(2F+D8IRCM*<A@V&(<HYE'C`<\;_'5.+AF6
M?P0Q#.DV\OH?8Q<5=41&'3[$T44B%L(\,J-O+Z'V,'BJK%T^Q3X*GX?JC;R^
MA]C!XJJQ=/L1X*GX?JC;R^A]C!XJJQ=/L1X*GX?JDS'Z@^QB^NK<0SC0J^%I
MN'ZHS'Z@^Q@U]:+8#.-"/"TW#]49CR^@'8Q3Q55BZ?8CPE-PCI1F/+Z`=C!X
MJJQ=/L0*2F)AP_%+MY?0^Q@\558NGV*W@J?A^J,QY?0^QB#5U0M(Z?8@T=.!
M'A^*3,>KUOL8CQM1P_15\+3</U1F/5ZWV,'C:CA^B/"TW#]49CU>M]C!XVHX
M?HCPM-P_5&8\N7F@`?L8LVJJW^Z!9E]BD4=.<'#I2[>4/0[&+Z^MQ#.-"GP5
M/P_5&WE^MV,4=5U3#!PMY?8CP5/P_5&WE^MBGCJG%PS(\%3\/U29C]0!V,'C
MJC%PS*#24PL/#I1F/5ZWV,3XVHX?HH\+3</U2YCR^@'8Q'CJG%PS*PHJ<B/#
M\4;>7ZV#QU3BX9D>"I^'ZHV\OUL'CJG%PS(\%3\/U1MY?K8/'5.+AF1X*GX?
MJC;R^A]C%_%U6+I]B/!4_#]4;>7T/L8/%56+I]B/!4_#]4;>7T/L8/%56+I]
MB/!4_#]4;>7T/L8/%U0MAT^Q'@J?A^J-O+];%/'5.+AF1X*GX?JC,>7T`[&#
MQU3BX9D&BIP(\/Q29CU>M]C$^-J.'Z*OA:;A^J,QZO6^QB165),`.GV*124Q
ML'#I2[>7T/L8MXJKQ#.-"GP5/P_5&8\OH!V,1XJKQ=(T*#1TXP\.E)F/+Z`=
MC!XJJQ=/L4>$IN$=*,QY?0#L8/%56+I]B/"4W".E&8\OH!V,'BJK%T^Q'A*;
MA'2C,>KU@[&(-94BPCAF1X6FX?JC,>KUOL8CQM1P_1'A:;A^J,QY?0#L8L*N
MJ(B!PS(\)3<(Z49CR^@'8P>*JL73[$>$IN$=*,Q^H/L8N)]:1$`9QH1X6FX?
MJC,?J#[&#75N(9QH1X6FX?JEV\OH?8Q3Q56+(=/L5O!4_#]4;>7T/L8/%56+
MI]B/!4_#]4;>7ZV*>.J<7#,CP5/P_5&WE]`,'CJG%PS(\%3\/U29CU>M]C$^
M-J.'Z*OA:;A^J,QZO6#L8CQM1BX9D"DIC9P_%+MY?K8/'5.+AF5O!4_#]49C
MR^@'8Q(K:DF`'#,@T5.!'A^*3,>7T`[&+>*JL73[%7PE-PCI1F/U`'8Q!JZH
M6D=/L1X2FX?JC,>KUOL8CQM1P_1'A:;A^J,QY>N`=C$>.J,7#,I%'3G!PZ4N
MWE^M@\=4XN&93X*GX?JDS'EZP!V,'CJG%PS*#1TXP\.E&8]7K?8Q/C:CA^BC
MPM-P_5+F/+UP#L8NVIK'B+0(<OL5A1TYM'#I1MY0]#L8MKZW$,XT(\%3\/U1
MMY?K=C"W5E4TW7"WAD1X*GX?JC;R_6Q7QU3BX9D>"I^'ZI,QZO6^Q@\=4</T
M5?"4W#]49CU>M]C$^-J.'Z(\+3</U1F/5ZWV,'C:CA^B/"TW#]49CU>M]C$>
M.J>'Z(%)31MX=*<3TQ<]O;!]?#Q651I'&8`.?V*7TU&*EMR)$1CTK]1MO<O)
M<+[;/[I,'UO&NM+C\LUU3.]3Z)_'?>.;5S<B^YTDN5]CU6*ZS_B8MO\`2DQ*
M%V-)Q##EG0]Q`\X7\4`CCT?D1+E-E3Q9A/Y+SWFNZ9,J&`8(!?';H^=2&G_3
M!5AKHW&GM4E)W*I*H6$Q3A[`5#"L:(N73<<S4(>@;FP,TX*D]CGZX!FM]T/V
MPY9#MQ[;?/=ZHVE4$4LN4^()-XD0,.J1`&)"\MLK:CJ*E;?)`'X+Z2:;^D.A
MDM-72;7IGJ4H:AIM.Y,U7^E2D&\@W[\T#75^:>6HBHHNDD$#(/%8Y@T>`[=K
MHD*D"YS@)1`,Q^;S=S-K>)DRNLZ60;Q(.!L(6W8`EQ!YCB7K:3>C9UQQ+1;@
MAR_S8(*F]G^D0MQ;:7T52\E1=QI-CI:TN7LL/6Z$<^BDQJJJ[O,IYLTJ.'36
M7%%PP8*3?.+'.5-4H@.0".W'I9'EU7NHI]PMOO<"`8P@+L08-!XCT<BRUF]=
M`PZP``@:?W+VV]U[6!@J;Z-RIZHHR[`W=T'U%*T^\CX-:$6H6K+9S4A-R;AT
MR5<.$Y=*KVAW;<J)!$J*I@'G#".Z.$GRXVD9\VQIIWL%V,8ET($.%V%V$(<>
M%8I6^E)=:;;X/#^)9+"=)W2MC6]EW(6YJNH9"W>M>_>I2HE)-XR!%]1%\HJ7
M@58&,756=':UY`-),%DQ.46N\3=',!'%9WEM7D3"V%LIH$8^\"Z,>K@M$.=;
MAOI2EL,O#C4F/NE#M/":EM,]R("7U!W*M/::1NTZJ.DZPI*V-`G@TKJ0KF(7
M-0L%0B3)C(O(PCTYEUY!0W=:A2J&*!AQ3T[V@94P.NMFN:($$X0(P/5L$;.1
M5;OE2`@EMG)_S*/K+=(C9#2^E;VEK5V]N35=%6SUG5WJ"BWE9N(5M44Q;BX%
M(+4W*QLLZCE3HFKJ.6?K':B`=SBF0H'$1RRN[R^VA4O=$@3720(<0<"X]F-V
MU::;?"E?>8!8&./-9^Y011VHC21837'8S4I8&F+_`$M;&WE825Q:ZA+G24":
MM)>J)60E7PQM*%:JJL&$=&DDQ(*AC@9XJ0%3@`[,;YNX>U9^R9E-/$MM4YA`
M`)+;0,)+8PC$<F5>6V1OE12ML$M'4O'EP\JNPKTN%E(.I['DA*:U+78@K=:A
MJQU`3U>Z@)NEZ@NC$A4T%+QK:V=M2LA*TA:(CUY(I!3,IF9$@#PXXU#Y<[09
M->^<&L<0+&$EO+:W#Q<B]A/WUHY[X0C#'A_XEQMH^DHTPPD5IEN%="V=\5[Y
M:+`NNPLO#T;-P06TN#'W%EI>0C7-Q!?*A)1,C$A*Y+G;`<%@(!39AEDR;Y=[
M4=-<R7=-),%I)-YIP0:+L(0$;>-+^[J"`,.L.G^Y:.UG2=6]IQG8B)N!;BL'
MT/$6BU+VCOL-,/F$7)G3U'U8_JD\U;!4''-\W2_/D1%%P"150S#@$<;9NX-<
M)/\`C(OM>UPCC&/J\N!<^IWSI)4UH:.J08\+RN;H@U;Z7Z@JV!TW6IAI5&Q>
MG#2+=FB*'I_4!4-$15Q-0E0W+G63NHZ<20G'!*!28K1Z&XBV=+B5(Q=[(=['
MEMI;J[8IP3-O!\R8`+EXP`]TGJQ$0('B$<2[FS=Z]GS(7H0RP[R@36'J?MM8
M:[>JB`C:UFKWU9J.L;ILB6#)J[I5>"L+45L:F85$:T<K+T8*,&XB*?BXQ)%,
MT>)DRBJ'*.6W8^YNTZFG9/,0&3WD@QM!:1$`MPDF)3-I[T;.!+6@6L`XN\HO
MK77)HRJ75M":PJ76UCV=NW5T@>4O7+TG+TA+P5)*DI-E3QV%!0LNHZ;U'3]2
MN60&=-Y#(#M1,D`%`1QH=N/M4M?)FM89-[JX;1&/6%VPX<'&N'(WHV>)H<W"
M,.#2J$ZY;XVEU&:C*GNM96V1;345,14*S&+;Q<5!2-3SS-BBE*U[)PL(`04`
M\J!<ISK,6A02^Z".>>/KNZ-`=E[`DT50Z,UKGQP<;R1Q#BR+QV\-8*[:TRID
M#_$X-AS-`.-5'((`1,HE`NZFF3<2()4R`0A2@0A1S$"E`,@QZ2,K&N)&;B64
M`S`!R-UL/:)1:+0B,W(ERZANMB82L:(S<B3,OJ@^KSL%V6B,W(C,GJ@^KSL%
MV6B,W(E[7U1.N'8PC7+/&=B1VOJB=<.QB1-!,#@1&=B3=G$)!'D`=OUL.A*R
MJ8SL27(>3K!M^M@A*QJS3-BC++AS`.40V?6P0E)L9N1`;O$.8\@</UL4>)8:
MJN,V'$@=G"`];[&$QE8PE1G8@F[P<ANM]C!&5C_!$9V((W@Y#=;[&",K'^"(
MSL02AVW``[.4/L8L'M;[MJNPS;8I=T>3T/L8G79$R,U-$=W8(#YP?8Q!>QUK
MK"B,U`;>`#=;$1E8PIC-R)^0Y!L'K=7S,1&5C"2\S;W$C(>0>M]C!&5C"K&;
MD31#J&ZWV,3&5C"<S6W>))F4.$P`/(/#];$_X\:M&;D1F3U8?5YV#_'C1&;D
M1F3U8?5YV#_'C1&;D2YD]4'U>=AX$M1&;D3LNH;K8(2L:(S<B,NH;K8(2L:(
MS<B;F3U8?5YV((EP*(S<B3,H\!@$>0.'ZV$_X\:F,W(E`.H;K?8Q$96,*K];
M=XDO!PY@'*.P/K8C_%C"3&=D1F7(>V#K]7S,2#+!5F:V]Q),RCP#GU`V_L8O
M?E9$W_+D2^=UPQ9IE..%4>9J,L^``'ZO,Q>$K&EQFHR'D#K?8P0E8T1FHR'D
M#K?8P0E8T1FI<AY!\X/L85,U0.'B1&;D29@'".0\@[!^MA?^+&B,[$$F9?5$
M\\0S^MA[!*+>-$9V)+EGP;HARAM#ZV+0E8T1G)=G&)`Z@CE^QA+IH:8#`HC.
MQ([7U1.N'8Q&N1&=B3-X/]-YP;/.V<&'#5D1.%.!FP3\NH;K8F$K&K1FY$W+
MJ&ZV$1E8PI_RY$9=0W6Q$96,*#K8'`G9#R#UOL8B,K&$B,W(C(>0>/B^Q@C*
MQA2TS8C`F#L#/(W6Q,96,)\9N1(!@$>3^*#(.OEB[-470BJ.,V&!/V#P"01Y
M`VC];#;LK*E1G8D9#R=8/L8I,$H##QHC-2Y#R#UOL83&5C"(S<B:.0<([OF\
M?H8D&5Q%,EF;;@29D]6'U>=B?\>-,C-R)P9"&P=[;Q?Z&(_Q<92GF;'B1L#A
M'+J#L_8Q'^+&J1G8@D[7U1?/_P!#%A,#1!MH36&;!+EGP9"'*`;/K8G79%:,
MU)EU!ZWV,072W6N,"IC-1EU#=;!&5C"/\N1+F7U0!YHAG];$?XL:0==$V!+E
MU!'JY?8Q$96,*(S<B,AY!ZWV,$96,(C-R(R'D'K?8P$RL81&;D2E`0,&S9F'
M%P;=O%ADN9*?1F)QI3M=XD6<:_45;T1\ESOML'+X2(,.#9_E7VEV^9EC\SUT
MN7ZGT>"'7/\`9-7W.EUOV15"!C=9_P`;%<?IV-&%Y];.HC3W1UGEZ/:2=&6E
MK>I9%2KI<\4V<,WU0Q<:FBS,F@NH+@BO;&WRE+N\`B.S&#RHVU3[$E3)E2XE
ML3[OM(6_?O9$_:<YKY3;(#"/85\51Z!K6Z8@$-/62W-@"F%4NMP`'8.[_!^>
M>7!CZ?,\T-WO$P>R<2#^SIZR\;+W+VI72(2@UMT&-X.@0,,(!>?Y@_6WOHCW
M]LD9=`JVX(5>^36*D<HY<X(L>963`/3%,41RV`.,5;YJ[NM=U6S/[.\GT&X5
M;,9U;@Y8]U>I'H&];G/$(,Q9%042"*(>ZQT4V9MIE%`"/$A\AX`S'&RD\V-D
M&22R_=AC;'_C2ZSR]KBX-BRT_NR_M2AT#&N,#E`L[9!3?_DH!53LNX<H@<%<
MS1P`'-E+GPYCEEB_JULKLS,[>^L\ORWK&X2SI[J4.@<UOF*`EG+*9*'.N&]5
M;HI39CS0N3&/'[I53@/I1V[N*O\`-O9+6Q+9I^'OIY\OZMK/X8<_=6'YA/6_
MN*B6>LJH=,#'544K%T0R:8;0`H'CBD,57/(-T1'&*;YM[)>(-9-'P]]+^PZJ
M'%T]U(ET!^MU3,?=!95-$@`H*H5<\32V$,<3"8\<`Y%W<N#A$,6H/-/9AJ"7
M"9[A[.3]RU4FY$^2]Q<(@L(X^/\`I3AZ!?6X.6]4%DE";B9TS*5:]#,IRB)5
M$@-&`)\LLA'@VXV3_-+9H.!\/Z>\N-3^6=;)JS4&Y=)/$>,Q[*87H%M;A#<X
M%060.H0!YL3U8\-M'9N[A(TQS"(<&0#C/*\TMF3"0ULP$#]O?6^9N%7!Q>V&
M8]U/+T"VMP1)E.V5`5<A%(M3/1%0B^8%6!0T:!`2WR"7AS`>'+$.\U-F-,+L
MS^WOI#=R*]SKHP\^A,)T"^ME`H)I3MC^UWB'WZN=F.FIO?=43;T=D"B60<&8
M;>'%V^:FRG`@MF?V]]:W>7%<X->^X219A[J:KT"VMM3F1-45EQ!N*QT3#6#S
MFT53I@45E44HXQE"@7880R'++")GF3L29[S)A^#O)C-P=HR_=+?[NZD)T!^M
MQN444J@LLB3FR[J`5>^3*J)NV,=9-9BLH8%#&S*.]GNY!D&6+RO,W8DAEQC)
M@MC_``=Y:#N'M*:R#KI=_5W5F^87UM$,3?GK)@9/=5)S=6.]PBI/Y'F0(T2K
MICQ[W!A4SS.V2X]5LT?#WEDE>7&TI;[YN9G=U!N@9UKF,8_?VR^\H(G/E5[P
M"BH;:H)0&-[4HF$<@XL,;YD[($L.(FYV]Y-?N37B8609$9#B_E7@E>@FUI0\
M5*S+N9L\9C#Q+^9='0JMVL<6T>T</%DTR%CA'G3IMC`7/(,Q#,0#;ALGS&V1
M/==;K1SM[R3.W-KI`BYK,Q[JUU'=!WK.K>DJ8K.&G+0)PU60K.=BRO*H>)N2
M,WJ?.)$<IDC3`18H;!`!$,^/#W^8^RI(@=:88BWO*).Y];/A=:P1Q@Z%O@Z!
MC6\(Y!4%EA$!R$"U<[,8`S],8H1HB`=3AQG]4MCQ@&S\[.\M$S<:OEB\X2X<
MA[J0>@:UN!OCW\LH8"F*3>"K'XD,8W!DIWMW,@_;#GD4>'#)GF5LF6`7"=;E
M9WE+=QJYW%+S'NH+T#.MTVY_#-E<U!$$BA5C\ZBF7IC<T6-$Y"AEPF``Q,KS
M*V1--@G`#*SO)X\O=I'!JLSNZD#H&M;A@.8L[9(2D-N[WNQ=]MP9"4.]N>0Y
MXTS/,G84L1(FGD+>\L?V!M#]F8]U.'H&-;OLY9,P9;<JO></J/Z&\(XP.\VM
MW@[5AE1>-F%F'XU!W`VB`3U+,A[J=\PKK;WS$[_63`Q!(!A&K7Q-W?\`VP">
M,`#;G'EGA<SS6V-*,"V>3D+.\K2O+_:,YMYIE@<CNZFAT"^M\03,%066R5`P
MD_KP<@(B7A+NC&@;>'+#I?FCLF:V\UD^'*WO*OV'7LFAA,LGD,/^%*3H&-;A
MRE,%0V3'>$P&(>KWA3%$H>H[V`8VWU.>,DWS;V)*-US*G.SOK1]A[0_[68]U
M(/0,:VP'=[_V2*/J@J]Z4.'U1XT"AGBX\U=B3&7@V?G9WE!W!V@\0_Q#F/=3
M0Z!C6Z.0#.V:,;@,G[K79=PPCDF`F&-`@E5XC`(E#C'%F^9NQGF`;.SL[RKZ
M>;0[4K^[NK)\PMK7S*`5!9<3";FQ*%6O1R5#^2)%,$9NJ&2#TVZ(AACO,C9#
M1&$[.WO*KO+[:+1&,L\Q[J/F%M;';![H++;Q3"`95<[.4Q0_;@<D:8G#LR$=
MX!XL5]2MC]F=G;WE3[!VACEYCW4@]`MK<`,RS]F.KE5SSSN&,Q1_FSNY1$"J
MUK;^")8,&'"[*$^3Y?[1,8&5SAW=2!T"^MX0S[_V9\P*M>"/%_Z,ZN-1\V-U
M1+UFM,/YF=Y#]Q-HL,")1YCW5R%=="=K"M[!-:AJ":M*=B\J6G*50[DJAVJJ
M:4JA^$='%W31Q`YLJXYGX]W@S'9@IO,O8.U&.FT;GEC'73:TVPCQ.A@/&L,_
M=.LD36RGM9%PC@.A=FKT"6N!$XIFFK-IB&7IJK>AO9AF(@'>L1#(=@YY#F&%
M/\R=CL?<_P`I/*WO+6W<?:#FW@)<.0]U8QZ!?6]L_A^S`>;5SP/0[UXOZB[(
M_P"YG;WDA^Y-:7?P9CW4GS"^M[\H+,>^YWX,Q/J+LG_N9V]Y4^R*W]N8]U'S
M#&MW\H++^^YWX,Q'J+LG_NYV]Y-&Y=:UH$&9CW4X.@7UN&_IW97/B$U7/0WO
M,'O;EBLSS'V1+PB:>=O>3&;DU[\`EYCW5D^83UN@&\,W9("@&8F]V#P<A]2(
M!'".\&!OF/L4@&+Q'&6]Y:/L':&.3F=W5C#H%];?LW97+B$*KD-O5_H9P8MZ
MC;$[3\[>\J_86TN(2SS'NIGS#>MO,I1G;(`<0'>(%8/3BF;B(<Q(TQ0.(<6>
M(E^9VQYANM$_.SO*WV#7XY.8]U.'H&-;^S=G;-&WS`FD'NK>D,HL<!,DD!3Q
M@"3GB!F4YLB;-HYX)OFALB5[PGYV]Y'V!7XY.9W=3B=`KKA.`;L[9<YAR'<"
MK7@@)<]T3;X1NYN@?M1R'APBG\V-BU/N-J`,I9WU=WE[M%N$R<SNZG#T"FN`
M#;G?FRF_QE]USXN74$QHT"!U\/=YF[(%A$ZW*SO+*_<FN880EQY#W5C#H&=;
M8@(EF[+9`.Z8X5:^W2FY`,,;D;SL+'F5LB."=_;WE`W)KW&`$O,>ZD^88UN\
M5067]]SOP9BX\R-D$P_RYV]Y#]QMH7"2)<.0]U'S"^MWCG[+FZ@U>\R]",#%
M_479'_<SM[RS?9%;^W,>Z@>@8UN`']'+)^?5[[P;BKO,391$&:R/*WO)LG<>
MN+X`,P8CW4WYAG6YQ3ME"]4M7O!'S-L;BGJ%LX<;\[>\M/V+M#%+S'NKEJYZ
M$?6+0%&U+7$_.VA5AZ6C@DWZ;*JG*CHZ0NFS,I$2J1Y$N<,JZ+EO&*&0#MP^
M3YA;/ZQ`FF`XBWO+%6[FUU.UI>&=9T+`>ZNH;=`UK8<-V[E&=LZFD[:M7B(J
MU2]+OH.VZ;A$P918[0(H`#U<9IGFKLJ4XL=*J8C^3OJTO<3:$UM]MR'(>ZLO
MS"NM[\H+,#_\5OO!>#U5V7\FJ_L[ZJ=QMH-L-V/(>ZD^87UNA_3^S'GU:\#Z
M\8&#U5V9\FJ_L[ZK]D5_'=S'NI!Z!C6Z'_O#9<.I[KW?@S%F^9VR9MKF3VG$
M;O>3&[A[0>+PN0Y#W4%Z!?6Z8VZ$]90QLL]M8NP,`?Q/>X!RQ5_F9L=@C=G'
MD+.\H^QJZ,.K'D/=3QZ!;6R&YG/63S.(@4/=7([QLM@[@=Z\S@''EP8JSS4V
M/"`EU`^#O(^QJ_\`9F/=3!Z!C6V4<AJ&R9!X`)[L'68\6S^#>/T,,'FIL:`B
M)PYV=Y-;N!M%W'+S.[J3YAK6X'#.V5S_`.%SX1ZY8S+%QYK[OBQS*@G'%G?5
M7;@[1:XM-PD9#W4OS#.MSV<LO[ZI$?1[U;<,'FIN^?X)^=G>5?L.O_9F/=64
MO0+:V!*<PU#9,A4PS,)JO>%'@S$`(,9OB/G8PGS<V)?+0RH@#C9WUJ^P=H-`
MCJ\&(]U8OF&];0B?=J.RIMPAE395<]R*D5<J&\(]Z_39FW@+Z<2AP8:WS5V.
MX1N5$.5G?2G;DUS<(EYCW4_YA76[NB;W066`H9;35>Z)GGU#1@#B6^9>R#Q3
MASM[RL_<C:#,(EGF/=3/F&-;OL_9?/\`X7.^O_0S$'S,V."!"=:<;>\E_9=<
M1"$O!B/=1\POK>_*"S'ON=^#,/\`479/_<SM[R3]D5O[<Q[J/F&-;O'4%E\O
M^%[OP9@'F+LDF'^3.WO*S=R*T.'N9CW4XO0+ZVS&*4U067R,(%R]UKP=HCD4
M,BQF>T<1ZC;)OW/\L>5O>6C['VA=O`2\Q[JY`O0FZP3W&&UY9NT(5(6BRURH
M92J7A6*46:74A@;J*=[N<[L%PF)P`"[FY^VSV8TSM_MFTU,:O_*YH($&EL;<
M4706$[IU;YOAPUH<>.!A9S+L1Z!36Z4N]W^LF`#QEJ]X(^C&98Y_JILOY-5_
M9WTS[(KOVYCW5C'H%];OY067#_XO=>#,79YG[+GFZ9=0T"V+KL/^)`W'KCV,
MQ[J/F%];X\%068'S*N=C]:,PWU%V1QZW.WO*WV-7?LS'NI0Z!;6]MWIRS!OX
MJK'VSS,HS$'S&V/_`-S.WO*/LNNE$"ZUQ=D/=3@Z!;6UD(C.V3*`9<-62&\.
M?(4(S>-YP8I+\Q]CS'W!K,[>\MHW#VB6:R$H#D/=1\PMK<S#^'[+IE'/:6JI
M`P]013+%F5`HCLSRR##:GS#V52@%PFN!$;"W\W+,_<>N<;-7S`]U-#H%M;^T
M!F[+"<!R,4:Q=&,0>(IA)';N8E$!\P<86^:6Q7NNW)XY;G>2OL>OQ-/,>ZD'
MH&-;P;!F++>_!YX.QN]3MA26=9LX\A9WEIE[B[0NX&<X/=2AT#&MT?Z>V9)U
M`JUX;S]D88<6I_-/8%2ZZQLX6\99WD'<G:'9EYCW4[YA76_F`=_;-9B&90&K
M'@"8`X1[:,#(`ZN+5'F'LEDPPUA&0M[RI]F5UZZ6L!Y#W4GS"VMS@]T5DP$0
M$Q2C6+D#&*&P1R[V]KM#CRP@>8VRCQ3<[>\G_8FT81A*S'NIH=`QK<':$Y98
M<^/W6/QS\\L9EUL6]1=D8IF=O>2CN!M$F/4S'NH^87UO>S]F0Z@56^R#J!_!
M?!@]1=D?]W.WO*/3_:/[,Q[J/F%];WY068]]SSP9@]1=D_\`<SM[R3]CUHLZ
MN8]U'S"^M[\H+,>^]WX,P>HFR38-9$Y6]Y`W(K8_P9CW4]/H%M;QSD+[H++C
MOG*7(*O=B([Q@#(`"-S'APIGF#LV0?"/UAF'C!;"W^I.?N#6B<'F;(@#^[NK
MZ\VZTFW7'H'K]Z-SO*6+=0-0T!;Y%[WQ5&FCRHZJK2.#..[00[I!D".>T4]_
M,.#:&/E]96RSOQ2;0O?XP''#Q7)@AR\Z^F2-D/9NU.V>2S6N#1'BL<TVV1XE
M]@;_`*F6M.DB"7,@::ZA.42*"BH']?D842[Q2GSS''A=C4LV10S#+?"!.->B
MFU4F:0'L!S'\EN`*01`"D2`PB`%$2"``(B``.?.&RR'CR''D64M?5UY:Q[H%
M\,)X[,:]#L^?04].\/8WW#Q#%R*G]W=8E+6FU'VLTZRM#3+Y*Y45$OWUR49!
MB6GZ/>U%,/Z=IQK,-UDB/E4I6=:)MRG3$"E%<HB`Y"`^PD^7VT:IULUQ:,KM
M*\H[;U)1B!:!'(-"\=/ZT*$J#4W=33@I3<A`0UH*.EZLF[S2<DS1HIR\IDS$
ME41;4ITDG/\``!WY054,KS:B@"0N1MF.F_<"NHZ)T\377866NM)P<?&L<S>6
MDF/O71$<FA2RRU)Z?G5#U1<D+L4X2A*/?-XRK9IT+N.=0R\@4HQPJ0[YNG+&
M/+(JE48\TBJ#K]IF`"..+]L;6[9Z=*I]S4G9;F&A0I16LB+N7(.EJ/BZ,EZ<
M6U,IV$I^HI"IN]0U3$,Z1/,O)V$CWC1N=>?3643249&`JH@8Q@'9B?M?:I]Y
M[H<^E,E;R4;I@:YK8<@T*8DM4FG)[[N#1UWJ<DV]L'YVU9&:MIEV$03NHT:@
MFS<)11D*A,69+W+N,A7/SVSB'$?:NTNT[.=*V_7J"'NMS#0N3\:NC)^Y>F^C
M[:'BJ]I?4`]N@Q]V;=_S+FDG]KXEJ]F6KZ#=(IN4GZIWX()H'(`E,41.`;`Q
M9N[FTJ<ZR\[%QZ5>7M[9Y/N-S#0MAXTEO8NYM^*!K95.@8.Q3&V+R8N#5$F5
MK`287*;.#0R2B::`.XQ5!T4J*@]ND83@)2[,6^@U\S^,QY3I3?K]!V&YAH70
ML]46G-U;NI+MIW@I1.V])SQ:3J"LB.)$P0-3*N4FC>--$+,C33IXZ75R200;
M'5<(#SI`$@#DR3N]M&4ZUSNM9QZ55^W]GN:06#HT*&;;:PHRZ$BQ/3D)23FG
M9G4+5ECXZ5/5IVIW]/040UE1J*GVBS0AI)=V<`4,@42JH$4[8?N9P#7-W6K[
MEX.=>A'"=*PR]O;.UGNMPY-"EQ'5;IO=LZPDF5VJ:D(ZA)<(FJ5HI*?>F8OG
M)SMV:,6@QB3KU0=RZ;G1%1D"Y2G3$3"`8YU/L"OF%PO.,".,Z5UZC>'9S6LZ
MHM;DT+C)C6[IKAJHL?3I*T+4">H*9D8"BI6";R+YBB[B!4!XPJ`Y6JRT,Y>N
MB"V(BKN*)K$-O@&-/VW7]IV<Z5F^Y-F]D=&A9V6K2U5-6Q8W&O35]$6\0D:\
MK^B8OO-/OZN;21:'GW<4=XDI!LEW3UVDW;_S45-OS;0Q-Q0X"`CA4S=NOO>\
M[!C.E,9O-LX#W1T:%UM8ZJ=-]OV$3*UE>BBX6+J&!CJHIQXX<N'9INFY90$6
M$XQ2:E<J#$@H(%76,($;&'(^0@(8I]M5_:=G.E7^Y]G]@=&A3PV79O6S9ZQ<
M,Y!D];H.V4@T^[,WS1RD19N[9KE4`J[5PB<#)J`&1RB`ACB[0H*^EF&1?=U8
M<9XX'&H9M:CJ)AG-8+IR#B'(N<KI(ON!N(?<)E[A:JW2E3*3/FJ>DS"!C=L<
M=[/E'"*"GVC?@7NB,ITJE=M"ENV,!YAH7":=DBJ6!LL!P(!26OIQQNE%7+(S
M81!,N2H;0#CRRQW*RGJVRA%YB1C.E5H=H4@EM=<&8:%Q.HO4:>PSJS5/QM`'
MK^I[S5A*T?3\::JX*B&#!:'@'51+*RL_4)",$$SL&@E)F?>,<0VXU[$V-45`
M,R9,(EC"3&P9U.T-M4K;+K<&(:%S%IM7,'=KX%)9K3$71=-W*@[LR4O[LJJ;
MQM14S(6DD#,:@3AX\C,\=5E%Y$,JM*H*%0!,@FVXZ%=NY7M<6AQB##"=*Y$O
M>6D!M:(\VA8:ZUO63:6;O==.T-54_=N3LA2["=FJ182#N/[I9RKHB+1XN^=L
M6RCB.<IF$S=TVY]J<0`F^`X51;N[0M-XQY3I71E[S4N&Z,PT*37&IJQ$16U)
M6PJFZ-+P%TZPB8/O?23AX^.5&3GV39Y"1$E)()'A8V9F!7W&S9PX245$`$`R
M,&,4W=_:CVDE[H8XGBYU;[DV?@NCHT)LUJ:L:QGI6B(VXM'O;BM"5,RCJ0=*
MO$$IBI*69.W<M%+RZ2:S%D>)!J)GH`=0S=/,1VXPC=/:KWM>'.A$'CTJLW>3
M9^K=!HC`XL7(M13FJ:T*M/6I/7]:4E1-<W7BV$K`TBQF'50(F:RC\L8P>LYB
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MS4PNDQ5$Z:0;_`&,+-UMJRYH87.#>4Z4'>.D:(EHZ-"AA_KCM/*W3CK;6MGJ
M1N6=K;R[M853+(3#MK'04Q;%LF*$*Y=N(Q)NK3#UV=5-20;BNBF=#>]+GCI2
M=V]H1]YW3I2ON>B[(Z-"P73US6NM%9:"K2HYRB"76GK74W<&#M0QJ,))I-C/
M/FJ#ANUGT&96#1B\!R4S5PJ9'ND2#N`(9XU3=VZ\L!O.A'&=*5,WGHR!!K1;
MDT*=5=0MEHRKZ;MQ5-=Q-,7#J)A$JHTU(I/&Z+"2E(HDP$"+X[1"-2<%:"91
M,IUA76`.U*.88S#=RO-H<Z'*=*5]RTF)N8:%&5M-;>F^Y=#5G<6/KQ&!IV@J
MZD*!GBU"R?-I)26;.EVD>O&1J+==[)H32S1;F$T$U'!02,)TP#+.?I$RC!=5
M2'U`."T=6&'WHX<F)6;O31LXA;PQ*R-&UE2=PJ;C*QHN;CZGIJ:37,PE8XYS
MM>>9O'#!\R/O&0<H/F+QL<BZ"R22R0Y;Q0SQPMH;5D4_^+P$R`_<S0NS2[9I
M:@1#`2>30H2U7`0+7T^()D*(7EL^IOE#,Y3HU8D*`DYP5``2*GS'E#%]CSIU
M=2S9M-+=3M$R!!(M-V,>K#D63:M93,K)0+!:R.`8SD5G'A$DW2Z8D*<4U#%$
MY][>.<<C*G'<.4H;RIC"&S8&6.;,IMHZPD/,.4Z5U9-?2ZD$-''Q#0O*)4A_
ME:8=3<,;T15SPP2*^'ONSG2K,K*-PB6-C'$-"-U+U"7[V/X7$ZBN[;LYTJ_B
MJ/L-S#0C=3R_D:7[V/X7%WTVT&R@\/=`Y3I5&5=*^<988W,-"Y^KZB0H^CZO
MK-=JJ]:T72\[5#UD14J2SAM!1KB2%HS3,F<#*O0;B0AA$0(8<QV8914.T*I\
M+[B.4Z4JNVA24C(W&QY!H5(K4](!2%8N(!.\%`/K`,JPLT74'1<_5-4P\S#2
MMMQEDH==W*KPK7>@7C60>-TS$<%$3\_F4!`HX[;=R-ISR7LG.PVB+K(B,,.(
MA>5^YI.M+2T7(G%H5@%-56FY-M34BO=>E2QU9"=2GGB`2SI)PS![WL2E7PIM
M2!#PSR6$&Z#MUS*2QAS*.6).XFUP+)KR>5W>7HZ7>79Y:TO:T<PT+#<?4]:*
MW#NKJ./7-/2MW:=H.;K6.MHF\<*KN%(>--,%92$@RWXZ-EG<<'.HM7*J9SI]
MMF(#AE%NUM&):'.(!QG#G7/=O/17C!HPY-"CNVFKJF:IC35#7B]"VMI?X'[3
MW'D)5_5:B\U$2UUU%D$XJH(TS,>\U/*R"(D9.S*'*.0AD(CBM;NWM#`7.ARG
M2H&\]%'W1T:%V3[4W;>H*:HJJK0U%1-P:>J6\,+:64=2-4*4VA$2+\HH/&D>
M+UB1=_,G=$,LU;BDD*Z>Z8#;NW"*+=>OE-O7G0&4V=*U'>6D?_",PT+=#J<T
MZ'D:[C&UV:<>*6R642K5!BC*2:L0)#&0*DU<LDW*-0O.[R]RG08@N=)<0*?(
M1RPU^P-HFJ8R\[K/`X\?*D3-M4@8Z9=%@)XM"X:0U:4%,UCIQA+9/H&X\#?:
MX=5V]=5.T>N68T<^I&GSS[U!Y"/&[9Z2373%,A$%2HJE$V8E$,,K=WMH2`8.
M<'#ETI--M^C>1U1'FT*VN28[P<VF&Z82CVAMN6?_`.MZF/+/I=H,FAI>[CXS
MI7=E[2I)@A<$#D&A)NI>H2_>Q_"XMJ*[MNSG2G>*H^PW,-"-U/U"7[V/X7!J
M*[MNSG2CQM&VVX!S#0EW4_4)?O8_A<1J*[MNSG2CZC1]D9AH4`:JBE\7*[Q@
M31,!:81WB&3[4P&FXD`W@$Q\\AVX[&QS54SYKYCB06`6DGCY5Q]K[0I"R4`T
M'KXABY%.$:F0(:"#=*80@8,-H"!0_@IH.1-P2=J&?'C#6UTT3B..*Z%'7TIE
M6-&8:%[B@F7/[F3+9E_)//\`Y;B6UDV[A,4QM;2/)BQL>0:$[[D/\K3#_4F-
M]=7%O&3<9SJWBJ/L-S#0D$$_O:?[V/!^^XQ5(KJAXG2G$2P(83APXTR754A=
M<#!F&A:V<?MX>!GIM5N+M&!@9N?58-LB.G",'&N)5TFB``=0QCMVQLASR`>+
M'4V11U-0^X]YZ5FKZRDIY=^X!FT+YC#TF/<-LY"N9JP,W2Z]0V'J2_5GFCRM
M(&>C;BT?3,^SAIIM)K1B)7E'2[8CTBY2N"Y&+VN0FQZ2?NY.<XME/)(@#:;(
MB./$O-_<%+"]=`!Y.+F5Q:'U6V`KNA*AKN&N53$O"4,VA$J^&)5E.>I&9F(U
M!TVBE&2S5O)2+EVZ,=-N#=`X+;N93&''G*K=[:<8,<Z//I6^5M^CA[HCS:%Z
MDM46G96DH*MFUUX-U3M234C3D&NV8S+R1?3,0&<NR&&*S[^H&A1$`?"JV(+4
M3!OAD.>-<G=3:3J9DPN=$BVTZ5J&WZ"'68V/(-"W\A?RS,36D+;N2N!!-*TJ
M%"*<14.H=R"10GM_W/MIF4`.]E/2<YS*G<[5THFL;<`-W,P8SS-WJ]AA?=AQ
MG2I^O[/[+<PT+S'O0Q'4O"Z:0@GZLO/V>D+N(58=R";5I'1T^G`F@A8@8R_=
MBAE`6!7?YHI-@@([</E[MU9@;QCSZ4B9O!1\31T:%6Z+UJOUIA63E*-3?6VK
M;5VCI<L_(Q;Q9H]45CHUXC4%;SA5]X7C5M/,3H)E3RWQ#,!R#'1E;M56"\8X
M>/2N=,WAI`Z%T0YM"L78*]\9?FE:IK&,IEY2Y:8NA7MK7#*0=I/!>/:#FAA'
M<NB<$0(DTDE`YQ)(0YQ,NPPY[<<_:>R:JD%KS#GTKLT&U:2KLNC,-"FK=3^]
MI!_W,?PN.$REJYL2'NLMPG2MTZJI93@TL;:<0T)=U+U"7[V/X7%=17=MV<Z5
M;Q5'V&YAH1NI_>TOWL?PN);(KKPZ[LYTJKJRC#2;C<PT)0YL!`>;3X0```A@
M$!$=A@$%=FZ8<\`IZ\S`;YPXSI4&OI=7>+!F&A5Q1,8=8YP$V9#Z:VH"4Y!,
M)SEKQT.\H(J[<LMF/0S&UE/LYTQ[B61'&<F5<.174;MI!MP0@[B&+D5D-TH$
M(`E2$`SV<T/'M#;SO%CD>,FXSG7<\31]@9AH31!+[VF/_<Q_"X7-FU-0VY+<
M008X2H?64;!&XW,-"3)(/Y20?]2<OUE<(\/7]MV<Z4KZA1]AN8:$XH)".7-$
M+U1YW+_ON*.D;0XGNSG2GR*V@>27,;9D&A>==4$4W*Q"B0K-H\>J\UFF*B3-
MJLZ4`JZO.)E-N(B`%S`3".S@QJV=0[0F3@2\YSI2=H[7I)4DZM@Z,7(OF$RZ
M2YJYH<M<2]@YVEHFK[9W8N%9>1=5I$R:%>N;.N7"-5PU2M&35.2IDZC=#?05
M4**!@,&>9@Q[?Z%4U5.Z+SK&0''QB(X\2\?(WADAS@YHC'$%:ZU>K73_`'1H
M)U6<3<>DFX4G35,3URXML=^L:@O=-'-I!`BQ%6R+Z5:G5<BDBL@FH5=8AB$'
M,,@\C/W<VD)Q#7.PXSI7I:+;FS3;,:V'(-"VZ.JC3@M1P5[\*4*K39ZD-1Z7
M<L7-NJB-5)4>[3P*M(IL_=&A((Q0@\6(9ODBU'G#"!=N+C=S:SP&ASK<ITIE
M3O%LQDZXQK870>+0MY4.H"Q](5-`4E5-Q:7A:@J8L0K$LECO52%;U`.Y`N)B
M5:E4C8!.=4$",@>&0%P8P`7AP#=S:M-U@YT>?2F2]LT$QMC6QYM"Y2[>I"$M
M1=&)M6^HV2EW<K8:ZU^>^24D@U.G%6J:E=O*?.W$K@Q)*8(8`14`XII?MP''
M5IMC[0GRPY[W7B883IXUAJ]K44MY<&@CFT+F;,:MH"\E<4!0,71$I#J5]IJI
MO4H1^Z?%,5C$5+,*0Z%-'$A2">09G)O*+E`J)P#M2AC#M+9.T*6)#W693I10
M[>I9[@VZ.C0K:E!(1RW"#D3>WC<X(_Q(CS@9FY1QPQ(VA"U[H\ITKL?4:/LM
MS#0D`$OO2?\`'_A<3J*_MNSG2CZA1]EN8:$FZE][2_>Q_"XG45W;=G.E'BZ,
MVW!F&A&ZE][2_>Q_"XELBNO#KNPXSI1XFC=U0QL3D&A9$B)BLD`I)Y"J0!`"
M&`1#>#,,^='+,./&[554S:`_R'WLNE<>KI-68A0;;U$@Z4+[%WUA3#7'`Y)\
MYVH%\9NTX;@9%X!SX\=.HHZGZO3LO&_!QPG!=?E5FP\(YN0?B%*E_1%36K28
M"(D.&F6H<BG(H;@KR,$1.+=-?<V!QXX]&*_P;^M9R!=5E32"(=+B?YBMT';"
M4N\">^)2\XH(%(GO"`;YS`(B4A,\Q$`S``QRMDS:J75.!M(X[,ZNYTAPZ@@.
M4J@VIC2!4E];@7+K2/J2$@6<YIMC+=6_<NV:IY6E+STK7Z5;T57#A51'G4(J
M/D6Q!`P``G((FSRV8]YL_>3:%%[POX\`_)>3VILZGG&#3`\Z@);HWKA3=)M:
M=D;E4P>6E-*%=VTN)5C9R^6>U-?2O[AL+@/*J=-DEBG=TZ5\T.BZ$A@4*V5*
M4/29#V7;\53^J^3%G&+S<'PK%(W?ENE%^L&#$=*W2^A&XAK;KKQT/;2F[X1-
MS+-W'YQY75=7!HBXR5FD3-XJ(J\TXV32B63Q)=4Z""!3IMNU3,53AQ0[X-<"
MTTSH$<3Q^-U5^WY?S!F]JZ6)T57AEGL',U?.6TCIB2ULFU-3*=!1KU*%84_*
MT)*4P2G*0([CCD]UL;+R)%3+`1!,VX7>)D&*'>T:O5MIG6"PEX)YR6Q/*58;
M`8#>U@^$Z4VEM,^K>E=.Y+`0%4V<A8ZB*@;JT17E)(R4965R*56N&^J.>IRM
M9YS%.EZ(E'K=QS9GC8%52.2"<H%*(83]T$.+A(=$CMV<PA`*_P!#;#_8,QTK
M!8+0]<FU5<V0JZ>J2BWC2WUW=0ER)IBVDIV5=.&-Z(^.:PD+$R<DFF#Z59NV
M:HKN#[O=`;1*7(,9JS>B8^3!L@QCVAE_:KLV&R-LSBQ'2MO?O1=7UU:GU/3L
M54E&#'7NJ#31(4]'S*AUU8MC9.51<5='SR8'$IAD$_N:)"[#F$-N6W&.7O3-
M9`FG)_K'=3OH<KYG0=*==71U<FH:IN?7=OY.VC:==ZK;6ZD+:T]/MEFU'/T:
M$I!*DY&GJY3BT%%VK@S510S,$$S9&$!',<\;9.\SI[1+U!:&C"7@QCS*DS8C
M!@F#,=*UT1H@NTX>TJ_K&I+:0[M#5C<&_=7-*#92T6UI^F;@T),4@TBJ,CS,
MD@(_A7<X!A`4T@6,H*@!O"(AV_NTZG4^'/N@1O@X./W8K*W8$MKP[6C#V3I6
M.D],VK^D-.E):?HBJ;+4RPM=(P,;"3U'*U!`5;=.AX6I9&5J*#J:HDV+F2H2
M8DVCA,17;J.%C*)G'?#>RQQI>WC3/<XR2Z\8^\!"R&*U/J-C,G!H$R`:(8#I
M7EM7HEO):1CITFH>5ME.3=H]2MZ+NS$=+GFW,7+4#>1J=)U%L)=TQ?.WU34H
MW4`Z/.I9J*9J@)#F'#7;T%P@9#A'$^'X#A@6<;OM^:/A.E:NCM$E^;2.*!K6
M@92S-6UO2HZCJ=E*-KXDPUI$M&7ZJ-[-1U31$@W9+"WK"&;/1(Y*4N3H"`!M
MT1'"YV\KIH$))$'-/O#B,88.-,;L)K+!-Z/:ME2^@"HJ(B&,"6J:/GH^-T27
M$T[MY"9@\G?N_KFI)*=/*1$>\:/"-:=;N'Y4B;@E4YM/,%"\&)=O*XP_PFPQ
M]X:.A'T,?-'PG2OH9;"E)"@K:6\H647;.Y2C:+INF))PP5558G?0L6V8N>XS
MN<EA;`JB.X`[`#8&S'E]KU<^LJ75#&W6N`LL.``88+TNS-GT\BE:V8X%T3Q'
M'RK:UT;^Q]<'>*H&]0=8B`@3?+LIR2#A*(CZ&,FSS4ZS]$VJD4DP7<!YUP6G
MDHEL#9,0.4P&MC2^]MRR#N?:7;D/7`,/VP^J$D/!P<BF134[)36BVS"H,UH:
M;*HU".M/4A`0-LJR96=N=.U7.4-=TTPA1M;1DO3[R.1CSR$0U>/4WK%RY`P9
M$`HD+S899YANW5W@J:.,O5DNA`&+;(\<"T@PRK+5[*D55EZ&?2JQ0O1SW)3A
M:)I.I;FP32*CK8:E*3GD:62E4/@^<7N7;O:0I>VS-=4X)4+1YFQ47.^`'7:G
M.F)0$PFQZZHWM,TG_`02;>L.ZO+.V'+:\]?C/$=*VDUH>OQ<*DZR2KQ_96E:
MP:Z3X'2U;Z+MY'R:5-2[9C5#2H)"M:M:)L6R,8(IM038L"\Z5L)C"*A\\L*I
M]Z=1&$@D$Q]['_3[$\;,E@8>++I6SJ+0S=R8F+A6W8U-;%>SEX+U6HOM5]93
M#"22NC24C;1O3;:0INF6A&B2;M%RI321&3DSE,C`JA]XA\Q'&YN\4I[P_4F^
M`0.M9;C$('\<1M6+Z0`(7^CVJN5E:7KY;4?7<=-VUJ:;=5K7&I5M'-9UC4D*
M33K$UU&NH]K<&1E%V1*,EXRL44TBE&/?.W1R";-,F]C3-W@9,DD:J!$#[V(Q
MQ9%9FQ@7`7[#D.E6CL=I&OKI^JZ@INFY&R%;,'NGZUEG[J)UBF[63I!"A)YT
M+:H+7$WEPE8V;*Y`#,A*DLD]R44,8`RQP:[;OBB+K"P\5L?R77D['E26EL8C
MGTJ9;T64O>UU$T]J7T]3-`/ZJ+;$]G*^H.\:LZR@J@I;OD$C`5#!S$-N/4)>
M$?JCD&X;G2B&6[EGCE/VC4293G1B!Q6:%1VQ93IHF!V#(=*@ZYFCW5!=F[],
MUC7=Q:#EH")NM::Y<:V0D9Z*BJ00H-NBE5M)P=&D:]QS,@_<[ZZ4P_6.XR`J
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M1?14PD&\@1;<,F<P&WCG*`@VLWGLEO$DQ8\GW@,+2,651]#:6ENL`CD.E29<
MW1_?VX=\:+KB5KVEY&WE#W7LU<RDFS^1J%B%,TQ;R`;1514D>E6C(K"6FG+Y
M$3(2S@5%P+]SW!+A3-YM:PRM00T@CWAQ_P!*2[836$$/X\7M7+5#H2O2^I&8
MI1">M\=.E]753ZE+5NX^:JVEUJVA:L+)N)VG*[EHI$DA34K'H/LF#Q$3&(;/
M(G!EUZ'>N=LX37RI(-^6QMI:872X_P`33VM)0S=]LX@7_=,<!X^?(KU:<;5-
M[-6O;TFC34/2CY]4E2U;/0L%4M15A')5!4[Q.1DWA*GJ<I)&97?F$JBJHE`1
M4$=[;CQ&T=YMIUM08!C!'L,/_P`0O4;-V73TMCW1`Y=*TFJW>-:V`'=,/]F6
MT1=TO;*9!5C8V\4@>FSY,\7E5-9X=SIA#K<(#6\6"`_%,VK)HYM9*<+(,AQX
MRK0/0`[UT<3;F\NH(%.&1P`#"&1@'+=-LX,>9FU54)I`;QY%UY5+2B2+1"&5
M>(V11RWBCL]4`8<VIJ2/=_!6ELH9;;I@3'*DSZO6',,3XFI['X*T:'L])3!/
MD(AEG_J@#J\&&3*J?,DB7"ZX<BI+;1,G&=Q'BM_%<O7]./JPMY<&DXQTSCWU
M84-4M*Q[B2-NQB;^=B74;SSXQ1%4Z9.Z`,`%,3@X>/&K9FT)VSG1<V_F'Y%9
M]J4E%M%MUI#,YT+YT-NCGIR!T8.+'TC#4@WOK5-OZ$H*KJ]F9B:G&DP[IVI8
MV>D8%@K,/W2D73AR,S*$1:&;(&.!`',`QZD;UU9`+60'*.[:O).W>IFO($P<
ML#I6XOOHFG[A7O=U]$Q%(UE0%4VDHNTU8VUG*RK.@8>&3H]^FY[XP[:ER%9U
M%&J`!S)LA!,0<""HJF`-W$C>JL`]TYQH2SL!A/5G0'\ITK>L=,-Z*/J?4Y3-
M&N+3REH-1;.5E23M7I2;JZ-$2A[=%HUE1S.14(Y:S44R(0#%<++IG$N0;H#M
MPR1O093K[Y!+X'`^`MA&R&2R."V&%5^AL%@F"')[5#DGT>MTGU-S<"M4=`+A
M*VDTAT`N"I)A5IW3IRJH\Y52BR:C86KIE*-U0%(3EW!`^0<N+3MZG3B(2"!_
M,.ZH&PF$_P"P?"=*F.M-'E:U)7-:5%#U#14;$U9J^M7J(9,F1$V*K6BZ#I+W
M)2$2FWCFZ2:4ZW54,9CS8$,)BE`X'$=[&B7O*93;@DF$(6N!_$6KH,W=E-,=
M:(_RG2N8I33#JQM[9*I;$4C5]E(2-A*B7EK>72:)S*-SZOIV;N`I54O`U7)=
M[5"TV_D&"QFJSUL(K$<[CG;N;@HE[;?,KI4\RR(/!A$8^1.F[%I_#O:7B):>
M(Z5X+)Z&+HVYJNU]4S-14FNA2>JFYM^JA8(S-12[XT/6E"Q]--H_OK)(I=_9
M9G,M3@5VN&9D\Q*4@;,:ML[==-:;DO'QC0L>S]B26D$OZH.(Z5]1A#=W^V*(
M&.)Q$#!LS$=G5Q\SGU=4ZH!N61/&%["104TANL<00!@MMZ4P!`>`?XX.SB_B
M:GL](38T/9Z2G<''Z(=G!XBI['X*KO!.$`(9T@F^H1RP>(J>Q^"7JZ/'^*@3
M5-F?3E>`A1*(C2Z`@7>S$=V=B!$`#+:..CLV?/+WWV671QC&N/MB32%DJ&'6
M9<2G"./E$08"!B",!!&W5`YM0O\`!34-I3<6S8/'CE5<UPFD:LX<:Z%')I-2
M(8.=>L#$RX?1`?\`K@Q#9KR+99CRI\IE$PF(PPQHWB\0AYYLOV1Q:^_Y9SIX
M\#BZ2C>+Y_4$!#EX1,&&:Z89)E7;L3CBJ?\`U&S0]K8B&,K5SD>>:INJ(9NN
MDV?3-/5!!,73DP)HME)FGY"/3/SA1$P)F>+D%0?4AEQYXB@G55%.UH-X1P0@
MD;292U\K5AMP\L="^:%)=&_!TAHQJZS\!'TF7456-F'MMZANE(NY&4BV[AY.
MM9Y6+:).UWQH6GI!-(I%FC---0XE#-;'M)&\D]TII,O`<8Y+;%XUVP)<IUW6
M`CD/'SKL:VTH7C!Y>*>M-6U%4/*5O:G3#;V`.W:R4:)4[-+G;UW#F=C&K)P"
MM5M1YA.7YE1TW03*=(2J'$V'R]X6RFW1(,(D^]C,3A&,IS=E2@;7?CI4&M]`
M][(:W$]!T^M;IM<U]?>K[OT7<I6N*T2J>S3NJV+-@9]"U"X9N'-7.3HH&*_9
MOB'2DB"7>W!#/&X;T_XPT2"("'O#NJCMD2G.)OPYCI7>S.@^K)2^U35]504O
M>&C+BUQ;.XU1.Z@KJN:,>TS7MNH:$8N99A1D`W*PJ8HRT2=XS*=1!$AEC%$A
MLQ$>;,VPYUC9=UO*#^2@['E_,Z#I4O:BK?7.IZ\-9:K+=-25:\I_255MC:3H
MR'34-6DK<BKJE;N*;FDFIS@1".9H"+A<3!F3<$HY<(5;MF8P1+#9E&A;_H,E
M[!U[88CI6N7TESJ-G]$E!TW-PD?(Z=KHVZN]<A[-K&Y^>5;-9EQ5Q0W.<%U*
M'EJA645-F8<R`&W+/%G;SS&`C5$Q_<.ZD.W:EFT30/Z3I4U:6K)U%8BA*UI2
MII.$E7M4WHNQ=)BXIU119H2&K6HN_,6V54<*G'NCFS"01V9Y9Y!P8\YM?:U1
MM1L&MU=F0_D%W=E;-H]G&\]XF'D(TJQ^?+U\P^K9CB4_BI&%][F`73J/!3WA
MS>J`8PM*,P]4'VP=G#_$U'9Z0K1H>STE+Y_\<7LXNRHJ2\"[^"7--"99`;;#
M&4F8"(!F4.V#+,P;1`0Y,QVY8AT^J:^(%D<B2V52NEV69U71$@EUB`H8#Y#I
MO0S[7+=_K[=>GVAEF/!RX[%15SW[-,MS"6Q;QC(N334]&S:0F'!!V/C"L>*B
M8E+M';YG%L]5P#CA7W_+.=>@_P#HPP=)3-X@_MLNM^ZQ(G366LEF/*D3FT+V
M0A"W*CM>(_7W0_Z[%O%5/8Z1H6;447"*:;@$`-GGQAD.7HXNQU3/L'4AR%&H
MI<+/S6)R@9XRD&J:A"KK1$FU3*H("3G7K8[1-XH13-OS+,RP&.)@$P!P<..E
M13YU&^^[KG,E3Z.GGRRP_FOF5;7H[8&@-*U=V])&TH[U+5G;2Z-`IW4<RDS*
MPL>%?/GR\,$&PDY!ZSIZ.=%<%+(%:)H@H)=H\>/2C>F<&W1*L@.,:%P)V[U.
MU\0\6Y#I723&D>\T>WK%>U-<T10%2R6E*R-B8B49,B%CX^J+72QI"IW#=VT8
M*MF\=,-E5FZ+YPDY<IK*F,F!1*`BEF\)8^^9)-I/O8^;H23L&7Q3@/Z3I4.-
M-`]Z&E!7(;-O@Z7N37%Z@N]0U5.+C5R%76=EEZ4)3K:JJ=K3N969J*3:E;*`
M^:/DBLY!DJ+<2E*(&#>-[@'AYIC=A@OCNK-,W?#GWC.!_I.E=14>@JNJDNI+
MUS5[VE;QTI=.+LRM<LM4U95=`*LJEM4R9)FF6]/TB!HZHFSN28@Z8MC\P1JI
MEO`;,0Q6HWK;.E:MM,6XNN#_`/%;Y&S62?XXGD.E6-OUIRJVZE[(2Y$%-0+"
M&B-,%\[(KQ\J9XC/NJHNRT!O!RI!5$G\"-7`9*'-D.[R8R4V\3I$(R8@&/O`
M<?(GSZ*1.E:O`[':N-T[:6*ZL_<^V-<SM1TG)QU!:.:,TTRK>&.N,@^K*EYY
M29>S+'GUA(K%G3,"0`!?3`([P\&,.T]L3MHAS0RY>)(M!A'F"5L_9LFBF7W&
M]T?F5?DZW.9G$V9C'YPQNU()@';NB0#"!<>:ULYO5-I"]6QM(]H<8"(P)!.`
MB(AD`9CD&\78')PX-?.4ZNCQ_BC/S?0Q3Q-3V/P3HT/9Z2C+ZMXO9P&IJ1;<
M_!2#0QP=)3FYQ%=`,@#-5,-IR@`=N`;1$=F$4)K9]2)Y,`#@@/Q6/:4R5@:>
M-0O;TH^*G?9//(1UQP.1A$O-C_C.6G'8IO;HAU<>DFU$YU=*FQZS6D=#A^:Y
M32-2X\7M"[C4%1UVZUUJ4FQM%(6Z:/V^FF?":<W#:3SIJHB-PXM`@MSP)1/O
MAGGERXW4-33R-GOF3K070`%N'BP\JPM;-+X-PK>CI^UL9;:JTQG#@,4T/<@2
MF`=@E,!EMT2B&P0'8(8X]+44DF=,<8P(.#+SKH,9-,(A--8/6J8PJJU9I?*X
M,4`,N6%KLJZFZ7<1+SA"#ND1*``0H!VN6*^(E'C66JIIUZ)P+*6PFM82"4]3
MZ73%$XJ`D6&N*FF500W53E(!NU%<OIP$1*/#E@\1*P15Y%-.U+H8DGP":TA3
M(7W3:71,`"<I%H2OE$"G*("15JD42`'-FR'>'/:'!B/$2L:IX6H3!L!K2$IQ
M-4FE\ZATS)G4/%7##>$X@8R@E)N$*H8X`(F+NF$-F>#Q$K&@4M1P@D&P.M-3
MT]3:7=H"`[L3<$@9;@%`X%(&7=*F0%44',5$PW<@'ML&OE<9.9'A*CA!9RV$
MUK9J_P!<VEY,50`=U&!N"DF!A#=6W=TX""2I,NU#+=$,P'$BHDMM<;%>533@
MZW$FDL%K4+O;E2Z7TSCNCODB;BE`HI%%-($RBH?=+S9A`^>8J9YCD(8MXJEQ
MK1X>;B35+`ZU3$'^N72YF8HEW#0UPU4"&S`0.1,YMXAB99E$#`8IMN8\&&2Z
MVG:26E*FTTX@6)/@!UK',8YZGTOJG%05=]:%N$JISG-E(10RIA%911(Q`,43
M&'(0#(,,\?)RI/AIV5+XOVM,=W^NG3"F"92IHBG#7!*HDF0W.%R.)1%10RYC
M&4.;,5-[(<@#:F;5RGD84>$GFU/"P6M5,XF1JC3"B(YF$Y(.X)%>=-F<QP-F
M8@%45$1,`%#,O:YY!A>OE8U'A9ZP!8#6@F"9!J+2R":?.&!((6X)$Q.J(F,8
M2'$XY"H(CEGLSR#$>(E8U/A9YY$GP!:UR%*4M3:8`+O`8R:,9<E,YCD$HD%(
M"K@5,N9<S%#8?/$Z^5C4>%G\(+-\`FM<0#.J=,>\(`*@FC;E'$RG[<W\F'=W
MC<6T`X,/%72B4&NM<-/*IU-4T0&!<A7]D-9K*@J]4<5'IH[F&A:P[J!G#5V5
MXLG[G9$#<T=R@KF<`Y38U4-72,>&D1B1TGE6*9*JL`PP7$Z<K):R)&P-FW,1
M4VFY*+5MS39&)9.(N&,@1N#0#%[K[F5*W%;,1SW.UQ&T*VEF/=*A@/#C72D,
MG"0R][UU3&>P.M<QC'"J-+O.&;BV,<8.X0B8HJ\YOCD)!S`O:\.]EMWL8Z6K
MI*9]X\.E.N34'L#K6,H0I:DTNIE$QLU>\-><ZL<I-Y+>.)15.)![4H_M0#:`
M\.&FMIC:!AM4ZAW&G!8;6B8I0)4VF'-0-XO.PUPC$$@"`BHU2`"*$R#:(&`1
MSZF*^,I\1BCP[EC+8#6ID4IZKTPE*!CB)!A:_P!T$E2CSZ"9@,*J::YQWAR-
MQ>?A+*R%I684[L:]`V+UM`")4ZJTR$`A$B"<(>ORBJ9+=%$#*`!16(B<.T+L
M$N09B?@QK\>VX08V@A2VG<'1Q%>=2PVM,P&`M5Z7S@#DZQS##7!,D*JQ1[I'
M<.8W-R+IX`&44$H$$H9`4.'&/7MQ%:8'(FI6&UI@H)RU/IB()@W$5#P5='`I
M#`4"F(<4S'W`6SXBF`2AEPX!/8<,8(@4_P"`'6ED8#5+IAR4(FB.]`7#S72,
M5-1RFX*H4RBQ57(B.]D40`,:6U\N6VZVQ!:1A2GL+K5/L&I=,"P;IBD,VA:^
M1/N@0$P(0Y"`8G-\!1'TG"(CA,R?(F@GC57-)"P$L+K54*!1J+2^F4"[HBA`
MUZ!MWC,)2@<%G0%SS.;8)MN6%ATMF"P%+NE9#V(UJG2,8]3Z9RJ""93%)!5P
M"BH-P*#54JQ"E*4Z8[P',)@,<`X,,;/8XP=$M"7-)8T$0B3PR)B=A]:JY,T:
MLTQ$.)%0'^!+@G0+SPA]U22-VQ!5*&>1\A*;:`"&&BJD2[;5$H.<;<"]/B_:
MU`,=0*ITP%4/S8`88:X)A'F]PQ14S[50_.I%,(B&T`RX,`VE)M!71ER[@).$
MIOP!:URB(C5&F`O)E$7&(7(3"<W:I'(7:J<P]0!RX`#&69,D'K"*RU+)SC_B
M59M5UF=6T;;FF"U#.Z=7K9S>&U*;,L5&5VDNC(!5")FZAUGP*%YHQB@42[P!
MQY8Z^R*RF?)F29F&,<F!>?K95:*ACG8OS5FE+$ZU7*RZ_NGTR#SBHJ9'B[@I
M*)\X4JG-J<P"*:AD]_+>`!SY>(.?,GT9?$X?;RKNR959JK/=X9$!8/6J(;*J
MTQD#D[T7(4\_>YX.'%O$4F(\.=)=+J@4?`#K6_*W3+YT-<<`ZW.C@\128CPY
MU%RJ2_`!K/'T]4Z8Q-QB,7<H!'S@4R#9A+YTDN-V,.&53<JT?`!K0[?*JM,1
M0,4A0*$5<H2`)1SWS%%00.8?.Q372U&KK$\;":VS;X#5.EXQ5$RHF/WGN."P
MMRB!R(%5`_:)@<`X``V[VN>#Q$H<:UMD3KHB+8+"73]K7S`QJETL$,4PG*4D
M'<,&Q3B.8J$;G,<2GWASSW\3XF5C4^'FXDI;!ZT2[Q/=/I;!/?<"4A(.NR;J
M;E8JIT\A3.B8P`42[PI[V0X/$2L:R&EG\()#V!UI?=!3J33`(J@0!#O+<+FP
M%-$K4GW,#9<R5L0"B3/(3`!N'$B?*QH\-/">2PNM@HB(U9IAS$X*"5.(N(DF
M8Q0W`YQ/,_.?<M@[0[;MN'&GZA)6K5S<2Q$T_P"M=,$P)56ETH))\T0@0-?\
MR!!4$YA%(0'>5-GEO"81#AP?4)7%A4.E37-+880G>+_K4#("U-I>R+N[G.0U
MPSG3%,O-I"0Y13,'-DZXB(XKXYCO]B5*IYTLQ@GC876P)1(>J-,!BCEF/>FY
M!1V9<'W7,-H8!446&!O<GM6N:^<Z26#WCI3"6!UHE'/W2Z8AZG>VY0?ZZ.#Q
M-)B.;VK!JJM/-876F(=I4NF%,?5=[;DFV<F7.!B?$4F(YO:C5U:8%@];'Y6:
M80\V(N0;T.?Q'B*3$>'.C55?#]%`&JFR6K^.T[7:6GJBTX/HLU+D*NVBH6ON
M[SF"9B12%`SHRI"9&X1#(<=#9M51B:6$'K"'YXUR=KR:O5,.)_#B4T0UB]9[
MR&A%$:DTTE:]XX<&H.8RO@<)H%CVY4TEU$$T!.J4H!O9Y@`CLQCJIU&9KH\1
M(S+=12JS4@Z%LPL#K2`-E3Z8PY<X^XX_ZX&%BHI`+8\.=.$FJO'V)P6#UK_M
M*JTPARYQ5QS^B"P98#44>(\.=6U56CX`=:YMHU5IA$>I%7)+Z`*CGA3Y].3U
M8@<B=+ESPWKBV*>6P6M@N8%JK2^`&(9)3.(N083HGR$Z>9E>T$1`!`P!F&*:
MZ2F7)N)`V!UIB=$YJETNG%$R6Z8\+7QE>:(<YCI@L*7.[RN^`;YA,)0#8&'L
MJY#6W;4A]//<Z(6(-/NM,!$?=)I<])NE#O+<02G,(`0YW0',?NH#D``W1R`!
MVABWC*?*J^%GK)\`.M8/_>C2Z)RFYQ)92%N"HNDH(`4X@<0`#)&(``!!#M0X
M\6\?(%EJCPL].&P>M42[GNETNE*)")J`2&N$43I(Y`@4#"!C)BF`;1`<S<>#
MQ\C*CPL](2P>MI-8%DZLTR)&+O"F*47<A,0,8FY]T.53?5(`";M=F8FXL7=7
MR'#`8PQ+4)<T-`XP$WX`-:P<V!:KTPD*F)S[I(FXY0YY38JH7,YQ*"A=@EVA
MQXQOJ9+D7)V).&P6M3(<JITP@8P%$<HNY()\ZGL2.5(JA2D*F41#=X!Q772E
MDU=6D^`+6OQU7IA$.,.]-R=O_P!M@$Z5&W`C5UB0+`:T0$!]TVF(<A`<N]MR
MMN7_`'7&CQ-)B.;VJ=55\/T60UA=:`E$/='IB#,.$(ZY.8=<^6+MJJ0.!@<W
MM5)LJKU9AA@L);`:S]\@C4VF3(#@;/O9<13+=,`[W-J<X0V[EGD(#BLRKI'.
MB.+AC59<JM#+?R5:4K/ZNSZQUH\9[3J6I/%T;F76[UUP6+48!7KH$UP*BFBX
M!0XAED79GPXZ;ZJD=0$C!$?DN;+E50V@T$&,#^"LS\`6M02@7W4:8^USX(JY
M&>T?^V\&.7XBDQ'ASKK:NKXT@V!UIAPU1IE]J[D!_KN)\129>'.J/E51"3X`
MM:(\-3:9C>9&7'_95P>(I,O#G2M34H"P.M/]I4VF<O+_``5<8^?)_+MF%S)]
M/9<,%III<\$WLB?\`6MC=W?=5ICR`PG`JT/<<2"?FSID,8@+!O[@GWLA'+,`
MPOQ$H<:UW)O%%."P>M@#K'+56F(IEB*)'4)%W'(L**H%!5'?W]T$S99AD4-T
M1V8CQ$K&C4S76P6'Q?=:PAVU3:6#&*4A4Q[PW"W2`F&ZF84S*F*=0I`#:.P3
M=MEF.#Q$G&C43<2>>P.M<XCSE5:7SB8!%0PPE?`HHILYM0ZR9"+")``0RWMT
M0V9!QGB)7$5GFTT\NB,2"6`UI$/SA:DTM@<`'<$(.ORD+F';9I$(4APSX-@"
M'*/#B?$2L:7X2H3BV%ULD*!"57I@!(#&4,B,/<8R2AU`W5.<`5-\4A)Z4@&`
MI3=L&W$>(E8U/A:A(-@=:9C%YRIM,"I"AN@!HJXX*%3#TB::Q3%,F4O+D(B&
M#Q$K&CPM0L8V`UH9CG4^F+//;NQUQRAYQ><'+!KI6-&IJQ8/R2?`!K/_`"GT
MQ_B%Q_PF#72L?0C55?""?\`>MCBJO3%EQ?P5<C\-C0*BDA:#'AE1JZOA^BS?
M`+K1_*+3#[77*_=XDU-)#`<WM4ZJK3`L+K43$IB5'IA%0@@<@#&W(R$Y1S*`
M[PJ%RSY2B'4'%I%31L'5!YOU66?*K"^W\E"5N::NH.DR_P!2IWE#?":7753[
M))\FTERT,$@;4Q:-416;J-2R9VV0&`.;2'(V0CL`<0\M\:P_P_JMS`?`/''`
M?BKOG3(;7C&E$H;P:6IT"'#,.;RN9`[2D`0((CSX\(#P8Y(#I<G5WB6WHVK7
M*(+K1A5PS$#FQ$3'R$HY@)QRRRVYCR98YS96HF%P<71,+<JV!\&W@+52+5-J
M*K&S566>HFBF%M2N;E)W`=.9VY]4FI*FHI&BH!.:;M2R11`P.Y14_-9B!@*&
MT`SQUJ?9\J:'%[WAHA@`)M7/FUDV9"+6DGE6:T>LFW->6O1KJI7"E%S<;:&/
MO+6U+.TG+U>EZ1?OY&*1D"/1;-TY%JX=Q"YDC%+F=$2CEF.*3:%DMY:'.A&`
MP*\JLF!MP,$./#C3X_5?2L6[N#+5DJ+:D8NX%"41;I:!C)"4F:D/7='IU-&1
MY8UL19PHZ=GWBIE3*&>0`.6T0H:3B#C'F3?$G$%N:,UGV,K>9AH2'DJC9O)U
M>H8N/=U#2TW3T.%3TFW5=U)1KV5E6Q63*JHEFV665;&$0!)(1`XCD`G@B;+Q
MX<R!4G$%@C=:EA9MI4#E:<GX:/@:8D*X2D9^EY."8U)24.Z3;R=0T@X=IA[H
MHV,45*"XH9B`#O`&0ABYV>Z,+W3[%;Q)Q!;*!U:6IJJ(JR6@2U[(/*,"G.^%
M*)43.I5:_9U:BJYIR8BH%9$'BL+,MVYU&SE44T5"IF[8!$H"J=LXD!MXVGB(
M/Y*15$6W0L`ZM+/FC:">MW]42#RY<M-P%*P+&EIQW/O9BE7`MJH8.XM)#?B7
M$0LF8JG.J&``#>S$`'"!LRT@S']&A3XT]EO2NVIF_=KJP7H)C3-1+R#ZY1*I
M5I-FDS='773HMVHRJ8LIN@4D0I&NTA2,"XER4$"[1V8D4`E1Z[R>;0K-J3,L
MN@+!.Z@J&I6NXJWLTVJ]A+3TPTIR(G'E/2"%%.JGD&JSJ.IKW3BF9(LF\YH4
MBF!$4C+;`'#&T9+;UYT.&1+?4W'0@%`%>:_[8TU$4S.TW3->UM%3-ZH:R+V2
MBJ8FT&+:HY"0<14J>(7>LVG?PE/R384EQ2+NFR$2CD&-3=F`&$Q[ASC0E,K"
M\1NA35):I;51=<%M\\E)<DVG4411DG*=ZW3BE8*M9QF+Z*HZ7GVP&1:U&^1`
M`(UW!."ARE$<]F%BA`%XN-S(1&')!-\0<$!%<S#:H:&N,_HQ>@)D#4S.UQ*4
M4M+U'!SK$E0OH2.DWDFTH!=-N=.8D8YU&J)+`J0J89"!0,8!Q5U"6X7'AS*I
MJP#@"T=<ZN(%K1]RS4=&3R%Q*`IV.J9&GJS@'U-]\X!W4K2GCSL:LZ!,SR*)
MSYSY[J:AA*':@`[3P3HVN/#F5?&-X@U7.B%!<QD>Y.?G3KL&KDZH%`H*G7;I
MK&,!<LR@8QQV<.,,V4;QEES@`M$J=K#"`NKB[M#E:NYVP,RVZK=0!$`'+<IV
M0#=+F`[I1X\L.IZ8RB"'N-O'!,FM:&Q(&!1_I$3)XL-B-TH%+\&5+&`H;0+O
M1R1Q`!',<LQP3J>].+B]T8Y,<4N6Z+`8#`K%\T7]G@#L84^E#_XG!,CD"C*[
M4?6LM;BMHNW4\QI6O'U+R[6CJIDTTU6,-4"J!BLG;EJJ`%$J)\LQ'9C2UF!L
M2D.,`3QKYK6GU)FLTW:4C<&-N!&U;3]64O!:CFUR*O"JEZ.4K:G7[&C;E4E/
M'%&->6_J6JV:318P"D#,71!%/(,QT2Z8/(%XVK$^I<T8!$KK*@UDWL=4Q[HJ
M-MC139I'V2G;]R25234P22<TA'UDI#0$6S8I-T%49*JZ:!-ZBJH(I)F4R$-W
M9C:-F-EN#0XQ+[O*81Q8`,)6<3*J$;C80RJ/ZEOQ>^MHO61*IS,0QMY"6!MQ
M7=NHB,<JMZIIB7K2AV4\BU3EDR"T*LH[.=-14$S9&]+MP[P-PAKC![G$9@3F
M1K*@Q@T71RKK9O63<VV3>JZ-K^B*>F;@PA;'(4H-'R<E*0C]"\3N6BVQYLJ2
M??9Z^IAS3*SATFD43NBFW4MHAB6;.<\7@3=MPV8+,!"#,J`(%K8\_*L;+4!J
M<K6YVF.+90\90$?4EP+KTA<2/J6GIR&;W'C::I6-F(RL:5;ORFE(^*[C7-S)
M%!`P.MI@$H98HZAERKSGNBUHB80,.)6$RI<0+H$3E784A?BY<J]I"VEI:=IT
M)NK'UZ*L>RMS:KF95C'TO;VOD*6?"T5(W2?*O5W<@ES9!.*22>8@4`+GC!/H
MJ=SBXS'AHA"`!XNA.:9YL#1%=9J7"H9^YNDJWZE5551T#<&MJW;ULVHBH7<(
MH_&'H9[(MHY*68BB\1;=\405*8N0[F>>&4S93+S28P;9')@LPJKS-$("PJHD
M_6FHF8BU+8T'=:J9*KK1ZNZ@IF@ZK=.695[LTU1-`.JZ:VXK==`AF\\R4>%/
M$KN""FJ*A"F,.\`CC=J:9PO.)#2T'BL),#AARE(O5`,+HL.7]%N66LIY+4!J
MWN0PK679MY&I[-T!;J.?JG</+=U]7-#PT;4\-'Q2:1WK)Q2\^^75<H`0ZA%$
M#*9;N6(%#*;,NM>2"#&T<6#.L]2Z<]D'B'6TJ<])NI",AK-O:6K6J*XNW5-I
M[B.+32U;1E/3%05'6;98B,K25:3"16K-<J$M$R/W14$BHE%$P$V!CGU=-",'
M.ND9/P6N@9@#HQ!7TD9F(N!#E%02G334*8Y3%_DA`.`;IPS(8`'(Q1VE'8..
M3+D0?$N-B[#V`PQK8F3*8,N#J@`?L@.-3A>;=)*EO55)==:12VNH?>[9,U];
M,[Q#@!B#N5>B?=W,LNWRR$>'+#-G>#I9IDU$QS;\39=CBXX6+!6:]TUKI3&N
M:,,8Y<2N>7=R[;+/M<@[7(H"0H@4-@9%#/')K)TN1-#07$DY%T)<QSF]8-``
M2*',0V0"0`R`>+C\P,:M55/`=3PU9'&2#'F"L&O=;+#2WG3.>/RDZ^(U&T?V
MYSH4ZN?V6]*3G##MS3^V^Q@U>TQ8&RR.5VA1<G]EO2C?'E2^V#]S@N;4[$K.
M[0BY/[+>E/!39Z8OV_V,6U%:;2&1Y2INU'9;TK"=7>V`(@.]NY[P9;1`,_2B
M.)\+6?LSG0KAD\#W61YU2JQ/2`:7-0U=5W:Z@+IT^6YMMZMG*-JJWM1JITY5
MK24IZ55B9`[*-DS)C,-Q73`2"U,J(E',<L=69N_M:GEB;42GAA$8AKH0PX;N
M)>:I]MOGS#+<V6'!Q&'$8<95U><1(4QB[PE(0IQ%0PI@`F'84X&#G""(<I<<
M6HFR*8ALUSP2;,'(N^TM?+OB$5ZPW1_:AP<@=C"WE[,!*7+G7^(++S9-FSA\
MSL8U2I<0'Q,4V.0)W-%^H"]C#G"]QP58Y`@4RC_H!V,+U9[3E`@#&`2<T7E'
MK%_<X-6>TY6O9`CFB\H]8O[G!JSVG(O9`FF3*`9[>'D+^YP:L]IR+PQ!52UO
M)E-I4O1GO!NTPW-F0W-F[2<B#9`<@`8N]ED.7%C;02SX@-O&VS\5@VC=,D&`
ML/YA6.I<A1INGLB@`=X(80#=*.6<<WXQ#,>#&:?3WYA+G'WCB6R3#5-@`+!^
M`71`F40X`#SB]C"Q*+;+SE;`4"D4>IY@%_<XG5GM.4WL@0"1?-\XO8Q(81QE
M$<@1S9.3T`[&)NY2HCD".;)R>@'8P7<I1'($<V3D]`.Q@NY2B.0).:)R>@'8
MQ0RHF-XJ;V0(YHGU`'8Q&I_<Y%[($O-$Y/0#L8=;"$3@1'($G-$^H`[&%&5'
M"XHO9`DYDO*;^-_<X9!3>R!+S)>4?XW]S@AE*B]D".:+RCUB_N<+U9[3D7L@
M2"D4`SX>H(%R_P"IQ(EF/O.57.%TV!-$A<LP``V#P``<7*`9XPS91O\`ON5F
M.ZH,`J6H@'S@*Z>1<O%;9;H[I1,4/A"=!D!A#/(<L=9DHFDO7G606"(%:!`8
M#^"NL"10XQ_C>QC/JSVG+?>R!+S9>/;YH`/[&#5GM.4$QX@CFR\@=8.QB-6>
MTY19B".;+YGF``?L8-5C<Y2"!@`2<T4>';UNQ@U64J;V0).:+YGG%[&#5#&4
M7L@1S1>4>L7]S@U0QE3?R!'-%^H`[&#5#&5%[($<T3D]`.Q@U64HO9`CFB<G
MH!V,&JRE%[($<T3D]`.Q@U64HO9`CF@ZGVI>QA@$!!%X8@CF@ZGVI>Q@@B\,
M2.:+RCUB_N<4U9[3D7L@1S)>4>L7]SB-6>TY%[($SFR@7;VVW+;EV,6D2M38
M'$\J54P<+0,*^8]NASMC?LNZ7=#I!*>(!<NUR\9*T^W+/9PXZ3IA,UK^,-/X
M%86C_"[%8IV-_EYQO_RN3W_293>,SO=3)/O<Q5PAX!+P``<(</G<(9^=C!-P
MQRA:Q[BJ7>C2Y3E[[IV,KNM20\["V@<UB^/2<S$D=MZA?U-&I,&SP05.9%L:
M&,B54H&+DH8,N`<L=:34W&.+;"8<@Y5DU"C2^VDRL+BSE9RU`UQ3EOHZZ-FD
M;+5NQE*96EA9Q$9).9""<4HBA(,6T<NAW8HCNJ<ZWYLVQ,#;<5F3@9C0(D1P
MHU1:"08!;&'TWQT54,5#EN''FGX^X5L;KA$&9-RR:S2WE&K4*9,&`J',DB[7
M5WRKER*`YAPXN2#;C"H(\X6NEM&C&<9TM"R-9J][H2]ET+HN@9QB9%G\9="F
MZ@@WD`"H./YB>QYZB*N1P8HD'FLMW@'!?NF\.&%3`KBFNC&M9V%A8"O[J04P
MA;NUM26DM*YA:16:JQ\)/BQBW,S7)'[]VE+3"<'$H(E*U!NB943JB00$"@:X
M`V#"HM7:UYI*J"8JFN*QINX804E4\'9F""+5:2";*2C;3-WY5XNI7D?)M'2T
M).G>"L"9#EW%$B;PY"(##7V`$<:EUJZ&T^EM>WE0T14#FMF4J^HVH;O3SQO%
M081L>Y6NLNL][WHG[Y.7,6E!MEBE*<!`ZV9<\\\\!<"+;%`$#8N+T]6'GJ1U
M&ZF+ASC)^C0+^HDX"R]/R39!LQBF-1M&]0W,D8=+G4@/$U+6)R'3$Y3J`<AQ
MSR'%9EH`X^--E825N*NTHU75-Y1N&[N0V<TXQNC2%R8QK,1C^;GH;W*-DT#T
M5#J+RC6$BZ<.Z!58ATFAW29Q`=\P;`O+<-7!*G?[$R8TVN*HLW0U#T9<B$0J
M*UM[5+GQ%1KL1FH92<8UE+5*]IV:9QD@@YYH[>:,DJJ"Q%2F$-X"\&&3IA$R
M)&%O.E2(W2!C6L9:-$F%Z*FN4I\',[!UM71[I2251TK)25;TY5JK9$'JU&R[
M.;:,",TG[5)RT,NV47;@8P`83#OX6)H`#88`G&,8XUWT-IE7CZ4L?2Z-7G!U
M:"IZAJ499.-*!YH)5G/-$`8YG6[D<QZ]1%%(YA,<13.8>W$1Q4SF`D.L)2GR
M)DUP>W`%#M/Z'ZO[UU4TJ:Z+23<SEM/@U0G&T7)N7SDR%8-ZK5K";>2TM('=
M3,@LU!!4J8)(DW=B89AB?%2LJ5X*;'#^*^DD.W.UC&+50QCJ-V+9N<Y@W1.9
M%!-(3B7]H)Q)GEQ9XYTTATUSFX+%T:9AEP:[WOT7$W<#*UMT`_YMJY]&G7XX
MT-PC^8+5-,99.1<#I$_R8+#_`-["E/ZF(XB9_L/*DRO]8Y%8S%$Q<Q5=+PE8
M4],TU4+,7\).,EF,HR!=9MW2W7+N'`'#4Z3I$X!P&(<HABS1U@D3/<*HE5VD
MRR-;6BO;8:W:\8U?5<ZA86Z,_4"\O6$Z0&SF%F%6LLO)NEW:CAK3*":<8(JY
M-CG(?(1`1'7+<6"]E7.F"]"&%6:?61ME(,G39[2D8LRD;;M+1ODE`5+W;;E(
MJ*;>FRKMQ17*W4!N0Y!`V^42Y`..;X^O!'5-CB1APG#QKI_X\)P06A'3'9<9
M=[+C2((.9.V\;::2CV\K*I1LE04,1)"&CI1DDX`BBS!HD"**XASR9!],([<6
M^H5\8D&,218;(\ZC_%@*U=SK(V"6A*VJJY$#%LX]U1=(QM65$\F)2+6CJ?MR
M^?25*2"<PP70?0ZE,.9!95)\BH5P7>'>$<2-I;0&`.%L>.V/.B$HIPV`LG+P
M=LQ<MUY-M1E1IU?;JH9&J9%Q-#-3K0%1>,IM=[W;))5&P`B8H&.9,Z)`#<V9
MXM*K*R9-NO:;CK'880RJ?\8MQ<.E:-[IYTZ7).>.3B&;A>VU5SSE1W3DO*04
MI`5+5IDYFKHM>0CG;=<C271<)JK-Q."(E.4=W/;C5,;,.$$1/X(ULK#$+N+M
M:>K07PC*(B[BP#F7;6\FB2]$N&E03,3(1SL8]2,,LVDXQ^C(+D68*\V<JJAB
M+@&1@$,\9FB9+=$QB@OE.LL6VIZR-L*4BJ1C8&C(^';T1/R-1TXDU*Y*6/J"
M6;*HR%0O"F7!=],/45#@HJH<QC"<1#DQ<S)G&<*B,L+F(K2S8B&J>1K2`M]#
M-JAE[FGO/*2""AP1=W2=P1Z96K+FE5569Y<8P1*)03YH#]L!0-MQ85#V-,38
M1!4?*ESH!O$8J3X6WU'0=:537\7&I,*JK*.I^+J:40<'14EV=/%73@3.&[<Y
M6[=5`C@Z8&*0IC$V"(ABKIM]L#:`F,DB68C"I)2*.\)C".]D':Y@($$<\R9A
ML-NCQ\/+A0`!B$V*SXE"^6/3%75EK'Z(*]O%`1T=+3MK*GH&N8B-ES+I13]]
M"U&V50:2"J!B*`W6.80,!3D,(<`ACL[N[#I-L[8ERZHP`!MLQC&#C7&VS7SJ
M&GC)$21'\<H7YF2_2@]79P`QK,:;Q$Z353)*0K`X)BLT06%,3DGSE.8@GR'+
M@'9Q8^OS?*O=]KFZR:#'&6]$9:^2UF^^UFSRR6#",,![RRE^E":NBAE\"NG$
MW5,\K$P^9F,[P8[K/);9U4P3J2K#9)&`OMB,/NRX*TK?_;=.S5W(\>`\?]2=
MY4+JZ_0GIP_&ZP\.XMZ'2/\`W&?&[_QJ_J-MSY?0>^FC]*$U<_H5TW!YKNL,
M_P"KF+CR/I(6UK8_SG_QJ?4?;GRSF/?3O*A-6_Z%M-_XU5_AS%O0^B_]UO\`
M^0_^-3ZC[<^6<Q[Z8/TH35QG_:5TW_C=7>',+/DA31LK60_G=_XU'J+MSY9S
M'OIYOI0VKL@`)+(Z<ELMT<BNZP#@$-G]'<5]#Z?_`-UGQG_QJ1YC;<!MEG,>
M^O@37%RZ@K^[E77N2<FIFMJRK6?KLK^E'SZ-7IB5J-\K("M3;Y-R,H@U*"I]
M\I5M\52E',`V#]2H=W-E;1D>$GL9!K0W`+;H`C:#AAB7S&;OAMB1/+^M:\GC
MLMCVE]KM%GT@7598$\#1%]D%-2UNTQ2C6"LBJ+>[38P*%*9./F&`'<5`^*39
MW,NU.(Y9<YMSQ\LWU\I=W6LFU5,^6RH;+):TW;L6VX!+CP"^C;M[X[8JBR7,
M#S+<X#^+CL[2_;AISOK&ZA[3TA=N&HJX5!1M8-.ZFM+7.I=S2=71R8&W>Z'L
M8[.90S-SPI*%`2F#(=F>/S95TY88$=9?:9,`1#$K!@&P.IA4JQD%L!L3L74(
MP(1@0C`A,/P>?^P.!"JCK>V:4[U?\%DOZM1(8V4'_P"TSE_(K#M#_1PQA6-I
M7_V9IT>6`A?ZG-\*F_['#]Q_%;9/^IO(/P"Z,O`&$G"K'"EQ"A&!","$8$(P
M(1@0C`A&!","$8$(P(1@0D-P#YF)&%5?[I6(?2#_`!(_6QBF^^5:7[H5*T-O
M2`J&XS:6V6?)_;"=CLQUI?\`^D>4+`?_`-YO(?P"NUC*MZ,"$8$(P(1@0C`A
M&!","$8$(P(1@0C`A&!","$8$+$/I?/Q<84N?@'*OF-;L`^#*_?5Z06GAZVI
M*T^'GWA_*L3?]3AR*<C&+X^4:/!_BN3P!G_?,IK"FRI_AM:\@F]`69%>5/IR
M^Z(@C*KAE-F(CLV#MXOV<<FF,^=.>R>1=&"`@MH=*NV8$;B6>>]M'TVWT_$&
M]D.W=XL=,`M$`J7Y::L8H%':)LQX``#>8`%'A#/BP0O8+'<7*H+I9$,)*^7V
MJAK7*-[JKK"AZ\GJ+D[?Z2:DJ]%>`AD783\C!U4^DV47+.7"1S*,%%FP<XW2
M^Z*)B``(!C;34U0X`/+;I=#!QKG5,QTNV7B4=VZU(WEK&X%'V?=5!S54U#"Q
M&I*6EDXE-N@XL$YH!-TK&9G3#<Y^Y+PD8(CDN4B1P`,@SQU9FS&"1K0[`;N#
M^*,/Q7*\?6"9<($,.`8(1441^J>[S>B&]<6^O$\O?5T]I_JNNJQI<U,D[V6F
MJ9I)L&T+-11&#03QA5DSKM@:/><,X;)"X)P#A#=E3+Q#H``P!Q\B8[:$Z`((
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M5RG2MPR4O1M5JTZ\;JEJZ#*Q9J!)(,P3<K`N54@AO98ENSYH,&EL"(VBSDX!
M-=->XQ(*Z9>[%2(SM-T745RU;#V\GZ]U!'FZ^IJ*:1(DGZ5?,$J<IM:46:*M
M4@<-EU'117*+A^"0)F'/%YE#.>'//^28(0`LL,5:2Z6VQ_5BN84N]J1JZU<U
M6BUR*CHF6H#3!,7<:-XV`BP4N'/4I5M61](5/+)G3.HV85G3L,B9Q'MP`,E"
M\`XSS=GS&`7"(DPY#","KZ^7"V.=?6ZV$TO5=O:+JB113:2%44E3D\[10WRI
MH+242T?;J0*E*<@IF6$1S`!`XCCDSI#Q,(<;1998M4F<RY8N_!-$,NIEEMR#
MAWAV!D&1C;1ZN$ZC*G:YJ>'-ESR$-N>>WA$=HB/5$<6$HA1?9>O<:CF[N[\%
MET!`>&VU<?\`%R0PP:P<.-!FL<"#@`4<Z1E1+IBL0'_-C2G]34@Q8MF.ZQA%
M9_$-80P#J^U6.!0!XP`>3%"UXXPGMFM<$Q40YLV8Y[/V?-PQ@-X*)CF!IBOB
MM<RH)6EK]Z@E*1KJYM,W5E;V6-/;BBH9@_&BZV;JQE-Q<ZXDD"L%&4S%%8&>
MD?F562*U%N0PB.[D/0ERBYH;A!PY%SICI$;`8C*M_!72K2I;[2K:D:QN%2I)
MRG=0L)/LJNEY>IV%)2%((+GIFJ5*6;PB#.E422*8&9I"LHHNT$=S,<L=!U',
M:P>X6@MA8+<5L;?S6,5;HJ+!O/=@*'MS3"=5U/$0,5<BJJ6N=>1]7,Z6E*FG
MT:=8RL#,0E<!3QI2FJ9>/16*F@NW,D1;=2$W:XDT<UL7=2_#!=$8<GXE2VJ<
M7`8RN6O_`%E<*2MG<FDKQ7GKMM*)Z9(&5M*:V,/,&HV[DM-2TVA5C@[-6-<O
MJJEX5F6,;N$5@0(4'(KE`0-EA0I9][JW#$V]7!9^:T7WXBK@:M8!JYL;I2DI
M&6K:F82D[NV#=U))4J_D(QU$PJD`1F:3D.]S=P[:QK9T"2*IC)[J0JB`AVVQ
M%.TB80"PP!/NY2(9^A3,>X,BX'.HZJDM=437US+M474]P45W&LBTE+-:3:"=
MO152TE5$31U/5'*3,2V9N#S$<[0=9%D#"4&QDQ..PHXT$,>QK"(188F&`V0M
MSI.M8(FTD''A4>T'<?4--O;D50ZN5W!64-`WO]U%O7#J9>U.T;0RDFE0H4Q0
M[N$:L:65I]^+95-UW2HB]05`Q0XL4?)I19;=LA^=JH9I_@!#N5;*[595G;JD
M*7IUG<:]7PCPUI*0NBE6<E5+H&565/-S,:64C(FFF4*\]UBK!0%4WT>84BL$
M5";HB!L);3TY,2;(FSCR<,2#/G#B,5LZMNW5X7;KZ#A[MW12NO"7TMK3M`VH
M9(`A1KVEZMAX5W5AG*98L[9]%MV#MT_4=++D.Q63(`%$0`!M*V?)JG!HB6AI
M<2#"$-.!'C:J3%S(7C9:(V'$INTSW&NW6E_:EM'5503)R:6DZBB+C2SE`[8+
MD2E>23AY:%PNN0@)/D&U$;ZZQ.T.1REF(;I@SSU.SVR&-F2C8X1''9"/1^*W
M4U7/F$B="S$(+Z:MS9`(!M+F;MQV;Q@4.!A'@S-RCQXYQES&^\1F71+H`$#"
MO1OB/`&>(NNQA5OG$J#](C3=/UK8N&I"K(2.J.F*GO19Z#J""ED!<QTM$NZM
M1!TP>(;Q`506`H`8.,,;**;-I)[:F6XMFB,(1AQ80LM2V5/EF74-BT_@@.C'
MZ/X"D(&D6R&XF`E3*:C6)MPF\8VZ&\!AW0$=@9[,=6;O3MUP%ZJF&"X#MVMW
MWS#-=(-\GM%.#HR.C_R#_%$L9[RF/8PG[OWF_@K)P;D<X?@5K;L#85VV3T^Q
M+\V1T?\`\D.QGO*88/N_>C_W9_QNTJ?M_8/R1PYD?-D='_\`)#L7[R6'8Q4[
MV[S$Q-9/C_._2C[?V%\GI]B:/1C='\.T=(5B_>4PQ'W9O+_[D_XWZ4?0-A?)
MZ?8E^;'Z/_Y(=B_>2P[&#[LWE_\`<G_&_2CZ!L+Y/3[$INC*Z/\`[7=TB6,#
MMB@;^LIAD`9AGP<F(^[-YH&%9/C_`#O[R/H&P(_Z0.=?D8H[H+-5&I?4[?&3
M2IF'TUZ?&MZ:Z94M/50U!&5=4S'5(Y%D6@*01$SKO>:.32*F=003$N8APX^Z
MU7FK(V50R_`O:Z?JFQLO&-T1/%QQXU\Y^P!65#G3Y9$LN,(0%D;.6Q?IVT5]
M$%HYT6HL9JE*):W-NFDD51]=2XJ$=/U/W0.>80+8[<8Z$;$.(B4$RF.7(.VS
MQ\FV[O\`[5V],<)\^ZTDP#(MCRZ!!>VV1NE1;,`,MAB(1C;!?5M%!,A0WC&-
MED)2G,(E`0'A`HY!F.0#YO!ECQKG37^]"*]4TRA@BO4!^J&7U=7%`UXL"OK6
M)V^7U0=<,6NO4ZQB-\OJ@ZX8+KT:QB-\OJ@ZX8+KT:QB-\!X#%SP0=QJ0]A*
M8;>$-ABCMX@P6J]Z6,,5536X'^*G>K?'9[E4LLMFT)J)'&JB+A4-(PQ_(K'7
M.E&5QPC^85C:6,3W,4WVP!G`0W6[W-LL4F!Q>['>/XK3+>T2Q#!`+?E4*.89
M@&75#"(/CA"HV<UT8V)V^7U0=<,%UZMK&(WR^J#KA@NO1K&(WR^J#KA@NO1K
M&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR
M^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#K
MA@NO1K&)IE"[H[0'9P8LUKKPC@5)LUHEDY%B$PB01#@W1^MA$V5_DPX2K2)S
M',!/$J8(9>/\L/!NZ6F/7^$)V'UL=-K"*%V1P"S%\KQ8[4#^`5UM\OJ@ZX8P
MW7K5K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1
MK&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(W
MR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#KA@NO1K&(WR^J#
MKA@NO1K&(WR^J#T,%UZ+[3@PK"!@-D&^4<Q#@`>'%BV8#&R"JZ7-<.NOF5;[
MM;;WU('I3](5`$-L_:^,Q:T@9<@[J>-)DU%@,-9=LLXE@`FB+!"Z2.'X+G=2
M&KC3MI*UGT;5.HJZ4%:Z"JS3?-PE.R4ZB_4:OY)O<.(>O2`:/;.S`/<R1,@R
MV9=7&K8.Q=L;3HW"2R^\/QM'$<91M.JV=L\7YINV95[2=-+T8?'JXH$O'_L&
MJASRR'\G>3&N7N'O#KW.9*+G'BBRS^Y<VEWLV,>IK+1D=H3QZ:7HP,A_QN*`
M_$*K_-[#/3W>CY!^)G>6O[GV/\P9G:$P>FCZ,$^0#JYMZ`Y[!!G58"`\O_L\
M&)/E[O0`2))!Y6=]'W1L9HO&8+,CM"\2_3&=%DX7,[<ZKK:+N#-Q9G66C*D4
M.=FID"C,XGIX=]JK^V3'M3<88J-R-[Y8A</]G?23O9L)UA>,SNZHQ3Z3GHCD
M[AU7<8FK&B#U-5-`Q]M'(MFM6)M8NC(UV^D$(R*:D@`:1Y.ZI!50YTBE,<1+
MO9[I<FC<_>]T&W#`&/\`!A^)+=O'L%]@>(G([0ME1'2F]$=;RGVM.TIJ<MDP
M8M8U"*!R6)J`7[YFT!0K-M(N@IH'#\C0BAB%%439$,)>`<7.YF][A:QW]G>2
MOKVQA9>&8Z%T<7TM?1.PB!$8G4E:.'**G=!TXRG9QF07&2I0<`5O2Y`*L0%C
M;I@R$H&V98K,W+WK=9,8XMY6=Y2-X]BRA><X8L#NZO2?I>^BI,\6D5=4=KSO
MG+(8U=XM"5"LX6CC)\T:/454ID3J,C$SS2,(DVB.68X5]D[R#_IG.SO*1O7L
M+MC,[NKR1W2X=$U#MBLH?4U:>(:$64<I-XFG9V/20<J@4#N6Y&E,)%0<"!0R
M.7(P!QX/LK>@?ZV.!Y6'_P"2L-[=A#"X9G=U9%^EUZ)QRNU=.-3%I'#IBY5>
MLG+BF9M5PR>+G(JNZ9K*4N*C=PNLF510Y1`QU`WA$1P?9>]W$UW]G>5ON[8/
M:']W=3)#I<^B=EFO<$KJ;M1*1_/]U%CW]/SSM@1WS@JB\(T7I@Z)78J#F*H!
MOCQCBCMSM[F'W3;_`"=Y+?O5L*9@<+/YNZO:?IA.BM%)5(-4UL`(NS)'+I#!
MU`9%>-(04R1RR/N9YM1B0HCDD(;@9CLVX:S<K>YUI:XC^CO*GW/L2'O@G^K0
MMHUZ9OHNVB2:*.K2WR::1"))IIL*I(DFFF0"$332)3H$333(4`*4````,7^Q
MMY_XY)+N5@_^28W>K8K1"^,SM"]/ST_1@!_G;V^\]G58#_Q>#!]C;R_(/Q,[
MRM]V;&^8,SNZCYZCHO\`Y6UO?Q2J_P`W\'V-O+\@_$SO(^Z]C?,&9W=7&7&Z
M9+HSIVWU?0\7JQH!S)3%#U;%Q[0&M4)G=NWD"^1111,I3X%,<RB@!QAGBS-Q
M=Y"Z#I)#3QWF69?>0=[-C`63+>0Z%Q&G#I@.C;HFPMH:2J7510<7/T[0-.Q4
MO'.&M3F79/FC%--=!4R5/<V)RF#/9LR'$OW%WC#KK9)(''>8(_W*GW3L4F-\
M1Y':%-/STW1@\(:N:`#/D854.7G^YW%/L;>3Y!^)G>6J7O/L<_QC,[0E-TTO
M1A"7(=7=`"'\X54'_)W/%6[E;Q@_Z#9^YG>4OWFV.,+QF=H6K7Z9'HLG*B:Y
M]5MMU%T^<`C@\34AG!05RYT`7-37.ASO[;;VP<.-;-R]YH$"G/QL[RQOWGV,
M3[XCR.T+RCTQ/1:F,H<NK"V^:I=Q81AZC$52@!0^ZF]S0'5-NERS,([!'E'&
M?[*WN'\#O[.^DG>;8V"\W,>ZGCTP_17`T*S)JGM@1H4I2]R%@Z@!EN%,)]WN
M/W,]SY;QA$>UX<0=RM[H>X[^SO*WW-L0$.OBS(>ZL@=,5T6ARI;^J^W"G,$`
MB)S1%2"=`@%3*8J!QIH11!0J1`.!<@,!0SX,)^RM[>R[^SO+3]W;![0_N[JR
MGZ9#HN5@$BVK*W;A$Y2D527BZE626(0=Y--8JE-F*<B9AS*`["B`9<&#[*WK
MCUF$M_H[R@[V["<+H<(G^;NH-TQO1>&R_P`;&WAB!S8B!H^IS;PH;W,F/G3@
M[YDA-F`CM`0#D#$_9.\L+9;L[.^E_<NQ<%X0Y':%YB=,%T62:RKD-5EN.Z5B
MB1=TI%5(JX6`1[85USTT*JQS;`$3".8``<08D;D[RFS5$\[.^F2]Y]B-=$N&
M9W=64>F*Z+,YT5%-6-N55VN\+=9:*J191`3!NGYLZM-&$@*AEO@&6\(!GP!B
MWV/O-\D_$SO)_P!T[#[0AR.T+F*;Z5CHDZ4?U'*PNJ.W361JN<]T4VN#.K%%
M'4L+!K&BN@9:GSG9$.T9)@9-$2$,("80S,.9]D[T2[62G`\K.\E3=Z=A78WA
MAQ.T)M'=*KT3-#RU;ST!JJMZA,W$J-.J:OE%6E5N7LK,(L48QHHNNM`*'(DQ
MCVY$4$PR(D0,B@&8XI]E;V.@`PP_H[RJW>[83!"\(\CM"[OYZ+HPBB80U=4`
M`F',=YE5668``;`]SX9<&W$R]Q=Z6DF9*+HY6#_Y*_WEL2$`\9G=U.#II>C$
M^5U;\?,8U4/_`"?'#?L?>0?]`_$SO*#OEL0X7C,[NJL&J_I:>CIN'05(PE):
MHJ%FI)E>:TL_(-D&E4$6;0D7523B2D0`]/9'(V03.(AQ89+\O]XYY),DM:..
M\PVXH7E)WLV+-$0\668':%9X.FDZ,(`#/5U0'!EM850)NU[41/N4]D!C"7/B
MV#P98R3/+[>;`9)C_,SO(^Y]B<4P9G:$\.FDZ,#+_*YH#\0JO\WL93N+O#*-
MPRR#RM[R8S>C8T+)@S.T)?GI.C`^5S0'XA5?YO8C[*W@^6<[>\K_`'1L?Y@S
M.T(^>DZ,#Y7-`?B%5_F]@^RMX/EG.WO(^Z-C_,&9VA'STG1@?*YH#\0JO\WL
M'V5O!\LYV]Y'W1L?Y@S.T(^>DZ,#Y7-`?B%5_F]@^RMX/EG.WO(^Z-C_`#!F
M=H3/GHNC`V_XW5`9&',<V%5C_P`GMF#[)V_\LYV]Y'W1L?MC,[0L`],]T7^>
M]XW%!B8`R`1:59L$3;PG`/<]L.;C-PB&&5&X.\#F0F2R&_S-[Z4=[ME1BUPS
M'0CYZ#HOMN>K2@#`(@.1V55F*4<\\P*-/"`9=3!3^7^VAUA)+C_,T?\`R2SO
M7LYQ@UW0="S_`#TW1@_*[M[YS&J\_P#B]B_V3O!\HYV=Y:ON?8_;&8Z$[YZ7
MHP/E=4![7U7^;V#[)W@^2?B9WE'W/L?Y@S.T(^>EZ,#Y75`>U]5_F]@^R=X/
MDGXF=Y'W/L?Y@S.T(^>EZ,#Y75`>U]5_F]@^R=X/DGXF=Y'W/L?Y@S.T(^>E
MZ,#Y75`>U]5_F]@^R=X/DGXF=Y'W/L?Y@S.T(^>EZ,#Y75`>U]5_F]@^R=X/
MDGXF=Y0=Z=C-$=8,SM"/GINC!^5U0'XA57YNX/LG>#Y)^)O>5?NS8WS!F=H5
M?-572Z=''<'3U=2C:3U441,U'.TV5O%131C4_=;Y9&6C'*B+8IZ=W3J<RD8>
MH`".-^S]Q]X73[))NC";S+!R7K5EJ]Z]BE@!?&W$[&,BFN!Z9OHQFD'"M7&K
M6WZ*K6&B&ZJ/<E4*'16)'-P404$E/CDHD/:CU0P5.Y.\EK=081/\3,?\RVRM
MYMCZH0F`<SM"VX=-+T8'%JYH`/\`<%5C_P`GL<X;D;P`G_$2?YF]Y4;O-L8$
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MQ_F#,[0CYZ7HP/E<T`/4[@JL,_\`^'L6;N3O#>$))C_,SO*DW>?8VK,9@A#$
M[0D'II.C"$HE+JYM^!A[4A1858(&.;M2@(A3V89F$`Q5^Y&\)>+THVG&SO(I
M]YMC.99,LY':%6!/I:>CM+K$<7)'5%0PT6:P;:CBS0-:E!$D\A6KZ069&1]S
MPKF'N<Y,AXL=0[C[P#9SG&40Z\+(MP66QO)/W/L;Q`%\8,3L7(K0?/2]&!\K
MJ@/:^J_S>QR_LG>#Y)^)G>6G[GV/\P9G:$?/2]&!\KJ@/:^J_P`WL'V3O!\D
M_$SO(^Y]C_,&9VA'STO1@?*ZH#VOJO\`-[!]D[P?)/Q,[R/N?8_S!F=H1\]+
MT8'RNJ`]KZK_`#>P?9.\'R3\3.\C[GV/\P9G:$?/2]&!\KJ@/:^J_P`WL'V3
MO!\D_$SO(^Y]C_,&9VA'STO1@?*ZH#VOJO\`-[!]D[P?)/Q,[R/N?8_S!F=H
M1\]+T8'RNJ`]KZK_`#>P?9.\'R3\3.\C[GV/\P9G:$?/2]&!\KJ@/:^J_P`W
ML'V3O!\D_$SO(^Y]C_,&9VA'STO1@?*ZH#VOJO\`-[!]D[P?)/Q,[R/N?8_S
M!F=H1\]+T8'RNJ`]KZK_`#>P?9.\'R3\3.\C[GV/\P9G:$?/2]&!\KJ@/:^J
M_P`WL'V3O!\D_$SO(^Y]C_,&9VA'STO1@?*ZH#VOJO\`-[!]D[P?)/Q,[R/N
M?8_S!F=H1\]+T8'RNJ`]KZK_`#>P?9.\'R3\3.\C[GV/\P9G:$?/2]&!\KJ@
M/:^J_P`WL'V3O!\D_$SO(^Y]C_,&9VA'STO1@?*ZH#VOJO\`-[!]E;P"W5'X
MF]Y'W/L?Y@S.T+%\]+T811#=U;6^``':8S2J@*4,\\Q$:?R``XQPR1NGML,+
MM42WE;WEAJ=[:`N#0_CQ'NJ(+>:G+$*:/+]:GB7'@AL2WUO4]6:MQ]]T:""$
M/J8M4`2&QF5X1`JZI29"F81$^7F99E)M!NTY=%=_RN!$+,1./(M<O:$MVS9E
M8#U6P.=P&+*OC/\`2D4-R[FD4Y,TQ)0]PP[01(0`[XQ1MJ91!,0*;;M`0Q]I
M\C94R;+G&K)>T.,8\@A@R07S#S0FSY4YDN0ZZT@8OS7YAZ;H>N:S*Z-1E!59
M6)F@D*\]R5-R52$CQ.`':E>=Z6RY2+/TDS"4IA+F(Y!EC[76;:V-LVJ$NXUK
MB883R8U\VD;+K7R!/EQQG*`M(ZCU(URY:24>O&2#5<$',;(-5T7K-P0<G#>3
M;&1`T2Z1'A14$1SV9XZTMS*T$TTQH'*%AJJBK!C):1S>Q>8Y2`()@9KS@F`_
M;`D4!)ZD3;NS/@Y<6942*>H;(J'M+R881I5Y4V>Z01-:2XC$="Z"D**JVX%0
MM*0H>E9JL*JDA<(1E/P,81:9D#((KO7RR$6<14*E&LR[YU1'=%,@[,\5K:R3
M+/5FM`Y6I`$WB8Z/(5H#E(WYP%DD&HD46(*:FZ<Y7#=PX;N6!DD]T[9=`Y``
MX'S]+EB]$65<P294P":08&SB2:J=6RJ=SI(<'B$+,%MO$N@IFAJQKY[(QE#4
MK*55)14(_J*39T]&!)/F$%%(`ZEI4[1,2'(RC6A1465X$R!F.>%5.T)%'-U$
MV<V_ENX5TJ&9/=(OSF$OY_R"VMKK7US>BNJ;M=:VF'M75M6<DHC2L#'G0!>8
M.BU.^5;.'3@Q$(I%NP9*K*K''=(01SX0RS[5JI>S=GMVIM!X=0NF!L+(`D$@
MV6X`4BDEUNTJ]](V(:V4YPLXQ#)E6O:T#6C^KI"@X>D)RIJSBW<A&O*<I:/<
M5%(`]BW3EO-';H0J+X[F.B%4-PK@-TBF60"(B&+NVEL&73B<^4V!&-W'SI-!
MLW:3JMTN>XN8";(#'D"TDA#R$4[5CIB,?P<FS4.V>14RS5C7[=VEM-W0R?HM
M7[/G$LA!-5,,AX!'!*K*"<P3*.[+!PP.'.5NF4WA9[FSVWVPL%MF9:W<(H4#
MMP4$3'$HE`B9N;%,>WWP$,P*;>V#U!QODSZ<GKO&<:5DG.:/<E$'^I=)2M&U
M97U0,:6H6FY*M*IDTWBL72M-,NZYJ12C6BKU^**.8[A$&Z1CG4'M2E+C-M2L
MH)$L3&S&M..(TJ**EK*Z;"2"UHPB&&.#"G35&U33$93T[4M+S,%!U<U=O*1F
M)=H:/85(SB%U&LNXC78I+)O2,'B)T%1+N@"R9@#&G95;33Z1SC,:7MRB(LXU
M6OV?M635-ERW.:RRR`Q\B\\O2E0P",>O4U+U!3*<RV(_B',U"R$6WDV:P<XF
MZB3.6F[+M#HF()#I#VPF$,MF.9]5HW,?XMX=-#R`3#W1@%D,JW5^R]I29K-3
M>U9EM)@.,Q6*7IJ>IT[-.I::FZ95DV*4BU3J*"=Q:KEDNIS+9]$IO44#N&JJ
MF69LA`-[%::JI)[RT/;#E&E)ERZF5_N83GT+T4[1U4UB244HZDYBIA@:?=U7
M4B4-%@_&GZ:C`)WTGY$$\A;1#$ZFZ<1S$=W/&^9*IP^Q[0.4:4/J&!T-61\2
MT.ZW(!.:(W<FR,?=4%,PG35)NBX0$/2D52',`#+(!Y<5U4GY@Z-*KXEGRSF<
MGBFVYLITBANB`"45BIIDRX@!8^^8Q0RX<-D2*>\737M+8XQI1.F/$L3)<LB-
MO&NGI2C:JKR9:TS0E*2E9U*^9OGC"%IYF#V5?-XIOWPEEFD6406.UB8YLL=9
MP([AR@)B@`9876S=G21U'-'.-*K2U-2Y]K7'F.A<H/W-/=51$#$5.FH42IE<
ME,F<2G(9+(1(<IBY"7A`=F)H*.DFF_.<T@VX1I6FJEUT(L<0>3V+H*?I"HZI
MDCP=(4G459S::*CLT;2%.R<_*\PU`#9IQ<8V<O5^ZP-D([I0#+9CF[8J*>B,
M)+PT#D_,I%/L[:D\DE[LPT+KHBR-XYI.(5AK0W#?I3]5OJ$A#(4A(%&0K6)1
M/(R5%HHKID?&JMG#9.5FYTB%*3;O!C/3;9(,*B>(9;N!7&RMJ=MV8:%'KMD5
MB\<1SQ)5E)LG!VTHP=)I$>QCQJ=PU>1C]ML[C?$<)@`)B8>V#+/'=%=(F2R1
M,;&&3$JNV7M%C2]SG%H$38,&9;V8HFJJ?@Z;J.<I2:A*=KA*15HJ?F(UQ'0]
M4HPJQ6<JK3KYRD5K-%9K'#G^:-FF/+C$RI$QUULYI<,-K8CE'%SI+2)9O3)9
M+>=<N4F0[HE(">8&5,HF4I-PH@<0`P#GD8`R'J8V,E!_^Z8#(A:++5=U3)>W
M5T\N[4'W3UK#SV+HW%%5>VI>,K=6E9MI1,],R=/1%9.6)24M(SD6":[R,CWY
MC`!5VC53?,!Q'/=RQSZ843ZPL>YIECBB,&>*TU5'M)M&)LIQ$P\=FA>IU;^N
MV%/IU:]MY7,;2B[$SAO53^D9I.FSI+.0[G>C-`S,P*T41(8J1A-D<1V#A=15
M;.E[4;322T1:3".(<JO3[-VK)V6ZOK"9DL.#;0!A-F`+E11;JB8Z9"F*4X@=
M5,R9T!WR%%`R)PR'FCAF(YXZ$OPLS^)N<:5B+YN$,.8I003`P[PE+L$3G(5-
M0@%`,RES_:B8X`&-1ETC&AP>T<6$:5#9LQIC-EDMY]"Q`)U"E5!%(I03^[`!
M2$,F(&$`(8!$0SRVX4V=)8Z)F"$<B#-E.]Z4?[DB10*8#E(D<JF>8!S1Q+N\
MN8#D`YXT&HV=4]4N:2W+CYTM[Y8_URC_`'+T[J1S"(HE$A=AC@*)03$<L@,`
M``CF'UL5N[.QMS^U+UCOEGI7F`4LSY(D,4#&*"A=U(X@=,2`&^02G,7MAX\@
M$<^'%75NS*0:IP:7.MP\V-/E2*V<-93Q9+!@1C/.%EYGF@3(=%,BA$R%/D4@
MY[@`4@F$`VB"8`'*.6W""!/MDV-*<9SI0_RGK)!33':)""/\07L8NS9].6QJ
M&ATS'DYBJBI<\1EF#4G-)?>R?:E[&+?3J'Y;<YTJ=?.[2.:2^]D^U+V,'TZA
M^6W.=*-?.[2.:2^]D^U+V,'TZA^6W.=*-?.[2.:2^]D^U+V,'TZA^6W.=*-?
M.[2=N$]03[0O8P?3J'Y;<YTHU\[M)=TOJ"?:%[&(?LS9[_>EM/.=*N*JH&!Q
MZ$T$TPX$T_M"]C%6[*V<VULIN<Z4SZA6`0OF'(-"?VH[-Q+]Z3_<X;X"B[`Z
M=*1KIO:*Q\TE][)]J7L8/`478&<Z4:^;C1S27WLGVI>Q@\!1=@9SI1KYN-'-
M)?>R?:E[&#P%%V!G.E&OFXT<TE][)]J7L8/`478&<Z4:^;C2\VF'\K)]H7L8
MJZ@HX6,$>4Z55TR>\76N,4`5,.!,OVA?W.%>!I>P.G2J7:KM%/`0*)3%*!#D
M.4Y#D*!5"'(.91(<H`<O5R';QX9+II,HQEM`)4.EU#O><5A(@W3*0A$2%*FD
M5$O:!GS9!,8H&,("8Y@$P]L81,/+B7T\F9[[04UKJUH@'F`Y-"?S:0_RLGVA
M>QBK*"CB26#.=*@/J&>^XF*3FDOO9/M2]C#/`478&<Z5;7S<:.:2^]D^U+V,
M'@*+L#.=*-?-QHYI+[V3[4O8P>`HNP,YTHU\W&CFDOO9/M2]C!X"B[`SG2C7
MS<:.:2^]D^U+V,'@*+L#.=*-?-QHYI+[V3[4O8P>`HNP,YTHU\W&CFDOO9/M
M2]C!X"B[`SG2C7S<:.:2^]D^U+V,'@*+L#.=*-?-QHYI+[V3[4O8P>`HNP,Y
MTHU\W&CFDOO9/M2]C!X"B[`SG2C7S<:.:2^]D^U+V,'@*+L#.=*-?-QHYI+[
MV3[4O8P>`HNP,YTHU\W&EYM+[V3[4O8Q!H:,"(8(\^E0Z9.>TLCA2;B6S[F4
M,A`0$"@`@)1`P"`@&>P0P@[/I'&)8(\^E58:Q@@UY`YD@I(B<#BF7?`@I@.Z
M&6X)@.(9<`B)@SSX</;32"W5EHU>)0/$-?K'N)/,EYI+[V3[4O8Q/@*+L#.=
M*9KYN-'-)?>R?:E[&#P%%V!G.E&OFXT<TE][)]J7L8/`478&<Z4:^;C1S27W
MLGVI>Q@\!1=@9SI1KYN-'-)?>R?:E[&#P%%V!G.E&OFXT<TE][)]J7L8/`47
M8&<Z4:^;C1S27WLGVI>Q@\!1=@9SI1KYN-'-)?>R?:E[&#P%%V!G.E&OFXT<
MTE][)]J7L8/`478&<Z4:^;C1S27WLGVI>Q@\!1=@9SI1KYN-'-)?>R?:E[&#
MP%%V!G.E&OFXT<TE][)]J7L8/`478&<Z4:^;C1S27WLGVI>Q@\!1=@9SI1KY
MN-'-)?>R?:E[&#P%%V!G.E&OFXTO-)_>R?:E[&(-!10/4&<Z5(GS8X4%23'+
M-,GI@#84`'AXA#(0'&`;*V>*8PE#`>,Z4]]94^)`OF$1BT+]1UODRC]%QOH`
M[W:W)@\A`YP-F.JRTQ<Q,!@,8=T>$1$<?FRM8T>9=))`_P`9O`C)<FG\E]JI
M9LS[+J7QZUUO_&Q;GZ4>(&NKI-$1``"A[BY".0`4.[XH!',<\@#'H_(><VJD
M5`;QN)S0"XOFV!)G2WG!8JF]%-7%/VST*=(M7=17GN'IZBX:H[$`I>:SM*Q=
M67!I5)VO(H(FIZ(EA")F._&1451W0YL@YB&S"_,2EJQMJ5+EDQ?,,!;;8,B7
MNO.IYNRS?%@9T9UWEF=#MI=0K;HX;IPEN*PO3$7ZNSJ2=:K+L2H.&\K5$!3"
M2[BCYJY\?$NTZ>I26<`3>YI/(3F$0(`CCFC>3;F[[YU,]Y:X0#8Q&$8>*(O6
M="V4]!L:HEM=!I''@TI^G?3/HP?4UI$H&O=+C"NJVU:5=K!HZ1N*I6TY"/[:
M0]H9.HY&E)B/AN>&/?RB3=BDU2.<P9IER'/%9FVMOU\Q^TV/<)4AK7Q,8871
MB8$PP8,'.K>`V,V8UD&WBZ$+(GB$`K%='UIOM%9.I-%%94-IJGKMU-=F@-1E
M<5QJ\"9GG"5GY>GO=)3L90SAFP<EIWFW\:S+VBNZY.<X"4N8YXY^U-M;9FOF
M2YCW"6TM$,L6N#C9'#9BLBM3=G;'`!N-CS:57^E-&6BBF-)=!UO=&DG575/>
MZVMZKFRMSZ>HJZ]5UW!7)C:@G31,93DE2:BEOJ2I>G46R99&-D@*Z4`QE##E
MC?LK>O;M%6>)+C=EN`@2<#A:>6TPP6B&-0[96Q9C;CFM@1DTJR^G73Y:/3[`
MN8>VVF"8EB51T9%977J+7.:HG;A.7K*OZ,=(SEM7#`7`TZ95,BO<P(H?=FHD
MS-D..9M#:>V=J5[:@N)9KVW1;A%HXC;QYEDFTVR*9CF`"%TXM*^-W1L`C9"S
M^K'7/*`W;/;%VG+9FT1S;Q4#WJO0S<T\1:-7/D;NZ!ID3*&$F>Z)@'BQ[/:^
MU:_:NR*38+R[6NJY;^/`RPV_U#EM7)IYFRZ&:^JE`7C+<WBX^0Y%U_1(W=G+
M5S]]8!W;*^E6TY=FFZ:MG4][M.<.C+7:T_5)*U2H:.J&':E1=/GT+*.70+O%
MBY)CS8;XY9XZGF=LNJV#L"FJ6ES7"Z;(@&+2+;!CB,JYFPZRGJJ][8`@YQ;'
M&KNSNF:R%HZMU8U=JNI-KKSN#2.K_3I:&)K&IY^6H^4=4[=J"1;K(UDV@BH-
MC5E3A'!><;E$R1E2=L(#GCR%+M+:TW8M&^DF7-8)EXPB^+;L"`8B`C;$<:]-
M],HG5,QU0T'!!;J\&@;295ZVH&V]B-,[.GZ^TP:U++V5AY!]=.?06O13MQ%8
MQS*0-:R$BL#&G(?.6*T270WW"90WDNV`<\$O>/;EV7-?,==F2BZP&`A"T61,
M8QA$K:W8>R7.+0&V')PL5D:#T@6'LY?'1M>.V5MJ6ME7[^YNIZR5PF-MF-PX
M>AW+>EK;5$JCS+2YBI)]_)PKUOW-WX3(5I)G*95+,HACG[0VQMJLIYDN:\O8
MQK(BVV)PFR%I$8<2T,V504-0PTS0+T39#B7Q!Z0$"^)]T:@&15.FC:Z]8`W.
M<69,PNQ/I%3$I3J')SP&$I@'8IP\>/7;J3-LS)-20XWXMO8<-P0C9B7D]X'2
MI=8PP`_5??>Y-HK;:XJ;L18&O'D#3;_1;:;2#J?7F714&2LI9&=H,YKG1HO6
MHD%TF9]3Z?:9F4,8PY@&S/Q59,VI139E0USP9L]X)%\ESP]P`P0$,`P!>_V6
M[951L]OBVMUH;QPP0&50_?J$M?KMJZQ^I"O+0)708TAH+N_>6TVG:F7;V%:W
M8<P%U'$!2D`<8LZ4L\8Q4!')++(MP%P.?`.+;/VAMBA=JY3W,#IEIM,"ZTF!
M!`,8$`V6\BYU9(V--<7$-P?MXL'&H2B+*6IM,%P[AVTM4.G*I-0G1+7<N-<G
M3XI*O)@MLZD0G8R&3(R[]K#-,6,BQ64<@S<@58VZ`Y;,>C9O'MHDRYSC,,M]
MCC$1XP;("(C"SC"XS]E;)<Z\`!$9%H;]Z']`5KK!I6[;4W*1M8I64LI5EN;[
M4]2%SIZK']5UN\@PJ.?K^MW+5:TGP;BVD3D(@BJ+E!0!#+>*.!F]&WWN:X$W
M;S@X=80%H$.>!MXCR*OTC8X!B!&&32NF)HLTW%UXVYTHS.@UW15FZ92G(F)U
M'/JKJUTPU&S;RT;J<@TG+@ZR4`_<2TN;NUB6/_FEN*92J``8RG>W;K9)GF<2
MUT.J!8WK0,#")LPWL"TS:#8S9390:V\!QPQ+RZ(-+L;8&LNCNN)-VKF+<7LN
M1)](+'5VG.MI%I4=1T71]$54C0#%>.?NA;0K-K!G3$!,!#N`V@&T,+.U=L[5
MU\ETP:L,:;28`DFTP!/$"$JBH=CM(?=$23BA"'*M+3.BO0M2.D2VU2W&I"1J
M^K;Q:>[G73E[N4G2%TJON'!7*9S\MWA)3LK2K-2V=.4Q39F8(RC>1$'"B>]P
MYB..]L[>'>";.=3R7$.E30RZ28%H@''`3CAE&&"?M#8,F5+$R$&.$1#H4!:*
M%[STWT5NHNNM'2$ZXU<GU%4?#U]*6UBVTO=R-LLDR,H@ZIF/3$'S>%DSBD*R
MK7M]X5`$-@Y9-XW[3JZJ7*J"Z[`D7HW"<$(PM<!&`Q1/$N33.E2(M:!:1S#1
M@5P[`?#16%%Z"TM3RU:QUW*GZ36X;:O"20ITE6+DWP&D,CWP")7[G9+%BBE!
MRL;=%1P`E$<QQSMJ':-/U6'JW&XX72;.+!$+KAE/ANA1=INTWZ,*M0TCTG=C
M38QNK7NLN^FKFV5178<5I/L).E&UO9JI9.`J6,CVJI&LI/@BB1-==SND`H;!
M'#J:OWA\/-GZV[+EB]QF(%K@8@PB,$!'.H<RC+2'-$"#'D7JM'I8M3=RV^@:
MG;D0U6W2@Z/M]KSJF+M1)U2_;LKH35IJX=,J1H.&227[IAD95JT(+@J``HYR
MS+F(X<_:>UJ,S)TKJSICV@N;$NP`!SHB!NC'9!<LTNR)_5%V`!PPS85SFD+2
MU:R]%<U;7-W-`%"6)M_*W(M/;AU;NX4A>&K*@HYY5#=TB\3H.A*54&HH!O49
M0%0LW/F)&LS)YCPAB)^]VVV4YE:YY>&.B8#K66$\0AALP\:0W8>SC,#Y36WX
MB&"Q0OTB5JH&R6B"-L?1R[[W(VXZ1G4Q2=-LY)Z1PZ[T1<0F@RCE'@J*&<BV
M*MS`.![8<P.(]J.-F[-5M?:.T'S029VJ:./`"Z'%C)2MM:NCI@PV-CHY%>&Z
MNKZV.F73%I[:W/O!6-3HW%Z,R.I&F]&<3047-V[JFKJF4DF$->"IZW<$,:*=
MPA\DB)A]TS3WPQRY^S]NS=[#JG.BR>7.M</=8PD>[Q@BQ>CI:B@G;J%L\"Z7
M,Q88G*H+HW2?HLJ>\FB?3(MIP:MJBK_2M!ZJ[D5[%U]+IS-UJDCJ7E5O@.IV
M/.N5DW85'(M2J.SIB1P8Q,D@VCCHU&U-X:)DZ9,F%K6S"QL`;`"!>C`Q-L<5
MG*5BIJ78LPM`#>C2N[MQH/TT7VD]']P:DTC*:9ZONFAJ;3JO2D^J*KTZ9G26
M:;+J414\\VD@6N$A#2[LR!781R9E5#'`2`*8"./,5V^NWI#!(?/>]U\0>0`;
M8V0$!9`9^1="LV5L4RFD-:#>R8N5<_4=A-"U/7[OPPGM(,6I$Z;-#[>\URJ$
MIEQ=:DJ4K.\S:717DF](2E5MHVHWU-1C$`:J*$2'G#F,0=F.M3[=WAJZ,.;-
M<U[YL`86AIC``0(C9F7/^D;%C8T6#)A6Y@M#&GNXFCRXM=5%IAMI9.JY[27)
M:HK9/[?SUTJHJVGTU'3N8APJ6LYA4MNEX_O6EW/WE0$SX"Y[X!D7$4FV=N2I
MQ(FNN&8&D&,;`Z(%F&];GA8KMV-LEP/5$89.-;:K=.W1_4-2VIE)[HCC*DF=
M*FG33KJ$4ET[EUBP-<6I[DQ$<,O2T^BW7%*#I1NZ4,LX*3G`,"FP``!QH;M_
M>$O8#/<+[GMA#%>@19A``B#988JYV'LBV#1`0Q+IT]`NDDFH>[MKJ,T[,:BK
M^X=MK,5]8:F[D-KB2-@:65K6A5*CJZWAJ]I!8PTU48*&,>.D)7=;@)2;VW9A
M<O>7:(G2IM:]Q8`X.@"28.NQ`Q6$F'%@3'[(HY5),%.!:<D(P7Y>9V,5@Y^H
M85=NFT<P]0344[:I.>[D&;J.D7#->/0D1$1DDHU1$6Y7'\N!/?X\?HC8-0UU
M&V8[$OC6TY1=5.8WB*U0YCCIS:@/?>;@@E,E&0VX["DR'"M;RJT0C(<&MY41
M",AP:WE1$(R'!K>5$0C(<&MY41",AP:WE1$(R'!K>5$0C(<&MY41",AP:WE1
M$(R'!K>5$0C(<&MY41",AP:WE1$)0`0Y,78^\Z%JD3&RS>.!+MZF&V*_C)?#
M]4;>I@L1XR7P_5&WJ8+$>,E\/U2"`CR87,==A!5=.;-P<23(<+UO*JQ",AP:
MWE1$(R'!K>5$0C(<&MY41",AP:WE1$(R'!K>5$0C(<&MY41",AP:WE1$(R'!
MK>5$0C(<&MY41",AP:WE1$(R'!K>5$0E`!SZ_P!;%FS(N`M4AX8;QP!+MZF'
M6*_C)?#]4@YCR8J\W6Q4&I9,%T84F0X3K>54B$9#@UO*B(1D.#6\J(A&0X-;
MRHB$9#@UO*B(1D.#6\J(A&0X-;RHB$9#@UO*B(1D.#6\J(A&0X-;RHB$9#@U
MO*B(1D.#6\J(A&0X-;RHB$9#@UO*B(1D.#6<JD$13R<)?XL/KAAP_P#USR%6
M?_\`M#E"_47;T?\`_5QOM_?+@O\`ZL+2A];'Y>KO_P#I]'RN_P#[<U?;Z7__
M`$JI_E9_QL6S^E(B8MVM)B(#D;W#W#$!]3_",5MRXP`0QT_(BH=)UMU@`).`
M07(\W)H=,EQ`(L7Y?V%555%PLW3$75$W'4U5:K)S5E.L9!VUAZJ=QHG-&NI5
MDDJ1H92/,<11!0H[F8@7+/'WZLH:3:%4)DZGE/FM/5+F`D903&"^9TVU9])2
MZN6YS6D<1A9BPKM:3OK?.WE+KT30EXKG451CJ3)+.::IFKYN'C5I0B@*%>&8
MQSYNW`^^4!,?=WNKCF[2V!0U$R_44LA[\$72VDV&(PC&LS-LU4L0EO>!D)'Y
MK1,KF7)CB4VG&W"K*,+1SJ:?4@9I4,J0*4?5(=16H7M/I$=`6+<SJJIQ>&1W
M#.!.(G$V8X?2[`HW4CJ5E/);+>V!`8`,T%9FUZE\YMY[XWL,3$<\5T=.7ZOQ
M2-.!1M'WJNA25)KRZU3.J6@ZVF8Z#+..043=OUFC=\1@X7>IK'WRF((B)A$=
MN$OW+HGDN?(E%QA&+!;#!_#Q+I_49\!_GF6?N*?2U_[]431D_;>B;SW/IBWU
M3JR(U#1U-UG(LJ>ET)7>/(I.V*3AN4B<@J817(F7=6S$#@(".$S]SZ"2PS33
MR7$$67!;Q=G*J/VM/D-U@G/,.*\=*P-K]WYCJ(B[9,;TW.BK<PC1\RAJ*85?
M.-:5C&$CF,F@>%;/08%:O2&,"J14P*KO"`YAGB6;O4+67VTDD&,?];8Q&`X.
M)9';?>_WRX\I]JW\IJ(KM[IHIW2>VB8&%MC#W(D[M2;]BV<)U35E2R3<K2./
M63LK@6"R,0T*8C%(A!YM/AW<@QEHMAR/JQJ'26%PE0`+00(.B"!"QUN'$!B2
M7[;;<NAMD>''@7(6RO%=JRLJ^F[-72KFUTQ*,31<J^H6HW].*RT>9,Z?<4HJ
MQ71[J:I$.8Q2FSW1X,=[:M!]3E"1M.6*B0,#9C;[1B@'1"O2;9;)=?D@,?C;
M8<X*T@7!N`HA*-1KZK'2$U4K6LIPBL^^7[^U@Q4%5E5\HF*@)O9YDH/W!X?>
M73'TI@QR9>PZ5K!*ETTILID8`,``CA@(0$5NG[QSH`ESX\OM6R/=F[/=,J^4
MN?<`'4]4<75LZX)4TH#J=JN%.FI#5'+*`[`\E,Q2B!#(N51,LD)0W3!EB/MV
MA`#12R;H$!_C%@Q"S`D_<U2#$/F1_F.E=94FI+456<PRJ&KK]76J*=BS'/%R
M4I6<\Y>11UF2D<L>/<N)`ZK=5Q'K'14,00$R9A*(B`B&)E[JT4P&Y22(61_Q
MBV&"-G%Q+9(V[4U0)=.FM+<'6/'AA:HREJCJ.=C(2(G:BG)J*IENX9TW%R<B
MY=QD"T=KG=NFL2R664;1Z#ETH*BA4BE`QS"8<QQOD;,DT`<)4B6R]A@T"/%;
M8,&#D6.HJS.=>FS7.<.,NB5T(W:NGW4XDPN/6Y)%S3+6BGCU*J)DCQ[13)'N
M9E2*C@KP%58)H@82)LQ$4"$'("@&,L_8M%4D'PLFZ#'W&^]$F]@PDF,<,4R3
MM&>&=6?,A@]\X,6'`B"NI=2EI>BYVE;CUW3LU;V-4B[?2<-4\HP<T;#&6%TY
MAH-5N[25AXX[DPJ&00$B9CCF(9X0[=RA<"'4L@@_]MMO0K>.FX=<_P"(KV3-
MX+O5-452UK45TJ\G*NK2'<4]5M3R]43#F?J&G7@9.(&5D5WAW;^&6+L,W4.9
M$P!M+A\O="CF,OMD26@\08!_\5BG;7JI<TM;->19_$=*V3J_%\WELFEF'=YK
MDR-H&8)),;92=5R2M&$!N;G&[1S"K+*M%HML<-Y),Y!(F8`W0#(,6&YE&#$2
M90<>.Z.ZM4G;<X#K.>><Z5F?:B[^RZ%`H2U\+KR+&U+E)];5![7TTZ&A)1NU
M,Q1=TL#ER<T:=)D<4"*(;A@0'<`=W9C/.W6V?)9JO"2"P"'^MNA+F[P3#,-K
ML./VKQSM_+]5+/(594]Z;J3U4LW,N]C:@D:RG'<I&N9]L9G-+1CU=\9PQ[[,
MC"BOS0DYY$=PV9=F-NR]@[-EDPHZ<$P#O\;;0(PC9;#B5!O!,;8"Z`R^U>BG
M]0-_:3H%_:^E+TW*IZV,PJL,Q0L/5\DPIA=![OC)E78(K$*4D@90XKE*7=4$
MPYYYX<-T:)LYT^7*E,F.),0T`VV]E$S>3:<T77SYQ9B+W$`9USMN+JW0LY.I
MU%:6X=:VTF4TB(]\Z#GY&`6>((D5(@FX<,G3518B*:QP*!A'=WARRS'!/W3I
MJAMVH9+F-%H#@"(PAQMPP)'(5F&V:F,0]\>4Z5[G%X[RNW[65=78N:XDV-1.
M:O8R+BJYE5XSJQXAW,[J9LY.],JA.N6P\VH[*(+')VHFRQ@?L.GF"[,D2G-@
M!:T&P8!@XN);OJ51\^;\16K97+N3&KT\ZC[AUFR<TB_E)6E5VD_(-EJ;DYP5
M#34A!*HNB*1+V7,L?NE5`2'6WAWQ',<0-A4UTRFR)5QUA%P0/*(6JIVI4-:7
M&=-(`[1TKTQ-V;I0#^E)6#N17,/)T(ZDWU$R$94LLW>4@]FEA<3+NFCD<AWI
M<2S@1.Y,CN<^<<SYCBSMW)3P0^FED'#%@T+&-O.;:TD<.5=PWU0ZFV<Y6%1M
MM0MYFU0W$0:MZ[EV]PYH7M6-V60,PFG*+PCEXLU`,DQ4.82!F`"&$'=&B>W5
MFDDAI$(ZMM@S+52[PSGSVMOO`)PQ]JC:H*\KZJ6:L?5%<5A4<>XEWU0+LI^8
M>2K):>DR@G(S2K=ZX62/*OTP`JS@0YU0-AC#CO;.W5I*1D9+)<N;`"+6AIAB
ML'*IK:I]0[_).>]N5Q*ULY4=350C"M:DJ.9J%O3D(WING6\T^6D$8*G6>]W)
M`PY7*BH1T.VYPW-MDMQ$N8Y%VXFGV!3TVTO&SFL,0Z)(%I(`B;+38!'(%H;7
MW*/P^M<)<19>LLR+;>[ZX!IVFZE5KBL!J&D&3&+I.H"5%*]^J5C8L#C&,:>?
M]U=TQK&/$X@D@D8B)"F-D`9XI7[O[/JFE@E22UT?X1:3S<:O)K6@B$UP,,:M
MG8K7]?JT]\'E^:WFW^H*J).@:@MI-_"]5=0NG3:E:B10:O"4=.M'QY"F7ZZ+
M<B(N6BB:NWAQX/;/EQ35LMC*>2P.;,#K&@8`;+&\BZTC:XDQ=,>7B$($Q$><
MX5X=3NN6ZNIF9I5T)5+94?0=N%K34Q1%*5)4TTZ<T4[>=\9:-N#5=0/59BN5
MW\D(J'[M.L40R`>#'4V9N#+H9+@YH)+[]HC`P`ZO5L`A9RG&L=7O%&QG5LA9
M9^:@1._M]D*#8VO3O/<L+;Q[5XP84,RJB9:TJTCWR`-7<:6"3?$C>X5FH<V9
M($^;$F899#CH2MS:,O<_52KT8QNC#;;[N&TYUQ7;P5;G=1\QH_F.E<TYN7<A
M\2<(]N#6[Q*IX5C3=2MWLZ_<)5'3T6!"QD'-IJNCDE(B-(F4$&ZP'22``W0#
M#_LVDL(E2HM)(ZHL)PPZMD8VXU7Z_7?-F?$=*[N(U,ZDH%.I$*?O]=V(-6\>
MPA*G!M64X5*?B8EL#6.B90Y)`%5&[!H'-H;V944^U+D&S&=^Z]!35#-92R)E
MAM,MI@#Q6BR.);).UZR?3O:ZHFMMP7S;9RJ#QW<S&!0RASF,=03&.H8%C&'G
M=Y<XB9<QCYF$^8YB./5RM7*D:N7*8T#$T!<AE.Y\Z^Z8\F/&Y-SRXL8GE]ZQ
MHAR)M1(!F1#W8!QHWNI]77Q2,S%T)'A_WNSHSSPYLN86QNIK9+0V!=;RHV_5
MGBVJF=E6U3.UT^Q&"#Q9=&9),FT]8YT?5]6W!U^R,RC4?O=G29_5MP7AV1F1
MJ!VG9T9^9Z/9P%PA[HS(U`[3LZ7>ZGU=?&>,S%T(\/\`O=G1O=3ZNOB09D1U
M1AQ*1($1UW9T9X?UNR,R=J6]KI]B,\'6[(S*KI+;MCK>7V(^KZMN#K]D9DK4
M?O=G1G]7U#B07-M+0.90:<&PN)'*DS\ST<3K#B4>%EXSG1GYGHX-8<2/"R\9
MSHS\ST<&L.)'A9>,YT9CU/1[.(+XX1T*13-&!Q'.C/S/1Q%X=D9E;4#M.SI0
M'ZOJ'!$GW6B'(HU'[G9T?5]6W!U^R,R-1^]V=)G]7U#@C#"T1Y$:@=IV=&?F
M>C@O#LC,IU`[3LZ,QY0PESGQL;9R)K930/>Z4;>4/1Q%Z9V>A3JF=KI]B7/#
MQ>A[HS(U+.UT^Q&>#K=D9D:EO:Z?8DS\ST<%X=D9DG4#M.SHS^K;V<%X=D9D
M"0(^^[.G9_5D/9Q%[]HS)WA6]LYT9_5D/9P7X8&C,H-(PV%YARHS^K(>SBVL
M=B4>"E=KI]B!'ZMN*/F.+8`*122V&\'6\OL3=O*'HX5>F=GH4ZIG:Z?8E`1#
MD'&BG+RXQ8#9B5'R6D6./,4";E#ZNKMQ,Z8876L:#R)6H';=G1O=3K_Z.,;6
M3VDEPL*GP_[W9T;W4^KKXM&9BZ$>'_>[.C//ZA[.",SLIC*9I%KSG1G]6WLX
M+TSLA,\*SMG.E`>I]77PUC)CQ&"3,IP'0#W9T9]3ZNOBVJF8E34?O=G1GU/J
MZ^#53,2-1^]V=&?4^KKX-5,Q(U'[W9TFWZL\3JIG93VRFP'6Z4;?JSP:J9V5
M.J9VNGV),_,]'!>`LNC,DZ@=IV=&?F>C@O#LC,C4@6WG694\@=L7DS#CZN&:
MUU/2.OMB1'",BJZL$ZI!8V`CB]J_49;W_P#Y<;[!_P`Y$$.?_P#=?:7;C\NU
MVT6GS0HYVK;`.>V$!#_7-MA'"ONM),__`,'JK!&ZS_C8KY=--H:J_79J1L=1
MU)W$IBWIJ#LM6E2.)2I8QY))O"RU21400B?<>THE-M#D$<\<?RPWQH=DT\R9
M")<2?RQ9(K5OMLOZC5L8X<0_!?)'R>6\V0AXS-K\C#F8/<Y4&1AY3`"';#GY
M^/ILOSAH9=0;!9R:%QW[@-?2M="R"3R>*\^>8:FK6[VT`_K7J3/@X,^8X!PF
ML\ZMGWN+H[JQ?8C,7#.CR>*]0;1U,6M#J^Y>H]G5_D&W#:?SGHIDDLECKD0'
M"ZCT_P!:=5+'^1U@Y<Z0/H\5Y>#QF;699[V04M49.VY<Q;[H#U<5]6LAS^Q6
M]*MHY>']2<;Z/'><V0CJ9M>(@&11]SU09E_B1%#9BCO-R7+%^;'5C#$^Q6'E
M;62S?G1,L8>$4!]'AO24!W-3-KP$0R'>I^H"@(<@Y(9CC8WSFH-78!#F[JOZ
M;`G`>'.FE^CN7F+M'4G:DH9#VQ*>GL\QRS#8W#8/'CFR/.B@;6%S0(W3BQC]
MJ7,\M1"P<:7R>&\P#VNIBUX>93L^'UD,:IOG70<8'1W5>3Y:C$</#C2^3RWF
M+EO:F;8"`!D&]3=1'``Y"@"/:AA=/YT4#GF`!LR=U:)OEKU1Q\.5(/T>2\AQ
M`0U,VL`2\`^Y>I,]O)DCLX,:_6:@[(Z.ZD>FV0H#Z/'>4/\`.9M:/_PS41?^
MJ0VXH_SRV?3=4@"]R=U6;Y7U,X1D1$,/"(2^3R7G$-FIBU^0#P!3L^'^L<.$
MGSGH*FT`0YNZLT[RIK^.]'AE0'T>&].0;NI>UF6>?;4]/@(&Y0#F/1PR7YPT
M,IL+L8F/%W525Y5UX;83"/#C3O)Y;S%]/J8M6!ASS$*9J%3,!Y3`AMSXPPSU
MEH>R.CNIOI7M#+P_J2#]'GO'QZF+6CD``']:]1\`;`#^0\`82_S=ES'7I0@S
MFT(/EU,IVW)PC,&'GYUX)GZ/Q>:%@IJ=5U*VR4;0D-,2ZC9K`SZ#ET2,CU7A
MB%%9`Q=H)98KZM\O#F6&;N2&<JT-"]`G>6O*+I*NVFHNV;%I6%/LYYHS>0D\
MHZ:(OB&.1%4Y4-SG"Y<6S+&F=YR4;*4"8W_(!`QA;T+=)\NM;*;,A:X1X6KJ
MP^CRWGW0W]3-KM[(,P&GI\V1LMH9B@.>W'-D>=U`Q\6PX?TIOIJ#Q'ASI_D]
M-Z`'/QF[8YY;N?N?J$-G)_(>#J88?."\;P/5-N?F2#N&UO5NX$P?H\UZ3;!U
M*6J$`X`&GJ@'(,^(.9V8!YO8SPS(^PVFR"=Y/3>3Y3%K_>S4GX#&[UDH>R.C
MNI/I5M'+P_J2>3SWB^4M:WWL5'^`Q5WG-0L:7P%@CQ=U3Z6;0;:^-P8>3C_B
M2A]'GO(`@)=3-K2CQ"%,5&40'E`W,[!ZN,/KML_%TCNJ_IOD2A]'EO/P!J:M
M=VP[0]SU0%`P]400Q>7YWT52\2)=DQU@X057^6KG,(E"$PX,.E'D\5Z,MNI>
MUF7*$!4!AX>3F-N,M1YP.8^Z'6\,BV4WE+73)=YT8\,J;Y/#>8-HZF+7E'E]
MS=0F#K%0WL:?55]33]4VDCA@7/J?*S:+'71&'#]R4/H\EY_E-6P'/9D6FZC(
M.7&`B9#(0'DPD>9\R7[QL"K*\K]H#C.'AQI`^COWE`H%+J6M;NEV@4:>GRE+
MMWLR@"```[VWS=N-,KS?;+)+\$+.$%T&>6U53B].B6FP8=*7R>*]`CF.IBU^
M\/[8(&H3B/FB*..?,\Z`^;JVX\?L5SY=EXC"(X94GD\-Y0#_`"F+899\`4_4
M`!YN7,98Z3?-8L8'"/6Y-"I-\NQ3PLC%)Y/%>7Y3%L/>_4'X#!ZM'+G&A)^Q
M!V>&=1Y<[H);M6QIME43S4';J91?U53-)%9,*>J`7H+U:_[S(N@`$,^:;J.`
M,(\H8VT_FO3F2YU0#>!L-D.3!^2Y5;N#4OJ6,IXAI;:+<?*I(6^CN7H;J*-S
M:G+6K&1543YXE/S^2@`<PES("&ZF=,!W!`.,N.=ZRT)?!P@#Q6:%W9/E?6.E
M7R2##AQK%Y/#>K]KJ9MAE_P=GQ]'N<<-?YO4-[BP9.ZDN\LJXG">'.E#Z/%>
MC]MJ9M?GQ_UNS_K?DPOU=H>'Z*OIC7'CX9TOD\UY`V#J9M;F'+3-1&'K@AD.
M*.\ZJ"4=686<.REGRUKVF$">'*FC]'BO2(YEU+VK$!V@/N>J$O\`&BAF&*^M
MU!DX?TJ/3:OQ'A_4CR>&]''J8M=GU*>GQ#SON&-S/.&A>P/LM$>'531Y95I$
M28<.5'D\%Z^+4M:O+JT_4&>7%G]PX<7]7Z+)T=U3Z95N/AG1Y/%>;Y35K/>O
M4OX#'-/G'0Q.#H[JCTRKL?#.G^3SWC'_`#F+6^]BH_P&*CSDHLG#^E'IC6X^
M@Z4GD\5YOE,VO][M0>M\:?5VBQ<,R/3"MQ\,Z/)XKS\6IFU^?%_6[4'#Q?\`
MB^);YNT0<+./AQ*#Y8UH$8\,Z:'T>&]F9=[4U;``$Q0$0IZ>#+,0#/,6^098
MU>K]%Q`<.94]-J_$>'.N'IGH'KN515MSZ10U#VW8N;8R].Q+R56@)U1M,C4<
M&G.II()D0`=]$J@#LRR`.3%?6"CLLP\EG+8AOEK7DPM`X95W'D\5YQ_SFK6C
MYE,U&4>N9#+$^K]%DZ.ZF^F5;CX9TH?1X;S_`"F+7^]Z?_`83/\`."A:R.7)
MW4>F-;C_`!TH\GBO3^UU+VM$?]-3\^`9><APXQ^LE#Q?EW4>F-;CX9TH?1Y+
MT$VJ:E[5@`\&5.U"?;Y@(;,1ZR463H[JCTQK<?1[4#]'EO(?@U,VL#+_`/*]
M2#P^8AU,'K)0Y.CNH],J[B/1[4WR>*\WRFK6>]>I?P&)]9*')T=U'IE78^&=
M*'T>6\Q?\YFUH^9351%_ZI#;@]9*#)T=U3Z95V/\=*!^CQWG/M#4Q:_DV4[/
MA_K&-=/YP4+F$Y<G=1Z8UN/\=*3R>6]1-@:EK6"'#F:GZ@`?^\8T>KU%DX?T
MH],JW'PSI?)X[T&VCJ7M<`\A:?GQ#_O&,,_SBH6S(&'1H1Z8UN/\=*/)XKS_
M`"F+7^]Z?_`85ZR4'"&A1Z85N/\`'2O+)?1Z[R1L;*29]2=M%R1D3)RBB9*=
MG^?6)%1CZ7.W:D[GR.8Y&`AMPT>;]%=O`1X<B4?+6O!A;9PQKFK>=`G=ZXM!
MT?7C349;B.;5A3J,RW8NZ;GR.F9'.XN5!P0$``%DRCD;DQ;U=HLG#F4>FU?E
MX<Z[`WT>&\PF,/C,VOVF$?\`V=GN,?\`M.-3?-ZB@+.+A_"I]-J_$>'.D\GA
MO-\IFU_O=G_P.)]7J+%P^%'IM7XCPYT>3Q7K^4M:KV@J#\!CF^LE%DZ.ZG>F
M-;CZ/:CR>*\_".IBU^7'_6[/CZ`(9CB/62@X0[J!Y8UL</XZ4[R>>\7RF+6^
M]>H_P.#UEHLG#^E:/3*LR\.='D\UXQV!J8M=F/)3%1@/7%'(,'K)19.']*/3
M&LR\.=('T>*\H;?&8MAY].S_`.`P>LE#DZ.ZCTQK,O#G2C]'DO.(9%U,6M$>
M0:>GP#_O&+,\XJ%SH6</Z4N;Y95K6$B,>&5-\GAO4/#J8M8G_I@I^?$?,R%`
M>'#_`%=HLG#^E9/3:OQ'ASI/)X;SAM-J=M<;J>YNH#;>7(C?/&BG\WJ)KG0X
MVGA@5F>6M>XPMZ=*>3Z/%>DYB))ZF[5E,LHFESIJ=J%$$P4$2;!5;B!C'$V0
M!PY[<<P^<M$:F[A;')W4P^6-?CX9U'UON@GNQ<-.M%F6H:W45[BZ\G:`<H.X
M"=."[F`%(%':9BH9B"W.X[U?YLT+*>20(!T;;,EF#"$>F5=C_'2I!\GFO+\I
MFUOO=G_P&.7ZN47"'=1Z95V,].E(/T>:\W%J9M<'F4[/_@,'J[0\(:$Z7Y8U
MA!B3TZ4T?H\=Z1VEU,VM$.K351&]$J&6)]7:+BAPYDSTQK,O#G1Y/'></3ZF
MK6@/(%,5+P?B^%N\Z*&2;EG#^E)F>6-=>LP</W)?)YKQER`=3-K1'_@Q4G[+
M?%?6V@R</Z53TQKL?0=*/)Y[R\6IFUV7_!RH2^@+?,,3ZVT&3A_2CTQK<?XZ
M4>3QWF';XR]K1SVYC`U"'H<SLP>MM!DX?TH],:W'PSI/)X;U<6I:U>7_`.`5
M!P?O&(];J#)P_I2CY;5X,('ASH\GBO7\I:U?M!4'K?!ZW4&3A_2H]-Z_$>']
M2=Y/->8-GC,6M][M0?@,5]9*`VZ-":/+&MAA_'2D\GBO/\IBU_O>G_P&#UDH
M.$-"/3&L%L?QTI4_H\%[!53`=35KP`3E`3#350*`7,P9B*?,!O@&>>689\&.
M@SS>H*Z26`6'%^BB5N&)4P.<,!7TVMYHYJ@W0BWXT6&KRGSU&34C`VX)7A8Y
MT$"BY-JHM*H+I2(S[M,0Q!$H%]-F8.3'RJHVU3.WOD;5LN-#C#+=?QPRKZ!*
MV0&[&F44+'`=!!7U@OV&6MFDR_M?%FJ'9Q;*]C,MG!CQ6SZ0&C>19AX85VZT
M`UC8Y%LB+CSA,MP!$Y`S4R!,.V#^2"(Y`0./J8XFS:.]4O$3;'AA7=VG!M(P
MXK5\_;^ZQJNL?JHM=:)2CH*3LG44%2<G<>M';R0]TU).:SJY6BZ;D(SN0!9=
MX1F52**BKV@$5R-LQ['9F[)G8;>'*O$UFUO#F/%PR+DHC7X+?5!>R@:Z9TU3
MVFBTMOZVJJ.N<963<S]23%NI*)I6KE3H.LV*\26IWAR18-^%QL'8&.G4[CG4
M^)%@A'AUEHH]\Y<L7'`1P8/^53"UUYV55I&J:I=-*XC9>CIBAZ8D;<.(%N\N
M%(3UP@,I;EO#-&2ZB,T[K%`!423`P"F0HB;++&.5N@X\9S_\RU3-]&FR'#X5
M$U":SJIJZ77=2$DQH6G'^LKX!8=C6%!2))UQ2Y*25J!_3\R@0X!2U3FD6BBJ
M[X-XB;=N80PV?N>74YM,;./+_,L+=[1/F"5##^7]*GJF=8-#5U3U9U32-O[T
M5-2]/BH$+4"-#JJ1MS!:SBU,J+V_DUG"1)@D5(H[AG"W-@HF7/@VXYGV:X6Q
M.?\`YEH^N#'PS*.8+64G<R[>EB"M2"R=#72JB_E#W2B*JB56U5Q]36CB&+EQ
M$L3;ZC2)<)2$B(J&*8P#NAD.(&YAP\/^)!V\&VFWAR+93^LV/MG=;4U!74;A
M%VYL(TL46,EH-FM)3DR\NJ@X;BWDHU#(SP$7IB%,K^V'(N68XG[,.,\/ZD?<
M(Q</A6W)KJLX2B*KK5["W0825&71B[/+VOD*)=1=T)&NYY,DC`0,=2J:IS2!
MYJ'6!X@NF8![D$H&RQJI=SBUSB#Q</XDN9O$T`1'#,HIMIK+JBM9>&=5!+,*
M+@Y75U7%F6<-4EN9*+J5U2%/P#^<=L'ZJBPN:9JN+%-?G'2N9#I)CN\&"=N:
M\Q`)CP_<E?<K,7#X5.-)ZQ:/KRC9RNJ)MW>JH*6B%B&I232H0P,[IM#/G41W
MPH%^Z<I)O(5!=H8.ZEA)OF*(Y;<(E[DEOO&)X?N396\T/=X="BHO2"T9/59I
MR@K?VYN15E/7ZKBO;=2<JVCEVKR@*AH=!=&9C7$:""J;^0+(%,1T!7!`00+S
MA<][/#?LPCCX?$F_<YX?HO926N:GF5$1,O49ZAO)7545U>:/A:4LQ;1XUD5J
M2M;43^+G7Z=..9%V5K'TFU9B5TZ$Y1=+$.8"@(AGFG;J&4^[$X(X?^95^Y^M
M#)PXEO:JZ0/3[3D%3DW'#<"OF%7VJ4O3#I4;1#Z:>IV[82:\9-3DPV4.0(=.
MDWK<Q7A-I@$HY`.$_;#L`)S_`/,MLK>@`8+>&17(AZ@C:EA8:I81UWP@ZDB8
MZ?A)#[I_-T3+M$GK%YN*COHBNW6*84Q](/:\6//[2V::6>9,39#CQ@'&MDK:
M(K'^(XCDQ68EJJY$3V]N$;/AH2L>+@RIR2P_9=*2X$QA''[53:$\78P$>0:%
MP&GD1^`"RG][*F-N?^UQQT]H48U=AMAPXT4E4!)9#!#AQ*9Q6R,8!#/(P_5P
MX\L*3KGB*ZLJK:;0!AX<2J7JIO7<FTH6(@+6L*(?57?.\\;:XSFOVTB]A:?1
MDHAY*EFS$B<E/YF+'^ESSQ]"V;L%KF!\?X8]$>TO-5]8)3B[]Q_'D441^N5.
MV[RZ-`ZFZ:&'N-:VXU(VW4"T3.H:J@KB.Z^C5)2W4I2;9;<G&KB;91CI-4A]
MA'V[GD7'3F[!;,8'@V.$1PBE46\(DDM(&;_E4U--8-K#0]72LBA6L.M0ES+<
MVFJ>)EZ<>-)>)KVYZ;`U*1#F/*<R::[5)^'=9\Q*5/,>''D7;JO/5MCR_P#,
MNA,WH:1'BX?M62,UB6KF[LQ]F&,+<-]+SM7U;;Z-JIA3*(4>YJ>@DTG%9QS>
M0*MW:#:G3K)[JFX&\578(Y8J=SIHB^VP1PXOZE@?O+>-SB)AGYEP557QO]7.
MHFO;`:=X6V#!.S%(T75=SJRNHM,E;RTC<(B@4O1-',:>`7,<LSBXDZRSUSF0
MIC9CCJT&QVRVVPCPRJ?JO#@%(,EJRH6G[G1%H:RIFNJ9J>>3J!"GJC>4YS%'
M534],TX:H:EC(1ZNX-+N68-T5#)G,0N92YALQJF;O^*FAC;(\,85'[8$MA>1
M8.&)<;;S7CI]N.X<"P4KFF::1MO4-W8VL:SI=Q3M+5-;BE7"B=92U&2!SF-/
M.:=>*I)G3.!3&3S$NW+'*JMS#K,)SGO)'W,.$="@"4U^251SUTGE'-I^UMOZ
M/TLPMZ(62N[;&44GAD)*KDHEE4#:)6>(+5!1<O$J@LU(F<H@8X"8,L;I&YCM
M0#$Y_P#F4?<S81/#H77WNUY,:.[TTA;I"?FZZCZ[L53-85BXH-X>V328N.O$
M*RE..I@)-R:#JI2`>E<<SN"1NGVN>8XM]G./&8\O_,C[F;Q#A\*G6I-6EO*0
MNC\#TW2MU6532`50QH=R-,&/&UW4%"0RTW.15.J`Y%U).EH]/>:I*D(1QS8E
MSVX3.W)=-9$&P6X8`\]Y!WE!%@MX?M406TZ0VA*OLE;*Z=94%75'5+=-Y5\=
M3=M8M@22D)4U`G?J554E+OWZR*#ZCHEFT!9TL<2G!USB``.X&-$S<OP\LVQA
ME_YE2FWD)G`.%G#(KE6TN12%X*!I.Y]!2Q9JD*UB$)F`D02%F99FH8Z2Q5(T
M<^XU47R2I#;>V$N/+5NR9E*\`N-OY<Z]E(VJVKE@D`W?SYEW&8\N,7A']H\.
M=.\2WLCAS*MVJP1"UT`8!$#?#790,P$0'+W8ES#,-N6.WLZD=X69;'K?ERKA
M[2JFBLE6`=7\SD5G9!3<>N0Y53CP=7;QAQACC3:-VLLP<,J[4FK&J%G#,O*!
M]X,]OHA^SC/.I")L`3@'#"AM9'BX^'$D`5>(=G^J_8QHET;CA/#.K^+R<,R^
M=>K35M<FR=WHRW-(2%F8"/1L'6EZG\K=F1F683*M+R";$E'4\O$R<:$9/5$!
M^:145(Z`39!ED./:[)V!+G4<NIXW.ASQAC7D-I;<?(KIDH8!#\!D77T5K_M1
M-M6K:K("X-)U-`6H@KL7;;N*2<.J>M=`SU+A449[I*B2%)..;S2)128`0HG<
M&,7,,Q'&ROW2;/;!L(\/W+!]Q/X?HI9M%JNM'>-:L6,+*O:/DJ*:T\^J*(N`
M@T@GS>$J]D22IB9;NP740(SD4E2&YL3<X4!R$,\>9?N8]CH1.''_`,R[U+M@
MB2V81:6QX6*JE\-;-VK?!JQ9VXH*C*QJ*R%P;#4;:UE(OW[="L7-Y&"*K]S+
M.4MY-4J+H1[D,78*8@./5;$W4#0+QB>'[ER-J;VB22T#!P[*YNJ^D?F34;6]
M:4'2-/23:D](:]Z7\;.J27?")N[35R6U"550]3`3(X1\',K+*I9``F2$N&-W
M1U1)="UQY\,/XL2Y4C>-\YT!&!X8E8*V%_;SQE[+<V2O[35O"KWGM>ZN;:ZX
M5M!J%C$NWD4PBI*I:5F86K-Y9N=K&2I!(^*.2A@R`,>=VILC5M,,1X85Z&15
M.F`.)L5V17Z@A]7FX\<-GG+G]J[DFLMCDX<2`7SV9=3]C/AQ9FSR'@Q.''[5
MT)=7@/#\$9CD.8CP#EMZ@X?X1XF0CU8\.-9ZJJ`;'BX9%7>U.]\.>K3:.1:W
MMULX@RH-J&8!Q<..X^C_`/Z:ZW%^(RKDR:W_`.R(CA`Y%8G>'U7U\<'P;L?#
M.NIXP8N&9)GU<6;),@WR;,"GQ0?8D$5,A!,%#J"&Q-(2<XINAO&`N_\`M4RA
MOFRV[I1P2*;Q$Z'$2FSMJ^'E<6#%[%\N=1>NBY5FKS7?HRGVMF7%)6;I&T%5
MN:=K%Y4C&XMU#7`?IQTE&6Z5:*\YW5%(.N>3210<"JJ7=,4I>VQ[[96PY;SJ
MW>^YO5&'!:>.RQ>)KMX3/?`?PF.?F78V>UY-IZY-8VWNO3M7P[N1U*R-FK>U
M7$4@Z/1E.<["L)&F::KFHT4N;;U2LH*Z:B`+*'V!OD)O!FVKW3#L'#^Y*D[P
MEAZPLX9%-+_6C:B`KFI*"K"-K^AI"%INLJZ9S53TTJSAI^*MP`N*R+39B++E
M3<-TR$(D1P0!7%8HEV`..),W2+'1''P[2ZLG>4`&.'AD2'UD6U1MU0=RI*G;
M@QQ+HSPP5KZ/>4ZV]UU?*)Q"DXNX@V"CP8PZ#:&*"QW!3E(4.U'(VS"_M9W`
M_P#,F_<S>'_\5R]V]8<;%Z0R:K+*!%5C&NYNBX2)85,D_;%2=U)6C6E:D:SS
M2*S<MIB$4.8I"`(I`<N>>T<,.ZY;3N=$X<?_`#)$S;^NF`C!"'"Q76`!*FD&
M\)AYA$XF',1$RR1%E`$3=N(%45$H";MMT`SQY>9LTR)MA.''[5V:28:@11SH
MD[7;_H^?@=2EYO+I:W4?XR(PX94=T#U?J\_%?!94>+&+AF6FJ8XC2M8FWAS]
MQ]5"'#F']:LL&P>+'1V=1G6VVCAE62KJX,P<,RBC3.8PZ=K(&$1'.A(7,1$<
MQS5$-O+B=MT<)(NF'#E6:CK(OA#AF4W`N(``9<'U<N.9+HS<;:<`X84Q\_K&
MSC2@N/)]77Q?P9QGASJNO.)4WU:ZAZ_LM4FGZC:$>6JIV0O=5U7T^ZK:\AY4
MM$4LE1]*OIKNP1AI6'.7NS/<#8;AV`/!CVNP]@;/8POF.B`(G"3_`,2XNT-J
MF2<G#(JG47TFT\M45`3%QK=3B-O9?3[<*X=2PULJ0D*O=JS5!7$=4X^N9%NE
M#(RZ-LN\C$[EL"H9\VKF(#CO;3W#HY\LS6.$0TGCPPL_C6.CWMN/:T#"1P]U
M76N#K!M=;4E%RE1QEPG%$URTHMVRN7&08OZ+9!<%1LE3$A(2"ZQ'BKIZH[(V
M5(1,Q&0\([,>-&YCL9S_`/,NC6;SB_DX?M7HC]7=HY$EWY-0]4Q=#6(=3S&N
M;F/8MNG17?2'4;ISD/%O><[N6E6+QP0$"'3`BIE,BB.&R=S':YH)X^'\2D;S
MQHG@8;O#B6ZM!J9MY?)&N6-'(S]/U5;R$9S\Y2U;1Z,?*L8F>BG4M2%0E1CE
MEDQC:@9MA7SWM_=#(0#;BE5N9_DPGA_4IIMXR9=HZPX=E5GT[:RJ]O'4FD:'
MFJ7IV.::AK0WHN/4BK#NWG(&4MM5!X.,91W/=IE,-1!=7/+(HB`8*G=8T6SC
M4Q]TM&<@=I4D[<-56"2!80>@<B^CHK9@8>'<'<^K@QPO!9>&==;7G$F<Z)]G
M!EM^K;U<0:*`,#;PRJ\NINNB<7#B2`(BNAGM[<.N!T\A\W%)%&[6B)LX943:
MR&#%PXE6_3:/\R7[VC_E(7&V[?\`:>.UM&C<94J)AA_+*D2JRTQM/#(K'@?<
M(7CS_8`O5#EQRO!8SPSIWC,G#,G$/OFSY`R^OU<'@[+L>&=9YKC/F-=@@(<,
M"XNY-4NZ'MK<FMVC<'3FC*'J6JF+41-S;^0AX5\X;,'?,O6S@&BZF0#NE'S<
M=396R1-FB)L)X<:K55CJ>5$88+X]N^DJOBVM35-4/&=F9ZI3V(M]?F(F[;-Y
MN4AK<FJ&LXN!D;9W(BYE9PDO44A'O3.6'<"G/"L00,4`RQ[=V[+9],70P$CB
MM@,(ZV"U>5F[><R?S<.)?1"D]8%!5A2=?5!!T==I.:M9(TQ`U+;^0HUS%5X,
MG5,8A)4VO%03U<J*\)4#%7NDKY50!03,`&VX\N_<Z]-NMMY_^9=BCWE#6".'
MA^U:**UT69J1M;8U*Q5?U'4ESJ@K"GXZWC"GV;>K(N:MP[!C7@/5Y9<&:3>G
MP=IJCW*<QG.0F(`B.6-[-R2)8?'A\2O,WH:9KH#%P]U;R8UI6/B+H)6I6DIU
MQ)A7,5:9:K$HLAJ/C[K3,;WTAJ%DW[A4))K)R")0YT.;%,BFP1#9C%-W?$G#
MQ<,:UR]Z&BV'#X5$>H_6!7=E[@ZD*2@::IN70LAI.@-0T`[E0?E4EZGDJK4I
MMZSG"I=H%--&Z1NU+M%QNB`98T4F[['/C8"X\.-<^KVL9CC-;QF/"Q2I934#
M5-S+YWBM3,1<+'1%NK86)K>&D&O.=]I)S=2E5J@G6TL)MA21;DADV@\.X4,\
M.J=W6W.*,>'&G;.VH;Q'#\%:\%@```N8E```!,';"`!D`FV^F$.'JX\,^B+7
MD1P$_CRKU'BP;8<,R=F/*.*>#(MCPSJ15@&,.&99FXCSZ'#_`"9/C'U88K3D
M_4V0-EY8MH5(G=4``<,@4(V[(7Q5+\\&?CTP`\'"/C.VFV^;CU\X_P#]2DXM
M6?\`A<L`ISX<O)X695*-_.VUK4EEVV>F2H1#+;F`5W&;0RSV8P[/GS11O@UW
M'Q'0E5I!K&N&!;?(>4Q-FPY2`<Q!]64ANU.8N>8`.P1X<<+9M3-%3,(8ZR/$
M="[VT',F4S&@@Q(!M!51[UZ0*5O95MQZGJ2J9>.^$73XM8)Y$Q[5`24VNE5"
MM6PM>,'8'`R4O%R#5-PFFEVO/%`,\>OV9O#.DP<6NLR'0O,[3V-*FBZUS2.4
M:5$2/1Q6P5I6F*(DZYJ%[!1&F>HM/CMPM'-RO9^0J6L4JYDKL.I%;G3KU$ZE
M6HNA:KEYLZB@D-PXZ-5OM5EKI0:^#L-AY,2Y,C=>27AQ<W.-*V8:"4W-K_<&
M]N;3\/7$#7E!7%H6Z]&V?@:+D(BI;;I9TZ\JJ";/7"55JRC9T(NSJ*`FDLIV
MA>'+%+WKJ!86.S'0M4W=>1"-]N<:5N(?0ZFJYB96LKRU#7M1&U,'U+U5*OZ;
MC8PU03Z]*/J1D*:-&M'1T(ZF]Q\*A!3`PE$N\)1`,:6[TS62M6UC@T6`0-G0
ML;=W)4A^MO-B,HX^=:%OH.J5K9YW8-OJ8K-U:F%GXV=M-3[BD6Z04;&,*H=5
M(%/U7(,W35>XD:NX=J(+IK<T4&6Z00-P85]T/OZRXZ_"&`X(QA@3_IDO!$9P
MME:30E3UGJIM554?7S]\-L;B7CN4A&,Z::0<+-35Z(V-BIF,0CTEUU8*'@BQ
MP*(;FT1/BWW5.-@:_,=";*V1*F.@7`"&,:5T-S=$\-<VI[YU$^N#-PJE\)&Q
M\V[;MX1DZ;4PXL,^3D(I"-<J'!5\2I2ICSQCY"3+,.V`,`WIG]A_PG0M'T*3
MVVYQI27.T81]?S=QZOBKJSE&5S5]^J'U$4;6#.&1>$M]65&TVI3)"*11S`6I
M8249FW7*:V1AS#9D&%.WGG-8&-EON0A"Z<&+`J3-A4Y`O/;G&E:Z&T,,4G,(
MYK2[-25Q(,;[U=?VI7\E3;"+6K"2KJE7=(S5(F;-%^8BV9T7BCAJX((F0)D7
M9C;)WHJ'0%UP'(="5]`INTW.-*YY#0E5*=E8NQ#S4Q4\M;RAZDIZ4M13[^AV
M/>R`@Z;FW4PQHBN&;&19.*V@93NHS915=?=W2`*A!SQ+]Y'R71:QP+C$P!M.
M#%D2YFP)9A<<TCE&E9Z/T'I6WC+-%H>\DS$519.^-R;T,YCW'1@QE3/+I,Q9
MUC1!:?(LI'Q+))%P)8MTF8PH`7(1S#"G;TS'M+'M<6G(="H-@-P@MSC2O#$Z
M#7MOW%(3]J+]S=`7%IB2O<W)73BCX^I8F:HB^$Z^J&?HMU!NERBA(,W3LYT7
MN[L<EWL\LL9*K>"94$%S'%H`XCQ&(XE4["E@PO-SC2NFI30K1-"LFT53%9U1
M&Q##3'5VEU1!RQ;OWG<E8RC^3G*^<O154.:77D7QS"F3>*0BN1=@#A1V[-=8
M6G#ET+=*V))'O/;#E&E6\H&D$[?4#0]OFSA1ZRHFEH2EFKPY0*H[1A6*3(CD
MY0V%,N5(##YN/-;5JZBIJ'3;CRTPP-)P`#$O0T%%32989?8($\8X^=>BNP`M
MO[A@7TH4'6`@(Y?DW(B/HXOLN=/#H%C\/9.A-KZ60)<+[/B&E<%IV*8=/UE<
M@$<[9TSNY!F!OYG$<@$`VXZ>T*B:9<`QUZ&(Z%BIY$D,:+S<XTJ9!`<S;!SS
M'9U/0QYD/J+Y_P`<SX3H72ER)(PO8.4C2JR:F=/,M?UK:X*>N=)6GJ^SET8R
MZ%)58TIIC5[-T_;1#MCW*[@I8S5H<$^?W<Q$<>KH-X)[0)<QKA`0P'DQ+SE;
M2RYQ<`01>/XJ,$-"M/F>1-33MTZMK&ZJNH&B=0E?7'E8IHV?U[4%$1BD3`TV
M2+CE$&D!3C=.3-FFF(@&[MX,=2;O&]DL2V-(:!```V#%@5*/8,F82Y[F@PXR
M-*6MM#YZXNG6]<,K]533%#71NO;J]-3VO:TE'/$%+CVT5C^X94]0+J`\2I<K
M6/%)V@`;ZQC;Y0$0P4^VGEP+FF/(="J_8<HX'-SC2JZ:>=/FI:W6JJ6N&YH9
ME%0E6W9NC/7*J:JU:?E*=3MU4KD58!E;6>9R"]0M*IEWB:"BH)LVW-M^T5..
M0X[AVJU].Z)MN&%N3I6+Z$QLT.B,.,8^56UKC2M5CF]<W?FR5\*EL%65=4Y3
MM+7-:)4I!UQ"5K&TOSB4$X!"6<'3IZ8:Q1SIHK)$,`G-F?;CR4[:\V41=:X\
MQT+H?2V8QG]JBF-Z/6/:WFCKLR]Y*BJ!:#K:JZYCBU%1Z;^L0>5O12U'S4%*
MU6I)+(J1+`7@K-DD4P3(4-T,LL=:DVRYDLSC&\T<ZH_9,I[2PD0.7VKL(S05
M1+>B;74!.UU-5%3-KM/5T=/)2=P),G,]`W)<LUWU2'53/SA'M/JM`(BF/\F(
M&7`.,E1O/.,PN#7VY#H2/M^F[3<XTKCBZ!)N2IZLXRX6I.IJ_E*GTZ1FG"&G
M5:(CH9M3M"0<\SE8R93:,SBH]E&ZC1)LY,<`451+F&>-DC>B8R3=:UP),80/
M'S(^@4W:;#E&E>J;T"'<3E4$I^^-4TU:VJZZM?=JJK5GI.)?-YJX-J&D;'M9
MM:H7`*ND8.JD88%%VA`WPR)P98D[RS"\3"Q]\`@&!P&$1@R!'T"FA"\V'*-*
M]\-H*BHV_P!'7U>W9F*@7IJY]?W'CX>7IIFYJ)8+CP"T=*4])UZ>0-(>Y>+:
MO3EB&R2638`W1RX,*F;U3I$H,9+?<P0@ZP9D'=^G=&#FQAC&E<@7HYVS:BK6
MTJ2[H24M8VJ[@2-JIBKK:Q%4PT71MU7J\G+T'4E*&?HH50WCUESN$7BAP.50
MA=[DP\[SS9\MS[K@]P$;#;"P<2K3[O2VSA><+HRC2K[V[HQK;^AJ:HYH6)W(
M%@+(YH*"0IV*64!910[EE#,U3LXU%R)^<!`A0%,3"`B;B\AM+:$Z>]I#'0$>
M(Z%Z^3LV12RQ![;<HXN==EERAEYNS',\3/[#LQT)NHD]MN<:56O5A_:JA.I>
M>RXCU`&LVX`(\F8AD&.YLRHG&EF=5WOXCBY%PMI4\KQDOKM]W&,9RJT,@`B]
M="';`+AP("&T!#GE-H"&P0QR9TZI,R(8^'\IT+L29=/J@-8R/\PTKR9#EP"`
MXRSIT\S8W'X!_"="LV1)/\;(1QC2D`!Y,:)=1/&%CLQT*QD2>VW.-*KI66FF
MC:[U#T3J#JPD54R]"VUF;<Q="5+`1<W`F<U%,(OF=2D,]2.HVD&*Z0Y&#/=`
MH#P8]!3[S5-#2MD2V/-T'B...)<"LV')J*ETZ\SK0XQBAC6FJC2E1U9S&JE]
M4,_*O8?5A25&4;4E,L$&[5*CV%%0O>9%[&.`%,KN3%7)XW+D"92D$G'C;L_>
MNHG/:Z:QX(B+0>/#Q<:S?;TDCWV9QI7/V>T>4=05)SM'7*3MK=Z.E489J91&
MTD50XN64"FFC`OI\J#QP:H9%9%(HBJ7FLC[1*7$5F\U1?-UCS`XCH6V3LN2&
MB47-L$,(TK3U/H@I:HIR[LRVK"5IU"YMQ;"7.)"Q40U3;TF]L,LDWA:7CQYP
MV^QET$B[P@(@4.$1PRAWMJ99M8\<QT+C[2W6II_6OMCRC2N*K;HV[<U37^K&
MN8.OI^CD-55M$Z$G*;CX9N[B*,J5_4$344C7,`BJ<")K3LK#I@Z9E^XFRWC#
MMQT9>]4Z;`.#A=.(XB,65)I]VY,@@Q;8,8TJ6[0Z592A+A0=W;I7BJ&_5TZ5
MH%2V=OYF3IV+HN`HJCW+9)G)IPU.Q+ITT<2ST\85LHNMNB*10,&P0QQ-I;3F
M38W&F!R'CP\65=Z112Y3;H<,6$*VXI<WL+VP<H;<LL>;$^9\MV8Z%ME4TH67
MFBS&-*3(>(!P>(F`^X[,="Z$N1)A"^S.-*0>U*<3;``IMHY9!VAN$1PO7U!F
M1#'PCV3H6>IE280O,ARC2J\VF`27PU:@8!+_`%X6W#(W:[1H=H(!M`-HAM#J
M8[LRHF_37=5T;+('&,BY$FFE>)'6;G&+E5B,A]3C@>(J.P[X3H75\/*[3<XT
MHR'DQ=CITXW'-<!".`A3J93+;S<X31*!Q3(.\)C*H@1(HBF=8=\!,F#@/]CA
MN9B8V89E`0X\3)F3:>=$-<6@XCH39M!(J)4"]F#M#2J[PVFZBF&I&X>IB5:Q
M-:557=,4+2T+!U'2<1)-J+2H,%%&\M3\Q($.Z9J3R91%SN@51,Q0$-HACU3-
MY)]'*%QKR'66`Q_!><9NU2NGN+GLA#&-*X)/1W#(.)T0N+,.$IO5OXV2Z80Z
M8)!,\V0ON.2>.7(@ZA@,4"`L<F^!C`.61<,&]M4<+'YCH5)N[U.WW7MSC2HQ
MHGH^FM%743NNQO/-2-00YKL(TTZGZ'8U%.I(W<=J.WB=;S$E(*H5P6GCKBT0
M24*#4C4`*)39@(:)&\+YX-]KA#&"%E9L"4(]9N<:5I%>C;@$:*A8\+A)C7E.
MW=G+O0<U[B&3BW$1(5'#IPE54-%6ODY-6+CZ4>LTRK.03.5,%P$Z!,]F-'UL
M]DJ_T&3VFYQI5@JWTL1%?:9$--LA5+*`8C(4M+/:MH:BHZG&"[ZF*H:5$16-
MI5N;N5BUFEV^Z<P")Q#MC;1Q@K=X)K&ZMC70(C8"?R6NFV'(8/>;&.,:5:T`
M$I4TA`0YA(C<"[H%R!N4$BCNES(7G"D`V1=@";'CWUU1/FVL>+>R="]%2RI,
MC`YN<:49#R8'SI[70#'$<AT)TQDF8^]?;G&E&0\F*^(J.P[X3H5-1)[;<XTK
M35*&=*UF&7_N?50CMV[:6E0#9Q9CLQT=G5$_6VL</Z3H6*LE2+D-8S.-*BC3
M.`ETZ6/$0$"^X6$#,=@9\Z.S,>/%MMSISI/58\_TG0LM'*IP_P#V,C_,-*F\
M`-D':CP!R8Y3)]0&`7'8!_"="Z_@Y!MOL^(:4N1O4CZ&+:^H[#LQT(\%([;/
MB&E5YO3ITI2]]:6-JZK.;>,+#594=8DHN5@V=00]?JR]/.H8D-),'A@9I-F0
MY*%$>$0QMII^TJ0Q;>S>Q<6OV13S@6WFPY1I6IKK3-#UG<2I[A)U4XI5E-:;
M*ATQ-Z?@X)!K'PT-43MR^/546DW$%&2K%9?F@;IANG(&7!CORMN[0:R+K_5M
MP>Q8:?=2E<W6.>P$?N'%SJN-P.C:@Z^>P))6\DVE"P5%6>HQ6%<TLE+NXY:S
MSXCJ$D;>/7$@0U+-ZP[A!:4%(HJ;X<`B(89]U3NR[,="Q5>P9)=$.;".,:5V
ME4:"(:XE;7GJZX-PGCU"\-NY>VSF'I:D8Z@2-&LD\;2L-,5HX9NW\76534@\
M:E3:N3M4U3)9@)P$<,D[U3M:WJNPXCH3).P9)IW"\V,++1I4OZ==.2MBJ<JB
M!>5!1U7KU'$%A32],6MA;</3,(J&[Q,7$N#-X^<U-(L$W"B@*N#I@<53&*7,
M,15;SSW/L8^'(="WTVP)#9?6<V\<HTJ/;*:+:>LK,Z=9R,N+/U`.GRW5R[=Q
M+1]%IMDZI9W,F`J-[*OSD,)T5X9R[,@F40S,!<*K]OSJK9;J<M=$EIP'B(R*
M:38DF17MF!S;H!XQQCE5V"@8HF`"CD8=[/+AS\W;CR_BIO9=F.A>@\#)[3,X
MTIPYAPAEYN6#Q,YP(:QQ,,1T*CZ22P1O,SC2E1_V0CD'[8.#:&TZ>"GFU.M!
M+'P_E.A8YTB3VV8,8TJN.FX!.UON)0W@'4?<8P;NW,HBR`#`(9YE'+AQV-I3
MY[),J\Q]L?X3BY%GE29,3%[!SC2K&;APX2&#SA[&.3XN;V79CH3M3(^8S.-*
M:)3`8O:B'#Q#AS)TU\LNNNB#B.A2-7+<&M<T@Y0N?KRE4J]H:MJ!=/5HMI7%
M(3U)JR;,!4D&*4^W)&NG[5,V20+1C=<5T\Q`3')D&%4^V*NFF]67,A_*[0G5
M-!3U$KK/9;E&E5?D-$]OG&DY+2A!O6%$1RM+T-!35PZ=I&-934X-%R\?,LYB
MH$4S`%0RTR=@7G#JB)FIEC"7;GCU,K>NH%."]K[P)(B"(1$,7&O.S-WI#G$A
MS8&S"-*UUU-&3:Y,O=R;2NA/4[*W7JVT%5.XU.("0B&ZEHH9O'-("8:F?(!5
M4!4Q41%TS$R2(F#MM[%*3>>:UX%UP`R''R)9V#+;@(SC2HN4Z.1C\$</9R-N
M^1C3S&Y$[<]_+%MG'DJ:/FY^H(^H$SV]?LI-!Y;U\T=-.:2404,U1:J[ITS&
M*81[1WIF'JAI(-API!V$TOM(Z-*D*%T0TS2M]YV[5/U'!+0%25O'W*G:+K&W
M\'5U3$K!DU28RIJ9N2JNFK!1DXFV!TZ,=$[A%R012,._C#-VL9V`606V5L.6
M+7.;G&E;V\NCF"O76%\JIE:XF8!2^6GJ)T\2K5M'(K-::CX6IFM4HU;'O0/S
M[U^Y<-00%,>U$IL\\<N5MNH94EH:^ZQQA88&PC#!:IFQI(EBUIYQI7>6ST]1
MUL[GW,NFA4CZ>=W/M_:2B)&`5:$:H1*=I88*>9OVRI1R<.Y9,><42'[F4PB`
M;`PRJW@J;L`Q_P`)T+9L_9%.#:YH/*-*L48.V'(H@&8Y`(``@&?`(%[4!#D#
M9CRKJFH<XNN.M/9.A=74219?;G&E)D/)B-?/-A8Z'(="!(DQ]]N<:5E1S!5$
M1S#)4@B.P`V&#,>IEB*>5,^I-<&NNWL,##.L>T)$N5UFN:><:5"MO3AXJE]S
M;,AUQ0(Y\67C-VGVY\&608];.A]1DV_],_@]<\5!\.6?P^T*0[^6RN/<O6S2
MT;;NY+&V;AEIOGUY)=_0[&K@E61Z]B4N92%T\;E9;BAPSY<^K@HZQE+0.+HF
M\Z'.5G9*+W6V<.)='XH6I8"B8=5E/`4`S$1L728`!0X1_P!F<`!CBTE:)4Y[
MC$Q!P?JM[*<D60@D#2'J0,(E)JMIL3`.[D%C*2S*82@<`$`>[,RB`^9B?&OX
M?JK>"EI`TBZE2B)@U8TWO$';E8ZDA$#;N_ED#T1$=W;RY8/&/R\.='@V)?%'
MU+)]MXV%-[<][?L720ALVCF7NWB\[+!XQZ/!L3RZ2M2P[H^-;3``8HG*8MB*
M2*(E``[8IN[,LMH=?!XQZJ^B8YL.'X+(&DO4N`F`NK&G1,`[@A\!M(Y@;(!R
MV/<\P#!XQW#]4GZ<W)PYDTVD?4N;(0U7TV83%W@WK'4ED)`SS,&3[:`9>9BS
M*Y[#&U69L]@,3#AS+`;2#J5,(E+JPI\QPR$Y/@,I(2AOCV@@`/!X1X.7#?J4
MS&>'.F^"EIA=(6I4P@)=6-.#VXDS)8VDA[8!W1+_`+,X0'9U,`VC,R\.=+?0
M,(`'#H7J#2-J6(7/QL*?`-T!S^`VD<LN#/\`V;P9XGZD_+PYU3Z<W)PYDU32
M+J5..0ZL*<S()@$#6.I',H@4#"`AW;LR+M'J84^O>_'PYTR70L;&,.',L0:1
M-29C&3+JQIH3DW`.4+'4B(EYP,T]X`>[-\.#EQ3QCLO#G3/!RTOBC:F4S%W=
M6-.%`V[EE8JDS;PFSW<A!YQ\6#QC^'ZI3Z"6YW-PXDX^D;4L8O.&U8TYNE#(
MQAL9210#<X<_YMXL'BW\/U5/IS,%G#F2!I#U+<'C74[D`@7,+&TEEF8=T`_V
M9PB;8'5QH&U"R2&DD0T\JHVAA,@(0X9%QEP=*FI./H&OGJFJ2GGD>WH2LN[6
MR=E:69F=%)3\D"@`[1<+'3W?2B.[F&6&T6UB'BTFWAQI5=218281`7':;=+.
MHN<L!9B0C-3D+%1R]N:<491ZEE:6?G9HG9@9-$7RSE)1UEGGOF*41SX,.G[5
M<)KC"(CPXUGH:%PNN,(0C^(Q*93:0=3)0S'57`#U0L52?F[?YLPH;6<ZP#AG
M6JKHRYO%@X<23Q0=3(_YU=/[?^8JDO7F,;JD.))C$E2VF@T6\7#B1XH.IGY5
ME/\`Q%TEZ\Q&O;^Y3X88TGB@:F/E64_Y]BJ2'@Y0[LVX=XT8CPYT>'&-.#2%
MJ8S`?&JIP!XA"PM)`(>8/=FS!XP8CPYU9M.(BWC3PTB:F\P_QKJ?X?T%TGR_
MSWB/&-Q'ASK3J.19#:1-38E$!U60`AEP?`727KS$>-;B,>&54F4\6$"'#F7G
M\4+4QGEXUE/Y_P!XNDO7F+>,&(\.=8O".QCAS)Y-(>I@I@'QK(`!Y?@+I+//
MBR_FSAP>.NV@&/#*KLHKSH$B'#(E4TDZEP`N>K&G@$P@)<[%TB.>8[H9!W9Q
MCL\W!]2?EX<Z=].;DX<R0FDC4P`_Y6-.CLV?V"*2XQ'E>!PB4>MBS=HN/O!Q
M'#*KLHFRS$03SZ1-3)\@'5;3PY;?[1-)%X?,>8M]1;B=F]J9X?*%C\4#4OQZ
MK*>^(ND_7F%3:ULR$`X0X8T>'/[4H:0=3`<&JVG@_P`!5)C_`.>83XC^9'AS
MC"K'JQTRZ@*=MQ3"T[J2A)UFYO':1NDW1LQ3$?S#U2JDR,W9S).#@X*U6-OB
M3DVXW4FT=2TL%ZTQR?BL%7L[7O#[#`0X6*SZFD?4VY4.JIJKI\@FRV?`=2IN
M`I<Q[9R3=S'/9EU>/%9NU[QX^'.K2MD@"-D>&181T@:F/E64^/5^`NDA_P#/
M,)&T`_K6GARICJ35&[8$GB?ZF/E5T_\`$727KS$^-&(\.=5U&5'B@ZF@X-5=
M.Y=6Q5)9[>'_`,<Q/C1B/#G1J!CX9D_Q0=2^7;:J*=$>,?@*I+;_`.68/&C$
M>'.CPV7AF3?%`U,<6JNGPVCD`6+I+9GR?S9B/&C$>'.CP^5)XH&ICY5E/_$7
M27KS!XT8CPYT>'RA+XH6IKY5L#\1=)^O,'C!B/#G1J!CX9D*:0-3)N#59`=4
M/@*I+(?_`"S!XT8CPYU)IH<?#,E)I`U,E*(#JL@-H?H*I+UY@\:,1X<Z/#QX
MT@:0-3'RK*?#_`727KS$&M$,!X<Z&T\2!$84>*+J82$3DU64_F&8_P!HFDS9
M\.8`4'9A',.H(XO+K@+2'<.=$VC=#BAPR*L]G]-6H.7OCJFC6VHV'CWK&LZ)
M+./#V>IM\6544HMDJP5*@=8"H`B@8`RS#+&N;7-U0PQ<+/;:L<NE(FQLLX^`
M5E_%`U+[?\:R`$/VH#8JDNU#D_V9LV8Q>-&(\.=:_#Y4>)_J8^573_Q%TEZ\
MP>-&(\.=&HRI?%`U,?*L@/B+I+UY@\:,1X<Z/#C&$>*!J8^59`?$727KS!XT
M8CPYT>'&,)0TAZFRY[FJNGASX=ZQ=)<7!_XX/+B16C$>'.CPZ/%&U.Y9#JKI
M\`'U%BZ3XMFW^:^K@\8#Q<,Z#(2>*!J8X?&L@,QX?[!5)<7!_P".8CQHQ'AS
MH\/E"3Q0-3'RK*?^(NDO7F#QHQ'ASH\/E1XH&ICY5E/_`!%TEZ\P>-&(\.='
MA\H2^)_J8^57`?$727KS!XT8CPYU/A\J3Q/]3'RJZ?\`B*I+UY@\:,1X<Z/#
MY5SE:Z3]2T;1=8NW&J&GWS)&DJB4<LB6,I1%5RB2$D1.F5P5YV@B`\7!C32[
M2:V;`Q'#E6:JV8)C+X@3PR*+-,.E_4=.:>+,2,-J<A8>)6H:'481REF*9<BT
M3.H8R20G%<><%,.USS'/&BKVHVU@O1&;!RK-1[(!?>.#AD4[!I!U-"`"?5;`
M"80`3#\!=)[3<8[7@#M'J8YWC0;8'ASKI&F#3=B+$OB@:F/E60'Q%TEZ\P>-
M&(\.=1X<8PE-I"U*DRWM5].%WC;A<[&TB&\;9VH?S;M'J8/J3OW<.=:_!,2^
M*%J7RW@U74Z(`.[F%C:2'(WJ?]F\.(.T7.$#>MX8U5U$RZ<<$!I#U,@(#XUD
M!L'/98ND^7/_`/;,)U[?W+#X0XQPYED'2-J9,`E\:R!VAEML72>7_P!\Q/B0
MWK",0KRZ0B8#$8>'$L?B?:F/E64_\1E)^N\1]1=C/2MWASDZ4>)_J8#;XUM/
M_$92?KO!X\OZI)*CP\>RE#2!J8'@U64_\1E)^O,1X@?N4>&_E0.D#4V4,RZK
M*=S_`--8JDC!UA><.&R:[4N+A&)$.%J7-I2YL!##PXDA-)6IM%5)4=5-/*'1
M7153`MCZ4;%*=-0#%,<2.C<Z!<O2#L'#Y6U3K+T28<7`KG3:(Y.',JS:8--F
MH.HDKZ'B=2$)"=S7_KQ*1*I9BEGB4A(D4;%7D$2*.4Q9%6V!S(9@7+JXW[6V
MCKY<EAO6`G/9^272[.$XN),`(<,"M`.D74R;AU64]L_YBZ3#_P`]QQ=>W]RV
M?2&X^&98SZ0=3)LO\:NG^/\`N%TEZ]'#9=?J00(VX_U5V[/U5C3AX8EC\3_4
MS\JNG_B+I/UYAGU4\/U5O!GA^B<.C[4R<I2#JKI_(!$W]HND^$1_GO"9E;K7
M7C'ASIS*8M;"SAS)3:0=3`Y9ZK*?V%`-MBZ3X`_W7BGB!^[ASJ_AS^U-\4#4
MQ\JVGOB,I/UYAC:MK1"!S>U3X?D3@TA:F`#+QJZ?'@_N#TH;S-O=FW$^-;B/
M#G1X<9$'T@:FC`&[JM@`V?H+I,.L'=>8?L8>W:I:`T-L'#&CPXR)H:/M360?
MXUE/\`?W#*4Y/Y[Q/U=W9X9T>'Y$SQ/]3'RK*?\`B*I/UYA7C@;8'ASK.:1T
M<*4-(&ICY5E/_$52?KS$&M$,!X<Z!2.CA3O%"U-)F*8-5D`4Y3`)#!8ND^U,
M`@(&#^;0'8(8FFK6RHQ!X<Z754Q)LAPYE!ENZ"KXNE6_=$&N"S4KD^N.GXY.
MX/N58$00=AJ6M,877N7*X,R5`Q2&+N&.7+?SX@PQ\T>,:_C_`%5&R_\`Z;AR
M?BKJJ!GKQC0__I;G]G^$RF\<YLUWA+CK'7X_BMK&M,PPP%6_,`\R<`R`0*/#
MP9Y"&T,PV9XY-(YXJ'&:"&D\?Y+=U6RXX@5\C:XUF7=B-3]56DI=]1TFM3=X
M+;4-`6H<4](>Z&MJ'JRFV$Y6=3^ZY1]W!'/J,0=*.`2$HB9%`<RCCT(HP6CD
MP\2Y(VBTF`(*E:8UUV_FD:YIJB@D&TL2`N$A;BHG'>_O7/U-;Q@[4E6[&.05
M4?QH)G;JE(JJ4I7`)#NXM]/FB#B(-X9%?QCB+%(WC1-Z1+9N%N!2LVJK<&'H
M!HYKQ@C&$A4:PK%@U!(CR)6==^VK,9$X)"Y*F*8*F#:(84*0$DQ%T<7&@UK@
M+<*P(:SJ(>5,VBUJ&N,RIAW6=6V];7"?4XU]SCNNZ-92CB2B"EYSNM=LY0B5
M@;.@*5-98H$#AVV\`^/%8`>/CP*!7MC`FU8J9U.-+F,;2U7#)S-*TI<"M'<#
M"LGT=&S;FK&"4-(2(%*NU<B:D2IHQQR+`N4%"G$"B&W/%?"P#HVN;T1QIHJK
MQ%W`5I(/7-;B3%![(4K7E'4V_H>J[@4E-SU.(LD*UC[>N@3JQC#-A6.=!Q&`
M9+<5,($716%3,``1"QH7VAHB<BK,J]6T.?8(J1[1ZL*,N(K7#"5B)"VCBA)>
MGX)V:N)");Q<@\JV(&>@BP\LW=K(/!=M%0`Q`.(DW1XPPLTCQUB#S9,*6*^]
M@Q+15%K"MU3;Z\!YJ#K!E2]E5(^'K"NU8XB-,GJ"619*L*4IM^"A%I!205D4
M`%9,!`H*`)C9#B/#&,/XH6!,;5DB)%BY^,UP45(,C)L:*K":KPE<,*""WD*W
MBYZ0;5)*4R>K8TR,U&N#Q@13FF4S."J@<QDQ`P'R-L`\*X"!SJWBQA"U\)K:
MI6M2),6-'UY2*-2TU<=>E:AK"F6R#)S4UO&3Y2IZ;[TF<]T/96G%V*BQ@`0(
MYYK8.6>+MHR</%#I2WUP9",+5SS'5U7"-4UM1B%MIBL8>B=+4!?1G7+%)A!I
M53*R361<BP6A#JF5B$G:D:`\V(F$I@4R$0#%C1!N$X70]G*H;7%WNVKI:.U7
M/I2C;27.K>*E:$3K&R%47:F[>IQ;:567)"P\=,.W474)53%:MU&[X3H)G`3+
ME#+9GBAI6VB(O`P_5,%42(E>EOKHH`S2<D)*B:^IA[$TW1%64[!U!#,F$O5%
M.7'?H1%(.X<AUA3CV[Z76!-R*XAS68;=N+B@>YI+;8<?)A575TMIZQ@I^L)>
MF+O=3=23$;3$]2_N6K.;H619SY$@>'EJ9<&0?J(KME%6SI%-T0<E"&,4P;<\
M\8:NGU9N/PP!6ZDF2Y[=8T@D_DNRNQNFM-=/=*!0&W5;G``#+::FI`PCEQ"(
MCA%&&MF-$?XA^(3*J4"PXX</P7!Z1<PTP6'R#^YA2GF_T,1QIG0US@#9%)IF
M!LIHR*Q>T0$!#KX7@P)SVAP@C=Z@>AB(I=S(F"&09B&0!PCB(N5+F1:Y:5C&
MQSI.)*/0533!4Z2SULDH1(V>ZH8AU2G*F;(<C"&0Y8SCQ)P`\.=7U619>[6>
M8!W4W#>4(B7-4A0.JJ43II)B80!110A1$H%S$0#,,3"JQ.47`+8!9`<MP4YO
MGB<X4-\2;P9Y`(@.SCRW1S#A#+!"JQ'ASJU^7C"RF<H%*!C+)`42B8#"<H%W
M2@`B;//(``!P0J,,#8K7I9LB%@%=$1(H"H;B@$$AL\@-SHF!/+,`VJ#P!PCB
MMZ>,<.=$&8>JFJN4"ERYX`$P;-TX`(APY[VT`)LR$<,DF:7]?W4N:YDMEX07
MSTNQK:J&TU57;@YFU2\NTM66W+AV:&J-`[V>;70F@A89./:KI%W%F.X=94`V
MB!,@S$<=$26N'4-JS"H<3"P\BF^V&HV&N9>NN[1P<$[[DHFAZ1K9O6)'#48:
MH$*K.L@HP8,TCG507A';<Z*QA$2G4`W&`@%)TF9)EAQ!`)@GRW.>8.%D%:;=
M-GZ4>`.3B$>SC+?.5/@%D*3AW@\SZ@'$AQ.-$`@Q.#=#S?J'$Q*B`5+-=`@6
MU5#$$0`QK\6=R`1#,?ZZ4^#;U,0)TB6^[.>&N(LB5!ESG_ZFEW(%<P#D,`B!
M@$!`NT!`=@D+UAPM^K<+T<*:P/%D$I1*(=J.8<N,CI[91N!PARJDV6YSXD6I
M>MB/%CM=)2]5D2;P!R8/%CM#.C4GLIX"&0<&)\6WM#.K:K(DZV(\6.UTJIE9
M$G6P>+':Z2C59$=;!XL=KI*-5D3\PZF)\6WM#.KZO(C,.I@\6WM#.H,O(F=;
M$>+':Z5#94'`PXT@%*`"81RR`1SV\&7FCATNJ9@O`ISF`\2IQ8/(NH_64`Y`
M(5G;@P?Q)[>Q0E'_`%08T3*EIE0#A$))D]:\!:5<GAXL9->_&JZK(C;R8@U)
M:(EUG*C59$G6Q7Q8[725.JR(ZV#Q8[724:K(EW@#AR#S<`JV\;QG*LV23@:D
M$Y1X!`?,P&K;Q/&=#I)[*`$!X,L'BQVNE5U)'\*.M@\6.UTE&JR(ZV#Q8[72
M4:K(G`.SBQ(JQVAG5A+LP)!X>+$&K':&=5,JW`N*N0</@\KPN8"/N+JD,@VC
MF,#(9;.KEAE/->Z9>C%D5:9+>)75!P?D5"NC0#$TKV'(<HE,%O8$P@(9"`%`
M3&S#A#(!##:NH($01'C2*5DX>\T@JSW6QE%78.MTISI1))AQIN^7E#$^+';&
M<HU#NRJP:M]2E)Z1["U[J$K*)FIND+?Q[%[.Q=.D*M*+Q[UXDTY]BU-NBLX;
MBKOB7,!.4,L\=ZAI)NT9C9%"TS9SL`;:3PBL$ZL\/+,V=U90XRM!I3UQZ9-8
M5+-ZEL+=.F*L/W.F:4I?NEM&5G`.#%`RK:<II5;NYLNF`]MD4Q`'CQOVEL#:
MVR6@[1IYL@/)NEXA&&)8:7;^SJM^KIYTM[AA`-H5N^Z$<P+SI-X1$`*)@`PY
M;1R*(YB`!CS<VLII'^Z8UO*5W6:J9[A:5F(<IAV#GM$-G*`;>M@EU5//$)4Q
MKHXBKW`,2S9`/$/H=G#+@QH@,B3<+R#U_LXD-#3$840&1.`H!P!BT2H@$T_!
MLY?V!P&!%N!6`:3:O,8F]N;.!0@^<`[1'J87+8T/B"E3&,R*F>C(!%OJ'#C#
M4E<@!\TKAJ`AYPXZVT!#50['YI-.`V]#&KJ%+PYAYF.=$K3'(G99<`=?_1Q1
MS;W&K"'&DR-R!]7GXC5Y4=5.`-FW%@(""@@($H#PAB8E1`)@D#D]$>SA+W3;
MQNQ@K0"7(>3%(SL11!J=C0V-T1PJ(!+B5$`L0E',>U#A^KCP@F;'C5X,0!1S
M#M0^KS\$9N5$&(.&>0\.-$N,+<*S3VV@KYD6[$/@POT&S,.D#IXH_P#^25J-
MF-;C_G:[B@?P*0V[X9W-^(4Y&_R\XW_Y7)[_`*3*;PEWNJ9/O<Q5P#AFFJ7;
MF(#D`#D/"/`([`';C!,,#'*%KA>EW<8(5,:MT=TO4;ZYE0J5+,Q51UY=&WEX
M6DRD*&=(5;;N-B(IJ6&6[5SWGF(V)%)\@8P%.54X<`CCHRJUPP>[B7.9LYK;
M70+B5RU(:*X2CB5C34/6KDEOJLC*TCXN&)1E-GJ>G/=J9TM)JLZV%B>;=MFD
MA(K&;<Z8#%$^68E#/&M]>]\DL(MB"M;:>6T75BD=$L'(5M$U`%P*@;Q\?(VF
MD'489HQD9)[(VA8-XV*8)3L@DY>LZ6DFK8AGK-L5,@N!W]_9M2RI<`1C29M,
MPVXE$5G;"N9&J9=:O;V/S,Z'OW<.I6%JXMQ&+1\1<>K5YOW,'7FUTDUI5DE3
MLL95M%B!MUWNCD.[NCI?5.`O`1);".3@5C%,P&.(X%*MK-+E$M*KJ2I"W+DZ
MCJF*NDPJ*KD:?BV=/0/?^#I=S3R<?[G&S<D<P7>,IKNE^Y9"0CAR!=[,0$,(
M-4^$`.):94ED<-JCF^.F*'-2E#6XHFME)&[-$V>N_2-OZ<GWZ<*E4T%6$G%I
MU&Y>2`-7+9F+!/<;MS*$$BPGYLP"4XB#)-86/<^&&'Y!,JI#7R0S*NXTLV0J
M*E(^L("YM$12%`K.:7>T="5E&TI*UDYJ2+;OT*BFY(E/LD8/O29$S-&.,(`L
M@1N?MMU3:3JESC8;+<"SR:9@S*5:PTJ4/6E%W?H>0DI_O?=VK&E:.'""Z!'%
M*SD2V8(Q2D>W53,U%"-78)'[C53,DJF`D'&9L]Y='^(6+4Z2QK88`5HJ)LO3
M\-4E'TI,W$CYFM[<3J%RQ84W1,#1S=S&2-.S]$M$'[*`:)M%U"K*N5C9G%8H
M@.P"X;KWX8=7E2]4S!$9DU[I$I>22H-FM6-594"[O`\9D[G8"M)A>=G*1\R!
ME3)CN-8U*?4(W,&6>Z(CGEG@%01&/'!9YU.QQ!B+%[XC2;'PM:(U''UM/H1#
MVQ$-I^K*FSMV*S:JJ9@6\DQIV51?G1%Y$3+%"56%3<`2J[,]F>*OJ+T+#&,1
MRI\JG:/P7+$TTTG1=$VXI.O[N2R_N>H2IK"TG*OX]G%N'\753=&(@V*B+=,6
MRLQ&1;$B:9]G/[N]QXHZ>8Q;QF/.M'AV8%'^IC1M.5532LY0#F6J6I0H:U-L
MI*`?23*!>R-#6XJI&??O8:06:NF/NL?`U*)$UTS-E!R#>)A\FO?*!;"RU99F
MSV/,>-6-TFT9<VA+?3<%7T<SB8].J9)U0,6FUA6]2M:3?)HK%"L30*+6&<5"
MM)F55641+VQ1#,1'&:LG"H_R\9`Z%HHY(IR)7$#'.I@NL4Q;372*;+?&W%<"
M.[GD)AIN1WC!F(B`"8>#BQ@I?]HY1^(6^H,6<VE</I$_R8+#_P!["D_ZEHXU
M3/?/*L\K_6WD5B\45T8$)I]I#>9MSX,N/T,"%\Q]9]LJ'J.\ND*3D6#PSBM;
M[-*4J@49F98(S=,(TA/.481TUC7C9)Q'J.`(?,0R`>$<QV;98@USK.JVQ),\
MF#>(F"T-/5Y<F:IBE:AK%>C).D3ZHHNU=!TDPA7D>K3,/3DG4<,A,2DPF^,Z
M>U"5LQ(1/>S1%/(1S,.-[&R;Q;`EVKC'BR0"Y\VH?"W'!:J(O'JIK&;MZXC;
MA6WAH:[=7:A*49-DZ.,^>T<PM0>I74!/,^Z%SI2DR]9TV=F^(L`H&%8#$X,+
M,F2TDP)A#CQG\DG732(*,V>LK4C7D=0C&@:>ASU$-HW%?RJD>R@'435U3(UA
M)4JK#@:??-T8R'[FA>=<F9\X=`ZI0R`=F+>&9!UMA4>(F"!A@76WCU!7I1:Z
M@J%J>KFMKJCDK1U?4UE4:78Q%2,3A3-+1TI*/4*I;NCO6U5PT@LZ(]0<((@F
MD5,Z'.;HB"13,@"+54U$S&LU:ZDJ]MS:&V)X*[3:<K2)L71]UJH<K45%OHFI
M8J1/&1J;F8G'<TT(T[X+JJ%(W:$57,J&^)0-LQ#*=CX\4#!7$R8\AD;#:KZ+
MV+MG<196O:AI!J[FZWCK=RTVX.Z=&%VM1:B-04D"K;GQ;IDA99V=4I2B(&*&
M0YXSZVX+(69%NE2@M];FP5N[8SBM0T=33.GI5>`3IAPHS<NETSP2$[*5$WCP
M%PH<Q@),3+I<3"&8"MNAVH!EG=5/G?XC[HM6QK;H4Y\>>W@X-G5VXHK)<"$8
M$+Y1=-#<2J+1Z"[FW2HITT95=;R9HFKJ8=/F8/FR4Y%5(T.T%1L.0KE$#F[4
M,Q''=V!24576AE;"Y#0O-;PUM?2,'@XP(MASK\B"'TACI,DR!E<NU)N<*141
M5MDDH;MTDQ*';.BG+VF6PP`8!X0Q]KV5Y?[HU<H.G%X)';=H7RJKWMWDDSB`
M+(XAI60?I#O2;?M;CVD$,OT7(>O,=";Y9;F-=`%WQ/T)7WEO,ZT?EI2>4.])
MO^D:TGQ7H>O,+]--S<;OB=H4?=^\W"&E9R?2'^DR`H`:XMH][;GG:U$>,?\`
M;?)B?33<W&[XGZ$?>&\V(]&E/\H;Z3(=OPC6DV\EKD/7>(],]S<;OB=H1]W[
MS9>C2O,;Z0YTF^\.5QK299CE_8O0X,_Y\P>FFYN-WQ.T(^[]YN$-*3RAWI-_
MTC6D^*]#UY@]--S<;OB=H1]W[S<(:4>4.])O^D:TGQ7H>O,'IIN;C=\3M"/N
M_>;A#2E\H;Z3G](MI?BN0]>8GTSW-QN^)VA'W?O-PAI2>4.])O\`I&M)\5Z'
MKS$>FFYN-WQ.T(^[]YN$-*/*'>DW_2-:3XKT/7F`^6FYT+"Z/\SM"D;W[S$C
MV:4AOI#_`$FQ2F,-QK1["F$,[8H$*`[HY"8W=FP"CM'%I?EGN><+G1_F=H59
MF^&\PLXHXAI7(0'3K](/2M2UG5T17UK6LW<22CY2J7"UMD!*\>1$*QC&!VR`
MNP430,Q*4Q0,`;,;YOEON@Z0&F-U@LM=$QQF%JQMWNWFODF-IR:5V)OI#O29
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MB+%W^[!YL^X/IS9`'+C92^6FY@<'1=$&/O/R9,"I4;W[S:JR.#)I6FHKIZND
M2MS2%/472]PK6-J?IV&0CXA!W;=J[<%:I+`@W,=VF],BL&P0S`=HXG:7EUN=
M,>9Q)O'$YP&:$%GH][=YKUVV'-I77#](=Z3#,<KDVC$,QVA:Y'(>J'\U<`XP
MM\M-S2T&+L':?H6P[W;SQ-AZ-*;Y0_TF>?\`;$M%P_HM1]>8MZ:;FXW?$[0J
M_=V\N(]&E0U?OIF]=6IRU56V1NO7%NY:W]>LRQ=1,H>BF$4]40:.4C`*,H*@
MG0`SDQ``#@41,(98Z-#N#L38&V)4ZF),P8RXX0,:5M3>K:51LYS7\;;<'$OF
M]256UO;*HXNMK=594EOZOB4T%&%14?-2,%.,Q1,55(J\G'BV*Y.B<@&.W-SX
M#ED<HAF&/JNUMV-E;6H6&IND`1M$<.)>.W:VK5OG37\8;%?K`Z)_ID=<]Y:X
M@[(7%L)4&J>$36:,WEYZ$CT82:HR,/S3<7U<2S\6-*2R:`"*BW-*%>'`!R#/
M'YF\P-RM@4$S6T4QC66W@03&."%ED+>6*^Q[K;=K*J#)P)RK]?#414(V5,50
MHG*"I2*[O.)@N0!,B<2")1.B.P1S'S<?&&LI)+BR7"]&`R_JOJK#?EWCB6QP
MU0C`A&!"8IZ7S_V!Q!P%"Q!^SA<OWTN8J9:,/Y!J*_\`F5N=_P#?&V.MM#!*
M_D2Y&%W,KJXYRT(P(1@0C`A&!","$8$(P(1@0C`A&!"Q#Z7S\7&%+GX!RKYB
M6Z_M97]__2#T]_\`4G:?&AWO#^7\EB;_`*7<RG10P$UXQYS]J4-+<[VQ@$`'
M.YE/`&0\>U(W6PD'62K[+6Q@GRI;PZ)RJXF>T=@\F.<)C)[RR68D&WB6MK7`
M"*PO@$[5<"9[P(+"`@(D$#<T;=$#!M*.?&'!C6QTL&W`EO<8=7"OCE3EO;MU
M"WMC)51<C4(5:O;;W_DKDMQK&HH]`]0T\^>N+?$0:-#I(T@5N1%/N=O'D8=V
M``;X*9CC8)U.>JW#$<1YUA(J"^\?=`.+BC!1?(7SO]2UKZVD:YGKHA6%<:-:
M)=VMATX.?/+.KJQDW(QE2*IM(]JHQBZJ>))MU54E$$5C-B'.8Q@SQJ;*DA[2
M/=!MS:4ITV:6NB(N(LP8Q^45L+P48ZDA95+6+6O(Z&I_6G9&JYZ8@%ZAAW@Q
M"]L(UA*3[H*>;E=O6#:8D@`R@;Q$G&TV6Z.-4:?5AHL,,O#&N?-;5N)NCI"E
M^[M;3D#-"A5-6W&I>VDQJH1I.6EZ6[[1TI)6W7MM$N0:#)Q(+RYJ?[[)'4.^
M;@#HRH"(G*&W"+LHMB"+X$0.**M)%4QP#V]2-MHC#2HN@G]\)"#;5;2!JZJ.
MI(VSFIAK:"J:O82:E8N:;1J=DVH5W,G=KD<.')6F\JR%XFJ[623W\P.)`&[/
M!M!$SW3APX4\^,F"ZP=891@5F-%[FJYAC6LDI<X:IIF0HZE$34HL>NJAE*+K
M)*-=)U')/I6X;*,>B\D5!!16,1W4VYD0R-P`.>I?3.MEQO1Z,Z?)DUC87P,X
M56R5U<2+IB9IAW55T)ZD(N\-/!=C4%1DY7TC(U#1TRM/<_'L(J3,22HF?IT2
M((29XIN#84-PZ2ALAPR0*41)]Z[9APJM3XL!HA9'&%(EW9*LXR#N+5&G][7T
MJV>62L^A#5?(C4<M4:](HW)J(E7K%F':@3Z\K%TV\56%8^^](DH.X03"`#H8
M*0L&LL=&V$;5E<:T'JBSE"RT$QKJK@MG"LKPU5/6QJZ_3D5_<._KE!S3]&0U
M%=V&HV=KJKV:%2O8)[.M2*@9))H9,YSIE6R$0PBHG4K/=B"6FR'&H#:ISP'@
M78BV(P<:U#&J[FFN46-;U)=M/4!'ZF'$,K0+I]+'M]XN:;Y^V"2>023-Q21Z
M:)`D%V9\F9.65>I)IBN.\(80:FFP1/NXCA6ICI[?>%L5FMM5UR45VU%Q\U6U
M<(T_?"WQ)Z\A'-4S4%7M-3IYH[B+>1-6@=6@IFG$4T.^(,1,T*($!-8-\P`&
M?1&TDQ@1@*8#4N<'-%D<84^Z-YRI4JXO!0TU(U'<-PP?JU$K>1U)5&G3$^K(
M2LBT0I4*3J%$`IB9I:+(!#)QYE62G:GWA$V,,U\IWNQS+?*<\#KKZ,-MB11,
M4""<HFW=TI3!O#GVX$,<@GRX1`<A'"7$-E9/:F-:3,+Q[I4>W;`0M9=#/(,[
M<5N`9B&T34[(9!P\>*4ELT0R?BF32"V`PP7`Z1!RTP6'#;LMC2@<`\48B'[&
M-$UP$P@X8I4H$2P,BL7O!U>L/8PJ^U,@4;P=7K#V,%]J(%)O%Y0Q-X*%S$G3
M$+-/(9]+Q4?)NJ=D#RD&Y>MD%7,/(@D**;R+.(?S*H")C$SSSR'"V3IS8Q%B
MDLENPX5Y"432Z;1LP3IV((S9SGNC:M2-&Q4$YOG%%N^YB```:2,HL<W.99@8
MW#C2*EX$;;T(+.:=D<D5@0H.E6HQX-:9@6Y8AU*NHH$F2"8L%YLIS3"K+<(/
M,!+'<K`YRVJ;XYYY[:>)F\ROJ)6)<7+V"M).M8!G*VRHE\WI8S@U.MW-/QW<
MD*F[==VO48\C9%J=`CM\'=&YVR?.AO<.W$>+>SK.)@H?32W-+0%M36>MT$U,
MU`G0],A-5''A%3DP:)CU'[^/.0&[IJ[47:K&7;O&P\VLD8QDUDR[IPR'`=HL
M-D3#D.A9_`@+0*:>;-JLX.+/:B@S1=,LG,=3[#O"R[CAHE9QW4:+C4"%329M
MUW>2HI$("!>``Q5^T+[;K#%W)[%=E$UCKRFIHF*"#=`$B)$00(B4B10(D0A2
M$*1)),G:D32`-T`Y`V86R>#[^%:F,NA>LHCF.>>7%L^QAFLE&UN'G5W`0LPI
M^\'5ZP]C!?:JP*-X.KUA[&(,Q@PH@4F\7ER\W9]?!K6(@52#7U'QTO9RE(^5
MCF<Q'.[VVA;NXM\@BZ9R")ZL;\XS<MW`';K(+$`0,4Y1`<-DS'!VLEF!"7,;
M)+2)N'B4X#IYL:.0ELY:L`'MLAH*F`$N]VP$^YL$@R(40`,PSR#AQL?MK:,A
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M#@$HT%38@)1V&],U`/2CB[=X]JG!.FP_F*EVQ]G'_IMZ54>QED+./=0&KB/<
MVHMPNWB:SH%O'MW=&P;I!FT5H"(6,DS27;B1H59R8QQYL``<MO#C9.WGVQ-D
M!IF/ZN)T(\L`(\\5E&PMGAT2P=.E6V\7FQ_Z&[5>\.G/6F,'W%MGM3/C]B;]
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M.0,4Q5"M.<$X#P&`0'#Z?>';)F7F39N&/OJ)VQ]GNEW=6W!ETJ(-)-C+,S.F
M2Q\B_M);-ZX>6^@%E7+VAJ><K+*;3!SBBC<RJAA';F.>>+5V\.W7DOO/B?W@
M#!BA!(IMA[/88W`<^7*K'^+U8X=HV9M9F/)0-.@'G!W+L#"&[P[8#0#-F1AV
MUI.Q]GQ_UMSE'B]V-_0W:SWATYZVQ/W#MCYDWXBH^D;/^6WI7S\Z331VUNUH
MFOI;33Y8R@WEWZHC8QE1R</3E/4XX,_--1ZKA<)I`C4[%))L0QS',H0!`N6.
MMN]OCM:5M)E3M5\ULEIM!>9@AR`?DN1M#=39]11ODRF#6$681^:^4^B7Z-A1
MM/\`>6MM;M8+W!F`1:NU+1T0Z4846T<HG36*TJBI2J=]:FYHY1***()M\N!4
MV/H>\'FO.J97A=E.=<NPO.;`'D%V.>"\IL+<.913W/J6!LMQA`.!LYG+]-=M
M;.6VLY2[.B+5T13-!4G&-TVC"#IF*;QK,$B@4O..2())JNG6X4`YU510PCM'
M'QK:FTMK[1>73'%T<9'X0LYE]#H]B4%$V[*`APRE2JF`$%,H`.12@&>W9D&6
M66,U-32Y30^9$S1PQK<X/O`-A<'(O1O!U>L/8QKOM4P*-X.KUA[&"^U$"C>#
MJ]8>Q@OM1`IAQS#CX>0>0>I@+P0>1`!6(!#,N>S,V09[-N7!MQ261?YE1['%
M4UT9@)$-1.^`ESU+7.RSXP[L;;0Z@XZNT7M`E$]A+DL<TNCD5T=XO+GYFWZV
M.9K6)\"EW@ZO6'L8!,:<"(%&\'5ZP]C$WVH@4;P=7K#V,%]J(%&\'5ZP]C!?
M:B!1O!U>L/8P7VH@4;P=7K#V,%]J(%&\'5ZP]C!?:B!1O!U>L/8P7VH@4;P=
M7K#V,%]J(%&\'5ZP]C$WVH@5B,(`4-O'AH!BD5#F@".-?,2W0E^#*_N1RCET
M@]/9Y&#8/C*6FV#R".>'%[20>(-@L+9C=0X\BWUV;K#:S6S3$@%!7#KH9/3+
M/->X:`@PFUVRB=QHIQOO4E'+;N<AB!L$1';C;3TK9E"Z[`$/C;^JB7/>'6@V
MQ4DAK'#;_BWZFO-&W*(<?+WUQQZ62UTY]R%[*5N;.<0!`PX9%D#6,0P@7Q<]
M2XY[,AMVB(#GLR$.^FW/&K5']JM8L0ZNDAWBCIRU+Y`4P`8;;(`(B/`8XEE"
MB)B&]+D(=7$F7=%X78\,'*BPV+SDU:@("F.G?4P!3G,MVEN&Y/NP<V<1.`2I
MS'*Y4S$P;-T`$./%;SH\2IJAEB@VK@`251#3EJ7$#'5`,K<)F%0IQ`QQ4WI8
MH<VXWO2\)-T,271XQ%`E@66P7,SVH2EZBD*2F9W3#J7D)*B9A6?IMP>W@<['
MRRS59J=P)PF`!<H).CD*4V90``'(=F(O$"#80*-6%T?C;F-SAATZZF0'>`29
M6\#FQ.8X&!84S3`;40*7M1R+VN0!M'%@`XP$$J;&4V\(DQ0;5RJ4,O%ZU,+9
M\X81"W"1`.<<ASW>^R>YSQAS'A`N66&OEM(ZL%F%1-C;%(35FH1R51/3SJ8Y
MI/?-NC;AN7>*80R34,E*%5.(%])GL*(;1'/%9@AQBT=*=)<Z<2'1L2%U9[H\
MX73QJ:%<X""JWP;)F',PFS5%(\R*9C<V(D,4<RAL$H!D.:B<4,*?JQC,4JFK
M<A2MBIZ>-3"8IY$R"VZ&9$1S`2&WI4I#$W!$!*4`$<^'9BUTO$;(\O2IU<,$
M>'$G^-HB42@73UJ7)S8&324+;AN)RI``$WM\94Y]]4H!M',Q0+NXD2S'K!L.
M51J\IS)IM6A?NA2:<]3*B8@9-/F;=HMQW3[IE1$Y9<HF.JIF?,0S*(Y!B-7"
M/NYTIXNN$(P@CQN")'5`-.6I7=.=-4^Y;5NB=PKED958Y)<IC'R`,Q'//+%G
M2AA;#.J`NXP5[$M892ER'3CJ6-M,(&&W2.>0B(@&7?8>`-F%OE&[:1!:&37!
MD(%<9<O5OW;;ROVGBZZCT.ZZ"K%('+FWK<J"(FI^0R,H(RH[I0X<\L-HZ=KI
MK80`B,RRS)[AQ$V<.)<#IEU9A":>;,10Z?\`48_%C;NFFXO6-OD%6CD4V)"B
MJW4+*`51(1#8(`&&5,G_`.P^%V%Y79/?<%A!APXE.?CC!\G+4O\`%TEX5PC5
M?RJVN?EX<R/'&#Y.6I?XNDO"N#5?RHUS\O#F3?'$3^3?J7^+E#PK@U1_:IUQ
M_=PYDOCB%^3GJ8^+E#PI@U7\F?VHU[_W<.9'CB%^3GJ8^+E#PI@U7\F?VHU[
M_P!W#F1XXA?DY:F/BY0\*8-5_+G]J->_]W#F2CK%#+;IQU,9?WNDO"N(,B(@
M;L.51KW9>',D#6,4=@:<M2XCU+=)>%<+\(W(I\0_+PYD#K%`NT=..I@/\'27
MA3$BF:#$`9_:CQ#SCX<R4-8Q1V!IRU+\O]KM'PKBVH&)JC7OR\.9-#60`B(>
M+CJ8#+_FZ1R]"6'$B3#LHU[\O#F3O'&#Y.6I?XNDO"N)U7\J-<_+PYD>.,'R
M<M2_Q=)>%<090X[J-<_+PYDGCC%^3AJ7'_!RB/UY7%=2/VJ=>_+PYE5?5[JB
M"I;;4HW^`#4-&=Q7HM$]*I(4$V;%6.G528@BB8\F<#J"`>EX1QJIY`$22+JQ
MU-0^(`!X<RM-XX9`$0-IQU*"/!O%MTCD;=`"YCG*\>[UL)?)XNJ4V3/+L((/
M#(G!K#2RV:<M3`>9;E#+^JN,YI@3;!;6/O-B8\.9+XX:7R<M3/Q<H>%<1X5N
M3.KQ"/'#2^3EJ9^+E#PK@\*W)G1$(\<-+Y.6IGXN4/"N#PK<F=$0D\<(GR==
M3@=0+=H9?U4P>%;B&=1GZ-"7QPTODYZF?/MRAX5P>%;DSJ8A'CAI?)RU,_%R
MAX5P>%;DSHB$>.&E\G+4S\7*'A7!X5N3.B(1XX:7R<M3/Q<H>%<'A6Y,Z(A'
MCAI\6G+4SGQ?V.4/"N#PK<F=%Z%HC%,'6,7;GIQU+B&0B(&MV@(#D`B`9=]-
MHB(89+I&QAU<Z2^<Z'&JM67U2EC+\:JI@;`:A7QIRL;?J"U:T$V5=,$T*`C2
M`#U()(IFZ@FV``B(CGC7,I&ME`@B,,^!9Y$YSIX!&$E6F\<A,3;GBW:F`'U1
M;<(B`9=7OJ(;<9-1_*NFE'6(3BTY:F0_P<(!_P"M,0:=KK"&YTJ:XL;$$QBD
M\<0OR<]3/Q<H>%,5\*S$%GU[\O#F2AK$)QZ<]3/Q<H>%,'A&<0&=.DS"\F,4
M#K$(/!ITU-E_B;=-PS\W^%,'A&XFYT^"`UADX].FILW\5;IN.7F92@8CPK<0
MSJCK$OCAI?)RU,_%RAX5P>%;DSJL0CQPTODY:F?BY0\*X/"MR9T1"/'#2^3E
MJ9^+E#PK@\*W)G1$)!UB%XM.>IG+^]RAX4Q/A6<8&=)?-<UT!&'#(D\<0OR<
M]3/Q<H>%,'A68@JZ]^7AS+EJZU>$=T16#<NG74DB=W2E3,Q<N;=HD10WH.0^
MZ*'&5$"D#C'+#J>G&LNB`$43Y[Q)!`.#2HHTJ:JN\&FZRD,II\U%2(,:$A$2
MO&5`-EVK@J1C%!9-0DF4HD/EO`&0;,:*N0`\D0N'+D2:.>\F!C'AD5@0UC%$
M`$-..I?(0V?V.DN#B_IKC*)+88&\.=.=.?>.'#PXDGCB%^3EJ8^+E#PI@U#<
M3>'.C7OQNX<RP^-VFJ8%#Z=-3!1R[4"6W3*H3/A`5"2P`<I@XAQ;P\N'%'AE
M5#/F1PF"]!=8!"@!"Z;]2^S9_:X0`.IM[ZY;<0)`C9=5Q.=9[T>&1-'6"F00
M_P`6W4J`Y[!"W3?K[)3%M4?V\.=/,]^7AS)0UCE^3CJ8^+I+PI@U1QM5'3WP
MX^',E\<8/DY:E_BZ2\*X-5_*DZY^7AS(\<8/DY:E_BZ2\*X-5_*C7/R\.9'C
MC!\G+4O\727A7!JOY4:Y^7AS(\<7/@TXZF1\RW2/7_HK@U7\JNR>^.`X.'$F
MFUB@)3&#3=J7.9/F]U(]N4?N@G4`G:B,J/;%SSQ#*>\ZPM!QQ59D]X,8&(X8
ME5?2UJG[P)7V(:P.HF1&2U!7"E"]PT`V<`U3>.4#IMG`EDR@FX3`.V(.8ACJ
M[4IQ=DD7;MR&'CX<:1)GOM!!PJU/CCE^3CJ7+_@Y1#/K2N.3J!^U/U[\O#F2
MAK&+Q:<M2_Q=)>%<2),,%U1KWY>',CQQ@^3EJ7^+I+PKB=5_*C7/R\.9'CC!
M\G+4O\727A7!JOY4:Y^7AS(\<8/DY:E_BZ2\*X-5_*C7/R\.9'CC!\G+4O\`
M%TEX5P:K^5&N?EX<R/'&#Y.6I?XNDO"N#5?RHUS\O#F1XXP?)RU+_%TEX5P:
MK^5&N?EX<R/'&#Y.6I?XNDO"N#5?RHUS\O#F1XXP?)RU+_%TEX5P:K^5&N?E
MX<R/'&#Y.6I?XNDO"N#5?RJ1.=$8>',F'UCD`N?BW:F!RS'(+=("(Y;<@`)8
M,Q'BQ<2'QPMSJU<0!;&*JU;RY13Z<K\W#]Q5=E!/7=`/_<:>&3+7)\]2%IR]
MRI18+[AW8<YF)1/Z4!V[,.,IFN#>*['G7-;_`/K.X8E;%T.YKOC`(&WQ79Q5
M4QC&[<27&A$@[4NP,A6#SL\8V5!ETQD3(ET8X_Q74!E-=&!BI5NS?VCK,M:<
M-5`2<C,5E*]YJ/I2F&2\Y5-4/2)`NY")BD1(8R+-'MECJ&3(0.$<9J.EJW37
M.F%NK()%I@(".):!.D0AUHKHZ>NW3514O#U887M+L)Q95JU:5TW&C)=%TDJ=
M!1NZC)\[)TFJ55,0`"@;>#(Q<RB`BQLN:X1$.E5+2,)Z5U:]6P35=BT<S,0U
M=R!A!DV>2C=HO(%*(=O'(.E$E7Z:@#F0R8&*<.`1Q9LF<[BL'*J:P7@V*1:L
MX`BRS-&4C'D@D@LY[ULY!JM**IMP4%4$8\JP.SG*9/=$-S/,>3,<7U$V$2(<
MQ3K,84;15_Z!E9:+IP7RL96LO1KJO6=`29DF]7GIELZ79"^-%%74*`*.&Y@(
M&^.]YNS`^1-8TN@3`PLM57O:QI<<`7;4]7D9.0#6H#$7BD7;9%V=C,G38R,<
M1P)N8))(J+"DSYXA!,0XG%,Y0S*8<)NS#_`^/(D^*E<(:5LTZKAW$D>(0DH]
M243(BJM&I2"2S]NFX(0[=19FDH9PFFNF<#`;=W0+M$0`0'"WF8&!S6N$3")"
MLV:R98#;"*CBZU]Z*LY2KNK*P=[C=FXC$#P\>X:.ZB<C+2K>%:G81`/".'B8
M2#C<,8F89$,(9Y!FUE+53,!'3H2W3I33`DQ4K%FX\4TSE>-!*JJJW34%X44%
M7*._OMD%M[FUG!>;-F0HB8,ASRR'$-ES6NNS,//^:89LN6T./&H*N/J5HFW<
MC;2'(8U7S5VJJ<4C1T13$A&.G3Q^PC'TO)N#JOI&/8H,XUE'G%43*@J8YB$3
M(<YMW&IM'.<"XB#0(VQR9%0U4KA!3:UJ%FX0%7NE`V\=9)("*EW5E6Q=YR1L
M<YR%=\R.93&3WB%.0Q1',I@#.YCFF"L*B61&V"\Z%6P3GN\&LW$/.]9RDE.Y
M99DOWK,<H&`LAS;DPM!+O!GSF[EGGP9CBL)F16U\O!H7)/+RVX9U+1M(+UG3
MI:BN`2H3T=&$FFJBU0%I8H'FN]XHK'37%H4Y<P`<\QRRSQ9LN:X1`'2F-GR(
M=8V\RV-/7*@IR`3J%RHK2[)1_(1P)U<9&#<=T1SQ1DID#M8$U$W"J8BD)3CO
M%$!'+`94X&$!TJPG4^/\-*WCJK(=DX;-GLM%,EWJB"3-)W*,D%'2KDN\@FB0
MSD#'46`0W`RS/O!NYCB7R9QEQ;=CSX^14\33WBR#H\VE<W=18PVIN<XWCD.G
M;ZM1``.?+-*G9(!$2FR$A@'BX0'ARP4K9C9C;Q!ZP_%+FE@!)O8"N#TB`;Q8
M;$B)A,)K9TN;>$QA$=^/3,&8B;,1R'%JB]KW8(Q5I):Z4US8P(5B]T?5#UQ[
M.$=;(F694;H^J'KCV<'6R(LRIA>VV`8P</"/#ER;<'6R(LRK$98H<`G.`#D<
M2B`[FP1`3`)P$<QV;,QP-O.P05BR&&*4J@&'^6`79D8?2FS`O!D83;!-D.8!
MM#%B'@1L5.KE64=@@`B8<^J.7GCGL#"[SL2M`)`.`Y]3_3F'T,2'NC:+$71C
M0)\@$<A'+B#>$>L`B.+7\AS*8!8^?$"@8"B.\/:`!MI@'+(P`8P9!O#EF.6%
MS9I:V(!C'$H@WC*AU]?ZT$?-2<`]N=1#"8A`:=^8M_/,VKR*[X+D:Q_=R#A9
M(R(OW)RIHY_R0XY%SPV535<UI>P6`9>-4?,E,][`I!85?3TC/2-*MIR*7J6)
MCX^6DH)L^;*2K*+E16+'2+ID1P=P@S>*-E"IG,4`.9,<N+,,J?+M?"'.ERY\
MF:ZZR,0%T^Z/!O#UQZO5ZF*];(G694;AO5#UQ[.*N$PX(*;,J:("7A,;;U1[
M.*W9N,=*.KE5+]<RJB5JJ)%/?$QKZ6>+O@<Q!+G5:&>Z8IMX3Y!L#CQIIM9?
MN"%\YECJ6WG`!CG#((JY1%0`-HFR[4"[V]O"'-D';F(#F(YXSSYK);[CWL:[
M*8)C3<$2R9#D3^=*.W>,'4SR^N8<.EAQ;$77#&+0K-<^8+S&/`RA'.$^^#UP
M[.+W7XE:$WLNS(YPOJS?;!^ZQ4W@87>A1"9V79DN^7U9OM@_=8B+NR<R(3.R
M[,DYPOJQZX=G%[KL2(3>R[,CG"??!ZX=G!=?B4PF]EV9'.$^^#UP[."Z_$B$
MWLNS(YPOJQZX=G!==B40F]EV9+OE]6;[8/W6*1=V3F1"9V79DF^'JS?;!^ZP
M1=V3F4C61M:Z'(F\Z4.$PY>;_P!EBS`]V$0*E[^*X_,J:6$.`:B]8Z6:B>=;
MV^6$X+&$3&4H&,$"%*)LB%*0.++;A\YLPR&@#BLL_!9VO&M)#)@/'8KE`J4`
MRWS&ZN>WT38PZNHX13M:>P_,E!4H_MC>>)<O^JQ:6R<'=86*6O+C"X_,EYP/
M5_QP?N\.NNQ="O`]B9F2@H`_MQ\XP?N\00X<70HZPP-?F2[Y?5FZ_P#V>*Q=
MV3F1%_9=F2<X4/VX]</W0XL`X\70H.L.!KLR.<)]\'KAV<3=?B40F]EV9'.$
M^^#UP[."Z_$B$WLNS(YPGWP>N'9P77XD0F]EV9'.!Q''KA^ZQ4W@873F4B]#
MK-?'D1OAZOT?^RP6]DYE;^EZXJXZ@?!]7H`;>_K,JD!+OY9?P#(;0-O9E$?0
M#;BLIL[6X#=B(*DTP9:Q^#$H5T;&,72M8C-103C;V``1,J)^UR'(-\3B)MTF
MS#JH3HFSK\\<"52D=B8!R*SP'#(.W,.P-N\&WJ^FQCNS\16@DQ]Q^9+OAZLW
MVP?NL%V?B*+>P_,N.JZO*8H*(<5+6D]$TK3[55HW<R\_*MHF.;+/UTFK0%WC
MY5!FGSSA8I0S/M$=F>&-DU$QUV1"8Z.!L25,XLD2]8ZT0XEM6<ZV?LT73-8B
MZ:I2J)JHJ*+D61$?Y,@=+?!9`0]*H7-,W$(XI4,GTL#.L%Z!R'$8X,JR4M;(
MJR=6'Q:(VPMXX"!-JVZ:N\0AC&.&^(`7,#9]MP"8"B.Z&7&.66),Z6++S#R%
M:I<QLP1#'M_F$"LX9Y^F-UQ]#,=N+!SG8!8K.<P6<:4-HY;QNN/9P=;(JV94
M_='U0]<>S@ZV1%F5()1`,]XW7'LX.MD19E6,1V;!-]L(>B`C@BX"-BD0"Q`4
M^\7MC;N\`F'G#B.11W@``'9VV60]3%);GE\#"$%#RS*J::,2G,AJ(,90XG'4
MC<@IMY0YP**3AJF($WAV$V;,=3:1F.;*M$;B3)N1(;%74`I@_;"/FB;LXY<)
MN,=*?U<J7='U0AY@CV<6;K!A@BS*C='U0]<>SB>MD4694;H^J'KCV<'6R(LR
MHW1]4/7'LX.MD19E1NCZH>N/9P=;(BS*C='U0]<>S@ZV1%F5&Z/JAZX]G!UL
MB+,J-T?5#UQ[.#K9$694;H^J'KCV<'6R(LRHW1]4/7'LXGK9$695B,4VZ&1A
MX>,1[(X:#;;!(J@X@73!?,>WA!^#>_)MX!-\X+3^W(P;IO&0M2&7"(F*/FAE
MPX;&;'"(P7-;*?J'"SA!3BX$#:\HX`XM+4\&W^^;37(.$3I?^,.*U'"N+U&T
MO7<%>6Q>HJCZ'E;C1]J(FYE*5?0L"NS]UG>NOVK)%K4E*QKTY&DD[:.&@)F*
M<Y#`W4-EAU,\:MTLG"%,0('$HCO#3=P+A5=3=R:OTY5?7E)SEG*QH*+M<]?Q
M+ZH*`KB0FN[8>J)MF#X\6T).1I4Q+(MA[HBU&XE+D&6-4LL`#0YHMCS:4I[Y
METD`FQ4G"$]S=RXND[Z.35&A:V9TOQ-754Q;-Z@J]E7$*HI(1--4@61EFTJE
M3!EW**,PNR:KIG3((GS''1:^2)9N`7B#^JY]^=K03'#P"M\KILN$TFJ/KN$H
M]P%:*ZH;L555=0$F,I<;1U=2]2,XM`9%RX56-3I'ZC7F61A,")AS!,H[05?E
MN,'.%RZWXHVK9K9T(`&,3F6*WMA*WI&[UCJYJ6V2TI(-M+=56D<5<V)'NI"A
MJV"HG,[$#*+\X$B@A-1C@44G!3*E$YMP0+GG@F3Z>6U[B1=O#%:+`?SY[4M[
MISFP,39^B\2NGV]:;BR5-(0$NWHZ[MOJ!H#4@N,^9)S01+42AZDBG[@BCQ5:
M2-4C0JL4JHF8#&(J`GV9Y5.U*,NOEHO`F&#%R+.)<_W1$1PYUDLMIYKR*ORA
M+W"B;D,9ZGKGW%K!M6T##TN6BJIIRH3K-XB*F:V[I3JI:!"`.BW".63W`5;E
M$FP`'&>JKJ:HEB6P-%H-G.FR&SF/),<"YK4S8RXM8UI?)!M8><N=,W`K.R57
M6BN&E.IL6=$P-&/(9&<@7!%7B1H$E,OH]=Z5N@0Z<D1X83#O[,:J5TMLML7M
M#1&(XR3@*S33.,TV$DF/(./AQ+T1=LJGJK4!?RR[LLQ,V=LVTK&Y$"]I:56+
M..*MO]$F(]H5-9951NSF:*9I+KLDC)G(4BY!#(1-A),EQ#C`.)`MY[>&-:GB
M<^6,-D2O5;73[7T]4.FM6K[11)Z4LY=JN'5.SDO3L+3U2N*$D[8R$9!5C6U+
MQYABVE2*5-S2?/-O3G;)KG`#FRQJ?4RC+=+#N*%D.+$DZN>""08+G8*S6H02
M6?MRM:RK6S&T3G4NQGK@/)B,&+JEA<!*KW="J0:2"YGKM@JXJ!(044(51LX3
M$0V&#&9S:<N+@YI!Z%=LNHA`@\,2?5&E>Z<!",V%O;8JM(N5TO4!"7&IV.J5
M1@\KFX5-7(9RU24])O&\BV"4J:8HQ-TCW2J50IP5!(X[H!A;1)M)(A'HT)AE
M3[`!;!2T[M4TF[QZ4[M4]I9?TM2E&2MV(2:IES`T\E.4DI5]/L6D%6SB)25%
MM&P3B18JBJ5N;G!.)3BGVQAQ+;H#F%S8Q_4*'7VFP'!P*XQU9NOX%O0+ZX]C
M9>_%+QU&7II!S2#9W'/GD+6-9U[*3,!5C^/E')8T4)>`<),>[DC;\85,#`&&
M.=*_@(#HBVS!Q@*C73!:X$B'Z=*YN6T?74DK,7`95-2IJUNK!Z<[7TS;ZH%)
MI9<Z5:TS,2$NX1@C+.56S>8I\S9JDG(D*DHN8F8YD$!'/4S6AL&6-!6RCEN>
MX..&*^H]8MW[73]6#664<K2R%G:C2DU7AP4>'D$Z-<D>F=J`=0%'!G`&WS`8
M0,;,0V8YM-,C-;D(71J)?4/(M%I$_P`F"P_]["D_ZEHX;.,9KCE59(A*:,BL
M9A2:C`A>=384YB[-WAX^ILP(5%=1]SM15N+AV6IRW4A:L8.\=;C;M`U7QE1*
M24`][U/I9*93!BOS#XAR,A3.D(YYF`0XQ![&`@D\00]_$%G@=5L56#:-:TPH
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M(=!="BF4FDR%5.86&0156$J[P#%2:\X<"YB(8LVCBZ!P!+F59+("$2HAO)I`
MEKW5E=JJ4'U)>YN[2>GMPW(^9**.R15KZ@;U)*G=;J8B@ZE6)MUFHF<P@H.2
MN09XU2JB7):&B.`]/#F6>8)\S&5)FGW3G6-MKW5O=VL*@@JFEJUMK3-$2LK'
MMW!))T[I2II]U$"LHL4A"1S:FG[1$"%#,71%C#VHD$45LQKY8+<?Y+112)DN
M87/XV_FKV=7E`/V>SCFKI)<"$TQ=[+;EE@0OFOTJ-U(2Q^E63N]4<7*3<';&
MX=KZTE8R'(0\BY8Q55-Q7*S*H=-,5\E`RWC`&.YL"A\?7MDXUS-H[P2=A"]-
M;>);'BY./D7R<+]*(TOE`0\7:_?"`@84('MBB0H$.)>^1A3YP@`(!L'(0Q[:
M=Y(;6VM-8=<RTV$!XY(P:O%S/-'9S9ERX8_TZ5D\J+TO"`9Z=K^9_P`[0/A'
M'7?Y$;V;/A3283I8:#>:UY%O%:`8A(F^:5!*?=U9P?MTH\J*TN_)WOY^+0'A
M'%/17?+Y9^!VA*]5J'Y9_M[R/*BM,'%IVOYE_.\!X2PA_DQOD'$:H_`Y'JM0
M_+/]NE'E16E[CT\7\`>3N:!\)8KZ,[Y_)=\+D>JU#\L_VZ4>5%:7?D[W\_%H
M#PEC0WR6WR+0=4<'8=H1ZK4/RS_;WD>5%:7?D[W\_%H#PCB?17?+Y9^!VA'J
MM0_+/]O>1Y45I=^3O?S\6@/".#T5WR^6?@=H1ZK4/RS_`&]Y'E16EWY.]_/Q
M:`\)8#Y*[Y0_U'X':$>JU#\L_P!O>1Y45I@^3M?T/]SP'A+&;T9WR^4[X7(]
M5J'Y1_MTH\J+TN_)XOY^+0/A+$>C.^?R7?"Y2/-6A)`U9P_MTH#Z47I>'8&G
MB_89[.V;T^&7%PC(Y!EADOR7WP(_U&/\KM"N_P`TJ(8)9_MTJ#[<_2-M.%#W
M-OC7;FQ=\'K.[514U,0[,B<&+MBSI^F6<$Z%XF=^4"%4=MA$@DS#=,`#MQHF
M^2V^AE1,HP&`77+&WS5I3-@9=D?VQ_XE-X?2C-,/'IWOQ_J4($1ZPR.,GHQO
MG\IWPN6GU3HOE._M[R7RHO2_QZ=K^`'\[0'A'%V>2^^1=#5'X7(]5*(6F4?[
M>\E#Z43I='_-XOV'FMH#PEAWHKOE\H_`[0H]5J'Y9_M[R!^E$Z7@]+IWOV/+
MDV@/"6%O\E]\@/\`4?@=H1ZK4/RS_;I2>5%:8/DZW]_%X#PEA7HSOE\H_"Y'
MJM0_*/\`;I1Y45I@^3K?T?\`<T`/_K+#9?DQODZ/^(_"[0CU6H?EG^W2CRHK
M2]QZ=K^!YK:`\)89Z+;Y?+/P.T(]5J'Y9_M[R/*BM+OR=[^?BT!X1P>BN^7R
MS\#M"/5:A^6?[>\CRHK2_P`6G6_H^8V@/"6#T6WR^6?@=H1ZK4/RS_;I1Y45
MI@^3K?W\7@/"6$O\F-\@Z&J/P.1ZK4/RS_;I31^E%Z8?D[WZ#J"W@L_0D<4]
M&=\_DGX7(]5J'Y1_MTK25/\`2==+T[3%1P1-/M^&R\W`R\6@NNE`HM@7D8YR
MR)O+&D!R!,ZP";J!LPV1Y+[Z.F"$LQ![+UH?YI;/$IKQ+-XC!U=*X>QOTDO3
M1:VSUN+<R=A+Y2#^CZ;80#UW'I0AVBJ\?L44;J+/RG52,'`.6T.IAM3Y*[Z@
MEYEDD\=URI3>:FSWN@Z7:<5W3P*E4WTHO2Z4H"&GB_@AD&0=SP&8!ELS_A++
M/&7T9WS^4[X7*C_-6@#R-6<)[.E)Y47I@^3M?W\7@/"6#T9WRP:H_"Y5]5J'
MY1_MTJCG2(=._8#6EI`NOIQI6R]WZ;J*X:$(E$3M5)PQ*=9+1<JTD%#*/&\@
M*S=;<;"!-T-X!'/'>W8\G*[<K;<N=M>;KJ8&)#KSB8BR%]L(!8-K^8S!LY[F
M,@XB(P8,7O+Y<:,.ERUAZ*EXZ%I*NU+FVL:*;J]IKIN7\S`ID`Q>Z#4[43A5
M6?I1842B!%`.LW,;:!`Q]'WP\K]C[S2)9V;+9)>8VM:UL2<=UEMJ\/NUYINE
MU+W.M:VT@VX.+WE^N31+TZ>C_5LI"4A4\V>P=WY8$&B-"W!63)&3TJ)R(D+2
M%6<YW',$<.#`5%$VZN<1#M<QQ^<M[?*O:.ZDR[.B]A),6WH-`P`Q`P_DOL&P
M_,6AVV8M;<.4-MS'\E]OD'!5]S(P_P`K^Z?RI0%";Z9D3^E5*H4=F6/",G-8
M=01UL"]FV6Z:1/!LPP7O`F0YY^A]G#D]/P(2"&898$+$8NZ&>>?G8@X"A-#B
M\W]C"Y?O\R7,X9U3/1CL1U%%Y-2MSMOFO&W8QU]H"R4?V)5/A=S*ZF.:M*,"
M$8$(P(1@0C`A&!","$8$(P(1@0L0^E\_%QA2Y^`<J^8UNS`-M+]FV[.D'I[_
M`.I*U`<O5QH/O#^58F_Z7<RG$Z8CKRC\QRSTMSVW+@_LF4UMX<$T@T[>4K1J
M8NPJVRK)(-XXB)#[3%62#<53,/IE"JY[^\(!M#/='DQRC/,LW0V)<88<::VG
M_BC@M5#):_-2TA4=?4[1],/JXJ&4O^UM1%1=5U(DPI^&5DJ01J@CR,6;-!69
MT\P2`QU6N1UC',82'#/+&QM,\=;6"$(X#I2W36&R[:BG+PTI5MDZNU/3]F:>
M7N+9US6M-R48FTCGLJ>HZ)F%89^RI^JW\<9R+&04(!4SJ%$R(#L-LQI;*G.>
M),HETQPL`XSBM-B3U(WX"`7(5!K&O!1ZM8K5;96GVD5;TUMY^L)%C6R:Y4Z%
MN4Y;I,%(=NX;HD<U'!'<@JX;G,!5T2'`@@.6<LH]H3(%LLF+B!:,(P\?$FZQ
MHL+5VGC?!(1",PUHITH60U32FFMBB9\D*I@3;2:B-8D!,$B)JF,W`"H',;FT
M^V#ASPP;.JC,U-2VXV[$Q(,!@!L)X[%5\YK&7[L5"UH+WWQ6KS3E;Y!>+J*W
MU;V7O54E:2DT[<IUJ::HZNI&/BWC9R#8Z!1;L`,W(4Z@`<X@;>`"Y"QVS:9H
M)<^P.`P'"8:4EM8TV"68P)PC0NS@]3]QR4=23*WMMQKE^-F*IN[,2=?U@X;'
M:QM+U/,Q`P?=R449=S+S2#%8K104TVR(E#>$Y1SPFHV6V[!DP`AP&`FR&##C
M5I=4R8;MPX,:Y5MK#7IPUP[DHL9*H(^X\OIYAK64G-.'2;*'F+CP$HLX0=HP
M[>0<)$9&2*9RFS0%982@8"CGO`QM',8+I>#9B]J4Z6QS[Y%JLE:N]3BKK37'
MNU&VEG&-74VO5K28I^.AW;*1N)-4@W$C)_33R1B8V:FXJ7()48]PNWY[(#`(
M9`&*>'+'C6/!#K!9"'2M39C0V$+5%]*ZLJYKB-MS!T%1=#5%="XSRM'CJ))5
M$E%4]0\+1!(I::;52=^@G4B%7).)=HD=B"`%`YCF`=T-M'T#VNONF@,Y"C6M
M[*Y:3U0U)9^H;H)5$U5GYZJ;ZT9;JB8N1>+KPM(OY*@4)>21>#%MG,PX@8I=
M-01,1N4ZN8&``RQH=37KLMKQ`-C'':I$Y@MNKL:+U>UW74M;Z"B[/GIY:<A:
MWJNO']6+RL)'TO3M#3QH67GH-BXCF\I.(3ABBXCEC@GSB9LA+MSQ0T5VUTP#
MF*MKV=GI6I9ZT*W00HJIY>S(*4U>RG*WF['(0=3E?U;/2U(QCF<:T_4+$&1D
MH]Q5<$T.LV4:(J"@4`24+OAF*GTQ#BULP$B$;#9%+>Z6\WBWI6VIO4=(5X6U
M-5-&JDQ+2M/W?>*4A;J=<K1CJ:H^G8V4+1M6PDS'IRR=8@"O,II'33.V7-OY
M'*(!@\,Z/^P1&14A+[*G_3/>I:]]O_=:])2\=+ED#H2U.0CV0<OZ5<FYTP0]
M5Q\D@SD8B=9D*":I#EW3G*)B")!#"Y\HL;=)B;;5HDM`ZXP'B4E77+E::Z&T
MQL[;UR("<!`V[[G)'<SS$1]+EC)3LNS`08VA:)C@\0A"Q<+I$'_%@L/L_N84
MIR>QB.'S1_D/*J,;=:&X@K%^</H=G"U*7$7@A8S$WBG+GEO=3@VY\N(O-QH4
M#79LJWN;5=E:H<3CF-4LW<HEQ&;5)'GBRRG>60B%8Q4PF#FDCE?B<#;<LLLN
M/#Q4,:TM(M(@D.!B#B*X%MIE:(4;2](*52^40IB]![PMW)62!.<7[Y2\@6"*
M@'W))N/?A0BBF0F4#/>X<:6U\N_$-M(AGX8%D=3.<(7N-%-Z:B4V:VBB=6.7
M0VZGKP334RD:U*=_\+*L\HNF?/>315C"3AB"<`^Z%)L`,\:#4RR286F''B5?
MI[A_&,RK[%='XRI<U$OJ>K"G)5["TJ]H:IRW#H6,K6-J&GG%7R=7MA:1[U1-
M*-D6CF552`P[Z1B#M+LQ+ZYD#$&`Q&"CZ<[BF"/(5WU7Z.D*RN%5E82=:)0L
M=4MMJHMP2*HNGH^F73IC4<0E%-W-7O6@<U58TP"9CQA%T_YEWQ*`[NS"?J3.
M)ICRQ_)'TU_;&9<E5.B6KJTIZD(27O,1R[B+41UHIU=Q2;9S&+0T.\269U)2
ML(=R#.!J]TR0*@Z=G!8#ES$A2XEE?+B6L:1$QPITNB<QX>]P(`A@@OH9"Q!(
MB*BXTAQ52C8N/C"&.&U0C!JDU(82".Z0IB);VZ`;#&'')J)4R;,)8^',M[0Q
MH`Q+;()%3$1`A""(?M"`4.'J8O`L:`XQ5W.!$`O5B+S<:HC$@@X$(Q*%\XNE
M)M;3MZ=+;JT]7*R*%+W)N7:^CJ@6AG(LIA*+E:G;D<&CWF1RH+@4FP1*;:..
MKLC:9V55BK#2^[Q`@?BL5;0TE=*+*AMYV`&.!?/+R:'H_P`<A/4-_A,!4R&/
M\(QM]3<2(4ACB$=D)BD`"^8&/4SO-G;KW!DIC99&+VE>.?Y=[,FSC.#X`G!#
MVI?)GNC\';[HK_!YMQS>#L;I?G!OBQ@:V:P#*T$YTR;Y?;,<Z)=;#%[4>3.]
M'Y^4=_?C'-X.PSUBWR^=+^`)7IYLOM'-[4X/HT&@``R"IK_``<`?".;P;BA\
MWM\28Z^7\`4>G>R^V<WM1Y,]T?H[1J._HCQB-QS>#L5]7=\?GR_@"/3O97:.
M;VI/)G>C\_*._OQCF\'88/.'?("&NE_`%/IYLKM'-[4GDSO1^?E'?WXQS>#L
M3ZQ;Y?.E_`$>GFR^T<WM1Y,[T?GY1W]^,<W@[!ZQ;Y?.E_`$>GFR^T<WM2^3
M.]'Y^4=_?C'-X.P>L6^7SI?P!'IYLOM'-[4[R:#0#QU+?_+^^./@["_5[?'Y
M\OX`CTZV7V^CVI/)GNC]#AJ*_P!EQ_V1S>#\5/F]OB!'7R_@"NWR[V4'`WCA
MQ>U)Y,]T?@@.[45_R[!V_".(B&SA`.]H[0P,\X=\HV3F?`U.?N!LHX3T>U5Z
MM?\`1]=#E:77U!41*U#>]6+M;45)0T$LWKPR4@=G-4RVFG2#QQW`)5D@<N0$
M,BE',F?4QIF><F^8DDZUD(6]1O0L8\OMEWXWK!@L_&U6%+]&=Z/P``Q:@OX0
MW$(7&-F&?^]PAM#&'UEWOA'7-^!J?]@;+A:[H]J4?HS^@`0R-4M_A#D^$8P?
M6CL,E^<F^!=`3FQRL:JGR_V41"]T>U-'Z,YT?@_^\E_@\RXYO!V'^L6^?SI?
MP!5]/-E]HYO:@OT9WH_B9B6I;_!G_P`XYO!V*N\X-\G6&?+^`*/3S9?;.;VI
M_DT.@'\IK_?&,/@W%?5W?'Y\OX`CT[V7VSF]J/)H=`'Y37^^,8W@W$M\X-\F
MX)\OX`CT[V7VS\/M31^C/='\;TU27^'_``CF\'8OZQ;Y_.E_`%/IYLOMG-[4
MGDSO1^?E'?WXQS>#L'K%OE\Z7\`1Z>;+[1S>U.#Z,_T?X;"U+?X`Y/A'-X.P
M>L6^?SY?P!1Z>;+[9S>U+Y-#H!_*:_WQC#X-Q0^;^^3C$SY?P!'IWLOMG-[4
M@_1G^C^':-27]$>4;CF\'8KZN[X_/E_`$>G>RNT<WM7,5;]&VT#4_3%2SS&H
M[]*.H*GIV9;(.K@BY9G<1T:X=D!1$\>`"!A1RX0X<-I_-_?(3(B<R$;>HU5J
M/+K9SI4`^!A99[5'FG_Z.]H5NE9>V-Q)^?OJE+572\=-NT65P1;MDG3X!*L5
M)(&`@5,%-H!Q!LQHJ_-[?(B`G,@/V-6:A\NJ`$DS`3D!TJ:"_1G>C]#(1J._
MP[..XYN'S.]V,0\WM\8?[V?`U;/3O9<3%QCR>U/\FAT`?E-?X`_OC#L__=N#
MU=WQ^>SX&J/3O9?;.;VJ@O24="#H^T?Z-KN7\M;(WAD*UHAK!*PB52UDYFX1
MZO,3#6*'G8AO''5?+%*YWMQ,@&'@#AQZ'<KS0K*W:TL[=A/I#&/\+@1@XB(<
MR\_O)N,V50OE2XN?Q6`?FOE=HIZ%?6=K!/&U%(4_\!-IG:C4QKAW)BG;"3F8
MXZJ>9Z8I!3FI24030,)FQU^YR`<`W\PSQ]$WP\UMF2PQNRV.E3&&-V]>)A;#
MW1".,KYYN[Y<5,NN:^8(R"\7N*R-O\2_73HNZ%W1?H\&,G$*+^&.ZT<1-8UT
M[JHM:@EF+\@D4.I3$8LF,93[<JQ=Y($R"JGLR/F&>/@>]._FU-YYCC-(ER2;
M!A/.=`"^^T&Z>R]G?Z&0*^OB:)4@2*3=!,@Y$3`H`4I0`"E``X"@0`R+EP!C
MPS&RVQ<ZV8>->@;+F,(#7=0<4%[,7O-QIR,%YN-",%YN-"QJ"&[Y_P"P.`D$
M&&)6`B5C+D.6WCY,*E.C,A#&JS):IGHR#[EJ*'EU*7-V<F3UOCL5[KS97\B1
M)9=+CC5U,<Y/1B"0,*$8B\W&A&"\W&A&"\W&A&"\W&A&"\W&A&"\W&A&"\W&
MA&"\W&A&"\U"Q#Z4/-PQIC:ES\`Y5\Q+=?VLK^__`*0>GO\`ZD[3XTN'^1K<
MA'05B;_I=RA32^DF+37;%*NG;1D4^ER<*"CQXV:IK&&YD%VJ)E5"\X)>8V[-
M@#U,#O\`4&G`#^*O+F1=U8*VQZ@@SAGWYALPX/X58"`CMX?NX8QODM<0>/D*
MVA_5(R*#7%J+3.)U:IU%8XTVK7S>YHN._P"S*E[L&L*6"1?\R#K+FP8D`HDS
MR$-F>-$#C,.188%>:.LW9^-M_6ULFAF"%'7!F*FJ"J(\]3I+N7DG5\J,S/J(
MNQ?%%LF[>#F4I2AN`&6W!>GR_P#)3D^(%K;./BPB"L&G@0O+5=D+)5JTK=I4
M!(YTG<.*I"'JC<J)JB#IG0BB"U,]S@1V`M5F"[5,V\4<S[N0[!$,*;5;R,`#
M7$`$D6-XXD_PXRI(<>+I7#O-)VG>2KI*O7CM^I)(5PRN4VB?A"=)TNUKQG&A
M%&JE&GR27>WOL\9!N*G,F8!`QA``,.\$BIV\6B5/<?#XKK>:V['##C478^_[
MO*NF'3W9)K)VTFHIYWID;4I56PI=>*J])!0\-7;ATXJN(F$CO`;2T=(+.S&*
MFJ401'(2AG@O51LMX<RDMDBVS.H@J#1U:VHZKIGNJJ1C:`I2TDI:V-@J;KM[
M"31V4O4#F9E`?2;>4#NZ*E$'AT%6JX*E(`;R9BYB`7ES*D.Z\8<B@L9_!"/*
M%+,WIPL%.1,U#F9L8IO,.*.?)+0-4MXA]!2-OF98^BY*G'K!V@YA)*GVA1(D
MX0,500.8#"(&PX3'@QB<QT*"#P@I$IZBZ0@*'<4&:M9:2CW2+Q%69EJ\/(57
MN/2@504*A5?E?M54!(043D-F02\>8XJ7S"8\?(BZ>/\`$*"O%$L#W&U!"6GF
ME5-*H?U>I<QI<;N&XTI-3#5M'RZLM4C%RV.]0D8Q@W04(*8`)4"F',V8C;63
M,?0@`G]5UU0:<[)5(PD6KMZNTD)"J:?K4M5,:YYNLF%4TQ%)0T5-QU1+NW+M
ML^[@3%-<VTJY3B!@P:V9AB<WL4W3DSA=93=JK=4W+PM0%GEYV>@:3D:(9S52
M5B2;D'=.RSXDD_:3"[EZ4)$ZSL@=L)2@5,-P`#AQ!>XB$3AC@X\R(.&+.H[I
M'2K82AY!S(4[)2S+FX^?BJ8:'N,Y.VM\RJISW54(4``2`*4RX?J=J59$W.I)
MYD*(%V8H]TPGC/,H#3Q_BMY2^GBS=)"@]BY94]1)/*NEEZM>5D5Q4S^?K9@U
MB)NH7LJ+PKA68"(8I(H*@("EN`;:.>=(S,JF[PB%VEI;7VOL\WJ).F9@KR4J
M^:3J&K:EJ.JF4O452R;=N1HR4EG^:`.",FB9$DPW`'<*&8B.8XI-:]S+(Q3I
M9NB%F<+IKKS<,I:NYQ"S40=0]NZT2*(2;(P'.I3LCF!0*N8^P>++&>FDS&S,
M$5<OAA(4?Z39R':Z9[&-UY:,352MI2Z:B:L@R2.4Q(],H@8BBY3%'9P#ATV4
M^^1!`F"&%6%]TD%[,Q/MI'^N<+U4S$C6<B/=)!>S43[:1_KG%]0_$<R-9R(]
MT<%[-1/MI'^N<&H=B.8HUG(@:A@1X9B)]M(_USB-2[+F1S=*;W_@/9>(]LX_
MUS@U+LN8J.&%'NA@,@#OQ$;,OZ:1W%_NG%=5,Q%3K,HZ%B"=I_(2C+PH@)M[
M^B,=L'9_MKJ8!*FGB4:S*.A/&?IX?Z;0N?5D8T?_`#C%M0_$<Q4ZSD0$_3P;
M0EH4!Y2R,<4>N#G`9+QQ(UG(G#44"(9=^8CVTC_7.*ZJ9Q!&LRA`5%`@/]&8
MCVTC_7.);)F'"%&LRCH3O='!>S43[:1_KG%M0[$<Q1K.1'ND@N*9B1_WTC_7
M.+-EEN'\$:S*$OND@_9B)]M(_P!<8M=&-&L&,*FNM^:C'EKZ&2;/X]R?X=[-
M"8B$@Q54(D-6H@HL8A5\N;2+M$<\:)$D3(BTBZ>$4B=,%F`JY(3\&41`9B($
M<O9-@&60``9@9P`@.08P&0-9>A8M#)G)G":-0P/',Q`?[Z1_+_/.&.DN)B,'
M.I>\@X4GNA@?9F)]M(_USBNH?B/#F5=8<8Z$>Z&!]F8GVTC_`%S@U#\1X<R-
M8<8Z$>Z&!]F8GVTC_7.#4/Q'AS(UAQCH1[H8'V9B?;2/]<X-0_$>',C6'&.A
M'NA@?9F)]M(_US@U#\1X<R-8<8Z$>Z&!]F8GVTC_`%S@U#\1X<R-8<8Z$ONA
M@?9F)]M(_P!<X-0_$>',@3#'".A'N@@_9F)]M(_US@U+LO3H3K^5'N@@_9F)
M]M(_US@$D\<8<Z+Z::HH0I1$)F'S#C/*QX%RXQ,(.!$``N8X<V6!@C#D*I,?
M98J=V#EH=OJ(UA+J248DF\K6WZR"AW[$J3E(M`Q9.<14%QNG[;K8U5%.?#LO
M`VBU9&3!K2KC#4<$/].8GVUC_7..>:5N7,5I+X\82>Z*!'^G,3[:1_KG$>&`
MM;&/(5%_*$>Z&!]F8GVTC_7.)U#\1X<R-8<8Z$>Z&!]F8GVTC_7.#4/Q'AS(
MUAQCH1[H8'V9B?;2/]<X-0_$>',C6'&.A'NA@?9F)]M(_P!<X-0_$>',C6'&
M.A'NA@?9F)]M(_US@U#\1X<R-8<8Z$>Z&!]F8GVTC_7.#4/Q'AS(UAQCH1[H
M8'V9B?;2/]<X-0_$>',C6'&.A'NA@?9F)]M(_P!<X-0_$>',C6'&.A'NA@?9
MF)]M(_US@U#\1X<R-8<8Z%Q-QIV&/;ZOBIS,3O'HNJTB%[Y,#BH<T$_R`@$<
MF,)@RX,MN+R)#]:+#AQ(FS#J\(P*'-'$U%(Z6[%HNI*-;N"6\@S&25D6*1P,
M5/G=PQ#+@8@B)LA`0S#+;A]9(>'$6QY$FDF6V*S/N@@0V#,Q.8?^E&'KG&02
M'PP%/=,,3:,.1'N@@?9J)]M(_P!<XG4/Q'AS*-8<8Z%STN6A:A9#&U$>EIZ/
M.Y;.U&,LK#OV1W#11)9!0[1VLL@<4ED0.7,H[I@`0VXBDHS1`W";<A"O.K&3
M8-A8.'YK<#+0`<V"<U#ID*(9@618%$J91`2I(B5X7F2%$O`&P>3$3Z>;/<'7
MC`&."/2K,F2FM(``LQKTC4%/CG_#$0`CGM[Z1_'_`+IQ?4.Q',E:SDZ$[W10
M.S^&8G9_Z4C_`%SB-0_$4:PXQT)?='!>S43[:1_KG$ZAV(YBC6<B/='!>S43
M[:1_KG!J'8CF*-9R(]T<%[-1/MI'^N<&H=B.8HUG(D&HH(P9=^8GE_HI'^N<
M2V66&)5V3+4!4$&&64S$B.9>&48;`SX=C@<\L2R7UB>54F/)/%AQA4ST<34:
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M`,IPYK,4<&(J:@8/T_%?-NW2[4+77\6[K:BV'I`J>4[HY]($0`-25IQS%<3\
MP),@],!MW&U\L>):W(?P*PM_U.Y?S7372LS;F\&N"G8FXU)LJG91VF2>=1Y5
MG+]D9L8URHD@I[T>Y;"H0>KP#C.9A:V+<*HR5%XM*E0-"&EL!R"TL9Q?T^J;
MJ?\`I7"G5\UIP--H6]DMMWE68="6E[(?[$\7P#_3RIO"V-/CYV)F;VJNH;E6
M+Q$]+WZ)XP/]_JFR_JKP8D;0G@Q;!KN(@6C*$&0S*@VA72T3T]J8SCR*2<J<
MQQ``$1R`98`SR#EP':NU.*>_HT)>J;C3`T+:63E$0M3&B`B!@'OW4N0)CZ4#
MYRXY'S\["CMC:?\`U)CGLXP[`<P5)DEI81$H)H1TN@.8VGB.IG-U-EY_\+8J
M=L50_@9F*4RC:["XC,G#H3TMB;>-:F)$<A#M9RI0]`);J8LS:M1--US6@9`M
M4JAE-,2YT88@G%T+:6B\%J8L,PR_H[4_A;#?&3,F9/\`"RL;LP2!H3TL;1^"
M>+'/A'O]4_[,O@-;,R9E1],QONDGE0;0MI;'+*TD:</5%GZER+P9B8.^N8E#
M,.#$"MF9,WM5-0$@:%M+(9?V)8LX#MWR3U2F((<>7\+9@(<>>$S=HSV$70#S
M*-2!ABLGB+Z6P#M;3Q>0[0_AZI@SX-NR6RPKZI4]EN9&J;E6+Q%-+JG;'M/%
ME'@`._\`5'!P^RW*.&-KITP7B&@\BD26GC1XB&EO]$\8/5"?JCPMBWBIF3,K
M:AN,IP:$-+F0"%IHS/;PSM3#Z/?;/%_&32VX0V[R*?#,(C>(*XNYVB/3#%VU
MN&Z;6ICR+LZ$K!XF(3=2"05B4[(@439RP[`X<4EU3I;[P:U*=)#>,X%'^EW1
M5IGJ#3I92:EK7,74E)6YIIV\<=^JB3YU95B0QC;A98"ALR#8`;`PQ]:]SBZZ
MT1*EDF+08G`IX\0_2V.T+3QN7%G/5+GEQ9_PKPXIXR9B;F]JMJ/W%+XB&EW]
M$\;[?5+X5PWZC4"R#<WM4:@8RCQ$-+OZ)XWV^J7PK@^HU'[<WM4Z@8RF>(GI
M;X[3Q@!Q",[4W#[;<&$G:M4!@9PYT-,?>$%C\1;2X.8?!+'%R'(14FZG`#]5
M("S`B(9\N%_5ZK`X-N<=AP*Y:T@A8PT+Z6Q'(;3Q0!P&'O\`5/DD;+,I5##+
MY#O9\7!BWU21C&;VJC9(/\1Z%D#0II<_1/%CMX23]3"`<F8C+;,6&TY<8RR"
M_BL]J8:9EPN#W1YD[Q%=+8;1M/&Y!M'*?J7/(-H_TUX@Q?ZK.Q-S>U9]5E*Y
M:K-)>BZA8L\U65$4S3D.02<Y*RU3U$QC6P',!"G>OEY8K=JD)QRWS"!0X\2W
M:$Z:;D&YL7.J3`);;Y)A%<_&:=-!$O&R\Q'PM`.XJGV",G.OD:^DN;A8Y<@J
M(R$NF>=*M'1ZR0`9-=4`35*("41#`ZHGM_A;F*I+>QXC>X\:[N/T2:3Y1JT?
MQML(608OF;=\S=LZCJ1=NZ:.TP6;.6ZI982+MET3%,4Y>U$!PN77U+7&+6#F
M*T"4UW\16P+H2TO&SSM+'E\V=J;PKAWU&H_;F]JGPXQE/\1#2[^B>-]OJF\*
MX6^MFS(7KMF1'AQC*!T):70_N3QX^9/5,/\`ZUPOQ#\01X=N,JINL;1YIQI2
MVU&.XFU\:V7=WMM&P5,>9J-0!1=U0DB8>WE1R,GO"8O5QT**J=!TM\+A6.HD
MPG-8(W2,.=6P-H;TOKGWU+51ZI\@*=4T[4I1.8``!,(!*Y`)N'9CB5>TYE/4
MB7!MUQ'25U&44AK02YQ=S)HZ$]+OZ)XP/]_JFY?_`,5QT';69)-QSA'D]J2^
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M;/(=@_TUY,0S:\K`U_0-*7,DN)P6*J=D]'.FF4OQJTAWMM(U5E3]:T`BQ3&8
MJ,@HD7H"+.)3')*YF`!'9C3.VO+,@"(!_BP<T+5D;3O$V.56L'0EI;'(2VHC
M#%'C[_5.`^=_"V6,`VI(XW_AI6G4SDH:$]+GZ)HT/]_JF\*XNS:TAAB']'M0
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MJWB1N_E2"4%T:?D3IF'.5',!-P]3#*?;C=;U2,(XN+CX\2B=)=JP!Q`J*]*6
MC#39/Z;;*2LM:^-<OGU!1#ITJ6:J,I3N')`YXY0++```82YAAU9MQI)(+1*X
MK(\7+C6>DD/!$5/OB+:71V_!(PV[?Z/5+X6QE&VY<+'"'\OM6DT[B28E.\1/
M2[^B>,]OJF\*X/KDKM#-[4>'=E6ID=&.D2$8GDINW%/Q+!$R?=$@_JF<9QK4
MJK@&Z)5Y!W.(-B**J&`I0$W;''+&>KK9M19)+GNLP#DC@BM3)-QL9[&,//')
MA@MGXC^E8Y2F"U,8!39"`&GJEWC@8`$HD$)<2GV#^UW@ZN+TNU:NG:6S0&V<
M8C^,%EFR6N>-1=(X[?P3O$5TM"&RU,8/^_U2^%<-;MASNS'D]JE]*\8(I2Z$
MM+HB`?!/&>WU3>%<1]6J2^Z`V[C@=*J*<_Q$A9/$0TN_HGC?;ZI?"N'?4:C]
MN;VJ?#C&4>(AI=_1/&^WU2^%<'U&H_;F]J/#C&4>(AI=_1/&^WU2^%<'U&H_
M;F]J/#C&4TVA'2Z4,_@GC1XOZ/5-X5PN973GM@Z[#D]JLV2&F,24A-"NET#%
MSM0P(&\&TD]4VW(0'(0[[``E'+")52_67A".%+FR&QXU5'2CHWTY5"WOP$I;
M&.==Z=0MPXI@`2U0HB@Q:.4"))"9.6S4R$1',VW;CK[1JIA9*;9"Z3SI,BG;
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MJ/VYO:CPXQE'B(:7?T3QOM]4WA7!]1J/VYO:I$@`QB4TVA#2T)1`UIHT2FS`
M0[_5-M`>'^FVS,,5E5DZ6>K#!B5ZSKB(M52+=6JH$-/-_;6)TXB6AC:\J>C%
MZ=!W(<P=F.I"TRA41=BY%]D"B91S!0!V8<ZH.O;/@+UW2L#?];N'&%;(P?X^
M<8&8CNZ6YT`SZES8`?KK#Z&,;SU4Z3[V=7$`"[WI2\7%YF,$S#SA;&^Z%FW2
M\@=;&A2L2I"`F<=T-A3#Q\G'EMRP*DPP83D5!M4^IBI+/W+LO0$;5EJJ"C+E
MQE9/W=67/-*'BDY"E>]/<,#%%C';4ZSV84D1`#'`2%(4>/#93;[H0B%@=-@1
M!PP+6UGJ<EJ)D(A('L?6Q5+[0%M)^%HNE)1>71;SM!/:@291#?NPRLY,.9-$
MBC8Z6XB#3/?*(AO8WNH@&Q(LA@X\*5,G$L-O'Q*1(K61;*=]P,=&0M=/:HN'
M-U13L31J=+2I9^'E:)>$;U8WJ](S<&M/#`,U".W!EE0`J!RY;PCC.:;((#'^
M2M+FQ`MM1%:S[0R$V@P1;U>PAY8:T2I.N)2E9)I1=;NJ!:KNZD84W,K;B;AV
MDFV4%`IB@*X(*"3,`P>$<3!H$<F%:W5%UL8VKET>D!M&H!E1IRZ!6Q*<:UNF
MJI0$DDF[MZZ=(,U;A)+&6$B-)Q+I8$W*YPS`3`(!EB30SL1Z4OQ?[E),=JMM
M74+*)7BI-Z]4J"X`VSB8YI"R"\BYJ084U1(BDDD7)6+=0($=)NMB0IKDSRVX
MKX.:'0(."/-C5A6-`B\V*-:XU:IEI&O6](4_45(7&H(U$R+B`N'""P5?P-65
M0-/).V`MWATUTU#MU@WQ,`)G3#>*(#EB113C`@$@XD>.DXPNFDM8%O"5Q\&D
M<SJQU*OI&L:/CZO2IATYHU:M**IYQ.ST:[D&BA%$B1:"0<ZH"8$./:%$#"&`
M4;P(O%F5+?4L>>H>E>`NJZGJ/M_0E8U7$534$'4<'$RTE6])TI,^XJ/3DY8L
M0HZ%U)"5VU1;.52&,@8%5"ICO"?BQ/A6DEH`B%3761BKF1KONM(JI-WFC[PI
M"4<P43`1`BH;3;I52@!BAGF`#MVXRS&:MUV$+%MD.O,C&-JV(D*8<Q`!'%$Y
M,$I0'(`#K8L,"N,"CJ[_`/:LN?L#M;<5L(?ZFG7Y@]$<52'\?(H\TA_Y+]A_
M[V-*#UXQ$<"F7[@Y%8S(.0.M@5T9!R!U@P(1D'('6P(41WVKA];"S5R[BQC-
MH_D*&HBH:I9-'HJ%9.',+'*ODDW?-'(OW(8R7W3=,!MT-FW%I<L.(;E2)IN,
M)ML7S;D-8%WG5H;(U7%3%%U)-WQN_;N@59>U=&STZPH%C55,24Y-(2S>7E6Z
MSN5:KM4RM^:#=,3?`2B80$.FW9K'M<'"`@<-@A##@Z5R'UI:Z['"I!M%J@K^
MMZPKL*E4/24#`ZCT+!4I3504&_:*3B,<S9+2;UM/M'"S0T]/*F<[Q#F!./3(
M0Q]X#!C.[8=)"-X0NQXC^2;+K'1A&Q3:TUI6J=0#FHHR&KN0A%*[-;2"<LZ1
MDUU*PK4JKQ!>)I1`HBM+),%F"A%ER@5(#9!L#;BCMB2Y0+F%MYHC`&W\%L%4
M',(R++0NM&TU>SE.0,=%5Y&KU2[J>!B'<_2$I#1[JN:/(\4J&W*;AT4"'K-F
M@P64[G`11.0@@5439%%1H7BVWV8TH3LO2M!6E;PFJNW]]-/L1!3E)5VZH!=)
MI'7%IXT816*GU%8YA/-R'%P1:-"29J$-NF$X;H<&&RJ<R)@F/]T%+FO,V69;
M;7'G4&5-H=KN<=75&+JBE(UE=FWU(6VJA(6;L$I"#I2T\72J29&P"BV(`5HQ
M!=$PE'[@J;A,.8:9DV4`E2Z2=A7T.M53;VA[<T#1CM1!=]25&4S33Y9L0Y&I
MUXF);L%!:@(B8J)56I@`,QV"&,$Q[''J+IR93I?O8E)Y0V=MM'(!'/:`9Y\&
M>W"UH3L@Y`ZP8$)<@#@#+`A?.;I2+E4W9C2RZO!624BM2ELKE6OK2H4HAJ+V
M34BX6K&BCDK-OF4IUMQ39F/#C7LRGF5>TI<AF!P6&OG-IY)GNXE\[D?I*>@`
MY`,,1?(HB8YA+\&SH0`HF$R61DGRY3[R`E$1S#:/`&/8UGECM::637,B8"T!
MV&'\F/!D7A_OBE9.,@N-Z)XQC_F7I\I6Z/T,OX&O>/5-;:2`?XTQP]'#/2;;
ME3"8]LH&$+;\;/Z%TQOGLZ0+DPF]APCC_J1Y2OT?OL+>[XMY3L8/1_;.*3_?
MW$??.RL9SM[R/*5^C]]A;W?%O*=C!Z/[9Q2?[^XC[YV7C.=O>1Y2OT??'#WM
M`>3X-Y3!Z/[9_P"S_?W$??.R\?2WO(\I7Z/WV%O=\6\IV,'H_MG%)_O[B/OG
M96,YV]Y'E*_1^^PM[OBWE.Q@]']LXI/]_<1]\[*QG.WO(\I7Z/WV%O=\6\IV
M,'H_MG%)_O[B/OG96,YV]Y'E+'1]^P][?BVE,'H_MG_L_P!_<1]\[+[72.\C
MRE?H_?86]WQ;RG8P>C^V<4G^_N(^^=E8SG;WD>4K]'[["WN^+>4[&#T?VSBD
M_P!_<4C?G9<<)SM[R`^DL]'V7MCPM\2E`0S$EM9(QP`=FPJBB*8\/&8`ZN+L
M\H=M`V"1_?W%69OULQO\72WO*NEM?I!&ARA[LZ@:ZE8V\B\3=6IZ1E()%C09
MGR[9&$I=K#.C/RM7JJC4!<-0``$IAS'+'1G^3^TC3MU>JUL.O&]"-GN_X\&'
M"L0W[V?K";T`<%K>\K$&^DL]'\7<+WGO>;?`1R"VTID&09[?,QS/1_;.#_#_
M`'?^-/\`OS9O&[I;WDH?25^C]]A;W_%M*8#Y/[9Q2<[^XKLW[V63"]TM[R=Y
M2OT?OL+>[XMY3L8CT?VSBD_W]Q,^^=E8SG;WD>4K]'[["WN^+>4[&#T?VSBD
M_P!_<1]\[*QG.WO(\I7Z/SCAKVA_@WE,'H_MG%)_O[B/OG9>,YV]Y'E*_1^<
M4->T?\&\IV!P>C^V<4G^_N(^^=EX^EO>1Y2OT?OL+>[XMY3L8/1_;.*3_?W$
M??.R\9SM[R/*5^C]]A;W?%O*=C!Z/[9Q2?[^XC[YV5C.=O>1Y2OT?OL+>[XM
MY3L8/1_;.*3_`']Q'WSLK&<[>\CRE?H^^.&O:`\GP;RF#T?VSBD_W]Q'WSLO
M'TM[R7RE;H_>*#OB8.4MMI#(?,WE"CZ&)]'ML_\`9_O[B/OG9>,YV]Y<U6'T
MD+0!4%+5-3R,3>]!U.4[.PS,7%O3H(F<248X8E`RJD@7FP`%\P$Q?.QHI/*'
M:VO:':FZ'6^]&''#J84N=OSLT2R0>+&.\H_L!](9T)6NL[;6W<]&7K&:I"D8
MR'D@;T#S[<JS1+-7F5BR0%5(*@Y`8-@AC5M#RAVF'$RM5J861O1CE@R"ST>_
M6SW"#G1=RCO*9`^DL]'X(!E$WORR#+.W$D(Y<6T@F+UA$.KCF^D&VO\`L_W?
M^-;/OC9?:Z6]Y'E*_1^^PM[A_P`&\IM]#$>C^V<4G^_N(^^=EXSG;WE1+I'.
MG&T>ZL-'%XK#6I:7:95U741&(T\M-46O$1K608R2#]10TOW6`)*I`EVIB`!@
M-D(8]9NCY554FNE/VD90I6WKPMB8CJV.9#"O*[T>8FND&7LP.+[+1DPX'+Y8
MZ*.G"UBZ0^\U+5//JZ@K-LC-VZE&U_)N5:D@8E,Z9$T:=KMP"3IBL9$H@"+@
M5DA,.T,L>UW@\GZ"NDNF4$!,#28-A:86`P88KS6Q/,:OIR!61+8VQC8,D7+]
M=6B_IC-&.LIO'0D)6R-K;M.")=T6JN<NE3TNJY4$I"IP$HXYN(J1!14P%3,W
M5YU3B3Q^>]M[C;4V',`GRWAIXX.@(8^J(17V38N]E#M=O4<V/*(\W6*^L:2H
M&%/M2@!SB`&X0`NZ`DS[;MN=#:4P;,L>=EW6=3^)>@<]MD#A7NR#D#K!AJJC
M(.0.L&!",@Y`ZP8$)AP+EZ4!V\G4'DQ!P%"Q``9AD`!MXO,PN7[W,ES,*IKH
MT,(IZBPR``+J4N;EEU7C?AVXZ^T,$H_L2J?"[F5T\@'A#/'-6E)D'('6#`A&
M0<@=8,"$9!R!U@P(1D'('6#`A&0<@=8,"$9!R!U@P(1D'('6#`A&0<@=8,"$
M9!R!U@P(1D'('6#`A8A`-T-@>FY,7&%+GX!RKYE6Z5'X-K^J[I0'YP6G2CU0
M\9&TY<QZN6-#O>;_`"_DL3?]+CR*<#&+X^<?M#9I;G1#;Q#<RFL*>#="TL8U
MIL5Q.,-G'CGOO%PY4P.(L68=@"/4QJ3%YU1$Z9R;`WBB`CGEL'AVY&RZV*N(
M#23@57MO-+3@(5=J\L)3]>7CMI=.;.UD4[=4S6E.(TU*PL;,1L@6L5(A3NP2
MOFZR;8[(8P")J$*!R`8=HYXAE7(8+#UN59C32R8VV"'"Q175^D^=D9>8J6B;
ME)T=4KB]T3>>$?+4XVEV3%W$TJZI,:>D&"ZA$W4:#!T8I3)F2,4H[!`0#&UF
MUI3@)<RT72/PT*O@Y>4&.->FTFE)2@*BIJKIVNG555$R<W7DJW<A#(QS*K*B
MNJHR/)N&[0IC]QQD2V9))-DP,8^X7=,<V>)F;0IW,+19`B%N)2REEL-X7N/C
MQK@H?1'+,T*>I.?NNZG[4V\=UO+VQI<E/-6,[`359QDM$$>3$LAN)S3:GVT^
MZ[F2*DAD50=\3B`#B_U:GE'62AUS`&-JETACFAAC`*15])[-:!6ACU@]'G=-
M)].Y51;E*F=N9PW<&J?<%;,%%2(;O,;_`#?'D.095^MMO`]7WHX!BAPXU7PD
MO!;&&-0;1FC^3C-2-0SZ[N=96^@-.5,4)3\B06Y&TA=]Q3GN+G[I0C,JJ@Q\
M^WHY@V0`^Z)<P#=#>Q+-KM<RY9APY(Q@E3:.4Z$;UF7(MY36A9[%0]41LU<M
M*35GZ2HJEDEV5/*,U3Q]%58[JA"3EG+UZ^=O9>5=OC`Y.*I2!EF4@9B&-1VU
M(A@L67Z=*PQ?G4)VXLA?2*O_`%3,O+?+MO=;=2Y2L[/3XQC^F:9M?5T.1DQJ
M6AYA&3W#5(]?I@=1KW(10"@!3"(;<)?M2G>`QP-T`<?XK1)HI;(^]:<:F&K]
M`C^<BH6"97<=)0;&VU/V]D4INGB2R[(("IO=#[H:723>I,X>7G2Y(/#"DL4Y
M"Y@4HXJ-J4T22+>48,J=X27E7TACD!:-TDC#O'3322$0-O%$J"1$"'*&0`F"
MJ:8'$H<`FQS)LXS'7I9%WVQMSK5*8&-@W![%L.<'Z@^SA=^9D3+4`(F'/+8/
MU<N)$R9@,%;BRJ.;O?VK+H\OP;UO_P`7)#9C0P%T(\92GEL#'$H[TBF$-,%A
MP#+^UA2G]34@Y>I@<(.(4LA=$,"L<&T`'J8A62X$(P(477AH(+KVOKZVJDBI
M"EKFD9JFC3"20*JQ99EDJS,Z23$P%44;BH!P*.PV[D/#BDNLDRWAT<"4]M\7
M78%4BB-*-S$:6M#2MS;NP-4)V6N30E=TL]I6W[2DU7[>C*9F*77A)]HB^<-W
MJLHWE^=.N/;%$H"'I=NT;98T/NFU[8&/Y8EA=LV0X@F]$9?8NYA-*;*+/(G"
MKW"R<GJ<>:BG"!XQ`G-.G+%DT;TFB)!**2#,S!(XK!F<^0@81`PXS&OD\1.#
M'T*S=G2&FR]AQ]"VL1IE915+VIIKW5NG2=K;K/;G$?K,`25FEGKN:>+1;@6Z
MB8)`"TP81.0I0,"90$!VYV&T9(<77C@AACCPI@I)8;"+H`X^1<W)Z2R/6U#M
MTZYD6AZ+N;=BY*4DU8I(NSJW1C:C8&9,U4S$%HM!%GA735*7MS)`40VCAXVS
M+#B[JGJ@9HZ4>#E0XX12::=*TA8ZI752RU8M*H<NK=4];Q%G%08PB*3&#?O9
M,LU++*O'CR4FY8[C-P<Y]T5!$0*7/"Y^U!4,$N7=O1C@5Y--+EOO",88U=,"
M%*0$]PP$#=#(P[X"!/2!VV?I=F7'LQ@+ICL)"UX,"S$`-[CXQZFT0S]'%I0<
M'$D\2"2;#!9L/4(P(2"8"\(Y9X$+YL=*Q;*-O;I*E[/3,K(0\+=*X=L:(E9*
M)(4\BT8R]5-P<K-05S1(J4J89&,`@')CI;)VFS95:VK-V^W!&T9%CK=GG:,H
MR3$-(MAA7R;2^B\:9"D*`ZD;WK&+D`G%A2IN$H&`H'%L83@0#9`([<@Q]*'G
M5ML-$O4T5UN#_';^*\#-\L]F&>:ACZB^3V[/P0;Z+QID,.8:C;YALRR*TI@@
M;.H5J`9XB;YT[;F/O&71@PXI9'YI51Y<T]3,UA?/C`"Q\,"3R7;3+\HZ^OXM
M3/K;"_67;79I/@.E(],:;MU'QIP?1>=,P!EXQM]/Q:FO6^#UEVUV:3X#I1Z8
MTW;J/C2>2\:9!V^,9?/\6IKUO@]9=M=FE^`Z4>F--VZCXT>2[:8_E&WU_%Z:
M];8/63;78I?@.E3Z8TOS*CXTGDNVF3Y1U]?Q:F?6V#UEVUV*3X#I4>F--VZC
MXT>2[:9?E'7U_%J9];8/67;79I/@.E'IC3=NH^-+Y+OID^49?/\`%J:];X/6
M7;79I?@.E'IC3=NH^-)Y+MIE^4=?7\6IGUM@]9=M=FD^`Z4>F--VZCXT!]%V
MTR_*.OJ'5[FIG9_Y-@/G)MHB%RE^`Z5(\L:4D`S*B'\Z#_1=M,ABF*&I&^H;
MQ3%S!M30"&\42Y@/<_"&>)E^<>W!@ETI_H.E3,\K*)PAK*CXU"UO?HYVG6M[
MF7QH-Y?>\[%G:^H*5BXYXS:TP521;2U,-I=R#_<1-SB@/7AC`.11``*&W+/&
MZ=YR;9U`+&4L3AZF#I6)GE71ZSK/J<G7.A347Z+MIB*42AJ+OIM'/,6]-"8O
M4*/<VP,8?67;?8I?@.E:/2VC^94_&@?HN^F/+9J-OK^+TT/_`)M@'G'MHGW*
M7X#I4CRNI&F(F5,?YTSR7?3)\HZ^GXM37K?%_6+;7RZ7X3I5_3"F[=1\:<'T
M7?3'QZC[Z!_N:FO6^*N\X]MC!+I?@.E79Y7TA]Z94#^M9"_1>-,(9YZC[YCY
MK6FO6^*^LNW.)E+\!TI@\KJ+YE1\:=Y+SIAXM1U\P\QK37K;!ZR[=^72_`=*
M/2ZA^94?&FF^B\:8C9?XR%]`R_VM37K?$>LNW.Q2_`=*CTNHOFU'_P"18Q^B
M[:9.+4??0?\`<U->M\3ZR[;XV4OP'2EO\L*0'JS*CXT>2[:9?E'7U_%J9];8
M/67;79I/@.E4],:;MU'QH\EWTR?*,OF/FMJ:];X/67;79I?@.E'IC3=NH^-9
M`^B[Z9LMFHR^.758TH;T3-!,.+#SDVYQ,I/@.E'IE2<<RHC_`#K1U/\`1D=-
M-.TU4DTEJ*OBL:(@)>7*U5:4L5LNM&QKMXF0YNYC;@&.@&]D`=K@D><VVVSX
MW*0VV]0Z43O*^@?+_P!E3>`[:X*Q?T;K3A=FSUO+C/\`4)>N/?5M2T7./6K1
MM30MFQG0;XMVHB@.2210W<\QSX</K/.?;1):&4MS'</>QI-+Y6T0(<9E2#_/
M[%+8?1=M,F7^4??'\5IC\!C,/.7;L+)=+#^0Z5M],*'YM1\?L3?)>=,GRD;Y
M^<UIKT/YGP>LNV_ETOP'2I]+J+YE1_\`D5+.D#Z!NPFCG27>#412][+MU345
MO8R.E8V$J@D(E$.%7TFS8'1=)I"00.";@1R*("`Y98[6Q?-2KVEMF52[2$J5
M2.<`ZY$.$<1RKD[P[ET.QJ8S=E:QS@!_L-^,>8+Y!Z..BTUB:UWS)_;BW[VC
M;>J+D:OKPW*0>0E)QB('(#H\=&.Q"1JI-5L8QD0;H&((@`<YQX^M;[>8NP]T
MJ"7-W?F!]:1$B:X3!'BBWJV<J\30;LUNV:AK*IEVF+PUY8+I#28&!M@<1QK]
M<VB;H#-)NEMQ3=;W)(]U$7DAU&LDVJ>K.<9TQ34LW53<H.J1IAN<!:':N"`9
M%=0^\7+/+/'YRWD\U-J;S`LJVTK`>.7+#3TD@:%]DV-N)L78)'@G51_GF7O_
M`(A?>%J@5$A"@02`D4I$@$0$")ID`A$R[,]P@!LSS''SHS)4R;?`-XE>P;+`
MAALQKVE.(B`;,/3ED'%7$AL1A0F"(@&>%7YF12L8F$P9?5]?$M+W1#H8$"'&
MDXR^;^QB)5[60."U)F$*F.C0<D-1)MF9M2MS?0>-\=>O)+94>Q^:73PZQ"NH
M4PFSSXLL<]:4[`A&!","$8$(P(1@0C`A&!","$8@X$+SG,(``;.'%:9[Y@B^
M$5GJ7$0`7S0MTD7X-[^$V[OS@=.FX>/QC;4'X?XH,;77M8UN2"QM<?"N=QQ'
MXK870N+-V^UPTX_A+65Y<\\CIEGF2C2A"0:SJ-,%RX4PKR*<],01443@D4`$
M!$,.=+BW#"WAQE1K0#:I:#4_<;,!'2!J'X?O-M_V*_$?0'&5\H1QJ1/$5D\:
M.X7R0=0G[W;_`//+%M4.T%JUO[3PYDT=4%P#!EXH.H7;R$M_^>>)U+7]5[P&
MG"I$V)A=/#F6,-3-?`(#XH.H<3`.8&$*`W@#>$VYG[LO29B.S$_3Z3YS,QTI
MM[(4IM35?F#(=(.H?+>`1``H``$H;.;'^O+:D/&7@'!X"D%HG-CR%%[(4\NI
MNX`C_D?ZAA'B[2WPB``.8`4#UND4`+Q;=F#P5-\UN8HCRIQM3-PS%W?%"U&\
M(#O%3MQOAER&]WXB&?`/4'$^!I3[TUL.0HO'"F*:F;B"'^1]J,$!$!$.YK;9
M;`'(,AK[TO4Q(V?0_-;TJ+^1,#4W<(``I]'VH@"EW0("B-NR@&X&1=WFZY5'
M8'F8/`T;?=FMS%+F/!A9%-/J>N#O;WB@ZAAS#:7<M^),P$!`PE&LA#>ZN(\)
M3?,;F.E*O9"D3U-5\&]_B?:A=HYY<W;_`'2B.0YE+[LMT-H>=B#1TQ_ZC1S%
M-E'"8%9C:G;@F$!\4'4.`@8#!NA0)=H`(<59[<P';RX/!TV'6MS%-CRI2ZH+
M@D#=#2!J%RV9=I0`\```<-9\@86ZGEL,);@YN-+<\-,(%+XT=POD@:A/WNW_
M`.>6*:H9%76#LG/[$H:I+AA_F@:A/WNW_P">6(U0O<44ULP7(PL7"W-U,UV\
MMQ<5!QI,O\S27H2L&ZCA=*A!11(I3LAO'5%*KC"0H<NW+&N7)!($1AX<:R3)
MV'#@7%:8M15=16G>RT>WTJ7[E4&ENJ:12D&!+=F9NR$8D*55N9:NDE3)F`.$
MQ2CU,#Y0#W"/&KLG=01'$IP'5%<(HB7Q0=0HY;,^;M]MRV<5:&#K"(8490C[
MP5]=^T\.9'C1W"^2#J$_>[?_`)Y8-2.T$:[]IX<R/&CN%\D'4)^]V_\`SRQ&
MI':"G6_M/#F6/QG;@B``.D+4.(`.>0EH#;U!_KRVAB_T^D^<S,4V]D2!J:K\
M1#/2#J&-P``&+;\W;`)LC[:T*`GR-EF(ALP?3Z/YS,Q1>R+)XS%PLLAT@ZB1
M#(`'-*V^8Y<8C\(&8B(;!Y0P?3J/YK<Q1>R)WC-W$SS\4+43Q;.9MOELZGP@
M8GZ=1_-;F*+V0K$74I<`N0^*%J+$0S`#&);D3``[NP!^$'@S*`^:&(^G4?S6
MYBB]D*>.IRX1.W\4'41P9"`I6Z`HB(AVQMRO%3";9PY8AU%32A?ES&N?BM57
M/@,!2>-'<+Y(&H7[2W_YYX5J^1+U@Q'.E#5'<+Y(&H3][M_^>6);*&,!&MA_
M"<_L2^-'<+Y(.H3][M_^>6+ZD=H(UW[3PYD>-'<+Y(.H3][M_P#GE@U([01K
MOVGAS(\9ZX2G^9_J&'+U*=N^/^+KE'DZN)$H#^((UV0JI^L/4'7<U;JBVSC3
M#?&FTD;UVF>`YF"T$5%P9K4R:IF:)&M9NCJ.7)`W2`.09XV4VSY%4"Z8]L6\
M7'^.#F6.IK:B2X-D-L(PV*UB6IRXN[]RTAZ@S)YAN&(C;H`.7=+D82JUPW4(
M(AQ"7/&2=L^E99?!.2.E$NLK7_P'H68-3EQLMND'4/G_`-JML'_+\,1*H*5[
M8ZP"WCBF^+J&V.9;S)!U.W$^2%J*\Y"VPAU_=_AOTZD^:WITH\;4<3#T)P:G
M;A9;=(.HS/\`G>V_Y_XCZ=2_-;PYU/C*CL?@D'4[<//9I"U&9?SO;?\`/_$_
M3J7YK>'.H\94=@]"3QF[@<>D+4;GQ_<+;\/Q@8CZ;2_-;PYU;QU3\O\`#0CQ
MG;B<6D+49EQ?S/;;@]_^)^G4GS6\.=5\;4?+/0E\9RXWR0=0_P"]VW_/_!]-
MI/FMS'2I\9/[!Z$GC.W$^2%J+_%[;?G_`(/IU)\UO#G4>,J/EGH0&IVXF>W2
M%J+R_G>V_P"?^#Z=2?-;PYT>,J/EGH3AU.W!R'+2#J,$<N#N>V^W_P#F!BIV
M=2P_VMX<ZLVKJ"X"YQY%B-J=N-NCN:/M16_F``!TK;D+F)@#MCA7A]T`SSX!
MQ=FSZ6'^UO#G3)E3/%@8>A50LAJ#KME?K59)-]+M\Y`)JL:*679QX4$9>+%G
M0L4D=-T1S6+<HK.%-H;IN#@QLG;,IA)$9@!A;AMY+5E%=4ZRUEG,K6%U/7#-
MNY:/]1@;^>[O)6W#+=X1$?=_^VXL8?IE)\UO#G3O'5,?<_!90U-7$+M'2!J)
M'S$[;F'K>[_$'9U*VT36G/I0:ZH(L9^"7QG;B#P:/]1.?^F1MN`=?W?<.*^!
MIOF-Z=*@5E3QL/0D'4Y<8/\`-`U#!_W.V_Y_8LW9]*X_[1TZ5#JZ>T>X>A8S
M:GKBAE_B@ZA^/@3MM^?V+_3*4_\`5;TZ53ZC/&!OX)GC/W%^2#J(_>[;_G]B
M/I=+\T=.E'U*H['X+(34_</(<](&HGSD;;F_Y?XGZ92C_JMZ=*CZA4G^#\%E
M+J>N#E_D@ZB^'B;VW_/_`!!V;2_-;PYU=M;4$1+/P2CJ=N)^UT@ZB<O],C;8
M!ZWP@8CZ;2_-;TZ5/C9_&P]"P'U17#(;='2'J)`=G`A;P?1)6RI?1P?3J7YK
M>G2I\;/[!Z$\NIRX1R@;Q0=0XY\8HVX`=FS@-7J9N+C*&#Z;2G_JMZ=*GQ]0
M++AZ%Q]?:D[AN:,JYN.DN_K-%>DJH24=N#6^*T;">!D2BH](6L5#"0H<.X)@
MZN"3LZE$Z`>V,<N#.IFUE1JP^Z8PR**M)FHNNH?359")3TJ7[E$VM!0B!'\:
MG;LS%T4AS$!PU,M7R:W<ZOIBB<I39<(8=5[,I@3=>+N*V(LX9TJEKJEYM99S
M*?\`QH+@%[7Q0=0G:[-I*`$=FS:(5H8!'SQPD;,I8#_*WITJ[MHSPXBX<.30
ME\:.X7R0M0?[W0'YY8GZ;3?-;TZ53ZA/[!Z-"Y*O;MO+E4\\H^O=$%\*NIN1
M.V/)0$Y'VR?Q3\6CE%XU%XS7KTR3CF7"!3`!@$,PQ,FAE,?XEDP!P,>?.J[1
M,JH;=>!"S\EO(W4'5L*Q;1T7HVOW'1S)(B#&/9,[9-63)!,H%(W:-6]=E2;I
M`78`$+LX@PJLIOJCO\LTDAP<22;898C,K[.E4DJ7```B*]I=3M?9A_B>ZA?3
M%$,R4`.Z)39@(#[L<]@^=B&[,I&X)C!GTK?$XBO3XT5P^/2#J%R_[7;[\\L-
M-+3M;%LYA=B@55S@!&!2!JBN"&T-(&H3[2W_`.>>$ZK]P2M;^T\.9+XT=POD
M@ZA/WNW_`.>6(,J`P@HUO[3PYD>-'<+Y(&H3][M_^>6*:OD4ZW(<_L2EU0W#
M,.0:0-0W!GL3MX(_Q];I!Z/G8ELH8P+%&M`XBL:NIRXX@42:0M0@#SB8"4Q+
M<E4,4QP*84@"N%RF$@#F8#;O:\`YXM+DMOX0,I2)DW$+55/2CJ#KF'2OR#73
M!?"H"/M0-?OSGB$J$W62KE=N91HZ[LK1J(.4C!VVYO%QU=HR&M;*=>`ZL/;R
M)=+.]ZPD6?FK8CJ@N&3_`#0-0P9^J2MV'!_$5PMR\>6.690/\06O79$GC1W"
M^2#J$_>[?_GE@U([01KOVGAS(\:.X7R0=0G[W;_\\L&I':"-=^T\.9'C1W"^
M2#J$_>[?_GE@U([01KOVGAS(\:.X7R0=0G[W;_\`/+!J1V@C7?M/#F1XT=PO
MD@ZA/WNW_P">6#4CM!&N_:>',CQH[A?)!U"?O=O_`,\L&I':"-=^T\.9'C1W
M"^2#J$_>[?\`YY8-2.T$:[]IX<R/&CN%\D'4)^]V_P#SRP:D=H(UW[3PYD>-
M'<+Y(.H3][M_^>6#4CM!&N_:>',CQH[A?)!U"?O=O_SRQ!E"!ZP4B;;[IX<R
M8;5#<(<L](6H4-O$E;\1\X!K0,QZF>%T4H.;`D-2ZMT"+"JE6ZKZ;'3E?VNA
MMQ6!)<NNRG7X6_.WB"U<LMXRMIT1:HI!4"D2=<J9MX<W:90`HCM'8/1?+_\`
MLM;D/X%(;_\`INY1^*M8*(#KP8%,4IBAI;FPS$H;Y@"YL04`.?TZFSU0CC,^
M8\2[H-EBM+EL<[K#&KE;A,\MT,O]#&"9.FMP'C6IM/)(!NB/.G\PE][)]J&#
M6S^T4S4RNRCF$OO9/M0[&(,R<X0+C!2),H&(%J7F4OO9/M"]C"[IQE7@W$D%
M%+[V3[0O8Q5S77<)1=;B0"9"CF!"@/*!0`?K85!V53=:O&[=`U,4QA$B90,<
MYLB@02E(<QM]0PE(BF4`WC'$0`-W$M;-<ZZPVJCG,EVNP+P=]VP@W4*^;+(N
MA0!JJFY0%!R"I%#I\RL!]Q=1SN"!`(([PAAFIJN,GH5V39#K./G7E=S\<RD4
M(^1?1C9R[$HL63V39-WCL!*.^5NS55*X<J[^8%*0!$<L7ERGB.MM:AXE.`#0
M"5O6I"*E,<R1BES`"%63%-;+A$5$S)IB4<QR#A`0##=6S$EZMF)>GF$N),GV
MH86^6VR[8K-8T8`DYE+[V3[4.QA>KY5,&XD<PE][)]J'8PQAF,$&.("JZ7+<
M8N%J.82^]D^U#%]9/[3E74RNRD!%+,0YLFS+]J'8Q`FS8VN,5?5L#;H%BCR[
MA`+:ZYF[F7<MY69B@4QB@`^YV0VY%$`'AQKEN=>!XXI$R5+A@XBHVTC%+XL-
MB-@?VLJ7'SQ8$$>N(X)KW:QUO&I9)EEC8CB5C@01$`$4R"(AF(Y!BFL?C*MJ
M96))S"7WLGVH829L^/O%3J96)',)?>R?:AB-;/[14ZF5B6$Q4DRF4.4@%`,Q
MS*7(.J.09[,#I+C8S"G.#`,"U"<HQ5540352%P1-)4R*:K91TB5T!Q;**M"`
M9P@0XICS9C%R,(\>*>'GX.)9R]C3;@7C+5<*)5,IN$55;"?N_F)5DLBSYLOW
M7GSIF,9LDD4!$3+`0`-L$0Q84\_+F4F9)&);9*104%,A7#<QUTN=;)IN&QSK
ME$`,44]TP@N4R61]\G:@`[<+F2*@2R03&&)6:^2YX;9A0M(HMR;ZSILCF(HD
M!=1-N"CLVPC9(ZIP!141V;I0,/4PIDNJ.$GH5W:EIP6+5K3[-)5!FX=LTWKH
M0(U9/'3=DLN)39'<)IN^9=.4@-VHBDD?(<:1*J6VL/66>9-D7<`@G%F8ON\D
M:9XQ[XJ(BJE%]U,R/UDRFW14*T641=[Q!SWP!,0`,O/8!5C"X]"JQU*X1@.E
M;])),PF'=3,3@((%#S#`;CWBF#+%G3)K0(N,4[5R'#JM$5FYA'[V3[4,+U\W
MM%1J)6)*""/WLGVH8NR;,.%Q1J96)+S290'=(4NSB#+ZV+%[CA*C4R\2I/KH
M$P6LH<2@J(C?NS0%YK:("6JTS`(<`D$H_M@R'JY8=35DJ1/#)K2\N:8"WCR@
M*PD]@AHX8U<DBF[O$`52[H@415W@$YA3((GWC@H8Y=N6>?%EQ8X5;.JS4B7*
M83*B.&!,,^G8.N0'!**JA-@=N'J@`QO.S`@\&.H:5[K94PRV]F`-O.8ITHRY
M[-8QPA')^92=T*^I-YQ3_@\1X*?\\_"W2F:AA_B_#2G;RI^VWC!GQ;Q@RXN`
M29XRS'54EYEB+P..P1Z%G?+`<0)D!_2G;RWWP?MO_!X7KJKLGAS*FK'S/P6,
M5E`$0R,.7'V^WJ["98VLIJA[`\SBTD1A=;9D6ELEMT=?BR:4O/K<ANL?]Q@\
M'/\`GGX6J=0SM?AI3]Y;U?UOP>,9G58,+I,.30LQE_\`<_!&\M]\'[;_`,'B
M-=5=D\.91JQ\S\$;RWWP?MO_``>#7579/#F1JQ\S\$@"H`Y[QARVY;XCGEQ9
M`3/$B?5"US+.&16#`3#6?\*<*QQS],7_`$QM\"[-NW>2R##F5+SA99SZ%=\H
M!L;\/ATJEMAM]349K*`V^<X5U;@YB"HH4A$0M]%@F9`2HES$3!VP<>8YXVB;
M-F,$L@L$,-I_%(9*!FC_`"B[R-Q<JNB*BN0#NCP9?MOV298KJ'8-8<P6G5L[
M?X)O.J]4/,'L)XJ^G==_V.S!&KE_,_!`+JAM[8>ID8?0!/"=0X?]1WPJ1*EG
M`_\`#2@7"OJ3?:'_``>+-IIC[&S7-_I'YJ=0PX7=(TI.?5']J/VIOV4\6\'/
M_P#8/PMTH\/+[7X:4G/*^I_C1_!X/!S_`/V'?"W2H\/+[7X:4O="H<0^<4W[
M">#P4_YY^%NE3X>7VND:4@KJ#P[X>84_X/%315/\-08?RMTJ#)`]UXARC2D%
M8>`3G`<O4"/UT\1X&LXJ@P_E:H,K]XCRM5%^D(UGI:#-/CG4+)T:[N%"1==4
MA34W3T8X1:S)8FHUCM'#R,,N5%L+MH<F^4JAA*;/SL=;9.RJRLGBE8YTQ\(Q
M@!9S8ERMH5TNA9UI@O#DXUK-'O29:2];<,W4LU<R,2K'F"&E;8U2HVIZX,(Y
M'/GFYX9\J0C[N<Q1S4;F5((!F'#EA^V]W]L;/DQN.:YQ,'``X,>&"R;.VU35
M#R'S&N%EAL_""N5<4^];JO`-NF4]QE5;XE$3E(/>*2#,HF*40'9Q`&/.T4G:
M#;KJEW6YL/,NI45#2TB4;(6*&]&!!\5:Q)L][.W4#VP[1'8<>$<Q'&JLUX!@
M[K\RK0N>03,-L-*M"5`HE`1(GF(`(YE#//+C[7AQ#'/N")M@%H<!>/*LG,(_
M>R?:AB]YV-5@%C%N4P[PE+GEEGMX\`>X-N@]5*=3R7>\W\4P&@!Q@(9YY9</
MH8JV,L$,LBH;2R&D%K;1RZ5DY@GWM/[4!_ZW""9KL+B>9.NA.YE+[V3[4.QA
M8EW7!XC>!4EK2($""3F$OO9/M0P_6S^T4O4RNRCF$OO9/M0P:V?VBC4RNRCF
M$OO9/M0P:R?VG(U,KLI!2(3:4A0'@S``#$B9-,;SB1!3JI8P!8S``F)U3;>+
M@VAP=7%I<QY=`FR"3,DRXX%371H4!0U$`.8Y:DKE%#,QC9%([;E*4,Q'(`#'
M3VH]Y;*@;;B732I?6$+(A70%(AO3$`<N#,,_KXY`F3A@<<P6K4RL23F$OO9/
MM0Q.MG]HJ-3*[*.82^]D^U#!K9_:*-3*[*.82^]D^U#!K9_:*-3*[*.82^]D
M^U#!K9_:*-3*[*.82^]D^U#!K9_:*-3*[*.82^]D^U#!K9_:*-3*[*.82^]D
M^U#!K9_:*-3*[*.82^]D^U#!K9_:*-3*[*.82^]D^U#!K9_:*-3*[*.82^]D
M^U#!K9YLO%&IE8DTR26Z`\V38.SM0[&-#26V`P"I4,:1$BU?-"W:9!MI?M(2
MYIEU_4\4I<QR`HZCK4&$`VYY"8<:73'ZQKX]:[I65H'AW-XK/Q4W&_R\XX.(
M=+D[F'F7,IT0ZPG'KX0_W4R3[V=7##TW6_8QAF8><+8WW0LV8<H8T*8%&8<H
M8$0*,PY0P(@4;!X\01$00FGS`N8#EN]L(99YE#:)0VAD(ABEP*8JD&N6O%X&
MT;>WT-'5'4%27HJF'MBR@Z3,8]5.(.2WY*MWD5DNR!%=C239R!3"J3)0Y`SV
MXU4C6";%UH@5S]HD^'@.-P_-?/.'N4WI:V%F;65.\G+=I:=-=MLJ$YBX#PL5
M,I6F>*J3]`R55K'DU`,U>TW)\RY.=50@KMQ*([!QO.K$70_AXN&9<R5K#!H/
M'A.)2Q?BI*#H+4+&Z@T9RW%_J5J^5M#2SRW*-2=WW#M_(N9D[*FZXL\W8N%F
M\VV<K2`*238"%$$R&,*F0;N,M0YI8T-!LX\:ZU*'`NO85]BFV_OJF.!@$X$.
M4#`!1(!]XXI[H9B;<$VTP\>8<6,BV+V8$),PY0P(@49ARA@1`HS#E#`B!3?V
MQO.^MA#O?*MQ!1Q=X?[%MT.I;>MQ\\*<?Y#YV-3,(_F"4_`>0J/-(@!XL%A]
M@?VL:4]&,1'Z^"9_L/*HE?ZQR*QN*)B3,.4,"((S#E#`B!6LE'C1@Q=/WJI&
M[%@W7?/5U-B:#1FD=PY6..W(J2*9C#U`Q,F<USH#WH)4UY`@OB19>[4TAJ0I
MW41,4I="'I7515E<VE>SLZT!O0S:GHTZKNPLC$J=\5NY%IA**DD><!$HY*)9
MYYX[=R6^G@,+0#EB,8Q?BN>Z:2Z'&;,_YJ/=/2=/2>BR^KARK:)[4$E3UU(*
M4=4S54LYNJI')70G8]ZQKU([L[J+,WC!`K=PDFF8N1=N6)OMUHM==XQ"S`<"
MSZE]V'&N_M%45:VXU1Z?K`32M0U1.VCLM=.H;<-G+IXT5N9::9A81S1AI.47
M!PP5J:F'('BW9U\SBH4AP``$1Q28Z4Z2]S(@N_$6)TF7,$UD>+]?S4T:Z*BI
MUQ;&P=>7-2+;"MF6H.TIH:D:CKQDW!!$EP8Q"I73HT:^9LIU)*)."C@2D/S*
M(B(EV8S2"T'B(A^@6J=*?:05%%[92@YRJ=8TO74V"=RH&3LR?3J]0DUD:B+`
MR:,2\@'ELT17,$JSG*B,<'8MRG26,`E4R+EC5*).K:WW(&]9PP8%SYDIUUW:
MB(<(<:TT:[CI%[3L_4$F9#54AKI0B)PK!ZJYJ9A2W?0B#F`>1*2@FBJ$<4CN
M+"!2BWWR`(F$1V)J'2V>Y#5W>%J)<EYM=[][C7W);Y`=0,LLS*B0.7(X<Z.S
MB%0=F./,G-F=481^5BZTECFDDX%Z\*6A*&&2^-!2X8H7R;Z:NI*SHKH_;M5;
M;=_(Q=P*;DJ*FZ+>P[,\A+)U&PJ=BHP",9ID4,H]-O&`G:CP\&/3[HR]FS=M
M2Y>T2T,(,(PC&S&1E7`V\^LER(TL<'#B7XT"](?TQYQ-SEV=5>>93`56W<OV
MH'3(H*:8H4PY**:)CB0,S9[.#'WZHW9W&IV-F:J4(X<'*?XE\;JJ[>&=5&6Q
M[L-F'0D'I$>F/*.1+MZJ`+R!;N>R_P")_'BK]TO+FN(J-9+D$B%T%@P<<"^-
MJM-JM[:1VJDO?<A'CX_Z4GSB?3(_I<U4_%Y._F?A?V-Y<_\`M,SRN^E?4]\N
MV_I[JS%Z1'ICQ*&=V]4^?][N=_,_!]M^7M/_`(6LE30W^,W;>/B?"S!S)@VC
MOD1&],Z>ZE^<1Z8_]+>J?XNYW\S\'T'R_P#DRLP[ZGZAOCVG]/<6$>D2Z9',
M?[+>JCA_1W._F?@^RO+J;_E-0QA=;=C+ZL>*U\;,J6=I[Y`POOZ>ZL@=(?TQ
MX@`C=O53M#]'L_\`FAB?L;RY_P#:9GE=]1]3WQ[;^GNIWSB/3'?I;U3_`!=S
MOYGXCZ!Y?-ZNIE&%D8"W+[_&F_4-\>T_I[B/G$>F/_2WJG^+N=_,_!]!\O\`
MY,K,.^CZAOCVG]/<1\XCTQ_Z6]4_Q=SOYGX/H/E_\F5F'?1]0WQ[3^GN)!Z1
M'IC\A_LMZJ.`?[G<[^9^(.P/+]P@),J)R#OJ#M#?$"-Y_3W%B#I$NF/S#>NW
MJJ$`VB!;=S8B)0`1'8I229!S`-N8ABTK=C<2]$RI71WEFF[4WQA"],Z>ZN4@
MM>G2OQL]5LY`W4U)(SU5O8]:LUVMO)#NI:58,2,XEN[3+!'4:K)Q"`;HF``$
MA,N';CJMW:W`J`R76B7+IF_Q&Z`W.\"TP%JRRMI;Y"<.L^WE[JZ\O2(],>']
MUO5-L#+9;Z5$?_LZ95./6PW[,\H__9DYY7_D6\[2WR.%\SI[J=\XETQ_Z6]5
M'Q=SWYGXI,W/\HVMCXF3GE?^11]1WQ[3^GNII^D2Z9``_MN:J.']'D]U?_R?
MA'VEY2?^S*SRO_(I&TM\1@<_I[JQ?.)],C^ES51\7D[^9^$3]S?*V:T"FJI=
MX&VV5@__`"%'U/?+MOZ>Z@>D2Z9$?[K>JGXO)[\S\9OL?RY_]IF>5WT?4]\N
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M-8'2T77HN5I2X=K7%X--`T?4L:YOO=A96AJLA(\E/2HE=0,LHB?X1A1$FYEW
M.7(H`'.YAGC\G;W[)V31[0>^F+93!,BUK>,6<5MD>/I7Z#W9KZF=0265/6G:
MN#B>(V\G$OTKZ+CD'2M8?FC`9(;<0`D$""F`ER.`&*03'$@"`<&8X^8UE2S7
M.X[5]`E-N-$,"M,'`'F!B@,0","NEQ*$8$),@Y`ZV!",PY0P(@49ARA@1`HS
M#E#`B!1F'*&!$"C,.4,"(%,./:^?^P.(=@*%B``S#J#^QA<OW^9+F<,ZIIHS
M'[GJ+#B#4K<S+\<;XZ^T/=E?R)5/A=S*Z>8<H8YJTP*,PY0P(@49ARA@1`HS
M#E#`B!1F'*&!$"C,.4,"(%&8<H8$0*,PY0P(@49ARA@1`HS#E#`B!1F'*&!$
M"L9O2^?BXPI<_`.5?,:W1S?!G?TV8Y_.#4\7/J>,E:<N7F98T.]YO\OY+$W_
M`$NYE.Q\O'SCO_E;GO\`I,IK&8RWAEXDP)6MH`-@"N+D&%ZMIPJ\5AS'E'#U
M$3C*,QY1P(B<91F/*.!$3C*,QY1Z^"`1$XT"(B&0B(@.P0$>'!`(B5JWT+#R
M+E@^D(UDZ>11G)HQXNU15=1YWB9$G9F2YR"HV,Y23*4XD$!,4``=F`1!BU5<
MUKQ!X!&5<Q4%L+;5>VD655412U2M9=2,7E6\[`QTFE(K0IE#1"STKMNJ#A:+
M,L?F#&S%+>'=$,\6+WA5$N6,#1F7C86<M+$OH*3B[:T,QD:89&CJ=?-*7B4'
M4&Q,83"TBUR-049("8PCNIB`!GBI)=[T5<`-]T`*1B@!!,)0W1,.9A#A,.0!
MF(\8Y!@@%,2ES'E'KX(!$2C,>4<"(G&49CRC@1$XRC,>4<"(G&4N]EQX4Z5>
M=%!GM;U785'5W1SM7=#E&V];_P#%R0Q9LIUD"<*C7L-L,`4?Z1?\F"P^T?[6
M-*?U-1Q#F$.(<3%2'`@%MC58<3;1VCP\N(U9QJ+4S,>4<-`L4Q.-&8\HX(!$
M3C*P.FZ#Y!5JY2(HV<)*(.$%2E42706(*:R*Q#`)3I*IF$I@'8("(#BK6-9:
M`(J"`["M.>D:7481T6I`PZD7#K,7,1&GCVIF,8XC-[O<M'M1)S+15B!A!(Q`
M*),QRPP3'@Q;$'&JZN7B"Y&)LM:&!?3DE!6QH2&D:F1<-Z@?1=+0[)U-(NW!
MG3E.35;M4SO2.')Q4."@FWCB(CMQ.L>.,J;K<078C2]-=](^<"$BPFXIFXCH
M^8!@W[Z,8YV"0.F#5]S7=*#-P*">^F4P$-N!F&S%+SK0<"D``Q&%<[6=J+87
M&-''N!05)5L>(,J>*-54!'3G>TZYTU%SL@D&ZX-CJJ)%,8Q,A$2@."^\8+%,
M<:S.;86[>R%/RSBB:47EJ2:`QIB26@8Y5]3[$H$*5I$.E&YEF+<@$#=(00*7
M(,@#%FSIC,!('*JW6GB"]1+=T$E4QJU)2%-%K(Z1D%*I"%C^_P"HD<H%.124
M!`'AP,4H`(B;@#%"YSA`^[B0&M%L!%=<!2D](/"(B.68<(B(CYXXJ&,[(',K
M1*,QY1ZXXM=;B"(E.*;+/,1^KS<*F,)A<LY$:P-]Y.%0`]5A>KF8RC7,5*]=
M1\[540`9"56^UFVZQ#E*8BJ"M7(`JBH0P"4Z2@`&\40R'+#I$AYF"8PD3Q@<
M,(&0K//<V:+N%F)6^+"Q.0"2*C2^8P:!F/&/\C#;B)KZPV"<^'\Q4,HJ,F]J
M95Z'9&A90B(L-AHR.$>46+7]A/$2WSVM@][BZ.,J[Z>G+K9;#_2-".],3[%Q
MWXBV_!8OK9G:=G5/#TWRY?PC0D&+B@V=[(\/]Q-?P6&-?,A[SLY4AM*SJF6R
MS]H1WLBO8V/_`!)K^"Q:_,[3LY4QI?EMS!)WJBO8R._$6OX+$7W]IV<H\/3.
MZVKEV_M".]47[&1WXBV_!8+S\9SE'AJ;Y<OX0E[V17L;'_B37\%@OS.T[.4?
M_5%FK;F".]D5[&Q_XDU_!8F_,[3LY1&E^6W,$=[(KV-C_P`2:_@L%^9VG9RB
M-+\MN8).]<4.SO;'_B+7\%B"^;`P<Z/*4#PA,#+9#D"3O1$Y#_!<:.>S:P:#
M_K.*,?5##,?#^8J7RJ$8)4OX0J96$C(T^H[6.0\?'G32K.W96Z9F34Q$2GH*
M.5.5,HIB!`.JH)ARX3"(\>-=3/K7TK&39LQTL#J@N)`Y`LS95&9IN2I48]D1
M5SBP\3N@/>J-`<@V@P:`/%R)8Y8,Z'O.6G44\/\`7+^$)>],5[%QWXBV_!8O
M+=-+NL7$*/#T_P`N7\(3>]45[%QOXBU_!8?;C*/#TWRY?PA'>J*]BXW\1:_@
ML2"X8"<Z/#4WRY?PA+WJBO8N._$6OX+$WW]IV<H\-3?+E_"$=ZHKV+COQ%K^
M"P7W]IV<H\-3?+E_"$=ZHKV+COQ%K^"P7W]IV<H\-3?+E_"$=Z8H?Z61P?[B
M:_@L9YVO<X%CW`0QH\/3#_I2_A"3O-$#F(Q<8.SC8-!^NCA5VJXYCL_L4BGI
MOE2_A&A?,;I8M'E?ZS])TM8.S@TC`U74=>T5(.9^H"%9Q<'`0[TSJ6>*@S1[
MJ=+=SF[4A-AN`<>HW9VS4["JVU3W.+`#QFT1&4!<O:FPY=?3DL#6QP```6<R
MJMHDZ`_2-IE/#5?=),^I6Z[3F7)YNM6)%*-B':.\!.\M&&*K%&;MC@4$U713
MG,)=_(!'+'H=Y/,W:&U9.IH29($?<<0XXK`ZS.5YW9NYE*R?>FD.Y?\`^*^T
M5;P\4QM=6;)@S;,V;2A*H;HL6**#=DB@G`R12)(MVR:3=,A2E```I0`,L?/)
M+JN=*;,J7S#-<+2XF,8\:]FZ@IJ:5<E,:".,``_@HRT9&WM+%B#CF(FMS`"(
MFRS]*;ARRVX)E*TF#[3P.)-I7.<8$DB&E6C*/:AY@?6Q,`VS$FF,5B$1S':/
M"/&.+@""B)1O&Y1ZXXF`1$HWC<H]<<$`B)29CRC@1$XRC,>4<"(G&49CRC@1
M$XRC,>4<"(G&49CRC@1$XRESY<(J+UP7<,58$DI.,O\`%>AB9+8-).%5?^7Y
MJF6C00[GU$B/'J6N<'%GL>-N'&[:!<^X&FT-XDB2X,+B<BNCO%ZOH8YMR9C*
MT:]B:8<\LL_J\S#9;7`&]$J-9>]U-S'E'#41.,HS'E'`B)QE&8\HX$1.,HS'
ME'`B)QE&8\HX$1.,HS'E'`B)QE&8\HX$1.,HS'E'`B)QE*`CGPX"+$1.,I0X
M0#//M@PE@<`;V)1[QM7S-MX4OP:WXV!D/2"4^(ARCXR%JN'EVXVDB^,5U5#6
MW80$$FHYI53C5-2YK7U!>F'N86QE0E>I6WH^UE20JU'C65-B961<7#KFE#MI
M,LEN`DFW26`0$1$X"&0Q9JQ>'5C9;[%:V-F%:?O5K)XJ[U2?%/I;_71A'^+*
MK=98^]6L_P#+O5!\4^EW]=&(ZF5'61WJUG_EWJ@^*?2[^NC!U,J.LCO5K/\`
MR[U0?%/I=_71@ZF5'61WJUG_`)=ZH/BGTN_KHP=3*CK([U:S_P`N]4'Q3Z7?
MUT8.IE1UD=ZM9_Y=ZH/BGTN_KHP=3*CK([U:S_R[U0?%/I=_71@ZF5'61WJU
MG_EWJ@^*?2[^NC!U,J.LCO5K/_+O5!\4^EW]=&#J94=9'>K6?^7>J#XI]+OZ
MZ,'4RHZR.]6L_P#+O5!\4^EW]=&#J94=9'>K6?\`EWJ@^*?2[^NC!U,J.LCO
M5K/_`"[U0?%/I=_71@ZF5'631BM9N>VN]4>?4M-I<R_Z:,7;JX6I#[]ZR*Y:
MLHK5G[EZJ]T->:J_<_[DJC[^;EIM+^R,[RO^^8I[EZ<Q5!AOBF`Y9K;H9APX
M<RY9=A&/#B2G7N,NP8N+.N<LI%:F0M%;<+<UYJK-0?N0AO<D+^TNE\KX8+N4
MO>\7A3WK.<K@4<MX!$1ZN%ON7S>C>BM$N-P7<$%)_>K6;^7>J'XIM+GZZ<4_
MQ95?KI.]6L_\N]4'Q3Z7?UT8KU,JGK([U:S_`,N]4'Q3Z7?UT8.IE1UD=ZM9
M_P"7>J#XI]+OZZ,'4RHZR.]6L_\`+O5!\4^EW]=&#J94=9'>K6?^7>J#XI]+
MOZZ,'4RHZR.]6L_\N]4'Q3Z7?UT8.IE1UD=ZM9_Y=ZH/BGTN_KHP=3*CK([U
M:S_R[U0?%/I=_71@ZF5'61WJUG_EWJ@^*?2[^NC!U,J.LCO5K/\`R[U0?%/I
M=_71@ZF5'61WJUG_`)=ZH/BGTN_KHP=3*CK([U:S/VU=ZI.IN6GTN>?GG>C$
MBY^J5,UEEV*.]6LG\N]4_P`4VEO]=.+=3(E?Y>.]TZ5!6H6*O\-&4Z%TJ\U9
ME@OA'HD8LT?:73`=T-5!*%]S93%3O60H-C2&6^;/,.(!QLI+EXW87X=&95=?
M_BC!3N>+UEYAS==:H`#+@+:C3`(<(^E%2\Y3[N7!F&>,C]1$PC%;&7N/$F]Z
MM9WY=ZH?BGTN?KHPDX;,"EUZ-B.]6L[\N]4/Q3Z7/UT8A5ZR8,5K-S'^OO5'
MYUIM+F7_`$TX8+L+<*2Z_>/O).]6LW\N]4GQ3:7/UTXGJJO7_<GA%:S\O_;O
M5#Y]I]+N?_31BO4RI[;UT84O>K6?^7>J#XI]+OZZ,'4RJW66/O5K-_+O5)\4
MVES]=.+=59C?C_$CO5K-_+O5)\4VES]=.#JHZ_[D=ZM9OY=ZI/BFTN?KIP=5
M'7_<CO5K-_+O5'\4VES]=.`W8*1>B(WH)W>K6=F']?>J+TP?W)]+N66>W/*]
M&?!@;<_B5GWOX;R@VVT5J"^%:^GN6KS5D-;#,TK\(@.+2Z82LB/@IUN$*#`Q
MKU&34WHK=%01`A@V!M#(<:Y\-2V][L+.A9)/^^R]>MC[5.XQ6LO+M:[U1Y]6
MT^EO+T+T8Q=1='K)G>K6?^7>J#XI]+OZZ,'4RHZR.]6L_P#+O5!\4^EW]=&#
MJ94=9'>K6?\`EWJ@^*?2[^NC!U,J.LCO5K/_`"[U0?%/I=_71@ZF5'61WJUG
M_EWJ@^*?2[^NC!U,J.LCO5K/_+O5!\4^EW]=&#J94=9'>K6=^7>J#XI]+OZZ
M,6&JXXJ.LCO5K._+O5!\4^EW]=&)_P`.5'66,T5K&YPO.5WJBYW(W-Y6GTM[
MV[LW^;SO1O999;V7GXT`T>HA!VNQQLR60_-9)_BH]0]3D]J"Q6LCBKO5-_JK
M3Z7N#+C_`+-&66,]/X6]_D!ARV_@4AOB_P"$NS'2M%545JY]S%0]^Z[U4]Y>
M\LOW[YJT^F'G0B.XE>[.Y^9O1S@J=S;_`"#EGGAY-/K?\(ZL;(G\;!^JZ#[_
M`(<7O?A:N$L1%:E`L_;7X-*]U8&M_P"YME[E!D+2:8"/!@.9'O=W04]ZU%"G
M!/AS$1SX<1-U=\W_`'H<.)4I;T;?=XNE2^$5K*R#^OO5)P!PVGTMY\''_9HX
M<9S<BGF,2F=ZM9WY=ZH/BGTN_KHQ'4RJ.LCO5K/_`"[U0?%/I=_71@ZF5'61
MWJUG_EWJ@^*?2[^NC!U,J.LCO5K/_+O5!\4^EW]=&#J94=9'>K6?^7>J#XI]
M+OZZ,'4RHZR.]6L_\N]4'Q3Z7?UT8.IE1UD=ZM9_Y=ZH/BGTN_KHP=3*CK([
MU:S_`,N]4'Q3Z7?UT8.IE1UDXL5K,S[>N]4.67%:?2YP^?>C!U,JD1XTHQ>L
MS>+NUUJ@$,C;P*6HTO`7/9NY"G><Q@$!ZF0\>6);<BJOO0ZJ@>QL5J``ET?@
MWKW5H8GPM5@-8=W6DTOD$*S%RGWX*TYR]A]YH`[N0AEF/"`#ALSBOPP+(V_>
M-V/,IU[U:ROR[U3_`!3:6_UTXIU,BO\`Y?W=.E'>K69^UKO5'U=^T^ES/SLK
MT8J;GZ)LN_#K11WJUG_EWJ@^*?2[^NC$=3*F=9'>K6?^7>J#XI]+OZZ,'4RH
MZR.]6L_\N]4'Q3Z7?UT8.IE1UD=ZM9_Y=ZH/BGTN_KHP=3*CK([U:S_R[U0?
M%/I=_71@ZF5'61WJUG_EWJ@^*?2[^NC!U,J.LCO5K/\`R[U0?%/I=_71@ZF5
M'61WJUG_`)=ZH/BGTN_KHP=3*CK([U:S_P`N]4'Q3Z7?UT8.IE1UD=ZM9WY=
MZH<NI:?2Z`Y=0?AG'(<6.J_ABHZRYFAFC\-)5YV[*H+X*7!-JI@C2\L^H^V"
L5PT+LA?BW1DTH6GFU<K4*ZA35`5J111Q*(Y,C*G*03E(F<ZU[BA#H46K_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pg71a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg71a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P'L`P$1``(1`0,1`?_$`(D```$$`@,!`0``````
M```````'"`D*`@8!!`L%`P$!`````````````````````!````8"`0,"!`,$
M!0D%"0```0(#!`4&!P@1`!()(1,Q(A0*05$583(C%G&!%Q@9D:&Q0C,D5]B9
M4B6U>#G!T6*5U;9W6!H1`0````````````````````#_V@`,`P$``A$#$0`_
M`(AM^_/OY9L<[J[+X^HFW=HJ=.I^4['7Z[!1$+66\/$0S%=,C=!LDM#G6$W!
M0`1,)C"(CZ]`SP?N.?,UR/.[-[`>1Y#]'J0<#^(<?H/IQ^70<?\`]'/F9_\`
MW:O?_P`HJ7_T'H/R4^X7\QR[\9LV\642/%(A.(.W22KQ8A-LHN=P5ZA%%C"L
M$9HPB)1=D(5R9(`((]H=!JTKY\O,'*JMG2V^V=FBJ535K0EC9\D:BHV4`0&0
M6:LT4VRECY1$?U(Q?JP$?0>@^=7_`#O>8"&;`Q:^0+8MZ@E+MIX5IZYJV!Z)
MV)/8(V,^E4UG8PZA50%9D!O87.'<8@]!:Z^U#\B&Z>[6TNY4'M=LCDC.4%&8
M6J]QKM;NUA4?P=<FW604HMX[JT.9-)K7T5F!P(*#4A$@*)1[>X>@O9-O]D40
M'N*;@2B(F,<2]H`7W3'$3&5[0^81]>>@['0'0'0'0'0'0'0'0'0'0'0'0'0'
M0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'
M0'0'0'0'0'0'0'0'0'0'0>)-Y9ZG8\?>2G<^JV=I^GST%G:T%?-#F3<I$6<$
M;/F_\4@F(H"K-R0Y>!XX-T$<(\\CR/(\CR///(\_'G\>>@XZ#GN-QQR/'/=Q
MR/'=\.>/ASQT!W#Z^H^H]P^H^H^OJ/[?7H#N,/'(CZ?#U'TX^'']'06\/LSE
M52^2O)Z1552I*ZX6GW4BJ'*FK[<[#&3]U,#`13L,(B7D!X$>0Z"\UY4_)U(^
M++'D9GBY:LY.S;@-91E!7'(.,+C08QQCVTR\B#*NL[)6K7)Q\LM'SBIO:;OF
MI5$".C$15X.JGR#3:UY\:[6,88?V`VVTIV1U.U6SLM6!H&S5OD*/?,:D99(C
M5Y_'KJTMZ#*R5DK:%A@A(L91PU!%$PJ@!A(GST$_4)(LYN+93#!VG)1DPQ:2
M$6_;K$,V?1CM!)W'2+04C"FDV>M%BJD[A$3`/K^705^,W><[(^%?(,MXY!\>
M.8LKYYF*C(Y"QA'XVRCC)9*^4QO&S<W'V$#3<DP9PR9X&JRBKI%90SA)1`I0
M)R;H'&X6\J.3+SMOB'4O-GCWV9U9F\V5'(%JI%[RG9,<3=+G"8X;Q:MGAV;F
MGR\J=>5C_P!?:_4I`9-9`JJ(F+VJ`/0*9Y/_`"(6SQIX?+L;+ZV6_.6#(!5E
M'Y$F,>6VOQ5OI<C+N7+=B_"NV#VP?UY`4B>^YY`&_N`)O3X!'DOY^<I8NQ32
M]DMI?%WM9AO5>]#4G['.L-.TW(T-6*U:D#/8BSVZL5YR>S,(EW&+)JBH1$14
M4.4G`&,7D)\=>L_8EVDQ+1,^X+NL5D#%F2:^C.56SQ)U0(];'5.FLW?,UB)K
MQDE'."&1<-ERD7;KE.0Y>0Z!!/(-O9CCQZ8;I6;,KP\S)4BU9RQ;A:5DH5U'
M-3U`<G2;R,;W23&3.F@M!UY5J"KPA3`I[`F,7GMXZ!Y\4]9O6L:[C72#R,?M
M4GL>^9.4G;%^T=(?4MG;9=$ZI%&KQ%4%DS@82F*8.!XZ#HWBY5O'5,M=_N4L
MV@:E2J[,VJS33Q0J32*@H"/<2DJ_<*G^4B35DU.<1_(.@:;X^]U\>^0O6"D;
M4XM82$;3+M,7.%91TF/#MF]I-KEZC*B8PD3$Y%7T0<Y?3CM$!#H'L*`(D,`=
MP"(#QVCP;G\.!_#H(Y-:?)/@_9[<C<73"EF<-LDZ=RE18V)VJ^:N(^Z-+!%M
M',Y)5E)$QCE;4^;>)1DAW\B1RH4/Q#D)&U!X34'M[^"&'LY`O=P4?E[A$`+W
M?#D?AT$9^)?)KK[D[>S83QZ&?NZOL/@Q.OS416K2]9-AS!`R4`2P34YCL2*=
MJB%,3.5-VT4-]05,??[!2Y$`DSZ"";;3RV9HU;WEU\T@_N3S^3[5M/*R#?"]
MHK>8*9"LY:$KTU-$G'D\>:%)K!OVM7AE)<6ZJI/X!RI"/?Z`$ZB!U%$$5%41
M;JJ))G5;F.104%#$`QT142$R:@I&$2]Q1$H\<AZ=!^O01)9$\F-PLF:\F8#T
M8U2O.[%MPI/C4<VW>!O]&Q5A7%606Q$',EC.9R+?G;5E,WZ*8'*H[CXTBXLE
M%0(X$AN0Z#=-"-_[1MW;,_XHRKK7?=7<VZX6"OP^1,=7:PURTI.HRWQOZU5[
M)`3];55:2,=)QWSD.7Y3AZEY`0Z"39,PG(4P\?,'<''=\#>I?0P`(#P/KT'Y
MJ"!1[N3_`+P!VD'GW#"4.`$/P``#]G01P;<^2#&.LN1JU@JK8_RGLULW;H0]
MG@=;M?ZT-LNX5XJ_TPVFZ3*JJ%7QQ7"J%."#F7<MBO#E$J0'XZ!(W>WGD^;5
MG^:FGBG6=>ZJZ<,JR.WN#1M7Z8BV,Z9*O&HR(-5Y9RF;VA8(F,NBN0Q!`0X'
MH/N^.?R@57?RS9ZQ&ZP;F'7+/NJZM.89WQ+EMFQ:S%7G[VM:`A6\3+1KAQ'S
M#.33J3AT5<H]HMG*(AQSZ`MFV6\E6URF*WBRJX\O6Q>RMYC7,M2M>\1HM%KO
M)UY(CE%Y<)Q^_61A:=36+QH5NK(2"J1#'4*"0'$>.@0^<VT\B55QO5<D2/C+
ME[.LY38R-UQS3=BL6N\B4F'^F7=OTF\>YD$8FU3L<V`A2MFBPG.J?L'@2CT"
MPZ*>1S6OR#TVSV#!MHD6MNQ[-JUK*.(;K%+UK*^))UL[<,CQ=VI$E[,BS*=5
M!4A'90.W4`@_,!BB'0+[L]G2(UCUZS#L#886:GH'$E+F+I)PD.Z:-Y:080H%
M!5K%JNSE0(HL4W>03B/(<E#U$`Z#Z>LV?<<[48)Q9L9B69&=QWF&EP]QJC\Q
M%DC&8OD>QTW50<)I+HNH^216;+D.4!*LB;H%S6]SM#VQ`#"8`]0`?WN2@/K^
M!3"`C^8!T#`=2]]\2;A93W!Q?B[ZDTII]F9MA6SR)G2+E"PS+6!8OIM[$"3E
M!2+A[4N_BRG[A*N9F*A1$I@Z#YODAWK6\=FO,[LO.X.N&9<94PY%,BEH]NI=
M?FZO%N%4VL?(-HRX2#`9T7+]0I%2-#&.0G)@YX'H&/V+S29*Q=@JJ[4[!>-W
M93&VL%WJ-7R.RS54[IBK,<?4L=7-O%O*M:+W4\>3K^UUXCAM,MU3)BW4,4JP
M<\\"(!+7K?L1A[;7#5)V'U^R"SR+BC(\2#ZJ3T2?A),Y%%6<E'R#-8"N(^>@
MI%)1N[;K`19JND=(Y>2]`W;;7R/8#TZSKI]K[D^364NFXV3/[.*;]&Z;-4ZZ
M5-`&R%MLPNSIII5MQ8%D6!E"&#L56`1]`$>@D%`QO453^TH<O'!A`#)CWE*H
M"?/H9,QQ*!3>O'/0,CWTWEQ7X^<+UW/N;6TH3&KG*U#QC;9J)`5E:>WOCATT
M+97J0?,YBHMVV(=V8@=Q&XF,'J'0.QK%KK=XKM>N--L4?9JA:(QE,U^P0SU!
M_"SL1*-R.64C'NVQS$>I.TE"B0Q3?PQ]!#GH&W;JY_R=K#@"]9YQGAAWGH<<
M0,Y=;C1HVTQ=3G$Z75(.0E['+07ZP/LSTV5./*5O'EX.L8P`7U'U!H>%O)/E
MK+WC?;>0J*T]NLDQD(:4O\+@^KY%I4AD:<Q=")O5W5JC'CIRG$GGC-H\ZQ(0
M3?4G1^0.5/EZ!4?%UY)J%Y0];G>RF.J/.8PA4,AVFB.*);IR%E[K$.ZTHBBY
M>65K7U7#:&4EE5.]HBJ(&,F`CZAZ]!UO)=Y#77C\Q/C&^1&%K#GVWY?SE5<"
M4S&E:LD-6;!*VRWHO#Q"3)&5[S2)OJ6@%4(B`G3;G,N;A,@CT#V<(6;+]OQ]
M#3V;\8,,/7]^1%>7H<;<XR_M84RB153LC62&`(UXX;*&$ASHB*1C%Y((@/0+
M&0P&*4Q1[@$`$!^/(?GR/KT$*/EX\N3GQ/0V,[E;-<['F*D9AMC7&M-F*I?:
MQ`K)Y&7:.9<8.P0TR/ZBWC%(5@LHF^0*<GO%*FH``8!Z#7,G^7K(^GC>HV#R
M.Z-9)U5Q1;K97Z*SSA5,E8]SQC&LR5E5.U;DR#(X_?.I2F,@%`50=.42I"FF
M8>X!#@0G$BG[.6C6$K'.T'\=)LVTA'OFIRJ-GC%ZB1RS<MU2B)54%VZI3E.'
MH8H\]!W^@:)O+N+B[0?6K(VUN9DK"ZQSBQ.L&L3:KM$Y&:.-MN$%3(KZ)@<Q
M1<'-*3R7?P/RH@<WIQT#G:Q/1=IK\+9X-\C)0MCB8R;B'S99-=LZC9-B@\9N
M&ZR)CI*)+(+%,`E,(#SZ#T'WN@.@\9'S\*<^9+R$"0PG$<_R9`#Y#(&$M;KZ
M:A3"`\`J3X#^(?CZ]!$BW204(4#)F*4Q1*!2%`QS"02'.EWG*7WU3',!DRIC
MW#^X80`>X`MGV[[<34^H>/*(\F3[R36XVO4CB>(R4DU3U0;'NBDE/J1K*,I*
M,4EFY>-7GD9UXHR<_P"\@0GL&.0%"`)@"(G".J7C7V#O=8Q55]\\M8<N-QLL
M+7(J9V7UAK50QN9_-+ILTEW5NQKG+*;J"0^L5`@'DV;)L3N+[AP$W:`9>3?P
M][5>+&^P49FZ(K]NQ9>W"R6-LZXY.[DL;W(&CA1PO&+/Y!!NO7;<E%(E=*L'
M"0`9(5#(&<(I**$"(Y<HE5-RG[7=PH4G:8I0(H`')V=YC&%,2F`2B(^H>O06
MY_LS_P#U+LE_^7"V?^-PO06O/NP9([#PRYT;_P`T(5\DMD/![#],-'@\<7'L
MR;!/?Y>17%5/]/,@JU+(&5`!Y29F3$!`_01%[,;TZ<;?^!S47QR8SSOCJZ;>
M93QQI/@IE16TFUKZ./,B1[>I)6F8N!9");P[*&J;2`>HN/HUD^U<Z9$E`*<$
MU@NMZ\8Q_L6P9B7$HRZU@4QOCJI4T\ZZ5!9U*J0<,U9K/E%.]4PE<+)"8G)S
M<EX'GH*;6]6PN%]6_NV==<T[!W^#QCBBM:4'86*YV0RX0T6M8L<;`P4,B[(W
M;NE%0?S$@BB0G88!.<!_#H++>O/DN\<VY>;(C&6NN><9YRS/!4BY7>(0KD#*
M34C4*-%O:E!W%X2TN8)).M-)*0DXQ(Y57;89(W:!06!`?;!A'W1D2C->&S8;
MWGKUF$=/8YFFIH]ZFT-(*,9T5`9O.\44WC$Y5#"J@3O,8I`'UXZ!=L2W7%$O
MX&Z?:]HW3=;$#KQZD;Y:5?/7#GZFDAC%Y$/&2+@%E7#M9]'M"HH(E-[H&[2!
MZ\%Z!"_M?];\J:V^)_%#7+2DE'RN7[-9LVU2IRC,C5Y2Z!=1:-JHP<&38L0=
MEGVT4,ZF<YEU@0EDR&.!2D(0&V?=24ZZ;&8:T7T>QZ]DPNVVVTJ\)6V#%JXD
M(=](T6GGE6[Z81;`+CZ2.4F@#N+Z(D546-\B9AZ!S'VY.[F1MH].;7@S.0**
M;%:*WG^[1E:9*`@,_'U\9=C1YCWPCFK-X_0B8)9IRW(")F[5(_J<YN0V;STY
M2OEVP93/&M@)VLXV/\AKVR42-:L!(N_J>%*%!+7G+UH=HI"`IMY:$A0A$_>[
M4UCRBA2")B<=`U?[12^'G?%O)8P&2:OE,$[&Y?I:D>BD5-]%$G9@MW(63.`E
M$R[E:?46(`>H)J`'P^`3R[U;15W2_43/^REC.59OBC&UAL,+'+.0;+S]K,P6
M;U.N,%#`<5I&:L"Z""9"@8PF,``'X@%&*!P_E3PM;Y>(O?\`M\^^L$CY$(*2
MA-W"-)E^WCG&0]A;06V2R+]I*F>':1-48Y&B7"")%UDE'E34.(I`)!4#T4$U
MA,4`((@0R)3)+'$IQ.)N[L,7M$0.(IE`P!QR/04;-L_%YE7=C>GRM;/ZAY)L
M^']]].L\8$E\!S$7+&BV-MAW^%#3<I2U!5$R;:0L+UL)V3I3N:JJ@+99(Z1C
M=!+9X-_-0MY":W:-:=F:^_Q+Y`M<XAVVS13)2'6KC"Z1=?D$ZU*WR*CE^TD)
M-Q\FLBG,Q"GM"W=+`LW*+8X@@&I>4FN-D/-WX";D09523D,@;+U=43MT2PWZ
M?$XG?28*MC@<'?ZHHK/*BY*8/:*D1(2^HGY"R^`<``!\```^''^8...@^.Z4
M-P<06]D1$43>IS"D3D3K@"A%T2$4,W)R4_J*//>/R@/04KO!3O3C_!'DH\BW
MCWNV3J[;ZQLKMKG#9/77/<C*M31&:+$^M*E8M\(RF#-XZ)M-BDXRNE#_`'`P
MM3.XQ_[7<"8=P6I\E7G3W4:TVC.F8[_A[7J>SBYJM<LF1\H9`@J$WOTE1H,[
M&K5X9*R3;6*5?0=?-VI(-2$.HD/(B)N>@='5+'"6^MPMIK4U&6.OV"/;RT+/
M0L@TE8B8C'Q??9R,9(L#J,WC%T@<ITE$S"!B"'J(]!J>8<E0V&,4Y2S!8VSA
MU7,58[NF2[`@P*!GZT31*O*VF52;%$I@%PM'1!B)^GJ8P!T%9S[7VYS&TV-M
MW/(+E&13M&<-J-G)$E@GGL4BT>P])I4?]%3\>1"Y2=J%9AVBH*H-$3"W;*'-
MVE`W(B%J/M*4@]QNPRHE^8X^IQ#U*!R\`7C@>T?S_'H&^!B/#^(,EYLVB1AB
M5VW9"QS5FF7K*S:G71E:QADMLE(:0<(1L>I)/Y6+C;2^3'O,JJJW(DDB4OMC
MR%<+[:S+,YO+EKR@>1G*CH\IF/(^Q<7@Z%%,ZA8:I8.HU:C;-0J57FRZ""[6
M-BD9T$R&4`'"I4RF7$ZG)N@M?K?,43E]1*(F*"?RF,0O/'S@(<=AP[A`!]>.
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M@B)5!8Q:X%$%!*`A7'^UDQ7E74[=WRXZ797D8R=G\363'%@?V5))0DA:)>8L
M%ZCW5A3]Z2?+HQ$S',VCI-NMW.4%%S>Z?N/V@$ROW)#%1UX:]PR-S-4?IJG$
M/3@NZ18D,DVGF"BI$3*JHE7<J%Y`B)>XZIOE`IA'CH'$XDR9@K%7AZP9=MCY
MR`B,(U_Q\X02R>>>>)HM'56E\`U&->PITBN$'"[ZQ)NP9-&R0_4.W+@B2(&4
M.0!!BOVQNKN4]9O&?!(Y7A)NIOLSY2NV::72YQ\Y</JWCJUR!4J888)9`@55
MI8H-HE*E:&5.N!WICK@DL8Z)`A+\F^OUM\KS[RD>0;'<A+K3'C,N5,P]IT2$
ML*TY7IYO@&4+?,]VN.B6RC,II2R20"V23#M*@=N8P`L?GM"X)XZMFC[CZ,ZO
M;,O56SN5RUB"LS-G<M4$&[=>ULT%H"ZGCFO=RU:FMT(\,"9_0I2=H!Z=!'O]
MPI1Z9E33;"6+\EPMAGL79(WKU;QWD"+JJY4+*[JMVF)^O*NZ_(*'$K5>-D)1
MLZ56,0_M(-U3=IN`#H(:,(9JV8^V9V7B]2=M)&T9G\2&:[8[8ZZ[#@P<33[`
M<A+.C.2U^?1;E=.63>/6=`$I$&$0]H/KH_W">XD`6J=P+1#VK1'9VU4>8"RP
MT_K+E2<KMAJ,C'=TLTD\<RRL(\@9%Z+J'<*O2&**"QP%`JG[Q?B'0-6\!Y2)
M^(O1\H<@8^)2+#W)E3,8RDW*J*F/V`!1.=13N,;_`%AY'H(2<LQ$OX`_+Y6<
MWU%9A&^.SRD9"2K.7ZZK&)QE;P'F9[)B\0E85K%N2Q#%LFN_!V!_81[V*ZB0
MF$40,(2OZ],WN_?DJRMME:GD?8=7=%91]@+3J+;*D>U6VYVEX-,^9<\,'2:I
MH^POJ]$R_P#+T4L)%$VPK+KMU`4(!N@G9`I>"AVEX``X``#@./AV^GP#\.@R
MZ"H=]X@:E?W*=44[$60_F=3<NEEH:S8JH1Z$G_+$\:=/+^WSWM_Y8^J!,.##
M[PEX#D.@E3\[=AHBOC#VKQI:"(6BSYFJ#3%N)L8(.63ZXY&RY:;168[&M<H]
M:050?6&;;VTK5Z1-$RBB9$#&,`]I@(#Y]!\,V_7;275#!-_F7-AN^(]?\5T"
MV33P%@=R$_6:?%1DHNY!P[?KE7^K;F`P&76$#!QWF^(@ZQ8X)J=YC@':3O$3
MF$I$D@'A0X@`\'$1$..?AT%;KS'8^_Q*]G,%^(")LTA$UZ3P=F;;W88\3-GA
M'L-%U:(=8\UN"7.6,D2R4#*YML2+YVT1(LY]B)[O:+R"I0[_`-LKMU-9ST*-
MK7D-LO%9KT/M\CKC>8B4DUW4LO#5U5P6FRB[9TV1=,D$(M$8\2F.X[E69Q[^
M?3H+'+;CM,!14$I#F('N"(B(E$1,8##ZF`1-Z?T=!V.@\63S:0+FK^63?:%=
M2+V86C-@+"FK)OV+>.<.3+,XI?W'+=D(MV_)%NT@IC_$*4!'X]!%.*JO`D!4
MXD[/:`.XP`*8*>X!>WG]WW/FX_/H/0_RY),I+[-J@NHE\QD"MJ!2V+MPR<)K
M@V?,LG.8R39G.@!?:?,UBF06(/S%$#%-^(=!YY9C?.IW@9(I1*G_``D_;!`Q
M#<E,*?/=ZB'(\\#S^//0>@A!Y(B]R/M"KA9-C$V=KL&OR3FET6WW&:.YG6-H
MQK<X3^0;#$S[TR,DSG"1EI1@T6B2QBN628-/5)<Z?0>?(J4"F+P//*21OB(^
MIDRB(>I2?`1_;_2/QZ"W1]F?_P"I=DO_`,N%L_\`&X7H+-7W@8B'B-?``B`&
MV!Q*`_M#ZV4-P/YAR`#T#EL*:`:Y;R>"W4W%>5,=8W//W#QZX"3K&2YFLP*=
MAHER8X2@'U9N+*UJ,#RT0I"20>XLNBJ10&AET^X"JF`0:U]I5L5G++VC>:,1
MYEM$S>H[5C/$CB'&-QFW3Z4</Z8$222"':33_O4?Q5>?]Z+0@*'!NV,1,.``
M"@#*]U6E7DOO`]/(BXXRC,LP$UK)4H5W5IF$C[!&M5I:KYR8LK4ZCI-NZ:"2
MH/%TY'W1)W("W!0H@)>0"V+7=,-3<<;`16T-&PMCG'69T<=V/#I;Q3XUE333
M-(N,W7+.]K\U'0A8V,L#E29J+19LL[27<,^U4$!*#A;N""+[O,YD_#Q9"%%8
MON;)8*(X[N"E5-WV=4WHEPD8.],HF#@``X?GQT#+\R>#9CF3Q#ZO94TCE,RU
MC8O'.),7[`0&%+YGNW9DPIE!XPKC6S3U(-CJVVB<Q7''LKD#N8]NP9-&Q7*B
M;1W\HJAT$W?A6\K5%\G&M;%23098^VJPJW8T[9G"(LSU]S5K1%G=Q;6Q0T*\
M!!RSIT\>-,;V2IE5C79%&"H%!(IE09=Y,9.3N_GT\(>(&<S)D_D!EF;/<I'.
MG!B5=5B$?/54',>V(/!K2\&)]M0>P"E;)$`3?`.@;WN9D&'\,7G+Q-N4Z9P]
M$TM\D=.-B79BQ%AW"%<J.4*DHD^0OT@NT$"-9]VJ5L_>"D@NJLP;."@41,)>
M@>9X<2RN\VP&UWF'R'"V!I'9ALDKKAI7&61NS*V@-3L82940M]-2>)!-Q(9.
MN7U#M_W+E`CTBR!4_:(0YPCV^T7?6"C17DPUMG1J:[['6V;ZS/EHI^J[D33#
MV/0I[]5NF<[9=>N"2J%%FX%LB)UO=#N'CM*#L_.?%/=]=L=`/#O"W2^TJNYD
MMTIL?L=-8W5APG(C$^(VRKF/03>S?OLXZ60F1)),%U63PB;EN0XIJ"4J*@-A
M\FGV[]IL.DV8;A">33R,;!W?7NHRN<\8XWVAS2PREC-2U8P@I":50C8%O7()
M6.MTA5&SR,C'S5X0C-=T`G`R?>7H)PO"UO>V\@WCPP!G>1`4;\PA$\:Y=8+)
MN/=99-Q_S6[&\(=PH8P,K(NT"29]RJHIM71"*&%4#!T"`>.FY`CY9O-;C@6!
M4R*Y`UKR",I[P\`/]EAJZ9J8HCZ"H5,%/R+P/Y]`@'F;\.MLS19(/R/>.B0/
MAGR,:[K-[A%C5$TXR,V'95L5GS>J3;$I$8IY=7C951!J[<`=M+(K&8OP,F=-
M5$(FJ)Y1L6>3WRC^"G(@Q-BQ?MIB3*.QF(-H=?;'%NF[#'\VPQ#**MK'7UI&
M+,Z!I:9[]4322<.2R#$68M5D@,F*ZH7S2?N%]!#Y2^@@`"'H'H(%]`$/V>G0
M0=?<796R+A;P\[?73&<])UJSN(Z@5!Y,Q*)C/6]2OV3Z93[P5@M[#Y:-5=TN
M9>H%<D[!;J*"H`E$.>@3+-/BITP\G7C?U/C,4),<-2%1P?C&\:B;!4&'A(C(
M>-^::TF*>H]F(-C'NAK3^8?)NI9@V,W46?$!9(47!>2A7MV4\E>UTAI9F7PD
M>1'!Z;[?2US%`UVU^S!;X=PM3<T5BR6IG5D,X'L\RN:/;VFL,42N_P!99JB5
MQ[G:*1'`'3$+R^GV"4M8M6=?M>R.@?JX=Q+2:#(2!%5%D9&9K\&T9SLBU46(
MFL+)_,D760`Y2G!$Y0$`$!Z#;,\8V;9JP[F'";^77@H_,6*KYB]W,LTRKOX9
MKD"J3%1>R[1-4#(?4,&TK[J!5`[%%4^T?B/05,/M?,R6/5^R;<^'+8TL+C_,
M.MN7)ZS8X834A'1,I=Z]9I%U^MHUQ-VNBXNCY1R@6137CR&1_2G*9BE,4!.(
M7&OXZA5'"0>SP54OLJ=R953E#L1,KP)O;3(41,/:/(>GX@(=`C5GMF+<JSV6
M=:R7<G\])XGAI2_U:.!4LO7,?9D/;ZA5K/\`5JL%HQ!S+K5&9*S(*AU`.U$Z
MZ/M"D)@J4_:U'L.HF;_([XPLZ0AZ+G.G9G2S?%0,P]*VE[5573"-J82U:%4S
M<EAA"Q4<RD1=-40*+=ZF<>2G*4H7/3]Q@(H4Y2MTQ4/VI)@0ARB;Y2+`MW\`
M4>1$2E[A$/3\A"H!YG*/_B`^:;Q,:9XS+&S\GK!/S^SVQRDB1[+5.HX_/;L7
MVMM%WN,"-*S9FLT7C%2.:^^94RCF=;)"4J8G[@>7]S#+,_[I>IV.UH,TG'9!
M\B.ID>[:@D@>-/$0MP]QU&O6'!AD6<D1Z0A4P*8@`GP(<`'0-X^Y#UTR5@V7
MU5\PNI\='0.5=%;?'L<LA#,&<>$]A!\\8)I_S`WCT6B]HA*T)#,E6+A4R)(M
MXJF0@AP407G33+]6\PGDN=[F5%NO:M,-%L)TVGX`<3T<W5@);;[-<2PN65K?
M`E59%3>3>*J.=E`N55"(N(]^L8S<?;<"/0-GT,:SF(ONF/*+C-T[8/6F5<#T
MW**BJ:ZB+@K9TWH]IAT4VQN"O3M$KD=%PIZ^V<H`'Q'H)%ON4A$/#7M_P/'-
M;@`_J&Q1_(?U]`YK2O5O6S(.F6DF0KW@'$%VO1=1-69'^:K1C^KS<^J^B\-T
ME:-<GE9.,<NA<LE6Y#(J"83)F*`@/(!P';\L&WS#1?0'83.<3,,Z]>6%-=4+
M"B9DP.]ELPW--6M4>"J\>FZ9*2,^W=*J.T$_<`H`R$X@8A!*(0X:5?;T6NGZ
MR8\CK3Y/O(QC&S95I3G(&<,6X:S75X+!LC>\OLDY;(B\90IG'$BV.$J,G[+Q
M=V+E954AA.8Q>T`"/[[>#/4WH)Y5MSO#+E"[76SU$]@GHS6Y[>)F9?F@G.(#
MV.Z1E2B8=U[,!6F]YQC<7<S(J,FK9)U)L$S)$[5R\!-C]Q48$-<=%SBD"PG\
MM&B!%$CF,B4P$LUK4*F91,2"J4#!Z=W<`#Z\>@=!+SM3JYAC<G"MZU_SY38.
M[X^OD3*1CMC(LRN'4.Y%,X1]GKDBJF<8&U0+P06;NDA*H4Q.WGM$P"%)-MN%
MF3P"MMD_$KNVO:LK:@V[!67Y;2+9".J;I*?<GMU:D7;.@+O%91:%<L/UA4S)
MPS1-W1\FJDX-[31?LZ"TOX*YP+%XE-%W_P!$WCR!A2&CS)-B$0*L,6N^CA=J
M%3`I3KR'TPKJF'U.H<3"(B//0(Y]QQBB'RGX<MQ#281YUL<4]CEZ&7?L47PH
MS5,E6ZC)Q&'6`XQLG[3Q0J3A/M4)W"`"`&'H%8\&M-IU&\1^B4+39!*2@G&$
MHR=<331TR7"0E[!-RLS,G6=0*;=N_?MI1THTYX%9--`$U3&,4>0E3:S3%XO)
MHQ4FUD%(UR$8^3:.VKU*+E4TTSBP>)M%5E6+D$E4A42.!3$35(?M#N$>@V5,
MW<0AOS*`_P"L'X>O[P`;_+T%-W[R\/;U/T9.G\AO[[T0IR7Y1[_[,[>/?Z?Z
MW(!Z]!:FC-4=9(7(R.7XG7_#L=E1N]F9)OD5ICNJHW1O(V%=-S.OT+&6,"51
M>R[A(IW*I50.L<H"81'H%J.LDBO]$FJDB9))-5%LD)/?*CW=AE_IP6*8[,IO
MEY[>`-S^70?)L,O$UZ'GK),ODFT36XA](S#@5BG*SB&#562D'#T%7!"$*FW;
MB?GY3@4.`$>>@I_>/C27(7E3MVXGE0=;T[@:W1^T^9,A8QP<KKI-5_'[YWJW
MBF10JU'?JO[319:3KZLM)1*JY6L0LD";LBJJZJSI1<2@C&N>%WW@Q^X%I^*;
M1L!E;+6OODPQ2^<*9*S9923-VG\VA(NCI2N5[4DRA8*=M"UU921TW`-RKF1F
M6_>85!,8P7?E55R'3]@P+"!#`LF04CB'!NT#$3*9$PBFJ':;D>.WG\>@Q_44
M/=[?J#<?EV_-V^YV^YQW=OL^Y_!_=]SO]/V]!XTGGT53/YD/(4H3DR7]X&62
M$0'@@JI0,"FJ0Y!]#`55,?7\>.@AZ-^\/P^(_N_N_'\/V=!Z%6(\9V7.WV=5
M>Q_KKBR\V^S2#BZ]U/A4SVFRS<]#;)V0MSFXME'(F='8NK$5=9NT*4RB+,0`
M>>SGH*3U:T2W*MMG<T>"U+V%E+<W=*LG$2.*;NU<(+IK$;?[VZ=0R$>@FBY4
M`AC&4`#"/(CV^O03#^0W9B_:2Z%8Y\$$+$/8R>J\K!9HW;M4LU=MT9+*=I0K
MN28+$E,*Y*"2E;QRP"%<2[\@G!Q--?;0$$DU>X*VCCM]TW;W=@\"3N#@W8)0
M$O(!Z?#\O3H+=WV9X!_B390-Z$,&N%HX,(=QAYG8KDY>[@.TO``(?`1`.@L"
M?<=N=C]U&47X\\5ZR;,V*G5V;J&6;WD+&N%%<BM+HV6D4XJIEJ=C_4FD)$,H
M65=N%)-%0/KE#$1(GPB=4W01U8HS'YA*7@F+\?BK#>AMABDX^C,)2*=/T*@$
M,XU7%C6)+7$(*KY!F9D()R[7BG*3%%VL)A29E2(4>X3F`)B].-J*UXV=<ZYK
MQKUX=?*3%8ZI<H:4MD_8<65A[:)F5L1TW$U<K1(&GE5)Z5DWBI/X#8G)"B!$
MP*4@AT$(>[%3\J>5?*"U\G6N^J.^=$S72TZW3</4@^MU>39U'%[&O3<<^@+=
M(RLR[@[FG-LYB:!XGP'U"3WVA$G87D'AU7.'F!R#LMK#?-U,)[V9;QMKC>I;
M,K;!N'=+(#$K2X6M6F3]+KDG:9IE;E&$ZTJ[B=469MUE""B<3CVF[@$`4[S3
MY)VW\HFLM3USJ'C$\C%%HR&3H*\9'9KXFI3>X6/^7&C[^6T:W*2D](0\6A&/
MWZJKL5"&,Y`Q"%[0*/(."\;V[V\NI6J^-=>LY^+SR#9%4QFE(5*L6*JX/IE=
M5KV,H>+%2GM)INSLA4K)9E'I?IW:[4$D_G]X0$`$HA'#L;BO/:6ZA_)IXW-`
MO*!K#L[:HQZ:]5AQ@/'LM@K(SF9KLE'24Y.TZ5L:*KE[8R.&HG15(5LB_2+(
M&*"Y3=P)^1+S:Y@\E6M6]60=-MJY7)6&*E&T.%CI;!5)H6*V]7?E,I=:JX5?
MR[O]!D+(>2?NSSHK&;-G8D333[3!P$G7DFR=9_*1K==-6M@/#WY1,=Q\?;H:
M>H.2:30,=VN8B;+7'*P&FH<JL\9`(EXV2,U4%0IA=MG`F+Q^(/'UYWOMNM.$
M,68`Q=X>/)E$T+$%%KV/ZR13$E+2>K-(&/28EF7J;>R$:K3$\LBH^D5N"@H^
M6,8P")N@KFZLXP\D6@FZ6Q.Q^I.BGDF;5/9"YNW=ZK^1,(8DEHZ1KKN>DK,F
MJM!MIH'K:0KTG..`8F;K)G,D8Q3"/<(=`ZW6^V^3.E>31'R.[-Z4[U9JL$OB
MVT85E:/4]9:[3V%+QXH"SBDIU#BT"V5E47X@:54*8AW0GY,(@4.`G/L7E2RA
M-PDM#27AR\F$LPF(J6AWL2YPU55&<FQD6BZ#B.=D5M2C;Z5^582'[_D`!'NY
M#GH*Y/BTJ'D.\5.1I]##VF7DNN6M&4'-AM&2<(Y#U\H,C+,;6TB2,JC)TZQ1
M%F*PA)*1<+B#P4R^R=!HB5P'(<@"VZ4YG\F&`=[-A=OK_I9NA<FVV%DB"YDQ
M0EJXV1EX%C1F2Q:Y$42RMK*VC?J(^'.0BHK',@/<8>1-V]!/"GY9,PHE*5+Q
M`^3<A2]P%*7$=6`"@<_N'``_G#@`,?UZ"&3(.-Z5<?)CAKR?4_Q!^4W$>:<6
M6N2L-SA:KB&@J4O.;Z3I3^GMYNPQ7\RHK5R>B4IIP==ZCRI)]H"J'</>(30#
MY;<PE/[0>(CR=\@4W(!ARM]@`41`!(H%L[!$0_\`B#^CH$@SQOG9MF,.9&P!
ME;PX>2^<QSENI2U'MS%UB:H<?IDLV,D=5+WK.J0CAOWE526X$"+$#D0$.>@K
M7ZSU?SM>/2P)87TAQOY`'NH3ES,KQ$;L=JY6,CO<=M5Y!VM#Q]9HYK.+:)>J
MJJ`I(JLG";0Y3?PR``=`H]OTZMFS-?R0MY`_'OYDMH]F,BMHV2A=P6%-HE5D
ML&/XA192.HN"L<A8R(5R@-)!8RZC=\*A'7=Q\H%`W0*SH9L'YQM&;=7J"^TZ
M\F^S&I$*Y>MBT3,]$Q?+Y9C(5NW68PJ-;R,:566BXXO*:XQW)@3,0P>YP8!`
M+`,=Y:<Z.DO>FO#MY+8Q=.1DVXHI8SJ<J)4&3ERG%O$U$+.@"B<DV*102@'"
M`J=HB<2B80A]\HN((K>ZY4'/!?%CY7<,[94:L1DWCK/FN%=QO"7,CQN\(:&I
MU\D7\ZDP(Z@TDR&(LX,)V:)CI`8W(EZ!K]5V%^ZFQ@XK^+*'BS9#*%;+(2*0
M9%SC@3$<S:0268I.C(R]SDY)(1!@Z<D03=+)_3K]JOL@8"AP#S?&/D_:W2MS
MG[+>R.@_E7V9VPV>L%7DLU9%F<2T:08MF>/&,E"T^FU.5:6AND\IE>9OUQCR
M)D322(Y,4A0`.@[.]&+I/R.Y1QWGZD>/[RGZ7[EXA9L6F/=EZ15*1299TR(1
MZYC*K<'+VQ*Q\S!-WY^%7*H&69H\)@!TCB3H$4#9;[GRBP$32[UA#-,_`.4S
MLW&3<7X0P1>\L,H-FT=PI2/(YS(,HU:S2*JR,@9X)?<(9+D@>I@Z!\.CV0_[
MBU)N4Y4O%?Y4,K9CRU:F,SGG/^6*)6;+GC,EP*V2,YFIYXM9!784YLN911HQ
M;&28MC**$(D!AY$$&\KTCNKO7;M7YS&NDV]V,R:MYZC[K!PS;%./9=C-WEF^
MC14ODQ,3,VN@_P`=Q$0L@DBDU3]UV<78E`!1#D))LJ;FY6R=KQ=<39M\5N\>
M4(J^4I?'^0F,-C2G.$K(-KCI)E(R$96G4Z5(L:S49BMR;D&QC-^[DRG0-?\`
M'WGU?QT:LX]U4PQXB_*0]J%&5DI)_:9O#-&1LMTL\]*.)6;M-D3B[(B@Y?N3
M*D0*?M]U-FV;HE#A(O`-DM]4W%R+Y+IKRI8+U;WEPMDJ+PK_`&4FQ!E?7[&Y
MZI9J=%0<:M(UQ:4:S:UCE%K1*QK5PFN50'S9=(6[<Q2$+P"H^3W/NU?D,TW5
MU9C_`!V^0W$['*+^N)Y>LI-?X&R2):[!.$'<Y#U2*<6LR<6XEY0@"V=.C&.#
M4O(\']`!1]!=X-WM6-<Z3KYFOQW>0[.1,21,71<<7N%P!!5*</C&LQK>'JD/
M;V#BU'CI"<AHMDBW*NV`I5$R!W_B(@C7E:A-T=^F>(F*VI6XE5P[BC(]$V"K
MF+Z]BS'%OL=RR71G!G%>@+XO*RJ?Z)&E</505(`G;%0>*@IW`@("$EE?\I^>
M6-;BE)SQ&>1TDPS:L64S'16*JBLV+,(,$DW1(1-"U)('@T5DA!-<G:D8`*`!
MQQT$(?D:Q]ES;S9#7G=C7;QW>2K5;8[7>RRLN:WU77K'9IG)<S9'%8&/F[XJ
MK9!>6>(JT94CL5VRBASK,'QVX!VF``!:-\3^1'R6:VXQJ$UJKMWBE[K_`)%K
M.;W'Z?ANET_).1<Z8L4EY:A62E-[7.2,+$55A'21R?3G**CF5`A/1(`$0E!U
MT\C.XZV.XJ`SCXV-T9K*E>AX\]KML;C"NTRK6A\X4412-!M).Q+BK(-$DP,^
M[2D1!4PF3#L,4`!"?(1/PWD,U6R?@W8#Q0;VR,`LTA5:M,URDT5UE.H6F6+&
M2D?9L6_53!S`ZKCHZ(2:1U4VJI45VZI5"`8!#<=)\XY3T>TUQ5KS!^.S?R^P
MVOE!A:^E(R5-HB%TMJCEZK[OZ37HJ722?+,5G)NXB9B"FA\QN?4>@1'R+YMV
ME\BFGMVUMI^BWD&UYK&2;%#U'*LC(8CI[^]6+&@F3>2T)68EY/.6C6/EG2J*
M;EZL8HII(*%`!$>@WOQC9?VQU&UV@M0[?HMNCD"'P)$FK%`N5JH^/*:E)59E
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M.*YC-]&JLRN6;-M:[3&UF4:1529/&BPNG!`!4C<_>0OH0!Z!F%WLN0:]Y/4=
M\C:1>8*9N#;$4=B%[BBD-J=/ZR2<<LBW,UGR>W8VRA5D")@9ZP33^F%^)W!Q
M$XB7H-U\AVS.Y^QVO4UAG%>FOD-P4PRI&S-&OUCH>&,?WN]HUMZV]B42CEW%
MB2_0"23)<S=-\F;W0*8PI<&+T'4T2VRV"T4U/PQJ5/>+_P`@N32X3K"==@;K
M2,*5J+CYBN/W3BQPHS##^9VC1"VL6LR#>5!N3V0?)*>IC]YA!GOEO-D/RET[
M!3`/'#Y1\#9#UXR4ODW'^3X#`M.F++$R:IXA=1M%KK6M51F91_#-W)1+R4%V
MR9A#TZ!8]I+%N=LYI6]U+V2UU\F2N0DIJJ7%IL'JC1:E39N985T&EA@X.PL$
MK`A'NYTGT!RRB!N$%))0G;\P`'03I_S7<O[@GZU_*FT7\_?W=_T/]!^FA?[X
M'\P?RM_+_P"O\>[^B_VZ<?\`?GM=_L_JO^3H/)>\Y%E8W3RY;\6.,0=-64EG
M^?\`81DV_P!(Y1*UC(6/%5XB!A(B911L82\B(^OJ(\]!$P/0>@%BC+&1:1]F
MI#W:C7ZQ4&ZQ5AR%`1EKHLFYI]A8QL?M'=&3:.;355-%2+%91BV(!U04!9<>
M15.<3G$0J!XT\IOD9Q!86UJH6\&SS1^FNR5`L[F6\VY@JHQ<IO$T7D/;IB=B
MUVYU2<'X1X4*(E-R'IT%UCQ_W?4C[H;5/(V%MU\:U2G;Y8"C"K,L]8^81D+<
M9N%GF7T,!D]F)/IW$VUB9=FFUGXEZ0S/@[7Z<Y1<&]H*.>_ND^4?'MM5EG53
M+Y6;JSXZF4R1UCC$GGZ+<*M)-4I.LVN!7=(-E%(Z;BGA#F*9,ID52F2.!3D,
M7H+$?V:Y#H>3')[8P@(%UPM13EY`Y1XFX8P<"(<=O)Q]`]/7H/3_``3)V"F!
M0`G!B=A>2E`HB("``40`/ZN@"I)D("92%!,O`%)_J%`!Y`"E'Y2@4?AQ\.@R
M$A1'D0]>..>1]/41]/7T$!'X_'H,/82$2B)>3%$PE-W&[@[R]IN#<\AR'^?U
M^/0<E23(!@*0H=W'?P'J<2D!,!./Q.;L*`<CR/`!T'`HI&`I13+VDX[0XX`H
M!\```XX#]G0`HI#SR0!Y+V#SR(]O''`"(\AS^/'QZ#+VT_0>PO("(\\>O)OW
MN1_UNX1Y'GXCZ]!B*"1BG*8@"53D3E'D2FY#@?3G@/3\OQ]>@Y*BF7U*0`'@
MH<_$>"\<>H\CR''08%;($,)B)E((\_N\E#YA$3<``@`"<QN3<?O#ZCZ]!D*"
M)C`<R93&*`%+W!R!0*(B42E'DI3`)A]0#GH,@3(''!0#@0$`#T`./AP`>@?'
M\/CT`*9!XY*`B`B8!'U$HB'`B41Y$O(#^'0<`BD`F$$R<F-W&'M`1,/J'(B(
M<CP`B`?D'0'M)B``)0X#X?Z0_K`>@SX#]O\`E'_W]!^7TZ(\").1+QVF,8QC
MEX`H?*<3"<O($#G@?7CUYZ#\2=A>0-W>YWE*/'!SI`J(B4G?V=P)@`<\_AT$
M?`>4SQ_.=CF^I;+:+%S[.[NSDIS*EM9U)PFM=56R[@*6:93$8(UC<%2%(&?O
MBJ"YBIB7W3%*8'^'_P!F"HE`$OXONJ(]_8=`0(!E/:[#"=0_'H'!B@0!]>..
M@UNPVRK4]NQD+=/U^I,)>4CZ]$*6"49PZ<G/R9A;14,T,[422=R3LY>&Z20J
M&6^!2\AT#<[UN[JMC6OYMN.0,RU:F5[7>Z5_%^89F>%Q&H56\VE"!<52N*J.
M&Y?U.7GS65F#$&Q5O>56]L@"?N``4K#>Q>&MA/[04\,7N(OC+%.0)+%-_<P1
MG'L5V]PL8QE):`4642334<Q[>5;]XI"=(IS"F(]Q#!T"N*+I,V3F0DE"E09-
MUG$@X41,!/901%4ZITB@)RH(D2$1$Y3#P'RCT"6X4SSB#8S&L=F+#-Y@\@X[
MD'5C8M;'"O`<LOK*Y*O(*PMG)P.8S=U%OV"Q%$%"]Q0X-V^H#T#0,)^6WQX;
M`Y8-@[$FSV/[+E!1R^C8VMNEW4*XFI*(>-HUQ%P;R>:Q<;,R@.#^C9JJ<ZO`
MF(4>!Z"1-XZ:1[5U)OW+=LU8(/'ZSJ1$&R3!HW2%P]<NWBHE%FU123$Z@B`%
M*0OX@'/0)AB_..*\PXOB\T8QN<3<\6S))MZQN<(Y,^B':4#(R$3,J^^W#DC*
M/?Q:XF4``3`B8F'T$!$$TQAN;K-FFXT_'N+<L5>YW7(.(G6>Z=$0:CE1S-8<
M&?3J)+]$O"(&0<5M]:7/L-7!C`1<2*"0#>T;@'2$'^$4Q^PR@@7_`'D.T"^X
M`BF`)B`<\<!Z`/=P(AST#><F;68"P_ES#6",C91K=/ROL&]D(S#E/EETPE[_
M`"40*0R:,.D=4#'%M[I$C@(%Y45*!1]>.@7_`(!0HE$@)I"X**H^^58I!]EJ
M)`4Y4`B9A$WME[#<@;@X!\1Z#D3"HHJJ=N0XG(*0E`R8E4`@FY1$7`HCWE(/
MS?$GK^?/(<G*JB`F(D4J92\G)[9C^ZF!0$B8J&,1N4QDN2<AW`!N`]>@.XBA
MQ30]L@J`)!`"^Q[9!(4"H*&(0YDW:9QY`H@7T^'[O0=68>,H6/?S,N]81T;$
MM7,D_EY$R;.-BXJ/04=N7KUTL)DT$(ML@HJ=0YDR$)W&$0#UZ#YU<FX:U0D/
M8ZS)1=@J\ZS!Y$S,,Z93$/*LGI?>9RS.0CU'#-U&N?B0R(BD'/<!A#GH/N)G
M/R":1"J@!3',82D.D)B)`W$2F34,*(*@(B4I2A\I#!QR/0:TK::A&6J%I[VQ
MP,?<;!'2$C7*J\DF"-BG8F%]M&3=Q\>Z<%D9!%A[B(N%"$'V1,4IS?#@-J,F
M"(BL":29`4)[YA3*7DB8?,<QU!33*5+GY!#N'CT#H`J9CD(8Z29A`3BB4$B@
M4H]P*I>A1.B(#P!BFY+\X!^/0?B01,JH0X%.5-,G<7E-0`%+@$5"'#^*=(RQ
M#%`HD$04*80_#H$ASAGO$>N-,#)N;[O%8ZI2E@JU+:S5A<_3LWUDN<PWA:E!
MMDUSD57F)>:=D122(05#F'M#X=!W<VYMQ7K?C2UYESA>*YCK&M0;I.[%:["Y
M391K(ZQR-FJ9.3E6?RDM(G10:M42*.5US%3(!A,'0)QK%N/K7NC4YVZ:T98K
M&4X6K6!.`M00JRC>4@9@C0CP[&?@W!$IN+<+,G!3HE702%4.!*)B=`YW^+\Y
M.X#=Z8*=AC=HD$1$2G%8O:L*0#\@`!!$..@X,)15*`HB!SIA\Q1['!@]`.H4
MI^U<Q$!'T^4?B`_'H..XH*^ZLE[?M"*B9P)[8"!BE!1-4P\&`!.;D.[M`QA^
M`\<]`D5NSUA_'^2<?8?N>1JM7<DY6C;/+4*H24BSCY&>C*4T1=V)RV:N%2J%
M08-U!.!Q`"<D.`<B0W0;Q4;'!W&NQ]HJL_!6^O2K95>'LM;>-I&.G&0+JIJ+
MQ\BU<+L%&YE2"05DW"I#'3'U_``VL5._M*@)_;("2AU"B)$3)^AB>VH!3@8#
MI@("'P`..1#TY#6&UTK$C9)>FL;'`OK?764=+3E::RD?(3\%'37U(0\G)Q"*
MWU[-H^.U5(U,H0GOF*8"";@1Z#:&J!CI%^J(`J]P*CQ[@%`QO7@HG*DIP(?O
M%,'H(B4>>.@[/TS?CM]E/M[/;[.T.SL[/;[>S]SCV_E^'P]/AT'BW^;2$:5W
MRP;YQ3:,)!)1^?[`@$.E-3-B:-.^-B5RF_6K,Q93LH59PH8_#AJGV=W:4PE`
MHB$4!@`#&`/@!A`/Z.?Z1_TCT'H8Y/A6L-]FI2$&C6-;INZ=5)=0D&T(P1,Y
ME,L.W[EU(D$`!S(N'*YC.E@`#+*FYY'X]!YZ!CF`?WP'@0X,7GT_'Y!$`,4.
M1_#CH)@?`_L-D?7KRLZ63>/)EU''R+FNC8/N#(KX[:+L%#R[9(ZF6:'FV9A,
MVDVR#*4%XU34*()2"""Y.U5,A@">[[UR'HK/;?4>Q1J<0CD64P)88JU+(+F.
M^7K#*]3!ZLYD(\BG8"S5R^D4R+'3%0Z8E+W"5-,I`;_]FOP/DSR8(%$O.M]K
M$2B;N]?UN%YX$?7M'XASZ]!Z@@?#^L?](]!ST!T!T!T!T!T!T!T!T!T!T!T!
MT!T!T!T!T&@WQQ)L:->7D2BH]F$*G9WD0S[Q;J+R"$$_4CV*BR8_P2J."%*4
M_/<'///(=!5<\8D!X[&_@^P_FS>"BX\K4:RV$LMVRQ=7T?<EKK%;0J;.2_\`
M*S@+15FC?(:$ZTLZD0Q$(E<[$[0IBN%#-S/.@8'HYLIY(LZ>0>A[0PV1MHYF
MC6SR-9<UVRG`9"SACV"T46P6BG(-:O1<*X1MTU!71[DVIQ\:!_JHQJ[D"J,"
MBHJNHNZ3,##K'K%F;9C4#63:O(N^6\EAMF3/+/9\!1%'L.<;G8,?8^K43F6:
MKL'<<71LJRDG-:OD&BR.9HZ.](FF/";=$/;%,0=UOCBRW95R;MQ2KELOL%+P
M^'_-!H-B6H02%IGF+.,B;)A^FP;ZT2-B=&>1,W=IE8Z$HJL@FFI%R[,SL$TP
M?BGT'3SONCLQ$4[;G"-9R_M.[)G#[@G9'!KV8U]LSB"V29X7QG4*$Y_LEP;<
MY%PZAZ*3]1<(>P@4&IGB2!@)\J[@A@4;#+#R+[&H:3>.#;[9G;#`,@QQ7Y!,
MBRN5,3;.U&>SID1OB.428XQK66\D8WD;:@^1I*+DD5/1#]ZO+.E4U"K*-E3"
M)`FU^VYC%XWPZ4.(>/5).28W38R,DI5?WB.)&18W>>CW<BJHLHY<`M(*M_>,
MH8QS\G'N,8PB8P1;:`Z@[9^1'7+QIM+GKM@76W7K4?;4VP+W8AG;7<YGO.I<
M&Y4R2QI-1K-1<4YF_K=?D9-I]/-N9F9>'ED2MWK4B)?X'0=?`&YVS=CQ]XN7
MUES7:;@.PGD%\JN,,J"]O%KL<':J'`DO@U2N,WT],-I"8JU.3CTTX5JX,Z21
M;APFU4$`(4&R:*5C,6I&#_&;L70\];.7IONCMIL1K/?-9I#-9[)K3"XPNM=R
MJ=.WUS$3!J[)4K'1WD`,@4KM5LY23[S*)(=Y%.@^_BW:'-FJ&)L1L<87>.@[
MKBC[>/*5Y:U<L8X?K5*_K[-0U-@+TY=_4.*_85*\15^G%(`FJBV79JJ.C.DC
M@0@62/%EIYFC4&5L[+*OD$S)MN;+.$,/9'D\3;`Y&3RM=<5WUXK.HW"YTBPR
M0Q]H+B.X+%381S7Z!NT0>QJP$%53O$`K0>;/-D)D;?\`VSS%`L-D'F1?')$:
MIP&M66<=XWR!:,4X(R+%9$B\D;*/;9:*ZBO0JJYF*4"+7ZNQKF;()G44^E]P
MA50"4S'LIG3?K;S=+:6&W\SOI[1]-,V:X5K`U$D[1#0>L;G$$U1JY<LCGSEC
MF0.RK60PRK$V-X>*?O'R"K`[EB9!P8B1"=!\O2_)FP6;[ML)Y1[GO'E>L,L?
M;.[78BJ6E,K.1%GP9EO$.*J9/2%-PWCK'*LC6$"YM5E*<:02G6*#J8=M4G*1
M$C)G%P`-OUYRELYB*$\9&]<YM;M+F&W>5N?V`IN9,-VFVR-@Q%CR.N]!NUZQ
MNOC/'2SA1ABU?#<O6FQ%)...DDFS*J9RW6*4PB"C2^XFV5?;^"MHVR_E!X\S
M?I)Y&+#G`SZUO99S<[/BS!D39*79KE(,&S:/F+%6+2R+]!(*MQ[#N5`(4#J`
M80;-K72\V7+2^G95R!O+O'D62WU\9/DGLF6*W>\ZOYZH5F<U_:XWL5-EL60K
MN'$]*4<EM#R*?@FJ8DA#+J(*%[E!.`-W93[K#_B/\?\``U'>CR`.<LQFA67]
MCZ/JMK$^G&]BC9Z;F%7%>RSD_*D`\KD15=9,,D8F8L*M+ED/J/=.JDDZX.4`
M>E"Y9W*\D^?=#-?,H[.[/:X8_P`J:%9!R:KD#72;DL.6#*5\JN/L+6D;<>S(
MLBL[`C$VPYG"JD<9,HF=+M3'224,@((GKL7,>QFR?ABV,FMB<GV+8N1\;.X4
MW%7*VY)03QTYR!B9A9*O1W%W$D0W4^A6L4JUD+:HZ.X([-')?4E6!-3W`?=X
M++)EFK;2S^*MGMQ-VVVVSK"4C(YPU&W+*QM6-<AVDMD=R2.<-%+VQE@A@PO!
MQZR:+N-CVBJW\8JAU"M^TH`A_FZVCR#@/;ZW9LP?M+N;:K_@6S:=_P`P88QC
M(.,<:/ZW5JQY/:,91OM7*/C2T;DNVYR([!M!MB1H#'HD577!9,"D`/LK6#/V
M5ML?)+L1+;=;7P3O4[?O1O'F)L45+,<G!8!+4<B9FPEC2ZUNPXO;D)7+&RDZ
MM;EDUR*MB%%4$G0&^J4744!B6_BV7MS\<[#;S9*V7SHE"X5\QV(];L;:LML@
M?I^OC3$=1R]#5B`&0H#&.9PUAR.PE#*R",R<%'7893O`P\&Z"PSYVGBY+YX9
MJV9ZJA6;CYC]78^Z02[HS>!M40S:VB63C;)&F,,?/19)&/0<$1=$52!PDF8"
M@<I1`$X\I&6M7L)3VP]&U-MD;AGR1[53VF>OV;LFXI&P1]^QQBO,F9XW'58R
M5,H`V)0U+G&U:PR2#,Z2C.PI$=M%A6!)%LH`19;8WC;[1K%&\.C5/WGVFR1"
M8@W%\<$30=@LBWU]-[,Q-!VV;)/LETI[E!-N5TY@D)(W^Y+G`%4CG!$@%3X(
M`+)FV'WSQXSW?U)U4S%MMG/&6`MR-<Y7*QWN?T)#=":UNRWC"QVK)>/=;,R6
MXP225J3L5=0<)L&ZJ,@@V%5)DD8QR)]`MNK.V[M:<\2--Q#NQL)GK&=DWGVH
MQ#E8FQD-8:)G*OFC<'W6V0&MNQ;:<,[DKG?L/6.2CT%7JBZI%7P)EY*0I0*$
M:M#R-DC<6G:#V27R#?KK<)_2?RX4O)&0IFT*DR8T+1)6Q,I5[4IZ35<S:4JV
MDXAK'-08&.J>,7413[4CG``0YG,6S`OAJU(-C3;OR)JY$C="\M[:5+!.N-SF
MH"L8MFXO(BK5?,.<LK)V&*6K^L=4)&FB6-';H&,YD9!=9(3G-\H/GW4RQMWF
MY:.SO!;L[#X"_L.\(>H.^36@X1NBU.J&0-G;7,7!ZO,W!"00DT9>DNDO<0E(
M99,R,JF#4KI3L;=A@^'@6E;9Y&W?\Q.;-8<U7Z'VUNWCQTPR3CV-O-X;U[%#
MJ[[&8];V*;@5C6--=!.*HR2;QK1EU'+8L'(KF(=QV@=00F@\#-M4+CS.V,[)
ML1N_D7)M.E<;260,+>0Y)S)Y_P`'V^9J;E*W.JW>5E"(9'PCD*P,CO:X[8D%
MHR;MQ3!57W0.(3^>Z?MX]PG=[?Y$YYY[?>_VG;['/K^?'0>,IY]$0;^8_P`@
MJ)5%E"AGZ5$#N%U7*W"E=KZ@$%=<ZBIB)=W:0!$>TH``>@=!$0"(&(8>Q0Z@
M]HE*!@[@'Y>[W"\<C[@F^4"^O0>GU6-,,[[2?:GXXUNQY391;,TQKW6+=2Z1
M,(%K\G9!B;22SL8A$9-4R;9[-PHF69>Y[97/*9.4Q4[BAYL]MUVSI1YV2K5Q
MPMEFMV"-*I];$S&/+=&/&9TW!VAS+(.XGO4;@Y2,0JQ!%(XA\IS!T$X7A]U9
MI.K^1ZEY,_(-.)8&U^UMD7.1L04&X1C<<M;'Y>JGTSBL5?'>/I(I9XL6RGU6
MJXRZ[1-L58A`26`0,HF$>WE9\C%^\G6YM^VAN%=:TB->),:ICJB(+MY$U-H%
M=]Y""B9&52;MR3,VM[JCEZY["D.Y6."92I@0H!.1]FB83>3#)8CQS_=PMG/`
M<<_]^0OJ/YCT'J$!\/ZQ_P!(]!ST!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T
M'Y*((K$.FJF51)0ADU4C@!TE2'*)3D53,`D4*8H\"!@$!#H()(/P$:DU[88N
M5V.0L\JX,9YD<;((:0OLB2,AK(EL<YDEI8<LJUA<RD@NZ,\7$Y8U58\8F/!2
MI`0O9T&W4OP9Z<8^V[@=KH61RFO!4K)5BSKBS6A]>9937O%VPEY.8EUS+4Z:
M"P?3S5D;)MT_H3]T:V4:IJ))%,0O`;=)>%;3Z2T]B=,1/DQG0J[GJ0V4K-PC
M[J^9Y*K67Y:X.[K(6"`L[,S=W%MU9EZ<001$B92<>G(`/0;G8?%!K+;5[R:T
MN<B3[K(VU&&=N;%+OK=((R?]K>#*W4*S6I(7+5P@HX8S,74$R/0/S[[IPHJ(
M"?@0#2,O>%_4#(]"SC5(%&]XFMF9]HE]UT<N8PLSN%R/CK9<[-K'-LB4)^50
M&\6#$B1ESM%`,U<NG"JJA!./(`DU]\#&L\[C#7['N)\T[+:^V_`$CE@[?.>,
M<ER(9@R&CGYPO(9WB+Y:)_\`4EI)ED^3=+.7QB"4"&7,1+M)P4`D0THTHPOH
MUJ_4=5<(I67^S.IM[(@U4M$JXF9Z17M#YPO,OGKISV`F*BZQNU),I$B``"4O
MKR(;]JYK'C#3W"=7U]PVVG&N.Z9)6J7A$+%.2-DDT7EUMTY?+"=S-S+AT]<(
M.;'872B13&'V2F]LG!"%``C2I7@FU$HVQ57S\QN6P#^/H>9<B9TQEA&3RO.N
ML.X\R7EJ*<,K[-56M`L)&AK*\>.'+@YA$3G.4G/8F0`#C6;P6ZLZR9*BKK!Y
M)V'OE5H=IR!=\,X=R#E"9F,2X7R-DYJ_CKI=J95`719N[1+1<H9!-9\5S[0@
M"A.%/FZ!8Q\0FH;DD4A98NX6V#9ZF7[2E2MS]D>JQLIAO(UU1O\`+-UU&YOJ
MV-M96!JBHUED3D<ME6Q#E,!B@/0;1H3XR<>Z+6G)EZ99KSWL+>[_``E6H</<
M-@[XZO$]CO#%$6?+T?#E274$B*=4K3Z1<KIK*E4>KJ+"*BI@``Z!;:=HKK1C
M;&FPN*JI109U3:FT9`M^<59>6EK%*W*QY)C31<Z[?3$X\>ODVB37A-FV`X-F
M1`[42$`1Z"/N9\%^M[O+V/;["Y6SW4L;Q4#@&.SKKO`W-8,+;4O=6*]6J_A*
M7SM!O#NE9MW4T:E&J>VB)$GQ&P$<%.4P@(+I`^*#6VN;2K[+QTSE%6$<7&Q9
MD;:VO+M)K:V1&=KG&RD!9L[1>-E`^@;7J=@I5VT6(4/I@3>+#[0"?H-`PKX7
M-<,%9W@LQPV1L^6W&^/#9$>8'UBNV2)">P)KO-Y9CGT1>[+B>MNRJOX>2?1D
MJY09]RQS1Q5A%M[0@`@&KX.\'FN6',@0>1;/F?9S.<A08C-E/Q#7LL9>FYFK
MX5Q%FV(5@;AB^AQ,<9HW:1;..>&!%XIW2BROMJ*K',F40!VF)?'!J_B3&&#,
M3QE6EIZG8"PYF;"=18V"P3;\']'V"9UQIE>.L:*SLQ7A+(RK+,I!,(F9D,H1
M'L`QN@8!+_;TZMJUW%=:K.=]L<=L\8U+(V'3R=-RZ^C9VZ:W9&E5IU/6>PRQ
M$A>CB>I/%Q2AFZ!R.6[8QD`5]LQ@$'<X$\2>LNNV3,%YBH[_`"4O><%X;MF#
MX9_9KA)S#*9I-KBX>%5)*1+YRO&LW\:S@VGLG:IH]PH@)@$PB(ATZMX?]4JK
MC[4W&R7]I+RMZ@P&?:C02N+W.M3V*D[)UB1JN5Z;=E&#I!S-P$LQ>)G:)*'$
M62S=)1(2G(!@#Y&FOB-P[J%F%/-K_-6P.RF0ZE3I/%F`)/8>]'O)=<<0RZWO
M2F-\4=Z)!9QSY(I$'#MZ9=ZL@0J8J=O("&L;9>$W5/<;)6:K_E"TYZ@(_8*$
MQZPRQC7'F6+14\97FWXF=.U,5Y"M]:AG[5"Q62D+R(+,2._<;)&2`>P>/4%C
MA_%_KA68S8IK7G604)+9G+V!\NY+G9*XR-CFGMHU\M6-[954VKN;6==[:5G<
M;IJ29Q#WE"NG``(`"8%!J^:_`UK5F[,5]R,[S9LI2L<Y`S36=DIS7&F9#6C\
M"GV&K,\A-N\JGJ*Z3CW+/.NFP@LD!@;(D.842$,//023;AZ=X;W@Q$EB3,R%
MB1CXZX5C(]'M](L3^F9!QOD&G/TY>I7*BVF+40DXB>C9!,1`R9P!9(YDE"F(
M82]`RRH>&K7*KX>V+Q[,9%S_`'[+&TLCCJ=S#M?>\G2TWL3(6+#,VSL6![(P
MNKPQOT!YAM]"1Q8LC(J)%0:![X'[S\A\ZI^%+65A@&_8CR7>,RYQON7LI8NS
M+F?93+-N-/9OR5><.ST?.X\7E;`KRSBHJO&C$FJ#%BD@W*3N^43&$W0+%L3X
MLM<MBYB_7*<?Y0HN2+5E7&.<:_DK%U\L-1O^-\NXKKLI5H*YT&89/REC)`]>
MF%6ZJ`D.U.4QA$@B//0(%/\`@YU1=:_U7!5)NN<,:W*J[#S>UK/9ZL9'E5=C
MI+/-V;!%9<NLI?Y0SEPXDLE5M46,B4!!/YR*IE*JW(8`4W7[PX:;ZY0^OL96
MHBYVA#72FYWH]1<7^WRED=/XC8U^O)9%?2A%U@3_`%0SU^Z*S73(55FDZ4(D
M8H<<`V%]]O9J>ZI%;Q@3,NW$9CRJT^]XEG:="YTM,=!7C72[V@]W2UPE&S=U
M]2RQ16K.!7C!JW.0YC%."AC%,8!!U*/B)UI"D6BB2\QD6;C[-I-2-#';^2M+
MDTD;"^/'=@<5%5)VW.@NC,PRMC%'W`,'<@V2*83`'0:S?_#%J5D^5GG=EE\Q
M(P%[U+K>F^0Z/"Y,LD#6[[CZC*,7-!F[*TAWK8REIJAXXBK%;N*F0PF$Q1%0
M_<"V:&>.2@Z/GR)9&V8,U[$9,R6C4H.4RYG^UA;[['8\Q\P7BZ%C.'E"(-P9
M5"JM7"OMHE*`K*'[U1,8.>@D5^G1[>SL^7N[_B///N^]\>>>/<_#\O3H/&6\
M_G_K*>0;_P#/DA_]LUWH(@4GBZ(I&(8`.@H*R1Q#DQ5?X?:IR/Q,F*8"7GT#
MH'XLO*=Y%8U@WBH_<;.S&,9M6S%G',[L_:L6;)D4A&C-FT0]M!JU;$2*!$TR
ME(4I0#C@..@^=*^3;?R>>DDY_:W+L]))D32))3D^28D`12`02;_6R35RY,V3
M`?E2$PIE_`.@:;=<F9"R1,?S!D&ZVB[30?4%3D[3.24ZZ;HNUE'"[9F>1<N`
M8LS+K&,"*()IE$?E*'0:28YCB`F'D0*4OP`/0A0*4/0`^`!T%L3[.B7DV'E/
MG(YI$2SZ-F==LCDF))BR(XCX8D>M%O61Y=R?@[,D@Y("#?V^XRBP@40XY$`]
M2U(XJ%,/8)`[A[>X0Y,40`W(E`1$@@)A`0'@0$.@_7H#H#H,#F`I>1.!`Y#Y
MC<<?'X>HAZCT&7/K\?P`>/\`V]!ST!T!T!T!T!T!T!T!T!T!T!T!T'X"W1'T
M$GH//(<B'(B;N`1,'!AX'X>OIT&8)$#TX'CU]!'GGYN\.1'UX*;U#\N>@Q]D
MH\]PF.`E`H@80X]!Y[O0`'N'\^@X,W1.8AA(')!`2B'IP)1Y+^T0*;U`/P'H
M`6R1BF*<O>!A()N[UY$@]Q>?0.>#>OK^/09`B`<_.H/)P-P)O0H!\$RAQZ)_
MLZ#D$P#G@3!W#R/S?B/'/^7CH.`13*`%`."AW?)\2CW!P("`\\AT&(MDQ(*9
MNXY!`Q3`(\"8IOP$2@4>"_AQQQT&?M$X(';Z$`"E`?4``O';\>?4HAZ#\>>@
M"I$*42E#@H@(=H"(``&'DW''_:'U']O0!$BD$1#GD0``YXX*4/@0H``<%#GH
M,54"+<=_/)>[M,4>!+WE$IA`/4HB)1_$!XZ#D$$@$1`A>1'N$>`]3?P_7^KV
MB_L].@Q*W2)W=@"7N.94WS"/*AQ`3'Y$1$!]/PX#H.`;)E'T[^"APF`F$02Y
M*)3"GSR("8!]>>>@S*BF3D2!V=W'=V^G=P/(<A\!'\.?B(=!C],EV`00,8H&
M[_4P\BISSWF,`@83<_MXZ#DR"9A*/S`8H\@8!]1'GGU#@0_S>G09`D0H```/
M:`>A!]2@("(]P`("/=R/0<>R3\>X0]."B(\%X`0Y#C@>1Y]?V]!P*"8]W//:
M;CD@#VEY*//<`%X'N$?CZ^O0`()@H*O`^X8O88W/J8H&`P`(?N_$/CQST&)F
MR1P$I@$0'@0#T#M.41,"I>`#M4$1]1_'_+T&8(D#CCGT+V_'X^O/(A\!-W>O
M/QYZ#@4"#\>3``D,4#"`@4Y#"8#EY#D#"8?7H,0;)\`!C*'$`$.3G[A[3=@J
M`/IP(*"F`FY#\1Z#(4$A$!$@&'CM]0`0$.[OX$O':/S>OPZ`(@FGSV`)>XP&
M$.X1Y'U_[0CQSW#SQT&(-D@$PAW`)C`<WKR'>`\]P`("!3"'H/''(#T&0HE'
MGDQ^X>T._D.X`+P/:`\?NF$/4/V]!P+9(3@IV\'*)S%,`\"!CE[#&_:/9Z!S
MZ`'PZ#(42<E'@0[1$0X_(P\F*/(#\IC>HA^?0<%03)QV]P<=WP'CD#<<`/`!
MR!`#@OY!T&1$B$,<Y0^8X$`YN1]03`0)Z?NAP`_@`=!^G0>2WYN-&<KY*\L&
M]-ZA<EZ:Q458\XR#QA&7[?S2?%=P9I'KT`D5.P4')6>*M>:R]3$GS(2$<V4X
M^8`[1*80BK_PV\Y?\8?'_P#]3WQV_P#,YT!_AMYR_P",'C__`.I[X[?^9SH#
M_#;SE_Q@\?\`_P!3WQV_\SG0'^&WG+_C!X__`/J>^.W_`)G.@/\`#;SE_P`8
M/'__`-3WQV_\SG06C/M/=2LC8(\@M^M-PO6KUHCW>!K-&(,\,;C:M;`6A)RM
M),CE<K5#!>8;]9VT64A#%4<K-2-R'$/G`P]!Z,+/M]G@H!\H@43!VAWF]L@B
M?@!$X<\\?/\`/Z>O0=OH#H#H/R5!(2A[PE`G(?OB`%$WX<B/'KT&8=O=^'=V
M_LY[>?3^KGH,N@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@
H.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg71b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg71b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(0"V`P$1``(1`0,1`?_$`&X``0`#``,!````````
M```````'"`D#!08*`0$`````````````````````$```!P`"`@$$``,(`P``
M```!`@,$!08'``@1"1(A$Q05(Q8702(R)+2V=SAX.0H1`0``````````````
M``````#_V@`,`P$``A$#$0`_`-4?:FSTOM/[">J&;(Z5-YSU+HN_57K!JR]$
MN;^EW?0=5W*E/+)&QL#.1!W"JC:FC')-727V_NLWK@B@A\//`V.]7LW(+=;Y
M_/9#1I_5"8/NFS89#VVWNUI*Z'K5#MBI:S$7&8<)(+SEA@X&2;M57QR$,Z32
M34$/)N!HSP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#Y1.Y4)<?7ATKC]_V
M#-5=:[&6KV\U+M=4,ZHT.:Z:#:96<O[((&E5M]$,G2[JPC3(<C=0&P('7:_)
MN4!,/@0U`]6&QXK2O67EV\:%N.>13"TR5UT/L!I-WM+>BURH;GI6F3,E?J':
MW5]4KH4R6HURG25A./>D:JE%D@4H*BJ554+R9=W)ZL[?;GM(QO>,UU.=CX-W
M97!\^LS"WP0P<>JR0D9!M:X%1]5WJ4<YD$DG`(O#F05$2'`IB'`H2;FVS8_L
MS2=?Y!JN;ZJQJ\VO6K,\SB\5F[M:]8FI"J.8&<<5F3DT8F9;IG`QVJXIKE*(
M")0`>!)7`<!P'`BW:]KR[KIEETVO:+?'4/,<]AU)RVVF33>.&\:P(JDW3!-E
M'-GLG)/G;I=-!LU:HK.7*ZA$DDSJ&*40]11KQ4--IE5T3/['$V^CW>`BK34;
M3`O$G\-8*[.,D9&)EXQZB)DG+)^R<$43.`_4IN!YG:]=IF"Y/H&QZ%,1T%3\
M[K$G99F0E'R$:S^VQ0,+5D+QR(((N)1\9)LC\O\`$LL4/[>!@?U"E?8,G[(<
M%M_9+?;;:JKVQZW=@-ZL?5VM0S)#(NJE?B)G)&&%4U=^S2>2;ZV.H*VO?V4B
M_<II/I=-P1JG]M'@?2!P'`<!P'`<!P'`J]A'<[K9V7O^YY=BVFQ5UO?6^[K9
M[K\"S:23=2M65`/)DFSYVS0C+`P^7E,74<LZ036`4E#$5`2`$LZ7L&88XQK<
MGJ=YKE"C;=<*]G]<D+-(HQ;&5N5K>ECJY7V[MP)4"R$N^."2)3F*!CB`>>!)
M'`Q6]S.YN<=8="$&-"T+1EY+OCC5\DZYE^>RNC7$U3Q0[_1;4]B8:+6:F*NT
MCV`&`#K(_>^J8&^H@(9O6[I;W)WWU/>RF0SO,WE.U7M/W&3[G];^N^I1$$>=
MCJ]GMWQFWL86UUYQ\H=&W:6GDJYRQ+H11*JL@101%4YA"+=K[R^QHWKD[`Z+
M9,0?YI>=PG<6ZHX=E^4=7;'C<Y3KOK-ADFFL&+.VNPW">E(56FQRL<ULB8-6
M#&3?D.FD"J1%`"T7JU8]L.M-8[X4_0^C[SKGV&O6>0>I=>\NS-&-F,/LL9DV
M*QN:4^N0^C'=.22>QR,W$IO+`26^"KYRX^\!@*;X@'3Y_N_O<P5OUVP=;)W/
M;+0-%KE#[,ZMJFHM*K1T,OHR,)*S.W=3G+RMMTHM?4!LH,V-6D%16_RZZB)S
M?))-4H6W]FWLUB:%ZX='NN3U/8S[MJ-IK_4R(RJKU4W]9,PVS6F4@Q?0DQ'/
MV+R+CYRL0#.1<-G0"HT<.4V_V5?*R9@#/GU\^\ZHX#G777J?VDIO8,DM3KWJ
MV'ZIMVPQ9VUNR>OT1TR7R:Z;77F;63FS1=LK\RT:R,S\@:Q[TH@J<P>3`&O/
MKGV:8U7L'[$HNL;O9.PG7*E;#F1,9N$_,,[4P@K/:*&]F]BHM(M[5`H3-"K$
M[^N)'HE6<(,C**II'`!,4`]A[D*TYG?6WV>GHVVM:7/Y!58+L54YA^R;R$>[
MNG6^YUS<J;69%FZ*9%9A<;-06L2KY`1`CT1`/(!P*N>HGO#BT%F/7_U@:>\F
M\Q[V=;,!S*G:?BMFK\BG^0YA*!!R7\S5*RQS5U6Y:K3\(\0D6*IET3F07`@%
M,8@B(2![V$(9YTMI4?<5!0S&1[?]2&>N.5E5VL4US,^RU]2QN+"^0#S'P"1D
MD1<KF$$R%\?(0#SP-#.T'9').HV`:GV;TZ0BVM/RS-[/>G@MGT,TF+/%U6">
M6,*[5#OG+8DS,RZ#+X,&:1SG<+'(5,IC&`!#'[UY>U_L'VHT2YNM"SBCIY3H
MO5BU=R\#BJ<TEVN@99FL=IUPI%!HV^J/)>09.+5JM7@FTY%.F3=LFJ`/"`F!
M4B>0IMUC]Q7L\))9-V5[:]=<IK'KB[%=GG5#J>J1DLZ7U3*J7J3Y_#97%6>L
M5^,$[N$HTU"F;R$HNS_*<G>`"JG@@'X%L/9A[7.PW6+V.]"NGF$U>FSU8V^<
MSV=TEG(M%92^Z16;EK=:SIS4\T`2FCH-Q"04LZF7K]P'\-NV^0&(0I_(5;[P
M^\F9Q7VWXOCD1:[C2>K'7[2&.2=F8?\`I?9YN/VV<UO.;8\<6Z!M;*#<-V-8
MZY6-&MHOR)J_><OIDW@#(I&^0>IZH_\`TBRND[%UNR/LQU5=XPGVZ/H]NP?0
M:S9)"STVPY:S8)+90_>+?J5UTK-/V%N[@)A/R1%A)D1/\2)+%X&M6*>V/J?H
M_4!#MWI%WKV$Q,4VN1='S.W65A-:/FT]0Y^3@;)6)BLPB`V&0F6!HX'!DV[`
M1!NL500!,!/P-#:%>*SIE%IFDTR2)+TW0*E7;Q5)<A%$DY2LVN'9ST%)$35*
M55,CV*?I*@4P`8`-X$//`@3=^QT'4NHG9#L?D=CJ5T'(,9W6ZP;]*01D*TK<
MLCJ-JD%867<-%@^!65EKPM'J7R*H02G+]!X'SI^FBIZCU(ZBYU[*NUT<:9;;
M)AE!SNE9GUYS2PVF]?RSK^P2NL$U'8S*.#2,G:'D_<03=JH$_'BHI,H"4P@/
M`CGV?YY['O;;VPV[!.JC?+J]@7KNNF5S<'.:46X4"R+=KOU1[Y&7&K23%82W
M5O4*^(,2)JF+#_*0^1T!6*50`TEEO;C<('UJ5#9YB1PQG[!+_CEGNM-P4U>U
M8V?S.@TW98O'K)FR2:9SV-.6C;C+(ULSE1ZFU-.G_**!H\!#@;W*-6RRS=RJ
MW05<-!5%JNHBF=9L*Z?VEA;JF*)T162'XF^(A\B_0?IP.?@<2J""X$!=%)8$
MU"+)@JF10$UD_(IJD`X#\%""/T,'U#@<O`<#J%Z_`N5SNG,)$.'2CYG)J.5X
MUDJN>2CDBH1\@=91$RAGS!`H$16$?N)$``*(!P(>KG5_KW5+IKNB0F0TA*[[
MR]!]K]E?0Z4U*7LWZ..K9F4PM-C(%+"K0T2W14CT`28JB03G1,H8YS!)E+H5
M&S>";5;.Z74Z%668G,SKM+KL/5H)J*AA.H+:(@V;&/0$YS"(_%,/(CY'@0]V
MZZWUWM[UKV/K3;)Z5K%>V.ER5,E+#!I(KRT.A(?;$'[!%P=-!5PW42*8I3&`
MH^/J/`BKIKT3S[J'&6Z;5MUNW3>-1E(F>V/L?K)(5[IVBR\!7V%3KZ2ZT3',
M(^O5VN5F+;L8^,9$(W;H)_43G,8XA;B\4:G:94+%0-!K,)<Z3;8IU"6:K6./
M;RL)-Q+T@IN6,@P=$40714+]0\AY*8`,40,`"`43H7J=Z`YY)2DE'8`RM)9-
MB\BB0FJWG2]DJ4-#OFS%LK%URF:K<KA5(%NB#`ID%&S--PV,8P(J$*(%`)PZ
MP])>JG3*KRU.ZR8G4<H@9U<BLPE$_M9>1D$46Z+1I&.9^T24Y/G@(UNB!6D;
M^5^O9@8_V$4Q4.)@L.%3JP1#>OA6H`(%HHFJTA`AHX(AJJDH*J2C>-!M^&BH
MFJ83%$I`$##Y#Z\#.Y[TMLDU[6H+N_/QN>369TOIU(XA16\DW.K>:?ILMI43
M8WUCKJ(LW#)%@[J+-=BHO]UNND"PD(!RG/X"XVS=>,@WZD.\\U&FQ\[5G]DK
M-K>-6PJP[Q::JELKESCW'[:).SE$0=S%59%>`FL07C5,4%1,F82\#K\LZN=>
M,5I6=9WF6/46M5'(XM["9E&?I4)E>CQ,D]+(R#"N3$_^UFXYL^?$*JL4CG^(
M<A1-Y^)?`0OVRSOKAE>!=B=MF,>QJ*F(7,-.L<Q=EZ'1HN:_83%2D8F2EW]I
M7B4GA'<@@Y!)RX46^:J0_`XF`?'`DGI?6U*CTWZGU!=R5XM6.LV$UM9X0HD(
MZ4A<LJT6HY(0W]XA5S-A,`#]0`>!'O4/HQF?4G$]'P>-DWVET;3M6V74+''W
MJ/8O&2X[79I*RV2JK19Q=,'4"F>450^!R^%R&$3E\F$.!<R+BHR#C6$-"QS&
M(B(IFWCXR+C&J#&.CF#1(J#5DQ9-B)-VK1LB0I$TR%*0A0````#@<K=@Q:G=
MJM6;1LJ_6_)?*-VZ*)WCCX%2^^[.F0IG"WVR`7Y'\F^(`'GP'`\XK0:*L#4J
MU+J2I6/Y`LBJUR'4!G^7)IS3K\4#,Q!O^3,)%=J?#Q\W)05'R<`-P/6\!P'`
M<!P'`<!P'`<!P'`<!P'`<!P,N_==_P"IWOU_XWWO_3(\"\'73_KYA/\`PWF'
,^R8/@3)P'`<!P/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg71c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg71c.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P%=`P$1``(1`0,1`?_$`'D```("`@,!`0``````
M``````<(!@D`!0(#!`H!`0$`````````````````````$```!P$``00!`P,"
M!`4$`P`!`@,$!08'"!$`$A,)%"$5%C$B%T$C83(S&%%Q@7(DD<'1)4(T"A$!
M`````````````````````/_:``P#`0`"$0,1`#\`^_CT&>@ST%2_?'=FB\Y;
MQS#SECU6Q^8T?HEW;+`>T]!Z.[RW+:Q3Z`_@V$PQBYIBBNYF]-ET[`(Q49_M
MIN2LU1,<HF#T$+L_V";1+?93'<-Y54N="5"AU[,9O:[EJ6U/JGK4^UT:.=3C
MG_MWS=@T.&@I5=HV*FZ%RJ`"\6(0"B7R/H&QY_ZP7WK=.ML'5RRU9Q8.4KM2
M*>YFIZ3AI:.T:.NU5>V>!N->;Q+A4&T40J/M!%[\9R*@("'CP/H`;`_84WIG
M><UP9T]&U'-;G<H@NB<K7:I3$R[HFCY<^6>Q,97+K*SB;5C5MU0FH&0*C%)G
M4;R+5/Y6HF$0)Z!<+_\`8/W;1'F(Q,WS]S<#G0NV],XVOEE+H&G+4ZFNF2AA
MQ;1"J)0OYIX.[C[&\DFZ*15BZ'^SWE$!]`"*?]S73UFYKZ^TLO,N:H;7R#)Y
M_BDWF+&SZ1,1=NZWN.MSU'<9+3':$06:F*M,5-S7WL3+-4A,:0DU&ZY")H@8
M0MPZ;OW:--Q2I67GC-.?+AK:96;_`%-ELNGV?-\TH]6"`5D+9)1]I8,'<XNO
M&RC<I4CJID(#5,ZJABF_3T%<FH_85]C45Q3BW8><\L<P2L)/9I_+=HA+EM-X
M9&_D3NWI5R"@<61AHAR_O"-K8F!VP(_*BX.=0I?'DP>@9/L3[!O\+\UZ5H&2
MW+GI]T-AQ,.G-VQW2K^6L#G,#I,M7TK-"SZ!5!DV-B3AEW2<.R7*51Z\2(D(
M@J<I1"R2LZ!3=`9R3FA7FOVQ&*E0A)IW7)Z(G$H.>:'9'=0C]5JX5%C)`DNF
M<4%``P@;SX_N]!3OS#]A72/2.KKS=*=\4O.?:WI]NJFLYDYT>]077F)4>L+3
MKQ;1-!K-B:,H!:RC',D'+V(9E40;-W`*D5,('*4+(*)VIR3HU2K5\I73.0VN
MFW>P2-<IU@@[U%*QEJFX'\M>3A:X/S$++R+,&RH/$F_O$`3\&\#_`%";+].X
M$1GH<@?<<L3:9"T</M*<GN4$1&E,F+U=BYD;,)G@#%,TWS)9J=3]4Q<`9$!^
M8H%]!%![/Y310S"1)T-EBS#99R9J&2'96QH\'0[/7DF(S\'7TV@KJR<O!#((
MBX;E*"B"2I3F``'T"??8;V-=\&USEO!*AI^:\]I]%3=E;SO2FN0#NRTJB$JC
M8KQM5(>,<*,ZB:\7U\)&#-29=-VY$C*&((J%*409/`>@9IUEL('3]WPJI;9!
MTJX7:ZDS+0XN<I$AF])GGK`-GKBJCI1VUHTI"H-G$@FN(IQKPYVXG\%`?01F
MV]_\Y9?<]L9['JF5YG2LG?XE#FODCIT,Z77FMSKS>PTV!GZNT!69H[RP?]6.
M!P0Q9-HH"Z8^T1\`9F'6?-+S2ZUA<?O&7'UVWUE6V57-V]OC/YA-UM-H:3/,
MQL"509`R8L@%4$3`54Z0?(!?;^OH$ZVK5^XLKZWPAO%S>4WG!=UVY[G2V1-Z
MPK$V'.\.K&+36A7#HFV:6+O]P1LL7<ZPK$?M9D"PWQ/V*9EOR%_```*)WST3
M-Z;P_JHFJ%JY*^Q:3OM`R^JEJCRO73`[<T@;!>L4F)ZT-5U7-FB='I<`8)]!
M8I3QTB3VLA.D(#Z!I/K:Z<VCIJD]&2.VIT%O:<HZSV##(H<S:3(53^/TAS&M
M(Q1!6T@C/2T@(KF^5=VFFLH/Z>T``!$-)TC]P'$O*W9.3<+;'=[9%[WM#BC&
MJD='522DZJS#0)UW6:@:8LJ0@UA!D)=D)/:(&$3?^X/0:O[<NI]=X^YAIFNY
M'IE+RY^KTCAV<W*QWNE$O+/_`!OJ=O1J-A=Q$.N[:?C6*JQ\K^[-P.)D#DCS
MI*?VJAZ"$\8?996Y_&-KNW56\XPK5,FZ1M_/M#WN$0=4Z+W")@D6SJ-M1Z(F
M#Y2!L#M!P(.6L>15B42"<AQ)_=Z!R);OSCFN5[-KC.]+9.A5M8:2#W.Y9"P+
M.6MH2AY`(N07A2L&KQ<63>13%!7\@J7QN$3$+Y$#^T)Y3>N^9=.U*3Q3.]LH
M-MUZ&:V25?T"$F47-I9QE-G@JENE0C5@3!RVKME=?A.E$1.1)8X%$?/CT%&7
M9'V/=/XMV=TWAF:[[0D)?(ZOR[;L+YYF<@JTM);],[Q8V5>E\G9Z"K.M9QG:
MB$3=O&(HH"M\1/D6*")1'T%TMP[2YYS7<ZKSI?\`2X^L:K<B0RD9!2"#A*';
M2%B_("MU&2M1DRP:5IM(-7!8QC\HKOOQCF2#S^GH%,S[[C^)M6SJ^Z94K1K$
MO7J!<U,V2A&.17`)W2+LQEYN,5@L6KZ;,TOIKZ%5@G+ER:-*H"+1--5<2^/:
M(;>U_<+P34J_%6.5V.4<-9+-(S45(J!H%NFY6&IZMT>42PR5GBH]BO(PG\!F
M6:J%F;NP35A$TC*N/`%'T%DU=M<':H*!ME;G6,W6+)$Q$W6)V*<$>P<K`SK5
M*2@I6->`(I.F<K'JIB@X)Y`Y%R&_U]!\]V<]_P!\TOJ+8<(LO<$UFNA5[N*_
M<X9EA='YCK]T=R.>MZ&E=XJ;G;5)J?`$;#E*]*XL)52E:K-D4!()E1\A:W]:
M^R:)O?"/,NU:Y.M9[1='S)E9K=/,XIM!-7TJJ[>H+O$8IHHLVCS."MRB9(IA
M*!A$0'QZ!9.L^E]1P#[!N`L]1V*5@,@Z>L-[HEJHL[E[!QEY7#.M.'%08M-@
MCS'D(?5K7<E&S6&8J@*#LIU/?X*7]0A-7[@?Y#WUUCAO172S2'Q[#.?8[=W#
MO7<IB,EBFAI"9!68L677AJZ486_/:+6IB-CY9Q_<*4RX/[O"A_;Z!+"_<ANM
MWY9[KV`I\RJ,QBG6&3X_1Z)G5IC="TYCA^@(5)1PZ@RMEW36Z=!3+.2?+(1[
M<IDF3M%PBD!A:%$0/!>J;-MOUHSG66"]M=`YY5L(E]<C;%9KIS[GCO<-!EZ;
M)_L5<J=]I]F6;&K<C&3;ANW.8R:+U^@/R+D+Y`!"[K`%]!5R#)RZXK'N-:-D
MN;.M2<1A"(L5]#<U.+-<UFB"(F;)L#V4KO\`'(D)BIH@`>?`E]`:?09Z#/09
MZ#/09Z"I;[.^0M.[JRZT<T0V>8"2D:/#,H=YT!H$N]D=<Q98ELB925F\QHZF
M8S$?(N`91($0,>S0YS.UA$`,F3P(1[>N"+?O^\<@JV>D8A%Y7QY?\UU"O[D:
M>L3[HZ\RV:UPL&WIHP+2IU=C4XN<62*==\%ID0*B`^&8F']0*/*G+NR8QV7]
M@VX6MGFS?,NI;9CMJH"=3NE@G+J1_0*0YIUA=6Z$EZ97X:&7E45&YTTV<B^3
M(4@?J`CX*$9Z!XC#J?6ND8;?(6B(X#H.-XE4L@LU;MTHOK]0U?-)VVVUIK[&
M`DZQ&Q='GJ5.6M`L2^B9AXLLDT,"Q4RJJ)@`@S+Z^M,EN"NC.-^ANF(WHG=]
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MUN&:YD6@ZY9;/2BU6NPM=5F7Y(Q+\F-<O_S4D@76(W54$#`"I+AS0=QV&E7?
M=*ARC5=CP:_3,P/26)STX.T:7D=F@+)$.J1I]")1JNG$-+J,ZD629O96:9JD
M8D52,)SF*4`+R[]6]YQ"&^L.@:NOS"_1Y'E>L:M-,Q6&6DM)B]BCKA(4O0<V
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MD`0DJC!1EP-$.QCW48B\=-4W9A#^WY$_0;++OK`/F?V/7;K&U1W..A2&S:0&
MYQ<Y:96^Q>T8Q9(2FMJN\IN25YO*_P`(O5781QE01FW31F\CT`%(S8Y3^4P-
MMYQOLJP]O7.^Q<UR1+8^ZI--S-I'7.<O$SM&6\]SCUA.:O7HS,F,.G1Y1]M\
MW6`2.Z=RB92-85L"9CF(LF(#[F/ZY=NRJ6YPS?7M(J=OYHX1T>]V[D5I"J69
MMIEH_>64W6LS9[@8L5"4UJZR6G3\A'H.&39VE*BZ!0!;'+X4"?\`)-;9_6U7
M>A#]@[3SEG\/T/U9JVUY5/)7)U"L'"%T:I3TQ595S=FU<8#/0,?&@**310XN
M$S'']3!X$"(ZY$^LWN?7\N^PAI0<CZ%U;-)"!:Y?T#4[E-2B4/*9W8'4O58T
M[:LVP*K,NJO9WJR@?G-E5$US%#Q[/Z!*OL$Y2L_7E$PFN5&>IC-_D73&5]!.
M(S0&<^_K%Q+G?[U(04$_4J;^/?D'^2KL))%0AS-?FCR@JF(>/`)N]^M[8JKT
M]+_9(EK^/USJII:7+VT17\=MK;FIUBJ6;&H,VC+PS>TM9*,TYU7V_P"8M:W!
M7!D5$_B.BHU_0`7G*<UK_"%I1Z,IWV'<M45'NBOV-[=FFM*O"9]=-(6TJ=N5
M=TKGEBYO+)=Q"U:)NJL4,4S.A&2CAR+Q57YE@*('G"^);A@7V`9+MFV=:YG>
M].ELUZBSBB51.#4IEXT:@Z%=ZKI**M3S]&Q.*75&&1LH5A''_:F0H.2K?DOG
M"KE<?`0[9^"\BW;;OM!TV\])XZVK.A5'$8B7D*RRBI#3>,-JQNNL96CZ)+W(
M9E!S$31VWP/3L/\`]<'PG'WJ"4YO($G7?KMT?H>P89T1J?4=,FI?"WO+VOTR
M[*48#TR1D<FBYQ?4K&]A4[+_`!64AMH8R;-=NN\!R\KRB2JK)8I3`/H%\QS+
M,5P'`:GN5$^P?+VE3Y7Z<Z)GL(TJ]E80%%&B=5J,=$LN`=!DF9M9W.33^7E2
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M1`7\6FYCH9J58IOE6.4`)Z`]U3A5>ZZ+?=4[$O5&ZFEYK/K7AF?PKG(X^KU"
MK83>+5&VV9JL]6E+A;8ZZV2Q2$/%?DRJI6J((1+<Z+5N<ZQE`7&!^EO&*0.[
MK8A/1/-TW<^D\\Z4P>V8UGE68R6(W'.L[1H*<0Y@Y%!U"W.LNC.Y4ZL<N"+<
M!D5%$S)K")P`[0OU]*P&*(YLXV&4FK_;>F:-U)NFMIU&/A%=GO5>ML'.6UC(
MTM!V^A:O$W&(KS6,_#07<D1(3Y0\B80]!9DQ;F2454,;W?)[A$#F,93R!@*!
MP]QS_&`ID*4P!X`QB>[^H^?0;+T&>@ST&>@ST&>@X'234$HG(4XD,!R^XH#[
M3%`P`8//^H`<?'_GZ#!3((^1(41\`7R)0'^T!\@'_D`_KZ#]$A3!X$I1#R`^
M!`!_4!`0'_T$`]!\M_V294;6/NKP"HPO,]"Z/L+OZX-94CH&^Z/_`([A*>\:
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M"&2:K``2+GA*28<N=D\N]$)YQL)M1^O^L]:7KM+*GQX&<Z%5N-"F82UOM@D$
M9T[]KI4-8:Y\,"[*L";N)13\II@/M$&1ZAJI)WZX?KKVG,G5@=Z;A5HX;T3`
M7#*2CD;/8IJPL*EG\S695<'*3%\C<*%87C*011-[U4E%`'^[SZ#4_<HWWO1-
M?X2QSF6MY/:=I86+;]T5K/25G1K_`"Q,U.I9ZGG$NVT&!=QLBO:KX21UI%:N
MI,5_R6A&\@LJ0R`J^`J#PK==#V&%S"P4MOG#_./K+XEYWMM.Y<ZKH5L1<ZCI
M+FZ/JY<MKSJ+2G(B!+(M'<:I7J59A*Z3(Y33`K5,%C*G!G[%T/T_9?O@X9O.
MSXQU'F^=S"'0N;91C,FTJ[S-0J4OB*JY=J;K0E@5EI6V/74\X"PE>(D"(:QI
M2H`(J#Y!F?N*Z7Z]OW&]_@\6YNZXRO$YW*.B+#L.PT4E0K.O41AF=;1L&;F(
MP<7=-6(R+17#1T:T+H?-)A`,G#4B!1=^?0*?]@'1G54Z/UE-W_,O26;8#5-C
MX3FH2;A[#3DH[6]"O<#.FM>?Z77T+`,TSE:,P2:JQ:"3I=FLL+U59P("FD`;
MY]J?94G]]W/MUV['-=A8T*)VG6.9\G<+5(M`#/*U2$W$3=FSF/EUI:3NMN>'
M$TR=VJ5%%,4DFH%+[O(&[ZCYW?Y/[.?L(E>@Z;T@TT:[8#RS<[C*[FQI;6*H
M,X>9T\C+)L[94E92"99TRC78F@O:!7CE6(?+/CF76,=0")N]B^[-7[J,,BLC
MK(J?6*W3@75O=1CNG$KDK7B5J9)9E;W*/6W\LC+"VMCT"L6C9-0%$T$0$_M`
M?`$K[HF>A+VGZRFN)P&,7/94^RS/,JK/0SA\WS23GF=`G53'F_V5RTE558UO
M[E&_XXBK\P$_0?\`4`#9>UNLN-+)4,ZTNA<5Y_;C6WG.T;EBG-%<LIX=5?JG
MIQCB4O=;'<K998U.H%>5<J3J'=H,I5Q+2S9ZF[31;-@44"6Y3]JFXW[[$>G>
M)+/;^;J?!\Y1>Y7:CZ6HK+-X_>8>(K$7(UZ@Q:[YLM`,K-AL@JZ/H3ED\6.#
M8J94&J1TW!A!S.V-2O2WU,:?K4E/TV8N4OAU6D;%8<R>NY6@R"$Y8X)O9'%<
M=K%*Z=5%_#NE0*X-_<*`B`_VB/H%&^U"G1.5O\)ZPYLM5#NN^X"TRO$\%XM=
M5'+KQ7]1@=AT3/8D*Y'04JQ<7VFI*PS)%="0KCR&1338)N%W!4FYCE!+LEW;
M=,[[?VSL*;UT=AU6[?9:I]?T]Q%9ZU7ANN0<Z%7FB4&RT&<;5YU>JZVKT49&
MU"+10E8E(V2=JO#*/S@H`6%\"4O$X_I[[U,^80U)B\R7WZA(WBN0!(5"':-I
MGFQH-[?2$6S$4DY!XY<N?S16]ISN/<8W@P#Z"!+R-[I__P#GCL)+C!721F6?
M/FD4F(9,9&THVIAF_P#DRVU'+Y@IJM(*V86L7E:T6Z.#-T03LB%3$?8'@`K:
MJ^4Z[F=]Z<O5JVW+.H=CX?U3FCJ9KT=I#AM5L'[*RY3GK3,]JW.81U29R-8B
M=DQ]A,3#MO)PH3#J8>R4>1>/^<R)O0$IQJ>/X5]8.*8G]EZV<<VVO[!NC=:T
MTM*L48M95,0Q*]ZRZV1:*:M4X:1F8>3A:\9A$H-4D$_:Y=B0GM43\`'T+,MO
MMC"]%B39M1Z'PM#83"6*&Z?OFB0==0E)B691_P#$8.(I]D;$:,:K$514IUWL
MRNF95P=,GPE]J@&"F[$M40XZX=^SS?+''TSK3)>?^DM:V3F[?[I7H`Q^B-)G
MJI!-INX.TZK&(UE^RJ^NV1]4DI>#;,VBT?$'(U_VQ(MZ`S[W1ZOS)EGTHP]Y
MG(961HG8>8N[/=U8@GYDI.7#,+TXMDPVCHMFZ<MOWBS6%(KLZ*1$4O('.)">
M/`;/HZK'SO[4\'OW*>ZWBQ]$=!7BA1G6O-#%_#W/*TN6<VBGS:2TZV-56KM;
M([#6HQ][*Z]%VS<RCMR9!!-4@J"`7_L$"%,Y(H(+*IF!$R@F2'W)%^0R`&12
M(F1$Z:*OL'^WR8I2B(CZ#8@DD7_E3('@@)_H4/\`D`1$"?\`M\CZ#]^-/W"?
MV%]P^/)O`>1\!X#R/_`!\>@Y``!_0`#]`#]`\?H'GP'_`)!Y]!^^@ST&>@ST
M&>@ST&>@ST'@<F4*?^U0Q?\`E'P02G,4HG)_>=(WC_;#XQ`1_P!`,/H*^;32
M>#]#Z;HW4L^^S";Z5R*HWFAUG2T[RJC*5*MU5T_-H-=&,9RR,1(L8-Y8EPDB
MK(K?BG.`K>WVI"`#6;P[ZP=PM.S6N:;XM=K+V(QI>/[*]0OSDSK9B5UJG9J/
M2SLF\VBW450C8X'C=)`B:QVR0_\`,GY]!L8O!?K.@]F+ML.QQ!GJDO$U>G%G
M&5Q!LRD75A2?9K3EV]2:S?\`$"VF?;03R%:RGXI7Z[F/$"JBJF`E"N7LAGP?
MQGRKRII'*.,8!>,XQGMZ.P6`>REKL\_3L7:=):,]S+J95DT+)O$9-RDQ8/6#
M^-DBJ,FJB9CD(51(/(6,956OK0YQR"$=Y!.871L6D=.<W"GRW\J3G(!/2JK(
MJ++M(N8GYI\\C5:N=QX0:"H1C$D4#VI@40]!L][N/%&I77*[E=.G*IGN@\K7
MQAI<=.5O28.(F:W'V>,"L6.EW\[@CANO0=+K%D4CGK54R)5R+I+-U`4!,?0?
MO.C_`.MJF3LEF//UNP.1N6X'LKVQP4=;&%YM6BLV9WKZ>CI7^1RTR[?1#-]8
MC&_;?D!NDDZ!,J/L$QO01K)8GZJ\JR;<*GE<CSE!8[8)U5MM\6WMZ!H!R[L+
M]6.:0TRO-2;EPRK[IXW508MT%$HTA4S)MR?U\A(YFT_7_?<BQ_=!T_,?^W[D
M+1R6//9"LVT6N7U:Z0</)TR+CYV":^!F9"L&FA<PL<H3Y$9-)!P0A@(0!#GK
M71'UJ[/!YW`[3K_.UP86V+C;[E[>SV=NFK+05H7EH)I;JT];+LIN'C9:0B7[
M$[L3HE759JIJ``!Z"0V1Y]>&B7^*B+$^Y[L=_P":XY^Z@FCA^R;.\ZB\^;HO
M'L6X<,%T6;N(HR*B2[IBX%RBR,8B@HE5-Y]!.&;7EK;IK-^U6,E5[K,XK$Z1
M%YMK_P"XJ1<12(6YQ:,3>P36E%F+,Q'S%<$S+KD\F;J`8OZ?KZ"'7SJ_AW7\
M`U):Y[;G=KP2?F+%S'J#HS]^:-D+5=HX(2P9PW<-T$W:SV<AIPP^Y(HBB@/R
M@8""<2A!M9V/ZUK]5L+SK4=JP65@*S)TW<,)C7.BMTFK=7,G\I7*=?(5VQ7.
M"\=7GJCQ@NJX$$07`2*^/(>@,5'=<;=::E5>F,SEJ%M6F\^M[A0:SHU5FE96
M4S@+FV(E;:NNFR<(MV*LZV0*'P.D?<=$H'3,)!\^@4?-OL.^O*5^UK6N.Z.[
MD4^X[+0:U!Z9.MH:?-4["3*XF8N<)1S32P_MAYJKU>U/GBGL1(4YEU$C*"<G
MCT#X:[TEF^+7*CU/2+16*8C<JOJEX3DK'9V,4[9P&2QD5+VV=2AU1!U.0T6P
MFRK.!;`8K=(2&/X`?/H%/V7[!N`Y?!-.Z5@M!QWH-ERIF@=$-R5U1E:I>MM'
M;88VJW"!.1`ZD:64>*E1!RT]QC$$Q/U-^GH!]C6O\]FK&23G>&V\EZ=T5LQZ
M;,56TQN>1M0B6$9;TV=MR/.O_P!DK(D<JUF3E7*D6^E56SIV<Y3@BBH8WH*+
M^P/LTZYKVO,=&XQYOY.TS$H/8:O1(_-G>21TK;+I(]5)R[S+I=?6)-%F:'LN
M_4QJO89-A`I/56=?7:KR1BE=F$`L@SK[*,?UGI'=N,>O+ID&/<\Z;RES".1X
MR_B&-5E26#?*O)Q6B4AG:8X5&<O'PLTD+:,4*DV(W,!#D]P^`]`[=<WKZL\!
M<%K4ENV''OO(&?LZ[-W71K%%V?5*O5LPB8>C.5;)=%F999X^JK&PLV3]4A!4
M*+TI5`*8YQ`.,G]CWU-5VRUO;5NA>=HFZ7?.9>\0VFO(P@627RJ,LDE19:YG
MFD(8DFM7(VP5U1B9ZX$J!@3*F50$_;Y#V6;H[ZO[?C&SV7_,&,0.=:U8E<XW
M>\4]RO7)R=MLC$GEU8JVOX2-"P(3+FNE%THY=$\*1ZAS@I[!\^@GTY]A'UW8
M'%U7,;-T1CM,B(O%L\N]<K9W[AS7F6"6EDW@Z#:556[612_@<RP2*DQ=.3`1
MP!R@?_4?0;Z<W7@+.+9&<Z2-AQ2'F<^G&=CCL\;0,>XAJE8V=5DKQ'NSMHZ,
M<Q$)9&]2:C+$67\*E9`54GM$J8@`]9]U_6%T,RC[HIHV(ZI)5FK&NU74LU*;
M6*W$J;Z7&&:3U,CK!!.9:3;R4^8J*`L"G^=PJ7VB'D!]!V$^Q+AS58##ZM_(
M$KU&]+W^9Q^I9B^RR6LCY.R5";+5K;$Z[0'T2X_@,)4ITZ;-XM(MR-&*BR(G
M'^X@"!-Z0Z.Y'YGAJ5BVM0:+N%T4!@H?&Z!DLIH35E3OSP2D;).46D0KQE6,
MTK\FLB1Y+JHIL6ZX_P!P^X3"`02<^QOA1?4F.8V*YQQW4%.V&H1EWDL[E9/'
M8G3J6T44LF51FN/H=6D-M9CD&JZ0P[=T1\N+8R8`)T_:``&K?=+]6;Y!II<#
MHH0"NA,$UU;JIAMOJTG9JY7II_6YNU3,RO66ZSJ@9/)(_%/OWBXLH`RZ`KB0
MJI?07,UJ293,<VEXUZVDHV4:-'\?),3IJL9-B[1*Y:R#-5$3I+MG2:WDBA3&
M*<O@2_VB'D)%Y\#^H^/T#_[^@_?(#_0?/H,]!GGQ_7T'YY`?Z"'H/WT"[Q/5
M?.-BUB4PNM]!XC.[/"F?DE\CB=/I\EI<4$0BDM,'E*.RE5[''*10*E,L55N4
MI4SE$3%'T!^*[1,!!*NB<IR%,4P#Y`P&`HE,40$0$I@'R'Z_Z^@UQGYO"XD<
MI@<#?VD%+WD;H"J9NFLH50[4_DRODPB)@`Y2>$P,("(A[BNB%*4IU""<H`!Q
M\B/DP!X,/_*3^H_\`]!W@ND(`/O#]0_X_P#X]`+M*TZA9NW@'E]M=?J#2SVR
MO4.M/)QXU02G;E;I)K$U>JM?R?:HK(3DLX*D1`H?WE__`)!Z#YR^D_HLW2Y]
M=6G?N9.N66$99,;*71V."K0)9*N,%]NJ:%`[>_WI"-DO#G:Z\P148L0,,6W?
M+++%334`BH!)NL/I%U#5NC[;M7-73<+S>P:53';UC-5B*-!RB-)ZGPN"#+H#
M37I)6->QDO7W^2K*METT_P`8YEC"4R*GZ."@+^K/J&?]0W5:B<1]>YKD#W'>
M?J1S]U)7X>)<*3CS<,=ML3OW.EG/6(T\BE07@Z3+/9V7=I*#(#'22B"0.`<"
M=,"KV9P_IE"Y+S+#Y+:^4JQFN9].\J;54KOJSFQ9W+:_O-9N,M>]V<:M8(J)
MML1$3?0&IR90C48N(72CDW2P*E6`J+<P"C1/HKTG1=.7Z`FT\:M\7I]]UFW:
M]PU';1N6+\RPE;VJK1T+.FK6LYM5F-IMEF0<,@<OCN*K#1T^@I^.Y9(%*"GH
M(1W-RKE&0,NX\*?=`<(<KVKN>J\2%PFO:_;7MD-)0?+P-:Q=X>YQURH4@6GT
M^?A$6D/!33,[U^Q4;$>@<'A4SD#9=&\Y4_D[H4=DTG<.!^<6FL=_\P]@YI'6
MR\O8A]8,YQ_FMQB&XQ$'%MJ%&)NI&9L=B-+,$FCD6"ZCH#+&24*`*@']7^GG
MI6?QJW;-.:WQ3#EMN39+2Y&U6+89VLX$WIF<]"+:;F-B@OPL+K4+3H%Y499K
M"IQC@C]Q^<L*IY5T=3P8'"[!X]O>.Z_=NTKAKO'^*955>A.3^DLSS[4=$D:'
MD5OTG-\SM^::W0[V=Q01A8AW=F%P(^@K(R0FWOYD0T65C@.F44P7GH[8:9>=
MVG+]8K9QB3FWJWZW7//=IZ9L$K>Z[R]5IFTZ[JZK2K9!J$?F]@I6B:EGS1VZ
M55@)&4JDI*+($D4"L`^1$@&/%.'+KU'<2;UDG2G*F[\^PMKZLKE/>T^PKR]'
MO67[O0:C6$\UT'-J-2:RSKUZCWU;.E8[`M/2UDD?E3?BN19$J)@:6-^MCKNQ
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M](XC/_DI3,NU!TV4$#*&;?\`4\_T]!IH?D#ZY*O]G$EO\+18!A]B%UR66T!\
M^_<[@Y<.\VCDX#*)_0T8;\L:-&.3I3#2*6$I$G2R1Q]I0,<YO0;+MKBBP=0:
M=E.BPULJ\-'T/"NL\0G:W<(B5-'2[+J&D1=,:SY;#&/VZS'^*2U;;*BS(FFN
MNDL)141-[0]`BEY^H_>;71:;%-]/YYSUY#?63;>%]"BJQ1;$SH!;$-ABK#6[
MM4V3>1:DCZ>R7A2'?M7Y7"Q?D54`2G$3^@T%YY=AWW/O2MAL_9G.$AP'U)=\
M+T[8;Z]K97;?)7>3LLYS*^1E"L!YB7KND0FK3F4I,T7DF[:-JT<%%$64@)S)
M'"L?HOZ@<WR7>]#;U'[(Y?/L<T.88]"5>ET',-DNMBXXI+^$4I$#=(^'R"R/
MZC&UG_$*+ROQ5LNS:,CHJ&3=JH_,*#@Y@>^^<U<NXYH=BC:_W%STQR+J7CKF
M*AJPMWB%Y>ZQ>+\[&9M2;WG=M@;(\C++#SRW^ZZ>+LV$9$N5@6,\/X`GH(U:
M_J'HN<,]VP"3WKCNO6+N!7H2+YQO4OD=C9=26Y?=9&:T&[PDA/JZPM#2\-3X
M=5-%1]&QGLE&QDQ6_!5*4%P;[K[ZV*N6-L&N6_I++\6I<!]:*WU^IH3&=*,:
MHQFI.VQ$I7;\,H]O97W[0^ETFT,WKB",@]=&=)_"Y.J?XC@M]0Y%'I3:NFJ]
MA'V(15`3UUUD>@[?RY8>7=(INANX*B8\AB7F:<6.\Y!LL'E5U:-07CGD0VB2
MN``2@[=I',00:JE_4?K5+S'3<X-U=GTPST/@FJ<32LY.\W.'4E%%HIK>G$75
MBNGM#)/^+1L+:4F(P2@*"I^$DH=^8_N#T!%S#A_HSEJ,VTU#Z9I]KRS3J[`W
M'2LM>\_S$U=7VBUOGVOY/>'N56U#6FQZS&Z(>C,73!DYC)<S%53X$_E^8%O0
M*)Q_]=W1>J\,<LO;IMTQS5ON-\P3N#90LVQZ7A+=C2%LF8Y'1HB]1CF^_O5T
MD)2HP;>)/)Q\A6S-_<=VS(V5,40`!YI],\%H5@BLEI?;32;2YCZILF[2=_JW
M/%X1OF;7*V7;/[I<<IS#IJ9W.S22<P5K6BL)1@_<V%4S28!9R@#HI%P"UJY\
M-=4.MGH_2^8]K0%6VV)S;3L=T*P7OFYC?*Y;<HNVH2.C9<C$4N#U/-PJ%HQF
M)D#PS64(ZE4Y0I_>NV]_RE,"AV7@7.D];K?`FD]A1-ASS6=@U'O?-.<[;EYE
M]74OK$LK)7&2'48BY1["5S>%UBZO)Q2,/')OP/\`&T3D1*FH'H/7$?2%:F7,
M5=YU?=9P+]G#\5]0<8*6]E@#ENI-1>^Z$UTB%OBL8CJBK1&1IDDT.W7;?.<D
MV0X>%VYP,!@M.R'5<EYRB:/R9=-,C!T##\>YCI,K8)*(7I]?MSB\)V/,<U"!
M([>244C+6N8RV4\QJ3YVY:"0"")R"D(@U=VT"L9[4Y^]W6=956FU2(D+!8+)
M8#FCV$9#1K<RSQZ],LBFJ0$?88")$3.HL;VE*'DQ0$%RS[N#$]`M%0I2,A<Z
M;8M%*!<W'3,RO&=Q>BK'B3SJ:-(DK3$Q\399`T&7\X6*#O\`+*U_W/8(>?`-
MBD]7(*OSK!Y_50A3D+[C"<?A3(DBA\QQ2`$S&*`"H<Y_/D2AX`07O9NK<EP6
MTQM7U6Q*TUF[S'0M8E;I)-%"U&J4[,G%9:S\O9)@Z1&S$JKJT(D23,`?(1-0
MWDH``^@/-=GFT_%1<Y%/6LQ"S$,RFXF:C?:M'S$;*-T'T6_9F*H97X7K%P14
MOM*<@D,`@<1]!N1<J>T/U3!80,4$_D'VF$HD(8__`$??[".3`GY\>/`^?Z^@
M^,ZJSCRR_83%S&AMN?JAS_I_VB]0:91.BLX:)N>@YS5>2H)Y5XKGR3M\,LX9
M*(Z+%$>*-A\@L^81Y6J9Q*`B<&PL7V_]4NN8+UU2I&8ME^<Z/NF3YMSTU)%*
M:/IM)A;A+6>ONXN^T*!GY%S.76SRT*U*P5.1DBV!X)C,S%14\@'<R[:[JHU[
MVJ][ZQYJJVI5?9>'\;Z/N]/K$<\U&BY]<\;-HUPK[_(WEH2-8!S75]3@(=:8
M:**`G&N'SE(%CMDR%#T7#[G>RBZGT#S/E$OS=;^CK5]@/1>*\S!ICZMYYE^6
M8;SO)0<,^:;18'4HP>R%DO4BY.6,%,#2(F6`I4U?>F*8;"\?:O\`:=DE9UUE
MID'R`74WG6<3PGS\VK+"R0>-*Z\Z:1]OO&CZ9I5TL94*E5J#777[8R;N1$'\
M@;W*E$1*'H)B][KU[I'H3E[G[9=.P^F3M'Z_YWR^]4?%Y*/O@:=L-7QR0Z0N
M=C--O%&[JNY,C^WQ[.)=H(B1V^%RD!@$I!(!Z^Q#[;]KX9[6?9!+T&K-L!<\
MLP^C4FR6)-8\Q?=GG=HKM(<,(F0;JE19T>CUF;<.)T54RG9),?R!.1)4OD`[
MT?W5L,SK?0T'D5\PJ)N.=<[1%GP[5/X4T6=Y;`:]ME6S>MZ+$WJ:<J0<KGUE
MKCAY*.572+MI\:1/)2%']0"WUY[=T;6OMIV=]%3.=W3FCOGJ/H6K3,]+U>2@
MM'?S?&V!T"G.="K<DL=O`/*K;[L9-L5BP*H@8B"ZC8000`A0V7V/:GT_LG0/
M0.#9]M35&";=E<$8;D6+?M99&0J4]D^;/>R]CT*Q0I3H#8J79&)6#0K@WM3=
MN(8$3^?:4/0,QRI]H75O86L\N9?0*_D-=,3'L8V#JRT6R0CZ^RM+31)6?_?Z
MG@=3D'BMML-@C(*,0.<S<R;9F_4417,<2@3T'B[SI=MZ:^WC%L"R!E@;BYTO
MZ]M\'0I3=:^\N$?!Y9T!J.:U![.TN"AI!C*)7R)@863)'?EF%B<51*8#)_(7
MT$F^JK-<%Y+F>U,#V.\,)34<8WJJ4N.M_4DC`JZ?8>:ZQB]"8X8,1-V8R,<_
MI<6Q,Y_'_:O<T;F46^4A'"@E]!$^X8B:[;RJE<J_7SC&3:CSK7<WE-LTFISV
MB2V"043-6@SQ]SPR8L48=^^32B+&R4M#V.<-$VZ[(6_L]IC@3T$<XXZ5B-VZ
M=Y2V;I2;9,,L7^OZP9YFC'47<0XSFN]A9+ID7FW1P",E'-8J)U.5K44LNP'P
M1P]K#Q<2%`OR`(`;NAS2]1OG;$?C/[94<!WC3/JQP*6U.0BFP8TCTM4MGGM"
MT'2<_CG:2=?LO\;R-E58R2DFGX[,YFSA)<3`BH80M,^HQC9X^>[^0MS[.+G.
M$ZH9$<ZUBT`E6,BTMDTSVLL6$A6(*-65B&5D@&+<&-C.S.<BDJDH8QC&$3"`
MB^O[&/MDH/V7=XZ#V!HKBS<;Z)^<7GFO+6Y&4@HR2/:X8U9/4*R5N<]3:M*@
MDY2=II@0JZIO>?\`4/=Z`"]5ZHXY^^R^\?8M6&.B6G.>8JMDO"O0^7Y=7#V-
M]-P^PHVZYPM_-7(>10>REDSK1['52*`J()IPTLH8HD4*(@"KT[IO=N8W_?5"
MPNWYQ:>Z.@.\\EK=[VW7X6.J^8YI8M-Y@2T.4A)R9>(/81E%Y/-Q"T!#,GK9
MR@**9T_!U/!@!N4NC?M%F=C6S.)ZMQF86S6^<AY)JI\_Y^@W<-.3VWYU9+;K
MMTK4U9H^0!6%S.*B$W\<1N8S994X$7,"(BD4*Z:3U_W%NNX5/MBB6.G0G2F<
M\*T?)%,QB\[C9)YU?<+SVU=JT:A0\1+LW;NA*76G<Z&EI=ZR2*E!C("NV40:
M%`!!EXK[`_M.W/G"+Z@SC8<7R>0V_<\1RG->>2974=<OV8RFA7:ZUBTURV@W
MC(Z5K<96JQ$C(J*V(73PTK!N"E.FT<$1`+G/L#O&V06)9WRIC%^II^P^JED\
MQH]IN:"\!7W;:L025@VV]KL:JJT>09'-/9.S(I-0^/\`(7*D3Q^GH*(8>:LO
M/?"/V#?6)?8G**%?,^ZEYTJU4J=+?2<CCA.>>Z]IS.&9U&G)V]23F4X.O@XL
M(2[1T=44VSD!3]@&`0"R[ZZ-2H/-]L^T*L]3347F5]@.R]7MZ\EI+Y$LC;><
MI2&BY#%'E0,\*NXLF<PN<J-HV+C&*:Z;,Z*C;XP4\E$`*GDF'=*?8U+8;@#&
M!R3*FGU.+5R1AUJ`JQLU4HW3>RK6!ZYSB,6*5I4)*8KRRIW/Y7D44UP]J7Z!
M[07/L_/MV?QS'MCFVAX;;>:?J.'.:QSI8;W;K?([))9[RRY@)#IP]2?1+YM#
M2K+5H2J)5IT,F1U(KGA7`MS)BX]QPN#[IUO.FX?73OUW@):Z\XON@ZM)S;H:
MG/V!E5YS1LXM*N/:?/UHA%3M(>MS"ZB+IY)(?'&F>D5-[3I@(`&OLR[MSW/J
ME;Y;F>4K+CHJKPU)JS[J!:NR,KBN"5'<IQ:JDL-OU:OL91HL];)H`HW;-T)8
MK$5"&.FB8P"4%:OM]^PBAM*[;(SKZ7O=1Q'.OK^EOWN!H;I_&Z[=M'TR?H^R
MSMT*,$-HM&:.:"\,J=J8@/U'C`CP13/[SF!?4.GNGT96(Q^!Z_NV=V/??LU[
MI6M&KZ>QT:02RUIA&VT"MXYSI2&HU95J2DW3(7X232,]X1\BZ4(FFX\`LGZ"
MWCZQV76UAT/N*Z].;EIE\KU>ZCVGGGGF"L3*$KD$GE^=6Y<RNA,H2.BV"KF?
M>33APT;/%142)%M44T?]L/U"A_&[?U%BV3S>?R6G]%T^-N,1U[V%E=FCE)61
MM.^=?R?3;3+,<RUU(U%I*/YJ@$@8U%X>NO#D:NS+'5?G_%3*"87K_6I3>J5=
ML[NTKH??=>T6LAN[S.L@S:Y-6\9`T6NH5.GW"VNZU%I,T4W<=$W6S/(&)=HK
M&*ZB(A)<W^Z<Y2A5IT2'5KJS43[F8E7'+UGE=Z\HC_,:`TRG4U>@*?R:[.VP
MV2SQO8A>HO(>,EW`KW*P11(H459910P'!/S[@C72?V;]H<Y[-:\RSRI=8;XV
MROKCH64M&H2>)E+DU@J"V(M;?A^)Q2=!:Q!IRC,7BR\J[=MD$$VR+`2G,NY7
M$#`&^0MUT^X=T7![4M4ZYV`MPZ+J#EMJ-IH&GQ>:7*GYYPEO=WLK!5U;HUJW
M6SMETY9/%6@UT&Y(]$J*;=4/)">@;[5IB/I7T+Y1*EVK7]H?P^KX5;M&2TN.
MTM_I.OVE/7&=SUK#8>NO&*5NDB,G;.2_;8=<#,12B"H`J=#V*"#K:=VYSE]A
MG^*L:XQFG.MVRA:YFFW:\_CZ[.5"4Y4K&9.27D7UM862*B)2,TV?-'_M%>B$
MF[I-U(E$CD`:E$Q@I=S7[2NIB73),GOC[O.I8U>.;8O.IGI;4<'O,7,16B7'
MI1ZILVM6%W4_W12`F,]R9@O7:K+_`(:)!EC@L#<6Z8"(3GC.\]27K,HUA<(C
MNA71,XK&PTNHVC3,_E7UDM=:M_V$-3/S2T_=73Y[)I0.$DBFI$C^"&8_N)#?
MD(H)']`R%V1Z,RW*?L`[=RCJ/I::TCG/L745Y;F[1']B@L!N&>0YXN!C,LSF
ML2+-J1-JM`29%XB0B5OA)(E*(![0]OH/H'_8-E_[,1K0NYC_`#N'.81Y7OY8
MC/CIQLX$AT/D]_QEE0LA2I>?D%(7`_)^A`\"!BC<#Q2';LF<3E.>1C&,M1;U
M%,6%,KC1I%78I3D-;XU!",3(RLJJ2IB*/4_:X4*80,8?(^0KK[,^H[GKIV@Y
MU0J;#T[$8^A:E*ZL#6MT#\N'FK7,P,Q`?RJ68P4S5GBMTJG[XO(UZ16=*!%2
MP$<%34`OL$'BJG+V-0T)5V=AI%2T2TURO4^$D](O51JTQ?KM)TV#B81E;[I8
M#0Z;R=M#TL,DNLNL8Q07\B0I0\``>V9Y8YIGI9:R3G/>(R\\I9'-S7G)'*Z0
M_F'%N<NB/7-J6D'<(LY6L:[M(JIGIA,Y$Y`'W_H'@*S:CTOD^C?8)V9]<72V
M788^K>=U'/\`J[+I27J$"M7K16[-#_N-V?71E8&9VDCIU/>,B/',FF0WM8>#
MG/Y(/@`APUWEQ[O+/MKKJY0O*&+<\8/TPQPK&=<D*=4:M9IEI0*Q&1P6RS7A
M>)*F]2L<Y,K!6CL%BKEC!#W%]IP*(.=I/?WU/3,Z>#UCI3C*PR\.UDJ^0;_9
MZ!/O8IA(,&#RPUI!681>'9&?LUVYW#4%`*[1]H&(<4S`4$LKW?',;G[.-%YG
MONC<DI\PZ#R1S:OS7&.:K12+Z+8;Y8G7R5B`M*+1PTL=(?1+1(S**4(FS17*
M`I@'H'TM/>?U>YW9G$99>CN3J3:<<L4_`-X^8L-/AIB@V06AW-H8P#+XRKL9
M%=BLJ#P&10%8XF3,8Q_<4`+NX6C*,LR:S](5W/,_O=LD*^A*T652CZPUFM1N
MD[&$BLQC6]PD4&RPEGW4LBU%XHY)\$<JHIY!L0_M!&>4^Y>-K-R+S7UQTRRY
MIYATJS%L>72Y)2,J-=-2=6H<O+?Y`R:E6%2/;RKAG#2S-11-!FH/R"(JE`WN
M\B#)4_N#ZW;F^T3>:5O?,=ILF=9_$GUC4*[/5A]:ZMF3UTZ=0<=9IU-(L^G"
M%E53@C&^_P`E>F*F"?R"8/0`[4_L4^J&UUEY=C[SQOJN@,\NF;E3DK&ZAK1,
MR+`("2EHMN_!I!S=G0IIOVX1>J`@=1NV3.<$_D`/0,7E/5'.$0X@JM<K]SU6
M>B+%C333-*89@=8]0_8:]7F$[+/&-DDX>,EEX&!KSY%1LWD2I.TFBB9A0(!@
M#T`)E?L7^H):C&0E]PYJ/562EAL[6AR]>C2NVDFV<)LK'/DI3J`_>V\X?]Z(
MHNZ10_)%FN98PBE[A`-A]F.KQF#_`%^N=/QAED)WW\TYZC\J;6*C5>YYU+*:
M;K6?4^1=P=1=$8Q\ZM,4"W2*K=5N0JH)`<X`']WH"YDO<'#"MCLF*Y3M.*,K
M9EL!;[/I5'J39O7X^G%I#0LAI<K(1T0P0CF$O%$$SUPDJ/RJM#`M_<F(*&`6
MWG[B^#JK6,OLY-D_(K.XT;0KSFMY2I=QD*C_`!G.6_QSE]M#F/AU'D-1/W-R
MW;`]$A$G!EBIIB(G+Y#T9#W_`,A2,W*42[Z#A<5JW[SSEGNK6J"8)0F:Z7TI
MN=!+;JC4:A-R\:WD9^7GVL"*T<VF2I2238S`AB%.<"@&_D.L/KUF]*9YC(.\
MBLKV_5[8-DFK2K08AYGKAMR[824_2;EH5S/#JP;.:I-J4<LFZKQP=8QBJ`D<
MQ3>!`[8_TIR/LV4SG0&67S-93)*T>60M%T9MX>+C:VZJ[0[)VULBQV[1S%2#
M"+7`6Z:P$,#-8I`*!5``00S=.QL.=3G)68<M25'SO8>G=S7Q>N:;)XO^-9\P
MJ].HDWI5VE48-U#1$FP=66K.VL=#F=*-V+D]H0<E.+<RRGH)2RM%NZ`ZNZ-Y
MNYVE*/S9`<NMJ6IM.GQ>1T2T6W3-GT^JLKK5'%5:'6BTXB)S^'E#_G.GY1D'
MTF^<($`$TQ6.&R3Z[J?&<#3T/MBV?FN$V%:^VJMX=JD#7%6#RZT`"HI-[NZB
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M:O$"E`","KF16,4_M`0WNL?89RWF76'/%0BK[1U>([5B>XSVEMZ=GS2Q8\RL
M=(TQMGH7FX2%?@W4%#5F#M_N8.)!P4C%JN7RJ<@^!]`/>,^Y[=`N)-[T-T53
MD,Z_DG4N]0J-GJ;BUV>X\FI;'`8KS8PI6C5R,:5Q*5B])=/F$9!_&K+/T7#9
M)),2J%5,%RU"V;,=>QLF]DJ$]0:5'A9+!(,MVS*5S.TU!6HO5U+)8;'6;=$-
M)BN*,$H==VU>JIE!Q_:I[_C,0WH*A>-?L+;=H6_[&\QVO9,TKF%1],C]=QG0
ML1O58A+-F_+NHM'U?*;1;+%.IMQ4]A1?1SD72CA%-8HF`4P.`IJ"#-4+LSD;
MGG#L&SS%L2Z&EF[%8M!Q[*6>+7)SM">75UY',[1T(M"6)FG9PQD26).0>6Q4
M4FTN=V/P'454!/T$SMWVV<<9K_EV4TBT6^GT?,7#D&FA+TF;<4#5PKV@UK(-
M(DL9D8MBLO=(;*]3N+""L+U`AD6;UP(G,!2G,4--KOV_<5XU)6>HF<Z-I\Y3
M)^Y45_$9)DUCO+&2T'/ZM$WRYY^RDXF/5KQ[G5*I+'?/&Q5?<5)JX\_JF)?0
M30/LNYZ;ZIHF8DKVC*Q^7\V9ATQ+7X*PD>LS,=NRS9'+,F@&Z9@FY75;<U<E
M7:QB+,W^RF8@F]P"7T`:7^Z'E"FT>G6:_P!'Z`S>PVNIR=WFL[G\EGG$K5:E
M3]3>8AHMFM;^O,GM=+$YM:F13S"R:X@FR5053`WRE`X270?M*P>FVG0Z-(XI
MLMV?Y?T)AN#5-U$TJ%EX/4=3V>I)6QL.?OSNE6R#_/8&05"<_)_$=-/9[4P$
M%"`<'!E^'^4[ONM.ZCE<8AF&ZU!RTEHZ]0SF5JDJ\=-45$XLMN8UF2BXRWJQ
M(G]S?]U0=J('(`>[P`E$&S5B&*R:R9T0\.?_`.P(`7RX]ON%,%RB42+%2,83
M%*8!*!A$?'ZCY#M4CVZBB2HBL4Z0`41!8X_*F!CF!)43B83)@8X_H`A^@^/Z
M?IZ!>M7Y&P+;]`RO3-0I)K7:,8EG<W0"O)^Q(UZ/DW1R./RI2IM)1"LV0[5\
MF5RC^XM'0)KE`0_0`+Z!A_PP^'XOR'7N!+X@<?*'Y``)@,)_?[?;\@F`!\^W
M_3_P]![/0='XY/`%$3&3\#[DS^%"G$1\@8XJ`8XB7_3]?'H.PB9"!X*`?_0/
MU_\`0```_P#3T'G77%(/($,<P^XI$0*)A4,'GV`)B@((D,(?\P@(>!]!1#NG
MUCZ1T385M%O.O?X6N5)[*O&SQ5SSY_)R:=KY8OU8:5NW8;>&IDJX0KJ5IS5R
MR5,V4>-A.L`J`H'DHA715/J=F>@+'4]JP2X\K:5QPSZXW38F/.=0N&BU#*[S
MGMEQ^L<^M:E99R'KDQ)PUISEO27Z#R)41=LW24R^0^-!$Q?0-]&?4Y;=6NEV
MTQ/7.?Y#.KMTELN_4RN9'2*\%#=L%.78[FCGZOO%XUHK#&<T!Q'O)%^[9@=T
ML[`J@+@M[S&`:<__`$;[+EU8#([MJ.,3U-?TOEZO6+78.IV1AK4>TYLJ5E0A
M,^@6R$@V58U:5T&>).+29Y8PKG;^TS,AQ!8`W?&7UKYS*TK"*$^8<NZ?>.$^
MHJXEK.DL4K;?]$L#[/*[<K4Z+-/]`;FEL^F;);KVSFRP3)60BFWYSA0JRPN!
M%,+5^K.32];:]BE6V.@9IH?(>=(V*]W*BVZ1GY"<LFP&3(SI2SRHH1Z=8EJM
M58'\E1,SUXN51=\*?XY?A*<P4[ZISQR-P'*7[&]4ZNQ3GO&KAV-2.\.?L`DH
MJSC'YG4Z-%2T=?&$'%_BS,<UKLO;'J<@Y(S9IL62A3%,7R)C""U.?IWF^C#I
M2/(?7F"6PN74/EK/M?S"P9YH413K[8<WV2P=5Q:MCLE2G*B[1SZ]0ND(NT2L
MF2JRYTT_B=)%`2E"R76/J&>7.E]0HQMSQ+`;!O?$61\K5-/+*`K7JGDKV)N4
M[,Z`].JE(L)^Y0%R7F6<8Q!ZJ5T9LU,B(@F<$O0`:Y\A]%PL-=/K:8==<THW
M#==/+V)F%=L&/Z>M>-7I,#I%;N&XU.]2$=;9*GP5';3T>BV8*)*@[=HHID.W
M*(F.`%^P?6)I]2R7>YW?.JZ1+6)S"]RW>*Z()D\S'R^?*],5>-A7-DD:@2SV
M(9U+.JQ%#'E1;J)F,Q;(E*!S&,<@,6CSE-=%\3?7Y0\KV?)[A3L1N_+VDRNL
MLZS8(FN:S2\#8M'K7^#U49M_(UEW;'C!L15S).'((IH+@9`PJ)B0-18/K1T^
M3NDGK+;8<\L%WE.KNDM_6AM(RV8ME7LV2[C1&V;0&&N7L-;*Y-0H5:FQ[:.)
M,A\Y0;&/X8'`H%]`'6WU;S-KQ!QE64[_`(\RJC7F?<N/;*V"M6C7)*APU[M\
M!>6F7TF](:=53-8K.;'%`BY1E6[ETY8F21]K02%4`-T?ZCMBC*[>:S7NA\=C
M(^P=7Y!U!3&B_/=EG8^FSN;\VQF'R3)"'5V@$Y!*%GJQ#V6H+*+)J0<C')B_
M-+^XI?0#+/?IEW"@<MP/-?\`W09U9V[+#YS)I*:>9-+HC*66-Z._[A,ULK=>
M'MR<VV8D.Z/&6H@NUE'I"I+1ZD6H97W@\N]<@+W_`.MO3>==QON&92_>5L;1
M=M.R;*7M6QB%?UVS,;F\G/\`'DU>+#8)1HN,04C]5Q+G?.U3";W^\0+Z!(LQ
MG/X'UWCO66Q:NQ:9Q?ZMN.ER5O)G5^S3/;39-B1Q?,^;L"QNA6T5M(N>B$JF
M?S,L#(L8XG#JJ/C(-D6CE`@@;,00I>N=A=`],?7'TCCJ#K2(JBU?M;"-7RG8
MC7V.TJF,)IAGVI1U2L=LR&SYS,R%65:Q;UL[A21\F6-_VW!'15C^@V!?K.V&
M1[`Q;L:Z]`Y[LEJ@XJ5@-)A]>QF?D86MM%;@VN2"O-D5":55RYG^S/8])FQ_
M?#6M9H!SN?>LIX\``]'X1HF$9G@$E4.QJK13<G=+=0Z'I3P,_5G;9<[UW(AI
ME"CJA$56H76`LU?UYNVV8K&IN%R/73IRFBLFW52,5(X"3$_KXT_I;%+)4:KH
M=[Q2OTO$?KUPG,=[OF)S]3O]]-Q==W6I2$Q+8K>[*FHS@Y.WO03:)2"PHF=H
MBLJ5RF4I50B>'?5\E4[OJ7)&'=28>ATQS;O^7=>SVBV#D:QH:!:/Y;/3MTIL
M=T':8G9*U&:^4LE++/8I>-0BDHARB02)G]OM]`5,!)@NO<#7SZ=*']CL+I?2
MMOB^D<H+L%KY]TNEN;`Z-H<Z^W^/K,38Y*KQNBR=+D+!(I2ZD;9)'X3.DUE1
M42]I#@W7VBXQ$7'FWBW(KKU1+\SS\;U]S)%U39*-FBE@D[GJ$%6+W'Q=5AJI
M(2IF-17LY&KIPS?OC2R#%XT1%5NN`$\A7'S[];F%9CI]_P"#;QV^IIM@B\*R
MG']WSS1,8:03*<QG2=RL&I5NO8M96%DCV,1?=:G2?#8%%@GU7[U!5R1NB`E3
M3`^RWT-6]\FG(Q';DS#6"FQ0Q>/,F..T]#,\[BZWTU6>FL^ITM5V$FA,V6E4
MF>KB22[1Q+MGSI57W@[3)X3*%A>OM7FUUN4^OE;JW.I;IR<@:WJ>VPTOG:;U
MW.\X2&F$=6BH,Z77K/$#5*9<XEH:H(.GLC-2"<2X,=TFZ65!T8%^Z=^EK$MQ
MFG:>)2=1Y`HMMY]O^)Z72<*R&L50VGJR\I&6',[#9S(E;0LM%9M98H':+%U&
MF<O154(1XU\CZ#SU3ZL^B&%OPO9+!WW9E>AZ1F4]SINNETWGK/ZNQV3!'SJ+
ME8&E0U/E"VV%SFTU:1B$"I3R)GQEFRBJ9DS&^,Z0:XWTZRJ]"/2F?5$M6)?.
M<^)DO*]ZJN70Z$]DN;/-ZI6\R3G04;)/V.-TC3'%KH[-L60(C"QJ;=("ECA5
M^03!*L'^F#/<'C;-"M>@MOTEI8+;T%>F\QHQ*:^G8&V]&T%A1;78XN5AJK#F
M-*,UD'#QNL;W"BHZ,F5,42E``%FA_2;;Y*1H5PRWOWHG-[QG27,9H=];*7E.
M@0\]8^8@E(>FW2[U]*IPS69LC.K3#EM&BT<M&C9845W#1T<IRG`U5'Z>:+#X
M]HF37?H;==8<W;+-UQ4NFW%OG*>F56A[O=HS3;/#5V9@:?$-5O%BB_RS'=M1
M46>.UC^XJ((((A-+M]6<#I;77J]<MYTV>HFPV'-K:CG<W!9_)0V=7#,DZXC"
M:70YUU10L\5I!UJR4YEE':C!$%S_`!-2&]J@!;+$MBLV#)H5=PZ_$9-F8O7J
M@*OWWX:)&X.WJOL*99PM[!,<P_U,(CX_7T&S]!GH,]!GH,]!GH,]!TBG^IO:
M(@`B(B`"(#[A-Y$?=_42C_X?T]!%+-,QM:@929FG(-8>!8O9F8?B)4&C2'BV
MRS^1,L/_`$3'08MU#>T0`HA_40]!\>_,6F=+4"G=`8709VP058^VQUK_`%5Q
M/M&>PKQK6>4J&\N%W@]\M]IGF)D?X3*P>2MJW:*WY/\``\GI,S8G@0.)@G'.
MO;'45?H'UH</\$2>!QZJ'&6#Z=I^I[W,$<5F:=7J1G(*0AH27][A:QS,2K"K
M2+EC'J)R;E=R9'WI&1.'H(]2OM4^T/\`Q1':]<KCA3DE4R&7W;2ZA%XV^:+'
MJ[7K0F"T>*:NC)KOX,;U5BKS)SK`HY123(9'QY$1`!U[O/K/B*3Z+ZRR%7+]
MTQ[J3K#J^YRN(0E*DW1\G8TL:_@.1:YL.I)BB_R6,FM3CHDDE`2#<SI:-??F
MHBDB)A`+9N?MU^TN[=8<X9;I_0_)4CF^A9QM&S7:KXY1F5VOU?SW/M3"O49I
M,7I-)O2%)#2HJ=3B4U(Q!`J+R!?"`"H4QO0;OJ7/M/W+[3M`BN<+/@[76\X^
MOZ@U^PQ.]Y4IHM=:5G0][?2<TC&.')58J*DIVJ)K-3D]IS.`$@+`*7H$IQ_[
M`?\`$_1'<>&4QO!XW<(;:.D;I;=,+FH/*;)4KGC&<6S_`)RQ*M)R;$8V7F[+
M/3#QRDV8*&581[5=!,A1.3P!/JO:?V83-CU9YTLRQ^'H&3]%\3Y)*Y72\K<6
M!"=MO1+')="LD`:V6,BCU:-Q0EL1($FQ`JBLK[ECC[$@+Z!2+U]G)ICOG#-P
MB;C1+7IVJ<UR69XW#WJD2M6I/-BFD="VB+M(:M9&D=[F+NL9G6DW3Q*04.H]
MD%$$">`/[?063\^]KZ1TA]-';'1/1<VQG9VEAV'2#3-?I2U);/\`.,V=2</4
M)9.J_A(E4D)&O`1R`))F!Q\H)@(C^GH%?<]$]E\B\[X9'X9?:A'8%SEP-]:N
MD6*@2>3)3MEM,]T5K\5CEHKLO*J,SO4(H*LWEGZP,O8\8.6B9E/'O]!^:?W7
MV/<YAY07O4,+1(^R?93A]7K>OXGG+-[0*UQSHL'9+E1X5C>FT6J\G)BSIP2,
M=/LY(BDE&.G!DG!P3\>`&<Y]E?3C/)H?6ZQL,=F^JP7`'7.QJ5F1Q6-9Y=IN
MRY_T<:GH+O:S'0B:K:V5FDM&C@PIC\$J@)Q\F*)O`$F(^TG:.P(+)IJ+U>Z<
MT4N([^P#(9EQ$Y_/TO1+C&4[FB[;=>V4U&NHIT=UD?0NH5^.@XPJ12*?M1E!
M4.4JZ7M!Y/K;ZV[8Z$Q7H'K'>+)D=LK,EG<KHF#<L8^Q]^B4<T%&6&9:5ZY7
M!BPCG$E.6[]J;QG[4X^1_'.TE"JG'Y`]!7+O^_=N=D\]9SA"VL4-C']BON7:
MSJ\O!4Z.<USDW3]1WVN-6?/S8(1M&2-U1G<_;OCRW[@=60:.&AC&4(CY*(6]
M]*2Y,\^QSD.^]"*-$.5:_B>PP69W-ZS._J]:ZYDWE178R%Y08-5XVH@KD$38
M$:_)+@1L@Y<+MTCIJ+)^05'O#[&JS1-'J-4X6@Z?_P!Q&X61+#=#Z_FL_2#-
M,[BX2OWW0(2N2>DS<"^J5RM-=G#_`)QXARBZ258NUP;*_E+)>P`+UMTM]D5*
MJ';,E(=4.(F@9^''F9919<OY]B(I,]NZ0C8$]XO#:ZG8&NS>JYP[*JHW=$*8
MWN?`FZ+["_H`4ZWN'2&G;3G[R"NS_/[!C?</;-U97F/P6J?R&;A^0.+8^TX]
M:[I2%X@T3I$8RTB9>,49($%D$T)INW1.#E%O[0Z8K[3^L-!:9YLSO2)>HS')
MW+]5T'6L;95V;AT^L=/US!*G*VV_HY?"UY)T.8Y?I-D<2*RSUR1FFSK[Y&/3
M(NJ<?06%?47ID<OI7V8:38M1U/8Q)>LHN\EJNC5.>B96R5RKXHS>6$:"A(0T
M813(V<I^0G5FC4QRBU#]2E$3>01:`Q^X63ZP+1]FT+IVHM=/HU$^P7:N-XZJ
M982&O&>O]SO>D-J]9+5'HL1N$Y<U:7&-F;8YOD*R!RFJ0JBB"*@@&-=ZATK[
M1I2O9=:[UTMAE5HO3U%OM!OC?`IVA7ZGDYXXULEQEM#K[-_"+1<?:]BV*YO$
MJXT4,I^1'1IP2%%=(@&`&U[H?[#L]Z-AK/L--U^7[4D7G)TQ;J_6<2F&5"TZ
MK9O@EENB-7U/1Z^U4@H![)R*J3AQ&)^XRC\HD$Y#']GH/I!^M;;JC:.=M&Z/
ME.DNB-K3DZU5=/U6MZ[&V8R&0WDE/<VB[T?)(:9@HR9;5A-XJNR"'036;(*,
MR(E$3^0]!62"?7>=])\4?:/HE-R:8SGIC;9:L)TO/<]T]?J2M8UUUF\8&$4K
M7G+I8]5BX_+%*'6&T[\+=!JQ=/7S@X![#>0E1>RM)DN>4=!OFL]<U*>V_>ZQ
ME?=2E:2N;`O`;Y:-EW4C7>?X,M:>V>)8.I%FWB$YF(,Z;HG(HZ7,8RP#Z`@S
M]JZQ:7:&:XUM'1]VLE<V//,/H%>L;JU3D-9>-)"B?RK4>GM;C)ULVK]HT.1+
M*G&(L+DI9!H]B2-B)`90WD$_YPZ(^T7=\';T>,NG2>:ZAG^'\.04/I&A41ZX
MD=:T'9NBGZ>_ZL_1M*"C9['9?5X1:$<MG!4OE(DO\B8HG3,8-Q9M@ZEQ*^X&
MRG[[V]M3_!]G^U"&@VA(>[7&8U^U4BP_C<WK:Z9FFS:6?+H"F/U9EJFLI\2S
M-HFW0]QDP`0$&>6+JG:MMJ&/X7V%]GS[/=!ZSPR9T719U"_4Z.:Y%:<,L9M=
M6SZ]6ILD_:U)]H!OECDDDTPC19I>2@*1?(&F0ONYK6)@77=B[-S6YL?KIUC-
M,ZVIG#Z:_KL/HEAZLMN-PN@Z^5`'94+<VC$:LZ4F")J/#-E#R21?@23`H?1]
M]>T?(M>+.:G$Q_E=&9F<DI=BF6>V7.6OVGQ\M-PS>1DHNTVJ<`)&1.P>.3I(
M%.4H(MRD3```H!Z!RRD`!]W]3?J`#X`/!1-[O:'C_3SZ#GZ#/09Z#/09Z#/0
M9Z#I73(JD<BAA(0P?J8I_C$`_P#=Y_3]/01><8U<(%\6R.XL:\DS=&EE)YPT
M&'&.*T6!]^Z@]4)'+1XLQ/\`.5R!T3)>?>'CSZ""PD?CIJ/`J565S<F9EI;H
MT(2`+3O\?*9VFW3&2_8TXX`KZ5)42.A^2"(GCQ0*0#``^T_H!/56_%7XE$-1
M7G*HQ(H*CEI:D7&R1Y4@DI7\H:!^T)G1_%&5*_`Y8\1*#H7(F\G$_M`CMV^#
M'3EC,'F.(L_V2+&=38)T0Z(5@\C[8$LLHF'PC`DF`\L?G**`.O\`I^3^@C3)
MORF++5QC7?.W[<C+31MU!BGFH1QIO\9HE9/\PE;*E07E!:F3%\$V(J!Y2,H'
M]I?(3"E(X9^>S_QLYR8)(M91)'_PLM*/(&J0S$@5L=(8+PX-7@L17HI?%[&O
MYPKC^JOO]!((]IGHW:;_`&IY3!T?]FARV#\`:\2ZEA"J'_9CS(,P+/FBU#^X
M&GY`BW`?/QA[O(^@A4DVYV!(!EW6)`B>]NSD_=/X`=`-!32;?N+=`KP/A3N@
MD^(7)P`9,Q1(!S?H00">R"%%$)(LHYI?L&;8IRP/@@@.%J,A&_L9GZJY@.%A
M(Q!J"`J__+,04A2,4/9Z`2O&_)BB$JF]><Y(HF6$9I0Y,L]P.?WOR7\X715$
M4U2V(A@$%RG,9X)OZ*_KZ`G&2RC^`OQ57SDV9%;OOWKV$K*=`,W!R<9`9(OO
M-7P:@Y'_`.2"HB0R@?W_`*_IZ#I7:9?^WR'Y#VB!%&C8(TE\_P#&`C@@%'9D
MZJ5[\X';!&DEDU31@F]K<KHQ_A+[_/H-'6TL*+669:DYQP]7+:0!JK6R4,D`
M>]%!Q\QVY8TAXH+2HG\GN*0/S`#W_J`>?0>YVAB)FR!W[C*R,BUZ4.@4XTL&
M9Z7^4<LND4KE-5#^+E?B870D]K4RW_4_N#T'L(AE0OVOX[K./W3\N-20`J=8
M%ZI-%A1&#6;BD=-PG*!6#'!#X_"IV0A\8@B7P(=M&:YH=DN;,7=$+&?DO4WQ
M:`:MEC32?Y:@RBJY*Z`)$DC//<"_DP&!3W"8/?Y'T"_VW-N5K5<\DMKJ]T&$
M<436PD:/6:[:J)`56T;/(MUV<,VFX5@"!K;>HQR)UHQN50L@1P!A\*?J'H&/
MLK*CE@9)2ZNZP>JD*=Q.!:G$/_&3H&20:@271DP+%#&D5,FH"2W]GS^PWGR!
M?01=JUQ(M-@/Q'>5FST9ED%/!#^'_P`+)8`^7]M+7_88T(>9$Q5!3%O_`/)$
M??[!`!,'H)7+M:D1FY&R.JD:+2=,S2!9H8C\(Z@E+^"E*&DCJ(++B`A\!E/!
MR_I[/Z!Z`,K97D#;J9'69+0C.=RF<6>TNFY[,W*!590>>PUI2DKE;*)054D[
M"C^[V&3C$;"^3659K':L$U2IG*7W@5`9YF+Z7,J^I1Y0M10-.`7^-(N2T'VO
MRLC39$BE<K5`$_R_C*Y,:-$15$"?\P`$O,VBOVHI_GC_`-C!B8X?*LV-"C$&
M9?[I?C`2,1C31W_C[D2(_P!``OH.B*:PY(QB>'>1IH%1D3\$D<#(T-^WF:D!
M(8C\4?PV[,&92_'\7E($OZ!X'SZ#9.VI#BBHX=BF/RI))%5$OP"L9P"B)TDE
M#?I(`H'A,X#Y#^@%$/T]!P;L1!L=)D]$$#F4`#H*$,*:@G$5A3.43"!Q_4!\
MB82CY'S_`*`'`K5L`C[GB)D_E15`A?@`"IIN/]E`5`,)E$S."G\B/_.H(C^A
M@'R'#\1J'P"HY:&521,5L<R@%3^'\<P*"9N=<X.""S_01.)@`@>[]/(^0]B;
M0XF,9-T(!\92`1LH0A2I^_Y$#&'VJF.<J?\`8`B/@2?Z>@\?X;?\MR8'+?\`
M+,8JK@"KI@N0G@I134*)CJ?"<G@/!O[`$0,4"B'GT'K0;(()NBN'"*I05'\C
M\HZ2QB_)\1VY':AA*50Z11*"8G#W_'[`\CX\B'8\:HKB(*KF(0Y"%.!%E$3#
M[5BF`2'35(9(?F`O@2^!$WZ#[@'QZ#@JT$?U%VH10XJ``G4*)?U((*BBFK[P
M3.*8#Y$@@`?K^G@1#T'`[53XD3`^(FW3(7W$^-)5HL44E`((E4,/L)[U"&*'
MO$/:0`#P`^0#V,$"H$4(185B^2"!C&]Z@?V`'@YP,(&\^/(?H'@!\?\`'T'O
+]!GH,]!GH,]!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex23logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23logo1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!0`>4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#FO&/Q=\>:
M5XUUO3[37$BMK:^FBAC2V@<*BN0HR4)SC&<G.>M8G_"[?B'_`-##_P"25O\`
M_&ZQ_B1;"T^)7B.,/NW:A+)G&/OL6Q^&[%<O0!Z!_P`+M^(?_0P_^25O_P#&
MZ/\`A=OQ#_Z&'_R2M_\`XW7G]%`'H'_"[?B'_P!##_Y)6_\`\;H_X7;\0_\`
MH8?_`"2M_P#XW7G]%`'UW\&/%&J^+?!4VH:S??;+Q+V2$OY*Q[0%0A<*`#][
M.<=\=J]$KQ_]G'_DGFH?]A63_P!%15TFO?$:?0O&%EX;?P[<3W-^?]$D2Y0)
M(,D9.>G3.*`.\HKDM$\=Q:AXB;P[JFD7VC:QY1FC@NMC),@ZF-T)#8QS^/7!
MQTM]-<06<DEI:_:IUQMA\P)NY&?F/`XR?PH`L45YEHOQ7U'Q%IT]_I/@?5;J
MV@F,$C)/$"L@`)7:3G@$=N]=MX8UP^(]`@U,V4UD\CRQO;3_`'XVCD:-@WOE
M#0!KT5YW#\3+^X\97?A6#PE=2:K:1B69!>1;50A2&W$XQ\Z^_-:/AOXC6&N:
M_-X>O;"[TC7(@6-E=J,LH`.58<'@Y^@)Y%`'9T45B>'/%%AXF&I"S)$FG7TM
ME.A()W(V`P_V6&"#]1VH`VZ**P[7Q/;7?C._\-Q1DS65K'<2RAN`7)^3'KC:
M?^!4`;E%%<[JOC"PTCQ?HOAR?FXU5)61@W^K*XV@C_:^8`^JT`=%117/:CXP
MT_2_&.F>'+O,4VHPO)!,S`(7!P$^IYQ[\=30!T-%%<EXF\977AS6-.L/[#DN
MQJ4XM[62.X5=SXR=P(^4#GGVH`ZVBFQEFC5G78Q`)7.<'TS3J`"BN2D\975[
MJ]_IWAW0Y-5^P/Y-S=-<+!`LHQNB#$$EU!Y`'!X.*M^%?%7_``DHU"&;2[O3
M+W3YQ#<6US@LI*AE((X((.:`.BHHHH`**YB_\7L-:?2=$TBXUFY@8+>-!(D<
M5J3T#NQ`W8YVC)'XBJ-UXF\8V$,]W<^"4DM84+%+34UEF;'HNP9X[`Y],T`=
MK16/X6\1VGBWPU9ZY8QRQV]T&*I,`&4JQ4@X)'536;<>+[FZU"YLO#>BR:PU
MJ2EQ<&=8+>.0`'R]Y!W-@\[0<<4`=517#WOCO5/#T*77BCPM-86!<+)>6EVM
MU'#D@`OPK`$G&<$=*[*TN[>_M(;NTFCGMYD#QRQME74]"#0!-16'=>*;&T\9
M6'AF4,+R]MI+B)LC'R'[N.N2`Q_X"?PW*`"BL;Q%XEL?#4%E)>$DWE[#9PHO
M4M(P&?H!EC]/>MAMP4[0"V.`3@9H`6BN`T[XC7^JZ]JVBV7A6XEOM+'^D)]M
MB49/0*3@$G\JV/#7CG3?$FH7>E>3<6.LV2AKK3[I0)(QTR""0R\CD'^(=,T`
M=/16=KVLVOAW0+[6+PG[/9PM*P!&6P.%&>Y.`/<U)H^IP:UHMCJEMGR;R!)T
M!Z@,H.#[\T`7:*@O;E;*PN+IE++!$TA4=2%!./TK.\+^)=/\6Z!;:QIL@:&8
M?,A(+1..J-Z$?X'O0!L45#=23Q6SO;0+/,,;8VDV`\\\X..*YKPOXPN?%?AV
MYU:TT9XFBF:!+::X`=V4X;)QA<=O7!Z=:`.KHKE/`_CB'QK!J+)82V$]A<?9
MYK>9P75L=P.G.1]0?2K7C+Q4OA#1HM0:RDO6EN8[9((F`=V?(`7/4Y[4`=#1
M5>REN9K59+NV6VF/6(2>9M_'`JQ0`45Q7B_Q]+X1UW2=,DT9KPZO)Y-DT-R%
M9I,JI#!@`O+K@Y.><XQ3[KQ^-%UBRT_Q'HMWI:7\@AMKSS$F@+G^%F4Y0].H
M]3T!H`[*BBB@`HK&U?Q/I^BZSHNEW;E;C5YGA@[`%5R2?Q*J/=A6S0`4444`
M%%%%`'QA\5/^2H>(?^OL_P`A7(Q[/,7S-VS(W;>N.^*Z[XJ?\E0\0_\`7V?Y
M"N/H`]FUOX2>&-%^'\?B^36M2DM98()HX!'&KOYNW:!D]0&R?8&N/\/Z'X*\
M0Z@NFG6-4TN[G98[:2Z@22)G/`#;2".<#\>U>I>.)EG_`&9M"=)'<"&S3+@`
MY4;2..P(P/85\[T`=+XV\$:MX%UK^S]3571UWP7,0/ES+[$CJ.A';Z$$\U7O
M'Q(U+^VOV??"NHZADW[SQ*K[`&8A)%8GT!"Y..IV\>G@]`'TS^S=)*?!.J1&
M/$*ZB663^\QC3(_`!?SIGQ0OH=,^,?@>\N!)Y,08OY4;2-C=CA5!)^@!-2?L
MWS!O`^IP93*:DS\-\W,<8Y&.GR\<^O3',GQ`51\=/`;8&XA@3CDC<?\`$T`3
MMKFC>.OC'H:VER84T&WFGS.C02W$LFT"-4<!B%`R>.YKUJO(_P!H/3HV\&6>
MLQ,8;_3[U#%,G#@-G(##D<A6S_LUZEIKSR:59R7087#0(90R[3O*C.1VY[4`
M>)?!SQGX:\+>&M7L=6U2*RE.KRNBR*Q&PK&HY`(ZJ>^>":]B\.:UIWB+0H-6
MTG)LKAI&C)CV%B'8,<>[`GWSFO._V?55?!6KJI4J-:F`*]"/+BZ5Z=I\5A:V
M[6.GB%(K5O+:&(C]TQ`?:1V.&!QZ,#WH`\HT"1$_:C\4JSJI?2T503C<=EL<
M#UX!/X5=UW3_`/A(OCSH4NFNC?V):F349DP?+!+;(R1W))X[`DU@P^'M)\2?
MM*^*+36;&.\MX].CF2.3.`XCMU!X]F/YU85'^"7C)5#RGP+K,W.[+FQGV],]
M2.!SU*CN4R0#VIW6-&=V"JHR6)P`*^9OAUJE]X.\0Z)XCNI4.C^,))H9HUW8
M@D68JI/8X)&#Z,_'&:]]\57RQ>`M;U"U>.95TR>>)@=R.!$S`Y'4'CI7`V?@
M]/$W[.VG:4+?9=+9"[M`$P1,-SJ1_OY(SZ.30!Z5KNLVGA[0KW5[YPMM:1&1
M^<$^BCW)P![D5XMX`_M2Q^.4L^J@B]US2GO+B$D_Z/O<.J#_`'515YZ<U;\/
M^*?^%L7GA+2)%D>'3HC?ZV,$!IH_DB&[`R&;YRHSP0.JG%WQ6!8?M)^#[YT_
M=3V3090#)<B9<G_OM>?0>U`'L5?._C#1Y/%N@:]\2K"XE2[LM07^S6C<_+;0
M$(64YQDMNDXZ;>#R17KGQ+U.32_A[J[V_-U<1"S@4/M8O,1&,'(Y&[/X5AZ?
M\&="MM!CTR6^UGR6C`G@BU%UA=\?,=@P.23V[T`=CX7UV'Q-X8T[6H`%2[A$
MA4'.QNC+^#`C\*\Y^(_A2V\:?$O2=(GG>!_[(GFBDC/*2!QM)]NM2?!BX;1)
MO$/@2[9C=:1>O)"S8_>0,0`1CWPW/_/0>E:VI1"/X^:)<`9:;1)HFYQ@*Y8'
MW^]VH`R?A_X[U/3M;E\#^.I1#K43!;.ZD/RW:GH-Y^\Q['OT^\,'0^**;O$7
M@!RY11KT0W!L<\8'XXQ6[X]\!:=X[T?[-<_N+Z'+6EX@^>%OZJ>,C^1`->3)
MXMU27Q=X.\+>)H777]'U<1RSLPV7,3+M20,>2QSZ?-P>I(`!]"TA(4$D@`<D
MGM2UP7QFEOX?A5K+6!`)5%FX);RBZAL?@><]LT`<A\,_&%EH_C?7O"]U.#:Z
MGJ,M[IEZR[$N"[8(#'&[=A=I&02#@\BO4M6UC0/"BR7VIW%OIXO907F=<>:X
M4*,D#KM4#GL*YJ]\'Z!\2/AKHT$J+$HLHGLKF#!:V.Q1@>J\`,IZX[$`CS;5
MO$>N7.G1_"OQH\5I>RW,$;ZQ+./+EM%;?O+-U<[%"D_>)^;:0<@'T-'(DL:R
M1NKHX#*RG((/0@US7Q$U^;PQX`UC5[?/VB&$+$0,[7=@BM^!8'\*Z2&*."&.
M&)0D<:A54=``,`5@>._#[^*?`^K:-%M\ZX@_<AC@&12'3)[?,H_^OTH`S/A-
MID>F?#/10L862YA^U2MNW%VD^;<3ZX(^F,=J[6O,?@SXI-]X=/AC4Q]FUK1#
M]EDMY&P[1KPI`)YQC:<<#`[$5Z=0!Y]\1+]/A_\`"W43HBO;R.[1P%&/[IYI
M"SL#G(QN<CT.*VOAU80:=\.]`B@0+YEC%/(0<[I)%#NQ/?+,:R?'VG1_$+X8
MZG%I#&657D:WP/\`6202LK*/7<48`].0:?\`"7Q5'XG\!V0=U_M"P06EW%GY
ME9!A6(Z_,H!^NX=J`.TNK6WOK2:TNH4FMYD,<D4BY5U(P01Z5Y)\&IKC1O$?
MB[P9*\CVNF71>R#D';&78')SW&PX]SFO6KR\M]/LI[R[F6&V@C,DLCG`50,D
MG\*\X^#NF3R1>(?%]Q'+`/$=^US!!+U2`,Y0GZ[V]L!2.M`''_%[3=1O_B%<
M:UH\K)>>'-(M[O:$R7Q.Y)'/15)8_P"Z17LOA3Q#;^*O"^GZU;8"7409DS]Q
MQPR_@P(_"N?\.1&X^)WCXRP*;<K86_S8(?$#,P(^D@KS>TOM3^&FN^)?`EH7
M,FK%9/#S#HKS-Y8.?X=H.22`,Q'U&0"I\8KZ_P!?EG\16,R_V3X>U".R@'42
MS'+2N.Q`81K^!KZ)AECGACFB8/'(H96'0@C(->6?$OPO::'\!+G1[*)I$TV.
M`QL`<EA*N^0@>NYV/;DUW7@NZ:^\"Z!=.RL\NG6[.5Z;C&N?US0!P/@+;#\9
M_B"7D3;NA);/`SGC]<59TVR@\0_'.;Q+I&R33=/TX6MQ=QGY)KDEAM4@_/A"
MH)Z`KCKBLSP5IUEJ7QB\?17]G;W4:3PR(D\2N%<$X8`C@CUKV2@#@/'B1^)?
M$F@^")&+6=V7O]3C4D$V\7W%)!!`:3'(Y^7\\GX-W=QI#Z_X$OB3-H=VQMW/
M'F0.Q((';GYNO_+0>E)X3T&T\;>*O$7C&]>[13>-86#6E])`?)B`4G,3`X8\
M\GJ.@'7"\=!OA1X^TOQ3IOVF2PU-!::AY]P]PYVNA)W2%CDH,#GC:>E`'L>O
M?\B]J?\`UZ2_^@&O#[72]5^&FC:-XY\+0R7&B7MC;RZOIC2%L;D4[QGT)//\
M/IM)KV;Q2T%QX)UIFF86\FG3DRPG)V&-OF7&<\<C&:A\"?\`)//#7_8*M?\`
MT4M`%WP_K^G>)]%M]6TN<2VTZY']Y#W5AV8="*Y+X/\`_(H7G_85N_\`T97,
MZQIEQ\'?%,GBC1K:2?PKJ4@35+&)?^/1B21(@`P%'0`\<[>-RD=#\%;B.[\"
MS7,6?+FU*YD7(P<%\B@#&\=VDWP\\9VOQ`TM,:;=2);:U;1Q\%6/^MP"!N^O
M\6.NXUU6G/:>,/&K:S#/'=:7HB&WLGC;=')<N,RR`CAMJ%$'7EGK0^(,$=Q\
M.?$B2KN4:9<.!G'*QE@?S`K)^#:P+\)M!%N[.GER$EO[YE<L.G9LC\.]`'=4
M55M=3L+Z>Y@M+VVN)K5]EQ'%*KM$WHP!^4\'@^E6J`/)OB[)`/&GPVC9";AM
M:5D?'`420[A^)*_E6O\`%(V?B3PP?"EE/#<:MJ5Q"L$4>)&B"R*SRL,_*JJ&
MR>.N.]8?Q>4'Q_\`#-MZ@C5\!.<G,L'/3'&/7N/?'JUI86>GI(EE:06RRR-+
M(L,80.YZL<=2>YZT`6**CCGAEEEBCEC>2$A9$5@2A(!`([<$'Z&L7QKX@3PM
MX-U76GW9MH#Y>T9S(Q"IZ_Q,O:@#R?QQ:7/C*3Q9XFLY21X5EC@T[KM#PD27
M#<'&?Z*.E>O^%]>@\3^&-.UJW`"7<(<J#G8W1ES[,"/PKD_"WPPTNU\&06.H
MR:H]Q=P;[]5U.YB22211YF45PIZD<KSWK'^#TG_".:SXF\`7$Q>73;HW-J74
MAI(&P,^@ZQGZR<9%`'K=%-,B"18RZAV!8+GD@8R<>V1^8IU`!1110!\8?%3_
M`)*AXA_Z^S_(5Q]=A\5/^2H>(?\`K[/\A7'T`?2&HZ)>Z]^S1I-K8+&TZ10R
M[9)5C!`<@X+$#//<C/;G`KR3P_\`"SQ1XAU2.SBM(X4R#+-)/'B-,X+8#9/T
M`KU+Q#+Y?[*]@N)#YD5NN5/`_>@_-[<?GBOGZUN[FPNH[JSN);>XB.Z.6%RC
MH?4$<B@#M?B;J.H1ZG:^&6M;RQTG1HA#96URNUY!C!F;L2Q!(QP!P.^>$KZ5
M\#:E8?&CP-=:)XJ"2ZK8-Q<(`D@##"RK[Y!!&,'`R.:^>]>T6\\.:[>Z1?H4
MN;20QMQU'4,/8@@CV(H`^BOV;P__``@NIDCY/[3;!SW\J//'Y50\6^!O&_BK
MQ1_;4^EQ1SVY5;)X-65/LZHQ92O[OKDYR<G/H``+G[-RN/!>JN9$*'42`@`W
M`B-,DGK@Y&/H:]GH`\:?PWXZOFM9]<T./6[FTE$MN+[65$$;#&&\J*)`S#'5
MB>I]:Z"\U#XIW5G)!%X?TFU>1"OGPZA\Z$]UW*0#]0:]%HH`\`TKX>>/]`@:
M'1()].B=B[);ZY\C$@`G:T97/`YQGCK72^&K'XD^&+&XMX-$L;U[FX:YFN;[
M53)+(Y55R2%'0*H'':O6J*`/#[;PC\0;3QA/XIATJ!=5N.)I/[5!61.!L*[,
M;<*HQVP,<@&NAUF+X@>(])GTK5?"&@3V<Z_.C:@XZ<C!`R#D#!%>GT4`>$6_
M@CQ_;>&)_#<6GI_9$W#VS:NK`#(.%)C+*,C.`0.OJ:ZO0X?B5H'AZVL8-)T:
MXBMP(88I[]C)'&J@*,B,*5&.Y)Y_+TRB@#R;P_I7C?PS>:C<Z9X+T*%]2N//
MN=NI-\QYX&1\HR6('0;C]*S?%/A3QUXMU:PU.^\/6$-W8?\`'O):ZJ8RA#;@
M?NGD$=:]KHH`\6U;P_\`$S7)M/EU&SAF;3[E;JV`U&-%253E6*K$`Q';(/4^
MIKJ?[7^*/_0KZ'_X'M_A7H%%`'B=WX5\?7'C)_%<&AV=EJSH$>2VU3"L`H7Y
ME9"&X`ZYZ#TJ2]\/?$>^\60^)FTRUCU*",PP-'J2;(HSG*A3&0?O-RV3SUX&
M/:**`.!?5_B<=NSPMH@XYSJ).3^58>J:5XYU?6]-UFZ\&Z#_`&EIS[H+A-09
M7QS\K''S+R3@]"3C&3GUJB@#S_\`M?XH_P#0KZ'_`.![?X5%<WWQ+O+6:UN?
M"6@2V\R-'+&]\2KJ1@@C'((->BUPT_Q/TV*]3R],U*;2OMOV&754C7R$FW!0
M/O;BN3@MC'IF@#S&V^''Q)TN1XM":72=.E8M)96VM':"?[A*Y4\`9Y/'6M5O
MA]X@O+"YMK_P1H=W-/AY;Z\U666ZD<``'S3E@>!P"%]J]HCU.PEU&73H[VV>
M^B0/);+*IE13C!*YR!R.?>LZ[\7Z!9W5C;2:I;-+>S>1"(Y`WS;2W.#P.,9]
M2*`.(\,^'/B+X;B\JWGTV:W"A5M[_59IE4```*3#E0.F`0..E;$FH?$Y+AHU
MT'PZZ`$B5;Z3:W&<#*@]>.1U]N:N:E\0]*TLV<5Q!<I>7NH-86]JYC#NROL9
M_O8"9QSG)R..:UK?Q'9_V)!J>J-'I$<SF,+>SQIAMQ`&[."3C(&<XH`\X\0^
M!?%/BC6%U"[T+P]::E`5,>IV>IW$,AQC&"L>21TR1D8X-0+X)^);V,D<NMR&
M,@@0/KLN_@\8=8,\X[MT/->E>)O%NC>$=-DO-6O8HBL;/';^8HEGQC(C5B-Q
MY'YU-JWB"VTCPU-KKQ33V\<*RA(0"[AL8`R<=QWH`XK04^(FBZ99:/9^&="M
M[.V01(TNHNVT#N2`2?RK)N_!'C"_U^35[;2M'T;49`&FN]/U>XA\_G.UU5"&
MY`)RO/<FN\TKQM8:CJESI=W:7VD7]O`+IH-11$+0D[?,#*S*5W<=>M6O$OBB
MP\+Z>E[>[VC:XBMV$>"4,C8#-DC`')_"@#S?4?"WQ%N[N+^UX;37[=,.UO-J
MA2VD((($D211J^"H.""/KS73Q:A\3<.@\/>'8UC!VC[=)AL#@#"\=.^.M=#<
M^+-(AMM-NK>Y6^M]1O4LH)K)UE3S&W<E@<8&T@^]36WB"QET>'4[MQIT,LAB
M`O98T(;>5`R&*Y)'`!SSZ\4`>>:#HGQ'TK7-1U);;37FU"13<F[U$LDA52%8
M!8LK@`#C'5>"!Q9U.Q\=W7B*QU:;PIX=N;W3@ZVURE_(``X`;AE!/XCCG'7G
MTYF5%+,0%`R23P!7.>$?'&C>-=/N[[27E$-K.T,AG4(>`"&`S]T@\9P>N0*`
M.5UF/XC>(]'NM'O_``WHL=K=QF.1EU%@0.O!"GT]*D\,Z1\0?"VEPZ=!:Z-=
M6,"J(X)M1D+(N22JOY(]?XL@8&/2O0DO[.2U:Z2[@:W7K*)`4'X]*;-J5A;V
MJ74U[;1V\A`25Y55&)Z`$G!S0!Y%H/A3X@Z/XDOM=M]/L4O;WYKHW&I;DN#G
MH56+CUXQ@`C/8]7?1_$O4;&2V$/A^Q,@VF2"^F$@!'."86QUQD<C'![UW321
MH<.ZJ=I;DXX'4_09%5;C5M-LVC6YU"T@:3;L$LRJ6W'"XR><G@>IH`\Z\/:1
M\0O!NBP:1IFEZ)=641<Q(]^Y,66+$9\M2=Q)(SG\*;XQ\-^,_'>E_P!FZGHN
MB0VUO<"9`NIR[I&564$$1="&/!`-=_;^(M+NM6U/3(KN,W6F(CW2DX$8<$@D
M].@.?3C/45<2_LY8!/'=P/"3M$BR`J3Z9H`\IT_PS\1XO#;^&@MC#IOE-;J9
M]2+L(L%2BL(2P!#<=U"``J.#I^&]-^(OARPCT:WLM$ELK=-L$EUJ$C!%!X4%
M8@Q]>1P.,CI79:QXJT70]%.KWE_"++S4B$B.K`LS``#GG&<GT`)[5HB^LS=K
M:"Z@-RR[Q")!O*^NWKCD<T`<G.OQ"NK>6WN-+\(S02H4DCDNKAE=2,$$&+!!
M'&*S/#F@>-/"FE?V9I&E^%X;02/(J-J%T^TL<D9,><5Z!<WEK9JANKF&`.P1
M#+(%W,>@&>I]J2YO[.RV?:[N"#>X1/-D"[F.<`9ZDX.![&@#@M:T_P"(OB31
M9],NK70;.WN4*3"&_E#.A!!0GRFP".N/SZBH/"OAWQ[X0TA=*T^+P_)91DF*
M*XOYF\K)+-@B`'DL3R3[8KL?$_BO2?"6E37^J7**(T+K`KH)90"!A%8C<>:L
M:]KMIX=TPWUVLT@,BPQ0P)ODFD8X5%'<D\#)`]Z`."\/^%_''AS6-=U6VL/#
M#SZQ<BXG`O)U`QG"@>5CJSG/<MS6^L_Q(*@G3_"JDCH;VXR/_(57O#_B^#6K
MF]L;JPN])U&R42S6MZ%!\IL[9`P)4KP<\\$$>YV8]2L)K**]BO;:2TEQY<ZR
MJ4?/3#9P:`/+O%?@7QGXQU&POM2BT2.6PYMA;ZE.@C8D$L/W).>%_P"^1736
MS?$JWMUAEM_#=S(,GSY;R4$\]"%A`[C&`.G/-=+_`&]HXTDZL=5L?[-&,WGV
MA/)&2`/GSMZD#KU-6DN[:2..1+B)DDC\U&5P0R<?,#W'(YZ<B@#S73-"\9:/
MXBO]3L?#/AF*\U-B;JZ_M&<JV.>A7C)]%ZGFH_%'A#QSXO$46J)H9M8B&6UB
MU&98BPZ,R^1\Y]FR/;DUUVN^/-$\.7%W%J+S(EK917KRH@96220QJ%P<EMR^
MF,<YK;BU33YI8(HK^UDDN$\R%$F4F1/[RC/(]Q0!RD-]\1D-O:OH6B.R#;+>
M2:DVR7'1MJQ`J3R.G4]`.*Y34O"7CC5_',7B,:7I>GZA;IY45U#J3!"HW8R/
M*);(8CYEZ8&!BO6Q>6IG$`N83,<XCWC<<=>.O%9=AXMT+4=$DUB+4[9-/CE>
M%YYI!&JLK%3DD\9QD9Z@@]Z`.9M_#WB2;Q?IOB'5-&T&34+91:M>0:E<;E@.
M[=B,Q!6;YFQT^]CT*^@4BLKJ&4@J1D$'@BEH`****`/C#XJ?\E0\0_\`7V?Y
M"N/KL/BI_P`E0\0_]?9_D*Y!5+,%&,DXY.!^=`'T+XH3;^RYI?[AY,16S;B"
M/+R_WN.W..?[P[XKYYKZCUBY\-:Q\'X_!Q\8:!'J$6FVT6_^T8_+,L84@;L\
M@M'CU`(..E>#77@'4K1$F;4M!>T;C[3'J]NR`]QC=N)'H`>M`'5?L^SR1?$T
M(C86:RE1QCJ/E;'YJ/RK%^,EW!>?%G7I;>59$62.(LO9TB1&'X,I'X5;T7Q3
M8?#C1KQ=#N(K_P`3WR>5)?QJ3#9Q9!VH6`\QB<$G&T$#[P'/GLTTEQ-)--(\
MDLC%W=V)9F/)))ZDT`?2W[-Q_P"*)U0>4P_XF)_>YX;]VG'X=?\`@0KV:O%/
MV;857PGK$WFH6>^"&,'YE`13D^QW''T->UT`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`5X[X/\=Z?X4\`V>D23+?Z_#JLNGO8>8(YWD>Z?+E.
M6`PV>AY^6O8JH_V+I7]K?VM_9EG_`&EC;]L\A?.QC&-^-W3CKTH`\+\*+;I\
M2M(N6OM-&I'6=326V@MG:\;<9`WV@[A\H`!4XP,GKAJK:%H/AN/P5\.-1ETZ
MR,=YJC)?7-U"A\P_O!L=B.5RN`#QQZU[[%HNE0:I)JD6F6<>H2C;)=I`HE<<
M<%\9/0=^PI'T/29+""P?2[)K.W8/#;FW0QQL.A5<8!&3C%`'B-OI5DFL^&XG
MM(',?B_4(074.=BNQ"Y(Y`(!^O-<I!;_`&GPAX-L[VXTVTM&TO5$$NJQYCC<
MSN&*9(_>@;=OH<<5]0"PLQMQ:0#;*9UQ&.)#G+C_`&CN//7D^M0WNBZ5J4$4
M%_IEG=0Q/OCCG@5U1O4`C@\GF@#Y[UI-%3P9JYUR[M[F\;P[I1T=[R,)<%3O
M/[H9)')`;:3T.[BO6/&?VBZ^#LY63,[V=NQDD.3G<A+'(.3W]SW'4=7?:'I.
MIW$=Q?Z797<T2E(Y)[=)&13U`)&0#5R6&.>)HIHTDC889'4$$>X-`'D/C_P?
M/I/@'Q1KNI:G<:]K4]E%:_:)8TA6*`3*Q"HF`.?F/7.T=.<XWC?6M(UF3Q/Y
M%[;7=@FJ:2TL\;+)$5*D-\V<'&TY'3W]/=YH8KB&2&:-)(I%*.CJ"K*1@@@]
M0:J6^BZ5:6365MIEG#:-C,$<"JAQT^4#%`'C-K;V-SXHN9O#T]I_8$'BS3GM
MX;10(%?[.4E,>W@Y9ESCCY<]ZRO#"^&VL/"W_"70V\>D#2M4^SQ7;_NUF^UG
M*J>%+[,XQ@YVD8.VO?;72=-L+..SL]/M+>UB??'##"J(C9SD*!@'/.:;=:+I
M5];);7FF6=Q`C[TBF@5U5LYR`1@'/.:`.+\0ZS;67P5BET>.[VW^G0V6FQR<
M39F0)'DYX8!LYSCC@GC/F^OV^J^&(M=T/6H;*WM]1T_3G)LKB1HS%;S10/C.
M"I,97<,8(7KQS]#-!"Z(CQ1LJ$,BE00I'0CTQ3+BQM+L@W-K!,0CQ@R1AOE8
M89>>Q`&1WQ0!XMKP\'MJ-A'HZ6B>&1K]N=5=60:?))Y!90I!V$``;Q]W)7()
MJ8_\(?-XJT>/4%M%\''2[_\`L];X_NO/%T?,*9.W;LY3'(4CI\M>L1>'M$AT
MN32XM'T^/3Y3NDM$MD$3GCDIC!Z#MV%+<Z!HUYI\.GW6DV$]E``(K:6V1HXP
M.!M4C`Q[4`>(VFIQV7P\@_M:[A@EG\%74$`EEP9,N5C5=W))7;P/PXJNFD6%
M]::XU[9VERUMX%M9K=F42>4ZP'#(3DJ<CKUKWB^T32=3\C^T-+LKO[/D0_:+
M=)/+S@';D'&<#IZ5-_9UD(3#]CM_*,/V<IY2[?*QC9C'W>3QTH`\%NAH.C:K
MX^EU+0[:[66#2C%`6\C>)%7S',B\JADVER."<`\FN8U)8[K0+ZQ:72Y;1O%M
MJ&BTK*VOSP."8L'A2`1[XZ\5].W&D:9=R/)<Z=:3.\!MF:2!6+0DY,9)'*$\
M[>E0Q>'-#@0)#HNG1HK(X5+5``R`A#P.J@D#TR<4`>(^*=,TZ"[\>V,5CIUK
MINF:EHURL8@5402*J/@8PH/4XQU;/6K5BWAW2/B2DD(TS6EO-?9(A'F+4-.G
M;Y?N_P#+2V4#C^$`@CIS[B]I;2"8/;Q,)L>:&0'S,#`W>O'K5==&TM-4.III
MMFNH%=ANA`HEVXQC?C.,`#&:`/.OC/<V(TU+2XATC[2^FWTL,^J,<(%$8*0+
MP#.Q9=IZKM/'S'/)/9:9K=CJ6HW:6VH72>`89]\JI)]GG"2`E1CY&&T'U!)Z
M9KW>ZTZROI(9+NSM[AX&+PM+$KF-B,$J2.#CTH_LZR\IHOL=OY;Q>2R>4N#'
MS\A&/N\GCIR:`/G7Q*VB3Z%XTE\0O8MKGV?3CI^7'F[/)C*^4"2<98[]G'7/
M&*]4^*FU-*\-ZG(XCL].\0V5W<R."!'$&*ECQQ@N.O\`.NNN_#^BW\\4]YI%
MA<311^5')-;([(G/R@D<#D\>]7Y(TEC:.1%='!5E89!!Z@B@#RSQOXQLO$>A
MZ]INFF*ZTFQ^PO>ZC!.'C99+A=Z+MSD!%)8YQC<"/7F9K72[V]URPTRWM)?"
MD_B?24@%J0;>1W""=5VG;C[N<>OTQ[=;Z1IEIIK:;;:=:0V#*RM:QP*L1#?>
M!0#&#DYXYS1;:/IEG91V5KIUG!:Q.)(X(H%5$<'<&"@8!SSGUH`\&OM.TB'6
M=5LEO]*TLVOB&5[&SU*V!TR7_1UWI*,;$XQ@]>N`3R)8M7TNV3PSJWV:/1='
M?1-4B@ADNC(GF!SN"%CN;<2"HQDY``XKW>[TRPO[>6WO+*VN8)B&ECFB5U<@
M`98$8/``Y]!3+K2-,OH8(;O3K2XBMV#0I-`KK$0,`J"."!QQ0!X'J=G9OX4O
M&,,<C_\`""Z;,VX;ML@8@,,]"%`Z?UJYKVJ>'9_&FES:-%H%E!!JVECS@X-S
M,A"-^Z`.(H50A6P,$@YQSGW1-.LHUVI9VZKY(M\")0/*&<)T^Z,GCIR:K2>'
MM%FD\R71]/=_+$6YK9"=@R=N<=.3QTYH`\>T/2;&?5K[4'L[=KL?$"Y@:<QK
MO:$QL#&6QDH=Q^7.*RX+;P_+X-T6.UU#0+#4;75[SS(-3MD-I.X>3:EP<?+^
MZ(VL<]@,'!'T`ME:J<K;0@^:9N(Q_K#U?_>]^M5;C0-&NX;B&YTBPFBN91-.
MDELC++(.-[`CYFX')YH`S?`-S:7?@31YK&T-I:F#$<!F:4(`2,!VY*\<9[8K
MHZ9##%;PQPPQI'%&H1$10%50,``#H!3Z`"BBB@#XP^*G_)4/$/\`U]G^0KCZ
M^F/%?P"7Q-XIU#6E\2FU%Y+YGDFQ\S8<`$;O,&>GI6:O[,]J(@&\43&3=DL+
M(`;<=,;^N><YZ<8[T`?/-%?0TW[,]JR*(/%$R/GDO9!@1CT#COG_`#S3$_9F
MA$C%_%;E.P%@`1^/F?TH`^?**^AX/V:+-8W%QXGGD<_<,=F$`^H+G/YBI3^S
M5IFY\>([L*5`4&W7(;G)//(Z<<=#SSP`2?LUJP\.:VV#M-V@!QQG9_\`7%>W
MUR7@#P#8?#_2;FRL[F:Y:XF\V264`'H```.`!@_F?:NMH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HILC%(V949R`2$7&6]AD@?F:=0`4444`%%%%`!1110`
:4444`%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex23sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23sig.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"``J`.<#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#W[</6FK+&SNBNI9"`R@Y*YZ9]*X7XB>(=9L4M
M]"\/QJFIZC;W$WVV7/EVL<299N`3N.0HXQDBO.?AK&;'Q[X9\B>Y^T:IHKWN
MI^?*VZ>0L^UF4LPSMQM/=3NP"<4`?0=%(OW12T`%%(3BDWT`.HII8`<TH.:`
M%H)P,FD+8.*&("DL<`=2:`#</6ESFO)O!/C7Q#X@\765S>W%I_8FKP79LK&'
M:SVWD.H#.V,DD$CKZ\#BO6!TH`6DR*K:C>Q:;IEU?3L!#;Q-*Y)`X49/)X[5
MY;X4^(?BG5M6\-S:A:Z8ND^(7N5MT@W":`1`\L2?FR0.1Z=N,@'KE%(.E+0`
M4444`%%%%`!1110`4444`%%<GXW\>V7@>UMI;JPO;Q[@N5CM5!*J@!=FR1@`
M'K_*NCLKZ#4+&WO;9Q);W$2S1..C(PR#^1H`LT5GQZWIDNL3:1'?0/J4$0FE
MM5D!D1#C!([=1^8]16A0`4444`</X@T6YG\:_P!K>6Z6":#=6LUR\PV(S,K`
M;,Y'`8EL<C'H*\A\!Z'J'A2U\(>+;+7T/]LWT6G3:?+&.8'F*L%)8DX(#<`8
MSGZ^X>.?#=YXK\)7>BV>HFP>XVAI0FX,H;)4XP<'';^1-<AX,^$]_HU[HMWK
M^M)?C1HV6PLX(ML4+/DNV3RQW'@X'0>P``OB?XO76A>(+W3;+PY'=VUE,EM)
M>7&HQVJ>:R[MHW#'3OGL:X[QE\8?'OAK7#!=:18Z8+FVCE@M)9%N=B[F!?>A
M&2Q4^P&.,\UJ^)O`6HQ?$G4]9A\&P^)HKY8YK9KBZ$4=O(!AE=2V''RYY'<5
MWA\":3XBO]+\0>)=&A;58;!;9[)F$EO'U.-O1L%F`/(YSC(!`!H:5K>H7G@"
MVUAK>WN=3?31<FW@F`220Q[@H;HNX_4#/4XR?)K#X@?$IO#MOK%IIJZM'K$T
MD\'E0,5LTC9U>(GW"`KDYZ]2<5Z=X9^'.@^$M6U#4-*2X1KU2C0-)F*-2<E4
M7Z^N<=.*Z:PT^STRQBLK&TAM;6($)#"@1%R<G`'N2:`/(?&_Q-2_;2+?PYXF
MM=+M+JSDOIKUT#2+MR(XL$]6<%2,9XST!KJ+7XF6/_"JE\83O:O,EN!+;I(4
M!N<<Q#.2,GIUP.>1S6]<>!_"MW</<7'AK299GY9WLXR3QCT]JH:C\-?#>HZ"
M-#:S>#3A>_;?(MWV*'[CIPIZ8'X8H`\\\3_&2YG\%>;;1W/A_P`1I/%,ME/;
MO(+F#=G*2;0-I&"2<9`('7->UV]R+JSAN41T66-9`LBE6`(S@@]#[4Y;:`1)
M'Y$>Q%VJNP84>@'85(X^4]J`/#U?1_A_\>9FO=5BBT_4;>2:-6^[:33.NX-U
MVABN<G``(S@#->T07UM<RS16]S!,\#!95CD#&-B`0&`Z$@@\]C7AVO:_IK^+
MO'EE=V4&I:MJ#VNDZ99O"I8':?F)[*'*MGKE5Z<8]2\#^#+'P3X=AT^RC7SV
M"O=S@DF:7:`6Y[>@XQ^)R`6O&]G-J'@37K2#:99K"95W'`SL-9/P[U"UO/AC
MX>U.:-(5M=/$1D?!*"(;'.>P/EYKM#T->?M\,!;6ESINC>(]6TO1KHDSV$3+
M(.3E@CN"R9S@X/US0!A:3\99=7\5016=E:-X?N+Y=-@=Y66Z>0\^<$Z&,`8(
MP"-RY(SBNOMOB9X3N-:?1SJRPZ@DTT#0W$3)AH\EB6(V@8!()//UXJMH'PH\
M(^&M4BU'3].<W,(_=M/,T@5N/G`/`;CK[G%<[??!FPUOXDZQK&K0B32+J%)(
MDCF97\\\/G';Y2?3YQCH<`'HNB^(](\1P3S:/J$-[%!*89'B.0'`SC/?J.1Q
M7-W'Q1T>V\>#PK+#<1MYJP-?.`(!,R[A'GU.0/J:3P?X)?PCXQ\1364%M#HE
M_#:FVCCX*/&K*5Q^.23UW#OFN`A\(ZEXA^+OB/2'E$6@6NJ0:K=C>#))(4!1
M`<[L$.Q]!CL<4`;]A\9OM?Q2?PU/90P:8T\EC%/O+2FX5B`2/X5;A0,=>=V,
MX['4/'^@Z9XOMO"]U=,FIW*J8P4/EEFX5"W9FQQ]17$:Q\";._MKZZM]1,.O
M7.IO?)?[7`C1F)\H*&QQG.[KGVKJ[[X=V&L:YJM[JS_:H+ZVMX%0+MDB>(D^
M8K@Y!R1T]^N:`+'@OQU9^+K!6;[/9ZGNE#Z<;D/*JHY3=C`;!]<5JV'B;1]3
MUN]T>SU&&>_L0#<0IG*9]^A[`X)P>#BN-M/@?X/MK2)9H;VXO48N]\;MTEE8
M]<[2`!SZ?CUSFV.A:9X3^.6BV.C6<,%M/H4D;JF=V1(S>8QZL3@#)]/84`>N
M4W>-Y4,,CJ,]*'!/2O/?#`OA\8/&LEU:7D,$T5H+9YD/ENJ)M)5AE>2<XSGD
MY`((`!QGQ&N=?\2?$RY\.Z!IKW,D&DFT:5@H6W\\JTLA)[&(;,$@Y)(YZ^N:
M;_9^AZ?:>'X;^)I]/T]`L3R*9?)10@D*C!QQC.`":JZ5X5_L[QEK?B)KQYI-
M32&,0E`JQ+&,#GO]:N2^&=)GUN?69+"-M0GM39R2DGYXB>5(SC\>N..G%`'S
M'?Z%?P:%I_Q,'B,V]UJNL.@D6W*>2"TN93M)/_+,Y0`\'OTKZCOM>T[3=3L-
M.N[CRKK4'9+6/8Q\PJ,D9`P./4BF0^'=)AT6UT==-MVTZV""*WD3>J[3E3\V
M<G/.3SGFM,HK,K%02O0D=*`%!SUHI:*`"BBB@`HHHH`****`"BBB@`I",C%+
M10!1CT?38=1EU&+3[1+^5=LERL*B5QQP7`R>@[]JN@8&*6B@`HHHH`****`"
MLJT\/Z?8Z]J6M6\)6^U$1BYD+D[_`"UVK@=!QZ5JT4`%%%%`!62_AZT?Q3;^
L(2TJWD%H]F%##849@W(QU!'8]ZUJ*`"D()[TM%`!1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23logo2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!0`68#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`KF
MO&OB:7PQIMG+!]@6:\NUM4EU"X,-O$2CN6=@#@80@>Y%=+65KD>HSP)!9:9I
ME]'(&$RW]PT:KQ@841OOZG()7]>`#G]5\7W]EJNAZ/'+H<=Y?0>?+-=7++"1
ME1MAP,NQR2`=N0!SSQTG]I3+XA33'M-L,EL\\=QY@.XJR`KMQQ]\<YKFK[P=
M=W/A*T\(8M'TU+>.*34#(5GC93SY<6PJ/EX4[^,]#CG>GL;Z3QA8Z@L5K]AM
M[*>!I#,WG;Y'C;A-NW:/*'.[)W=!CD`R_%OC1/!^J:1]OA4Z5?.\,MPI.^W8
M8(<C&"G7)ZCKSTINN^)-7T^3Q"NGVEK='3=-AU"!"6W2AVE#*<=3B%B,==P%
M:.K:9>WWB/2;A(+.33[=9EN/.E8.0Z[<!-A##URPZUG>&/"A\,:QJ"2ZO]LL
M[JWAM["UG`\RWAB:4^5GK(H\[@GD#`/04`5K'QEJ%]XSM]*BM;4Z9=6*:I!>
MY89M2""3GC>&,0QZ/GM6WH6JZCK'A==4-K#'<7"/):Q,64,F3Y1;/(W#:2.V
M:XM_A5J(NU^S^(Y(;*,/81P!,XTUSO>'/7?N.T,#PJ+]*]/5510J@!0,``<`
M4`<O9ZGXGN9=8M!;Z2]S9O;QQ2)(XC+/AI%<8R"L;(P`Z[A3=)\8VX@/_"0:
MAI-G+->S6UFR3E4N!$0K%=^.0^Y<#T'K5G0-%U#2/#=Y;O);#5;FXNKEYH\E
M#))([(3D=E*#IQMQSBLFU\%7=E;^#)56RN+K0K8P7$4KL$<NJ>9(C;2=P9-P
MR!G)Y6@"[X4\7Q:Q)=:?J-[ID>KP7US;+:PS`/(D4C*'$98MT4_EFD\2>)IM
M+U^STI-1TO3/M-N[QW&HQLZ22[@%C&'0#N>22>`!6-:^%WM;:RN[C4M,B=/$
MTVJF1)?E=9/,!C#$#+?-CWV_ET^MV-Y=W85X]*O=+FC$;6>H)C;)\_S*V&W;
M@P!4C@+P>30`EGXIL(Y8=-UC4=.M=9-O]IDMEG&-GS'<I/4;4+'T`R>*M'Q-
MH8@@G_M>R,5Q-Y$3B92'DSC:,=3DC\QZURMOX%GT2TO;>VN-/>RN=$^P3R72
M,-KIYI4@9(\LB;!!/`C4<YR(F^'PU.P\.227.GWL5EI(T^2.1&>"5"$(E38R
M_P!P?+T(/48!H`[!_$>C1ZE)ISZC`MW&C.\1;D!1N;ZD#DCKCFI=*UG3]<TQ
M-1TJY2\M9!E)(CPWMSCGMST/!KCM*\%Z:WB;5+A+O3-0`O)IY-RF2XMGF#;H
MSA]J\-P2N<<8[UTGAO3I=,\)VVBK?V\LUA`+,7%NGW2B[58J2<-C!(/<T`<W
MX2\82ZW''J4GB'2V@6-Y-2T^11%+I_REL;B02$(VL6&#@D$8KI]>\0VNCZ3>
M7*W5AY\$*2[+FZ$2!7;:C,V"54MD`XY((%86H>#+KQ';EM5N=.2X-O<0?;;&
MU*O.DL+19;+'`PP;;EN57D8JC<_#K4M5M=0CU'6+1'NM'CTE3;VC814D9@YW
M/R2#R./TY`.G3QEX?DUN]T<:D@OK(9N49&58AM+Y+D;<;03UXQ5BUUBUU_2[
MJ30=0MY)55D20J66.0KE2R\''*G'&0:Y2;X=?:;WQF1K:A?$<4:31I;_`#VY
M5&`(._D$MD@@9'&>];?A[PVNAZ?>Q6+Z7'>2J$-S;610[U4A3(#(Q?;GA=PP
M,@8S0!DP:]K]I=ZSI\]Q;WGEWUK8V5X8-F))5!EW*#AMBD,,8SG;D'H76O>(
M+#P]XPCDN+=]0T.-YH+MK;"SQF'S5R@;A@=RYZ<`X/2BV\'ZU=>&X["^U>RC
MN()XKRVN[2!F+W"OYC2R!FPVYL_*-HP3VP!JW7A>XO\`0=>M;B_B%_K4#0S7
M"0'RXE,?E@*F[)P,G);))/;"@`V]+N)+O2+*YEP9)H$D;`P,E037->'OB5H'
MB?Q5J'A[3C<F[L@S-))&%CE"L%;8<Y."1U`]JT$U[0?#=M;:5JWB+2H+JWA1
M"L]RD#$`8!V,V1D"I]+\+Z!I6IW&K:;IEK!>788RW$2_-(&.X\^A.#QZ"@#F
M/%_B>]TKQI:Z6NM1Z;:3Z9)<(QLS.6F5P`.`3@J2?^`^]:6B^.+*3PGHVI:S
M<1PW-W91W,_D(\D<0(Y=RH(C7(/+D`$$9.#5R^\/7\WC"'Q!9:E;0&.P:R\B
M:T:7.Z17+;A(O]U1C'KZ\<^GP]M]"T[58X-=\F#5X#:WQNH1(&:223;Y(W`(
M2T[*%PP)*\$YW`'5OXHT2/4QI[:A']I()(`)5<+N^9P-J\<\D5/IFMZ=K!E6
MQN/,>((TB%&1D#C<I*L`0".17)Z'I-GX5OI_#5GXLL%CNI#+%IUPJ-=IN7D*
M2_S+QGE#QGMTL>#O#MKX>\0:L!K=O?:A<6]L+J%$(=#&&Q(X+L07WD\XZ<4`
M8>G^,-8N?']SI$>K6\\D6L/:MIC0*"MF(]_G!A@[@QV\G!QTSU[-_&&AQZA+
M8F[D-Q&)>!;R;7:-=SHC[=K.`"2H)/!XXKEQX9TMHI]:_P"$EM<W&N&_T^_M
MU`2*1ML7DL=Y$BMY84C*Y/H<8O:IX0A&L?\`"1ZKK07[))-(CNA`CBDB,9CY
M<C`W,1@#D\@]P#3M/'&CWVE6-_;"\D-['YL%L+23SW08W,$QDJ,CYAE3V)R,
MQM\0O#O[UX[F>:"&&*XEN(;:1XXHY"P#,P&%P5.<],'/1L8NFV^C:58:/J]O
MXJTY#86+:1#<3J!$\:[3M=2X/F+Y0)((X#9`'2B-%\*Z+:WNCIXIMH?^$ETU
M+:+<RNS[S*?-4YP0YFDP.`<?*>*`/4*\GT?6;O5=?FL[CQGK,6IC6+RQM[:&
MV@,7E1%R-V8L9VH>2<^@KOK.*[T4WDVHZDLFEPV\*P!E&Z,HI$C$@9.X[<#+
M'(//.!S6EZMX<\.>"=1U1O%,366H7US,M\8L>7-(68HJ#YBP()V]>*`-GX>7
MU]J?P^T2^U&>2>[GM@\DL@`9LDX)P!VQSWJ'Q!>3Z5XQ\-SG4;Z.SO;AK.:$
M[/LHS$Y3)V[A(TGEA><'!'US_"%[I=KI?A\P^,%O--F@^R:7`\2P-/Y8"'@@
M,Q7;CH,9Y[5I:K=:;+XPT_2K_4[AY]Z7EOI\=H[+D!@C/(JD`!D=AN(Y'H*`
M*2ZG<:/\2KFUO]6O/[-N--DNU6[11"'1P3Y3`#`2,_,"><@\\U@P>/=5U71O
M&MY:7,!-G)"=-BB`W^2ZJ1@8SYK!L;3G#G;CC%=U'X=674X=0U.Y.H36\4L$
M'F1*JJDFW?D#AB=@'T[<G.0?AUIOV[6;J)DMWO[JVNX&M[=$:UD@"[2.H8%E
MW$$8^8^N:`,S2M0@UWPOK4@\0^(-,M--OG:>:X54NXHTA5F4AD)"Y);D9[>U
M=AX:2_C\,Z<NJ2R27OD*96E`WY(SAL`?,.A..H-9MWX.6]TK4[6XU"5[G4I8
M7N+GRE!98RN$VCC!"D'O\Q]L=/0`4444`%%%%`!1110`4444`%%%%`'"_%&R
MM;S3-"6YLH+L_P!N62+',BMN#2`,O(Z$9!]NM<L/#VL>&_&/AQ-+@TY+VY.J
M3Q6D\[F"TB(AQ"KA<[0<M@*`"[8]3Z5KFFZ!K*Q0ZREK,+659$663:8W.0IZ
MC!/./TIMQ>^&6U%-1N;S2S>6$,A$\DR;H(RP5SDGY1N&TGUR.YH`YFU^(E[J
MNBB[TW2X/M4&FMJ-U;W,Y3[DCQM$C;>NZ*3YCP,+P0V1"?B)K$\US>VFD68T
M6VM;*\E>XN'6<QW"[L!0A7<O<9].>>.@31O!2".R2UT918A@L"E!Y0=?,8%?
M0C#$'@C!J2XM_#=PNM7%M#I5Y>W=JDUVI"3><@3]T9%SRA`X[''%`&/HGC?6
M-?\`$%TEIH8&B075Q9?:YIDC/F1+D,<MOPQ#`KY?RC!R>0+WCC4;V#X9ZC>1
ME+:ZEM461X9MRP"0JKNK\;M@9F!X)VCIFJWA+4O"OB"QB\2XT-M;;3XI-3E@
M*;H-T>YPQ))4<L#D]L$G;QKWNL>$YM(:SO-4T?\`LZ=6MC&]U&(V`^5D'..,
M@8'3B@#$\;Z&]O;6>LVEMH]U;Z+;%(=,U"UW(^6CXC?=A),(%0[6Y..,FL6;
M5=2C\7:GXDF2UN[?3M7AT6*SDA8S6\4GE!I86#8W,THR-F6"@;L`"N@BN_AW
M;W%G-)JOA^:^TFW6VCN;B[A>>%%(4;F)R#GN>['^\<Z]S+X437+*:Z;1QJTX
M5K227R_.?(VJ48\G(R!CKSCO0!2\/111^-O%_EJJEYK5GQW;R%Y_E67X3N_[
M(\`ZN;CSVTW2[S48HW1B)!:Q/)CR\<$C&T8P!CC&,5T=KJ/AJXU:\M;#4-+_
M`+6N1_I*VTT?VA]HV@L`=Q*CCGI4%CKWA71[1],M]6L+>'3(D$BM,JB-"VP,
M6/!^;@G^\<'F@#R6*[UGPMI<B3"RCU$^'+6+3+ZQ?"K`T\41,P/)D0R*5;&"
M`V,$FNEO-2UK2?#5_P"&+329KH6-REI/=:(NUOL[1"1W`=V*S'<026)RV_.<
M9Z[2M3\"QZ?<WFF7&A6]G=2F.>6+RHDF?G(8\;CR>N>IJ_IM_P"'+"XMM$TN
M73[=I(?M%O:VH5%=#D[E"\'/)X[<]*`.4^&6M-%\./#MLNE:C)*UI(5*P_N\
M)NY+YP-Q``'WCG.,9-<MX>UKQ!#X[\0ZE-H.KS:U-HB3?9+E41$<.P5(\-_J
MNB@\EBKL<9P/5XKS0=`EL/#\4]I9R,FVULE8*=HXX7TSQGN?>HH=9\-MK=V\
M=]9_V@EOMGDW@'RHB2?F/!"ESG'0GF@#Q_P->^)-,O/'U]:Z/JUUJ5V8&22>
M*/<)0SJ^4#`<%V95&1A,9'&7Z!<:O!X`\5V]IHVN?9Y];NS<72R1?:1%LPV[
M=)DR;D57(&`&8J<CCTJ/QQX"L9KF>+Q%HZ2S./.9;E27.3@]>1R>1QS6QJ$F
MC:%H&HWURL<.G%9+BZ95R'W#YC@=2?;KF@#/^'4\EQ\./#K26TEN5TZ!`LA!
M+!4`##!/#`9'?!Y`KGOA@WQ"?4=</C/_`(]?-Q;;PH^<$AO+QSY>,=>.F/XJ
MZ3P1XET#Q-X?23PX6%C9D6BQ-&4,>U1A<'MM(Q4USXNT?38YI=4U"SM(ENVM
M8F:;<9&502,8X;.1CGH.YQ0!RNL#5+GXK7\&C)I=P_\`85O'<PWVYD*&XEW+
MA>Y4G@\<C/%.A\?7=QXL&D17VEF.YM+IHKC[/)Y,$T4A&"[,OFKC(8KM&5X/
MIIZMXGT43Z*=*O[%+S7KDVL5]$BR,`JDG/'/S+'&0<8+CTI+SQ#X1@L+V[C_
M`++OKV"/<R[$1KAV.P8)'(9B!N&1\W?/(!G^%?&6J>(-(DU*34M%MIY+ZWM1
M8SDCR!E5D&<@L\F2T8Z<H,GG&[XCD0^+/"5O/D0-=SR+D95IE@?8#QZ,[#IR
MH]J\WTCXA:HGB:W:;18KFRE033S);1Q[(/-$*RQ$$L45L@;N649&*ZKPEXJT
M[Q?I`A\07MG_`&GI][-<X1C%Y:P2\.>PPI&1G[K<\$T`2S+J&B?$>VDTS5X[
MZVUN\?[?IK1Q[X0D`7S0ZC<`GEJI#<?,!]XYK*^']_?V5UHUE+?6^I6FN:=/
MJ5\/+426MSN5GWE?X3YHCP^3E.H`VUUI\6^#=.LFU<ZCI]M#/+Y33[=C.Y&[
M!XSR.>:C'C/P3:W5Q$NIZ?'-+)Y<VQ/]8Y!(4D#YF.3QU.30!RUDMG<_L_:R
M!%!'"L6IO%%#\J1LL\S1A>>,$+@?2NB\7RSR_#^T2ZG>TN[F6R0W;)@6LQEC
M(E8#&-K`'!P,X!P"2)KC6O!!TRT$EU8+8SRBYB6,;49HW`#,%XX=0/FXROJ.
M+DGC+PQ+?R:3)J=N]P9_L<D#*2/-8[?+/&,D\8[T`>=Z7)JMA:1:_/>6%[?:
M+J>H6\YFE,":J)$5M\6Q6_>`JJ!%4@D,.O-2VLUCI'A7PSX'\0W5E9W%R/[2
MODDE$(MXUG\Y(5!.2Q<K&%'97(Z"O06\5^&D:;-_;XL5<NZH2L03A_F`QQC!
MP>U1#QCX5E1M06^AD:%A$&6%FE)92P5%"[FR%8X4'.T^E`%Y]3N%GU`7MK_9
MFG0*!'J$]S&/,8\95>0H''+XR3]VN)T'5I/"?PX\2:M=-'>1V-_>S6=TZ!3>
M;G)5V(`!+2.R[EX(QCC%=A'XLT.[:PB@N3<C45+0^7`[@IG:2^!\@W?+\V.3
MBGZUXCT31Y8K75+@"28`B%87F(7.`S!5.U<\;FP,]Z`.5\2VT6B6?@.SN;E#
M*FNPF66209ED:*;>Y)QDL[9Z#EN@Z5?UB)(O'6F7>EZO<MJ,LZ6][IZW0:/[
M.(W8LT1^[C@AN.6QSNP=IO%>C)JG]G-=L)M[1AO*?RVD52S1B3&TN`"2N<]>
M.#C-B^)?A*9=R:H^SRO/#FTF"M$"09`2F"@((+#@'J10!UE%%%`!1110`444
M4`%%%%`&:GB'1)-4;2TUC3VU!3M-H+E#*#Z;,Y_2M*O$[R>ZUSQ-JME<)I\>
MA7_BJ.TGODC9IXIH(8O+0=AN:-4R<X+OQR*Z$_$#69XM7O[>*PCTR&ZAM;.5
MX_-D^:Z$#2-&DN]E`^8*5C;+`#/)H`]+HKQV?QGXHL)'OM2T[1DU:+2(;QB+
M-TFMX'F;SEV-,&D"I"7P"O.,XJYJOQ)U'2]:UJ!+BQNMLEE9Z;:K&$9WDA$K
MSG<XRN&^Z6`^51N4DD@'JU07MY;:=93WMY,D-M`ADED<X"J!DDUYDGCWQ7IL
M&L7>NQZ%Y.E6%O=206*RNTDDX98T\PMM4;URS`.`I')Y-9OB;Q;K-]X(N]/U
M/5-)TVXGAD%TZ*DA\F240I&%65E5BK,Q.YMH"]R2H!UGBWP"GBR]%_9:G]CC
MN;41W)B16\\H=]NX;G&Q^<CE@<9Q4>L_#>'4['38#J)MG$<UOJ5PD2;[R.=O
M,D7D$`M-AA_=R<5H>-/%%YX5GT'[/;VZZ==7JP7MU.&V6\7'`VGACDXR,?+@
M]17,67C6\\4-X::2WTI[2[O+4.63=LG"W$KJI+$*Z".WP.H,A&<\``M/\."V
MAZ=I4^OK_P`)`)C<2WJQ*&GA$:VTBA#D8$+1KG!^;!/WC6MH'@V[\-:4]FNI
MQW$#![=Y+B',B6:B3R(U*D#*%\DD'.YL8XKS[3O'6M7%AHWB`ZIIM]=V5AF^
M9H@N%NKV%!&=K`(RB,_-CH.5R=U>@^.-?O\`1]6T."UU""SMIUNY;OS8=Q=(
MXL@*<C!W,,`<DX/(!4@',6WPXB\4>#K"-+W3X$ATS[%;WVG!O],7,1WRC"G'
M[H@KDYW,<CI5Q/!2Z/?Z'KFL#P_86FF3SS7CF>4JS21K$K&28G<2<,2V""JC
M+'YJQ['Q;J_@SP[9^%[FZLI-74V5I`/*2,VJO#N(<-(%8C;M!++N+9P<;:Z7
MQW+<7_PKL[.^NK,W^KRV-JTD$A6!WDEC+88'/EE0W(ZB@#*B\.V,MDFMQZ_H
M+Z=9ZM?WCW"S"2%8[E2NPL,!64N/R4]\5!!X1DU_3+?2].\2:+<Q6-I913+:
M/\_GV[#!EQDD%1C#8V'D*3DFY<Z)=Z%\1=(US6[X3V^IW$CWAB3RK.VN$MU2
M`X9B<X$@W$X+%<!3BNEU/7-"M)K[5=+^S7FN>7%81^6W$TLA)AA+CY>O)YRJ
MG)P",@&:OA&_GNX+JWGTLRV_BB34G>(D$0%&1D)`SYF"N0>..O05REU)+%X.
MG\.6>JZ!JS6L"0V9LHI)[JZ59E9@54G.T`,X0N3R3MJOG6=%T3Q1X6O+.6WO
M;J&WU4^3=FX:>-G1+QMP"G)"NQ51QO;';/H6NW^E:EHVEV.AW=E-.U[926<=
MJ5<(B31NS!5/"",-GD#'&>0*`.9N[.RUW4[@Z3XNT.UUK4;D?:+:%P)5"1-&
M54$[UDR6+$*I*X4X`R=;PO\`#[4/#=]:31ZM"5@MDA?9$P$VR(HH=,X.&;>'
M!#8^3IS7*Z8\^J7.GR)>V5_IMQXNGO4LH$/VL*LT@24MN.(U8*Q&Q?E&-W.#
MTOQ;TWQWJ5AID?@J:5-DKM=K!<K!(>!L.YB/E^]D9YR.#V`+]WI>H:'K,VM7
M6O::EE?"V2_:YLV!21!L!A82?NPV3][=L)SD\BJ(\&3Z;I.E1:KK-E%::)!<
M0PW;#RC+YR&(>9DX7&X9P3N8`\=*U_'$!G^'LNG:C.HFO?LUC)*I"@R2R)&6
M''3+$].`#QVKSWQ'J&L7/@L:-J;W-O+X=O+6*_N&P([YO/C6+!/W@4)E([$+
MF@#I;;X7W.R..ZOK-T&A/I))@9\,8HHQ(O(QCRR>N<''&<CMH=%BG\+Q:)JR
MPWD1M5M[@!"J2`+@X&21^>17GUQXI\4ZEXEU:&RUK3-.M;'[7&MF\<<D[;%<
M*Y3<7ZH'!(08;^/(JKHOBCQM%KUC_:^H0R64CV'GQ"T4;6N(I"8U91_"0I)R
M3G;V.*`.[\#Z)X=T/0&A\,PM'9O<2^89`^]I48QONW\\%"OX?C6?=^!;F?4+
M>Z74;8B/Q`-8*/:'(7RQ'Y8._KP6W>I'''/FVE>+O$OA+PE:7]O=VVIVUY&\
MDUL?+5-+FGN`R;Y<\EO,DRKD;<#.._:^%KWQ9?\`B^"TO/$<-YI<>FQ7SO:6
MT9$K.\B*AE"X(/EEMRA<XXP,D@%N;P1%;3O<:GK=O#:-J5Y.A$7DM_I:&/9O
M+XWAGX.#GCC)JC/X*LS/X:TCQ'KD0:RM)[#24M(VADF'EHN]B68;U5`=N,9Y
MY'RB7QW:ZAXVN+OP[HPT^XBL8&:[\^Z,9CN74^21M1N4&6P<`DKR"*R;S7G\
M8-X)FTZ]":A<Z3J%S&\>-\=S]G\K@<`X=I>PY3TH`S]&\*Z!I&OV=OJGC-;B
M*V:.&,K;R11S&"0-'#),7:$['QF,`-G&>>*MR^%=!O+Z]\)S^*K%&^V7<UO;
MQP&.XAEN4<",DOAU"N3@`%L#ICGJ-)\1^$[GP?IVBS3VMTQM(;632<"2<'"H
M4:'&X8/4E0`!G@5A:5:V^H:WXJ\2ZIK<,>C6.N>:Z(@!+VT2!"T@;[HS]P+E
MBHY()!`-"'P.BB#1#JVDK>075IJ<B6^G,KRQ0L<!PTS<,PP#T&&PO/"ZWX3A
ML7EGN->MK<77B&'5X$:Q,DKR(H_<J%?<Y.P'Y1D#=P<\8L$>MV/B_1/&]_:V
M*6^JW)MY9(;QWD%O<*OD(Z[`H\LHF2K,"68_[0ZK4=0CT?XIQW>JO]FTR;1Q
M!;WDV%A2;SB70N>%9AY?7`;:!U`%`'/_`/"!KXCT[5K+3_%21VMU<74DUK]A
M>.2W,[K(JR)YBL"H!P'`!#9V@@&M^Y\!W=VVOL^KVZG5[JSNODL2!$\#1G_G
MI\P;RQZ8))YK-\8^*YI39KX5U*UM)+PM')K$L9,)"+E$1S&ZN29=PP""`X#`
M\BK)K/BZPU]YGU6XO;!-?33EMOL4<8>,VY=CD(6`\PJJL&]<YXH`VKKPCJ.G
M^$M>T:SU))M+N+6]^SVHL\SHTP=MOF;\,-SL0-H/0;N.:>G^"=4U#2K34KC5
MOL>LM:6L!Q9-&J11;B8I$$NXDER&977.T8P,AN>T/6O%.H2>%]%BUV6UV6<-
MW=WE[$6ENY'<EX@I0[@F-A^9",Y)..>X\'W&J'PO?7VN:U<W7^D7(BG>VCB:
M.&.1T5@BH.2%W<@]1]*`,#PSX,M!=V$5GJ331Z!=2J)VTYXF<M,[ND<VX!@'
MW(XPPXQA3DGI6\+:A%KJ:O9ZZT=U+;+:WIFM%D\]%9F1E`*A'&YAGE3_`':X
M;P]=:Y9>&M#LX]3O3))I5K>6HCC4FXN+B9F922N"J)C()X#Y/12.O\"IKR6N
MJW?B'6;N]\N^N;>`3011*(8I&4/A%!R<,>N,8P.`:`&PZ+IUMXECT:;5_,+7
M<FNVUB8\2JY<[R9`<&/?)D+@-UY8!A4*_#A8O#=OI$&KR#R-)N]*$DD(8&.<
MJ=VT$?,NQ>_.*Y[51>SW=E\1H/LHM;?4D`064GVO[&3]G<;MQR/F:39L&.N<
M\5+>>,_$6DZGJ\<>GZIJ"PZK=M&QM6>,Q+:`Q0@HHX,ISGJ`IR23D@'>VVKV
ME@S:7?7A^TV,%KYUQ,-BR&5FC1@23RSHPQGKZUKR2)%&TDCJB("S,QP`!U)-
M>2Z9/?IXQEDL[W7;\W%]IT$EY+;,J20K%-([#Y=HC+.P*C&#T]:O7UW>S_`^
M]N99KV:[G#%XKQ"DK[Y^;?!YY#>4,9Z@#/`H`[6W\4Z5<W-O!')=#[2<0RR6
M4R0R=<;960(<X)'/S#!&016S7"ZYK%AXTTN/1]#O"VH&[M)I%V,DMFJ2I*7=
M3@H0$(`."20.]<J_C?Q1IUI&B6.MW;1_VD\ES<Z<VT.LK)"K!$^ZJX=L<<X!
M)&``>L7NI0V-UIUO*LA>_N#;Q%0,!A%)+EN>FV-AQGDCZB>VN8+RUANK:5);
M>9%DBD0Y5U(R"#W!!KQL-KC7%R?LWB:[^S7FI7=@\L4XWC["$BPQ'R;F>78!
MC!R!@G!V;;3?$E]-J4@UK5[2]M-+L'MC(-D4\JQNS>8&&TAGP&`*L,$'`/(!
MZA16#X,O+[4O"=EJ.HJR7%[YEV(V;<8XY)&>-,X&=J,J]!TZ"B@#573K)(Y(
MTL[=4D8.ZB)0&8'()&.3FL#Q+X%TKQ%9K#Y%M;-]I^TR,MLC"9MKJ?,&/F^^
M3GKD`]JZBB@#%TWPQ86>C6FGW:+J1MT"^?>HLCM@DCJ.@).!V%7[G2]/O%F6
MZL+6=9BIE$L*L)"OW=V1SCMGI5NB@#CKO7H=.^(%GX6N[.S.GZI9%K9EAP1)
M'G]V_.TJ54E>!C;CG/%*RU[1=3\<:SHIM=,72]!M5\V22%`%E=B6^8\*JXP?
M<G/2K>M^#;O7=7U:Z>[CM3+%:#3KN--TMK+`SR!]IX8%I&!&1P,=^.>U/P";
MZZU6V\.ZOI\<D4%I#)")6$K21RM,3<-&=RM(6)W#!XR!WH`Z^X\9^#YK2&6Y
MUK3)()0DD8DD4Y!8JK!3S]Y2,]L5C:WXTT;39?#%S9:AI\6AW-Y<+-=`*8TV
M1R$A3V)?Y<CKN/7-4IOAS9:Q#<6L6H:=;R1:8-*GCLH2_DLTJRR$[G+;BH4#
M<<_,6.0<5<A\`7]EJJ7]K?V#2+=ZC/'YUJQ$*W3HW`#X9E",.<`A^G'(!NS:
MYX1L(UAFO=*MXGMEN0KE$4PAMRMZ8RV1[G(K0M;W1_$%J;JVEM+ZWAD>/S0`
MZJPX;!Z?B*\]M_AO:V>IZUHHU""5+_1W@L5N(Y&EMDV11;A\WED`HA)"A\[>
M<5W=_H\H\*-HVDR1P'R5MT>0$`1\!ON8(8KNP1T)!H`P-"\3V^OZEKT6K:=!
M;6,$4-]:M<HN9K5@P$ISU&48]/E#`'G@:D?B?P?K,\&F)J6F7CL5\J'*N"2I
M*X[=,C].O%86L^%-`\+3Q:[:WMKH-E':RV5YOA:19DD"B,$[OEV%>.".<<5G
MZ9I6C3S:7I^E>)X'O(8;2WMWCL]S!;-275N<*S>=N^;N>C8H`Z_4/&7A*`7%
MMJ&M:<JQD)*DTB[23NP.>#]QAQG!4CK5.V\4^&3927+76E+I,%R([0QJ<B4)
MO;Y"HPP!W?+GCGBLC2/AE):Z`-*U"ZTZXVW5M)]I6TD,TL<4WFD.[RM@N2?N
MX"[GP#GAM_X=GT.[N?%EGXALQ';W5[<7+36#3QQQOM#_`"Q.&9T\K:3GH"#C
M'(!T]QXJ\+6E^[7&I64=VEL9&=N&$(`?[V.F&5L?[0XY%3:#J/AW5&N9]">S
ME*$":2W0#J-PR<<Y!R#WSFN;NOA]J5U>W\K^(81!<V^HP)&NG_/&+H[MQ?S,
MEDVH,@#*H!@9).OH=C9Z5XIU"SM]460_8K8"P,0#Q)&"@<MW#`8Q@8Q0!E>'
M/$>D:>=4DU*?3[(MJ]W9V86!86>.$@%?E^\00V.YR.,\5T1\6Z#F+&I1-YMI
M]M0J"08,,V_('`PC?D:R-,\$36D6E+>ZE#=/9ZK<:K,Z6?E_:)91+CC>=NTR
MD]\[0,#K65;^`'TT6MA_PD\<#'3)=+@$<!26>+8VW>#(5<QEF<%54]>V:`-$
M_$;P_-%;7RW<,FGND#%#$_GI),ZK$=I&-N-Y)SGY>,UMR:YX=U"T4R7EG<V[
MSR0KNPZM)&K,X'KM",?PKG(/AY?17BWC:]&]P/L)/^@X1C;;\97S.A#^O!`/
M-,3X9NFJB\76V6$3W\HMA:C8/M.[D?-PZ[MN[H5&`%))(!NKXS\-II5CK#WJ
M0VVI[?(D:)@TN6"#(`R!EE&3P,CI6CJ^O:9H4<;ZE=K`)-Q4;68D*-S-A02%
M4#);H!U(KBM)^%UQI.KV=\-=2[6&VM[62"ZLR\>R)(U!C7S`$8B,')#@$@XR
M!6OXOT2#5-5LT?57MI+^TGTM[<6[3&2"78TI0*1Y;80#S&!49&03B@!NE:S!
MK?BG7(+6[BBT;2?W-U!Y">7<RNI9W9SV7I@8Y#$Y!&$L+GQ!XB\/Q>(M)U80
MM=1&>TT^>V3R2O54D;[^X@`%@V!DX!XQG>%;W2M(LM4L[NSOH9=1O'N3IRVL
MMS-#"RK''YJQ*QCW+&#\Q]>:T]"T6^30+:RTCQ-:R>'_`"MEK+#:EKA8<\!9
MO,V$@?*&\O.`._-`%S5/'_A?0[PV>J:S;6UTH^=#N8*?ER"0,9^=3@\X.<8J
MEJ/Q!T1&NK:POHUOA:1SI<36DKP`2/LCWE1GEF'&1G/7K5*;X8Q7!U^&;4(I
M+36)S,V^TS/%NE61T$F_&TX(&%!&0<DJ*K>*[?2&FO[K[9<WPUJ*RN8[73+%
M[J21+>57#@QG&QL@`G:.203TH`ET+QA9:_XINYI/$CVT=E<7,<-@L82&:"-0
M'DD9ER2&.[(8``=.M6/$GQ%T9?`FL:GI&HR231QSV\$D-M(Q2X6/()!7A060
M[C\O(YY%5)OAM_;GA[3X;N^NK"5+>_#QJ%=@UV_F$.>GRGJ`>>F[')R;KP[:
MZM\/);U/$"6.E1V=W:W+V^E/M5%F&YUB\QF!#1'<<L6'/RXH`Z3Q[K6I>&_A
MY#<QZE]BU+S+6!KG8D@#,ZB0G<"O3<<D4GA'Q@SQ/8Z_?[[MIKE[&=H/+-W:
M18_?D*-J@\^F<9'!I[7-CXYM=-MM+UM#<:=<V]]*+VPD628*-R/Y;&,A6)#!
M@"N1Q4?C70K3Q#XDTNPEUB\T^[GTZ^AMQ!$K*X81B3)/(P-O'&1T(YR`5(?B
M-H\7C"]AGU6;['>65I)8`1,4RT<DA;)&%9E*85N3M''-+X2\8!='LSJ.K/=R
MQ:5923P&U<SRW-PID78>DF5!&%'&TDGKBM9>$]$O-2O])DU:YD,<ZQ^5):B)
MS<1V:1JP8`!E6-@P``PQSD\5MQ^`!%-;W2ZS=?;;=K=XYC#$0&BB>+E=N""L
MC?0X(/7(!TG]KV@T+^V6=H[+[-]J+2*4*Q[=V2#@CCL>E<9H'B(ZWX;U]/%=
MS'$+6[`D%I*V%@D"/''OCP6/S>60.201SGG>U-(/$=P=$M]6A+:=<02:I:O`
M)#+&1O6-N0%#8#9&>F,8)!K:GX$M+V[O)K6\DTY+F"W3R;:&,()8)O.CE(*D
M,<X4@\%>/3`!;M?$FFV\5C8PV-]#(Q6%+/[(P>"/<(P[#^&/)`#=.N/NG$$G
MQ`\/P^:;BXEAC0(Z2/"V)D9]GF)CED#$9;&!D'H:E/A/?K,>JR:O>O<FS%E<
MG;&!<1!V<`X0;>7897!QCG/-9S_#>QFTN*RFU&])@M(;&WG38KQ012K(J_=P
M6/EH"2,$*.!SD`NZMX^T'1[\64\L\MP6D0);PF3YD569<COAOT;.,&G+XXTE
M[M84%PT3:=#J"SB(E&25PD2+W9W/`4#D\=:9#X%T^(C-Y?2XDNI3YC(27N%P
MYSLSD<X]-QSD8`J1_#FRMA:_9=7U2$V\5I".87#"VW>42&C/(#'I@9P<9H`D
M/Q'T562-K;4Q,Z3NL7V1MQ$+E)1Z94AL\]O<9DN_'6BQ37\4\-Q)%9S6L0D$
M.Y)I90LD:H>F0&0\XY(Q38OA]IRZ>]G/J&HW2/:WMJ7G>,N!=N'E;(0?-D<'
MMD\&I?\`A![,V&H6#:C?-:7X431,(6&Y84A5AF/(($:-[,N?:@#5FT32=0O[
M75;C383?0@-%.\8$J=\$]>/0\9K3ID48BA2,,S!%"@NQ8G'J3U/O3Z`"J.JZ
M/8:U;QV^HP>?"D@D"%V4%@".<$9&">#D'TJ]10`BJJ*%4`*!@`#@"BEHH`**
M**`"BBB@`KR\ZG?V/Q!U;7-,MI-0M;RX&B/!"0?+N(XT:.20_P`*;GE1L]!@
M\[@*]0I%55&%``R3P.YZT`>&Z9XDNO!_AC4+2RU&UN-2N/$=Q#=:I<L!"&$:
MLSMN;Y<D!!D]B<$X!W?^$D\9W6LOI\.KZ:N[54TZ&6#3BX)^R^=*6#2`X3C!
MXR<\8P%]555484`#)/`[GK2T`>*V7B?Q#JEWHFJVLMN-9?1H`;5H1OOF>Y=7
M55)78%$19G&0`0>!C,]EXU\8Z[I%[K6GZAIMOYEU;PP:68//EMMUP(2LF"-I
MPR,=QS][Y5!!KV'RX_-\W8OF;=N_'./3/I3J`."^)"3GPIH^D2:G%%/?:G9V
MKW<\8VNRMYA8J,`9,><`C)P,C-8GB74]6\-^(K"ZU79?ZBEE?-:W-I9NL432
M26Z*SJ"<*B*S,68\<9S@UZQ10!Y4^L>+KO4[/3M)U_S+*XU%[6#5);**0W$0
MMM\D@*A4_=R*ZK\N&)')VG=SFK^(Y-4\"2:3>W6I6KSP)-,L6F*LM\TT[;]P
M"878@!8J`26!R>C>\44`>;^$?'%[XG\;*(S>QZ7-9W+?9I+3"PR).J1[GV9#
MF,,Y!;`WJ,9`)6^O;]_%?BVZT>ZMO[0MO[*T^`O#YGE;I2SJP&#M82\D'(YY
M&T8]'HH`\MG\3:U;/;Z:VM7<EQ#K,MM(PM(DN9X-X6/:C1A'`+KN*;3M^8<9
MJK-K>O"&[D%SJDDZZ=K-Y`);%/\`1Y4DVP(&V;LA=_?!.T=.*]<HH`\CT[Q7
MKUKJ>G:1%>:C=VT\>E+%<7.G/N56<F=I)2.2R@+E@"2ZXQ@N:J^)_%'V-;.U
MU*[@N-1O+V3[;?VV1:*DH2*)`(V#$KAB-N#G`*YR/9J*`.;\6ZG>V+:5;VT\
MEE;WERT=UJ"1!S;1B-W&-P*@LRJH+`CD\9Q7*^"GU[5O&\.H:S=3LUKH8!B=
M$3'G7,FUF4`%6:.WC8C`P?086O3JHV.DVFGWE]=PB0W%[())I)'+$X&%49Z*
M!T`X&3ZT`<IX<U:#0+KQ!::Z[VEY)JMQ=(98R1-`Q'E,K`$-\@5<9R-N,<5D
M/K.O:IXKN-,TR[E\-Z?$ID42V7F23&2)I7D*-$0,._7S!@H05)88]0HH`\=O
M=0\:0^&M`NKG6=4CU.;2;_49!%:Q`><D,;11,GED8P6.TC.XGD84")'UMO$O
M]L6.H:A%+&='TN:"*SB^2%U$DP*^6<8$F[C&TDCH`![/5#2M&L=$@GBL83&)
MYWN969R[22.<EF8DDGH.>P`[4`>9:?XE\0G3QJ&JZI=QP:K=(C+:6OF-I:K'
M)*T:YB&7;]W'C:^.3N)(IB3W%C^S=+']GO(KZ>TE@DBDMW\QI99&#_*1GG<Q
MSZ'BO7Z*`/-M2TN\\+1Z5K%GJE_>74UW9VDSQ:>)F:Q0.?)5%7Y`222_7)Z]
M!7,-=>*]:U5-2W:MIVLII$RVB1V2JT\LET[1Q,74J(T$<6YN,KR3@\^X44`>
M,QW?BK2KGQ!>65CJ$(EGNWF:.V9XS)]HMH1+&I4[L1+(X&&&`>N#7I%K>)IO
MA62]AEU._4!FA%W"YG<EL*NT(&P3C!(Z'.<5O44`>9VNBZWX4\56NJ/';:A+
MJ-I/!=?V=ITB#S\^<KROO?.7+KGY0-P&``,-M[[5[[3M'COKGQ`L%_Y@U5XK
M:2*6"Y6)2(HML8=8]Q?YAQF(#=RP;TZB@#S35#XB0WYMI_$$FH6TLL41ABQ&
M;5+?(.&7RI)'?!#`%MQP,*"!26X\=ZM;2INUG2V@&E0VLOD19N"SD7,TBE6P
M`"25XP%7(Y(KUBB@#RF_7Q)I&K6C)9Z_JD.D1ZA-:CS2XNI6*B%93D;E56<@
MG)QD`$\&72]+\1SZ@Z0WWB2.TGN;1I)[R8J9(?)E,Q"-DPEF;!50I4JF-N!7
MJ-%`'F-C'X@D_LV6]DUZV\G1+F!7\II72<N%6210<2.$`(#`[B<]>:[?PM#>
MVWAFP@U$.+V*+9,SS/+O<$@N&?YB&^\-W(!`[5KT4`%%%%`!1110`4444`?_
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
